0.21784335.16027115.html.plaintext.txt	0	high secretase activity elicits neurodegeneration transgenic mice despite reductions amyloid levels implications treatment alzheimer disease edward rockenstein michael mante michael alford anthony adame leslie crews makoto hashimoto luke esposito lennart mucke eliezer masliah1
0.21784335.16027115.html.plaintext.txt	1	neurosciences pathology university california san diego school medicine la jolla california 92093 0624 gladstone institute neurological disease department neurology university california san francisco california 94158
0.21784335.16027115.html.plaintext.txt	2	received publication june 28 2005 revised form july 13 2005
0.21784335.16027115.html.plaintext.txt	3	abstract top abstract introduction experimental procedures results discussion references amyloid peptides widely presumed play causal role alzheimer disease release amyloid precursor protein app requires proteolysis site app cleaving enzyme bace1 although increased bace1 activity alzheimer disease brains human h bace1 transgenic tg mice results altered app cleavage contribution molecular alterations neurodegeneration unclear therefore used murine thy1 promoter express high levels hbace1 without happ neurons tg mice compared happ mice hbace1happ doubly tg mice increased levels app c terminal fragments c89 c83 decreased levels full length app contrast non tg controls happ mice hbace1 mice hbace1happ mice showed degeneration neurons neocortex hippocampus degradation myelin neurological deficits also severe hbace1 hbace1happ mice happ mice results demonstrate high levels bace1 activity sufficient elicit neurodegeneration neurological decline vivo pathogenic pathway involves accumulation app c terminal fragments depend increased production human thus inhibiting bace1 may block dependent also independent pathogenic mechanisms
0.21784335.16027115.html.plaintext.txt	4	abstract top abstract introduction experimental procedures results discussion references amyloid peptides widely presumed play causal role alzheimer disease release amyloid precursor protein app requires proteolysis site app cleaving enzyme bace1 although increased bace1 activity alzheimer disease brains human h bace1 transgenic tg mice results altered app cleavage contribution molecular alterations neurodegeneration unclear therefore used murine thy1 promoter express high levels hbace1 without happ neurons tg mice compared happ mice hbace1happ doubly tg mice increased levels app c terminal fragments c89 c83 decreased levels full length app contrast non tg controls happ mice hbace1 mice hbace1happ mice showed degeneration neurons neocortex hippocampus degradation myelin neurological deficits also severe hbace1 hbace1happ mice happ mice results demonstrate high levels bace1 activity sufficient elicit neurodegeneration neurological decline vivo pathogenic pathway involves accumulation app c terminal fragments depend increased production human thus inhibiting bace1 may block dependent also independent pathogenic mechanisms
0.21784335.16027115.html.plaintext.txt	5	introduction top abstract introduction experimental procedures results discussion references precise mechanisms leading neurodegeneration alzheimer disease ad2 completely understood however diverse lines evidence suggest alterations processing amyloid precursor protein app leading accumulation amyloid peptides play key role pathogenesis ad 1 3 various products derived app alternative proteolytic cleavage enormous progress recently made identifying enzymes involved 3 11
0.21784335.16027115.html.plaintext.txt	6	introduction top abstract introduction experimental procedures results discussion references precise mechanisms leading neurodegeneration alzheimer disease ad2 completely understood however diverse lines evidence suggest alterations processing amyloid precursor protein app leading accumulation amyloid peptides play key role pathogenesis ad 1 3 various products derived app alternative proteolytic cleavage enormous progress recently made identifying enzymes involved 3 11
0.21784335.16027115.html.plaintext.txt	7	cleavage app secretase results secretion large n terminal ectodomain alternative pathway secretase generates shorter secreted n terminal fragment app c terminal fragments ctfs c89 c99 remain membrane bound latter fragments cleaved secretase resulting production peptides site app cleaving enzyme bace1 accounts secretase activity brain 1 5 7 9 bace1 typical aspartic protease cleavage prodomain generate mature enzyme occurs c terminal site resulting generation mature protein starting glu 46 12
0.21784335.16027115.html.plaintext.txt	8	cleavage app secretase results secretion large n terminal ectodomain alternative pathway secretase generates shorter secreted n terminal fragment app c terminal fragments ctfs c89 c99 remain membrane bound latter fragments cleaved secretase resulting production peptides site app cleaving enzyme bace1 accounts secretase activity brain 1 5 7 9 bace1 typical aspartic protease cleavage prodomain generate mature enzyme occurs c terminal site resulting generation mature protein starting glu 46 12
0.21784335.16027115.html.plaintext.txt	9	recent evidence suggests pathogenesis ad involves alterations activity bace1 polymorphism bace1 gene reported influence ad risk 13 compared nondemented controls bace1 immunoreactivity increased around amyloid plaques ad brains levels bace1 elevated ad brain homogenates 14 17 correlated levels app ctfs a1 x a1 42 18 potential pathogenic role increased bace activity investigated vivo analyzing metabolism app human h bace transgenic tg mice 19 22 studies shown expression hbace1 moderate levels happ tg models results increased generation happ ctfs cases associated enhanced amyloid deposition studies confirmed importance hbace1 app processing vivo however relationship high levels hbace1 activity app processing neurodegeneration remains established address issue used strong thy1 promoter express hbace1 neurons tg mice either alone combination happ high levels bace1 activity significantly increased cerebral accumulation happ ctfs caused prominent age related neurodegeneration neurological decline
0.21784335.16027115.html.plaintext.txt	10	recent evidence suggests pathogenesis ad involves alterations activity bace1 polymorphism bace1 gene reported influence ad risk 13 compared nondemented controls bace1 immunoreactivity increased around amyloid plaques ad brains levels bace1 elevated ad brain homogenates 14 17 correlated levels app ctfs a1 x a1 42 18 potential pathogenic role increased bace activity investigated vivo analyzing metabolism app human h bace transgenic tg mice 19 22 studies shown expression hbace1 moderate levels happ tg models results increased generation happ ctfs cases associated enhanced amyloid deposition studies confirmed importance hbace1 app processing vivo however relationship high levels hbace1 activity app processing neurodegeneration remains established address issue used strong thy1 promoter express hbace1 neurons tg mice either alone combination happ high levels bace1 activity significantly increased cerebral accumulation happ ctfs caused prominent age related neurodegeneration neurological decline
0.21784335.16027115.html.plaintext.txt	11	experimental procedures top abstract introduction experimental procedures results discussion references generation hbace1 hbace1happ tg mice tissue processing cdna encoding wild type hbace1 produced reverse transcription pcr human brain mrna described previously 23 cdna includes kozak consensus sequence gcc acc atg 5 end enhance expression hbace1 cdna inserted exons 2 4 mthy1 expression cassette kindly provided dr h van der putten ciba geigy basel switzerland purified microinjected one cell embryos c57bl6 x dba2 f1 transgenic founder mice identified pcr analysis genomic dna extracted tail biopsies doubly tg mice generated crossing heterozygous hbace1 mice lines 1 39 happ tg line 41 described previously 23 happ line 41 expresses mutant happ751 direction mthy1 promoter produces high levels a1 42 resulting plaque formation 3 months age tg lines maintained crossing heterozygous tg mice non tg c57bl6 x dba2 f1 breeders tg mice analyzed study heterozygous respect individual transgenes non tg littermates used controls
0.21784335.16027115.html.plaintext.txt	12	experimental procedures top abstract introduction experimental procedures results discussion references generation hbace1 hbace1happ tg mice tissue processing cdna encoding wild type hbace1 produced reverse transcription pcr human brain mrna described previously 23 cdna includes kozak consensus sequence gcc acc atg 5 end enhance expression hbace1 cdna inserted exons 2 4 mthy1 expression cassette kindly provided dr h van der putten ciba geigy basel switzerland purified microinjected one cell embryos c57bl6 x dba2 f1 transgenic founder mice identified pcr analysis genomic dna extracted tail biopsies doubly tg mice generated crossing heterozygous hbace1 mice lines 1 39 happ tg line 41 described previously 23 happ line 41 expresses mutant happ751 direction mthy1 promoter produces high levels a1 42 resulting plaque formation 3 months age tg lines maintained crossing heterozygous tg mice non tg c57bl6 x dba2 f1 breeders tg mice analyzed study heterozygous respect individual transgenes non tg littermates used controls
0.21784335.16027115.html.plaintext.txt	13	different ages mice anesthetized chloral hydrate flush perfused transcardially 09 saline brains peripheral tissues removed brains divided sagittally one hemibrain postfixed phosphate buffered 4 paraformaldehyde ph 74 4 degrees c 48 h neuropathological analysis snap frozen stored 70 degrees c rna protein analyses
0.21784335.16027115.html.plaintext.txt	14	rna analysis total rna extracted tri reagent molecular research center cincinnati oh snap frozen hemibrains dissected brain regions neocortex hippocampus stored formazol buffer molecular research 20 degrees c rna analyzed solution hybridization ribonuclease protection assay rpa essentially described previously 24 samples separated 5 acrylamide 8 m urea tris borate edta gels dried gels exposed kodak xar film eastman kodak mrna levels quantitated phosphorimager readings probe specific signals corrected rna contentloading errors normalization actin signals 24 following 32p labeled antisense riboprobes used identify specific mrnas protected nucleotides genbank accession numbers hbace1 nucleotides 1305 1599 accession number af190725 genbank mouse m bace1 1280 1574 accession number af190726 genbank mapp770 811 1314 accession number xm128362 mapp exon 6 9 m actin 480 565 accession number x03672 genbank
0.21784335.16027115.html.plaintext.txt	15	rna analysis total rna extracted tri reagent molecular research center cincinnati oh snap frozen hemibrains dissected brain regions neocortex hippocampus stored formazol buffer molecular research 20 degrees c rna analyzed solution hybridization ribonuclease protection assay rpa essentially described previously 24 samples separated 5 acrylamide 8 m urea tris borate edta gels dried gels exposed kodak xar film eastman kodak mrna levels quantitated phosphorimager readings probe specific signals corrected rna contentloading errors normalization actin signals 24 following 32p labeled antisense riboprobes used identify specific mrnas protected nucleotides genbank accession numbers hbace1 nucleotides 1305 1599 accession number af190725 genbank mouse m bace1 1280 1574 accession number af190726 genbank mapp770 811 1314 accession number xm128362 mapp exon 6 9 m actin 480 565 accession number x03672 genbank
0.21784335.16027115.html.plaintext.txt	16	western blot analysis hbace1 happ app ctfs determination protein content lowry method frontal cortex homogenates loaded 15 microg proteinlane separated 10 sds polyacrylamide gels blotted onto nitrocellulose blots labeled rabbit polyclonal antibody hbace1 prosci inc poway ca 11000 mouse monoclonal antibody n terminus app 22c11 chemicon international temecula ca 11000 mouse monoclonal antibody happ 8e5 elan 120000 rabbit polyclonal antibody c99 c89 app ct15 courtesy dr edward koo 120000 mouse monoclonal antibody 4g8 senetek plc napa ca 11000 followed anti mouse anti rabbit secondary antibodies blots incubated 125i protein icn pharmaceuticals costa mesa ca exposed phosphorimager molecular dynamics piscataway nj screens incubated super signal west pico chemiluminescent substrate pierce exposed film details regarding antibodies utilized described table one control variations loading blots stripped incubated mouse monoclonal antibody actin chemicon 1500 signal intensities quantitated imagequant software molecular dynamics
0.21784335.16027115.html.plaintext.txt	17	western blot analysis hbace1 happ app ctfs determination protein content lowry method frontal cortex homogenates loaded 15 microg proteinlane separated 10 sds polyacrylamide gels blotted onto nitrocellulose blots labeled rabbit polyclonal antibody hbace1 prosci inc poway ca 11000 mouse monoclonal antibody n terminus app 22c11 chemicon international temecula ca 11000 mouse monoclonal antibody happ 8e5 elan 120000 rabbit polyclonal antibody c99 c89 app ct15 courtesy dr edward koo 120000 mouse monoclonal antibody 4g8 senetek plc napa ca 11000 followed anti mouse anti rabbit secondary antibodies blots incubated 125i protein icn pharmaceuticals costa mesa ca exposed phosphorimager molecular dynamics piscataway nj screens incubated super signal west pico chemiluminescent substrate pierce exposed film details regarding antibodies utilized described table one control variations loading blots stripped incubated mouse monoclonal antibody actin chemicon 1500 signal intensities quantitated imagequant software molecular dynamics
0.21784335.16027115.html.plaintext.txt	18	view table table one antibodies bace app app metabolites used study
0.21784335.16027115.html.plaintext.txt	19	additional western blot analysis performed highly denaturing conditions described previously 25 modifications neocortical tissues homogenized 98 formic acid 80 final concentration icn dounce homogenizer centrifuged 30 min 50000 x g 4 degrees c supernatants collected used highly denaturing acetic acidurea page western blot analysis briefly 10 mg mice without plaques 50 microg mice plaques total protein determined micro lowry assay loaded per lane 41022 step gradient polyacrylamide gel containing 6 m urea 10 acetic acid electrophoresed anode cathode 625 acetic acid running buffer overnight 4 degrees c gel neutralized five 15 min incubations trisglycine transfer buffer 20 methanol ph 84 transferred nitrocellulose membrane 02 microm pore size membrane boiled phosphate buffered saline 5 min blocked 5 milk tris buffered saline 005 tween 20 tbst 1 h incubated overnight 4 degrees c anti antibody 266 57 microgml 25 membranes washed three times 8 min 1 bovine serum albumin tbst incubated anti mouse igghorseradish peroxidase secondary antibody 3 h room temperature membranes washed three times 8 min tbst detection carried super signal west pico chemiluminescent substrate pierce synthetic a1 40 a1 42 peptides 750 pg biopeptide san diego ca run standards
0.21784335.16027115.html.plaintext.txt	20	additional western blot analysis performed highly denaturing conditions described previously 25 modifications neocortical tissues homogenized 98 formic acid 80 final concentration icn dounce homogenizer centrifuged 30 min 50000 x g 4 degrees c supernatants collected used highly denaturing acetic acidurea page western blot analysis briefly 10 mg mice without plaques 50 microg mice plaques total protein determined micro lowry assay loaded per lane 41022 step gradient polyacrylamide gel containing 6 m urea 10 acetic acid electrophoresed anode cathode 625 acetic acid running buffer overnight 4 degrees c gel neutralized five 15 min incubations trisglycine transfer buffer 20 methanol ph 84 transferred nitrocellulose membrane 02 microm pore size membrane boiled phosphate buffered saline 5 min blocked 5 milk tris buffered saline 005 tween 20 tbst 1 h incubated overnight 4 degrees c anti antibody 266 57 microgml 25 membranes washed three times 8 min 1 bovine serum albumin tbst incubated anti mouse igghorseradish peroxidase secondary antibody 3 h room temperature membranes washed three times 8 min tbst detection carried super signal west pico chemiluminescent substrate pierce synthetic a1 40 a1 42 peptides 750 pg biopeptide san diego ca run standards
0.21784335.16027115.html.plaintext.txt	21	view larger version 58k figure 1 bace1 expression brains bace1 tg mice non tg controls brain tissues obtained 3 month old tg mice lines 1 2 39 age matched non tg controls 60 year old nondemented human c human h mouse m bace1 mrnas frontal cortex quantitated rpa representative autoradiograph lane contains sample different mouse human b c relative mrna levels expressed hbace1actin b mbace1actin c ratios correct loading errors rpa signals quantitated described previously 24 d relative levels hbace1 protein frontal cortex determined western blot analysis representative western blot demonstrates association bace1 particulate fraction lane contains sample different mouse e western blot bands quantitated imagequant software f bace1 activity determined red fret peptide substrate based swapp mutant assay differentiate activities human murine bace1 levels non tg controls defined 100 g j photomicrographs depicting immunoperoxidase staining hbace1 frontal cortex non tg mouse g hbace1 tg mice lines 39 h2i 1 j bar 25 microm p 005 versus lines 39 2 tukey kramer test p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	22	view larger version 58k figure 1 bace1 expression brains bace1 tg mice non tg controls brain tissues obtained 3 month old tg mice lines 1 2 39 age matched non tg controls 60 year old nondemented human c human h mouse m bace1 mrnas frontal cortex quantitated rpa representative autoradiograph lane contains sample different mouse human b c relative mrna levels expressed hbace1actin b mbace1actin c ratios correct loading errors rpa signals quantitated described previously 24 d relative levels hbace1 protein frontal cortex determined western blot analysis representative western blot demonstrates association bace1 particulate fraction lane contains sample different mouse e western blot bands quantitated imagequant software f bace1 activity determined red fret peptide substrate based swapp mutant assay differentiate activities human murine bace1 levels non tg controls defined 100 g j photomicrographs depicting immunoperoxidase staining hbace1 frontal cortex non tg mouse g hbace1 tg mice lines 39 h2i 1 j bar 25 microm p 005 versus lines 39 2 tukey kramer test p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	23	analysis app metabolism related pathways human peptides quantitated enzyme linked immunosorbent assays elisas described previously 26 a1 42 elisa detects a1 42 whereas a1 x elisa detects a1 40 a1 42 well forms containing amino acids 1 28 analysis app ctfs cortex homogenates analyzed lowry method determine protein concentration loaded 75 microg proteinlane 25 50 microglane j20 i5 mice respectively onto 14 tricinesds polyacrylamide gels blotted onto nitrocellulose probed antibodies app ctfs ct15 11000 phospho p app cell signaling beverly ma 11200 tubulin loading control 1500000
0.21784335.16027115.html.plaintext.txt	24	analysis app metabolism related pathways human peptides quantitated enzyme linked immunosorbent assays elisas described previously 26 a1 42 elisa detects a1 42 whereas a1 x elisa detects a1 40 a1 42 well forms containing amino acids 1 28 analysis app ctfs cortex homogenates analyzed lowry method determine protein concentration loaded 75 microg proteinlane 25 50 microglane j20 i5 mice respectively onto 14 tricinesds polyacrylamide gels blotted onto nitrocellulose probed antibodies app ctfs ct15 11000 phospho p app cell signaling beverly ma 11200 tubulin loading control 1500000
0.21784335.16027115.html.plaintext.txt	25	evaluate effects hbace1 expression related pathways western blots probed antibodies neprilysin cd10 mouse monoclonal abcam cambridge ma 11000 insulin degrading enzyme ide rabbit polyclonal calbiochem san diego ca 11000 notch4 rabbit polyclonal santa cruz biotechnology santa cruz ca 11000
0.21784335.16027115.html.plaintext.txt	26	analysis bace1 enzymatic activity bace1 activity determined adapting bace1 fluorescence resonance energy transfer fret assay kit panvera madison wi uses red fret peptide derived swedish sw mutant app substrate sequence described previously 6 briefly brain homogenates tg mice incubated bace1 substrate final concentration 1 x reagents stop buffer containing 25 m sodium acetate added signal determined 545 nm spectrofluorometer control experiments performed standard curves generated using baculovirus expressed bace1 bace1 product standard rh evnl bace1 inhibitor provided kit
0.21784335.16027115.html.plaintext.txt	27	analysis bace1 enzymatic activity bace1 activity determined adapting bace1 fluorescence resonance energy transfer fret assay kit panvera madison wi uses red fret peptide derived swedish sw mutant app substrate sequence described previously 6 briefly brain homogenates tg mice incubated bace1 substrate final concentration 1 x reagents stop buffer containing 25 m sodium acetate added signal determined 545 nm spectrofluorometer control experiments performed standard curves generated using baculovirus expressed bace1 bace1 product standard rh evnl bace1 inhibitor provided kit
0.21784335.16027115.html.plaintext.txt	28	confirm bace1 activity levels independent method extracted supernatants homogenized samples neutralized tris assayed bace1 activity utilizing substrate bacterial maltose binding protein mbp fused c terminal 125 amino acids app mbp appc125 described previously 27 briefly assays carried 20 mm sodium acetate ph 48 006 triton x 100 10 microgml mbp appc125 reaction mixtures diluted 15 incubated 37 degrees c 2 h quenched reaction mixtures loaded onto 96 well plates coated polyclonal antibody raised mbp cleaved products detected using biotinylated sw192 specific reporter antibodies purified hbace1 used standard activity assays
0.21784335.16027115.html.plaintext.txt	29	confirm bace1 activity levels independent method extracted supernatants homogenized samples neutralized tris assayed bace1 activity utilizing substrate bacterial maltose binding protein mbp fused c terminal 125 amino acids app mbp appc125 described previously 27 briefly assays carried 20 mm sodium acetate ph 48 006 triton x 100 10 microgml mbp appc125 reaction mixtures diluted 15 incubated 37 degrees c 2 h quenched reaction mixtures loaded onto 96 well plates coated polyclonal antibody raised mbp cleaved products detected using biotinylated sw192 specific reporter antibodies purified hbace1 used standard activity assays
0.21784335.16027115.html.plaintext.txt	30	view larger version 29k figure 2 decreases fl app increases app ctfs hbace1 tg mice homogenates frontal cortex 6 month old hbace1 tg mice non tg littermates separated cytosolic particulate fractions analyzed western blotting antibodies fl app 22c11 mouse monoclonal app ctfs ct15 rabbit polyclonal actin mouse monoclonal expression levels quantitated representative western blot samples different hbace1 tg lines lane contains sample different mouse b c quantitation western blot bands n 4 micegenotype d double immunolabeling confocal microscopic analysis hbace1 red app ctfs green frontal cortex 6 month old non tg d f hbace1 tg g mice bar 20 microm p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	31	view larger version 29k figure 2 decreases fl app increases app ctfs hbace1 tg mice homogenates frontal cortex 6 month old hbace1 tg mice non tg littermates separated cytosolic particulate fractions analyzed western blotting antibodies fl app 22c11 mouse monoclonal app ctfs ct15 rabbit polyclonal actin mouse monoclonal expression levels quantitated representative western blot samples different hbace1 tg lines lane contains sample different mouse b c quantitation western blot bands n 4 micegenotype d double immunolabeling confocal microscopic analysis hbace1 red app ctfs green frontal cortex 6 month old non tg d f hbace1 tg g mice bar 20 microm p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	32	behavioral analysis mice free access food water experiments carried light cycle experimental control groups contained similar proportions males females water maze test carried described previously 28 briefly pool diameter 180 cm filled opaque water 24 degrees c mice first trained locate visible platform days 1 3 submerged hidden platform days 4 7 three daily trials 2 3 min apart mice failed find hidden platform within 90 placed 30 platform location used sessions mice starting point mouse placed water changed randomly two alternative entry points located similar distance platform day 8 another visible platform trial performed exclude differences motivation fatigue time reach platform latency path length swim speed recorded noldus instruments ethovision video tracking system san diego instruments san diego set analyze two sampless
0.21784335.16027115.html.plaintext.txt	33	behavioral analysis mice free access food water experiments carried light cycle experimental control groups contained similar proportions males females water maze test carried described previously 28 briefly pool diameter 180 cm filled opaque water 24 degrees c mice first trained locate visible platform days 1 3 submerged hidden platform days 4 7 three daily trials 2 3 min apart mice failed find hidden platform within 90 placed 30 platform location used sessions mice starting point mouse placed water changed randomly two alternative entry points located similar distance platform day 8 another visible platform trial performed exclude differences motivation fatigue time reach platform latency path length swim speed recorded noldus instruments ethovision video tracking system san diego instruments san diego set analyze two sampless
0.21784335.16027115.html.plaintext.txt	34	immunohistochemistry vibratome sections 40 microm brain tissues incubated overnight 4 degrees c primary antibodies hbace1 prosci inc 1500 happ 8e5 elan 120000 table one binding primary antibody detected vector abc elite kit vector laboratories burlingame ca diaminobenzidine tetrahydrochloride 0001 h2o2 double labeling studies performed essentially described previously 28 briefly vibratome sections incubated overnight 4 degrees c anti hbace1 1500 developed tyramide signal amplification direct red system perkinelmer life sciences 1100 sections incubated overnight antibody app ctfs ct15 1100 followed incubation fitc tagged secondary goat anti rabbit vector 175 imaging laser scanning confocal microscopy lscm mrc 1024 bio rad
0.21784335.16027115.html.plaintext.txt	35	immunohistochemistry vibratome sections 40 microm brain tissues incubated overnight 4 degrees c primary antibodies hbace1 prosci inc 1500 happ 8e5 elan 120000 table one binding primary antibody detected vector abc elite kit vector laboratories burlingame ca diaminobenzidine tetrahydrochloride 0001 h2o2 double labeling studies performed essentially described previously 28 briefly vibratome sections incubated overnight 4 degrees c anti hbace1 1500 developed tyramide signal amplification direct red system perkinelmer life sciences 1100 sections incubated overnight antibody app ctfs ct15 1100 followed incubation fitc tagged secondary goat anti rabbit vector 175 imaging laser scanning confocal microscopy lscm mrc 1024 bio rad
0.21784335.16027115.html.plaintext.txt	36	neuropathological analysis vibratome sections incubated overnight 4 degrees c mouse monoclonal antibodies neuronal dendritic marker microtubule associated protein 2 map2 chemicon 1100 axonal neurofilament marker smi312 sternberger immuocytochemicals baltimore md 1200 astroglial marker glial fibrillary acidic protein gfap chemicon 1500 described previously 29 binding primary antibodies detected vector elite kit diaminobenzidine tetrahydrochlorideh2o2 fitc conjugated igg secondary antibodies vector 175 immunoperoxidase labeled sections examined olympus vanox light microscope fitc labeled sections analyzed confocal microscopy 29 30
0.21784335.16027115.html.plaintext.txt	37	neuropathological analysis vibratome sections incubated overnight 4 degrees c mouse monoclonal antibodies neuronal dendritic marker microtubule associated protein 2 map2 chemicon 1100 axonal neurofilament marker smi312 sternberger immuocytochemicals baltimore md 1200 astroglial marker glial fibrillary acidic protein gfap chemicon 1500 described previously 29 binding primary antibodies detected vector elite kit diaminobenzidine tetrahydrochlorideh2o2 fitc conjugated igg secondary antibodies vector 175 immunoperoxidase labeled sections examined olympus vanox light microscope fitc labeled sections analyzed confocal microscopy 29 30
0.21784335.16027115.html.plaintext.txt	38	ultrastructural analysis blocks neocortex hippocampus postfixed 2 glutaraldehyde 01 osmium tetroxide 01 m sodium cacodylate buffer embedded epoxy blocks sectioned ultracut e ultramicrotome leica nussloch germany analyzed zeiss em10 electron microscope carl zeiss oberkochen germany 31
0.21784335.16027115.html.plaintext.txt	39	statistical analysis analyses carried statview 50 program sas institute inc cary nc differences among means assessed students test one way anova followed dunnetts tukey kramer post hoc tests indicated learning curves analyzed repeated measures anova null hypothesis rejected 005 level
0.21784335.16027115.html.plaintext.txt	40	view larger version 40k figure 3 decreases fl app increases app ctfs hbace1happ tg mice homogenates frontal cortex 6 month old hbace1 tg happ tg hbace1happ doubly tg mice non tg littermates separated cytosolic particulate fractions analyzed western blotting antibodies fl app 22c11 mouse monoclonal app ctfs ct15 rabbit polyclonal actin mouse monoclonal expression levels quantitated representative western blot samples hbace1happ doubly tg mice singly tg hbace1 happ controls b c quantitation western blot bands n 4 micegroup d double immunolabeling confocal microscopic analysis hbace1 red happ green frontal cortex 6 month old happ tg d f hbace1happ tg g mice bar 20 microm p 005 versus non tg controls dunnetts test p 005 versus hbace1happ doubly tg mice tukey kramer test
0.21784335.16027115.html.plaintext.txt	41	view larger version 40k figure 3 decreases fl app increases app ctfs hbace1happ tg mice homogenates frontal cortex 6 month old hbace1 tg happ tg hbace1happ doubly tg mice non tg littermates separated cytosolic particulate fractions analyzed western blotting antibodies fl app 22c11 mouse monoclonal app ctfs ct15 rabbit polyclonal actin mouse monoclonal expression levels quantitated representative western blot samples hbace1happ doubly tg mice singly tg hbace1 happ controls b c quantitation western blot bands n 4 micegroup d double immunolabeling confocal microscopic analysis hbace1 red happ green frontal cortex 6 month old happ tg d f hbace1happ tg g mice bar 20 microm p 005 versus non tg controls dunnetts test p 005 versus hbace1happ doubly tg mice tukey kramer test
0.21784335.16027115.html.plaintext.txt	42	results top abstract introduction experimental procedures results discussion references expression bace1 brains mthy1 hbace1 tg mice micro injection mthy1 hbace1 construct yielded four tg lines three selected analysis based levels hbace1 mrna determined rpa hbace1 mrna levels whole hemibrains tg lines 3 8 fold higher frontal cortex humans without ad highest levels detected line 1 fig 1 b three lines levels endogenous mbace1 decreased 30 50 compared non tg controls fig 1c consistent mrna analysis hbace1 protein levels fig 1 d e hbace activity fig 1f neuronal hbace1 immunoreactivity fig 1 g j higher line 1 lines 2 39 three lines high levels hbace1 immunoreactivity observed pyramidal neurons layers 4 5 neocortex fig 1 h j hippocampal formation hbace1 immunoreactivity detected pyramidal cells ca1 region granule cells dentate gyrus line 1 pyramidal neurons ca1 3 granule cells lines 2 39 shown moderate hbace1 immunoreactivity also detected subcortical nuclei cerebellum three lines shown brains non tg controls immunoreactivity background levels detected hbace1 specific antibody fig 1 d e g
0.21784335.16027115.html.plaintext.txt	43	results top abstract introduction experimental procedures results discussion references expression bace1 brains mthy1 hbace1 tg mice micro injection mthy1 hbace1 construct yielded four tg lines three selected analysis based levels hbace1 mrna determined rpa hbace1 mrna levels whole hemibrains tg lines 3 8 fold higher frontal cortex humans without ad highest levels detected line 1 fig 1 b three lines levels endogenous mbace1 decreased 30 50 compared non tg controls fig 1c consistent mrna analysis hbace1 protein levels fig 1 d e hbace activity fig 1f neuronal hbace1 immunoreactivity fig 1 g j higher line 1 lines 2 39 three lines high levels hbace1 immunoreactivity observed pyramidal neurons layers 4 5 neocortex fig 1 h j hippocampal formation hbace1 immunoreactivity detected pyramidal cells ca1 region granule cells dentate gyrus line 1 pyramidal neurons ca1 3 granule cells lines 2 39 shown moderate hbace1 immunoreactivity also detected subcortical nuclei cerebellum three lines shown brains non tg controls immunoreactivity background levels detected hbace1 specific antibody fig 1 d e g
0.21784335.16027115.html.plaintext.txt	44	high levels hbace1 expression increase app ctfs decrease levels full length app full length fl app detected western blots brain homogenates triple band fig 2a compared non tg controls high expresser hbace1 tg mice decreased levels fl app fig 2a b decrease marked two upper bands contrast levels app ctfs 2 3 fold higher hbace1 mice non tg controls determined western blot analysis ct15 antibody recognizes hbace1 generated c89 c99 fragments app fig 2 c well secretase generated c83 fragment 32 double labeling analysis confirmed intraneuronal accumulation app ctfs higher hbace1 mice non tg controls fig 2 d moreover neurons displaying highest levels hbace1 expression also showed highest levels app ctf immunoreactivity fig 2 g characterize effects high levels hbace1 expression happ processing homogenates happ singly tg mice expressing familial ad mutant happ line 41 23 hbace1line 1happline 41 doubly tg mice analyzed western blot singly tg happ mice showed increase overall levels cerebral app expression compared non tg controls fig 3 c compared mice hbace1happ mice lower levels fl app higher levels app ctfs fig 3 c immunoreactivities hbace1 app ctfs hbace1happ mice colocalized neurons fig 3 g consistent notion increase app ctfs resulted increased cleavage happ hbace1
0.21784335.16027115.html.plaintext.txt	45	investigate app metabolism greater detail mice app ctfs detected immunoblot analysis separation tricinesds polyacrylamide gels analysis revealed increase app ctfs hbace1happ mice represents primarily accumulation c89 results app cleavage site fig 4a whereas secretase cleavage c99 would result production a1 x secretase cleavage c89 would result production a11 x surprisingly hbace1happ mice decreased levels a1 x truncated species hippocampal levels a1 x fig 4b a1 42 fig 4c much lower hbace1happ mice happ singly tg mice elisas used obtain measurements specifically detect peptides containing first five amino acids also analyzed levels antibody 266 raised middle portion peptide amino acids 13 28 table one 25 extraction hippocampal proteins formic acid followed high resolution acid urea page western blot analysis 266 antibody confirmed reductions detectable species hbace1happ mice compared happ singly tg mice fig 4d consistent biochemical data amyloid plaques detected 3 6 months age frontal cortex hippocampus happ mice hbace1happ mice fig 4 e f data shown
0.21784335.16027115.html.plaintext.txt	46	investigate app metabolism greater detail mice app ctfs detected immunoblot analysis separation tricinesds polyacrylamide gels analysis revealed increase app ctfs hbace1happ mice represents primarily accumulation c89 results app cleavage site fig 4a whereas secretase cleavage c99 would result production a1 x secretase cleavage c89 would result production a11 x surprisingly hbace1happ mice decreased levels a1 x truncated species hippocampal levels a1 x fig 4b a1 42 fig 4c much lower hbace1happ mice happ singly tg mice elisas used obtain measurements specifically detect peptides containing first five amino acids also analyzed levels antibody 266 raised middle portion peptide amino acids 13 28 table one 25 extraction hippocampal proteins formic acid followed high resolution acid urea page western blot analysis 266 antibody confirmed reductions detectable species hbace1happ mice compared happ singly tg mice fig 4d consistent biochemical data amyloid plaques detected 3 6 months age frontal cortex hippocampus happ mice hbace1happ mice fig 4 e f data shown
0.21784335.16027115.html.plaintext.txt	47	view larger version 59k figure 4 accumulation app ctfs decreases levels deposition hbace1happ doubly tg mice homogenates frontal cortex 3 5 month old singly tg mice happ line 41 hbace1 line 1 doubly tg hbace1happ mice non tg controls separated differential centrifugation particulate fractions separated 14 tricine gels analyzed western blotting antibody app ctfs ct15 rabbit polyclonal representative western blot samples happ hbace1happ doubly tg mice confirm approach detect differences relative abundance different app ctfs included samples hippocampus two previously characterized pdgf happ tg lines expressing comparable levels familial ad mutant j20 wild type i5 happ 29 consistent known effects swedish mutation app cleavage bace1 j20 mouse c99 c83 fragments whereas i5 mouse mostly c83 b c hippocampal levels a1 x b a1 42 c 5 month old mice n 6 7 miceline determined elisa d a1 42 a1 40 a1 38 species detected high resolution acid urea page western blot analysis 266 antibody described previously 25 lane contained proteins extracted neocortex 1 mglane different mouse e f deposits detected hippocampal vibratome sections immunostaining 4g8 antibody 3 months age happ tg mice line 41 amyloid deposits e whereas hbace1happ tg mice f g comparison levels neprilysin ide notch non tg controls happ hbace1 hbace1happ tg mice western blot analysis levels actin immunoreactivity used loading control homogenates frontal cortex 6 month old mice h quantitative analysis levels neprilysin ide notch expression analysis phosphorylated fl app app p phosphorylated app ctfs c99 p c89 p c83 p happ hbace1happ tg mice homogenates frontal cortex 6 month old mice separated polyacrylamide tricine gels transferred nitrocellulose probed app p thr 668 antibody j quantitative analysis showing levels app p c99 p c83 p reduced bigenic mice p 005 versus happ tg mice unpaired two tailed students test
0.21784335.16027115.html.plaintext.txt	48	view larger version 59k figure 4 accumulation app ctfs decreases levels deposition hbace1happ doubly tg mice homogenates frontal cortex 3 5 month old singly tg mice happ line 41 hbace1 line 1 doubly tg hbace1happ mice non tg controls separated differential centrifugation particulate fractions separated 14 tricine gels analyzed western blotting antibody app ctfs ct15 rabbit polyclonal representative western blot samples happ hbace1happ doubly tg mice confirm approach detect differences relative abundance different app ctfs included samples hippocampus two previously characterized pdgf happ tg lines expressing comparable levels familial ad mutant j20 wild type i5 happ 29 consistent known effects swedish mutation app cleavage bace1 j20 mouse c99 c83 fragments whereas i5 mouse mostly c83 b c hippocampal levels a1 x b a1 42 c 5 month old mice n 6 7 miceline determined elisa d a1 42 a1 40 a1 38 species detected high resolution acid urea page western blot analysis 266 antibody described previously 25 lane contained proteins extracted neocortex 1 mglane different mouse e f deposits detected hippocampal vibratome sections immunostaining 4g8 antibody 3 months age happ tg mice line 41 amyloid deposits e whereas hbace1happ tg mice f g comparison levels neprilysin ide notch non tg controls happ hbace1 hbace1happ tg mice western blot analysis levels actin immunoreactivity used loading control homogenates frontal cortex 6 month old mice h quantitative analysis levels neprilysin ide notch expression analysis phosphorylated fl app app p phosphorylated app ctfs c99 p c89 p c83 p happ hbace1happ tg mice homogenates frontal cortex 6 month old mice separated polyacrylamide tricine gels transferred nitrocellulose probed app p thr 668 antibody j quantitative analysis showing levels app p c99 p c83 p reduced bigenic mice p 005 versus happ tg mice unpaired two tailed students test
0.21784335.16027115.html.plaintext.txt	49	view larger version 17k figure 5 learning deficits hbace1 hbace1happ tg mice 6 months age hbace1 line 39 happ mice line 41 hbace1happ mice non tg littermates n 8 micegroup mice trained morris water maze locate visible platform days 1 3 submerged platform days 4 7 visible platform day 8 day 3 cued component test platform visible four groups achieved comparable escape latency platform hidden three groups tg mice showed significant learning deficits compared non tg controls p 005 days 5 7 p 01 days 1 3 tg groups repeated measures anova trend toward severe deficits observed hbace1happ mice repeated measures anova curves hidden platform different among three groups tg mice however last day hidden platform testing day 7 hbace1happ mice performed poorly hbace1 mice happ tg mice p 005 one way anova
0.21784335.16027115.html.plaintext.txt	50	view larger version 17k figure 5 learning deficits hbace1 hbace1happ tg mice 6 months age hbace1 line 39 happ mice line 41 hbace1happ mice non tg littermates n 8 micegroup mice trained morris water maze locate visible platform days 1 3 submerged platform days 4 7 visible platform day 8 day 3 cued component test platform visible four groups achieved comparable escape latency platform hidden three groups tg mice showed significant learning deficits compared non tg controls p 005 days 5 7 p 01 days 1 3 tg groups repeated measures anova trend toward severe deficits observed hbace1happ mice repeated measures anova curves hidden platform different among three groups tg mice however last day hidden platform testing day 7 hbace1happ mice performed poorly hbace1 mice happ tg mice p 005 one way anova
0.21784335.16027115.html.plaintext.txt	51	findings raise possibilities decreased levels a1 x a1 42 result alterations activity secretase availability substrate rate turnover enzymes neprilysin insulin degrading enzyme ide immunoblot analysis antibodies neprilysin ide showed roughly comparable levels enzymes hbace1 mice happ mice hbace1happ mice non tg controls fig 4 g h addition levels notch another secretase substrate comparable among four groups mice fig 4 g h results suggest decrease levels mice high levels hbace1 activity result increased degradation decreased secretase activity
0.21784335.16027115.html.plaintext.txt	52	findings raise possibilities decreased levels a1 x a1 42 result alterations activity secretase availability substrate rate turnover enzymes neprilysin insulin degrading enzyme ide immunoblot analysis antibodies neprilysin ide showed roughly comparable levels enzymes hbace1 mice happ mice hbace1happ mice non tg controls fig 4 g h addition levels notch another secretase substrate comparable among four groups mice fig 4 g h results suggest decrease levels mice high levels hbace1 activity result increased degradation decreased secretase activity
0.21784335.16027115.html.plaintext.txt	53	similar decreases independent line hbace1 tg mice recently related decreased availability mature phosphorylated app app p 19 consistent possibility western blot analysis antibody app p threonine 668 revealed cerebral levels fl app p c99 p lower hbace1happ mice happ mice fig 4 j results support notion high levels hbace1 activity increase happ cleavage early secretory pathway depleting mature happ p transported axon terminals large proportion generation secretase complex takes place 19
0.21784335.16027115.html.plaintext.txt	54	similar decreases independent line hbace1 tg mice recently related decreased availability mature phosphorylated app app p 19 consistent possibility western blot analysis antibody app p threonine 668 revealed cerebral levels fl app p c99 p lower hbace1happ mice happ mice fig 4 j results support notion high levels hbace1 activity increase happ cleavage early secretory pathway depleting mature happ p transported axon terminals large proportion generation secretase complex takes place 19
0.21784335.16027115.html.plaintext.txt	55	increased activity hbace1 elicits learning deficits neurodegenerative alterations 3 months age hbace1 tg mice highest expresser line 1 showed mild weakness spasticity hind limbs phenotype apparent 6 months progressed prominent spastic paraparesis 12 months age hbace1 mice intermediate expresser lines 2 39 showed obvious neurological deficits inspected 3 6 months age although 12 months mild tremor
0.21784335.16027115.html.plaintext.txt	56	increased activity hbace1 elicits learning deficits neurodegenerative alterations 3 months age hbace1 tg mice highest expresser line 1 showed mild weakness spasticity hind limbs phenotype apparent 6 months progressed prominent spastic paraparesis 12 months age hbace1 mice intermediate expresser lines 2 39 showed obvious neurological deficits inspected 3 6 months age although 12 months mild tremor
0.21784335.16027115.html.plaintext.txt	57	hbace1 tg mice line 1 developed age dependent neurological deficits precluded assessment water maze test hbace1 tg mice line 39 selected crosses happ tg mice behavioral analysis 6 months age hbace1 mice line 39 happ mice hbace1happ mice non tg littermates tested morris water maze examine spatial learning memory day 3 cued component test platform visible four groups achieved similar escape latencies fig 5 platform hidden three groups tg mice showed significant learning deficits compared non tg controls fig 5 trend toward severe deficits observed hbace1happ mice repeated measures anova curves hidden platform different among three groups tg mice however last day test day 7 performance deficits hbace1happ group significantly different one way anova p 005 compared hbace1 happ tg mice
0.21784335.16027115.html.plaintext.txt	58	hbace1 tg mice line 1 developed age dependent neurological deficits precluded assessment water maze test hbace1 tg mice line 39 selected crosses happ tg mice behavioral analysis 6 months age hbace1 mice line 39 happ mice hbace1happ mice non tg littermates tested morris water maze examine spatial learning memory day 3 cued component test platform visible four groups achieved similar escape latencies fig 5 platform hidden three groups tg mice showed significant learning deficits compared non tg controls fig 5 trend toward severe deficits observed hbace1happ mice repeated measures anova curves hidden platform different among three groups tg mice however last day test day 7 performance deficits hbace1happ group significantly different one way anova p 005 compared hbace1 happ tg mice
0.21784335.16027115.html.plaintext.txt	59	assess extent neurodegenerative alterations hbace1 mice immunolabeling performed antibodies markers neuronal dendritic integrity compared non tg controls fig 6a mice expressing high levels hbace1 displayed shrinkage pyramidal neurons ca3 region hippocampus fig 6b worst alterations seen mice highest expresser line 1 fig 6 b c compared non tg controls fig 6d pyramidal neurons layers 2 3 neocortex also shrunken condensed three hbace1 tg lines fig 6 e f contrast normal labeling neurites antibodies neurofilament fig 6g map2 fig 6j non tg controls axonal dendritic processes pyramidal neurons hbace1 mice diminished disrupted vacuolized fig 6 h k alterations prominent 12 months fig 6 l detectable albeit lesser extent 3 6 months age shown 12 months age neurodegenerative alterations hbace1 tg mice associated reactive astrocytosis fig 6n observed non tg controls fig 6 m o contrast non tg littermate controls fig 6p hbace1 mice line 1 showed collapsed neuronal cytoplasm accumulations electrodense material extensive vacuolization dendritic arbors fig 6q wide spread degeneration axonal processes splinting disorganization myelin laminations fig 6r significant loss alterations neuritic structures also detected happ singly tg mice hbace1 mice hbace1happ mice considerable damage also ca3 region hippocampus fig 7 compared non tg controls fig 7a happ fig 7b hbace1 fig 7c mice reduced levels map2 immunoreactivity frontal cortex alteration even prominent hbace1happ mice fig 7e ca3 region hippocampus three tg groups showed loss dendritic complexity severe hbace1 hbace1happ mice fig 7 f j
0.21784335.16027115.html.plaintext.txt	60	assess extent neurodegenerative alterations hbace1 mice immunolabeling performed antibodies markers neuronal dendritic integrity compared non tg controls fig 6a mice expressing high levels hbace1 displayed shrinkage pyramidal neurons ca3 region hippocampus fig 6b worst alterations seen mice highest expresser line 1 fig 6 b c compared non tg controls fig 6d pyramidal neurons layers 2 3 neocortex also shrunken condensed three hbace1 tg lines fig 6 e f contrast normal labeling neurites antibodies neurofilament fig 6g map2 fig 6j non tg controls axonal dendritic processes pyramidal neurons hbace1 mice diminished disrupted vacuolized fig 6 h k alterations prominent 12 months fig 6 l detectable albeit lesser extent 3 6 months age shown 12 months age neurodegenerative alterations hbace1 tg mice associated reactive astrocytosis fig 6n observed non tg controls fig 6 m o contrast non tg littermate controls fig 6p hbace1 mice line 1 showed collapsed neuronal cytoplasm accumulations electrodense material extensive vacuolization dendritic arbors fig 6q wide spread degeneration axonal processes splinting disorganization myelin laminations fig 6r significant loss alterations neuritic structures also detected happ singly tg mice hbace1 mice hbace1happ mice considerable damage also ca3 region hippocampus fig 7 compared non tg controls fig 7a happ fig 7b hbace1 fig 7c mice reduced levels map2 immunoreactivity frontal cortex alteration even prominent hbace1happ mice fig 7e ca3 region hippocampus three tg groups showed loss dendritic complexity severe hbace1 hbace1happ mice fig 7 f j
0.21784335.16027115.html.plaintext.txt	61	discussion top abstract introduction experimental procedures results discussion references present study demonstrates increased activity hbace1 neurons tg mice sufficient elicit profound alterations app metabolism neurological deficits neurodegeneration although bace1 required generation high levels neuronal hbace1 activity decreased rather increased levels hbace1happ mice compared happ singly tg mice suggesting main mediator increased neuronal deficits identified doubly tg mice app deficient mice 33 34 show neurological neuropathological alterations observed several lines hbace1 tg mice also unlikely decrease fl secretase processed app accounts neuronal deficits seen hbace1 tg mice likelier pathogenic mechanism involves accumulation app ctfs andor mismetabolism alternative hbace1 substrates
0.21784335.16027115.html.plaintext.txt	62	discussion top abstract introduction experimental procedures results discussion references present study demonstrates increased activity hbace1 neurons tg mice sufficient elicit profound alterations app metabolism neurological deficits neurodegeneration although bace1 required generation high levels neuronal hbace1 activity decreased rather increased levels hbace1happ mice compared happ singly tg mice suggesting main mediator increased neuronal deficits identified doubly tg mice app deficient mice 33 34 show neurological neuropathological alterations observed several lines hbace1 tg mice also unlikely decrease fl secretase processed app accounts neuronal deficits seen hbace1 tg mice likelier pathogenic mechanism involves accumulation app ctfs andor mismetabolism alternative hbace1 substrates
0.21784335.16027115.html.plaintext.txt	63	hbace1 cleaves app two sites generating classical c terminal stub c99 alternative c89 fragment 15 35 although current research ad focused potential neurotoxic effects app ctfs also shown deleterious effects example primary neuronal cultures accumulation c99 fragment promotes apoptosis 36 tg mice overexpressing ctfs neurons develop hippocampal degeneration well deficits memory long term potentiation 36 39
0.21784335.16027115.html.plaintext.txt	64	hbace1 cleaves app two sites generating classical c terminal stub c99 alternative c89 fragment 15 35 although current research ad focused potential neurotoxic effects app ctfs also shown deleterious effects example primary neuronal cultures accumulation c99 fragment promotes apoptosis 36 tg mice overexpressing ctfs neurons develop hippocampal degeneration well deficits memory long term potentiation 36 39
0.21784335.16027115.html.plaintext.txt	65	view larger version 135k figure 6 neuropathological ultrastructural alterations brains hbace1 tg mice vibratome sections 6 month old mice either stained cresyl violet f immunostained antibodies neurofilaments g map2 j l gfap m o processed electron microscopy p r b representative images hippocampus d o images neocortex non tg hbace1 tg line 1 mice b neuronal shrinkage degeneration arrows ca3 region hbace1 tg mouse c quantitative assessment cell density ca3 revealing significant loss neurons mice lines 1 2 n 6 micegroup d e neuronal shrinkage degeneration arrows layers ii iii fronto parietal region hbace1 tg mouse f quantitative assessment cell density neocortex revealing significant loss neurons mice line 1 n 6 micegroup g h loss phosphorylated high intermediate molecular mass neurofilaments hbace1 tg mouse revealed immunostaining smi312 mouse monoclonal bright field microscopy quantitation smi312 immunoreactivity showing significant decrease three lines hbace1 tg mice n 6 micegroup j k alterations map2 positive neuronal dendritic structures hbace1 tg mouse demonstrated lscm l quantitative assessment percent area neocortex occupied map2 immunoreactive dendrites neocortex revealing significant losses lines hbace1 tg mice n 6 micegroup m n reactive astrocytosis hbace1 tg mouse revealed gfap immunostaining bright field microscopy o quantitation gfap immunoreactivity neocortex showing significant increase hbace1 tg mice line 1 n 6 micegroup p ultrastructural analysis demonstrating well preserved neuronal n dendritic axonal structures non tg mouse q contrast hbace1 tg mouse line 1 showed considerable neuronal shrinkage condensation vacuolization dendrites d r axon hbace1 mouse showing thinning degeneration myelin sheaths bars 25 microma b d e g h m n 15 micromj k 3 micromp q 2 micromr p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	66	view larger version 135k figure 6 neuropathological ultrastructural alterations brains hbace1 tg mice vibratome sections 6 month old mice either stained cresyl violet f immunostained antibodies neurofilaments g map2 j l gfap m o processed electron microscopy p r b representative images hippocampus d o images neocortex non tg hbace1 tg line 1 mice b neuronal shrinkage degeneration arrows ca3 region hbace1 tg mouse c quantitative assessment cell density ca3 revealing significant loss neurons mice lines 1 2 n 6 micegroup d e neuronal shrinkage degeneration arrows layers ii iii fronto parietal region hbace1 tg mouse f quantitative assessment cell density neocortex revealing significant loss neurons mice line 1 n 6 micegroup g h loss phosphorylated high intermediate molecular mass neurofilaments hbace1 tg mouse revealed immunostaining smi312 mouse monoclonal bright field microscopy quantitation smi312 immunoreactivity showing significant decrease three lines hbace1 tg mice n 6 micegroup j k alterations map2 positive neuronal dendritic structures hbace1 tg mouse demonstrated lscm l quantitative assessment percent area neocortex occupied map2 immunoreactive dendrites neocortex revealing significant losses lines hbace1 tg mice n 6 micegroup m n reactive astrocytosis hbace1 tg mouse revealed gfap immunostaining bright field microscopy o quantitation gfap immunoreactivity neocortex showing significant increase hbace1 tg mice line 1 n 6 micegroup p ultrastructural analysis demonstrating well preserved neuronal n dendritic axonal structures non tg mouse q contrast hbace1 tg mouse line 1 showed considerable neuronal shrinkage condensation vacuolization dendrites d r axon hbace1 mouse showing thinning degeneration myelin sheaths bars 25 microma b d e g h m n 15 micromj k 3 micromp q 2 micromr p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	67	view larger version 52k figure 7 neurodegenerative alterations hbace1happ tg mice sections brains 6 month old mice immunolabeled antibody map2 mouse monoclonal imaged lscm d frontal cortex f hippocampus hipp although neurons dendrites well preserved non tg controls f evidence neurodegeneration happ tg b g hbace1 tg c h mice neurodegenerative alterations even severe hbace1happ tg mice d e j quantitation percent area neuropil covered map2 immunoreactive dendrites revealed significant depletion map2 positive neuronal structures hbace1 tg lines bar 15 microm p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	68	view larger version 52k figure 7 neurodegenerative alterations hbace1happ tg mice sections brains 6 month old mice immunolabeled antibody map2 mouse monoclonal imaged lscm d frontal cortex f hippocampus hipp although neurons dendrites well preserved non tg controls f evidence neurodegeneration happ tg b g hbace1 tg c h mice neurodegenerative alterations even severe hbace1happ tg mice d e j quantitation percent area neuropil covered map2 immunoreactive dendrites revealed significant depletion map2 positive neuronal structures hbace1 tg lines bar 15 microm p 005 versus non tg controls dunnetts test
0.21784335.16027115.html.plaintext.txt	69	increased activity hbace1 led increase levels app ctfs hbace1 mice hbace1happ mice consistent previous observations 19 21 40 41 moreover levels app ctfs different lines hbace1 mice related extent neurological neuropathological alterations highest levels app ctfs found severely impaired line 1 although previous studies 19 21 40 41 shown increase c99 c89 decrease c83 present study found significant increase levels c89 whereas c83 levels decreased suggests model app processing may occur preferentially cleavage site 15 35 interestingly despite overall increase c99 c89 previous studies levels c99 p decreased significantly hbace1happ mice decrease c 99 phosphorylation apparent mice expressing higher levels hbace1 19 compared happ tg mice hbace1happ mice showed lower levels c99 c99 p decreased hbace1 overexpression phosphorylation app post translational modification necessary maturation axonal transport c99 42 43 decrease c99 p indicates app cleavage hbace1happ mice might occur early compartments 19
0.21784335.16027115.html.plaintext.txt	70	increased activity hbace1 led increase levels app ctfs hbace1 mice hbace1happ mice consistent previous observations 19 21 40 41 moreover levels app ctfs different lines hbace1 mice related extent neurological neuropathological alterations highest levels app ctfs found severely impaired line 1 although previous studies 19 21 40 41 shown increase c99 c89 decrease c83 present study found significant increase levels c89 whereas c83 levels decreased suggests model app processing may occur preferentially cleavage site 15 35 interestingly despite overall increase c99 c89 previous studies levels c99 p decreased significantly hbace1happ mice decrease c 99 phosphorylation apparent mice expressing higher levels hbace1 19 compared happ tg mice hbace1happ mice showed lower levels c99 c99 p decreased hbace1 overexpression phosphorylation app post translational modification necessary maturation axonal transport c99 42 43 decrease c99 p indicates app cleavage hbace1happ mice might occur early compartments 19
0.21784335.16027115.html.plaintext.txt	71	high levels hbace1 app ctfs hbace1happ mice associated decreased levels human a1 x a1 42 determined highly quantitative elisa measurements results consistent recent study 19 differ results obtained hbace1happ models 20 21 40 41 several factors might account differences including genetic background mice analyzed however critical factor determining effects hbace1 activity might levels hbace1 transgene expression 19 although low intermediate levels hbace1 expression enhanced amyloid production deposition doubly tg mice higher levels hbace1 expression reduced production presumably high levels hbace1 activity shifted subcellular location app cleavage neuronal cell body early secretory pathway resulting depletion mature app p trans golgi compartment 19 thus lesser amount app might targeted distal axon would preclude secretase mediated generation synaptic sites
0.21784335.16027115.html.plaintext.txt	72	high levels hbace1 app ctfs hbace1happ mice associated decreased levels human a1 x a1 42 determined highly quantitative elisa measurements results consistent recent study 19 differ results obtained hbace1happ models 20 21 40 41 several factors might account differences including genetic background mice analyzed however critical factor determining effects hbace1 activity might levels hbace1 transgene expression 19 although low intermediate levels hbace1 expression enhanced amyloid production deposition doubly tg mice higher levels hbace1 expression reduced production presumably high levels hbace1 activity shifted subcellular location app cleavage neuronal cell body early secretory pathway resulting depletion mature app p trans golgi compartment 19 thus lesser amount app might targeted distal axon would preclude secretase mediated generation synaptic sites
0.21784335.16027115.html.plaintext.txt	73	factors may result degeneration neurons high levels bace1 activity recent evidence suggests toxicity ctfs may mediated caspase generated c terminal c31 fragment 44 45 therefore interesting test whether preventing generation c31 prevents neurodegeneration hbace1happ mice similar vein expression hbace1 mapp deficient mice might reveal app independent mechanisms hbace1 induced neurotoxicity conceivably increased bace1 activity might trigger neurodegeneration cleavage substrates app example vitro 12 vivo 46 bace1 cleaves st6gal sialyltransferase whose cleavage product secreted recently shown bace1 also cleaves subunits voltage gated sodium channels 47 increased levels hbace1 activity could broaden substrate specificity enzyme tg mice humans ad
0.21784335.16027115.html.plaintext.txt	74	factors may result degeneration neurons high levels bace1 activity recent evidence suggests toxicity ctfs may mediated caspase generated c terminal c31 fragment 44 45 therefore interesting test whether preventing generation c31 prevents neurodegeneration hbace1happ mice similar vein expression hbace1 mapp deficient mice might reveal app independent mechanisms hbace1 induced neurotoxicity conceivably increased bace1 activity might trigger neurodegeneration cleavage substrates app example vitro 12 vivo 46 bace1 cleaves st6gal sialyltransferase whose cleavage product secreted recently shown bace1 also cleaves subunits voltage gated sodium channels 47 increased levels hbace1 activity could broaden substrate specificity enzyme tg mice humans ad
0.21784335.16027115.html.plaintext.txt	75	indeed recent studies identified increased levels hbace1 immunoreactivity app ctfs ad brains 14 17 suggesting increased bace1 activity may causally involved also pathogenesis ad current study supports extends notion demonstrating increased neuronal hbace1 activity cause progressive neurodegenerative alterations vivo whereas inhibiting secretase alter secretase processing decreases production increases accumulation app ctfs 48 49 inhibiting bace1 may block dependent independent pathogenic mechanisms ad
0.21784335.16027115.html.plaintext.txt	76	indeed recent studies identified increased levels hbace1 immunoreactivity app ctfs ad brains 14 17 suggesting increased bace1 activity may causally involved also pathogenesis ad current study supports extends notion demonstrating increased neuronal hbace1 activity cause progressive neurodegenerative alterations vivo whereas inhibiting secretase alter secretase processing decreases production increases accumulation app ctfs 48 49 inhibiting bace1 may block dependent independent pathogenic mechanisms ad
0.21784335.16027115.html.plaintext.txt	77	footnotes work supported national institutes health grants ag18440 ag10869 ag5131 ag022074 costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.21784335.16027115.html.plaintext.txt	78	footnotes work supported national institutes health grants ag18440 ag10869 ag5131 ag022074 costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.21784335.16027115.html.plaintext.txt	79	1 correspondence addressed dept neurosciences university california san diego 9500 gilman dr la jolla ca 92093 0624 tel 858 534 8992 fax 858 534 6232 e mail emasliahatucsdedu u d
0.21784335.16027115.html.plaintext.txt	80	1 correspondence addressed dept neurosciences university california san diego 9500 gilman dr la jolla ca 92093 0624 tel 858 534 8992 fax 858 534 6232 e mail emasliahatucsdedu u d
0.21784335.16027115.html.plaintext.txt	81	2 abbreviations used ad alzheimer disease peptide amyloid peptide anova analysis variance app amyloid precursor protein bace1 site app cleaving enzyme ctf c terminal fragment elisa enzyme linked immunosorbent assay fitc fluorescein isothiocyanate fl full length fret fluorescence resonance energy transfer gfap glial fibrillary acidic protein h human ide insulin degrading enzyme lscm laser scanning confocal microscopy m mouse map2 microtubule associated protein 2 mbp maltose binding protein p phosphorylated rpa ribonuclease protection assay sw swedish tg transgenic tricine n 2 hydroxy 11 bishydroxymethylethylglycine
0.21784335.16027115.html.plaintext.txt	82	acknowledgments thank dr h van der putten providing mthy1 cassette dr e koo ct15 antibody dr lisa mcconlogue hbace antibody activity assay dr p seubert 8e5 antibody
0.21784335.16027115.html.plaintext.txt	83	references top abstract introduction experimental procedures results discussion references sinha anderson j john v mcconlogue l basi g thorsett e schenk d 2000 ann n y acad sci 920 206 208free full text kamenetz f tomita hsieh h seabrook g borchelt d iwatsubo sisodia malinow r 2003 neuron 37 925 937crossrefmedline order article via infotrieve selkoe d j schenk d 2003 annu rev pharmacol toxicol 43 545 584crossrefmedline order article via infotrieve selkoe d j 1999 nature 399 suppl 6738 abstr 23 31crossref sinha anderson j p barbour r basi g caccavello r davis d doan m dovey h f frigon n hong j jacobson croak k jewett n keim p knops j lieberburg power m tan h tatsuno g tung j schenk d seubert p suomensaari m wang walker d john v 1999 nature 402 537 540crossrefmedline order article via infotrieve vassar r bennett b d babu khan kahn mendiaz e denis p teplow d b ross amarante p loeloff r luo y fisher fuller j edenson lile j jarosinski m biere l curran e burgess louis j c collins f treanor j rogers g citron m 1999 science 286 735 741abstractfree full text cai h wang y mccarthy d wen h borchelt d r price d l wong p c 2001 nat neurosci 4 233 234crossrefmedline order article via infotrieve luo y bolon b kahn bennett b d babu khan denis p fan w kha h zhang j gong y martin l louis j c yan q richards w g citron m vassar r 2001 nat neurosci 4 231 232crossrefmedline order article via infotrieve citron m 2002 neurobiol aging 23 1017 1022crossrefmedline order article via infotrieve xia w m wolfe m 2003 j cell sci 116 2839 2844abstractfree full text asai m hattori c szabo b sasagawa n maruyama k tanuma ishiura 2003 biochem biophys res commun 301 231 235crossrefmedline order article via infotrieve kitazume tachida y oka r shirotani k saido c hashimoto y 2001 proc natl acad sci u 98 13554 13559abstractfree full text kirschling c m kolsch h frahnert c rao m l maier w heun r 2003 neuroreport 14 1243 1246crossrefmedline order article via infotrieve holsinger r m mclean c beyreuther k masters c l evin g 2002 ann neurol 51 783 786crossrefmedline order article via infotrieve huse j liu k pijak d carlin d lee v m doms r w 2002 j biol chem 277 16278 16284abstractfree full text rossner apelt j schliebs r perez polo j r bigl v 2001 j neurosci res 64 437 446crossrefmedline order article via infotrieve fukumoto h cheung b hyman b irizarry m c 2002 arch neurol 59 1381 1389abstractfree full text li r lindholm k yang l b yue x citron m yan r beach sue l sabbagh m cai h wong p price d shen y 2004 proc natl acad sci u 101 3632 3637abstractfree full text lee e b zhang b liu k greenbaum e doms r w trojanowski j q lee v m 2005 j cell biol 168 291 302abstractfree full text bodendorf u danner fischer f stefani m sturchler pierrat c wiederhold k h staufenbiel m paganetti p 2002 j neurochem 80 799 806crossrefmedline order article via infotrieve chiocco m j kulnane l younkin l younkin evin g lamb b 2004 j biol chem 279 52535 52542abstractfree full text harrison m harper j hawkins j duddy g grau e pugh p l winter p h shilliam c hughes z dawson l gonzalez m upton n pangalos m n dingwall c 2003 mol cell neurosci 24 646 655crossrefmedline order article via infotrieve rockenstein e mallory m hashimoto m song d shults c w lang masliah e 2002 j neurosci res 68 568 578crossrefmedline order article via infotrieve rockenstein e mcconlogue l tan h power m masliah e mucke l 1995 j biol chem 270 28257 28267abstractfree full text demattos r b bales k r cummins d j dodart j c paul m holtzman d m 2001 proc natl acad sci u 98 8850 8855abstractfree full text johnson wood k lee m motter r hu k gordon g barbour r khan k gordon m tan h games d lieberburg schenk d seubert p mcconlogue l 1997 proc natl acad sci u 94 1550 1555abstractfree full text roberds l anderson j basi g bienkowski m j branstetter d g chen k freedman b frigon n l games d hu k johnson wood k kappenman k e kawabe kola kuehn r lee m liu w motter r nichols n f power m robertson d w schenk d schoor m shopp g m shuck m e sinha svensson k tatsuno g tintrup h wijsman j wright mcconlogue l 2001 hum mol genet 10 1317 1324abstractfree full text masliah e rockenstein e veinbergs sagara y mallory m hashimoto m mucke l 2001 proc natl acad sci u 98 12245 12250abstractfree full text mucke l yu g q mcconlogue l rockenstein e m abraham c r masliah e 2000 j pathol 157 2003 2010abstractfree full text mucke l masliah e yu g q mallory m rockenstein e m tatsuno g hu k kholodenko d johnson wood k mcconlogue l 2000 j neurosci 20 4050 4058abstractfree full text rockenstein e mallory m mante m sisk masliah e 2001 j neurosci res 66 573 582crossrefmedline order article via infotrieve oltersdorf ward p j henriksson beattie e c neve r lieberburg fritz l c 1990 j biol chem 265 4492 4497abstractfree full text zheng h jiang m trumbauer m e hopkins r sirinathsinghji d j stevens k conner m w slunt h h sisodia chen h y van der ploeg l h 1996 ann n y acad sci 777 421 426abstract masliah e rockenstein e 2000 j neural transm suppl 59 175 183medline order article via infotrieve huse j pijak d leslie g j lee v m doms r w 2000 j biol chem 275 33729 33737abstractfree full text kim h park c h cha h lee j h lee kim y rah j c jeong j suh y h 2000 faseb j 14 1508 1517abstractfree full text song d k won m h jung j lee j c kang c suh h w huh o paek h kim y h kim h suh y h 1998 j neurochem 71 875 878medline order article via infotrieve oster granite m mcphie d greenan j neve r 1996 j neurosci 16 6732 6741abstractfree full text berger sweeney j mcphie d l arters j greenan j oster granite m l neve r l 1999 mol brain res 66 150 162crossrefmedline order article via infotrieve mohajeri m h saini k d nitsch r m 2004 j neural transm 111 413 425crossref willem m dewachter smyth n van dooren borghgraef p haass c van leuven f 2004 j pathol 165 1621 1631abstractfree full text ando k oishi m takeda iijima k isohara nairn c kirino y greengard p suzuki 1999 j neurosci 19 4421 4427abstractfree full text iijima k ando k takeda satoh y seki itohara greengard p kirino y nairn c suzuki 2000 j neurochem 75 1085 1091crossrefmedline order article via infotrieve koo e lansbury p j kelly j 1999 proc natl acad sci u 96 9989 9990free full text bredesen d 1995 ann neurol 38 839 851crossrefmedline order article via infotrieve kitazume nakagawa k oka r tachida y ogawa k luo y citron m shitara h taya c yonekawa h paulson j c miyoshi e taniguchi n hashimoto y 2005 j biol chem 280 8589 8595abstractfree full text wong h k sakurai oyama f kaneko k wada k miyazaki h kurosawa m de strooper b saftig p nukina n 2005 j biol chem 280 23009 23017abstractfree full text anderson j j holtz g baskin p p turner m rowe b wang b kounnas m z lamb b barten d felsenstein k mcdonald srinivasan k munoz b wagner l 2005 biochem pharmacol 69 689 698crossrefmedline order article via infotrieve durkin j murthy husten e j trusko p savage m j rotella d p greenberg b d siman r 1999 j biol chem 274 20499 20504abstractfree full text hussain powell d howlett d r tew d g meek d chapman c gloger murphy k e southan c d ryan d m smith simmons d l walsh f dingwall c christie g 1999 mol cell neurosci 14 419 427crossrefmedline order article via infotrieve sisodia koo e beyreuther k unterbeck price d 1990 science 248 492 494medline order article via infotrieve sisodia koo e hoffman p perry g price d 1993 j neurosci 13 3136 3142abstract weidemann konig g bunke d fischer p salbaum j masters c beyreuther k 1989 cell 57 115 126crossrefmedline order article via infotrieve koo e sisodia archer d martin l weidemann beyreuther k fischer p masters c price d 1990 proc natl acad sci u 87 1561 1565abstractfree full text kim k miller d sapienza v 1988 neurosci res commun 2 121 130 kim k wen g bancher c 1990 neurosci res commun 7 113 122 jung gauthier cashman n r 1999 neurobiol aging 20 249 257crossrefmedline order article via infotrieve seubert p vigo pelfrey c esch f lee m dovey h davis d sinha schlossmacher m whaley j swindlehurst c mccormack r wolfert r selkoe d lieberburg schenk d 1992 nature 359 325 327crossrefmedline order article via infotrieve muresan z muresan v 2004 hum mol genet 13 475 488abstractfree full text
0.21941808.16055825.html.plaintext.txt	0	brief psychotherapy alzheimers disease randomised controlled trial alistair burns md frcp frcpsych
0.21941808.16055825.html.plaintext.txt	1	department psychiatry wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	2	department psychiatry manchester royal infirmary manchester
0.21941808.16055825.html.plaintext.txt	3	federica marino francis charlotte busby mrcpsych
0.21941808.16055825.html.plaintext.txt	4	department psychiatry wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	5	department medical statistics wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	6	eve russell md mrcpsych frank margison frcpsych sean lennon frcpsych jane byrne frcpsych
0.21941808.16055825.html.plaintext.txt	7	department psychiatry wythenshawe hospital manchester uk
0.21941808.16055825.html.plaintext.txt	8	correspondence professor alistair burns department psychiatry 2nd floor education research centre wythenshawe hospital southmoor road manchester m23 9lt uk tel 44 0161 291 5887 fax 44 0161 291 5882 e mail alistairburnsatmanchesteracuk
0.21941808.16055825.html.plaintext.txt	9	correspondence professor alistair burns department psychiatry 2nd floor education research centre wythenshawe hospital southmoor road manchester m23 9lt uk tel 44 0161 291 5887 fax 44 0161 291 5882 e mail alistairburnsatmanchesteracuk
0.21941808.16055825.html.plaintext.txt	10	abstract top abstract introduction method results discussion clinical implications acknowledgments references background although good evidence interventions carers people alzheimers disease reduce stress systematic studies investigated psychotherapeutic intervention patients may important earlier stages alzheimers disease insight often preserved
0.21941808.16055825.html.plaintext.txt	11	aims aim assess randomised controlled trial whether psychotherapeutic intervention could benefit cognitive function affective symptoms global well
0.21941808.16055825.html.plaintext.txt	12	method individuals randomised receive six sessions psychodynamic interpersonal therapy treatment usual cognitive function activities daily living global measure change carer stress coping assessed prior intervention
0.21941808.16055825.html.plaintext.txt	13	results improvement found majority outcome measures suggestion therapy improved carers reactions symptoms
0.21941808.16055825.html.plaintext.txt	14	results improvement found majority outcome measures suggestion therapy improved carers reactions symptoms
0.21941808.16055825.html.plaintext.txt	15	conclusions evidence support widespread introduction brief psychotherapeutic approaches alzheimers disease however technique acceptable helpful individually
0.21941808.16055825.html.plaintext.txt	16	conclusions evidence support widespread introduction brief psychotherapeutic approaches alzheimers disease however technique acceptable helpful individually
0.21941808.16055825.html.plaintext.txt	17	introduction top abstract introduction method results discussion clinical implications acknowledgments references alzheimers disease devastating terms suffering affected individuals stress carers cost society medication effect symptomatic improvement burns et al 1999 psychological support reduce strain carers mittelman et al 1996 donaldson et al 1997 cognitive behavioural therapy carers reduce carer stress burden behavioural disturbance affected individuals marriott et al 2000 however studies investigated psychotherapeutic intervention directed alzheimers disease early stages disease psychotherapeutic interventions may beneficial insight often preserved psychological adjustment difficult may assume face future inevitable decline denial defence mechanism common affected relatives bahro et al 1997 individual psychodynamic therapy described bahro et al 1997 systematic research cheston 1998 related emotion oriented therapies including validation reminiscence promising woods 2002 cochrane review non drug therapies found benefit reality orientation koger et al 1999 neal briggs 2000 spector et al 2004
0.21941808.16055825.html.plaintext.txt	18	aim study assess randomised controlled trial whether psychotherapeutic approach directed towards individuals alzheimers disease could benefit cognitive function affective symptoms global well
0.21941808.16055825.html.plaintext.txt	19	method top abstract introduction method results discussion clinical implications acknowledgments references design study randomised controlled trial psychodynamic interpersonal therapy compared standard treatment people alzheimers disease independent assessments carried baseline 6 weeks 3 months fig 1 study approved local research ethics committees
0.21941808.16055825.html.plaintext.txt	20	view larger version 15k fig 1 design trial brief psychotherapy alzheimers disease
0.21941808.16055825.html.plaintext.txt	21	view larger version 15k fig 1 design trial brief psychotherapy alzheimers disease
0.21941808.16055825.html.plaintext.txt	22	procedure individuals carers recruited referrals memory clinic south manchester uk inclusion criteria diagnosis alzheimers disease according nincds adrda criteria mckhann et al 1984 clinical dementia rating 1 morris 1993 indicating mild dementia score 15 mini mental state examination folstein et al 1975 living home carer regular contact ability communicate verbally
0.21941808.16055825.html.plaintext.txt	23	procedure individuals carers recruited referrals memory clinic south manchester uk inclusion criteria diagnosis alzheimers disease according nincds adrda criteria mckhann et al 1984 clinical dementia rating 1 morris 1993 indicating mild dementia score 15 mini mental state examination folstein et al 1975 living home carer regular contact ability communicate verbally
0.21941808.16055825.html.plaintext.txt	24	following consent individuals allocated one two groups treatment control using computer generated random numbers organised independently department medical statistics south manchester allocated control group could elect therapeutic sessions study assessments therapeutic interventions conducted individuals homes taking anticholinesterase drugs treatment alzheimers disease psychotropic medication antidepressants clinically stable medications least 2 months prior study entry
0.21941808.16055825.html.plaintext.txt	25	following consent individuals allocated one two groups treatment control using computer generated random numbers organised independently department medical statistics south manchester allocated control group could elect therapeutic sessions study assessments therapeutic interventions conducted individuals homes taking anticholinesterase drugs treatment alzheimers disease psychotropic medication antidepressants clinically stable medications least 2 months prior study entry
0.21941808.16055825.html.plaintext.txt	26	therapeutic interventions treatment group received six sessions psychodynamic interpersonal therapy experienced psychotherapist control group received standard care consisted general advice regarding diagnosis treatment dementia patient review
0.21941808.16055825.html.plaintext.txt	27	therapeutic interventions treatment group received six sessions psychodynamic interpersonal therapy experienced psychotherapist control group received standard care consisted general advice regarding diagnosis treatment dementia patient review
0.21941808.16055825.html.plaintext.txt	28	psychodynamic interpersonal therapy psychodynamic interpersonal therapy formerly known conversational model psychotherapy hobson 1985 used treat wide variety disorders including depression shapiro firth 1987 shapiro et al 1993 somatisation guthrie et al 1991 hamilton et al 2000 self harm guthrie et al 2001 principal aim therapy brief format identification interpersonal conflicts difficulties causing helping maintain emotional distress client therapist work together find test solutions problems intrapsychic practical changes encouraged
0.21941808.16055825.html.plaintext.txt	29	psychodynamic interpersonal therapy psychodynamic interpersonal therapy formerly known conversational model psychotherapy hobson 1985 used treat wide variety disorders including depression shapiro firth 1987 shapiro et al 1993 somatisation guthrie et al 1991 hamilton et al 2000 self harm guthrie et al 2001 principal aim therapy brief format identification interpersonal conflicts difficulties causing helping maintain emotional distress client therapist work together find test solutions problems intrapsychic practical changes encouraged
0.21941808.16055825.html.plaintext.txt	30	adaptation technique therapy adapted people alzheimers disease full details available elsewhere brierley et al 2003 main adaptations included delivery individuals home involving carer treatment four specific psychological areas targeted autobiographical narrative used strengthen self worth important past conflicts resonated current difficulties explored resolved illness discussed emphasis placed improving social interpersonal relationships including emphasising role partner addition individual therapy therapist spent 10 min session carer listening carers needs informing carer therapeutic progress
0.21941808.16055825.html.plaintext.txt	31	adaptation technique therapy adapted people alzheimers disease full details available elsewhere brierley et al 2003 main adaptations included delivery individuals home involving carer treatment four specific psychological areas targeted autobiographical narrative used strengthen self worth important past conflicts resonated current difficulties explored resolved illness discussed emphasis placed improving social interpersonal relationships including emphasising role partner addition individual therapy therapist spent 10 min session carer listening carers needs informing carer therapeutic progress
0.21941808.16055825.html.plaintext.txt	32	implementation technique psychotherapy sessions lasted 50 min psychotherapy summarised manual shapiro firth 1987 treatment fidelity ensured regular supervision using audiotapes one session individual therapy rated adherence model using sheffield psychotherapy rating scale shapiro startup 1993 scale allows sessions rated according three main subscales one psychodynamic interpersonal therapy one cognitive behavioural therapy one generic aspects psychotherapy intervention showed high scores psychodynamic interpersonal therapy generic sub scales low scores cognitive behavioural therapy scale confirming adherence model
0.21941808.16055825.html.plaintext.txt	33	implementation technique psychotherapy sessions lasted 50 min psychotherapy summarised manual shapiro firth 1987 treatment fidelity ensured regular supervision using audiotapes one session individual therapy rated adherence model using sheffield psychotherapy rating scale shapiro startup 1993 scale allows sessions rated according three main subscales one psychodynamic interpersonal therapy one cognitive behavioural therapy one generic aspects psychotherapy intervention showed high scores psychodynamic interpersonal therapy generic sub scales low scores cognitive behavioural therapy scale confirming adherence model
0.21941808.16055825.html.plaintext.txt	34	assessments patients following assessments carried start therapy end therapy 6 weeks recruitment 3 months follow
0.21941808.16055825.html.plaintext.txt	35	cornell scale depression dementia 19 item scale assessing depressive symptoms people dementia alexopoulos et al 1988 rated three point scale absent mild intermittent severe score 8 indicative significant depressive symptoms
0.21941808.16055825.html.plaintext.txt	36	cornell scale depression dementia 19 item scale assessing depressive symptoms people dementia alexopoulos et al 1988 rated three point scale absent mild intermittent severe score 8 indicative significant depressive symptoms
0.21941808.16055825.html.plaintext.txt	37	mini mental state examination 30 item measure cognitive function maximum score 30 points folstein et al 1975 normally takes 5 10 min complete
0.21941808.16055825.html.plaintext.txt	38	mini mental state examination 30 item measure cognitive function maximum score 30 points folstein et al 1975 normally takes 5 10 min complete
0.21941808.16055825.html.plaintext.txt	39	revised memory behavior problems checklist 24 item questionnaire rating frequency behavioural problems dementia intensity reactions carers teri et al 1992 frequency reaction rated six point scale
0.21941808.16055825.html.plaintext.txt	40	revised memory behavior problems checklist 24 item questionnaire rating frequency behavioural problems dementia intensity reactions carers teri et al 1992 frequency reaction rated six point scale
0.21941808.16055825.html.plaintext.txt	41	bristol activities daily living scale 20 item questionnaire rated carer 10 15 min bucks et al 1996 twenty areas daily activities rated five point scale problem severe problems
0.21941808.16055825.html.plaintext.txt	42	bristol activities daily living scale 20 item questionnaire rated carer 10 15 min bucks et al 1996 twenty areas daily activities rated five point scale problem severe problems
0.21941808.16055825.html.plaintext.txt	43	assessments carers general health questionnaire 12 item self report questionnaire assess psychological distress psychiatric morbidity goldberg williams 1985 completed 5 min less item rated four point scale
0.21941808.16055825.html.plaintext.txt	44	assessments carers general health questionnaire 12 item self report questionnaire assess psychological distress psychiatric morbidity goldberg williams 1985 completed 5 min less item rated four point scale
0.21941808.16055825.html.plaintext.txt	45	beck depression inventory 21 item self report questionnaire assess depression respondent beck et al 1961 normally takes 10 20 min complete item scored 0 3 total score derived total score 12 suggests presence depression
0.21941808.16055825.html.plaintext.txt	46	beck depression inventory 21 item self report questionnaire assess depression respondent beck et al 1961 normally takes 10 20 min complete item scored 0 3 total score derived total score 12 suggests presence depression
0.21941808.16055825.html.plaintext.txt	47	ways coping checklist 42 item self report questionnaire assess carers coping strategies vitaliano et al 1985 normally takes 15 20 min complete rated four point scale applicable much used
0.21941808.16055825.html.plaintext.txt	48	ways coping checklist 42 item self report questionnaire assess carers coping strategies vitaliano et al 1985 normally takes 15 20 min complete rated four point scale applicable much used
0.21941808.16055825.html.plaintext.txt	49	global assessment clinicians interview based global impression change seven point scale used researcher external supervisor detect change patients 6 week 3 month follow guy 1976 scale goes much improved much worse rating completed following discussion research assistant fm f senior clinician ab masked group membership treatment control
0.21941808.16055825.html.plaintext.txt	50	global assessment clinicians interview based global impression change seven point scale used researcher external supervisor detect change patients 6 week 3 month follow guy 1976 scale goes much improved much worse rating completed following discussion research assistant fm f senior clinician ab masked group membership treatment control
0.21941808.16055825.html.plaintext.txt	51	20 individuals took part treatment arm study completed satisfaction survey four statements presented patients asked reply
0.21941808.16055825.html.plaintext.txt	52	20 individuals took part treatment arm study completed satisfaction survey four statements presented patients asked reply
0.21941808.16055825.html.plaintext.txt	53	statistical analysis randomisation calculation sample size analyses used intention treat principle effect intervention assessed comparing changes mean scores time continuous variables using analyses covariance baseline scores age covariants scores required natural logarithmic transformation prior analysis produce satisfactory approximation normal distribution scores geometric means detransformed log means presented rather simple arithmetic means chi squared tests appropriate performed categorical measures
0.21941808.16055825.html.plaintext.txt	54	statistical analysis randomisation calculation sample size analyses used intention treat principle effect intervention assessed comparing changes mean scores time continuous variables using analyses covariance baseline scores age covariants scores required natural logarithmic transformation prior analysis produce satisfactory approximation normal distribution scores geometric means detransformed log means presented rather simple arithmetic means chi squared tests appropriate performed categorical measures
0.21941808.16055825.html.plaintext.txt	55	current data upon base power calculation previous study marriott et al 2000 group sizes 14 sufficient detect statistically significant difference based data allowed withdrawal rate 20 chose recruit 20 individuals group part rationale pilot study obtain normative data calculate sample size definitive study
0.21941808.16055825.html.plaintext.txt	56	current data upon base power calculation previous study marriott et al 2000 group sizes 14 sufficient detect statistically significant difference based data allowed withdrawal rate 20 chose recruit 20 individuals group part rationale pilot study obtain normative data calculate sample size definitive study
0.21941808.16055825.html.plaintext.txt	57	results top abstract introduction method results discussion clinical implications acknowledgments references study groups fifty three consecutive referrals memory clinic south manchester satisfied inclusion criteria approached take part study 13 refused leaving 40 people enrolled common reasons refusal potential upset therapeutic sessions could cause already taken part research projects
0.21941808.16055825.html.plaintext.txt	58	table 1 describes study groups main results assessments 20 people recruited group commonly spouse cared patient 25 treatment group 15 control group antidepressants approximately two thirds group one anticholinesterase drugs alzheimers disease participants completed study follow
0.21941808.16055825.html.plaintext.txt	59	table 1 describes study groups main results assessments 20 people recruited group commonly spouse cared patient 25 treatment group 15 control group antidepressants approximately two thirds group one anticholinesterase drugs alzheimers disease participants completed study follow
0.21941808.16055825.html.plaintext.txt	60	view table table 1 participants characteristics participant carer assessments baseline 6 week 3 month follow
0.21941808.16055825.html.plaintext.txt	61	significant differences course study outcome measures patients including ratings cornell scale mini mental state examination activities daily living scale global rating outcome measures carers changes course study general health questionnaire beck depression inventory trend towards slight improvement carers reaction behavioural problems section 2 ways coping checklist showed significant decline p 005 section rates carers interaction people aid coping
0.21941808.16055825.html.plaintext.txt	62	significant differences course study outcome measures patients including ratings cornell scale mini mental state examination activities daily living scale global rating outcome measures carers changes course study general health questionnaire beck depression inventory trend towards slight improvement carers reaction behavioural problems section 2 ways coping checklist showed significant decline p 005 section rates carers interaction people aid coping
0.21941808.16055825.html.plaintext.txt	63	difference ratings patients divided two groups mini mental state examination score 24 however evidence carers less cognitive impairment score 24 benefited treatment blamed less problems section 3 ways coping checklist 3 months mean value 014 compared 035 p0031
0.21941808.16055825.html.plaintext.txt	64	difference ratings patients divided two groups mini mental state examination score 24 however evidence carers less cognitive impairment score 24 benefited treatment blamed less problems section 3 ways coping checklist 3 months mean value 014 compared 035 p0031
0.21941808.16055825.html.plaintext.txt	65	qualitative assessments every participant agreed statement able discuss difficulties counsellor became clear eighty three per cent agreed following three statements find things thinking much cannot helps feel less frustrated although sometimes felt painful talking past felt good get things chest felt calm able talk things difficult talk anyone else
0.21941808.16055825.html.plaintext.txt	66	qualitative assessments every participant agreed statement able discuss difficulties counsellor became clear eighty three per cent agreed following three statements find things thinking much cannot helps feel less frustrated although sometimes felt painful talking past felt good get things chest felt calm able talk things difficult talk anyone else
0.21941808.16055825.html.plaintext.txt	67	positive comments patients included
0.21941808.16055825.html.plaintext.txt	68	able confide talk easy friendly way drew points never realised beneficial dont know counsellor allowed bring things would discussed relatives friends
0.21941808.16055825.html.plaintext.txt	69	able confide talk easy friendly way drew points never realised beneficial dont know counsellor allowed bring things would discussed relatives friends
0.21941808.16055825.html.plaintext.txt	70	comments carers included
0.21941808.16055825.html.plaintext.txt	71	provided opportunity discuss problems attached full time carer husband b also made feel less guilty making time home c husband said enjoyed talking gone forgot afterwards would coming c chance discuss openly wifes problem
0.21941808.16055825.html.plaintext.txt	72	provided opportunity discuss problems attached full time carer husband b also made feel less guilty making time home c husband said enjoyed talking gone forgot afterwards would coming c chance discuss openly wifes problem
0.21941808.16055825.html.plaintext.txt	73	20 participants received therapy visited 6 12 months recruitment semi structured open ended interview carried five patients recollection sessions five confirmed found helpful
0.21941808.16055825.html.plaintext.txt	74	20 participants received therapy visited 6 12 months recruitment semi structured open ended interview carried five patients recollection sessions five confirmed found helpful
0.21941808.16055825.html.plaintext.txt	75	discussion top abstract introduction method results discussion clinical implications acknowledgments references main findings study shows possible adapt model psychotherapy alzheimers disease improvement found majority outcome measures participants carers however suggestion therapy improved carers ways coping symptoms disease
0.21941808.16055825.html.plaintext.txt	76	therapist clearly major source support carers patients
0.21941808.16055825.html.plaintext.txt	77	rationale trial chose target area received relatively little attention alzheimers disease traditional therapies tended pharmacological nature targeting either cognitive non cognitive symptoms tariot 1999 non pharmacological interventions aside behavioural techniques allen burge et al 1999 concentrated carers psychological approaches proven benefit reducing carer strain marriott et al 2000 far aware first randomised controlled trial psychotherapeutic intervention people alzheimers disease using standardised outcome measures psychotherapeutic approach determined following pilot study adapted individual needs participants model dictates joint sessions participants carers merely helped therapist focus symptoms considered important distressing
0.21941808.16055825.html.plaintext.txt	78	rationale trial chose target area received relatively little attention alzheimers disease traditional therapies tended pharmacological nature targeting either cognitive non cognitive symptoms tariot 1999 non pharmacological interventions aside behavioural techniques allen burge et al 1999 concentrated carers psychological approaches proven benefit reducing carer strain marriott et al 2000 far aware first randomised controlled trial psychotherapeutic intervention people alzheimers disease using standardised outcome measures psychotherapeutic approach determined following pilot study adapted individual needs participants model dictates joint sessions participants carers merely helped therapist focus symptoms considered important distressing
0.21941808.16055825.html.plaintext.txt	79	reasons non response finding intervention effect measures reflect core features illness cognitive function activities daily living surprising six sessions provided psychotherapeutic terms low dose treatment may partly explain lack effect addition longer study would needed assess likely benefits terms stabilisation disease beneficial effect carers indicated scores ways coping checklist showed therapy helped carers providing someone talk caring people mild dementia diminished carers sense self blame minimal involvement carers therapy beneficial effect patients inferred improvement global rating well
0.21941808.16055825.html.plaintext.txt	80	reasons non response finding intervention effect measures reflect core features illness cognitive function activities daily living surprising six sessions provided psychotherapeutic terms low dose treatment may partly explain lack effect addition longer study would needed assess likely benefits terms stabilisation disease beneficial effect carers indicated scores ways coping checklist showed therapy helped carers providing someone talk caring people mild dementia diminished carers sense self blame minimal involvement carers therapy beneficial effect patients inferred improvement global rating well
0.21941808.16055825.html.plaintext.txt	81	surprising involvement therapist appeared positive impact accordance experience field important therapy adapted use people cognitive impairment
0.21941808.16055825.html.plaintext.txt	82	surprising involvement therapist appeared positive impact accordance experience field important therapy adapted use people cognitive impairment
0.21941808.16055825.html.plaintext.txt	83	trend towards improvements carer patient outcomes attests potential benefit non pharmacological interventions group future studies area concentrate specifically approaches combine outcomes carers care interdependency aspirations outcomes people alzheimers disease carers emphasised project influence future studies area
0.21941808.16055825.html.plaintext.txt	84	trend towards improvements carer patient outcomes attests potential benefit non pharmacological interventions group future studies area concentrate specifically approaches combine outcomes carers care interdependency aspirations outcomes people alzheimers disease carers emphasised project influence future studies area
0.21941808.16055825.html.plaintext.txt	85	clinical implications limitations top abstract introduction method results discussion clinical implications acknowledgments references clinical implications psychotherapeutic approaches adapted people dementia treatments directed dementia positive effects carers people dementia appreciate psychotherapeutic interventions
0.21941808.16055825.html.plaintext.txt	86	limitations sample size small outcome measures chosen probably sensitive enough measure marginal improvements psychotherapeutic method previously validated older people
0.21941808.16055825.html.plaintext.txt	87	limitations sample size small outcome measures chosen probably sensitive enough measure marginal improvements psychotherapeutic method previously validated older people
0.21941808.16055825.html.plaintext.txt	88	acknowledgments top abstract introduction method results discussion clinical implications acknowledgments references study carried south manchester hospitals nhs trust funded generous donation sir halley stewart trust thank participants carers
0.21941808.16055825.html.plaintext.txt	89	references top abstract introduction method results discussion clinical implications acknowledgments references alexopoulos g abrams r c young r c et al 1988 cornell scale depression dementia biological psychiatry 23 271 284crossrefmedline
0.21941808.16055825.html.plaintext.txt	90	cheston r 1998 psychotherapeutic work people dementia review literature british journal medical psychology 71 211 231medline
0.21941808.16055825.html.plaintext.txt	91	guy w 1976 clinical global impressions ecdeu assessment manual psychopharmacology rockville md national institute mental health
0.21941808.16055825.html.plaintext.txt	92	received publication june 15 2004 revision received october 25 2004 accepted publication november 5 2004
0.21941808.16055825.html.plaintext.txt	93	received publication june 15 2004 revision received october 25 2004 accepted publication november 5 2004
0.21941808.16055825.html.plaintext.txt	94	highlights issue kimberlie dean bjp 2005 187 101 full text
0.22005783.15615772.html.plaintext.txt	0	elevated amyloid ss protein ass42 late onset alzheimers disease associated single nucleotide polymorphisms urokinase type plasminogen activator gene nilufer ertekin taner1 james ronald1 lars feuk3 jonathan prince3 michael tucker45 linda younkin1 maria hella1 shushant jain1 alyssa hackett1 leah scanlin1 jason kelly1 muthoni kihiko ehman45 matthew neltner45 louis hersh5 mark kindy5 william markesbery5 michael hutton1 mariza de andrade6 ronald c petersen7 neill graff radford2 steve estus45 anthony j brookes3 steven g younkin1
0.22005783.15615772.html.plaintext.txt	1	elevated amyloid ss protein ass42 late onset alzheimers disease associated single nucleotide polymorphisms urokinase type plasminogen activator gene nilufer ertekin taner1 james ronald1 lars feuk3 jonathan prince3 michael tucker45 linda younkin1 maria hella1 shushant jain1 alyssa hackett1 leah scanlin1 jason kelly1 muthoni kihiko ehman45 matthew neltner45 louis hersh5 mark kindy5 william markesbery5 michael hutton1 mariza de andrade6 ronald c petersen7 neill graff radford2 steve estus45 anthony j brookes3 steven g younkin1
0.22005783.15615772.html.plaintext.txt	2	1department neuroscience 2department neurology mayo clinic jacksonville 4500 san pablo road jacksonville fl 32224 usa 3center genomics bioinformatics karolinska institute stockholm sweden 4department physiology 5sanders brown center aging university kentucky lexington ky usa 6department health sciences research 7department neurology mayo clinic rochester 200 first street sw rochester mn 55905 usa
0.22005783.15615772.html.plaintext.txt	3	correspondence addressed email younkinstevenatmayoedu
0.22005783.15615772.html.plaintext.txt	4	received june 11 2004 revised october 8 2004 accepted december 10 2004
0.22005783.15615772.html.plaintext.txt	5	abstract top abstract introduction results discussion materials methods references plasma amyloid ss protein ass42 levels late onset alzheimers disease load linked region chromosome 10q plau gene within region encodes urokinase type plasminogen activator converts plasminogen plasmin ass aggregates induce plau expression thereby increasing plasmin degrades aggregated non aggregated forms ass evaluated single nucleotide polymorphisms snps plau association ass42 load plau snp compound genotypes composed haplotype pairs showed significant association ad three independent case control series plau snp haplotypes associated significantly plasma ass42 10 extended load families one snps analyzed missense ct polymorphism exon 6 plau plau1rs2227564 causes proline leucine change p141l analyzed plau1 association ad six case control series 24 extended load families ct tt plau1 genotypes showed association p005 overall estimated odds ratio 12 10 15 ct tt genotypes plau1 also associated significant age dependent elevation plasma ass42 24 extended load families p00006 knockout mice lacking plau gene plasma brain ass42 well ass40 significantly elevated also age dependent manner plau1 associations independent associations found among plasma ass42 load variants ide vr22 region results provide strong evidence plau nearby gene involved development load plau1 plausible pathogenic mutation could act increasing ass42 additional biological experiments required show definitively
0.22005783.15615772.html.plaintext.txt	6	abstract top abstract introduction results discussion materials methods references plasma amyloid ss protein ass42 levels late onset alzheimers disease load linked region chromosome 10q plau gene within region encodes urokinase type plasminogen activator converts plasminogen plasmin ass aggregates induce plau expression thereby increasing plasmin degrades aggregated non aggregated forms ass evaluated single nucleotide polymorphisms snps plau association ass42 load plau snp compound genotypes composed haplotype pairs showed significant association ad three independent case control series plau snp haplotypes associated significantly plasma ass42 10 extended load families one snps analyzed missense ct polymorphism exon 6 plau plau1rs2227564 causes proline leucine change p141l analyzed plau1 association ad six case control series 24 extended load families ct tt plau1 genotypes showed association p005 overall estimated odds ratio 12 10 15 ct tt genotypes plau1 also associated significant age dependent elevation plasma ass42 24 extended load families p00006 knockout mice lacking plau gene plasma brain ass42 well ass40 significantly elevated also age dependent manner plau1 associations independent associations found among plasma ass42 load variants ide vr22 region results provide strong evidence plau nearby gene involved development load plau1 plausible pathogenic mutation could act increasing ass42 additional biological experiments required show definitively
0.22005783.15615772.html.plaintext.txt	7	introduction top abstract introduction results discussion materials methods references previous studies others showed plasma amyloid ss protein ass42 1 late onset alzheimers disease load 2 linked locus 81 cm chromosome 10 together two independent studies provide strong evidence novel alzheimers disease ad risk gene locus acts ass42 urokinase type plasminogen activator gene plau located chromosome 10q21 22 95 cm within 1 lod support interval linkage peak 81 cm urokinase type plasminogen activator serine protease converts plasminogen plasmin 3 plau expression induced ass aggregates plasmin degrades aggregated non aggregated ass vitro possible negative feedback loop thus plau could important role controlling ass aggregation widely believed play important role ad pathogenesis ass major proteinaceous component senile plaques one main pathologic hallmarks ad 4 ass composed 4243 amino acids ass42 present senile plaques ass40 also found cases 5 ass42 shown elevated serum brain cell culture studies performed patients animal models familial ad due known autosomal dominant mutations 6 12 studies also shown elevations ass40 though consistently degree ass42 thus postulated although ass42 ass40 associate one pathogenic hallmarks ad owing consistent prominent presence along biochemical properties greater fibrillogenicity aggregation potential ass42 pathogenic biomarker ad
0.22005783.15615772.html.plaintext.txt	8	introduction top abstract introduction results discussion materials methods references previous studies others showed plasma amyloid ss protein ass42 1 late onset alzheimers disease load 2 linked locus 81 cm chromosome 10 together two independent studies provide strong evidence novel alzheimers disease ad risk gene locus acts ass42 urokinase type plasminogen activator gene plau located chromosome 10q21 22 95 cm within 1 lod support interval linkage peak 81 cm urokinase type plasminogen activator serine protease converts plasminogen plasmin 3 plau expression induced ass aggregates plasmin degrades aggregated non aggregated ass vitro possible negative feedback loop thus plau could important role controlling ass aggregation widely believed play important role ad pathogenesis ass major proteinaceous component senile plaques one main pathologic hallmarks ad 4 ass composed 4243 amino acids ass42 present senile plaques ass40 also found cases 5 ass42 shown elevated serum brain cell culture studies performed patients animal models familial ad due known autosomal dominant mutations 6 12 studies also shown elevations ass40 though consistently degree ass42 thus postulated although ass42 ass40 associate one pathogenic hallmarks ad owing consistent prominent presence along biochemical properties greater fibrillogenicity aggregation potential ass42 pathogenic biomarker ad
0.22005783.15615772.html.plaintext.txt	9	given genomic location potential functional relevance ad tested plau candidate gene load plau relatively small 5970 bp gene found nt008583 chromosome 10 contig also defined af377330 sequence wwwncbinlmnihgov genotyped total seven single nucleotide polymorphisms snps spanning whole length gene 72nd 5885th bp found evidence significant linkage disequilibrium ld among variants allowing complex genotype analysis article initially depict results association analyses plasma ass42 plau haplotypes 10 load families ad plau compound genotypes forming haplotype pairs three case control series establishing significant association plau variants two ad phenotypes plasma ass42 levels ad affected status focus single missense mutation larger data set 24 load families six case control series
0.22005783.15615772.html.plaintext.txt	10	given genomic location potential functional relevance ad tested plau candidate gene load plau relatively small 5970 bp gene found nt008583 chromosome 10 contig also defined af377330 sequence wwwncbinlmnihgov genotyped total seven single nucleotide polymorphisms snps spanning whole length gene 72nd 5885th bp found evidence significant linkage disequilibrium ld among variants allowing complex genotype analysis article initially depict results association analyses plasma ass42 plau haplotypes 10 load families ad plau compound genotypes forming haplotype pairs three case control series establishing significant association plau variants two ad phenotypes plasma ass42 levels ad affected status focus single missense mutation larger data set 24 load families six case control series
0.22005783.15615772.html.plaintext.txt	11	missense mutation variant exon 6 rs2227564plau1 causes proline leucine change p141l within kringle domain plau junction two ss pleated sheets 1314 minor variant plau1 appear affect plau activity yoshimoto et al 14 reported p141 plau zymogen binds fibrin aggregates less efficiently l141 plau zymogen suggesting possibility altered extracellular plau localization stability
0.22005783.15615772.html.plaintext.txt	12	missense mutation variant exon 6 rs2227564plau1 causes proline leucine change p141l within kringle domain plau junction two ss pleated sheets 1314 minor variant plau1 appear affect plau activity yoshimoto et al 14 reported p141 plau zymogen binds fibrin aggregates less efficiently l141 plau zymogen suggesting possibility altered extracellular plau localization stability
0.22005783.15615772.html.plaintext.txt	13	previously finckh et al 15 shown significant association major cc genotype rs2227564 load series germany switzerland italy article show evidence significant association load minor allele variant discuss potential reasons discrepancy find evidence significant association plau variants extended load families independent case control series using plasma ass42 load affected status phenotypes addition provide functional data plau knock ko mice supporting role gene ass metabolism results depicted subsequently
0.22005783.15615772.html.plaintext.txt	14	results top abstract introduction results discussion materials methods references identification snps haplotypes compound genotypes plau identified six snps sequencing plau exons load family members additional snp exon 2 identified using public snp databases seven plau snps locations ncbi snp names summarized table 1 snps spanned 58 kb plau gene analyzed 10 load families used link plasma ass42 chromosome 10 1 addition genotyped three independent case control series collected mayo clinic rochester mcr mayo clinic jacksonville mcj university kentucky uky snp allele frequencies deviations hardy weinberg equilibrium hwe allelic association results summarized table 2 given two exon 11 snps complete ld results one exon 11 snps summarized table 2 summary rare exon 2 snp showed hardy weinberg disequilibrium mcj mcr series case control groups apart one instance snp deviated significantly hwe control group exon 6 snpplau1 mcj controls
0.22005783.15615772.html.plaintext.txt	15	results top abstract introduction results discussion materials methods references identification snps haplotypes compound genotypes plau identified six snps sequencing plau exons load family members additional snp exon 2 identified using public snp databases seven plau snps locations ncbi snp names summarized table 1 snps spanned 58 kb plau gene analyzed 10 load families used link plasma ass42 chromosome 10 1 addition genotyped three independent case control series collected mayo clinic rochester mcr mayo clinic jacksonville mcj university kentucky uky snp allele frequencies deviations hardy weinberg equilibrium hwe allelic association results summarized table 2 given two exon 11 snps complete ld results one exon 11 snps summarized table 2 summary rare exon 2 snp showed hardy weinberg disequilibrium mcj mcr series case control groups apart one instance snp deviated significantly hwe control group exon 6 snpplau1 mcj controls
0.22005783.15615772.html.plaintext.txt	16	view table table 2 plau snp frequencies plau snp genotypes family members plau snp haplotypes identified using haplotyping algorithm within computer program simwalk2 1718 three major plau snp haplotypes identified three minor haplotypes collectively six plau snp haplotypes accounted 95 haplotypes families frequency plau snp haplotype 10 ad families summarized table 1 profound ld d 095 snps d2 04 snps except exon 8 snp five seven snps required construct six haplotypes
0.22005783.15615772.html.plaintext.txt	17	table 3 summarizes ld parameters lewontins standardized disequilibrium coefficient 19 d d2 estimated founders 10 extended load families profound ld snps easily appreciated table exon 11 deletion mutant complete ld exon 11 snp exon 2 snp rare yield meaningful results thus two snps omitted ld analysis ld also estimated mcr mcj uky series within cases controls yielded similar results individual carries two haplotypes termed genotype formed two haplotypes compound genotypes described subsequently compound genotype essentially unambiguously defines haplotype pair due profound ld plau snps limited haplotype diversity next tested association plasma ass42 levels plau haplotypes
0.22005783.15615772.html.plaintext.txt	18	table 3 summarizes ld parameters lewontins standardized disequilibrium coefficient 19 d d2 estimated founders 10 extended load families profound ld snps easily appreciated table exon 11 deletion mutant complete ld exon 11 snp exon 2 snp rare yield meaningful results thus two snps omitted ld analysis ld also estimated mcr mcj uky series within cases controls yielded similar results individual carries two haplotypes termed genotype formed two haplotypes compound genotypes described subsequently compound genotype essentially unambiguously defines haplotype pair due profound ld plau snps limited haplotype diversity next tested association plasma ass42 levels plau haplotypes
0.22005783.15615772.html.plaintext.txt	19	view table table 3 plau snps ld association plau variants plasma ass42 levels 10 load families test association plasma ass42 plau variants family members used variance components methodology implemented computer program solar 20 using within pedigree identity state model hopper mathews 21 plau snp haplotypes initially analyzed family members ages 20 65 years age group plasma ass42 linked chromosome 10 locus 1 age group significant association plau variants plasma ass42 levels table 4 inspection data suggested might association plau snp haplotypes plasma ass42 older family members performed second analysis using family members ages remarkably group showed significant association plau snp haplotypes plasma ass42 p002 plau association accounting estimated 12 total variance ass42
0.22005783.15615772.html.plaintext.txt	20	view table table 4 association plau snp haplotypes plasma ass42 10 load families association plau variants ad three case control series working hypothesis gene variants influencing ass42 likely variants influencing risk ad determine whether plau variants associated ad case control series analyzed plau snps three independent series obtained mcr mcj uky three series entirely composed caucasian subjects every ad patient age onset 59 years using computer program gold 22 analyze plau snps determined profound ld among five plau snps case control series similar load family founders data shown
0.22005783.15615772.html.plaintext.txt	21	important consequence profound ld among five plau snps analyzed relatively common genotypes 96 100 subjects accounted 12 compound genotypes table 5 table 5 two haplotypes producing six 12 compound genotypes d f j k unambiguous one snp heterozygous remaining six genotypes produced one one pair six haplotypes identified load families table 1 pairs could produce categories would include least one haplotype rare never identified unambiguously case control series simwalk2 haplotype analysis load families combinations rare plau snp haplotypes 96 100 subjects load case control series easily identified essentially unambiguous table 5
0.22005783.15615772.html.plaintext.txt	22	important consequence profound ld among five plau snps analyzed relatively common genotypes 96 100 subjects accounted 12 compound genotypes table 5 table 5 two haplotypes producing six 12 compound genotypes d f j k unambiguous one snp heterozygous remaining six genotypes produced one one pair six haplotypes identified load families table 1 pairs could produce categories would include least one haplotype rare never identified unambiguously case control series simwalk2 haplotype analysis load families combinations rare plau snp haplotypes 96 100 subjects load case control series easily identified essentially unambiguous table 5
0.22005783.15615772.html.plaintext.txt	23	view table table 5 association plau compound genotypes ad three case control series evaluate association ad compound genotypes summarized table 5 performed 2 tests series using monte carlo approach t1 implemented clump determine significance three series examined genotypes showed significant association ad mcr p0001 mcj p003 uky p003 compound genotypes tended trends two series analyzed eg 22 14 35 suggesting presence functional variants backbones genotypes
0.22005783.15615772.html.plaintext.txt	24	found association plau compound genotypes three case control series mcr mcj uky tested association missense plau1 snp larger data set six case control series results depicted subsequently finally went back test association plau compound genotypes three additional case control series gothenburg gothenburg postmortem scottish find significant association series data shown
0.22005783.15615772.html.plaintext.txt	25	found association plau compound genotypes three case control series mcr mcj uky tested association missense plau1 snp larger data set six case control series results depicted subsequently finally went back test association plau compound genotypes three additional case control series gothenburg gothenburg postmortem scottish find significant association series data shown
0.22005783.15615772.html.plaintext.txt	26	association plau1 snp rs2227564 plasma ass42 levels 24 load families plau variants analyzed rs2227564 internally termed plau1 relatively common missense snp leads proline leucine change kringle domain plau junction two ss pleated sheets 1314 shown functional effect fibrin binding plau zymogen 14 determine whether plau1 genotypes associated plasma ass42 analyzed larger set 24 extended load families includes original group 10 families take family relationships account analyses performed using variance components methodology implemented program solar 20
0.22005783.15615772.html.plaintext.txt	27	association plau1 snp rs2227564 plasma ass42 levels 24 load families plau variants analyzed rs2227564 internally termed plau1 relatively common missense snp leads proline leucine change kringle domain plau junction two ss pleated sheets 1314 shown functional effect fibrin binding plau zymogen 14 determine whether plau1 genotypes associated plasma ass42 analyzed larger set 24 extended load families includes original group 10 families take family relationships account analyses performed using variance components methodology implemented program solar 20
0.22005783.15615772.html.plaintext.txt	28	members 24 families change occurs plasma ass42 aging complex plasma ass42 elevated young subjects first decreases increases age 50 shown figure 1 plasma ass42 stratified plau1 genotype plotted function age non linear analysis analyzed age age2 plau1 genotype cc ct tt cttt interactions among age age2 plau1 genotype variance components framework showed significant age dependent association plasma ass42 plau1 ct tt genotypes ctxage ttxage2 ctttxage2 age2 significant p 005 table 6 main concern determine whether significant age dependent elevation plasma ass42 elderly subjects associated ct tt pooled cttt genotypes performed second analysis family members 50 years fig 2 analyzed using linear regression variance components framework analysis showed ctxage ttxage covariates significant effects p0003 p0007 respectively 24 load families table 7 ct tt variables tested single cttt variable ctttxage covariate even significant p00006 noteworthy even correct fact three age groups tested prior analysis 50 age group summarized table 7 using conservative approach bonferroni correction still highly significant age related plau genotype effect families overall corrected p values 0000024 model 1 000006 model 2
0.22005783.15615772.html.plaintext.txt	29	members 24 families change occurs plasma ass42 aging complex plasma ass42 elevated young subjects first decreases increases age 50 shown figure 1 plasma ass42 stratified plau1 genotype plotted function age non linear analysis analyzed age age2 plau1 genotype cc ct tt cttt interactions among age age2 plau1 genotype variance components framework showed significant age dependent association plasma ass42 plau1 ct tt genotypes ctxage ttxage2 ctttxage2 age2 significant p 005 table 6 main concern determine whether significant age dependent elevation plasma ass42 elderly subjects associated ct tt pooled cttt genotypes performed second analysis family members 50 years fig 2 analyzed using linear regression variance components framework analysis showed ctxage ttxage covariates significant effects p0003 p0007 respectively 24 load families table 7 ct tt variables tested single cttt variable ctttxage covariate even significant p00006 noteworthy even correct fact three age groups tested prior analysis 50 age group summarized table 7 using conservative approach bonferroni correction still highly significant age related plau genotype effect families overall corrected p values 0000024 model 1 000006 model 2
0.22005783.15615772.html.plaintext.txt	30	view larger version 21k figure 1 plasma ass42 members ages 24 load families curves shown plau1 rs2227564 genotype polynomial function age age2 cc genotype n285 b ct genotype n137 c tt genotype n34 d combined cttt genotypes n171
0.22005783.15615772.html.plaintext.txt	31	view larger version 21k figure 1 plasma ass42 members ages 24 load families curves shown plau1 rs2227564 genotype polynomial function age age2 cc genotype n285 b ct genotype n137 c tt genotype n34 d combined cttt genotypes n171
0.22005783.15615772.html.plaintext.txt	32	view table figure 2 plasma ass42 members 50 years age 24 load families curves shown plau1 rs2227564 genotype linear function age cc genotype n136 b ct genotype n59 c tt genotype n17 d combined cttt genotypes n76
0.22005783.15615772.html.plaintext.txt	33	view table table 7 multivariate regression analysis members 50 years age 24 load families basis findings re analyzed haplotypic associations 10 load families subjects 50 years age association even significant p0005 table 4 subsequently went back analyze haplotypes 24 families age group accounted 22 total variance plasma ass42 phenotype also significant p0009 data shown
0.22005783.15615772.html.plaintext.txt	34	association plau1 snp rs2227564 ad six case control series initially analyzed three series two groups mcr mcj series mayo clinic uky series university kentucky analyze missense plau1 snp obtained three series collaborators karolinska institute gothenburg load control series autopsy confirmed load series gothenburg scottish early onset ad load series
0.22005783.15615772.html.plaintext.txt	35	association plau1 snp rs2227564 ad six case control series initially analyzed three series two groups mcr mcj series mayo clinic uky series university kentucky analyze missense plau1 snp obtained three series collaborators karolinska institute gothenburg load control series autopsy confirmed load series gothenburg scottish early onset ad load series
0.22005783.15615772.html.plaintext.txt	36	mcr series significant association observed ct p0006 cttt p0008 genotypes odds ratio 17 12 26 17 11 24 respectively tt genotype enriched load patients mcr series enrichment achieve significance uky series first series plau1 analyzed tt genotype showed significant p0029 association load 35 11 107 three four remaining series mcj gothenburg scottish showed non significant enrichment ct andor tt genotypes table 8 occur autopsy confirmed gothenburg series testing homogeneity breslow day showed evidence heterogeneity among six series p045 meta analysis gave pooled estimate cttt genotype 121 10 147 fixed effects p0056 random effects p0051 fig 3
0.22005783.15615772.html.plaintext.txt	37	view table figure 3 ors plau1 rs2227564 cttt versus cc genotypes case control series ors shown 95 confidence intervals ad cases scottish series early age onset others load versus control series
0.22005783.15615772.html.plaintext.txt	38	analysis ass plau knockout mice finding plau variants associated elevated plasma ass42 predicts plasma ass42 elevated ko mice lacking functional plau gene test analyzed plasma ass42 11 plau ko mice 16 14 control mice genetic background comparison ko mice lacking functional neprilysin gene known involved ass degradation 24 analyzed parallel compared controls 3 6 month old plau ko mice showed highly significant increase plasma ass42 p0006 mann whitney test fig 4a plasma ass40 also increased p0003 plau ko mice fig 4b 11 months plasma ass42 ass40 increased difference ko control mice appeared increase small number mice analyzed two plau ko versus six controls thus plau gene influences plasma ass42 data suggest effect may become pronounced aging consistent genetic analyses load families remarkably brain ass42 fig 5a ass40 fig 5b showed detectable increase plau ko mice compared control mice implications result presented discussion
0.22005783.15615772.html.plaintext.txt	39	analysis ass plau knockout mice finding plau variants associated elevated plasma ass42 predicts plasma ass42 elevated ko mice lacking functional plau gene test analyzed plasma ass42 11 plau ko mice 16 14 control mice genetic background comparison ko mice lacking functional neprilysin gene known involved ass degradation 24 analyzed parallel compared controls 3 6 month old plau ko mice showed highly significant increase plasma ass42 p0006 mann whitney test fig 4a plasma ass40 also increased p0003 plau ko mice fig 4b 11 months plasma ass42 ass40 increased difference ko control mice appeared increase small number mice analyzed two plau ko versus six controls thus plau gene influences plasma ass42 data suggest effect may become pronounced aging consistent genetic analyses load families remarkably brain ass42 fig 5a ass40 fig 5b showed detectable increase plau ko mice compared control mice implications result presented discussion
0.22005783.15615772.html.plaintext.txt	40	view larger version 21k figure 4 plasma ass plau ko plasma ass42 b plasma ass40 analyzed sandwich elisa previously described 19 ko mice homozygous null allele results normalized ass present 3 6 month old control wild type mice values shown mean plus minus se numbers analyzed 3 6 month old plau ko 14 n9 control mice n6 11 month old plau ko mice n2 control mice n7 mice 3 6 month old neprilysin ko 15 n3 control mice n3 neprilysin ko mice used additional positive control 15 mice plasma ass42 ass40 b increased
0.22005783.15615772.html.plaintext.txt	41	view larger version 24k figure 5 brain ass plau ko mice brain ass42 b brain ass40 extracted directly 70 formic acid brain ass42 ass40 analyzed elisa following direct extraction formic acid neutralization previously described 26 values shown mean plus minus se numbers analyzed 3 6 month old plau ko mice n9 control mice n6 11 month old plau ko mice n2 control mice n7 3 6 month old neprilysin ko mice n3 control mice n3 additional positive control investigated neprilysin ko mice 15 mice brain ass42 ass40 increased previously reported 15 plasma ass42 fig 4a ass40 fig 4b also increased neprilysin ko mice
0.22005783.15615772.html.plaintext.txt	42	discussion top abstract introduction results discussion materials methods references identification load risk locus chromosome 10 2 also affects plasma ass 1 levels extended load families led search genes good functional candidates region plau good functional good positional candidate gene converts plasminogen plasmin turn degrades ass genotyped seven snps within relatively small gene spanning almost entire length found snps profound ld leading limited haplotype diversity region analyzed finding consistent previous work 25 27 limited haplotype diversity allowed us perform association analysis using compound genotypes make haplotype pair subject advantage approach require phase information compound genotype forms group per se nonetheless given small number compound genotypes observed series one identify underlying haplotype pair 95 subjects essentially unambiguously advantage compound genotype approach allows analysis haplotype pair rather individual haplotypes thus variants effective additive fashion encountered alone easier identify using approach determined significant association plau compound genotypes ad three independent case control series
0.22005783.15615772.html.plaintext.txt	43	discussion top abstract introduction results discussion materials methods references identification load risk locus chromosome 10 2 also affects plasma ass 1 levels extended load families led search genes good functional candidates region plau good functional good positional candidate gene converts plasminogen plasmin turn degrades ass genotyped seven snps within relatively small gene spanning almost entire length found snps profound ld leading limited haplotype diversity region analyzed finding consistent previous work 25 27 limited haplotype diversity allowed us perform association analysis using compound genotypes make haplotype pair subject advantage approach require phase information compound genotype forms group per se nonetheless given small number compound genotypes observed series one identify underlying haplotype pair 95 subjects essentially unambiguously advantage compound genotype approach allows analysis haplotype pair rather individual haplotypes thus variants effective additive fashion encountered alone easier identify using approach determined significant association plau compound genotypes ad three independent case control series
0.22005783.15615772.html.plaintext.txt	44	analyzed common missense snp plau1 rs2227564 larger set 24 families six case control series include initial series analyzed extended families snp associated age related elevation plasma ass levels individuals 50 years age plasma ass displays complex characteristic appears decline age related fashion 50 years age increase thereafter characteristic much pronounced subjects ct tt genotype plau1 also noteworthy significance association plau haplotypes enhanced 50 age group analyzed separately 10 families expected table 4 finding age related increase ass also evident plasma ass plau ko mice consistent finding humans mice significantly higher plasma ass levels compared wild type littermates however brain ass levels show significant difference finding could several explanations may suggest plau variants influence ad effect plasma brain ass42 conceivable likely plau influences plasma brain ass way evident ko mice thus plau may greater influence secreted cell associated ass brain ass cell associated 28 effects secreted ass easily detected plasma could hard detect brain alternatively compensatory changes triggered plau ko may maintain brain ass effectively plasma ass
0.22005783.15615772.html.plaintext.txt	45	analyzed common missense snp plau1 rs2227564 larger set 24 families six case control series include initial series analyzed extended families snp associated age related elevation plasma ass levels individuals 50 years age plasma ass displays complex characteristic appears decline age related fashion 50 years age increase thereafter characteristic much pronounced subjects ct tt genotype plau1 also noteworthy significance association plau haplotypes enhanced 50 age group analyzed separately 10 families expected table 4 finding age related increase ass also evident plasma ass plau ko mice consistent finding humans mice significantly higher plasma ass levels compared wild type littermates however brain ass levels show significant difference finding could several explanations may suggest plau variants influence ad effect plasma brain ass42 conceivable likely plau influences plasma brain ass way evident ko mice thus plau may greater influence secreted cell associated ass brain ass cell associated 28 effects secreted ass easily detected plasma could hard detect brain alternatively compensatory changes triggered plau ko may maintain brain ass effectively plasma ass
0.22005783.15615772.html.plaintext.txt	46	analyzed plau1 six case control series using meta analysis lohmueller et al 29 reported meta analyses published genetic associations various disease phenotypes 25 reported associations investigated meta analysis eight showed significant association replicated original study ors 11 20 range basis findings authors recommended large collaborative genetic association studies encouraged sound studies positive negative published reports association include meta analysis available data meta analyses plau1 snp six case control series indicate plau1 cttt associated modest or121 marginally significant p0051 0056 increase risk ad result similar lohmueller et al 29 whose meta analyses identified many common genetic variants modest significant effects disease phenotypes two groups previously published findings snp 1530 finckh et al 15 found significant association three case control series germany switzerland italy whereas myers et al 30 find evidence association plau snps analyzed including plau1 interestingly former found series cc genotype associated increased risk load whereas series ct tt genotypes furthermore another group germany also found significant association ct tt genotypes m riemenschneider personal communication thus clearly heterogeneity among findings one group significant results direction series m riemenschneider another finding significance common genotype 15 third group finding significance clearly results need analyzed one meta analysis subsequent publication nonetheless demonstrated lohmueller et al 29 discrepancies frequent among studies common genetic variants complex diseases particularly effect size modest many reasons discrepancies including small sample size gene gene gene environment interactions modelled studies intra sample heterogeneitypopulation substructure analysis marker variant instead disease variant varying degrees ld tried minimize factors gathering large series age matching mayo clinic series choosing variant likely functional still plausible problems may contributing inter series variations observed plau1
0.22005783.15615772.html.plaintext.txt	47	indeed association plau1 marginally significant confidence interval 10 147 six series analyzed nonetheless statistical result considered presence evidence family animal data effect plau ass understanding likely exist variants plau affect risk ad suggested compound genotype data case control series furthermore given likely presence important variants genes vr22 ide finding highly significant p values variants modest effect complex diseases may need await identification functional mutations multiple genes analyses multiple large series
0.22005783.15615772.html.plaintext.txt	48	recently published findings significant association two genes chromosome 10 3132 ide vr22 tested key variants three genes find evidence ld joint analysis key variants demonstrates separate independent effects variants vr22 account linkage chromosome 10 plau variants different two age related effects manifest strongly age 50 thus genes appears act independently one another via apparent separate mechanisms unequivocal effects genes pathogenesis ad await identification functional variants testing large series findings provide evidence existence load risk variants affect ass within andor vicinity genes
0.22005783.15615772.html.plaintext.txt	49	recently published findings significant association two genes chromosome 10 3132 ide vr22 tested key variants three genes find evidence ld joint analysis key variants demonstrates separate independent effects variants vr22 account linkage chromosome 10 plau variants different two age related effects manifest strongly age 50 thus genes appears act independently one another via apparent separate mechanisms unequivocal effects genes pathogenesis ad await identification functional variants testing large series findings provide evidence existence load risk variants affect ass within andor vicinity genes
0.22005783.15615772.html.plaintext.txt	50	materials methods top abstract introduction results discussion materials methods references subjects initially collected 10 extended load families four families collected via load patient extremely high plasma ass42 andor ass40 levels extremes top 10th percentile 545 ad patients series remaining six families ascertained via load proband multiple relatives load without prior ass measurements non extremes one probands non extreme families determined extremely high plasma ass levels family collection therefore family grouped extreme families subsequently detailed collection strategies family profiles families provided elsewhere 1 addition 10 families 14 independent extended load pedigrees subsequently collected additional pedigrees collected via proband first degree relative load patient except one probands 14 additional pedigrees elevated plasma ass levels load families studied article lacked clear autosomal dominant mode segregation ad
0.22005783.15615772.html.plaintext.txt	51	materials methods top abstract introduction results discussion materials methods references subjects initially collected 10 extended load families four families collected via load patient extremely high plasma ass42 andor ass40 levels extremes top 10th percentile 545 ad patients series remaining six families ascertained via load proband multiple relatives load without prior ass measurements non extremes one probands non extreme families determined extremely high plasma ass levels family collection therefore family grouped extreme families subsequently detailed collection strategies family profiles families provided elsewhere 1 addition 10 families 14 independent extended load pedigrees subsequently collected additional pedigrees collected via proband first degree relative load patient except one probands 14 additional pedigrees elevated plasma ass levels load families studied article lacked clear autosomal dominant mode segregation ad
0.22005783.15615772.html.plaintext.txt	52	addition extended load families six different case control series analyzed study series named follows mayo clinic rochester mcr mayo clinic jacksonville mcj university kentucky uky gothenburg gothenburg postmortem scottish mcr samples collected part mayo clinic alzheimers disease patient registry community based prospective registry mayo clinic rochester memory disorders clinic case control series mcj samples collected mayo clinic jacksonville memory disorders clinic uky series collected part university kentucky memory disorders clinic brains program mcr mcj uky series consisted caucasian subjects united states gothenburg gothenburg postmortem series consisted swedish ad cases recruited prospective longitudinal study patients dementia molndal prospective dementia study swedish controls consisted healthy volunteers gothenburg autopsy cases gothenburg postmortem finally scottish samples composed eoad patients lothian psychiatric case register scottish controls consisting local church congregation volunteers lothian region eoad materials selected non familial cases common presenilin mutations screened positives found discarded test set
0.22005783.15615772.html.plaintext.txt	53	addition extended load families six different case control series analyzed study series named follows mayo clinic rochester mcr mayo clinic jacksonville mcj university kentucky uky gothenburg gothenburg postmortem scottish mcr samples collected part mayo clinic alzheimers disease patient registry community based prospective registry mayo clinic rochester memory disorders clinic case control series mcj samples collected mayo clinic jacksonville memory disorders clinic uky series collected part university kentucky memory disorders clinic brains program mcr mcj uky series consisted caucasian subjects united states gothenburg gothenburg postmortem series consisted swedish ad cases recruited prospective longitudinal study patients dementia molndal prospective dementia study swedish controls consisted healthy volunteers gothenburg autopsy cases gothenburg postmortem finally scottish samples composed eoad patients lothian psychiatric case register scottish controls consisting local church congregation volunteers lothian region eoad materials selected non familial cases common presenilin mutations screened positives found discarded test set
0.22005783.15615772.html.plaintext.txt	54	clinical ad diagnoses series made according nincds adrda criteria 33 neuropathologically diagnosed ad patients gothenburg postmortem also fulfilled clinical nincds criteria probable ad met neuropathological cerad criteria definitive ad ads series except scottish series ages onset 59 years
0.22005783.15615772.html.plaintext.txt	55	clinical ad diagnoses series made according nincds adrda criteria 33 neuropathologically diagnosed ad patients gothenburg postmortem also fulfilled clinical nincds criteria probable ad met neuropathological cerad criteria definitive ad ads series except scottish series ages onset 59 years
0.22005783.15615772.html.plaintext.txt	56	study approved appropriate institutional review boards appropriate informed consent obtained participants
0.22005783.15615772.html.plaintext.txt	57	identification genotyping plau snps eleven members selected 10 extended load families gave linkage signal chromosome 10 1 genomic dna five family members two probands high plasma ass level two members two married spouses low levels sequenced samples came four different families three probands extreme high ass levels intronic primers flanking plau exons used pcr amplification coding regions 400 bp 5 untranslated region 5 utr 1000 bp 3 utr plau sequenced sequencing done via semi automated fluorescent method using abi377 sequencer associated factura software packages snp databases national center biotechnology information ncbi url httpwwwncbinlmnihgovsnp university washington fred hutchinson cancer research center uw fhcrc url httppgambtwashingtonedu also screened snp identification snps identified via sequencing effort used analysis well rare missense snp exon 2 identified bioinformatics screen seven snps thus identified analyzed haplotype analysis determined two missense exon 2 snp exon 11 deletion snp yielded redundant information therefore remainder analysis carried five snps
0.22005783.15615772.html.plaintext.txt	58	identification genotyping plau snps eleven members selected 10 extended load families gave linkage signal chromosome 10 1 genomic dna five family members two probands high plasma ass level two members two married spouses low levels sequenced samples came four different families three probands extreme high ass levels intronic primers flanking plau exons used pcr amplification coding regions 400 bp 5 untranslated region 5 utr 1000 bp 3 utr plau sequenced sequencing done via semi automated fluorescent method using abi377 sequencer associated factura software packages snp databases national center biotechnology information ncbi url httpwwwncbinlmnihgovsnp university washington fred hutchinson cancer research center uw fhcrc url httppgambtwashingtonedu also screened snp identification snps identified via sequencing effort used analysis well rare missense snp exon 2 identified bioinformatics screen seven snps thus identified analyzed haplotype analysis determined two missense exon 2 snp exon 11 deletion snp yielded redundant information therefore remainder analysis carried five snps
0.22005783.15615772.html.plaintext.txt	59	plau snp frequencies estimated mcj mcr uky series 24 load families summarized table 2 snps tested groups rare exon 2 snp hardy weinberg disequilibrium control groups mcj mcr snp used compound genotype analysis addition exon 6 snp hardy weinberg disequilibrium mcj control series
0.22005783.15615772.html.plaintext.txt	60	plau snp frequencies estimated mcj mcr uky series 24 load families summarized table 2 snps tested groups rare exon 2 snp hardy weinberg disequilibrium control groups mcj mcr snp used compound genotype analysis addition exon 6 snp hardy weinberg disequilibrium mcj control series
0.22005783.15615772.html.plaintext.txt	61	dna extracted peripheral blood leukocytes using routine methods gothenburg gothenburg postmortem scottish series genotyped using dynamic allele specific hybridization 3435 series genotyped abi7900 instrument using taqman technology taqman assays software designing primers probes implemented within abi prism 7900 ht sequence detection system utilized ncbi genbank plau gene sequence af377330 used pedigree structure phenotypic genotypic information maintained pedsys 36 httpwwwsfbrorgsfbrpublicsoftwarepedsyspedsyshtml also produced output files analysis performed solar explained subsequently
0.22005783.15615772.html.plaintext.txt	62	dna extracted peripheral blood leukocytes using routine methods gothenburg gothenburg postmortem scottish series genotyped using dynamic allele specific hybridization 3435 series genotyped abi7900 instrument using taqman technology taqman assays software designing primers probes implemented within abi prism 7900 ht sequence detection system utilized ncbi genbank plau gene sequence af377330 used pedigree structure phenotypic genotypic information maintained pedsys 36 httpwwwsfbrorgsfbrpublicsoftwarepedsyspedsyshtml also produced output files analysis performed solar explained subsequently
0.22005783.15615772.html.plaintext.txt	63	analysis ld among snps measured ld snps within 10 extended load families using gold program 22 program determines various pairwise statistical parameters ld lewontins standardized disequilibrium coefficient 19 d d2 ld detected founders married ins using expectation maximization algorithm slatkin excoffier 37 also detected ld within ads controls mcr mcj uky series using program
0.22005783.15615772.html.plaintext.txt	64	analysis ld among snps measured ld snps within 10 extended load families using gold program 22 program determines various pairwise statistical parameters ld lewontins standardized disequilibrium coefficient 19 d d2 ld detected founders married ins using expectation maximization algorithm slatkin excoffier 37 also detected ld within ads controls mcr mcj uky series using program
0.22005783.15615772.html.plaintext.txt	65	tests association plau snp haplotypes plasma ass levels load families estimated haplotypes five plau snps genotyped members ten load families using gold 22 simwalk2 17 highly significant ld among five plau snps crossover events observed 10 extended load families tested association plau haplotypes plasma ass42 phenotype using variance components method implemented computer program solar 20
0.22005783.15615772.html.plaintext.txt	66	tests association plau snp haplotypes plasma ass levels load families estimated haplotypes five plau snps genotyped members ten load families using gold 22 simwalk2 17 highly significant ld among five plau snps crossover events observed 10 extended load families tested association plau haplotypes plasma ass42 phenotype using variance components method implemented computer program solar 20
0.22005783.15615772.html.plaintext.txt	67	method described detail elsewhere 20 estimates amount variance quantitative trait owing residual genetic factors g2 shared family environment 2h individual specific random environmental factors 2e based phenotype covariance arbitrary relative pairs covariance matrix takes form
0.22005783.15615772.html.plaintext.txt	68	method described detail elsewhere 20 estimates amount variance quantitative trait owing residual genetic factors g2 shared family environment 2h individual specific random environmental factors 2e based phenotype covariance arbitrary relative pairs covariance matrix takes form
0.22005783.15615772.html.plaintext.txt	69	2 matrix kinship coefficients describing polygenic factors identity matrix describing sporadic environmental factors h household matrix matrix whose ijth element equal 1 individuals j share specified environment 0 otherwise family collection largely composed extended pedigrees measured plasma ass members family single batch elisas rigorously account possible assay batch batch variations may affect variance plasma ass included household matrix models almost individuals family measured one batch household matrix included element equal 1 individuals extended family 0 otherwise realize may overly conservative collection largely weighted towards families high ass segregating within family given shared family effect household overlaps kinship may corrected underestimated shared genetic effect including household term model scalars g2 h2 e2 estimated using maximum likelihood
0.22005783.15615772.html.plaintext.txt	70	2 matrix kinship coefficients describing polygenic factors identity matrix describing sporadic environmental factors h household matrix matrix whose ijth element equal 1 individuals j share specified environment 0 otherwise family collection largely composed extended pedigrees measured plasma ass members family single batch elisas rigorously account possible assay batch batch variations may affect variance plasma ass included household matrix models almost individuals family measured one batch household matrix included element equal 1 individuals extended family 0 otherwise realize may overly conservative collection largely weighted towards families high ass segregating within family given shared family effect household overlaps kinship may corrected underestimated shared genetic effect including household term model scalars g2 h2 e2 estimated using maximum likelihood
0.22005783.15615772.html.plaintext.txt	71	formulate association model plau snp haplotypes used within pedigree association model hopper mathews 21 model matrix allelic sharing within pedigrees ij defined ij1 individuals j pedigree share alleles haplotype identical state ij12 individuals j pedigree share one allele identical state ij0 otherwise association model solar estimates variance quantitative trait owing association a2 residual genetic factors g2 household effects h2 environmental effects e2 null model association a2 fixed zero difference log10 likelihoods two models produces test statistic distribution lod score genetic linkage analysis one degree freedom two models association fixed association tested one sided test performed
0.22005783.15615772.html.plaintext.txt	72	formulate association model plau snp haplotypes used within pedigree association model hopper mathews 21 model matrix allelic sharing within pedigrees ij defined ij1 individuals j pedigree share alleles haplotype identical state ij12 individuals j pedigree share one allele identical state ij0 otherwise association model solar estimates variance quantitative trait owing association a2 residual genetic factors g2 household effects h2 environmental effects e2 null model association a2 fixed zero difference log10 likelihoods two models produces test statistic distribution lod score genetic linkage analysis one degree freedom two models association fixed association tested one sided test performed
0.22005783.15615772.html.plaintext.txt	73	tests association load case control series clump case control series tested association plau compound genotypes load using clump clump program 23 measures statistical significance variety 2xm contingency tables simulation employed t1 test within clump analyzes raw 2xm table m total number categories application clump 2xm table consisted two diagnostic categories m genotypic categories corresponding unique combination genotypes five plau snps
0.22005783.15615772.html.plaintext.txt	74	tests association load case control series clump case control series tested association plau compound genotypes load using clump clump program 23 measures statistical significance variety 2xm contingency tables simulation employed t1 test within clump analyzes raw 2xm table m total number categories application clump 2xm table consisted two diagnostic categories m genotypic categories corresponding unique combination genotypes five plau snps
0.22005783.15615772.html.plaintext.txt	75	ass analysis plasma ass40 ass42 measured previously described 11 relationship plasma ass42 age plau1 genotypes load family members initially analyzed fitting polynomial regression curves separately family members rs2227564 cc ct tt cttt genotypes using 10 logass42 dependent variable age age2 independent variables analyses showed genotype specific age related effects plasma ass42 levels indicated plasma ass42 increases aging beginning age 50 individuals ct tt genotype
0.22005783.15615772.html.plaintext.txt	76	ass analysis plasma ass40 ass42 measured previously described 11 relationship plasma ass42 age plau1 genotypes load family members initially analyzed fitting polynomial regression curves separately family members rs2227564 cc ct tt cttt genotypes using 10 logass42 dependent variable age age2 independent variables analyses showed genotype specific age related effects plasma ass42 levels indicated plasma ass42 increases aging beginning age 50 individuals ct tt genotype
0.22005783.15615772.html.plaintext.txt	77	used 20 65 year age group previous studies found linkage plasma ass levels locus chromosome 10 1 described previously 20 65 year age group initially chosen observation plasma ass elevated individuals 25 65 years old addition plasma ass appears complex likely deposition related changes individuals ad 65 age group study determined significant age related effects plau1 genotypes plasma ass levels individuals 50 years depicted subsequent thus analyses performed ages 20 65 year old 50 years groups
0.22005783.15615772.html.plaintext.txt	78	used 20 65 year age group previous studies found linkage plasma ass levels locus chromosome 10 1 described previously 20 65 year age group initially chosen observation plasma ass elevated individuals 25 65 years old addition plasma ass appears complex likely deposition related changes individuals ad 65 age group study determined significant age related effects plau1 genotypes plasma ass levels individuals 50 years depicted subsequent thus analyses performed ages 20 65 year old 50 years groups
0.22005783.15615772.html.plaintext.txt	79	tests association plau1 rs2227564 snp plasma ass levels load families applied variance components methodology implemented software package solar 20 estimate effect covariates plasma ass levels controlling pairwise genetic relationships shared family effects among family members extended load pedigrees
0.22005783.15615772.html.plaintext.txt	80	tested association plau1 genotypes plasma ass performing multivariate regression analysis including kinship identity household matrices described earlier model tested two different models significance coefficients covariates tested using polygenic screen option solar provides p value coefficient comparing model includes covariate model excludes option causes covariates stay model regardless significance model 1 covariates tested ct tt genotypes age ct genotypexage tt genotypexage model 2 ct tt genotypes pooled single cttt variable encoded one subjects ct tt genotype zero cc genotype analyses performed family members 50 years age selected subset determined age related increase plasma ass42 levels age 50 individuals plau1 genotypes ct tt analyses performed ass values second time excluding two extreme outliers plasma ass levels plus minus 4 sd beyond mean plau1 ctxage plau1 ctttxage still significant variables model 1 2 respectively excluding outliers
0.22005783.15615772.html.plaintext.txt	81	tested association plau1 genotypes plasma ass performing multivariate regression analysis including kinship identity household matrices described earlier model tested two different models significance coefficients covariates tested using polygenic screen option solar provides p value coefficient comparing model includes covariate model excludes option causes covariates stay model regardless significance model 1 covariates tested ct tt genotypes age ct genotypexage tt genotypexage model 2 ct tt genotypes pooled single cttt variable encoded one subjects ct tt genotype zero cc genotype analyses performed family members 50 years age selected subset determined age related increase plasma ass42 levels age 50 individuals plau1 genotypes ct tt analyses performed ass values second time excluding two extreme outliers plasma ass levels plus minus 4 sd beyond mean plau1 ctxage plau1 ctttxage still significant variables model 1 2 respectively excluding outliers
0.22005783.15615772.html.plaintext.txt	82	determine age related effect plau1 genotypes plau1 genotypes plasma ass42 levels load family members ages fitted two non linear regression models taking account variance components described earlier model 1 family members ages age2 plau1 ctxage2 plau1 ttxage2 tested covariates addition age plau1 ct plau1 tt plau1 ctxage plau1 ttxage model 2 age2 plau1 ctttxage2 included covariates besides age plau1 cttt plau1 ctttxage rationale testing non linear models described detail main text
0.22005783.15615772.html.plaintext.txt	83	determine age related effect plau1 genotypes plau1 genotypes plasma ass42 levels load family members ages fitted two non linear regression models taking account variance components described earlier model 1 family members ages age2 plau1 ctxage2 plau1 ttxage2 tested covariates addition age plau1 ct plau1 tt plau1 ctxage plau1 ttxage model 2 age2 plau1 ctttxage2 included covariates besides age plau1 cttt plau1 ctttxage rationale testing non linear models described detail main text
0.22005783.15615772.html.plaintext.txt	84	logistic regression analysis test association plau1 rs2227564 snp case controls logistic regression analysis implemented sas version 8 utilized test association ad plau1 genotypes initially model estimated tested effects plau1 ct tt genotypes separately utilized results analysis suggested similar risky estimates genotypes given result plau1 tt genotype relatively rare second model fitted ct tt genotypes combined one variable cttt coded 1 ct tt genotype 0 cc genotype
0.22005783.15615772.html.plaintext.txt	85	logistic regression analysis test association plau1 rs2227564 snp case controls logistic regression analysis implemented sas version 8 utilized test association ad plau1 genotypes initially model estimated tested effects plau1 ct tt genotypes separately utilized results analysis suggested similar risky estimates genotypes given result plau1 tt genotype relatively rare second model fitted ct tt genotypes combined one variable cttt coded 1 ct tt genotype 0 cc genotype
0.22005783.15615772.html.plaintext.txt	86	meta analysis plau1 rs2227564 snp 10 case control series using genotype counts plau1 cttt versus cc genotypes ad cases controls six series described article performed meta analysis implemented statsdirect statistical package breslow day test performed test heterogeneity among samples pooled estimates calculated using fixed effects random effects model implemented mantel haenszel dersimonian laird tests respectively
0.22005783.15615772.html.plaintext.txt	87	meta analysis plau1 rs2227564 snp 10 case control series using genotype counts plau1 cttt versus cc genotypes ad cases controls six series described article performed meta analysis implemented statsdirect statistical package breslow day test performed test heterogeneity among samples pooled estimates calculated using fixed effects random effects model implemented mantel haenszel dersimonian laird tests respectively
0.22005783.15615772.html.plaintext.txt	88	analysis plasma brain ass plau ko mice plasma ass42 ass40 analyzed sandwich elisa previously described 11 brain ass42 ass40 analyzed elisa following direct extraction formic acid neutralization previously described 28 ko mice homozygous null allele results normalized ass present 3 6 month old control wild type mice numbers analyzed follows 3 6 month old plau ko mice 16 n9 control mice n6 11 month old plau ko mice n2 control n7 mice 3 6 month old neprilysin ko mice 24 n3 control mice n3 neprilysin ko mice used additional positive control 24
0.22005783.15615772.html.plaintext.txt	89	analysis plasma brain ass plau ko mice plasma ass42 ass40 analyzed sandwich elisa previously described 11 brain ass42 ass40 analyzed elisa following direct extraction formic acid neutralization previously described 28 ko mice homozygous null allele results normalized ass present 3 6 month old control wild type mice numbers analyzed follows 3 6 month old plau ko mice 16 n9 control mice n6 11 month old plau ko mice n2 control n7 mice 3 6 month old neprilysin ko mice 24 n3 control mice n3 neprilysin ko mice used additional positive control 24
0.22005783.15615772.html.plaintext.txt	90	evaluate brain ass42 ass40 used methods previously employed demonstrate endogenous brain ass42 increases transgenic mice expressing presenilin 1 mutations linked early onset familial ad 9
0.22005783.15615772.html.plaintext.txt	91	acknowledgements acknowledge mayo clinic uky adrc members help collection samples grateful individuals participated study without work would possible study supported nih grants ag18023 sgy ag06656 sgy ag20903 net ag21545 se 2p50ag05144 wm grant american federation aging research grant pd01062 net robert clarice smith fellowship net
0.22005783.15615772.html.plaintext.txt	92	acknowledgements acknowledge mayo clinic uky adrc members help collection samples grateful individuals participated study without work would possible study supported nih grants ag18023 sgy ag06656 sgy ag20903 net ag21545 se 2p50ag05144 wm grant american federation aging research grant pd01062 net robert clarice smith fellowship net
0.22005783.15615772.html.plaintext.txt	93	references top abstract introduction results discussion materials methods references ertekin taner n graff radford n younkin lh eckman c baker m adamson j ronald j blangero j hutton m younkin sg 2000 linkage plasma ass42 quantitative locus chromosome 10 late onset alzheimers disease pedigrees science 290 2303 2304abstractfree full text
0.22522588.11983636.html.plaintext.txt	0	genetic host factors dementia downs syndrome nicole schupf phd
0.22522588.11983636.html.plaintext.txt	1	laboratory epidemiology new york state institute basic research developmental disabilities staten island
0.22522588.11983636.html.plaintext.txt	2	center columbia university college physicians surgeons new york usa
0.22522588.11983636.html.plaintext.txt	3	correspondence nicole schupf phd new york state institute basic research 1050 forest hill road staten island ny 10314 tel 001 718 494 5301 fax 001 718 494 5395 e mail ns24atcolumbiaedu
0.22522588.11983636.html.plaintext.txt	4	correspondence nicole schupf phd new york state institute basic research 1050 forest hill road staten island ny 10314 tel 001 718 494 5301 fax 001 718 494 5395 e mail ns24atcolumbiaedu
0.22522588.11983636.html.plaintext.txt	5	declaration interest grants iirg 90 067 rg3 96 077 alzheimers association federal grants ag14673 hd35897 p50ag08702 funds new york state office mental retardation developmental disabilities
0.22522588.11983636.html.plaintext.txt	6	presented part blake marsh lecture annual meeting royal college psychiatrists 6 july 2000 edinburgh
0.22522588.11983636.html.plaintext.txt	7	abstract top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references background high risk dementia adults downs syndrome attributed triplication overexpression gene amyloid precursor protein app wide variation age onset must due risk factors
0.22522588.11983636.html.plaintext.txt	8	aims identify factors influence age onset dementia downs syndrome
0.22522588.11983636.html.plaintext.txt	9	method studies factors influence formation beta amyloid ass reviewed including atypical karyotypes susceptibility genotypes gender oestrogen deficiency individual differences ass peptide levels
0.22522588.11983636.html.plaintext.txt	10	results apolipoprotein e 4 allele oestrogen deficiency high levels ass1 42 peptide associated earlier onset dementia atypical karyotypes apolipoprotein e 2 allele associated reduced mortality reduced risk dementia
0.22522588.11983636.html.plaintext.txt	11	conclusions factors influence ass levels rather overexpression app may account differences age onset dementia downs syndrome
0.22522588.11983636.html.plaintext.txt	12	introduction top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references alzheimers disease associated characteristic neuropathology includes deposition extracellular beta amyloid ass neuritic plaques intracellular accumulation neurofibrillary tangles adults downs syndrome high levels ass deposition age 40 years early onset dementia however average age onset clinical dementia 55 years varies widely neuropathological manifestations alzheimers disease downs syndrome attributed triplication expression gene beta amyloid precursor protein app located chromosome 21 factors influencing age onset dementia unresolved factors influence formation deposition ass reviewed including atypical karyotypes susceptibility genotypes gender oestrogen deficiency individual differences ass peptide levels factors modify rate degree ass deposition rather expression app may important determinants risk dementia downs syndrome
0.22522588.11983636.html.plaintext.txt	13	amyloid cascade hypothesis top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references although controversy relative importance plaques versus tangles development alzheimers disease increasing evidence altered metabolism ass peptides amyloid deposition neuritic plaques causes alzheimers disease triggering complex pathological cascade produces dementia ass peptides ass1 40 ass1 42 two major species ass generated app sequential proteolytic cleavage ss secretases enzymes ones involved breakdown app secretase cleaves full length app producing soluble sapp subsequently p3 processing secretase precludes production full length ass peptides anti amyloidogenic younkin 1998
0.22522588.11983636.html.plaintext.txt	14	several lines evidence suggest deposition ass 42 important initial step pathogenesis alzheimers disease ass1 42 aggregates rapidly deposited earlier alzheimers disease plaques ass1 40 iwatsubo et al 1994 mutations gene app presenilin ps12 genes associated early onset familial alzheimers disease selective increase ass1 42 borchelt et al 1996 mann et al 1996 scheuner et al 1996 kosaka et al 1997 younkin 1998 brain levels ass1 42 increase early development alzheimers disease strongly correlated cognitive decline cummings cotman 1995 naslund et al 2000 plasma levels ass1 42 higher elderly people subsequently develop alzheimers disease remain free dementia mayeux et al 1999
0.22522588.11983636.html.plaintext.txt	15	several lines evidence suggest deposition ass 42 important initial step pathogenesis alzheimers disease ass1 42 aggregates rapidly deposited earlier alzheimers disease plaques ass1 40 iwatsubo et al 1994 mutations gene app presenilin ps12 genes associated early onset familial alzheimers disease selective increase ass1 42 borchelt et al 1996 mann et al 1996 scheuner et al 1996 kosaka et al 1997 younkin 1998 brain levels ass1 42 increase early development alzheimers disease strongly correlated cognitive decline cummings cotman 1995 naslund et al 2000 plasma levels ass1 42 higher elderly people subsequently develop alzheimers disease remain free dementia mayeux et al 1999
0.22522588.11983636.html.plaintext.txt	16	virtually individuals downs syndrome neuropathological changes consistent diagnosis alzheimers disease time reach 40 years age including deposition ass diffuse neuritic plaques wisniewski h et al 1995 mann 1988 develop dementia end seventh decade life lai williams 1989 despite nearly universal occurrence alzheimers disease pathology middle age wide variation age onset dementia prevalence alzheimers disease age 65 ranged 30 75 zigman et al 1997 studies shown average age onset dementia 50 55 years range 38 70 years lai williams 1989 prasher krishnan 1993 methodological problems may account variation estimated prevalence alzheimers disease downs syndrome diagnosis alzheimers disease population requires documentation clinically significant decline cognitive adaptive competence previously attained levels performance documentation absence condition might cause declines performance aylward et al 1997 requirements particularly difficult address adults downs syndrome given lifelong intellectual disability wide range premorbid levels performance associated differences level intellectual disability requires specific criteria clinically significant decline indicative dementia level function beginning developed yet consensus set cognitive assessment tasks diagnostic criteria existing cognitive assessment batteries differentiate adults downs syndrome dementia early stages presently diagnoses alzheimers disease adults downs syndrome made clinically relatively late stages disease without systematic cognitive functional testing time
0.22522588.11983636.html.plaintext.txt	17	virtually individuals downs syndrome neuropathological changes consistent diagnosis alzheimers disease time reach 40 years age including deposition ass diffuse neuritic plaques wisniewski h et al 1995 mann 1988 develop dementia end seventh decade life lai williams 1989 despite nearly universal occurrence alzheimers disease pathology middle age wide variation age onset dementia prevalence alzheimers disease age 65 ranged 30 75 zigman et al 1997 studies shown average age onset dementia 50 55 years range 38 70 years lai williams 1989 prasher krishnan 1993 methodological problems may account variation estimated prevalence alzheimers disease downs syndrome diagnosis alzheimers disease population requires documentation clinically significant decline cognitive adaptive competence previously attained levels performance documentation absence condition might cause declines performance aylward et al 1997 requirements particularly difficult address adults downs syndrome given lifelong intellectual disability wide range premorbid levels performance associated differences level intellectual disability requires specific criteria clinically significant decline indicative dementia level function beginning developed yet consensus set cognitive assessment tasks diagnostic criteria existing cognitive assessment batteries differentiate adults downs syndrome dementia early stages presently diagnoses alzheimers disease adults downs syndrome made clinically relatively late stages disease without systematic cognitive functional testing time
0.22522588.11983636.html.plaintext.txt	18	neuropathological manifestations alzheimers disease downs syndrome attributed triplication overexpression gene app located chromosome 21 rumble et al 1989 increased risk dementia downs syndrome may mediated increased substrate cellular production ass peptides recent neuropathological studies shown diffuse plaques prevalent alzheimer type lesion seen individuals downs syndrome age 50 associated dementia diffuse plaques contain non fibrillar amyloid appear younger ages neuritic plaques associated neuronal degeneration appear affect structure function neurons contrast increases numbers neuritic plaques containing substantial amounts fibrillised ass peptides observed adults downs syndrome predominantly 50 years age associated neuronal degeneration loss function wisniewski et al 1995 examination age specific prevalence dementia downs syndrome supports hypothesis clinical manifestations alzheimers disease downs syndrome closely associated development fibrillised plaques lai williams 1989 visser et al 1997 holland et al 1998 lai et al 1999 see fig 1 although prevalence studies employed varying sampling diagnostic methods remarkable agreement across studies risk alzheimers disease increases primarily 50 years age addition adults downs syndrome develop dementia even reach ages presence high densities neuritic plaques presumed thus triplication gene app may serve increase diffuse plaques adults downs syndrome factors distinct app triplication must account individual differences susceptibility formation fibrillised plaques wide range age onset dementia central task epidemiology dementia downs syndrome identify factors may influence risk alzheimers disease accelerating formation ass several avenues investigation suggested existing findings review role atypical karyotypes b genetic susceptibility factors c gender oestrogen deficiency d individual differences ass peptide levels
0.22522588.11983636.html.plaintext.txt	19	neuropathological manifestations alzheimers disease downs syndrome attributed triplication overexpression gene app located chromosome 21 rumble et al 1989 increased risk dementia downs syndrome may mediated increased substrate cellular production ass peptides recent neuropathological studies shown diffuse plaques prevalent alzheimer type lesion seen individuals downs syndrome age 50 associated dementia diffuse plaques contain non fibrillar amyloid appear younger ages neuritic plaques associated neuronal degeneration appear affect structure function neurons contrast increases numbers neuritic plaques containing substantial amounts fibrillised ass peptides observed adults downs syndrome predominantly 50 years age associated neuronal degeneration loss function wisniewski et al 1995 examination age specific prevalence dementia downs syndrome supports hypothesis clinical manifestations alzheimers disease downs syndrome closely associated development fibrillised plaques lai williams 1989 visser et al 1997 holland et al 1998 lai et al 1999 see fig 1 although prevalence studies employed varying sampling diagnostic methods remarkable agreement across studies risk alzheimers disease increases primarily 50 years age addition adults downs syndrome develop dementia even reach ages presence high densities neuritic plaques presumed thus triplication gene app may serve increase diffuse plaques adults downs syndrome factors distinct app triplication must account individual differences susceptibility formation fibrillised plaques wide range age onset dementia central task epidemiology dementia downs syndrome identify factors may influence risk alzheimers disease accelerating formation ass several avenues investigation suggested existing findings review role atypical karyotypes b genetic susceptibility factors c gender oestrogen deficiency d individual differences ass peptide levels
0.22522588.11983636.html.plaintext.txt	20	view larger version 14k fig 1 age specific prevalence dementia adults downs syndrome data lai williams 1989 data visser et al 1997 data lai et al 1999 data holland et al 1998
0.22522588.11983636.html.plaintext.txt	21	view larger version 14k fig 1 age specific prevalence dementia adults downs syndrome data lai williams 1989 data visser et al 1997 data lai et al 1999 data holland et al 1998
0.22522588.11983636.html.plaintext.txt	22	atypical karyotypes top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references evidence case studies adults downs syndrome atypical karyotypes including translocations partial trisomies varying degrees mosaicism associated improved survival decreased risk alzheimers disease prasher et al 1998 presented interesting case 78 year old woman partial trisomy 21 46xxrec21dup q inv21p12q221 conducted comprehensive analysis clinical molecular genetic correlates partial trisomy general appearance suggestive typical downs syndrome phenotype experienced several common age related medical conditions characteristic downs syndrome including hypothyroidism cataracts hypotonia hearing impairment analysis gene sequences chromosome 21 using fluorescent situ hybridisation showed partial trisomy excluded region containing gene app present two copies evidence decline cognitive adaptive competence 5 years preceding death pneumonia evidence alzheimers disease found magnetic resonance imaging neuropathological assessment similarly two reports women downs syndrome 25 86 disomy chromosome 21 respectively chicoine mcguire 1997 w b zigman personal communication 2000 women characteristic downs syndrome phenotype typical age related medical conditions including hypothyroidism cataracts woman 25 disomy chromosome 21 died age 83 following hospitalisation hip fracture free dementia death woman 86 disomy still living age 74 shows evidence dementia based evaluations cognitive adaptive behaviour
0.22522588.11983636.html.plaintext.txt	23	genetic susceptibility factors top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references four genes increase risk alzheimers disease identified mutations three genes app presenilin 1 ps1 presenilin 2 ps2 associated early onset familial forms alzheimers disease transmitted autosomal dominant goate et al 1991 levy lehad et al 1995 sherrington et al 1995 homozygosity common variant ps1 1 allele associated increased risk alzheimers disease studies higuchi et al 1996 kehoe et al 1996 scott et al 1996 wragg et al 1996 one study examined influence ps1 alleles risk dementia downs syndrome study adults downs syndrome significant differences allele frequencies individuals dementia age matched individuals without dementia tyrrell et al 1999
0.22522588.11983636.html.plaintext.txt	24	polymorphisms gene apolipoprotein e apoe associated risk common late onset alzheimers disease onset 65 years age three common variants gene apoe encoded three alleles 2 3 4 numerous cross sectional case control studies patients alzheimers disease found significantly likely peers one copies apoe 4 allele corder et al 1993 mayeux et al 1993 saunders et al 1993 apoe 4 protein may act increasing rate process leads alzheimers disease predisposing greater accumulation ass without alzheimers disease roses et al 1994 hyman et al 1995 polvikoski et al 1995 presence least common allele apoe 2 associated delay disease onset even protection investigators corder et al 1994 roses et al 1994
0.22522588.11983636.html.plaintext.txt	25	polymorphisms gene apolipoprotein e apoe associated risk common late onset alzheimers disease onset 65 years age three common variants gene apoe encoded three alleles 2 3 4 numerous cross sectional case control studies patients alzheimers disease found significantly likely peers one copies apoe 4 allele corder et al 1993 mayeux et al 1993 saunders et al 1993 apoe 4 protein may act increasing rate process leads alzheimers disease predisposing greater accumulation ass without alzheimers disease roses et al 1994 hyman et al 1995 polvikoski et al 1995 presence least common allele apoe 2 associated delay disease onset even protection investigators corder et al 1994 roses et al 1994
0.22522588.11983636.html.plaintext.txt	26	apolipoprotein e downs syndrome relation apoe genotype risk alzheimers disease downs syndrome difficult establish studies consistently found presence apoe 2 allele increases longevity reduces risk dementia role 4 allele controversial hardy et al 1994 royston et al 1994 martins et al 1995 van gool et al 1995 cosgrave et al 1996 lambert et al 1996 schupf et al 1996 prasher et al 1997 schupf et al 1998 sekijima et al 1998 tyrrell et al 1998 lai et al 1999 rubinszstein et al 1999 deb et al 2000 small sample sizes importantly failure consider differences age onset dementia among without 4 allele may account negative findings since effect 4 allele expressed midlife inclusion sufficient numbers adults 50 years age analysis using survival methods adjust age years follow important methodological considerations group used survival methods analysis found presence 4 allele associated earlier onset dementia greater decline adaptive behaviour schupf et al 1996 compared apoe 33 genotype adults downs syndrome 4 allele five times likely develop dementia age 65 one 2 allele developed dementia see fig 2 among affected individuals mean age onset dementia 533 years 4 allele 580 years 33 genotype four studies found increased frequency 4 allele adults downs syndrome dementia compared downs syndrome without dementia martins et al 1995 sekijima et al 1998 rubinsztein et al 1999 deb et al 2000
0.22522588.11983636.html.plaintext.txt	27	apolipoprotein e downs syndrome relation apoe genotype risk alzheimers disease downs syndrome difficult establish studies consistently found presence apoe 2 allele increases longevity reduces risk dementia role 4 allele controversial hardy et al 1994 royston et al 1994 martins et al 1995 van gool et al 1995 cosgrave et al 1996 lambert et al 1996 schupf et al 1996 prasher et al 1997 schupf et al 1998 sekijima et al 1998 tyrrell et al 1998 lai et al 1999 rubinszstein et al 1999 deb et al 2000 small sample sizes importantly failure consider differences age onset dementia among without 4 allele may account negative findings since effect 4 allele expressed midlife inclusion sufficient numbers adults 50 years age analysis using survival methods adjust age years follow important methodological considerations group used survival methods analysis found presence 4 allele associated earlier onset dementia greater decline adaptive behaviour schupf et al 1996 compared apoe 33 genotype adults downs syndrome 4 allele five times likely develop dementia age 65 one 2 allele developed dementia see fig 2 among affected individuals mean age onset dementia 533 years 4 allele 580 years 33 genotype four studies found increased frequency 4 allele adults downs syndrome dementia compared downs syndrome without dementia martins et al 1995 sekijima et al 1998 rubinsztein et al 1999 deb et al 2000
0.22522588.11983636.html.plaintext.txt	28	view larger version 13k fig 2 cumulative incidence dementia adults downs syndrome apolipoprotein e apoe genotype unk unk apoe 34 44 genotypes apoe 33 genotype apoe 22 23 24 genotypes based schupf et al 1996 kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	29	view larger version 13k fig 2 cumulative incidence dementia adults downs syndrome apolipoprotein e apoe genotype unk unk apoe 34 44 genotypes apoe 33 genotype apoe 22 23 24 genotypes based schupf et al 1996 kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	30	results studies apoe genotype adults downs syndrome mixed several studies found apoe 2 allele decreased risk dementia sample sizes small demonstrate significant effect 4 allele hardy et al 1994 royston et al 1994 wisniewski et al 1995 two case control studies adults downs syndrome compared allele frequencies individuals without dementia found significant association apoe genotype alzheimers disease adjust age van gool et al 1995 prasher et al 1997 one large study examined 100 adults downs syndrome 40 70 years age used survival analyses examine age onset dementia apoe genotype lai et al 1999 cumulative incidence dementia age 65 55 apoe 23 genotype 88 apoe 33 genotype 100 4 allele effect 4 allele stronger younger ages consistent findings studies general population effect 4 allele accelerate onset alzheimers disease corder et al 1993 saunders et al 1993 meyer et al 1998 cumulative incidence age 55 071 among 4 allele 040 among apoe 33 genotype authors suggested 4 effect study may attenuated high rates dementia advanced ages concluded effect 4 allele may dependent age study sample
0.22522588.11983636.html.plaintext.txt	31	results studies apoe genotype adults downs syndrome mixed several studies found apoe 2 allele decreased risk dementia sample sizes small demonstrate significant effect 4 allele hardy et al 1994 royston et al 1994 wisniewski et al 1995 two case control studies adults downs syndrome compared allele frequencies individuals without dementia found significant association apoe genotype alzheimers disease adjust age van gool et al 1995 prasher et al 1997 one large study examined 100 adults downs syndrome 40 70 years age used survival analyses examine age onset dementia apoe genotype lai et al 1999 cumulative incidence dementia age 65 55 apoe 23 genotype 88 apoe 33 genotype 100 4 allele effect 4 allele stronger younger ages consistent findings studies general population effect 4 allele accelerate onset alzheimers disease corder et al 1993 saunders et al 1993 meyer et al 1998 cumulative incidence age 55 071 among 4 allele 040 among apoe 33 genotype authors suggested 4 effect study may attenuated high rates dementia advanced ages concluded effect 4 allele may dependent age study sample
0.22522588.11983636.html.plaintext.txt	32	findings consistent reduced ass deposition polvikoski et al 1995 less plaque formation benjamin et al 1994 lippa et al 1994 2 allele acceleration ass pathology 4 allele hymen et al 1995 polvikoski et al 1995 size 4 effect relation presence 4 allele early mortality interaction apoe genotype risk factors dementia downs syndrome gender level learning disability remain resolved require larger older samples analytic procedures provide better adjustment age potential confounders
0.22522588.11983636.html.plaintext.txt	33	findings consistent reduced ass deposition polvikoski et al 1995 less plaque formation benjamin et al 1994 lippa et al 1994 2 allele acceleration ass pathology 4 allele hymen et al 1995 polvikoski et al 1995 size 4 effect relation presence 4 allele early mortality interaction apoe genotype risk factors dementia downs syndrome gender level learning disability remain resolved require larger older samples analytic procedures provide better adjustment age potential confounders
0.22522588.11983636.html.plaintext.txt	34	gender oestrogen deficiency top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references loss gonadal hormones following menopause may important determinant cognitive decline risk alzheimers disease ageing women menopause oestrogen promotes growth prolongs survival cholinergic neurons brain regions serving cognitive function toran allerand et al 1992 increases cholinergic activity antioxidant properties regulates metabolism app protect formation ass jaffe et al 1994 goodman et al 1996 petanceska et al 2000
0.22522588.11983636.html.plaintext.txt	35	human studies data show higher age specific rates alzheimers disease women compared men bachman et al 1993 approximately half risk alzheimers disease women received oestrogen replacement therapy barrett conner kritz silverstein 1993 brenner et al 1994 henderson et al 1994 paganini hill henderson 1994 mortel meyer 1995 tang et al 1996 findings support hypothesis oestrogen deficiency contributes aetiology alzheimers disease contrast randomised controlled clinical trials oestrogen replacement therapy women moderate severe alzheimers disease failed show cognitive improvement suggesting major effect oestrogen delay onset rather reverse cognitive functional decline henderson et al 2000 mulnard et al 2000
0.22522588.11983636.html.plaintext.txt	36	human studies data show higher age specific rates alzheimers disease women compared men bachman et al 1993 approximately half risk alzheimers disease women received oestrogen replacement therapy barrett conner kritz silverstein 1993 brenner et al 1994 henderson et al 1994 paganini hill henderson 1994 mortel meyer 1995 tang et al 1996 findings support hypothesis oestrogen deficiency contributes aetiology alzheimers disease contrast randomised controlled clinical trials oestrogen replacement therapy women moderate severe alzheimers disease failed show cognitive improvement suggesting major effect oestrogen delay onset rather reverse cognitive functional decline henderson et al 2000 mulnard et al 2000
0.22522588.11983636.html.plaintext.txt	37	gender differences effects oestrogen downs syndrome systematically investigated work needed clarify hormonal risk factors may influence onset dementia studies presented results separately men women studies compared women men found conflicting results different studies showing earlier onset raghaven et al 1994 lai et al 1999 later onset farrer et al 1997 schupf et al 1998 difference age onset visser et al 1997 lai williams 1989 gender two studies employed survival methods examine age onset distributions gender adjusting age level learning disability found conflicting results colleagues found men downs syndrome three times likely women develop alzheimers disease age 65 see fig 3a effect gender observed age groups 50 years schupf et al 1998 men women downs syndrome show elevations follicle stimulating hormone fsh luteinising hormone puberty indicative primary gonadal dysfunction appear progress age frequent men women hasen et al 1980 campbell et al 1982 hsiang et al 1987 hestnes et al 1991 thus older men may benefit relative preservation oestrogen proposed account lower risk alzheimers disease men general population contrast another study found women downs syndrome approximately twice likely develop dementia men lai et al 1999 see fig 3b study effect gender seen primarily younger ages studies gender differences largest apoe 33 genotype suggesting high risk associated presence apoe 4 allele mask gender effects basis different results studies gender differences clear
0.22522588.11983636.html.plaintext.txt	38	gender differences effects oestrogen downs syndrome systematically investigated work needed clarify hormonal risk factors may influence onset dementia studies presented results separately men women studies compared women men found conflicting results different studies showing earlier onset raghaven et al 1994 lai et al 1999 later onset farrer et al 1997 schupf et al 1998 difference age onset visser et al 1997 lai williams 1989 gender two studies employed survival methods examine age onset distributions gender adjusting age level learning disability found conflicting results colleagues found men downs syndrome three times likely women develop alzheimers disease age 65 see fig 3a effect gender observed age groups 50 years schupf et al 1998 men women downs syndrome show elevations follicle stimulating hormone fsh luteinising hormone puberty indicative primary gonadal dysfunction appear progress age frequent men women hasen et al 1980 campbell et al 1982 hsiang et al 1987 hestnes et al 1991 thus older men may benefit relative preservation oestrogen proposed account lower risk alzheimers disease men general population contrast another study found women downs syndrome approximately twice likely develop dementia men lai et al 1999 see fig 3b study effect gender seen primarily younger ages studies gender differences largest apoe 33 genotype suggesting high risk associated presence apoe 4 allele mask gender effects basis different results studies gender differences clear
0.22522588.11983636.html.plaintext.txt	39	view larger version 12k fig 3 cumulative incidence dementia adults downs syndrome gender based schupf et al 1998 b based lai et al 1999 kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	40	view larger version 12k fig 3 cumulative incidence dementia adults downs syndrome gender based schupf et al 1998 b based lai et al 1999 kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	41	one published study examined influence oestrogen deficiency age onset dementia women downs syndrome cosgrave et al 1999 menstrual profiles risk dementia 143 women downs syndrome studied twelve women postmenopausal diagnosed dementia significant relationship age menopause age onset dementia subsample r057 although sample size small results consistent hypothesis higher endogenous oestrogen levels lower risk dementia decreasing ass peptide levels maintaining cholinergic function critical neuronal populations association age menopause onset dementia confirmed supporting hormonal data provided oestrogen replacement therapy might prove important intervention delay onset dementia
0.22522588.11983636.html.plaintext.txt	42	one published study examined influence oestrogen deficiency age onset dementia women downs syndrome cosgrave et al 1999 menstrual profiles risk dementia 143 women downs syndrome studied twelve women postmenopausal diagnosed dementia significant relationship age menopause age onset dementia subsample r057 although sample size small results consistent hypothesis higher endogenous oestrogen levels lower risk dementia decreasing ass peptide levels maintaining cholinergic function critical neuronal populations association age menopause onset dementia confirmed supporting hormonal data provided oestrogen replacement therapy might prove important intervention delay onset dementia
0.22522588.11983636.html.plaintext.txt	43	individual differences ass peptide levels top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references downs syndrome alzheimers disease deposition ass1 42 precedes appearance ass1 40 iwatsubo et al 1995 ass1 42 predominant species brains young age 50 years individuals downs syndrome ass1 40 deposits observed decade later compared age matched controls general population plasma levels ass1 42 ass1 40 increased adults downs syndrome tokuda et al 1997 mehta et al 1998 one study found increase related dementia status tokuda et al 1997 group studied plasma ass1 42 ass1 40 levels 108 adults downs syndrome without dementia compared plasma levels 64 adults without dementia general population schupf et al 2001 ass1 42 ass1 40 levels significantly higher adults downs syndrome controls general population p00001 highest adults dementia downs syndrome mean plasma levels ass1 42 ass1 40 higher individuals apoe 4 allele without 4 allele regardless dementia status see fig 4 effect apoe 4 allele ass1 42 levels may related acceleration rate amyloid fibril formation ma et al 1994 diminished clearance ass mcnamara et al 1998
0.22522588.11983636.html.plaintext.txt	44	view larger version 9k fig 4 plasma levels ass1 42 ass1 40 adults downs syndrome without dementia apoe genotype 4 allele 4 allele schupf et al 2001 permission elsevier science
0.22522588.11983636.html.plaintext.txt	45	view larger version 9k fig 4 plasma levels ass1 42 ass1 40 adults downs syndrome without dementia apoe genotype 4 allele 4 allele schupf et al 2001 permission elsevier science
0.22522588.11983636.html.plaintext.txt	46	discussion top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references factors influence formation ass apoe 4 allele oestrogen deficiency high levels ass1 42 peptides associated earlier onset dementia downs syndrome factors decrease formation ass apoe 2 allele atypical karyotypes reduce app gene dose associated lower mortality reduced risk dementia important task future work identify sources individual variation premorbid ass levels since 95 people downs syndrome triplication app associated free trisomy overexpression app cannot account differences age onset dementia within population rather joint effects variety factors including reviewed others yet identified must influence development alzheimers disease suggests need focus younger adults downs syndrome identify causes individual differences lifespan development determine begin exert effects
0.22522588.11983636.html.plaintext.txt	47	clinical implications limitations top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references clinical implications onset dementia downs syndrome modified risk factors influence formation deposition beta amyloid well triplication gene amyloid precursor protein investigation risk factor profiles considered part differential diagnosis dementia downs syndrome studies younger adults downs syndrome may help identify causes individual differences development alzheimers disease
0.22522588.11983636.html.plaintext.txt	48	limitations reliable valid cognitive assessment batteries diagnostic criteria required detect dementia early stages improve studies risk factors studies small sample sizes controlled potential confounders modifiers age gender level intellectual disability studies used prevalent rather incident cases may mask effect risk factors disease onset confounding differential survival
0.22522588.11983636.html.plaintext.txt	49	limitations reliable valid cognitive assessment batteries diagnostic criteria required detect dementia early stages improve studies risk factors studies small sample sizes controlled potential confounders modifiers age gender level intellectual disability studies used prevalent rather incident cases may mask effect risk factors disease onset confounding differential survival
0.22522588.11983636.html.plaintext.txt	50	acknowledgments top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references thank collaborators work richard mayeux md warren zigman phd wayne silverman phd benjamin tycko md pankaj mehta phd edmund jenkins phd deborah pang mph bindu patel mph
0.22522588.11983636.html.plaintext.txt	51	references top abstract introduction amyloid cascade hypothesis atypical karyotypes genetic susceptibility factors gender oestrogen deficiency individual differences discussion clinical implications acknowledgments references aylward e h burt d b thorpe l u et al 1997 diagnosis dementia individuals intellectual disability journal intellectual disability research 41 152 164medline
0.22522588.11983636.html.plaintext.txt	52	received publication january 5 2001 revision received june 8 2001 accepted publication june 13 2001
0.22522588.11983636.html.plaintext.txt	53	received publication january 5 2001 revision received june 8 2001 accepted publication june 13 2001
0.22725685.14559775.html.plaintext.txt	0	fine mapping catenin gene quantitative trait locus chromosome 10 late onset alzheimers disease pedigrees nilufer ertekin taner1 james ronald1 hideaki asahara1 linda younkin1 maria hella1 shushant jain1 eugene gnida1 samuel younkin1 daniel fadale1 yasumasa ohyagi2 adam singleton1 leah scanlin1 mariza de andrade3 ronald petersen4 neill graff radford5 michael hutton1 steven younkin1
0.22725685.14559775.html.plaintext.txt	1	1department neuroscience mayo clinic jacksonville jacksonville fl usa 2department neurology neurological institute graduate school medical sciences kyushu university fukuoka japan 3department health sciences research division biostatistics mayo clinic rochester rochester mn usa 4department neurology mayo clinic rochester rochester mn usa 5department neurology mayo clinic jacksonville jacksonville fl usa
0.22725685.14559775.html.plaintext.txt	2	received july 29 2003 revised september 23 2003 accepted october 7 2003
0.22725685.14559775.html.plaintext.txt	3	abstract top abstract introduction results discussion subjects methods references using plasma amyloid ss protein ass42 levels intermediate quantitative phenotype late onset alzheimers disease load previously obtained significant linkage 80 cm chromosome 10 linkage region obtained independently study affected load sib pairs together two studies provide strong evidence novel load locus chromosome 10 acts increase ass42 vr22 large 17 mb gene located 80 cm encodes catenin binding partner ss catenin makes vr22 attractive candidate gene ss catenin interacts presenilin 1 many mutations elevate ass42 cause early onset familial ad identified two intronic vr22 snps 4360 4783 strong linkage disequilibrium ld showed highly significant association p00001 00006 plasma ass42 10 extended load families association clearly contributed linkage 80 cm lod scores decreased linkage analysis performed conditional upon vr22 association association replicated another independent set 12 load families p004 4783 p008 4360 bounding association region using multiple snps showed vr22 confirmed gene within region association findings indicate vr22 variants influence ass42 contribute previously reported linkage plasma ass42 load families
0.22725685.14559775.html.plaintext.txt	4	abstract top abstract introduction results discussion subjects methods references using plasma amyloid ss protein ass42 levels intermediate quantitative phenotype late onset alzheimers disease load previously obtained significant linkage 80 cm chromosome 10 linkage region obtained independently study affected load sib pairs together two studies provide strong evidence novel load locus chromosome 10 acts increase ass42 vr22 large 17 mb gene located 80 cm encodes catenin binding partner ss catenin makes vr22 attractive candidate gene ss catenin interacts presenilin 1 many mutations elevate ass42 cause early onset familial ad identified two intronic vr22 snps 4360 4783 strong linkage disequilibrium ld showed highly significant association p00001 00006 plasma ass42 10 extended load families association clearly contributed linkage 80 cm lod scores decreased linkage analysis performed conditional upon vr22 association association replicated another independent set 12 load families p004 4783 p008 4360 bounding association region using multiple snps showed vr22 confirmed gene within region association findings indicate vr22 variants influence ass42 contribute previously reported linkage plasma ass42 load families
0.22725685.14559775.html.plaintext.txt	5	introduction top abstract introduction results discussion subjects methods references late onset alzheimers disease load complex genetic disorder 1 onset defined 60 65 years age twin studies suggested much 74 risk load may due genetic factors 23 well established apoe plays important role genetics load 45 recent study estimated however four additional loci make contribution variance load age onset effect size similar greater apoe 6 given heterogeneity likely least five loci contribute substantially genetics load surprising large number single gene association studies performed far failed identify variants associate reproducibly load reasons failure replication possible gene gene gene environment interactions difficult account poor study design
0.22725685.14559775.html.plaintext.txt	6	introduction top abstract introduction results discussion subjects methods references late onset alzheimers disease load complex genetic disorder 1 onset defined 60 65 years age twin studies suggested much 74 risk load may due genetic factors 23 well established apoe plays important role genetics load 45 recent study estimated however four additional loci make contribution variance load age onset effect size similar greater apoe 6 given heterogeneity likely least five loci contribute substantially genetics load surprising large number single gene association studies performed far failed identify variants associate reproducibly load reasons failure replication possible gene gene gene environment interactions difficult account poor study design
0.22725685.14559775.html.plaintext.txt	7	several groups 7 9 suggested quantitative intermediate phenotypes may useful unraveling complex genetics disorders load clinical disease states load likely result uncertain complex sequence pathophysiologic events whereas intermediate phenotypes may directly related action set genes easily identified thus identification genes variants contribute specific intermediate phenotypes may tractable way identify least genes contribute diseases governed complex genetics optimize utility approach important select intermediate phenotypes highly heritable close biological link disease question
0.22725685.14559775.html.plaintext.txt	8	several groups 7 9 suggested quantitative intermediate phenotypes may useful unraveling complex genetics disorders load clinical disease states load likely result uncertain complex sequence pathophysiologic events whereas intermediate phenotypes may directly related action set genes easily identified thus identification genes variants contribute specific intermediate phenotypes may tractable way identify least genes contribute diseases governed complex genetics optimize utility approach important select intermediate phenotypes highly heritable close biological link disease question
0.22725685.14559775.html.plaintext.txt	9	studies focused levels amyloid ss protein ass specifically ass42 quantitative intermediate phenotype load ass secreted protein 10 12 derived set large precursor proteins collectively referred amyloid ss protein precursor secreted ass produced virtually cells readily detected human plasma cerebrospinal fluid secreted ass forty amino acids ass40 small fraction 5 10 two additional amino acids carboxyl terminus ass42 13 15 brains patients ad large amount ass aggregates deposited senile plaques much form highly insoluble amyloid fibrils make definite diagnosis ad large numbers senile plaques neurofibrillary tangles must demonstrated brain autopsy 16 load patients large amount ass deposited senile plaques ends ass42 one third cases ass ending ass42 essentially form ass deposited one third predominant form one third large amount ass40 also deposited 17 worth noting synthetic ass40 ass42 spontaneously assemble amyloid fibrils vitro ass42 forms amyloid fibrils far rapidly ass40 1819 brain high levels app mrna concentration ass cerebrospinal fluid 50 times higher plasma mixed fetal brain cultures produce far ass types cultured cells 122021 thus likely senile plaques form specifically brain ass levels higher brain organs
0.22725685.14559775.html.plaintext.txt	10	studies focused levels amyloid ss protein ass specifically ass42 quantitative intermediate phenotype load ass secreted protein 10 12 derived set large precursor proteins collectively referred amyloid ss protein precursor secreted ass produced virtually cells readily detected human plasma cerebrospinal fluid secreted ass forty amino acids ass40 small fraction 5 10 two additional amino acids carboxyl terminus ass42 13 15 brains patients ad large amount ass aggregates deposited senile plaques much form highly insoluble amyloid fibrils make definite diagnosis ad large numbers senile plaques neurofibrillary tangles must demonstrated brain autopsy 16 load patients large amount ass deposited senile plaques ends ass42 one third cases ass ending ass42 essentially form ass deposited one third predominant form one third large amount ass40 also deposited 17 worth noting synthetic ass40 ass42 spontaneously assemble amyloid fibrils vitro ass42 forms amyloid fibrils far rapidly ass40 1819 brain high levels app mrna concentration ass cerebrospinal fluid 50 times higher plasma mixed fetal brain cultures produce far ass types cultured cells 122021 thus likely senile plaques form specifically brain ass levels higher brain organs
0.22725685.14559775.html.plaintext.txt	11	app presenilin 1 presenilin 2 genes many fully penetrant mutations cause early onset familial ad eofad 22 25 apart early onset causation specific mutations eofad clinically pathologically indistinguishable load others shown eofad mutations increase ass42 sometimes increase ass40 well 1526 30 importantly observed plasma ass42 elevations eofad patients young cognitively normal carriers eofad mutations 31 also observed ass42 elevations plasma non demented relatives load patients ages 20 65 32 importantly elevations associated apoe4 allele variants eofad genes 32 finally mayeux et al 33 found longitudinal study unrelated elderly individuals subsequently developed ad higher plasma levels ass42 remained free dementia collectively findings show ass42 closely linked ad investigate heritability plasma ass analyzed extended load families found plasma ass40 ass42 levels substantial heritability 34
0.22725685.14559775.html.plaintext.txt	12	app presenilin 1 presenilin 2 genes many fully penetrant mutations cause early onset familial ad eofad 22 25 apart early onset causation specific mutations eofad clinically pathologically indistinguishable load others shown eofad mutations increase ass42 sometimes increase ass40 well 1526 30 importantly observed plasma ass42 elevations eofad patients young cognitively normal carriers eofad mutations 31 also observed ass42 elevations plasma non demented relatives load patients ages 20 65 32 importantly elevations associated apoe4 allele variants eofad genes 32 finally mayeux et al 33 found longitudinal study unrelated elderly individuals subsequently developed ad higher plasma levels ass42 remained free dementia collectively findings show ass42 closely linked ad investigate heritability plasma ass analyzed extended load families found plasma ass40 ass42 levels substantial heritability 34
0.22725685.14559775.html.plaintext.txt	13	given findings level plasma ass42 likely useful intermediate quantitative phenotype load performed variance components linkage analysis trait group extended load pedigrees analysis showed significant linkage locus 80 cm chromosome 10 35 linkage region obtained independently study affected load sib pairs 36 together two studies provide strong evidence novel load locus chromosome 10 acts increase ass42 sib pair group estimated effect locus equivalent apoe suggesting likely major risk factor load third group found linkage downstream region chromosome 10 focused insulin degrading enzyme ide possible candidate gene region 37 recently fourth group using age onset quantitative phenotype ad parkinsons disease pd families found suggestive linkage chromosome 10 133 135 cm 38
0.22725685.14559775.html.plaintext.txt	14	given findings level plasma ass42 likely useful intermediate quantitative phenotype load performed variance components linkage analysis trait group extended load pedigrees analysis showed significant linkage locus 80 cm chromosome 10 35 linkage region obtained independently study affected load sib pairs 36 together two studies provide strong evidence novel load locus chromosome 10 acts increase ass42 sib pair group estimated effect locus equivalent apoe suggesting likely major risk factor load third group found linkage downstream region chromosome 10 focused insulin degrading enzyme ide possible candidate gene region 37 recently fourth group using age onset quantitative phenotype ad parkinsons disease pd families found suggestive linkage chromosome 10 133 135 cm 38
0.22725685.14559775.html.plaintext.txt	15	important advantage variance components approach employed candidate genes identified likely effect ass42 evaluated systematically determine much various within gene variants contribute linkage study analyzed vr22 variants contribute linkage signal chromosome 10 location function make vr22 strong candidate gene located 80 cm peak previously reported linkage signal vr22 encodes novel catenin catenin recently cloned jannsens et al 39 catenins interact closely ss catenin play important role intercellular adhesion strong intercellular adhesion depends linkage cadherins actin cytoskeleton via ss catenin complex catenin closely homologous n catenin neuron specific e catenin expressed tissues catenin expressed high levels testis heart also expressed human mouse brain 39 catenin overall sequence identity 56 58 e n catenin respectively importantly jannsens et al 39 shown catenin interacts ss catenin functionally effective fashion makes vr22 strong functional candidate ss catenin interacts presenilin 1 40 many mutations increase ass42 262931 cause early onset familial ad 24 zhang et al 40 shown loss signalling ss catenin pathway leads enhanced neuronal vulnerability ass addition ss catenin presenilin forms complex leads stabilization former destabilization complex leads ss catenin degradation enhanced neuronal apoptosis presenilin mutations shown lead destabilization ss catenin presenilin complex degradation ss catenin enhanced ass production given catenins provide link ss catenin binding counterparts presenilins actin cytoskeleton possible postulate mutations catenins could lead disruption stability ss catenin presenilin complex resulting enhanced neuronal vulnerability cells ass increased ass production
0.22725685.14559775.html.plaintext.txt	16	important advantage variance components approach employed candidate genes identified likely effect ass42 evaluated systematically determine much various within gene variants contribute linkage study analyzed vr22 variants contribute linkage signal chromosome 10 location function make vr22 strong candidate gene located 80 cm peak previously reported linkage signal vr22 encodes novel catenin catenin recently cloned jannsens et al 39 catenins interact closely ss catenin play important role intercellular adhesion strong intercellular adhesion depends linkage cadherins actin cytoskeleton via ss catenin complex catenin closely homologous n catenin neuron specific e catenin expressed tissues catenin expressed high levels testis heart also expressed human mouse brain 39 catenin overall sequence identity 56 58 e n catenin respectively importantly jannsens et al 39 shown catenin interacts ss catenin functionally effective fashion makes vr22 strong functional candidate ss catenin interacts presenilin 1 40 many mutations increase ass42 262931 cause early onset familial ad 24 zhang et al 40 shown loss signalling ss catenin pathway leads enhanced neuronal vulnerability ass addition ss catenin presenilin forms complex leads stabilization former destabilization complex leads ss catenin degradation enhanced neuronal apoptosis presenilin mutations shown lead destabilization ss catenin presenilin complex degradation ss catenin enhanced ass production given catenins provide link ss catenin binding counterparts presenilins actin cytoskeleton possible postulate mutations catenins could lead disruption stability ss catenin presenilin complex resulting enhanced neuronal vulnerability cells ass increased ass production
0.22725685.14559775.html.plaintext.txt	17	results top abstract introduction results discussion subjects methods references association vr22 snps plasma ass42 initial assessment vr22 examined three snps 4825 ca 4783 ag 4360 tc intron exons 10 11 snps table 1 spanned 465 bp genotyped 10 extended load families previously analyzed linkage 35 order minimize age dementia related environmental effects plasma ass42 levels performed analyses 20 65 year age group previous studies 3435 effect three vr22 snps analyzed encoding covariate testing effect variance plasma ass42 regression style approach implemented solar table 1 control effect linkage linkage component included null alternative models tested 4360 tc 4783 ag snps strong linkage disequilibrium showed strong association p00001 00006 respectively 4825 snp showed marginal association p006 table 1 three snps also examined second set 12 additional load families table 1 34 vr22 4783 snp showed significant association p004 vr22 4360 snp yielded marginal association p008 vr22 4825 snp yield significant association p098 additional smaller dataset 22 families combined significance association reached p59x10 6 4783 21x10 6 4360 snps table 1 figure 1 depicts box plots 10logass42 levels 22 families stratified significant vr22 4360 snp genotypes consistent association results genotype dependent effect plasma ass levels observed 4360 tt genotype associated highest ass42 levels ct intermediate levels cc lowest levels
0.22725685.14559775.html.plaintext.txt	18	results top abstract introduction results discussion subjects methods references association vr22 snps plasma ass42 initial assessment vr22 examined three snps 4825 ca 4783 ag 4360 tc intron exons 10 11 snps table 1 spanned 465 bp genotyped 10 extended load families previously analyzed linkage 35 order minimize age dementia related environmental effects plasma ass42 levels performed analyses 20 65 year age group previous studies 3435 effect three vr22 snps analyzed encoding covariate testing effect variance plasma ass42 regression style approach implemented solar table 1 control effect linkage linkage component included null alternative models tested 4360 tc 4783 ag snps strong linkage disequilibrium showed strong association p00001 00006 respectively 4825 snp showed marginal association p006 table 1 three snps also examined second set 12 additional load families table 1 34 vr22 4783 snp showed significant association p004 vr22 4360 snp yielded marginal association p008 vr22 4825 snp yield significant association p098 additional smaller dataset 22 families combined significance association reached p59x10 6 4783 21x10 6 4360 snps table 1 figure 1 depicts box plots 10logass42 levels 22 families stratified significant vr22 4360 snp genotypes consistent association results genotype dependent effect plasma ass levels observed 4360 tt genotype associated highest ass42 levels ct intermediate levels cc lowest levels
0.22725685.14559775.html.plaintext.txt	19	view table figure 1 dose dependent effect vr22 4360 snp plasma ass42 levels extended load families box plots depicting median middle part box 25th percentile lower limit box 75th percentile upper limit box 10th percentile lower end line 90th percentile upper end line 10logass42 levels 20 65 year old family members 22 load families plots depicted separately vr22 4360 genotypes tt red ct green cc blue
0.22725685.14559775.html.plaintext.txt	20	determine snps region vr22 gene show stronger association analyzed 10 additional snps total 13 snps analyzed region spanning 88 kb table 2 hcv3096482 hcv11295092 snps 88 kb region linkage disequilibrium many snps region showed nominally significant association none showed association stronger observed 4360 4783 table 1
0.22725685.14559775.html.plaintext.txt	21	determine snps region vr22 gene show stronger association analyzed 10 additional snps total 13 snps analyzed region spanning 88 kb table 2 hcv3096482 hcv11295092 snps 88 kb region linkage disequilibrium many snps region showed nominally significant association none showed association stronger observed 4360 4783 table 1
0.22725685.14559775.html.plaintext.txt	22	view table table 2 p values association plasma ass42 20 65 year old subjects extended load families bounding association vr22 snps plasma ass42 bound region vr22 43604783 association evaluated total 49 additional snps spaced either side 4360 4783 snps snps selected several groups designed span entire vr22 gene 250 kb intervals well region 3 vr22 known exons vr22 433 kb median away closest snp closest snp group mean538 kb 22 149 kb given extent ld human genome estimated different studies anywhere 10 100 kb 41 45 extent one genomic region predictable priori possible miss association signals due variants snp groups however given size vr22 extent coverage throughout outside gene association signals identify 4360 4783 vr22 snps well bounded within vr22 snp genotyping design three six snps analyzed group linkage disequilibrium significantly associating 4360 snp snps analyzed 22 combined families fig 2a using covariate style regression approach snp analyzed association plasma ass42 10 12 22 combined load families table 2 fig 2b
0.22725685.14559775.html.plaintext.txt	23	view larger version 18k figure 2 boundaries vr22 43604783 association marker marker linkage disequilibrium snps analyzed respect 4360 snp horizontal line shows position 17 mb vr22 gene dashed line shows d075 b marker phenotype plasma ass42 association horizontal line shows position 17 mb vr22 gene dashed line shows p005
0.22725685.14559775.html.plaintext.txt	24	view larger version 18k figure 2 boundaries vr22 43604783 association marker marker linkage disequilibrium snps analyzed respect 4360 snp horizontal line shows position 17 mb vr22 gene dashed line shows d075 b marker phenotype plasma ass42 association horizontal line shows position 17 mb vr22 gene dashed line shows p005
0.22725685.14559775.html.plaintext.txt	25	3 5 sides strongly associating 4360 snp ld flanking snps fell essentially baseline levels within large vr22 gene 5 side snp association ass42 also decreased baseline levels within vr22 gene fig 2b 3 side significance snp association decreased 2 orders magnitude 00001 4360 003 significantly associated snp nearest snp group hcv1380042 fig 2b table 2 association baseline levels 3 side 1 000 kb 3 margin vr22
0.22725685.14559775.html.plaintext.txt	26	3 5 sides strongly associating 4360 snp ld flanking snps fell essentially baseline levels within large vr22 gene 5 side snp association ass42 also decreased baseline levels within vr22 gene fig 2b 3 side significance snp association decreased 2 orders magnitude 00001 4360 003 significantly associated snp nearest snp group hcv1380042 fig 2b table 2 association baseline levels 3 side 1 000 kb 3 margin vr22
0.22725685.14559775.html.plaintext.txt	27	bounding approach effectively limits region potential association 3 5 sides 4360 within vr22 thus data provide strong evidence association 4360 4783 snps plasma ass42 due variants vr22 gene
0.22725685.14559775.html.plaintext.txt	28	bounding approach effectively limits region potential association 3 5 sides 4360 within vr22 thus data provide strong evidence association 4360 4783 snps plasma ass42 due variants vr22 gene
0.22725685.14559775.html.plaintext.txt	29	given total 51 snps genotyped issue multiple testing raised many snps linkage disequilibrium therefore independent one another fig 2b therefore simple bonferroni correction assumption 51 independent tests overly conservative study nonetheless even bonferroni correction applied 4783 4360 snps still significant 10 families p003 0005 22 combined families p00003 00001 association smaller set 12 families longer significant overly conservative correction p2 4 4783 4360 respectively nonetheless inclusion analysis leads improved evidence association
0.22725685.14559775.html.plaintext.txt	30	given total 51 snps genotyped issue multiple testing raised many snps linkage disequilibrium therefore independent one another fig 2b therefore simple bonferroni correction assumption 51 independent tests overly conservative study nonetheless even bonferroni correction applied 4783 4360 snps still significant 10 families p003 0005 22 combined families p00003 00001 association smaller set 12 families longer significant overly conservative correction p2 4 4783 4360 respectively nonetheless inclusion analysis leads improved evidence association
0.22725685.14559775.html.plaintext.txt	31	contribution vr22 association linkage 80 cm next investigated contribution vr22 43604783 association linkage previously reported initial linkage findings obtained using seven markers covering 14 cm chromosome 10 analyze entirety chromosome 10 genotyped 26 additional markers spanning 165 cm 10 load families 10 families combined best two point lod scores obtained 4783 262 4360 217 peak described multipoint lod scores broadened flattened considerably incorporation additional markers maximum multipoint lod score continued 80 cm fig 3
0.22725685.14559775.html.plaintext.txt	32	contribution vr22 association linkage 80 cm next investigated contribution vr22 43604783 association linkage previously reported initial linkage findings obtained using seven markers covering 14 cm chromosome 10 analyze entirety chromosome 10 genotyped 26 additional markers spanning 165 cm 10 load families 10 families combined best two point lod scores obtained 4783 262 4360 217 peak described multipoint lod scores broadened flattened considerably incorporation additional markers maximum multipoint lod score continued 80 cm fig 3
0.22725685.14559775.html.plaintext.txt	33	view larger version 11k figure 3 effect vr22 snp 4360 multipoint lod scores mls load families effect vr22 4360 linkage plasma ass42 10 load families black line linkage gray line linkage conditional upon association vr22 4360 snp multipoint ibds used analyses generated using 31 markers described text
0.22725685.14559775.html.plaintext.txt	34	view larger version 11k figure 3 effect vr22 snp 4360 multipoint lod scores mls load families effect vr22 4360 linkage plasma ass42 10 load families black line linkage gray line linkage conditional upon association vr22 4360 snp multipoint ibds used analyses generated using 31 markers described text
0.22725685.14559775.html.plaintext.txt	35	reason broader flatter peak fine mapping analysis may several fold first utilized mcmc mibd estimation implemented simwalk2 package 4647 multipoint linkage results presented paper opposed regression based mibd estimation algorithm implemented solar used original paper 34 see also subjects methods second genotyping additional markers leads information regarding recombination could potentially lead decrease original linkage signal obtained fewer markers third utilizing larger number markers increases likelihood map genotyping errors despite implementation strict genotype quality control measures indeed others also found fine mapping markers lead lowering original lod scores obtained lesser number markers 4849
0.22725685.14559775.html.plaintext.txt	36	reason broader flatter peak fine mapping analysis may several fold first utilized mcmc mibd estimation implemented simwalk2 package 4647 multipoint linkage results presented paper opposed regression based mibd estimation algorithm implemented solar used original paper 34 see also subjects methods second genotyping additional markers leads information regarding recombination could potentially lead decrease original linkage signal obtained fewer markers third utilizing larger number markers increases likelihood map genotyping errors despite implementation strict genotype quality control measures indeed others also found fine mapping markers lead lowering original lod scores obtained lesser number markers 4849
0.22725685.14559775.html.plaintext.txt	37	evaluate extent 4360 4783 snps functional snps associated tightly linked pair account linkage observed repeated linkage analysis regressing effect vr22 4360 association including covariate linkage model regressing effect snp multipoint linkage signal diminished substantially 10 combined families fig 3 marked diminution lod scores indicates substantial proportion linkage signal plasma ass42 accounted vr22 4360 association residual linkage signal persisted regressing vr22 4360 association indicates likely additional variants contribute linkage though residual signal may also due random variation diminution maximum multipoint lod scores upon inclusion 4360 snp covariate also evident comparison variance component model excludes covariate table 3b one includes table 3c p value major gene effect maximum multipoint locus goes 0004 016 trend observed twopoint linkage 4360 snp assessed without including 4360 covariate table 3d e p value major gene 4360 locus loses significance p0009 p0038
0.22725685.14559775.html.plaintext.txt	38	evaluate extent 4360 4783 snps functional snps associated tightly linked pair account linkage observed repeated linkage analysis regressing effect vr22 4360 association including covariate linkage model regressing effect snp multipoint linkage signal diminished substantially 10 combined families fig 3 marked diminution lod scores indicates substantial proportion linkage signal plasma ass42 accounted vr22 4360 association residual linkage signal persisted regressing vr22 4360 association indicates likely additional variants contribute linkage though residual signal may also due random variation diminution maximum multipoint lod scores upon inclusion 4360 snp covariate also evident comparison variance component model excludes covariate table 3b one includes table 3c p value major gene effect maximum multipoint locus goes 0004 016 trend observed twopoint linkage 4360 snp assessed without including 4360 covariate table 3d e p value major gene 4360 locus loses significance p0009 p0038
0.22725685.14559775.html.plaintext.txt	39	view table table 3 variance components models depicting effect 4360 snp multipoint twopoint linkage discussion top abstract introduction results discussion subjects methods references study analyzed vr22 gene chromosome 10 determine functional snps contribute linkage signal plasma ass42 previously reported extended load families found two vr22 snps 4360 4783 showed significant robust association plasma ass42 20 65 year old family members extended load families two snps 423 bp apart strong ld give virtually identical results 4360 4783 snps located 177 kb intron exons 10 11 distance 14 kb exon 11 identified 11 additional snps within 6 kb 43604783 eight intron exons 10 11 three intron exons 11 12 none snps gave significant association 43604783 careful bounding showed large 17 mb vr22 gene confirmed gene within region 43604783 association analyses 4360 used covariate null linkage models reduced multipoint lod score indicating vr22 43604783 association contributes linkage large reduction observed 10 families analyzed suggests 43604783 association contributes substantially linkage signal observed families presence residual linkage regressing effect vr22 4360 snp indicates however 4360 association entirely account linkage thus data provide substantial evidence vr22 variants contribute linkage signal previously reported though residual linkage signal may due random variation could also indicate may additional variants contribute linkage whether variants large vr22 gene nearby genes remains determined
0.22725685.14559775.html.plaintext.txt	40	since intronic snps located 14 kb nearest exon 4360 4783 unlikely functional effect association ass42 presumably occurs ld one several functional vr22 snps sequencing vr22 exons reported vr22 transcript 39 failed identify potentially functional snps could account 43604783 association possible functional snps affect splicing known alternatively spliced exons strong ld 43604783
0.22725685.14559775.html.plaintext.txt	41	since intronic snps located 14 kb nearest exon 4360 4783 unlikely functional effect association ass42 presumably occurs ld one several functional vr22 snps sequencing vr22 exons reported vr22 transcript 39 failed identify potentially functional snps could account 43604783 association possible functional snps affect splicing known alternatively spliced exons strong ld 43604783
0.22725685.14559775.html.plaintext.txt	42	basic premise studying plasma ass42 intermediate phenotype genes variants influence plasma ass42 genes variants influence risk load results reported useful identify vr22 gene variants influence plasma ass42 thereby increasing likelihood vr22 gene one genes 80 cm region chromosome 10 variants influence risk load important unanswered question well effect snp plasma ass42 correlate effect ad phenotype unlikely change plasma ass42 caused specific genetic variant directly increases risk ad increased risk ad probably produced related effect variant within brain thus conceivable perhaps even likely specific variant strong influence plasma ass42 may sometimes little influence ad phenotype vice versa thoroughly studying several genes elucidating effects entire set functional variants plasma ass42 ad phenotypes question answered may effects two phenotypes correlate well variants genes poorly others
0.22725685.14559775.html.plaintext.txt	43	basic premise studying plasma ass42 intermediate phenotype genes variants influence plasma ass42 genes variants influence risk load results reported useful identify vr22 gene variants influence plasma ass42 thereby increasing likelihood vr22 gene one genes 80 cm region chromosome 10 variants influence risk load important unanswered question well effect snp plasma ass42 correlate effect ad phenotype unlikely change plasma ass42 caused specific genetic variant directly increases risk ad increased risk ad probably produced related effect variant within brain thus conceivable perhaps even likely specific variant strong influence plasma ass42 may sometimes little influence ad phenotype vice versa thoroughly studying several genes elucidating effects entire set functional variants plasma ass42 ad phenotypes question answered may effects two phenotypes correlate well variants genes poorly others
0.22725685.14559775.html.plaintext.txt	44	results reported indicate vr22 variants significantly associate plasma ass42 account substantial portion linkage signal chromosome 10 additional analysis needed identify entire set functional variants account ass42 linkage 80 cm identified important test effects ass production vr22 gene function biological experiments well determine whether functional variants modify risk ad
0.22725685.14559775.html.plaintext.txt	45	results reported indicate vr22 variants significantly associate plasma ass42 account substantial portion linkage signal chromosome 10 additional analysis needed identify entire set functional variants account ass42 linkage 80 cm identified important test effects ass production vr22 gene function biological experiments well determine whether functional variants modify risk ad
0.22725685.14559775.html.plaintext.txt	46	subjects methods top abstract introduction results discussion subjects methods references subjects collected 10 extended load families composed 292 individuals 205 ages 20 65 four families collected via load patient extremely high plasma ass42 andor ass40 levels extremes top 10th percentile 545 ad patients analyzed remaining six families ascertained via load proband multiple relatives load without prior ass measurements non extremes one probands non extreme families determined extremely high plasma ass levels family collection therefore family grouped extreme families subsequently except one family distinction extreme non extreme families made priori family collection based plasma ass42 levels proband detailed collection strategies family profiles families provided elsewhere 3435 addition 10 families 12 independent extended load pedigrees collected additional pedigrees proband first degree relative load patient elevated plasma ass levels 34 contributed 88 subjects ages 20 65 study approved appropriate institutional review board appropriate informed consent obtained participants
0.22725685.14559775.html.plaintext.txt	47	subjects methods top abstract introduction results discussion subjects methods references subjects collected 10 extended load families composed 292 individuals 205 ages 20 65 four families collected via load patient extremely high plasma ass42 andor ass40 levels extremes top 10th percentile 545 ad patients analyzed remaining six families ascertained via load proband multiple relatives load without prior ass measurements non extremes one probands non extreme families determined extremely high plasma ass levels family collection therefore family grouped extreme families subsequently except one family distinction extreme non extreme families made priori family collection based plasma ass42 levels proband detailed collection strategies family profiles families provided elsewhere 3435 addition 10 families 12 independent extended load pedigrees collected additional pedigrees proband first degree relative load patient elevated plasma ass levels 34 contributed 88 subjects ages 20 65 study approved appropriate institutional review board appropriate informed consent obtained participants
0.22725685.14559775.html.plaintext.txt	48	microsatellite genotyping dna extracted peripheral blood leukocytes using routine methods genotypes microsatellites obtained using abi 377 3100 sequencers associated genescangenotyper software packages single nucleotide polymorphisms snps genotyped using taqman chemistry software designing primers probes implemented within abi prism 7900 ht sequence detection system pedigree structure phenotypic genotypic information maintained pedsys httpwwwsfbrorgsfbrpublicsoftwarepedsyspedsyshtml 50 also produced output files analyses performed solar explained order location 27 chromosome 10 microsatellite markers determined marshfield linkage map two markers d10s1435 d10s1211 locations marshfield linkage map 51 placed linkage map according location estimates obtained map o mat program httpcompgenrutgersedumapomat 52 two snps found vr22 gene also used markers linkage analysis snps 4360tc 4783ag located 61137462 61137039 bp respectively chromosome 10 genomic map celera database httpwwwceleracom two snps placed linkage map based approximate centimorgan locations estimated physical maps
0.22725685.14559775.html.plaintext.txt	49	microsatellite genotyping dna extracted peripheral blood leukocytes using routine methods genotypes microsatellites obtained using abi 377 3100 sequencers associated genescangenotyper software packages single nucleotide polymorphisms snps genotyped using taqman chemistry software designing primers probes implemented within abi prism 7900 ht sequence detection system pedigree structure phenotypic genotypic information maintained pedsys httpwwwsfbrorgsfbrpublicsoftwarepedsyspedsyshtml 50 also produced output files analyses performed solar explained order location 27 chromosome 10 microsatellite markers determined marshfield linkage map two markers d10s1435 d10s1211 locations marshfield linkage map 51 placed linkage map according location estimates obtained map o mat program httpcompgenrutgersedumapomat 52 two snps found vr22 gene also used markers linkage analysis snps 4360tc 4783ag located 61137462 61137039 bp respectively chromosome 10 genomic map celera database httpwwwceleracom two snps placed linkage map based approximate centimorgan locations estimated physical maps
0.22725685.14559775.html.plaintext.txt	50	identification genotyping snps vr22 genomic mrna sequences initially obtained national center biotechnology information ncbi web site using genomic contig nt008663 af091606 order identify snps primers designed cover known exons 7 kb intronic region exons 10 11 load cases elderly control subjects family members extended load pedigrees sequenced identify polymorphisms initial sequencing vr22 exons 7 kb intronic region identified three snps intronic 7 kb region 4825 4783 4360 subsequently many additional snps vr22 flanking genes identified using celera database aim cover region using snp groups located every 250 kb group composed 3 5 snps separated 1 5 kb total 51 snps including vr22 4360 4783 genotyped throughout vr22 3 anxa2p3 5 sirt1 flanking genes snps within group found strong ld snp locations obtained celera sequence map
0.22725685.14559775.html.plaintext.txt	51	identification genotyping snps vr22 genomic mrna sequences initially obtained national center biotechnology information ncbi web site using genomic contig nt008663 af091606 order identify snps primers designed cover known exons 7 kb intronic region exons 10 11 load cases elderly control subjects family members extended load pedigrees sequenced identify polymorphisms initial sequencing vr22 exons 7 kb intronic region identified three snps intronic 7 kb region 4825 4783 4360 subsequently many additional snps vr22 flanking genes identified using celera database aim cover region using snp groups located every 250 kb group composed 3 5 snps separated 1 5 kb total 51 snps including vr22 4360 4783 genotyped throughout vr22 3 anxa2p3 5 sirt1 flanking genes snps within group found strong ld snp locations obtained celera sequence map
0.22725685.14559775.html.plaintext.txt	52	variance components analysis employed variance components methodology implemented software package solar 5354 estimate heritability plasma ass42 levels perform linkage association analyses detect quantitative trait loci qtls affect variance ass42 extended load families method described detail elsewhere 5354 estimates amount variance quantitative trait due particular genetic locus q2 residual genetic factors g2 individual specific random environmental factors e2 based phenotype covariance arbitrary relative pairs covariance matrix takes form
0.22725685.14559775.html.plaintext.txt	53	variance components analysis employed variance components methodology implemented software package solar 5354 estimate heritability plasma ass42 levels perform linkage association analyses detect quantitative trait loci qtls affect variance ass42 extended load families method described detail elsewhere 5354 estimates amount variance quantitative trait due particular genetic locus q2 residual genetic factors g2 individual specific random environmental factors e2 based phenotype covariance arbitrary relative pairs covariance matrix takes form
0.22725685.14559775.html.plaintext.txt	54	matrix probabilities pair individuals share genetic material identical descent given chromosomal location estimated genetic marker data 2 matrix kinship coefficients describing polygenic factors identity matrix describing sporadic environmental factors
0.22725685.14559775.html.plaintext.txt	55	addition effect shared environment h2 variance trait also estimated including household matrix model matrix whose ijth element equal 1 individuals j share specified environment 0 otherwise family collection largely composed extended pedigrees measured plasma ass members family single batch elisas rigorously account possible assay batch batch variations may affect variance plasma ass42 included household matrix models since almost individuals family measured one batch household matrix included element1 individuals extended family 0 otherwise realize probably overly conservative since shared family household effect employed account potential batch batch variance assay overlaps kinship effect 55 inclusion household matrix almost certainly overcorrects batch batch variance underestimates shared genetic effect reason performed heritability linkage analyses without household matrix model multipoint results shown figures 2 3 include household matrix analyses without household matrix yielded slightly better lod scores higher heritabilities general
0.22725685.14559775.html.plaintext.txt	56	addition effect shared environment h2 variance trait also estimated including household matrix model matrix whose ijth element equal 1 individuals j share specified environment 0 otherwise family collection largely composed extended pedigrees measured plasma ass members family single batch elisas rigorously account possible assay batch batch variations may affect variance plasma ass42 included household matrix models since almost individuals family measured one batch household matrix included element1 individuals extended family 0 otherwise realize probably overly conservative since shared family household effect employed account potential batch batch variance assay overlaps kinship effect 55 inclusion household matrix almost certainly overcorrects batch batch variance underestimates shared genetic effect reason performed heritability linkage analyses without household matrix model multipoint results shown figures 2 3 include household matrix analyses without household matrix yielded slightly better lod scores higher heritabilities general
0.22725685.14559775.html.plaintext.txt	57	scalars q2 g2 h2 e2 estimated using maximum likelihood heritability estimations compared environmental model q2 g2 fixed zero h2 e2 estimated polygenic model g2 h2 e2 estimated linkage analyses performed comparing polygenic model linkage model q2 also estimated difference two log10 likelihoods models produces lod score equivalent classical lod score linkage analysis incorporated sex age age2 sexage sexage2 covariates heritability estimations none covariates significant p 005 therefore excluded multipoint linkage analysis
0.22725685.14559775.html.plaintext.txt	58	scalars q2 g2 h2 e2 estimated using maximum likelihood heritability estimations compared environmental model q2 g2 fixed zero h2 e2 estimated polygenic model g2 h2 e2 estimated linkage analyses performed comparing polygenic model linkage model q2 also estimated difference two log10 likelihoods models produces lod score equivalent classical lod score linkage analysis incorporated sex age age2 sexage sexage2 covariates heritability estimations none covariates significant p 005 therefore excluded multipoint linkage analysis
0.22725685.14559775.html.plaintext.txt	59	order minimize age dementia related environmental effects plasma ass42 levels performed analyses 20 65 year age group previous studies 3435 since variance components methods based underlying assumption quantitative trait analyzed normal distribution 10logass42 levels used phenotypes extreme outliers plasma ass levels plus minus 4 standard deviations beyond mean excluded analyses thus 10logass42 phenotype analyzed normal distribution plasma ass measurements done using well established sandwich elisa system described previously 15 samples measured duplicate elisa plate included samples five volunteers results five standard samples used normalize values obtained reduce plate plate day day variance
0.22725685.14559775.html.plaintext.txt	60	order minimize age dementia related environmental effects plasma ass42 levels performed analyses 20 65 year age group previous studies 3435 since variance components methods based underlying assumption quantitative trait analyzed normal distribution 10logass42 levels used phenotypes extreme outliers plasma ass levels plus minus 4 standard deviations beyond mean excluded analyses thus 10logass42 phenotype analyzed normal distribution plasma ass measurements done using well established sandwich elisa system described previously 15 samples measured duplicate elisa plate included samples five volunteers results five standard samples used normalize values obtained reduce plate plate day day variance
0.22725685.14559775.html.plaintext.txt	61	identity descent probability estimations identity descent ibd probabilities genotyped marker estimated using pairwise likelihood based estimation method implemented solar 53 ibd estimates used obtain twopoint lod scores multipoint ibd probabilities also estimated centimorgan pair adjacent markers using markov chain monte carlo mcmc multipoint ibd estimation approach implemented simwalk2 package 4647 mcmc process run twice default length 1000 replicates second time doubling process length multipoint linkage analyses using mibd matrices done using variance components methodology implemented solar results using shorter longer runs similar results latter presented given computation time increases marker number two upstream markers yielded evidence linkage datasets two markers d10s1435 d10s189 omitted mibd estimations two major differences mibd estimations utilized previous report linkage chromosome 10 current study 35 results previous linkage obtained result genotyping seven markers 13 cm region current study utilizes 31 markers spread 283 1653 cm chromosome 10 second mibd estimation approaches used previous current studies different mcmc approach implemented simwalk2 4647 utilized study different mibd probability estimation algorithm implemented solar approach utilized initial analysis seven chromosome 10 markers sobel et al 47 demonstrated significant differences results obtained two methods using dataset concluded multipoint mcmc approach yielded accurate mibd probability estimates inter marker loci reason utilized mcmc approach study
0.22725685.14559775.html.plaintext.txt	62	identity descent probability estimations identity descent ibd probabilities genotyped marker estimated using pairwise likelihood based estimation method implemented solar 53 ibd estimates used obtain twopoint lod scores multipoint ibd probabilities also estimated centimorgan pair adjacent markers using markov chain monte carlo mcmc multipoint ibd estimation approach implemented simwalk2 package 4647 mcmc process run twice default length 1000 replicates second time doubling process length multipoint linkage analyses using mibd matrices done using variance components methodology implemented solar results using shorter longer runs similar results latter presented given computation time increases marker number two upstream markers yielded evidence linkage datasets two markers d10s1435 d10s189 omitted mibd estimations two major differences mibd estimations utilized previous report linkage chromosome 10 current study 35 results previous linkage obtained result genotyping seven markers 13 cm region current study utilizes 31 markers spread 283 1653 cm chromosome 10 second mibd estimation approaches used previous current studies different mcmc approach implemented simwalk2 4647 utilized study different mibd probability estimation algorithm implemented solar approach utilized initial analysis seven chromosome 10 markers sobel et al 47 demonstrated significant differences results obtained two methods using dataset concluded multipoint mcmc approach yielded accurate mibd probability estimates inter marker loci reason utilized mcmc approach study
0.22725685.14559775.html.plaintext.txt	63	tests association initially tested association snps plasma ass42 10 extended load families using regression based covariate approach variance components paradigm implemented computer program solar 53 order control effect linkage included linkage component q2 null alternative models tested used multipoint ibd matrix yielded maximum multipoint lod score 80 cm 10 extended load families multipoint ibd probabilities matrix estimated simwalk using genetic marker information described
0.22725685.14559775.html.plaintext.txt	64	tests association initially tested association snps plasma ass42 10 extended load families using regression based covariate approach variance components paradigm implemented computer program solar 53 order control effect linkage included linkage component q2 null alternative models tested used multipoint ibd matrix yielded maximum multipoint lod score 80 cm 10 extended load families multipoint ibd probabilities matrix estimated simwalk using genetic marker information described
0.22725685.14559775.html.plaintext.txt	65	test effect specific snp genotypes used measured genotype approach included copy number snp allele covariate analysis regressed plasma ass42 phenotype covariate individual measured genotype approach classical test differences trait mean genotype described theoretically previously 5657 approach also utilized previous association studies snps various quantitative traits extended families 5859 individuals xx xy yy snp genotype used covariate takes value 0 1 2 respectively formulation assumes snp additive qtl model includes covariate tested model include determine effect quantitative trait interest twice difference natural log likelihoods two models distributed 2 distribution 1 degree freedom order test association beyond linkage residual genetic household effects three components included null alternative models first tested association snps ass42 10 load families previously used describe linkage chromosome 10 35 order control effect linkage residual genetic effects household effects group estimated effect snp background model included 80 cm multipoint identity descent matrix well kinship household matrices tested snp association ass42 second independent set 12 load families also analyzed combined group 22 families
0.22725685.14559775.html.plaintext.txt	66	test effect specific snp genotypes used measured genotype approach included copy number snp allele covariate analysis regressed plasma ass42 phenotype covariate individual measured genotype approach classical test differences trait mean genotype described theoretically previously 5657 approach also utilized previous association studies snps various quantitative traits extended families 5859 individuals xx xy yy snp genotype used covariate takes value 0 1 2 respectively formulation assumes snp additive qtl model includes covariate tested model include determine effect quantitative trait interest twice difference natural log likelihoods two models distributed 2 distribution 1 degree freedom order test association beyond linkage residual genetic household effects three components included null alternative models first tested association snps ass42 10 load families previously used describe linkage chromosome 10 35 order control effect linkage residual genetic effects household effects group estimated effect snp background model included 80 cm multipoint identity descent matrix well kinship household matrices tested snp association ass42 second independent set 12 load families also analyzed combined group 22 families
0.22725685.14559775.html.plaintext.txt	67	linkage analysis conditional upon association conditional linkage analysis accounts association functional polymorphism one strong ld linkage locus decrease eliminate linkage signal 5859 reason performed linkage analysis conditional association strongly associating snp 4360tc performed test estimating proportion variance due linkage background model included snp covariate comparing linkage model excluded covariate
0.22725685.14559775.html.plaintext.txt	68	linkage analysis conditional upon association conditional linkage analysis accounts association functional polymorphism one strong ld linkage locus decrease eliminate linkage signal 5859 reason performed linkage analysis conditional association strongly associating snp 4360tc performed test estimating proportion variance due linkage background model included snp covariate comparing linkage model excluded covariate
0.22725685.14559775.html.plaintext.txt	69	analysis linkage disequilibrium measured linkage disequilibrium ld snps haplotype groups within 22 extended load families using gold program 60 used expectation maximization algorithm slatkin excoffier 61 determine various pairwise statistical parameters ld lewontins standardized disequilibrium coefficient d 62 algorithm determines ld founders married ins ld estimated vr22 4360 snp snps
0.22725685.14559775.html.plaintext.txt	70	analysis linkage disequilibrium measured linkage disequilibrium ld snps haplotype groups within 22 extended load families using gold program 60 used expectation maximization algorithm slatkin excoffier 61 determine various pairwise statistical parameters ld lewontins standardized disequilibrium coefficient d 62 algorithm determines ld founders married ins ld estimated vr22 4360 snp snps
0.22725685.14559775.html.plaintext.txt	71	acknowledgements grateful frederick pishotta computer support thomas dyer southwest foundation biomedical research providing us scripts obtaining solar compatible mibd files simwalk acknowledge mayo clinic adrc employees help collection samples grateful individuals participated study without work would possible study supported nih grants ag18023 sgy ag06656 sgy ag20903 net grant american federation aging research grant pd01062 net robert clarice smith fellowship net
0.22725685.14559775.html.plaintext.txt	72	acknowledgements grateful frederick pishotta computer support thomas dyer southwest foundation biomedical research providing us scripts obtaining solar compatible mibd files simwalk acknowledge mayo clinic adrc employees help collection samples grateful individuals participated study without work would possible study supported nih grants ag18023 sgy ag06656 sgy ag20903 net grant american federation aging research grant pd01062 net robert clarice smith fellowship net
0.22725685.14559775.html.plaintext.txt	73	footnotes correspondence addressed mayo clinic jacksonville 4500 san pablo road birdsall 2 jacksonville fl 32224 usa tel 1 9049537356 fax 1 9049537370 email younkinstevenatmayoedu
0.22725685.14559775.html.plaintext.txt	74	footnotes correspondence addressed mayo clinic jacksonville 4500 san pablo road birdsall 2 jacksonville fl 32224 usa tel 1 9049537356 fax 1 9049537370 email younkinstevenatmayoedu
0.22725685.14559775.html.plaintext.txt	75	authors wish known opinion first two authors regarded joint first authors
0.22725685.14559775.html.plaintext.txt	76	references top abstract introduction results discussion subjects methods references schellenberg gd dsouza poorkaj p 2000 genetics alzheimers disease curr psych rep 2 158 164
0.227683.9700196.html.plaintext.txt	0	organization expression polymorphism human persyn gene
0.227683.9700196.html.plaintext.txt	1	1school biomedical sciences university st andrews bute medical buildings st andrews fife ky16 9ts uk 2institute gene biology russian academy sciences 346 vavilov street moscow b 334 russia 3microbiology tumor biology center mtc karolinska institute box 280 17177 stockholm sweden 4neuropa ltd robertson building dumbarton road glasgow g11 6nu uk
0.227683.9700196.html.plaintext.txt	2	received april 23 1998 revised accepted june 18 1998
0.227683.9700196.html.plaintext.txt	3	ddbjemblgenbank accession nos af017256 af037207
0.227683.9700196.html.plaintext.txt	4	persyn recently identified member synuclein family distinct pattern expression pre postnatal development mouse peripheral central nervous systems synucleins persyn believed involved pathogenesis human neurodegenerative diseases however contrast synucleins high levels persyn mrna expression also found advanced breast carcinomas suggesting involvement encoded protein breast tumour progression used antibody specific human persyn demonstrate level protein increased ageing cerebral cortex breast tumours cloned characterized sequenced human persyn genomic locus localized long arm chromosome 10 q232 q233 region sequence information used search specific mutations protein coding regions persyn mrna persyn gene breast tumours tumour cell lines tumour specific mutations found two linked polymorphisms coding region detected mrna exons iii iv gene results suggest development breast tumours correlates overexpression wild type persyn protein detailed characterization human persyn locus important studies involvement persyn neurodegeneration malignancy
0.227683.9700196.html.plaintext.txt	5	persyn recently identified member synuclein family distinct pattern expression pre postnatal development mouse peripheral central nervous systems synucleins persyn believed involved pathogenesis human neurodegenerative diseases however contrast synucleins high levels persyn mrna expression also found advanced breast carcinomas suggesting involvement encoded protein breast tumour progression used antibody specific human persyn demonstrate level protein increased ageing cerebral cortex breast tumours cloned characterized sequenced human persyn genomic locus localized long arm chromosome 10 q232 q233 region sequence information used search specific mutations protein coding regions persyn mrna persyn gene breast tumours tumour cell lines tumour specific mutations found two linked polymorphisms coding region detected mrna exons iii iv gene results suggest development breast tumours correlates overexpression wild type persyn protein detailed characterization human persyn locus important studies involvement persyn neurodegeneration malignancy
0.227683.9700196.html.plaintext.txt	6	three genes synuclein family recently identified human genome first two code alpha beta synucleins closely related presynaptic proteins similar patterns expression abundant evolutionarily recent regions central nervous system 1 5 proteins believed natively unfolded random coiled 67 tend aggregate solution forming amyloid like fibrils 8 another important feature synucleins ability bind trigger aggregation amyloid abeta peptides 9 11 results together detection peptide nac derived alpha synuclein senile plaques alzheimers brains 28 raise possibility synucleins involved pathogenesis alzheimers disease 12 although mutations polymorphisms synuclein genes yet correlated alzheimers disease 1314 two point mutations human alpha synuclein gene found several families early onset autosomal dominant parkinsons disease 1516 findings together immunohistochemical detection high level alpha synuclein lewy bodies parkinsons disease patient brains 1718 implicates alpha synuclein pathogenesis certain forms neurodegenerative disorder
0.227683.9700196.html.plaintext.txt	7	three genes synuclein family recently identified human genome first two code alpha beta synucleins closely related presynaptic proteins similar patterns expression abundant evolutionarily recent regions central nervous system 1 5 proteins believed natively unfolded random coiled 67 tend aggregate solution forming amyloid like fibrils 8 another important feature synucleins ability bind trigger aggregation amyloid abeta peptides 9 11 results together detection peptide nac derived alpha synuclein senile plaques alzheimers brains 28 raise possibility synucleins involved pathogenesis alzheimers disease 12 although mutations polymorphisms synuclein genes yet correlated alzheimers disease 1314 two point mutations human alpha synuclein gene found several families early onset autosomal dominant parkinsons disease 1516 findings together immunohistochemical detection high level alpha synuclein lewy bodies parkinsons disease patient brains 1718 implicates alpha synuclein pathogenesis certain forms neurodegenerative disorder
0.227683.9700196.html.plaintext.txt	8	recently identified member synuclein family persyn shares main structural features alpha beta synucleins distinctive pattern expression 19 mouse embryonic development persyn expressed primary sensory neurons motoneurons postnatally persyn expression remains high neurons becomes detectable sympathetic neurons subset neurons cerebral cortex contrast decrease alpha synuclein expression ageing cerebral cortex 20 persyn mrna expression increases persyn protein accumulates mouse cerebral cortex age 19
0.227683.9700196.html.plaintext.txt	9	recently identified member synuclein family persyn shares main structural features alpha beta synucleins distinctive pattern expression 19 mouse embryonic development persyn expressed primary sensory neurons motoneurons postnatally persyn expression remains high neurons becomes detectable sympathetic neurons subset neurons cerebral cortex contrast decrease alpha synuclein expression ageing cerebral cortex 20 persyn mrna expression increases persyn protein accumulates mouse cerebral cortex age 19
0.227683.9700196.html.plaintext.txt	10	although persyn present senile plaques lewy bodies neurofibrillary tangles clinical cases studied far high level persyn immunoreactivity detectable dot like structures characteristic axonal lesions brains patients neurodegenerative diseases vl buchman hja hunter lgp pinon j thompson em privalova nn ninkina j lowe davies submitted publication clinical findings consistent developmental regional patterns persyn expression experimental evidence suggests persyn plays role regulating neurofilament network integrity 19
0.227683.9700196.html.plaintext.txt	11	persyn nearly identical protein coded expressed sequence tag est bcsg1 isolated breast cancer cdna library 21 although bcsg1 mrna cannot detected normal breast tissue benign breast tumours level dramatically increases highly infiltrating malignant carcinomas 21 level encoded protein reflects level persynbcsg1 mrna could useful breast cancer progression marker
0.227683.9700196.html.plaintext.txt	12	persyn nearly identical protein coded expressed sequence tag est bcsg1 isolated breast cancer cdna library 21 although bcsg1 mrna cannot detected normal breast tissue benign breast tumours level dramatically increases highly infiltrating malignant carcinomas 21 level encoded protein reflects level persynbcsg1 mrna could useful breast cancer progression marker
0.227683.9700196.html.plaintext.txt	13	dual role persyn neurodegeneration malignancy could involve common mechanisms changes organization cell cytoskeleton among prominent characteristics processes involvement persyn regulating neurofilament network integrity raises possibility may also affect intermediate filament network malignant breast epithelial cells important question whether breast tumour progression correlates high level expression wild type persyn presence mutations persyn coding region obligatory characteristic process multiple differences including three resulted amino acid substitutions bcsg1 isolated tumour tissue persyn isolated normal brain tissue consistent latter possibility mutations could somatic germline might reflect advanced tumour progression predisposition individual malignant progression tumour
0.227683.9700196.html.plaintext.txt	14	dual role persyn neurodegeneration malignancy could involve common mechanisms changes organization cell cytoskeleton among prominent characteristics processes involvement persyn regulating neurofilament network integrity raises possibility may also affect intermediate filament network malignant breast epithelial cells important question whether breast tumour progression correlates high level expression wild type persyn presence mutations persyn coding region obligatory characteristic process multiple differences including three resulted amino acid substitutions bcsg1 isolated tumour tissue persyn isolated normal brain tissue consistent latter possibility mutations could somatic germline might reflect advanced tumour progression predisposition individual malignant progression tumour
0.227683.9700196.html.plaintext.txt	15	clarification questions requires study human persyn gene persyn protein report organization human persyn locus chromosomal localization studies human persyn protein expression also show mutations persyn gene specific breast tumours confirmed differences result natural sequence polymorphisms
0.227683.9700196.html.plaintext.txt	16	clarification questions requires study human persyn gene persyn protein report organization human persyn locus chromosomal localization studies human persyn protein expression also show mutations persyn gene specific breast tumours confirmed differences result natural sequence polymorphisms
0.227683.9700196.html.plaintext.txt	17	results cloning analysis human persyn genomic locus
0.227683.9700196.html.plaintext.txt	18	two human persyn cdna clones previously isolated juvenile human cdna library one cdna clones clone h1 used screen human genomic library lambdaembl4 22 two identical independent clones isolated genomic library positions exons determined restriction analysis hybridization cdna oligonucleotide probes direct sequencing locus genomic southern hybridization figure 1 shows human persyn gene consists five exons span 5 kbp differences sequence cdna clone h1 used probe genomic library exonic sequences genomic clones isolated however another shorter cdna clone 4c isolated juvenile human cdna library two substitutions coding region found g c position 243 position 377 cdna sequence af017256 boxed fig 1 latter resulting amino acid substitution val110glu cdna library constructed individual juvenile brainstem likely substitutions result natural polymorphism persyn gene alleles gene transcriptionally active tissue
0.227683.9700196.html.plaintext.txt	19	two human persyn cdna clones previously isolated juvenile human cdna library one cdna clones clone h1 used screen human genomic library lambdaembl4 22 two identical independent clones isolated genomic library positions exons determined restriction analysis hybridization cdna oligonucleotide probes direct sequencing locus genomic southern hybridization figure 1 shows human persyn gene consists five exons span 5 kbp differences sequence cdna clone h1 used probe genomic library exonic sequences genomic clones isolated however another shorter cdna clone 4c isolated juvenile human cdna library two substitutions coding region found g c position 243 position 377 cdna sequence af017256 boxed fig 1 latter resulting amino acid substitution val110glu cdna library constructed individual juvenile brainstem likely substitutions result natural polymorphism persyn gene alleles gene transcriptionally active tissue
0.227683.9700196.html.plaintext.txt	20	figure 1 organization human persyn gene physical map locus displayed upper part figure restriction endonuclease sites ecori e saci kpni k xbai x shown exons vertical black boxes numbered roman numerals sequences exons adjacent parts introns shown lower part figure encoded amino acids one letter code shown nucleotide sequence nucleotide substitutions est bcsg1 shown nucleotide sequence deduced amino acid substitutions shown amino acid sequence two substitutions also found human persyn clone 4c result gene polymorphism boxed polyadenylation site marked arrowhead full sequence human persyn locus deposited genbank accession af037207 persyn mrna expression tumour cell lines
0.227683.9700196.html.plaintext.txt	21	persyn gene expression various normal tumour tissues cell lines studied northern blot analysis using human persyn cdna clone h1 hybridization probe single 08 kb transcript observed tumour cell lines highest level transcript detected sub line mcf7prime breast tumour cell line mcf7 normally express persyn mrna fig 2 21 similar results obtained semi quantitative rt pcr shown however increasing number amplification cycles detected low level persyn mrna tumour cell lines persyn negative northern western blots example line gi101 shown figs 2 3a 4
0.227683.9700196.html.plaintext.txt	22	figure 2 persyn transcripts breast tumour cell lines northern hybridization total rna isolated tumour cell lines human persyn cdna probe stripping probe filter hybridized nick translated cdna fragment encoding mouse gapdh provide indication amount total rna cell line present filter cell lines derived breast cancers except skov3 derived ovarian carcinoma
0.227683.9700196.html.plaintext.txt	23	figure 3 persyn protein human tissues cell lines western blot showing expression persyn protein human tissues cell lines aliquots 20 microg total cellular protein separated 15 polyacrylamide gel transferred hybond pvdf membrane probed sk109 anti persyn antibody followed ecl detection proteins extracted following sources tumour cell lines designations fig 2 b normal breast tissues n breast tumours four patients c cerebral cortices two patients suffered alzheimers disease 1295 25696 two normal individuals age group 10995 19796 fetal cerebral cortex mouse spinal cord unstimulated pbl pha stimulated pbl pha peripheral blood lymphocytes
0.227683.9700196.html.plaintext.txt	24	figure 4 detection persyn protein breast cancer cells confocal microscope section human breast cancer cells stained antibodies persyn green channel keratin 8 red channel persyn protein expression human tissues
0.227683.9700196.html.plaintext.txt	25	study persyn protein expression human tissues used western blotting polyclonal antibody raised synthetic peptide human persyn protein see materials methods antibody cross react either alpha beta synuclein western blots detects single band disappears antibody preincubated excess immunizing peptide shown persyn detected human fetal cerebral cortex abundant cortex elderly individuals fig 3c substantial differences level persyn noticed cerebral cortices alzheimers disease patients normal individuals age group fig 3c persyn mrna persyn protein also detected unstimulated phytohaemagglutinin pha stimulated cultured lymphocytes peripheral blood normal donors figs 3c 4 data shown
0.227683.9700196.html.plaintext.txt	26	study persyn protein expression human tissues used western blotting polyclonal antibody raised synthetic peptide human persyn protein see materials methods antibody cross react either alpha beta synuclein western blots detects single band disappears antibody preincubated excess immunizing peptide shown persyn detected human fetal cerebral cortex abundant cortex elderly individuals fig 3c substantial differences level persyn noticed cerebral cortices alzheimers disease patients normal individuals age group fig 3c persyn mrna persyn protein also detected unstimulated phytohaemagglutinin pha stimulated cultured lymphocytes peripheral blood normal donors figs 3c 4 data shown
0.227683.9700196.html.plaintext.txt	27	breast cancer cell lines pattern persyn protein expression corresponded mrna detected western blotting cell lines persyn mrna detected northern hybridization figs 2 3a
0.227683.9700196.html.plaintext.txt	28	shown previously situ hybridization persynbcsg1 mrna expressed normal adult breast tissue high levels mrna present advanced infiltrating breast tumours 21 detected persyn protein breast tumours normal breast tissue fig 3b
0.227683.9700196.html.plaintext.txt	29	shown previously situ hybridization persynbcsg1 mrna expressed normal adult breast tissue high levels mrna present advanced infiltrating breast tumours 21 detected persyn protein breast tumours normal breast tissue fig 3b
0.227683.9700196.html.plaintext.txt	30	used immunocytochemistry anti persyn antibody localize persyn cultured breast cancer cells paraformaldehyde pfa fixed cells persyn displayed punctuate cytoplasmic staining fig 4 pattern usually associated markers endoplasmic reticulum vesicular structures persyn co localized cytokeratin actin tubulin arrays cells fig 4 data shown
0.227683.9700196.html.plaintext.txt	31	used immunocytochemistry anti persyn antibody localize persyn cultured breast cancer cells paraformaldehyde pfa fixed cells persyn displayed punctuate cytoplasmic staining fig 4 pattern usually associated markers endoplasmic reticulum vesicular structures persyn co localized cytokeratin actin tubulin arrays cells fig 4 data shown
0.227683.9700196.html.plaintext.txt	32	sequence polymorphisms human persyn coding region
0.227683.9700196.html.plaintext.txt	33	nucleotide substitutions reported sequence bcsg1 transcript 21 shown figure 1a two positions 243 377 cdna sequence boxed fig 1a identical substitutions found cdna clone 4c substitutions present clones may correlated transformed phenotype cells bcsg1 est isolated study presence frequency mutations persyn gene breast cancer cells carried rt pcr mrnas isolated breast tumours tumour cell lines control used mrna isolated post mortem cerebral cortices pha stimulated peripheral blood lymphocytes normal donors pcr amplification products digested restriction endonucleases hphi styi mnli using digestions four mutations coding region reported bcsg1 including two polymorphisms present cdna clone 4c could detected studied samples digestion mnli generated pattern fragments fig 5a corresponds pattern predicted sequence persyn clones identical predicted patterns also obtained styi shown results reflect absence two g consequently glu lys substitutions reported bcsg1 est studied tumour cell lines tumours control tissues contrast rt pcr products digested hphi three types fragment patterns revealed fig 5a pattern represented figure 5a gi101 cell line corresponds persyn transcripts sequence similar h1 g243 presence hphi site 120 bp 135 bp hphi fragment t377 absence hphi site 155 bp 79 76 bp fragments pattern mcf7prime figure 5a corresponds persyn transcripts sequence similar 4c c243 absence hphi site 135 bp 120 bp hphi fragment a377 presence hphi site 79 76 bp 155 bp fragment pbl n figure 5a example cells transcripts expressed direct sequencing rt pcr fragments amplified four persyn expressing breast tumours reveal alterations apart g243c t377a
0.227683.9700196.html.plaintext.txt	34	nucleotide substitutions reported sequence bcsg1 transcript 21 shown figure 1a two positions 243 377 cdna sequence boxed fig 1a identical substitutions found cdna clone 4c substitutions present clones may correlated transformed phenotype cells bcsg1 est isolated study presence frequency mutations persyn gene breast cancer cells carried rt pcr mrnas isolated breast tumours tumour cell lines control used mrna isolated post mortem cerebral cortices pha stimulated peripheral blood lymphocytes normal donors pcr amplification products digested restriction endonucleases hphi styi mnli using digestions four mutations coding region reported bcsg1 including two polymorphisms present cdna clone 4c could detected studied samples digestion mnli generated pattern fragments fig 5a corresponds pattern predicted sequence persyn clones identical predicted patterns also obtained styi shown results reflect absence two g consequently glu lys substitutions reported bcsg1 est studied tumour cell lines tumours control tissues contrast rt pcr products digested hphi three types fragment patterns revealed fig 5a pattern represented figure 5a gi101 cell line corresponds persyn transcripts sequence similar h1 g243 presence hphi site 120 bp 135 bp hphi fragment t377 absence hphi site 155 bp 79 76 bp fragments pattern mcf7prime figure 5a corresponds persyn transcripts sequence similar 4c c243 absence hphi site 135 bp 120 bp hphi fragment a377 presence hphi site 79 76 bp 155 bp fragment pbl n figure 5a example cells transcripts expressed direct sequencing rt pcr fragments amplified four persyn expressing breast tumours reveal alterations apart g243c t377a
0.227683.9700196.html.plaintext.txt	35	figure 5 detection polymorphisms human persyn gene transcripts representative examples different cell types designations fig 4 different combinations persyn alleles shown sizes fragments given base pairs ethidium bromide stained 4 metaphor agarose gels fragments amplified rt pcr human rna digested restriction endonucleases mnli upper hphi lower rnas isolated breast cancer cell lines mcf7prime gi101 peripheral blood lymphocytes donor n pbl n b ethidium bromide stained 2 agarose gels fragments amplified pcr human dna digested restriction endonuclease hphi products digestion 286 bp fragment includes human persyn exon iii shown upper panel 330 bp fragment includes human persyn exon iv shown lower panel
0.227683.9700196.html.plaintext.txt	36	data confirmed pcr amplification individual exons persyn gene followed digestion products restriction endonucleases hphi styi mnli polymorphic styi mnli sites found illustrated figure 5b expected polymorphic hphi sites present exons three g243c four t377a human persyn gene alleles gene expressed heterozygotic cells instance peripheral blood lymphocytes donor n demonstrated fig 5a b expected two nearby polymorphic sites genome found linked studied dna frequencies two alleles genomes breast cancer normal cells 20 g243t377 80 c243a377
0.227683.9700196.html.plaintext.txt	37	data confirmed pcr amplification individual exons persyn gene followed digestion products restriction endonucleases hphi styi mnli polymorphic styi mnli sites found illustrated figure 5b expected polymorphic hphi sites present exons three g243c four t377a human persyn gene alleles gene expressed heterozygotic cells instance peripheral blood lymphocytes donor n demonstrated fig 5a b expected two nearby polymorphic sites genome found linked studied dna frequencies two alleles genomes breast cancer normal cells 20 g243t377 80 c243a377
0.227683.9700196.html.plaintext.txt	38	assignment human persyn gene chromosome 10q232 q233
0.227683.9700196.html.plaintext.txt	39	dna lambdaw6h genomic clone labelled biotin used fluorescence situ hybridization fish metaphase chromosomes prepared donor peripheral blood lymphocytes unique hybridization site assigned long arm chromosome 10 q232 q233 region fig 6
0.227683.9700196.html.plaintext.txt	40	dna lambdaw6h genomic clone labelled biotin used fluorescence situ hybridization fish metaphase chromosomes prepared donor peripheral blood lymphocytes unique hybridization site assigned long arm chromosome 10 q232 q233 region fig 6
0.227683.9700196.html.plaintext.txt	41	figure 6 localization persyn gene human metaphase chromosomes using fish metaphase plate arrow shows specific hybridization signals lambdaw6h probe chromosome 10 b magnified images chromosome 10 different metaphase plates two images shown chromosome fish signal white arrow inverted dapi banding black arrow shows dapi band 10q 232 233 hybridized lambdaw6h probe discussion
0.227683.9700196.html.plaintext.txt	42	members synuclein family implicated pathogenesis alzheimers parkinsons neurodegenerative diseases 121923 25 families hereditary form parkinsons disease point mutation gene coding alpha synuclein believed responsible development pathology 152627 finding suggests mutations genes encoding members synuclein family could linked neurodegenerative conditions underlies need studies genes
0.227683.9700196.html.plaintext.txt	43	members synuclein family implicated pathogenesis alzheimers parkinsons neurodegenerative diseases 121923 25 families hereditary form parkinsons disease point mutation gene coding alpha synuclein believed responsible development pathology 152627 finding suggests mutations genes encoding members synuclein family could linked neurodegenerative conditions underlies need studies genes
0.227683.9700196.html.plaintext.txt	44	cloned defined structure human gene encoding persyn recently identified member synuclein family 19 general organization gene terms positions exon intron junctions size introns similar mouse persyn gene unpublished data although complete structures genes synuclein family published available sequence data 15 deduction positions exon intron junctions known splice variants alpha beta synucleins 1419 suggest close similarities organization synuclein genes
0.227683.9700196.html.plaintext.txt	45	cloned defined structure human gene encoding persyn recently identified member synuclein family 19 general organization gene terms positions exon intron junctions size introns similar mouse persyn gene unpublished data although complete structures genes synuclein family published available sequence data 15 deduction positions exon intron junctions known splice variants alpha beta synucleins 1419 suggest close similarities organization synuclein genes
0.227683.9700196.html.plaintext.txt	46	addition potential involvement neurodegeneration persyn possibly involved breast tumour progression shown expression est bcsg1 nearly identical nucleotide sequence persyn mrna increased dramatically infiltrating breast cancers compared normal breast tissues benign tumours 21 shown expression persyn protein also follows pattern persyn could detected western blotting normal breast tissues whereas persyn protein detectable breast tumour tissue established breast cancer cell lines levels persyn protein expression found substantially different correlated levels persyn mrna find amplification persyn gene studied cell lines data shown observations suggest persyn expression regulated predominantly level persyn gene transcription andor persyn mrna stability thus breast cancer cell lines could used studies mechanisms regulate persyn expression investigate physiological consequences persyn overexpression shown previously experimental overexpression persyn cultured sensory neurons leads dramatic changes neurofilament network 19 interesting see acute overexpression persyn similar effect intermediate filament network epithelial cells immunocytochemical data suggest persyn could associated membranous structures cytoplasm breast cancer cells however subcellular fractionation neural tissues breast cancer cells demonstrated presence persyn cytosolic particulate fractions data shown results similar results obtained studies alpha synuclein believed loosely associated synaptic vesicle membranes presynaptic terminals 528 30 interesting light recent demonstration alpha synuclein able bind synthetic membranes vitro association dramatically changes protein secondary structure natively unfolded predominantly alpha helical perhaps alters functional features protein 31 one features ability alpha beta synuclein inhibit phospholipase d2 32 inhibition dependent bulk lipid concentration reaction suggesting interaction enzyme occurs membrane surface 32 thus involves alpha helical natively unfolded synucleins phospholipase d2 implicated various intracellular pathways including regulation cell growth differentiation interesting study effect persyn activity enzyme neurons tumour cells
0.227683.9700196.html.plaintext.txt	47	addition potential involvement neurodegeneration persyn possibly involved breast tumour progression shown expression est bcsg1 nearly identical nucleotide sequence persyn mrna increased dramatically infiltrating breast cancers compared normal breast tissues benign tumours 21 shown expression persyn protein also follows pattern persyn could detected western blotting normal breast tissues whereas persyn protein detectable breast tumour tissue established breast cancer cell lines levels persyn protein expression found substantially different correlated levels persyn mrna find amplification persyn gene studied cell lines data shown observations suggest persyn expression regulated predominantly level persyn gene transcription andor persyn mrna stability thus breast cancer cell lines could used studies mechanisms regulate persyn expression investigate physiological consequences persyn overexpression shown previously experimental overexpression persyn cultured sensory neurons leads dramatic changes neurofilament network 19 interesting see acute overexpression persyn similar effect intermediate filament network epithelial cells immunocytochemical data suggest persyn could associated membranous structures cytoplasm breast cancer cells however subcellular fractionation neural tissues breast cancer cells demonstrated presence persyn cytosolic particulate fractions data shown results similar results obtained studies alpha synuclein believed loosely associated synaptic vesicle membranes presynaptic terminals 528 30 interesting light recent demonstration alpha synuclein able bind synthetic membranes vitro association dramatically changes protein secondary structure natively unfolded predominantly alpha helical perhaps alters functional features protein 31 one features ability alpha beta synuclein inhibit phospholipase d2 32 inhibition dependent bulk lipid concentration reaction suggesting interaction enzyme occurs membrane surface 32 thus involves alpha helical natively unfolded synucleins phospholipase d2 implicated various intracellular pathways including regulation cell growth differentiation interesting study effect persyn activity enzyme neurons tumour cells
0.227683.9700196.html.plaintext.txt	48	substantial changes persyn expression accompany breast tumour progression also take place nervous system development current study shown persyn expressed human fetal cerebral cortex abundant cerebral cortices elderly individuals consistent previous observation persyn expression increased ageing mouse cerebral cortex 19 observe substantial differences levels persyn protein cerebral cortices patients suffered alzheimers disease normal age matched individuals results agreement immunohistochemical data implicate persyn axonal pathology neurodegenerative conditions dot like structures white matter without significant changes persyn immunoreactivity cortical neurons vl buchman hja hunter lgp pinon j thompson em privalova nn ninkina j lowe davies submitted publication
0.227683.9700196.html.plaintext.txt	49	substantial changes persyn expression accompany breast tumour progression also take place nervous system development current study shown persyn expressed human fetal cerebral cortex abundant cerebral cortices elderly individuals consistent previous observation persyn expression increased ageing mouse cerebral cortex 19 observe substantial differences levels persyn protein cerebral cortices patients suffered alzheimers disease normal age matched individuals results agreement immunohistochemical data implicate persyn axonal pathology neurodegenerative conditions dot like structures white matter without significant changes persyn immunoreactivity cortical neurons vl buchman hja hunter lgp pinon j thompson em privalova nn ninkina j lowe davies submitted publication
0.227683.9700196.html.plaintext.txt	50	important question whether wild type mutated persyn protein expressed breast tumours sequence analysis suggests protein tumour cells bcsg1 different protein expressed nervous system cdna clones h1 4c coded genomic clone w6h substitution two lysines glutamates bcsg1 changes overall charge persyn molecule disturbs ektkegv repeats highly conserved synuclein family changes serious consequences protein structure function however fact bcsg1 est generated rt pcr amplification raises question accurately sequence clone reflects sequence mrna tumour cells studied number breast tumours tumour cell lines presence mutations underlie lys glu amino acid substitutions human persyn sequence although persyn mrna exons persyn gene analysed mlui styi digestion pcr products mutations found studied tissues cell lines contrast using hphi digestion able detect two nucleotide polymorphisms initially recognized sequence differences persyn cdna clones h1 4c two linked polymorphic sites discriminate two alleles human persyn gene alleles transcriptionally active expressed similar efficiency heterozygotes find obvious correlation presence particular persyn alleles pathological phenotype although limited number samples analysed two alleles breast tumours tumour cell lines occur frequencies normal cells data suggest least spontaneous breast tumours high level wild type persyn protein correlates malignant phenotype reported mutations bcsg1 est artefactual may result taq polymerase errors
0.227683.9700196.html.plaintext.txt	51	important question whether wild type mutated persyn protein expressed breast tumours sequence analysis suggests protein tumour cells bcsg1 different protein expressed nervous system cdna clones h1 4c coded genomic clone w6h substitution two lysines glutamates bcsg1 changes overall charge persyn molecule disturbs ektkegv repeats highly conserved synuclein family changes serious consequences protein structure function however fact bcsg1 est generated rt pcr amplification raises question accurately sequence clone reflects sequence mrna tumour cells studied number breast tumours tumour cell lines presence mutations underlie lys glu amino acid substitutions human persyn sequence although persyn mrna exons persyn gene analysed mlui styi digestion pcr products mutations found studied tissues cell lines contrast using hphi digestion able detect two nucleotide polymorphisms initially recognized sequence differences persyn cdna clones h1 4c two linked polymorphic sites discriminate two alleles human persyn gene alleles transcriptionally active expressed similar efficiency heterozygotes find obvious correlation presence particular persyn alleles pathological phenotype although limited number samples analysed two alleles breast tumours tumour cell lines occur frequencies normal cells data suggest least spontaneous breast tumours high level wild type persyn protein correlates malignant phenotype reported mutations bcsg1 est artefactual may result taq polymerase errors
0.227683.9700196.html.plaintext.txt	52	mapped human persyn gene long arm chromosome 10 q232 q233 region hereditary disorders affected genes yet known located locus taking account pattern persyn expression sensory neurons peripheral nervous system motoneurons central nervous system interesting check possible involvement persyn gene infantile onset spinocerebellar ataxia sensory neuropathy iosca sca8 33 also intriguing loss heterozygosity loh 10q23 occurs high frequency different human tumours mutations ptenmmac1 gene located region implicated many breast carcinomas germline mutations gene believed associated cowden disease rare autosomal dominant familial cancer syndrome high risk breast cancer 34 however families individuals cowden disease mutations ptenmmac1 gene somatic mutations gene occur small fraction primary breast cancers loh breast cancers necessarily involve ptenmmac1 locus 35 37 correlation persyn expression breast tumour progression interesting search mutations coding regulatory regions gene hereditary spontaneous forms breast cancer defining organization human persyn gene reported important step towards genetic studies involvement gene neurodegenerative neoplastic disorders
0.227683.9700196.html.plaintext.txt	53	materials methods molecular cloning
0.227683.9700196.html.plaintext.txt	54	human persyn cdna clones h1 4c isolated juvenile brainstem cdna library stratagene hybridization mouse persyn cdna probe low stringency described previously 38 h1 clone labelled nick translation used probe screening genomic library southern northern hybridizations described previously 39 construction human genomic library lambdaembl4 described previously 22
0.227683.9700196.html.plaintext.txt	55	human persyn cdna clones h1 4c isolated juvenile brainstem cdna library stratagene hybridization mouse persyn cdna probe low stringency described previously 38 h1 clone labelled nick translation used probe screening genomic library southern northern hybridizations described previously 39 construction human genomic library lambdaembl4 described previously 22
0.227683.9700196.html.plaintext.txt	56	ecori fragments lambdaw6h dna subcloned pgem3 vector strands sequenced using specific oligonucleotide primers cycle sequencing carried abi drhodamine big dye terminators amplitaq fs abi reaction products analysed abi prism 377 dna sequencer
0.227683.9700196.html.plaintext.txt	57	ecori fragments lambdaw6h dna subcloned pgem3 vector strands sequenced using specific oligonucleotide primers cycle sequencing carried abi drhodamine big dye terminators amplitaq fs abi reaction products analysed abi prism 377 dna sequencer
0.227683.9700196.html.plaintext.txt	58	localization persyn genes human metaphase chromosomes
0.227683.9700196.html.plaintext.txt	59	fish biotin labelled lambda dna metaphase chromosomes obtained standard techniques pha stimulated human lymphocytes accomplished described elsewhere 3840 signals analysed using zeiss axiophot fluorescence microscope equipped cooled ccd camera hamamatsu adobe photoshop software package
0.227683.9700196.html.plaintext.txt	60	fish biotin labelled lambda dna metaphase chromosomes obtained standard techniques pha stimulated human lymphocytes accomplished described elsewhere 3840 signals analysed using zeiss axiophot fluorescence microscope equipped cooled ccd camera hamamatsu adobe photoshop software package
0.227683.9700196.html.plaintext.txt	61	rt pcr analysis human persyn mrna
0.227683.9700196.html.plaintext.txt	62	total cellular rna reverse transcribed amplified described earlier 41 amounts total rna samples normalized amplification 437 bp fragment glyceraldehyde 3 phosphate dehydrogenase gapdh mrna primers amplification human persyn coding region follows 5prime agcagcacaaccctgcacac 3prime 5prime tcttcaggtcatccacgctg 3prime amplification 441 bp fragment carried 40 cycles 95 degrees c 45 58 degrees c 30 72 degrees c 60 cells low level persyn expression amplified fragment purified agarose gel electrophoresis re amplified another 20 cycles amplified fragments digested appropriate restriction endonuclease analysed 4 metaphor agarose gel fmc
0.227683.9700196.html.plaintext.txt	63	total cellular rna reverse transcribed amplified described earlier 41 amounts total rna samples normalized amplification 437 bp fragment glyceraldehyde 3 phosphate dehydrogenase gapdh mrna primers amplification human persyn coding region follows 5prime agcagcacaaccctgcacac 3prime 5prime tcttcaggtcatccacgctg 3prime amplification 441 bp fragment carried 40 cycles 95 degrees c 45 58 degrees c 30 72 degrees c 60 cells low level persyn expression amplified fragment purified agarose gel electrophoresis re amplified another 20 cycles amplified fragments digested appropriate restriction endonuclease analysed 4 metaphor agarose gel fmc
0.227683.9700196.html.plaintext.txt	64	pcr analysis human persyn gene exons
0.227683.9700196.html.plaintext.txt	65	analysis human persyn gene exons human genomic dna amplified using primers located inside introns proximity exon intron junctions conditions amplification restriction endonuclease analysis similar conditions used rt pcr products except annealing temperatures 64 degrees c exon iii 60 degrees c exon iv primers 5prime tgcgagcctgactccagcag 3prime 5prime ggtgtggagtggagtgatgc 3prime used amplification exon iii 5prime ttgaggccagggtagacaag 3prime 5prime ccactcaggttcagggttag 3prime exon iv dna fragments analysed 2 agarose tbe gels
0.227683.9700196.html.plaintext.txt	66	analysis human persyn gene exons human genomic dna amplified using primers located inside introns proximity exon intron junctions conditions amplification restriction endonuclease analysis similar conditions used rt pcr products except annealing temperatures 64 degrees c exon iii 60 degrees c exon iv primers 5prime tgcgagcctgactccagcag 3prime 5prime ggtgtggagtggagtgatgc 3prime used amplification exon iii 5prime ttgaggccagggtagacaag 3prime 5prime ccactcaggttcagggttag 3prime exon iv dna fragments analysed 2 agarose tbe gels
0.227683.9700196.html.plaintext.txt	67	western blotting used detect persyn protein cell lysates described earlier 42 rabbit polyclonal antibody sk109 synthetic peptide human persyn vl buchman hja hunter lgp pinon j thompson em privalova nn ninkina j lowe davies submitted publication affinity purified recombinant human persyn protein bound nhs activated columns supelco used dilution 1500 secondary antibody horseradish peroxidase linked donkey anti rabbit igg diluted 12000 amersham ecl detection carried according manufacturers protocol amersham
0.227683.9700196.html.plaintext.txt	68	western blotting used detect persyn protein cell lysates described earlier 42 rabbit polyclonal antibody sk109 synthetic peptide human persyn vl buchman hja hunter lgp pinon j thompson em privalova nn ninkina j lowe davies submitted publication affinity purified recombinant human persyn protein bound nhs activated columns supelco used dilution 1500 secondary antibody horseradish peroxidase linked donkey anti rabbit igg diluted 12000 amersham ecl detection carried according manufacturers protocol amersham
0.227683.9700196.html.plaintext.txt	69	cells culture dishes washed phosphate buffered saline pbs fixed 4 pfa pbs 4 degrees c 10 min washed tbt 20 mm tris hcl ph 75 150 mm nacl 01 triton x 100 blocked 5 goat serum tbt followed incubation rabbit polyclonal sk109 anti persyn antibody 150 mouse monoclonal anti keratin 8 antibody mab1600 150 chemicon 4 degrees c 16 h 1 goat serum tbt detection tritc conjugated anti rabbit fitc conjugated anti mouse secondary antibodies used dilutions recommended suppliers jackson laboratories
0.227683.9700196.html.plaintext.txt	70	thanks due jim lowe department histopathology university nottingham tissue samples alex houston dna sequencing unit university st andrews automatic dna sequencing earnshaw j allan photographic work work supported grants wellcome trust royal society
0.227683.9700196.html.plaintext.txt	71	est expression sequence tag fish fluorescence situ hybridization gapdh glyceraldehyde 3 phosphate dehydrogenase loh loss heterozygosity pbs phosphate buffered saline pfa paraformaldehyde pha phytohaemagglutinin
0.227683.9700196.html.plaintext.txt	72	correspondence addressed tel 44 1334 463282 fax 44 1334 463600 email vlbst andrewsacuk page run oxford university press great clarendon street oxford ox2 6dp part oup journals comments feedback www adminatoupcouk u d last modification 12 aug 1998 copyright oxford university press 1998
0.227683.9700196.html.plaintext.txt	73	correspondence addressed tel 44 1334 463282 fax 44 1334 463600 email vlbst andrewsacuk page run oxford university press great clarendon street oxford ox2 6dp part oup journals comments feedback www adminatoupcouk u d last modification 12 aug 1998 copyright oxford university press 1998
0.23021185.11823314.html.plaintext.txt	0	old age psychiatry alistair burns frcpsych
0.23021185.11823314.html.plaintext.txt	1	university manchester withington hospital manchester
0.23021185.11823314.html.plaintext.txt	2	newcastle general hospital newcastle upon tyne uk
0.23021185.11823314.html.plaintext.txt	3	correspondence professor alistair burns department psychiatry education research centre wythenshawe hospital southmoor road manchester m23 9lt uk tel 44 0 161 291 3310 fax 44 0 161 291 5862 e mail aburnsatfslwithmanacuk
0.23021185.11823314.html.plaintext.txt	4	correspondence professor alistair burns department psychiatry education research centre wythenshawe hospital southmoor road manchester m23 9lt uk tel 44 0 161 291 3310 fax 44 0 161 291 5862 e mail aburnsatfslwithmanacuk
0.23021185.11823314.html.plaintext.txt	5	fashionable necessary days start presentation declaring ones conflicts interest editors special supplement therefore declare interest old age psychiatry long ago cynically described cinderella speciality old age psychiatry past years become increasingly popular clinical career choice community oriented multi disciplinary services remain relatively unfettered excessive bureaucracy would attractive option largely demoralised health care system reasons speciality thriving least enormous advances made past decade understanding neurobiological basis late life psychiatric disorders dementia particular attracted attention top level neuroscientists applied combination classical neuropathology molecular genetics protein chemistry reveal key events underlying neurodegeneration result conceivable effective treatments delay prevent onset alzheimers disease could available within decade something virtually unthinkable 10 years ago old age psychiatry clinicians near enough buzz feel excited differential diagnosis dementia subtype important part assessment convergence clinical descriptions lewy body dementia frontotemporal dementia give two examples covered issue allowing increased sophistication terms diagnostic reporting clinicians distinctions lead directly important management decisions avoidance neuroleptic agents lewy body disease use cholinesterase inhibitors alzheimers disease recognition disorders hitherto regarded functional nature organic basis stimulated research uncovering aetiological factors influenced clinical practice furthermore improved methods measuring symptoms valid reliable ways enabled effects therapeutic interventions especially drug trials assessed ways sufficiently robust allow regulatory authorities convinced worth
0.23021185.11823314.html.plaintext.txt	6	fashionable necessary days start presentation declaring ones conflicts interest editors special supplement therefore declare interest old age psychiatry long ago cynically described cinderella speciality old age psychiatry past years become increasingly popular clinical career choice community oriented multi disciplinary services remain relatively unfettered excessive bureaucracy would attractive option largely demoralised health care system reasons speciality thriving least enormous advances made past decade understanding neurobiological basis late life psychiatric disorders dementia particular attracted attention top level neuroscientists applied combination classical neuropathology molecular genetics protein chemistry reveal key events underlying neurodegeneration result conceivable effective treatments delay prevent onset alzheimers disease could available within decade something virtually unthinkable 10 years ago old age psychiatry clinicians near enough buzz feel excited differential diagnosis dementia subtype important part assessment convergence clinical descriptions lewy body dementia frontotemporal dementia give two examples covered issue allowing increased sophistication terms diagnostic reporting clinicians distinctions lead directly important management decisions avoidance neuroleptic agents lewy body disease use cholinesterase inhibitors alzheimers disease recognition disorders hitherto regarded functional nature organic basis stimulated research uncovering aetiological factors influenced clinical practice furthermore improved methods measuring symptoms valid reliable ways enabled effects therapeutic interventions especially drug trials assessed ways sufficiently robust allow regulatory authorities convinced worth
0.23021185.11823314.html.plaintext.txt	7	reason presenting series invited papers subject old age psychiatry inform general reader major issues challenges successes speciality today following contributions intended comprehensive survey increasingly widening field chosen give flavour richness clinical practice research chosen concentrate descriptions organically based syndromes differential diagnosis effects
0.23021185.11823314.html.plaintext.txt	8	reason presenting series invited papers subject old age psychiatry inform general reader major issues challenges successes speciality today following contributions intended comprehensive survey increasingly widening field chosen give flavour richness clinical practice research chosen concentrate descriptions organically based syndromes differential diagnosis effects
0.23021185.11823314.html.plaintext.txt	9	holmes 2002 issue summarised much current information concerning molecular biology alzheimers disease emphasising importance genes risk factors disease stepping outside often narrow way thinking tends tunnel vision equating genetics disease early onset rare mutations clearly field much promise terms treatment theme continued bullock 2002 issue summary new drugs alzheimers disease three anticholinesterase drugs available treatment mild moderate alzheimers disease approved national institute clinical excellence uk role drugs treatment alzheimers disease become apparent continued clinical practice influenced appropriate audit use benefit patients snowden et al 2002 issue provide date summary frontotemporal dementia drawing together clinical neuropsychological pathological expertise group instrumental clinical descriptions relatively common underrecognised cause dementia particularly younger people vascular dementia samples pips frontotemporal dementia post one common causes syndrome summarised stewart 2002 issue lack clear blue water alzheimers disease vascular dementia plainly acknowledged problem increasingly influencing clinical practice well taxing epidemiologists theme vascular disease continued review vascular basis depression baldwin obrien 2002 issue condition may explain elements treatment resistance practice also implications management patients subcortical dementia summarised turner et al 2002 issue emphasise phenomenological aspects dementia aetiological importance jacoby 2002 issue brings fore many legal aspects old age psychiatry increasingly becoming part everyday clinical practice particularly relation consent euthanasia mental capacity interface health social care highlighted challis hughes 2002 issue current political climate distinction clinically blurred many situations becoming important administrative financial terms costs care essential underpinning considerations clinical care kavanagh knapp 2002 issue describe models underlying many assumptions made predicting cost caring people cognitive impairment contributions concern dementia lewy bodies mckeith 2002 issue use rating scales old age psychiatry burns et al 2002 issue
0.23021185.11823314.html.plaintext.txt	10	holmes 2002 issue summarised much current information concerning molecular biology alzheimers disease emphasising importance genes risk factors disease stepping outside often narrow way thinking tends tunnel vision equating genetics disease early onset rare mutations clearly field much promise terms treatment theme continued bullock 2002 issue summary new drugs alzheimers disease three anticholinesterase drugs available treatment mild moderate alzheimers disease approved national institute clinical excellence uk role drugs treatment alzheimers disease become apparent continued clinical practice influenced appropriate audit use benefit patients snowden et al 2002 issue provide date summary frontotemporal dementia drawing together clinical neuropsychological pathological expertise group instrumental clinical descriptions relatively common underrecognised cause dementia particularly younger people vascular dementia samples pips frontotemporal dementia post one common causes syndrome summarised stewart 2002 issue lack clear blue water alzheimers disease vascular dementia plainly acknowledged problem increasingly influencing clinical practice well taxing epidemiologists theme vascular disease continued review vascular basis depression baldwin obrien 2002 issue condition may explain elements treatment resistance practice also implications management patients subcortical dementia summarised turner et al 2002 issue emphasise phenomenological aspects dementia aetiological importance jacoby 2002 issue brings fore many legal aspects old age psychiatry increasingly becoming part everyday clinical practice particularly relation consent euthanasia mental capacity interface health social care highlighted challis hughes 2002 issue current political climate distinction clinically blurred many situations becoming important administrative financial terms costs care essential underpinning considerations clinical care kavanagh knapp 2002 issue describe models underlying many assumptions made predicting cost caring people cognitive impairment contributions concern dementia lewy bodies mckeith 2002 issue use rating scales old age psychiatry burns et al 2002 issue
0.23021185.11823314.html.plaintext.txt	11	hope useful new information practising old age psychiatry two costs rapidly changing expanding field keeping abreast new information meeting rising public expectations might done uncommon patients present one burgeoning number memory clinics uk asking early diagnosis treatment well aware recent guidance national institute clinical excellence new antidementia drugs made available within national health service recently published national service framework older people sets specific standards care aspirations good practice across wide range mental health care issues challenges plenty collection papers gives indication responding
0.23021185.11823314.html.plaintext.txt	12	hope useful new information practising old age psychiatry two costs rapidly changing expanding field keeping abreast new information meeting rising public expectations might done uncommon patients present one burgeoning number memory clinics uk asking early diagnosis treatment well aware recent guidance national institute clinical excellence new antidementia drugs made available within national health service recently published national service framework older people sets specific standards care aspirations good practice across wide range mental health care issues challenges plenty collection papers gives indication responding
0.23021185.11823314.html.plaintext.txt	13	bullock r 2002 new drugs alzheimers disease dementias british journal psychiatry 180 135 139abstractfree full text
0.23021185.11823314.html.plaintext.txt	14	department health 2002 national service framework older people london department health
0.23021185.11823314.html.plaintext.txt	15	holmes c 2002 genotype phenotype alzheimers disease british journal psychiatry 180 131 134abstractfree full text
0.23021185.11823314.html.plaintext.txt	16	jacoby r 2002 old age psychiatry law british journal psychiatry 180 116 119abstractfree full text
0.23021185.11823314.html.plaintext.txt	17	stewart r 2002 vascular dementia diagnosis running time british journal psychiatry 180 152 156abstractfree full text
0.23021185.11823314.html.plaintext.txt	18	received publication august 1 2001 revision received august 9 2001 accepted publication august 10 2001
0.23021185.11823314.html.plaintext.txt	19	received publication august 1 2001 revision received august 9 2001 accepted publication august 10 2001
0.23021185.11823314.html.plaintext.txt	20	highlights issue elizabeth walsh bjp 2002 180 0 full text
0.23021185.11823314.html.plaintext.txt	21	old age psychiatry law robin jacoby bjp 2002 180 116 119 abstract full text
0.23021185.11823314.html.plaintext.txt	22	costs cognitive disability modelling underlying associations shane kavanagh martin knapp bjp 2002 180 120 125 abstract full text
0.23021185.11823314.html.plaintext.txt	23	frail old people margins care recent research findings david challis jane hughes bjp 2002 180 126 130 abstract full text
0.23021185.11823314.html.plaintext.txt	24	genotype phenotype alzheimers disease clive holmes bjp 2002 180 131 134 abstract full text
0.23021185.11823314.html.plaintext.txt	25	new drugs alzheimers disease dementias roger bullock bjp 2002 180 135 139 abstract full text
0.23021185.11823314.html.plaintext.txt	26	frontotemporal dementia julie snowden david neary david m mann bjp 2002 180 140 143 abstract full text
0.23021185.11823314.html.plaintext.txt	27	frontotemporal dementia julie snowden david neary david m mann bjp 2002 180 140 143 abstract full text
0.23021185.11823314.html.plaintext.txt	28	dementia lewy bodies ian g mckeith bjp 2002 180 144 147 abstract full text
0.23021185.11823314.html.plaintext.txt	29	vascular dementia diagnosis running time robert stewart bjp 2002 180 152 156 abstract full text
0.23021185.11823314.html.plaintext.txt	30	vascular basis late onset depressive disorder robert c baldwin john obrien bjp 2002 180 157 160 abstract full text
0.23021185.11823314.html.plaintext.txt	31	vascular basis late onset depressive disorder robert c baldwin john obrien bjp 2002 180 157 160 abstract full text
0.23021185.11823314.html.plaintext.txt	32	rating scales old age psychiatry alistair burns brian lawlor sarah craig bjp 2002 180 161 167 abstract full text
0.23021185.11823314.html.plaintext.txt	33	article full text pdf submit response alert article cited alert eletters posted alert correction posted citation map services email article friend related articles bjp similar articles journal similar articles pubmed alert new issues journal download citation manager google scholar articles burns articles mckeith g articles citing article pubmed pubmed citation articles burns articles mckeith g
0.23021185.11823314.html.plaintext.txt	34	home help feedback subscriptions archive search table contents psychiatric bulletin advances psychiatric treatment rcpsych journals
0.23427205.14718220.html.plaintext.txt	0	relation education occupation based socioeconomic status incident alzheimer disease anita karp12 ingemar kareholt1 chengxuan qiu12 tom bellander3 bengt winblad12 laura fratiglioni12
0.23427205.14718220.html.plaintext.txt	1	1 aging research center division geriatric epidemiology medicine neurotec karolinska institutet stockholm sweden 2 stockholm gerontology research center stockholm sweden 3 department occupational environmental health stockholm county council institute environmental medicine karolinska institutet stockholm sweden
0.23427205.14718220.html.plaintext.txt	2	1 aging research center division geriatric epidemiology medicine neurotec karolinska institutet stockholm sweden 2 stockholm gerontology research center stockholm sweden 3 department occupational environmental health stockholm county council institute environmental medicine karolinska institutet stockholm sweden
0.23427205.14718220.html.plaintext.txt	3	received publication june 7 2002 accepted publication july 21 2003
0.23427205.14718220.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references study authors evaluated whether association low educational level increased risk alzheimer disease ad dementia may explained occupation based socioeconomic status ses cohort 931 nondemented subjects aged border075 years kungsholmen project stockholm sweden followed 3 years 1987 1993 total 101 incident cases dementia 76 involving ad detected less educated subjects adjusted relative risk developing ad 34 95 confidence interval 20 60 subjects lower ses adjusted relative risk 16 95 confidence interval 10 25 education ses introduced model education remained significantly associated ad combinations low education low high ses associated similar increased risks ad well educated subjects low ses high risk low ses 20 years age even ses high age 40 60 years associated increased risk however increase disappeared education entered model conclusion association low education increased ad risk mediated adult ses socioeconomic mobility suggests early life factors may relevant
0.23427205.14718220.html.plaintext.txt	5	abstract top abstract introduction materials methods results discussion references study authors evaluated whether association low educational level increased risk alzheimer disease ad dementia may explained occupation based socioeconomic status ses cohort 931 nondemented subjects aged border075 years kungsholmen project stockholm sweden followed 3 years 1987 1993 total 101 incident cases dementia 76 involving ad detected less educated subjects adjusted relative risk developing ad 34 95 confidence interval 20 60 subjects lower ses adjusted relative risk 16 95 confidence interval 10 25 education ses introduced model education remained significantly associated ad combinations low education low high ses associated similar increased risks ad well educated subjects low ses high risk low ses 20 years age even ses high age 40 60 years associated increased risk however increase disappeared education entered model conclusion association low education increased ad risk mediated adult ses socioeconomic mobility suggests early life factors may relevant
0.23427205.14718220.html.plaintext.txt	6	aged alzheimer disease dementia education social class
0.23427205.14718220.html.plaintext.txt	7	abbreviations abbreviations ci confidence interval ses socioeconomic status
0.23427205.14718220.html.plaintext.txt	8	introduction top abstract introduction materials methods results discussion references several studies reported increased risk dementia alzheimer disease among less educated persons 1 10 different mechanisms suggested explain association katzman 5 proposed education might increase brain reserves increasing synaptic density neocortical association cortex stern et al 6 extended cognitive reserve hypothesis took account possible beneficial influence mental activity throughout entire life span occupational attainment along level education could influence risk alzheimer disease education might also surrogate measure intellectual outlook 7 well proxy intelligence turn could inversely related risk alzheimer disease 8 9 addition issue possible detection bias due later diagnosis dementia highly educated subjects raised 4 10
0.23427205.14718220.html.plaintext.txt	9	introduction top abstract introduction materials methods results discussion references several studies reported increased risk dementia alzheimer disease among less educated persons 1 10 different mechanisms suggested explain association katzman 5 proposed education might increase brain reserves increasing synaptic density neocortical association cortex stern et al 6 extended cognitive reserve hypothesis took account possible beneficial influence mental activity throughout entire life span occupational attainment along level education could influence risk alzheimer disease education might also surrogate measure intellectual outlook 7 well proxy intelligence turn could inversely related risk alzheimer disease 8 9 addition issue possible detection bias due later diagnosis dementia highly educated subjects raised 4 10
0.23427205.14718220.html.plaintext.txt	10	known education indicator socioeconomic status ses different studies shown high 11 moderate 2 correlations education occupation based ses nevertheless two variables represent different aspects periods life course may generate differences health various mechanisms 11 12 lynch kaplan describe education transition socio economic position largely received parents achieved socio economic position adult 13 p 22
0.23427205.14718220.html.plaintext.txt	11	known education indicator socioeconomic status ses different studies shown high 11 moderate 2 correlations education occupation based ses nevertheless two variables represent different aspects periods life course may generate differences health various mechanisms 11 12 lynch kaplan describe education transition socio economic position largely received parents achieved socio economic position adult 13 p 22
0.23427205.14718220.html.plaintext.txt	12	socioeconomic factors acting life course found affect health premature death well risk cardiovascular disease 14 15 cumulative economic hardship found lead poorer cognitive functioning 16 recently turrell et al 17 examined relation socioeconomic mobility cognitive function among finish men late middle age suggested stages life course play role influencing adult cognitive function
0.23427205.14718220.html.plaintext.txt	13	socioeconomic factors acting life course found affect health premature death well risk cardiovascular disease 14 15 cumulative economic hardship found lead poorer cognitive functioning 16 recently turrell et al 17 examined relation socioeconomic mobility cognitive function among finish men late middle age suggested stages life course play role influencing adult cognitive function
0.23427205.14718220.html.plaintext.txt	14	studies reported association adult ses based occupation incidence alzheimer disease dementia evans et al 2 found investigated markers ses education occupational prestige income predicted development alzheimer disease reported manual work involves production goods could increase risk clinical alzheimer disease dementia 18 however studies focused principal occupation occupational periods addition relation social mobility different socioeconomic levels life course risk dementia old age studied
0.23427205.14718220.html.plaintext.txt	15	general aim study determine whether reported association low education increased risk alzheimer disease dementia could explained occupation based ses specifically examined risk alzheimer disease dementia varied different combinations 1 education main occupation based ses 2 education lifetime number years spent low occupation based ses since education occupation based ses interrelated special attention given categories deviated expected pattern combinations high educationlow occupation based ses low educationhigh occupation based ses furthermore investigated social mobility patterns explore whether later advancement setbacks occupation based ses may affect relation education alzheimer disease incidence
0.23427205.14718220.html.plaintext.txt	16	general aim study determine whether reported association low education increased risk alzheimer disease dementia could explained occupation based ses specifically examined risk alzheimer disease dementia varied different combinations 1 education main occupation based ses 2 education lifetime number years spent low occupation based ses since education occupation based ses interrelated special attention given categories deviated expected pattern combinations high educationlow occupation based ses low educationhigh occupation based ses furthermore investigated social mobility patterns explore whether later advancement setbacks occupation based ses may affect relation education alzheimer disease incidence
0.23427205.14718220.html.plaintext.txt	17	materials methods top abstract introduction materials methods results discussion references study population study population derived kungsholmen project community based longitudinal study aging dementia stockholm sweden registered inhabitants kungsholmen district stockholm aged 75 years older october 1 1987 invited participate project among 1810 persons agreed participate signed informed consent form baseline examination 1987 1989 1473 361 men 1112 women diagnosed free dementia baseline detection prevalent cases dementia conducted using two phase design subjects given brief psychometric test screening test dementia persons screened positive suspected dementia random sample subjects screened negative suspected dementia clinically examined 19 diagnostic criteria procedure diagnosing dementia used baseline follow described time follow examination 1991 1993 150 subjects refused participate 22 moved stockholm area information lifetime occupational history unavailable 370 subjects refusal informant therefore current study population consisted 931 persons
0.23427205.14718220.html.plaintext.txt	18	materials methods top abstract introduction materials methods results discussion references study population study population derived kungsholmen project community based longitudinal study aging dementia stockholm sweden registered inhabitants kungsholmen district stockholm aged 75 years older october 1 1987 invited participate project among 1810 persons agreed participate signed informed consent form baseline examination 1987 1989 1473 361 men 1112 women diagnosed free dementia baseline detection prevalent cases dementia conducted using two phase design subjects given brief psychometric test screening test dementia persons screened positive suspected dementia random sample subjects screened negative suspected dementia clinically examined 19 diagnostic criteria procedure diagnosing dementia used baseline follow described time follow examination 1991 1993 150 subjects refused participate 22 moved stockholm area information lifetime occupational history unavailable 370 subjects refusal informant therefore current study population consisted 931 persons
0.23427205.14718220.html.plaintext.txt	19	identification incident cases alzheimer disease dementia follow subjects clinically examined physicians neuropsychologically assessed psychologists interviewed nurses incident cases dementia defined developed follow period diagnosis clinical dementia made according criteria diagnostic statistical manual mental disorders third edition revised 20 using three step procedure first preliminary diagnosis made examining physician second cases independently reviewed specialized clinician second diagnosis made diagnoses agreement accepted final cases disagreement third opinion obtained concordant diagnosis accepted diagnosis dementia made subject completely fulfilled criteria diagnostic statistical manual mental disorders third edition revised
0.23427205.14718220.html.plaintext.txt	20	identification incident cases alzheimer disease dementia follow subjects clinically examined physicians neuropsychologically assessed psychologists interviewed nurses incident cases dementia defined developed follow period diagnosis clinical dementia made according criteria diagnostic statistical manual mental disorders third edition revised 20 using three step procedure first preliminary diagnosis made examining physician second cases independently reviewed specialized clinician second diagnosis made diagnoses agreement accepted final cases disagreement third opinion obtained concordant diagnosis accepted diagnosis dementia made subject completely fulfilled criteria diagnostic statistical manual mental disorders third edition revised
0.23427205.14718220.html.plaintext.txt	21	diagnosis alzheimer disease particular required gradual onset progressive deterioration cognitive functioning exclusion specific causes dementia neuroimaging autopsy data available clinical diagnosis alzheimer disease corresponds diagnosis probable alzheimer disease according nincds adrda national institute neurological communicative disorders stroke alzheimer disease related disorders association criteria 21 161 deceased subjects preliminary diagnosis made physician consulted medical records death certificates diagnosis reviewed senior clinician discharge diagnoses hospitals n 50 death certificates n 11 available reported diagnosis accepted repeated analyses survivors cohort results similar
0.23427205.14718220.html.plaintext.txt	22	diagnosis alzheimer disease particular required gradual onset progressive deterioration cognitive functioning exclusion specific causes dementia neuroimaging autopsy data available clinical diagnosis alzheimer disease corresponds diagnosis probable alzheimer disease according nincds adrda national institute neurological communicative disorders stroke alzheimer disease related disorders association criteria 21 161 deceased subjects preliminary diagnosis made physician consulted medical records death certificates diagnosis reviewed senior clinician discharge diagnoses hospitals n 50 death certificates n 11 available reported diagnosis accepted repeated analyses survivors cohort results similar
0.23427205.14718220.html.plaintext.txt	23	measurement educational attainment information total years formal education collected baseline study educational level divided two main categories 2 7 years 6 years primary school cases 1 extra year practical vocational training border08 years intermediate university levels dichotomization based previous analysis 4 different levels education examined relation alzheimer disease persons intermediate amount education 8 10 years schooling differ university educated subjects border011 years schooling terms alzheimer disease risk data educational background missing three persons subjects omitted analyses concerning education
0.23427205.14718220.html.plaintext.txt	24	measurement educational attainment information total years formal education collected baseline study educational level divided two main categories 2 7 years 6 years primary school cases 1 extra year practical vocational training border08 years intermediate university levels dichotomization based previous analysis 4 different levels education examined relation alzheimer disease persons intermediate amount education 8 10 years schooling differ university educated subjects border011 years schooling terms alzheimer disease risk data educational background missing three persons subjects omitted analyses concerning education
0.23427205.14718220.html.plaintext.txt	25	assessments occupation based ses main occupation based ses specially trained nurses interviewed relative another person significant subject subject full lifetime work history questionnaire developed occupational hygienist eight occupational periods specific information regarding time place listed subject longest held job considered main occupation occupations grouped according socioeconomic classification system developed statistics sweden 22 swedish socioeconomic classification system primarily contains dimensions ownership means production division blue collar white collar occupations assessed normal trade union affiliation also contains aspects skills subdivisions inside blue collar white collar occupational categories however customary educational requirements respective occupations used information education individual level
0.23427205.14718220.html.plaintext.txt	26	assessments occupation based ses main occupation based ses specially trained nurses interviewed relative another person significant subject subject full lifetime work history questionnaire developed occupational hygienist eight occupational periods specific information regarding time place listed subject longest held job considered main occupation occupations grouped according socioeconomic classification system developed statistics sweden 22 swedish socioeconomic classification system primarily contains dimensions ownership means production division blue collar white collar occupations assessed normal trade union affiliation also contains aspects skills subdivisions inside blue collar white collar occupational categories however customary educational requirements respective occupations used information education individual level
0.23427205.14718220.html.plaintext.txt	27	quite women 21 percent homemakers longest occupational period information husband occupation frequently used estimate ses wives available instead including homemakers category used second longest held job estimate ses eighteen subjects housewives throughout working lives excluded analyses involving main occupation
0.23427205.14718220.html.plaintext.txt	28	quite women 21 percent homemakers longest occupational period information husband occupation frequently used estimate ses wives available instead including homemakers category used second longest held job estimate ses eighteen subjects housewives throughout working lives excluded analyses involving main occupation
0.23427205.14718220.html.plaintext.txt	29	first analyzed relation ses incidence alzheimer disease dementia using three categories blue collar workers white collar employees self employed persons plus academic professions since two last categories similar risks two groups merged
0.23427205.14718220.html.plaintext.txt	30	first analyzed relation ses incidence alzheimer disease dementia using three categories blue collar workers white collar employees self employed persons plus academic professions since two last categories similar risks two groups merged
0.23427205.14718220.html.plaintext.txt	31	lifetime occupational ses data gathered length occupational period subject lifetime occupations classified described exception substitutions occupational periods could made homemaker work periods instead classified nonmanual periods 1 women often held nonmanual jobs occupational periods 2 generally highly educated nonhousewives finally added numbers years periods manual labor obtain sum years spent low occupation based ses current study report results analyses number years low ses less equal 25 versus 25 median amount time spent low ses low ses fraction population
0.23427205.14718220.html.plaintext.txt	32	lifetime occupational ses data gathered length occupational period subject lifetime occupations classified described exception substitutions occupational periods could made homemaker work periods instead classified nonmanual periods 1 women often held nonmanual jobs occupational periods 2 generally highly educated nonhousewives finally added numbers years periods manual labor obtain sum years spent low occupation based ses current study report results analyses number years low ses less equal 25 versus 25 median amount time spent low ses low ses fraction population
0.23427205.14718220.html.plaintext.txt	33	socioeconomic mobility computed occupation based ses ages 20 40 60 years order estimate individual socioeconomic mobility patterns information particular time period missing substituted equal number years two closest work periods sixty three persons lacked information occupational position 60 years age instead information concerning occupational period prior chosen represent
0.23427205.14718220.html.plaintext.txt	34	socioeconomic mobility computed occupation based ses ages 20 40 60 years order estimate individual socioeconomic mobility patterns information particular time period missing substituted equal number years two closest work periods sixty three persons lacked information occupational position 60 years age instead information concerning occupational period prior chosen represent
0.23427205.14718220.html.plaintext.txt	35	covariates used covariates available information database may acted confounding factors major possible confounders considered age gender vascular diseases alcohol data
0.23427205.14718220.html.plaintext.txt	36	covariates used covariates available information database may acted confounding factors major possible confounders considered age gender vascular diseases alcohol data
0.23427205.14718220.html.plaintext.txt	37	information age gender derived swedish national population register information cerebrovascular heart diseases diabetes mellitus derived computerized stockholm inpatient registry system admission discharge diagnoses every hospital stockholm recorded current study diagnoses made time 1969 baseline examination used diseases diagnosed according international classification diseases eighth revision codes 430 438 cerebrovascular disease codes 410 414 coronary disease code 428 heart failure code 427 arrhythmia code 250 diabetes mellitus information diabetes patient register integrated self reports doctor diagnosis diabetes use oral hypoglycemic medication insulin blood glucose level greater 11 mmolliter arterial blood pressure measured baseline mercury sphygmomanometer trained nurses first reading abnormal systolic pressure border0160 mmhg diastolic pressure border095 mmhg two additional readings made mean second third readings used analyses 23 furthermore created simple additive index ranging 0 5 vascular diseases risk factors described
0.23427205.14718220.html.plaintext.txt	38	information age gender derived swedish national population register information cerebrovascular heart diseases diabetes mellitus derived computerized stockholm inpatient registry system admission discharge diagnoses every hospital stockholm recorded current study diagnoses made time 1969 baseline examination used diseases diagnosed according international classification diseases eighth revision codes 430 438 cerebrovascular disease codes 410 414 coronary disease code 428 heart failure code 427 arrhythmia code 250 diabetes mellitus information diabetes patient register integrated self reports doctor diagnosis diabetes use oral hypoglycemic medication insulin blood glucose level greater 11 mmolliter arterial blood pressure measured baseline mercury sphygmomanometer trained nurses first reading abnormal systolic pressure border0160 mmhg diastolic pressure border095 mmhg two additional readings made mean second third readings used analyses 23 furthermore created simple additive index ranging 0 5 vascular diseases risk factors described
0.23427205.14718220.html.plaintext.txt	39	information alcohol use collected relatives specified many glasses wine bottles beer andor glasses liquor proband consumed weekly since consumption alcohol predominantly female elderly population found particularly low 824 percent persons available data alcohol reported used alcohol 35 percent consumed amount corresponding five glasses wine per week decided divide alcohol data three categories use use information latter category included analyses reporting alcohol use sometimes sensitive matter found relevant investigate whether absence information associated risk dementia
0.23427205.14718220.html.plaintext.txt	40	information alcohol use collected relatives specified many glasses wine bottles beer andor glasses liquor proband consumed weekly since consumption alcohol predominantly female elderly population found particularly low 824 percent persons available data alcohol reported used alcohol 35 percent consumed amount corresponding five glasses wine per week decided divide alcohol data three categories use use information latter category included analyses reporting alcohol use sometimes sensitive matter found relevant investigate whether absence information associated risk dementia
0.23427205.14718220.html.plaintext.txt	41	covariates controlled analyses 1 cognitive status baseline measured mini mental state examination 24 2 social network baseline measured four grade index poor limited moderate rich social network defined previous study 25 3 engagement mental physical activities baseline graded three frequency categories 26
0.23427205.14718220.html.plaintext.txt	42	statistical analysis logistic regression used evaluate differences baseline characteristics participants dropouts cox proportional hazards regression analyses used estimate relative risk incident alzheimer disease dementia associated different combinations education occupation based ses well socioeconomic mobility follow time nondemented persons estimated date baseline interview date follow examination death demented persons half time calculated since dementia onset assumed midpoint baseline follow examination
0.23427205.14718220.html.plaintext.txt	43	statistical analysis logistic regression used evaluate differences baseline characteristics participants dropouts cox proportional hazards regression analyses used estimate relative risk incident alzheimer disease dementia associated different combinations education occupation based ses well socioeconomic mobility follow time nondemented persons estimated date baseline interview date follow examination death demented persons half time calculated since dementia onset assumed midpoint baseline follow examination
0.23427205.14718220.html.plaintext.txt	44	age gender vascular disease index alcohol use entered models additional models used verify possible confounding effect baseline mini mental state examination score social network leisure activities also repeated analyses excluding stroke cases purpose examining whether stroke might obscure increase diagnostic difficulties dementia due cognitive dysfunction subjects previous stroke
0.23427205.14718220.html.plaintext.txt	45	age gender vascular disease index alcohol use entered models additional models used verify possible confounding effect baseline mini mental state examination score social network leisure activities also repeated analyses excluding stroke cases purpose examining whether stroke might obscure increase diagnostic difficulties dementia due cognitive dysfunction subjects previous stroke
0.23427205.14718220.html.plaintext.txt	46	interrelation education ses explored using two stratifications first study population divided four strata characterized 1 high education high ses 2 high education low ses 3 low education high ses 4 low education low ses second used four strata combining low high education defined permanence low ses less equal 25 years versus 25 years
0.23427205.14718220.html.plaintext.txt	47	interrelation education ses explored using two stratifications first study population divided four strata characterized 1 high education high ses 2 high education low ses 3 low education high ses 4 low education low ses second used four strata combining low high education defined permanence low ses less equal 25 years versus 25 years
0.23427205.14718220.html.plaintext.txt	48	results top abstract introduction materials methods results discussion references persons dropped study comparable participants terms age 1 year increment odds ratio 10 95 percent confidence interval ci 098 102 gender female odds ratio 08 95 percent ci 06 10 vascular disease presence vascular disease odds ratio 08 95 percent ci 06 10 odds ratio dropping regard low level education 14 95 percent ci 11 17 however occurrence dementia among 370 dropouts lacking information occupational history similar among participants study
0.23427205.14718220.html.plaintext.txt	49	results top abstract introduction materials methods results discussion references persons dropped study comparable participants terms age 1 year increment odds ratio 10 95 percent confidence interval ci 098 102 gender female odds ratio 08 95 percent ci 06 10 vascular disease presence vascular disease odds ratio 08 95 percent ci 06 10 odds ratio dropping regard low level education 14 95 percent ci 11 17 however occurrence dementia among 370 dropouts lacking information occupational history similar among participants study
0.23427205.14718220.html.plaintext.txt	50	total 101 subjects developed clinically definite dementia follow period among dementia cases types 76 persons diagnosed clinically definite dementia alzheimer type table 1 provides characteristics participants dementia status follow
0.23427205.14718220.html.plaintext.txt	51	total 101 subjects developed clinically definite dementia follow period among dementia cases types 76 persons diagnosed clinically definite dementia alzheimer type table 1 provides characteristics participants dementia status follow
0.23427205.14718220.html.plaintext.txt	52	view table table 1 baseline characteristics study population n 931 dementia status follow kungsholmen project stockholm sweden 1987 1993 relative risks clinical dementia alzheimer type types relation education occupation based ses reported table 2 compared persons high level education border011 years adjusted relative risks dementia alzheimer type dementia types similar subjects intermediate amount 8 10 years education elevated subjects low level 2 7 years education see model 1a model 1b merged high intermediate levels education one reference category model 1b model 2 subjects either low level education low occupation based ses found higher risk alzheimer disease dementia even adjustment covariates examined however education ses introduced model simultaneously table 2 model 3 low education remained significant risk factor alzheimer disease dementia results similar men women although relative risks men statistically significant probably less statistical power
0.23427205.14718220.html.plaintext.txt	53	view table table 2 relative risks clinically diagnosed alzheimer disease dementia associated education occupation based socioeconomic status lifetime longest held job derived separate models models 1 2 model model 3 kungsholmen project stockholm sweden 1987 1993 subjects low educationlow occupation based ses category often female 83 percent subjects high educationhigh occupation based ses category 71 percent number persons high educationlow occupation based ses group smaller n 36 comparison groups contained largest proportion women 89 percent housewives 33 percent low educationhigh occupation based ses group differed noticeably 26 percent members self employed whereas 9 percent persons high educationhigh occupation based ses group self employed
0.23427205.14718220.html.plaintext.txt	54	low education combination either low high occupation based ses associated increased risk alzheimer disease dementia even adjustment major covariates combination high education low occupation based ses associated increased risk alzheimer disease dementia table 3
0.23427205.14718220.html.plaintext.txt	55	low education combination either low high occupation based ses associated increased risk alzheimer disease dementia even adjustment major covariates combination high education low occupation based ses associated increased risk alzheimer disease dementia table 3
0.23427205.14718220.html.plaintext.txt	56	view table table 3 relative risks clinically diagnosed alzheimer disease dementia associated combinations education occupation based socioeconomic status lifetime longest held job kungsholmen project stockholm sweden 1987 1993 stratified analyses relations combinations education total years low occupation based ses alzheimer disease showed results similar stratified analysis depicted table 3 compared persons high education less 25 years low ses subgroup low education 25 years low ses adjusted relative risk 31 95 percent ci 16 58 subgroup low education fewer 25 years low ses adjusted relative risk 34 95 percent ci 19 63 high education conjunction 25 years low ses associated increased risk alzheimer disease
0.23427205.14718220.html.plaintext.txt	57	table 4 model 1 shows relative risks alzheimer disease relation eight social mobility patterns controlling age gender low occupation based ses ages 20 40 60 years resulted borderline significant elevated risk alzheimer disease compared reference category high ses three ages low occupation based ses ages 20 40 years age 60 years also associated significantly elevated risks alzheimer disease furthermore low occupation based ses 20 years age regardless whether ses high age 40 andor age 60 associated elevated alzheimer disease risks though statistically significantly however additional adjustment education none significant associations remained twenty eight percent subjects high occupational ses ages 20 40 60 years 91 percent subjects low ses ages 20 40 60 years low educational level analyses type dementia showed similar results
0.23427205.14718220.html.plaintext.txt	58	table 4 model 1 shows relative risks alzheimer disease relation eight social mobility patterns controlling age gender low occupation based ses ages 20 40 60 years resulted borderline significant elevated risk alzheimer disease compared reference category high ses three ages low occupation based ses ages 20 40 years age 60 years also associated significantly elevated risks alzheimer disease furthermore low occupation based ses 20 years age regardless whether ses high age 40 andor age 60 associated elevated alzheimer disease risks though statistically significantly however additional adjustment education none significant associations remained twenty eight percent subjects high occupational ses ages 20 40 60 years 91 percent subjects low ses ages 20 40 60 years low educational level analyses type dementia showed similar results
0.23427205.14718220.html.plaintext.txt	59	view table table 4 relative risks clinically diagnosed alzheimer disease associated social mobility occupation based socioeconomic status ages 20 40 60 years kungsholmen project stockholm sweden 1987 1993 finally baseline cognitive status variables mini mental state examination score social network engagement physical mental activities included model covariates relations ses education alzheimer disease dementia substantially change repeated analyses excluding cases stroke associations education alzheimer disease education dementia similar results showed patterns main analyses
0.23427205.14718220.html.plaintext.txt	60	discussion top abstract introduction materials methods results discussion references main finding study low level education low occupation based main ses individually associated increased risk alzheimer disease dementia low education remains risk factor variables examined simultaneously similar pattern observed numbers years work periods low ses position added together life span individual social mobility patterns studied comparison highly educated subjects high ses main occupation twofold increased risk alzheimer disease detected among less educated subjects low ses also among subjects low education high ses position addition subjects initially high occupation based ses increased risk alzheimer disease independently later ses changes persons low occupation based ses young age remained category occupational life 70 140 percent increased risk alzheimer disease however even case low education explained associations
0.23427205.14718220.html.plaintext.txt	61	discussion top abstract introduction materials methods results discussion references main finding study low level education low occupation based main ses individually associated increased risk alzheimer disease dementia low education remains risk factor variables examined simultaneously similar pattern observed numbers years work periods low ses position added together life span individual social mobility patterns studied comparison highly educated subjects high ses main occupation twofold increased risk alzheimer disease detected among less educated subjects low ses also among subjects low education high ses position addition subjects initially high occupation based ses increased risk alzheimer disease independently later ses changes persons low occupation based ses young age remained category occupational life 70 140 percent increased risk alzheimer disease however even case low education explained associations
0.23427205.14718220.html.plaintext.txt	62	results agreement previous findings positive association low level education increased risk alzheimer disease dementia 1 10 evans et al 2 reported socioeconomic measures education income occupational prestige predicted alzheimer disease risk however included three measures model education income occupational prestige retained significant association alzheimer disease recently investigators nurses health study 27 reported strong association low education cognitive decline little association markers ses
0.23427205.14718220.html.plaintext.txt	63	fact association low education increased risk alzheimer disease dementia general present independently main occupation based ses fact association ses alzhei mer disease dementia mainly due ses early work life seems indicate unknown education related factors acting first two decades life may involved development alzheimer disease dementia interpretation agreement number previous reports recent article kaplan et al 28 concluded higher childhood socioeconomic position well greater educational attainment associated better cognitive function adulthood study education dementia italian population middle high socioeconomic level first decade life suggested critical period development dementia later life 29 hall et al 30 discussed possibility low education major risk factor alzhei mer disease rather marker accompanying deleterious socioeconomic environmental influences childhood poor quality childhood adolescent environments suggested prevent brain reaching complete levels maturation turn may put people higher risk alzheimer disease 31 32 results paquid study 33 showed occupation change risk alzheimer disease instead related cognitive abilities childhood adolescence early life factors question may early socioeconomic factors mental stimulation cognitive abilities cognitive abilities may affected environmental 34 genetic influences 9 since many studies like lack independent measure intelligence importance early life cognitive abilities difficult evaluate
0.23427205.14718220.html.plaintext.txt	64	fact association low education increased risk alzheimer disease dementia general present independently main occupation based ses fact association ses alzhei mer disease dementia mainly due ses early work life seems indicate unknown education related factors acting first two decades life may involved development alzheimer disease dementia interpretation agreement number previous reports recent article kaplan et al 28 concluded higher childhood socioeconomic position well greater educational attainment associated better cognitive function adulthood study education dementia italian population middle high socioeconomic level first decade life suggested critical period development dementia later life 29 hall et al 30 discussed possibility low education major risk factor alzhei mer disease rather marker accompanying deleterious socioeconomic environmental influences childhood poor quality childhood adolescent environments suggested prevent brain reaching complete levels maturation turn may put people higher risk alzheimer disease 31 32 results paquid study 33 showed occupation change risk alzheimer disease instead related cognitive abilities childhood adolescence early life factors question may early socioeconomic factors mental stimulation cognitive abilities cognitive abilities may affected environmental 34 genetic influences 9 since many studies like lack independent measure intelligence importance early life cognitive abilities difficult evaluate
0.23427205.14718220.html.plaintext.txt	65	number studies given special attention effect early life circumstances health mortality general early life ses reported connected cardiovascular diseases general health status later life 35 37 disadvantaged childhood living conditions hypothesized trigger unhealthy life trajectories increased illness risk sum several health damaging factors 38 new results random swedish national sample indicate occupational class differences adult mortality depend fairly large extent childhood conditions 39 examined relation ses alzheimer disease dementia lifetime perspective ranging school retirement unfortunately lacked specific data ses family origin thus suggest involvement early life factors development alzheimer disease dementia hypothesis
0.23427205.14718220.html.plaintext.txt	66	number studies given special attention effect early life circumstances health mortality general early life ses reported connected cardiovascular diseases general health status later life 35 37 disadvantaged childhood living conditions hypothesized trigger unhealthy life trajectories increased illness risk sum several health damaging factors 38 new results random swedish national sample indicate occupational class differences adult mortality depend fairly large extent childhood conditions 39 examined relation ses alzheimer disease dementia lifetime perspective ranging school retirement unfortunately lacked specific data ses family origin thus suggest involvement early life factors development alzheimer disease dementia hypothesis
0.23427205.14718220.html.plaintext.txt	67	alternative explanation findings education may better indicator adult lifestyle habits occupational ses lifestyle habits alcohol use smoking may explain detected association however data adjusted alcohol use additionally current social network index engagement physical mental activities entered model covariates obtained similar results smoking related alzheimer disease dementia population 40
0.23427205.14718220.html.plaintext.txt	68	alternative explanation findings education may better indicator adult lifestyle habits occupational ses lifestyle habits alcohol use smoking may explain detected association however data adjusted alcohol use additionally current social network index engagement physical mental activities entered model covariates obtained similar results smoking related alzheimer disease dementia population 40
0.23427205.14718220.html.plaintext.txt	69	regard cognitive function late middle age turrell et al 17 reported disadvantaged socioeconomic circumstances childhood may extent overcome later upward mobility however study low education remained associated increased risk alzheimer disease even adjustment adult social mobility
0.23427205.14718220.html.plaintext.txt	70	regard cognitive function late middle age turrell et al 17 reported disadvantaged socioeconomic circumstances childhood may extent overcome later upward mobility however study low education remained associated increased risk alzheimer disease even adjustment adult social mobility
0.23427205.14718220.html.plaintext.txt	71	potential limitations study must considered persons dropped study less educated participants since low education related alzheimer disease dementia may affected results likely skewed findings towards underestimation association towards overestimation occupational data obtained informants however single open ended question occupation without specification time place number years already posed participants baseline interview possible compare responses informant data regarding subject main job information two different sources used estimate ses agreement 80 percent swedish system classification ses occupation well established evaluated 41 however remains occupation based ses difficult evaluate education estimation ses occupation difficult housewives cohort 21 percent approximations likely create nondifferential misclassification ses leading dilution association performed additional analyses data shown treating housewives third occupational category affect results
0.23427205.14718220.html.plaintext.txt	72	potential limitations study must considered persons dropped study less educated participants since low education related alzheimer disease dementia may affected results likely skewed findings towards underestimation association towards overestimation occupational data obtained informants however single open ended question occupation without specification time place number years already posed participants baseline interview possible compare responses informant data regarding subject main job information two different sources used estimate ses agreement 80 percent swedish system classification ses occupation well established evaluated 41 however remains occupation based ses difficult evaluate education estimation ses occupation difficult housewives cohort 21 percent approximations likely create nondifferential misclassification ses leading dilution association performed additional analyses data shown treating housewives third occupational category affect results
0.23427205.14718220.html.plaintext.txt	73	finally must cautious interpreting findings reflecting direct effect education alzheimer disease risk one mediated occupation based ses fact possibility unmeasured confounders responsible patterns associations found study example work related stress may associated occupation based ses education may increase risk alzheimer disease dementia though currently clear evidence literature concerning association
0.23427205.14718220.html.plaintext.txt	74	finally must cautious interpreting findings reflecting direct effect education alzheimer disease risk one mediated occupation based ses fact possibility unmeasured confounders responsible patterns associations found study example work related stress may associated occupation based ses education may increase risk alzheimer disease dementia though currently clear evidence literature concerning association
0.23427205.14718220.html.plaintext.txt	75	main conclusion drawn study low level education directly associated increased alzheimer disease incidence mediated low adult occupation based ses regardless whether low ses occupational period extended substantial number years border025 years regardless adult socioeconomic mobility pattern results inconsistent already suggested hypotheses cognitive brain reserves 5 6 alternatively findings may partly reflect detection bias subjects low level education tend clinically diagnosed alzheimer disease dementia earlier point time 4 however possibility factors related early life ses may play role development alzheimer disease dementia disregarded findings support hypothesis stress importance collecting data early life conditions studying dementia old age
0.23427205.14718220.html.plaintext.txt	76	main conclusion drawn study low level education directly associated increased alzheimer disease incidence mediated low adult occupation based ses regardless whether low ses occupational period extended substantial number years border025 years regardless adult socioeconomic mobility pattern results inconsistent already suggested hypotheses cognitive brain reserves 5 6 alternatively findings may partly reflect detection bias subjects low level education tend clinically diagnosed alzheimer disease dementia earlier point time 4 however possibility factors related early life ses may play role development alzheimer disease dementia disregarded findings support hypothesis stress importance collecting data early life conditions studying dementia old age
0.23427205.14718220.html.plaintext.txt	77	acknowledgments research grants received swedish council work life research f01502000 swedish council social research 1997 0999 gamla tjanarinnor foundation solstickan foundation
0.23427205.14718220.html.plaintext.txt	78	acknowledgments research grants received swedish council work life research f01502000 swedish council social research 1997 0999 gamla tjanarinnor foundation solstickan foundation
0.23427205.14718220.html.plaintext.txt	79	authors thank members kungsholmen project study group cooperation data collection management
0.23427205.14718220.html.plaintext.txt	80	notes reprint requests anita karp aging research center karolinska institutet box 6401 olivecronas vag 4 113 82 stockholm sweden e mail anitakarpatneuroteckise u d
0.23427205.14718220.html.plaintext.txt	81	references top abstract introduction materials methods results discussion references schmand b smit j lindeboom j et al low education genuine risk factor accelerated memory decline dementia j clin epidemiol 1997501025 33crossrefisimedline evans da hebert le beckett la et al education measures socioeconomic status risk incident alzheimer disease defined population older persons arch neurol 1997541399 405abstract letenneur l gilleron v commenges d et al sex educational level independent predictors dementia alzheimer disease incidence data paquid project j neurol neurosurg psychiatry 199966177 83abstractfree full text qiu c backman l winblad b et al influence education clinically diagnosed dementia incidence mortality data kungsholmen project arch neurol 2001582034 9abstractfree full text katzman r education prevalence dementia alzheimer disease neurology 19934313 20isimedline stern y gurland b tatemichi tk et al influence education occupation incidence alzheimer disease jama 19942711004 10abstract friedland rp epidemiology education ecology alzheimer disease neurology 199343246 9isimedline plassman bl welsh ka helms m et al intelligence education predictors cognitive state late life 50 year follow neurology 1995451446 50abstract gatz m svedberg p pedersen nl et al education risk alzheimer disease findings study dementia swedish twins j gerontol b psychol sci soc sci 200156p292 300abstractfree full text fratiglioni l viitanen m aguero torres h et al low education ad effects diagnosis rather risk abstract neurobiol aging 199819suppl 4214 winkleby ma jatulis de frank e et al socioeconomic status health education income occupation contribute risk factors cardiovascular disease j public health 199282816 20abstract davey smith g hart c hole d et al education social class important indicator mortality risk j epidemiol community health 199852153 60abstract lynch j kaplan g socioeconomic position berkman lf kawachi eds social epidemiology new york ny oxford university press 200013 35 smith gd hart c blane d et al lifetime socioeconomic position mortality prospective observational study bmj 1997314547 52abstractfree full text power c manor o matthews duration timing exposure effects socioeconomic environment adult health j public health 1999891059 65abstract lynch jw kaplan ga shema sj cumulative impact sustained economic hardship physical cognitive psychological social functioning n engl j med 19973371889 95abstractfree full text turrell g lynch jw kaplan ga et al socioeconomic position across lifecourse cognitive function late middle age j gerontol b psychol sci soc sci 200257s43 51abstractfree full text qiu c karp von strauss e et al lifetime principal occupation risk alzheimer disease kungsholmen project j ind med 200343204 11crossrefisimedline fratiglioni l viitanen m von strauss e et al old women highest risk dementia alzheimer disease incidence data kungsholmen project stockholm neurology 199748132 8abstract american psychiatric association diagnostic statistical manual mental disorders third edition revised dsm iii r washington dc american psychiatric association 198797 163 mckhann g drachman d folstein m et al clinical diagnosis alzheimer disease report nincds adrda work group auspices department health human services task force alzheimer disease neurology 198434939 44abstract statistics sweden swedish socioeconomic classification reports statistical co ordination stockholm sweden statistics sweden 1982 guo z viitanen m winblad b low blood pressure five year mortality stockholm cohort old possible confounding cognitive impairment factors j public health 199787623 8abstract folstein mf folstein se mchugh pr mini mental state practical method grading cognitive state patients clinician j psychiatr res 197512189 98crossrefisimedline fratiglioni l wang hx ericsson k et al influence social network occurrence dementia community based longitudinal study lancet 20003551315 19crossrefisimedline wang hx karp winblad b fratiglioni l late life engagement social leisure activities associated decreased risk dementia longitudinal study kungsholmen project j epidemiol 20021551081 7abstractfree full text lee kawachi berkman l et al education socioeconomic indicators cognitive function j epidemiol 2003157712 20abstractfree full text kaplan g turrell g lynch jw et al childhood socioeconomic position cognitive function adulthood int j epidemiol 200130256 63abstractfree full text de ronchi d fratiglioni l rucci p et al effect education dementia occurrence italian population middle high socioeconomic status neurology 1998501231 8abstract hall ks gao unverzagt fw et al low education childhood rural residence risk alzheimer disease african americans neurology 20005495 9abstractfree full text moceri vm kukull wa emanuel et al early life risk factors development alzheimer disease neurology 200054415 20abstractfree full text moceri vm kukull wa emanual et al using census data birth certificates reconstruct early life socioeconomic environment relation development alzheimer disease epidemiology 200112383 9crossrefisimedline helmer c letenneur l rouch et al occupation life risk dementia french elderly community residents j neurol neurosurg psychiatry 200171303 9abstractfree full text del ser hachinski v merskey h et al autopsy verified study effect education degenerative dementia brain 19991222309 19abstractfree full text kaplan ga salonen jt socioeconomic conditions childhood ischaemic heart disease middle age bmj 19903011121 3isimedline van de mheen h stronks k looman cw childhood socioeconomic status influence adult health behavioural factors int j epidemiol 199827431 7abstract wamala sp socioeconomic status cardiovascular vulnerability women psychosocial behavioral biological mediators doctoral thesis stockholm sweden karolinska institute 1999 lundberg o impact childhood living conditions illness mortality adulthood soc sci med 1993361047 52crossrefisimedline kareholt long shadow socioeconomic conditions childhood affect class inequalities mortality jonsson jo mills c eds cradle grave life course change modern sweden durham united kingdom sociology press 200229 44 wang hx fratiglioni l frisoni gb et al smoking occurrence alzheimer disease cross sectional longitudinal data population based study j epidemiol 1999149640 4abstract andersson lg erickson r warneryd b describe social structure evaluation 1974 suggestion socio economic classification swedish stat tidskr 198119113 36
0.23427205.14718220.html.plaintext.txt	82	references top abstract introduction materials methods results discussion references schmand b smit j lindeboom j et al low education genuine risk factor accelerated memory decline dementia j clin epidemiol 1997501025 33crossrefisimedline evans da hebert le beckett la et al education measures socioeconomic status risk incident alzheimer disease defined population older persons arch neurol 1997541399 405abstract letenneur l gilleron v commenges d et al sex educational level independent predictors dementia alzheimer disease incidence data paquid project j neurol neurosurg psychiatry 199966177 83abstractfree full text qiu c backman l winblad b et al influence education clinically diagnosed dementia incidence mortality data kungsholmen project arch neurol 2001582034 9abstractfree full text katzman r education prevalence dementia alzheimer disease neurology 19934313 20isimedline stern y gurland b tatemichi tk et al influence education occupation incidence alzheimer disease jama 19942711004 10abstract friedland rp epidemiology education ecology alzheimer disease neurology 199343246 9isimedline plassman bl welsh ka helms m et al intelligence education predictors cognitive state late life 50 year follow neurology 1995451446 50abstract gatz m svedberg p pedersen nl et al education risk alzheimer disease findings study dementia swedish twins j gerontol b psychol sci soc sci 200156p292 300abstractfree full text fratiglioni l viitanen m aguero torres h et al low education ad effects diagnosis rather risk abstract neurobiol aging 199819suppl 4214 winkleby ma jatulis de frank e et al socioeconomic status health education income occupation contribute risk factors cardiovascular disease j public health 199282816 20abstract davey smith g hart c hole d et al education social class important indicator mortality risk j epidemiol community health 199852153 60abstract lynch j kaplan g socioeconomic position berkman lf kawachi eds social epidemiology new york ny oxford university press 200013 35 smith gd hart c blane d et al lifetime socioeconomic position mortality prospective observational study bmj 1997314547 52abstractfree full text power c manor o matthews duration timing exposure effects socioeconomic environment adult health j public health 1999891059 65abstract lynch jw kaplan ga shema sj cumulative impact sustained economic hardship physical cognitive psychological social functioning n engl j med 19973371889 95abstractfree full text turrell g lynch jw kaplan ga et al socioeconomic position across lifecourse cognitive function late middle age j gerontol b psychol sci soc sci 200257s43 51abstractfree full text qiu c karp von strauss e et al lifetime principal occupation risk alzheimer disease kungsholmen project j ind med 200343204 11crossrefisimedline fratiglioni l viitanen m von strauss e et al old women highest risk dementia alzheimer disease incidence data kungsholmen project stockholm neurology 199748132 8abstract american psychiatric association diagnostic statistical manual mental disorders third edition revised dsm iii r washington dc american psychiatric association 198797 163 mckhann g drachman d folstein m et al clinical diagnosis alzheimer disease report nincds adrda work group auspices department health human services task force alzheimer disease neurology 198434939 44abstract statistics sweden swedish socioeconomic classification reports statistical co ordination stockholm sweden statistics sweden 1982 guo z viitanen m winblad b low blood pressure five year mortality stockholm cohort old possible confounding cognitive impairment factors j public health 199787623 8abstract folstein mf folstein se mchugh pr mini mental state practical method grading cognitive state patients clinician j psychiatr res 197512189 98crossrefisimedline fratiglioni l wang hx ericsson k et al influence social network occurrence dementia community based longitudinal study lancet 20003551315 19crossrefisimedline wang hx karp winblad b fratiglioni l late life engagement social leisure activities associated decreased risk dementia longitudinal study kungsholmen project j epidemiol 20021551081 7abstractfree full text lee kawachi berkman l et al education socioeconomic indicators cognitive function j epidemiol 2003157712 20abstractfree full text kaplan g turrell g lynch jw et al childhood socioeconomic position cognitive function adulthood int j epidemiol 200130256 63abstractfree full text de ronchi d fratiglioni l rucci p et al effect education dementia occurrence italian population middle high socioeconomic status neurology 1998501231 8abstract hall ks gao unverzagt fw et al low education childhood rural residence risk alzheimer disease african americans neurology 20005495 9abstractfree full text moceri vm kukull wa emanuel et al early life risk factors development alzheimer disease neurology 200054415 20abstractfree full text moceri vm kukull wa emanual et al using census data birth certificates reconstruct early life socioeconomic environment relation development alzheimer disease epidemiology 200112383 9crossrefisimedline helmer c letenneur l rouch et al occupation life risk dementia french elderly community residents j neurol neurosurg psychiatry 200171303 9abstractfree full text del ser hachinski v merskey h et al autopsy verified study effect education degenerative dementia brain 19991222309 19abstractfree full text kaplan ga salonen jt socioeconomic conditions childhood ischaemic heart disease middle age bmj 19903011121 3isimedline van de mheen h stronks k looman cw childhood socioeconomic status influence adult health behavioural factors int j epidemiol 199827431 7abstract wamala sp socioeconomic status cardiovascular vulnerability women psychosocial behavioral biological mediators doctoral thesis stockholm sweden karolinska institute 1999 lundberg o impact childhood living conditions illness mortality adulthood soc sci med 1993361047 52crossrefisimedline kareholt long shadow socioeconomic conditions childhood affect class inequalities mortality jonsson jo mills c eds cradle grave life course change modern sweden durham united kingdom sociology press 200229 44 wang hx fratiglioni l frisoni gb et al smoking occurrence alzheimer disease cross sectional longitudinal data population based study j epidemiol 1999149640 4abstract andersson lg erickson r warneryd b describe social structure evaluation 1974 suggestion socio economic classification swedish stat tidskr 198119113 36
0.23731914.12456513.html.plaintext.txt	0	managing behavioural psychological symptoms dementia brian lawlor frcpsych
0.23731914.12456513.html.plaintext.txt	1	jonathan swift clinic department psychiatry st jamess hospital st james street dublin 8 ireland
0.23731914.12456513.html.plaintext.txt	2	behavioural psychological symptoms dementia bpsd common problematic clinical practice represent significant part day day workload old age psychiatry team hospital institution community settings improving recognition management bpsd positive impact quality life patients carers potentially delay transition home institutional care
0.23731914.12456513.html.plaintext.txt	3	behavioural psychological symptoms dementia bpsd common problematic clinical practice represent significant part day day workload old age psychiatry team hospital institution community settings improving recognition management bpsd positive impact quality life patients carers potentially delay transition home institutional care
0.23731914.12456513.html.plaintext.txt	4	behavioural psychological symptoms dementia umbrella term embraces heterogeneous group non cognitive symptoms behaviours occur people dementia concept bpsd descriptive one reflect diagnostic entity rather high lights important clinical dimension dementia recently ignored research therapeutic points view one approach description bpsd use list observed behaviours wandering agitation sexually inappropriate behaviours elicited psychological symptoms depression anxiety delusions finkel et al 1996 approach fails take account fact many called elicited symptoms depression delusions also represent observed behaviours looks depressed acts though hallucinating deluded fact symptoms behaviours occur isolation tend occur together clusters syndromes number syndromes described basis factor analytical studies using rating instruments designed measure bpsd frisoni et al 1999 syndromes include depression psychosis psychomotor agitation aggression apathy depression psychosis included descriptors dsm iv criteria alzheimers disease american psychiatric association 1994 recently diagnostic criteria distinct syndrome psychosis alzheimers disease related dementias depression alzheimers disease proposed jeste finkel 2000 olin et al 2002 likely diagnostic criteria behavioural syndromes dementia also developed near future facilitate recognition future therapeutic targeting specific aspects bpsd
0.23731914.12456513.html.plaintext.txt	5	behavioural psychological symptoms dementia umbrella term embraces heterogeneous group non cognitive symptoms behaviours occur people dementia concept bpsd descriptive one reflect diagnostic entity rather high lights important clinical dimension dementia recently ignored research therapeutic points view one approach description bpsd use list observed behaviours wandering agitation sexually inappropriate behaviours elicited psychological symptoms depression anxiety delusions finkel et al 1996 approach fails take account fact many called elicited symptoms depression delusions also represent observed behaviours looks depressed acts though hallucinating deluded fact symptoms behaviours occur isolation tend occur together clusters syndromes number syndromes described basis factor analytical studies using rating instruments designed measure bpsd frisoni et al 1999 syndromes include depression psychosis psychomotor agitation aggression apathy depression psychosis included descriptors dsm iv criteria alzheimers disease american psychiatric association 1994 recently diagnostic criteria distinct syndrome psychosis alzheimers disease related dementias depression alzheimers disease proposed jeste finkel 2000 olin et al 2002 likely diagnostic criteria behavioural syndromes dementia also developed near future facilitate recognition future therapeutic targeting specific aspects bpsd
0.23731914.12456513.html.plaintext.txt	6	although behaviour psychological symptoms included core features definition dementia syndrome two thirds people dementia experience bpsd one time point one third community dwelling people dementia level bpsd clinically significant range lyketsos et al 2000 figure clinically significant bpsd rises almost 80 people dementia residing care environments margallo lana et al 2001 prevalence estimates bpsd vary widely heterogeneity patient populations studied terms setting type dementia different definitions used bpsd recent application standardised validated assessment instruments resulting consistent data community clinic based populations two population based studies one usa lyketsos et al 2000 one uk burns et al 1990 show similar prevalence figures 20 bpsd people alzheimers disease unlike cognitive dysfunction dementia progressively worsens time many bpsd tend fluctuate psycho motor agitation persistent devanand et al 1997 research needed natural history longitudinal course bpsd inform clinicians appropriate duration pharmacological interventions advice information given families distressed symptoms behaviours
0.23731914.12456513.html.plaintext.txt	7	although behaviour psychological symptoms included core features definition dementia syndrome two thirds people dementia experience bpsd one time point one third community dwelling people dementia level bpsd clinically significant range lyketsos et al 2000 figure clinically significant bpsd rises almost 80 people dementia residing care environments margallo lana et al 2001 prevalence estimates bpsd vary widely heterogeneity patient populations studied terms setting type dementia different definitions used bpsd recent application standardised validated assessment instruments resulting consistent data community clinic based populations two population based studies one usa lyketsos et al 2000 one uk burns et al 1990 show similar prevalence figures 20 bpsd people alzheimers disease unlike cognitive dysfunction dementia progressively worsens time many bpsd tend fluctuate psycho motor agitation persistent devanand et al 1997 research needed natural history longitudinal course bpsd inform clinicians appropriate duration pharmacological interventions advice information given families distressed symptoms behaviours
0.23731914.12456513.html.plaintext.txt	8	occurrence bpsd often triggering event recognition referral people dementia specialist services patients families present crisis disarray relatively late course illness development bpsd major risk factor caregiver burden coen et al 1997 institutionalisation odonnell et al 1992 important regard enduring cognitive deficits disease process steele et al 1990 aspects bpsd associated caregiver burden paranoia aggression sleep wake cycle disturbance appear particularly important drivers caregiver burden institutionalisation odonnell et al 1992 development bpsd also associated worse prognosis rapid rate illness progression paulsen et al 2000 adds significantly direct indirect costs care expert assessment targeted treatment bpsd alleviate patient suffering promote caregiver well less effective interventions occur support system ruptured
0.23731914.12456513.html.plaintext.txt	9	occurrence bpsd often triggering event recognition referral people dementia specialist services patients families present crisis disarray relatively late course illness development bpsd major risk factor caregiver burden coen et al 1997 institutionalisation odonnell et al 1992 important regard enduring cognitive deficits disease process steele et al 1990 aspects bpsd associated caregiver burden paranoia aggression sleep wake cycle disturbance appear particularly important drivers caregiver burden institutionalisation odonnell et al 1992 development bpsd also associated worse prognosis rapid rate illness progression paulsen et al 2000 adds significantly direct indirect costs care expert assessment targeted treatment bpsd alleviate patient suffering promote caregiver well less effective interventions occur support system ruptured
0.23731914.12456513.html.plaintext.txt	10	assessment individuals dementia stages illness careful enquiry must made regarding presence bpsd emphasis must detect bpsd caregiver burn irretrievable damage support environment occur collateral history use objective performance based test must part comprehensive cognitive assessment history assessment focus behavioural psychological symptoms given high frequency impact patient caregiver quality life
0.23731914.12456513.html.plaintext.txt	11	assessment individuals dementia stages illness careful enquiry must made regarding presence bpsd emphasis must detect bpsd caregiver burn irretrievable damage support environment occur collateral history use objective performance based test must part comprehensive cognitive assessment history assessment focus behavioural psychological symptoms given high frequency impact patient caregiver quality life
0.23731914.12456513.html.plaintext.txt	12	recognition bpsd first important step devising management plan facilitated use standardised assessment scales behavioural pathology alzheimers disease rating scale behave ad reisberg et al 1987 neuro psychiatric inventory npi cummings et al 1994 characteristics behaviour symptoms together frequency severity impact patient caregiver must identified formulating tailored targeted plan action likely involve pharmacological non pharmacological interventions useful identify target syndromes patient primarily psychotic syndrome hallucinations delusions main problem psycho motor agitation sleep disturbance context behaviour symptom impact also key elements assessment aggressive resistance personal activity carried patient may warrant immediate pharmacological intervention also mis identification symptoms part psychotic syndrome distressing carers patients instances education family members rather drug treatment required
0.23731914.12456513.html.plaintext.txt	13	recognition bpsd first important step devising management plan facilitated use standardised assessment scales behavioural pathology alzheimers disease rating scale behave ad reisberg et al 1987 neuro psychiatric inventory npi cummings et al 1994 characteristics behaviour symptoms together frequency severity impact patient caregiver must identified formulating tailored targeted plan action likely involve pharmacological non pharmacological interventions useful identify target syndromes patient primarily psychotic syndrome hallucinations delusions main problem psycho motor agitation sleep disturbance context behaviour symptom impact also key elements assessment aggressive resistance personal activity carried patient may warrant immediate pharmacological intervention also mis identification symptoms part psychotic syndrome distressing carers patients instances education family members rather drug treatment required
0.23731914.12456513.html.plaintext.txt	14	pharmacological treatments drug treatments bpsd evidence based targeted specific syndromes clinically significant frequency pervasiveness impact depression dementia although little placebo controlled evidence guide practice clinical experience indicates selective serotonin re uptake inhibitors safe effective neuroleptic agents shown effective placebo aggression psychosis agitation dementia devanand et al 1998 de deyn et al 1999 street et al 2000 novel agents superior conventional neuroleptics terms tolerability side effect profile non neuroleptic treatments carbamazepine demonstrated efficacy placebo treatment agitation tariot et al 1998 recent placebo controlled studies suggest cholinesterase inhibitors improve apathetic syndrome alzheimers disease also decrease psychotic symptoms particularly hallucinations alzheimers disease lewy body dementia cummings 2000 mckeith et al 2000
0.23731914.12456513.html.plaintext.txt	15	pharmacological treatments drug treatments bpsd evidence based targeted specific syndromes clinically significant frequency pervasiveness impact depression dementia although little placebo controlled evidence guide practice clinical experience indicates selective serotonin re uptake inhibitors safe effective neuroleptic agents shown effective placebo aggression psychosis agitation dementia devanand et al 1998 de deyn et al 1999 street et al 2000 novel agents superior conventional neuroleptics terms tolerability side effect profile non neuroleptic treatments carbamazepine demonstrated efficacy placebo treatment agitation tariot et al 1998 recent placebo controlled studies suggest cholinesterase inhibitors improve apathetic syndrome alzheimers disease also decrease psychotic symptoms particularly hallucinations alzheimers disease lewy body dementia cummings 2000 mckeith et al 2000
0.23731914.12456513.html.plaintext.txt	16	non pharmacological treatments dearth controlled evidence psychological interventions bpsd individualised music therapy bright light treatment specific behaviour interventions found improve certain troubling behavioural symptoms dementia evidence required area devanand lawlor 2000
0.23731914.12456513.html.plaintext.txt	17	non pharmacological treatments dearth controlled evidence psychological interventions bpsd individualised music therapy bright light treatment specific behaviour interventions found improve certain troubling behavioural symptoms dementia evidence required area devanand lawlor 2000
0.23731914.12456513.html.plaintext.txt	18	interventions carer boosting caregiver support increasing time self providing carer education training management bpsd effective decreasing burden mollifying impact carer ostwald et al 1999 interventions carers may decrease carer burden improve tolerability particular symptom hepburn et al 2001 also positive impact patient behaviour marriott et al 2000 possibly delay institutionalisation brodaty et al 1993 teri 1999
0.23731914.12456513.html.plaintext.txt	19	interventions carer boosting caregiver support increasing time self providing carer education training management bpsd effective decreasing burden mollifying impact carer ostwald et al 1999 interventions carers may decrease carer burden improve tolerability particular symptom hepburn et al 2001 also positive impact patient behaviour marriott et al 2000 possibly delay institutionalisation brodaty et al 1993 teri 1999
0.23731914.12456513.html.plaintext.txt	20	behavioural psychological symptoms dementia accepted important therapeutic target management strategies including pharmacological non pharmacological treatments together carer focused training education approaches effective decreasing bpsd require concerted multi disciplinary team input old age psychiatry team well positioned address care needs patients bpsd certain resource training needs attached delivery care degree special interest development area bpsd encouraged within multi disciplinary team adoption evidence based guidelines standardised assessments promoted ongoing training professional education team members bpsd given priority highest standards care provided patients carers
0.23731914.12456513.html.plaintext.txt	21	behavioural psychological symptoms dementia accepted important therapeutic target management strategies including pharmacological non pharmacological treatments together carer focused training education approaches effective decreasing bpsd require concerted multi disciplinary team input old age psychiatry team well positioned address care needs patients bpsd certain resource training needs attached delivery care degree special interest development area bpsd encouraged within multi disciplinary team adoption evidence based guidelines standardised assessments promoted ongoing training professional education team members bpsd given priority highest standards care provided patients carers
0.23731914.12456513.html.plaintext.txt	22	american psychiatric association 1994 diagnostic statistical manual mental disorders 4th edn dsm iv washington dc apa
0.23731914.12456513.html.plaintext.txt	23	teri l 1999 training families provide care effects people dementia international journal geriatric psychiatry 14 110 11630co2 jlinktypedoicrossrefmedline
0.23731914.12456513.html.plaintext.txt	24	received publication january 16 2002 accepted publication april 29 2002
0.23731914.12456513.html.plaintext.txt	25	received publication january 16 2002 accepted publication april 29 2002
0.24103056.11823327.html.plaintext.txt	0	vascular dementia diagnosis running time robert stewart mrcpsych
0.24103056.11823327.html.plaintext.txt	1	institute psychiatry de crespigny park denmark hill london se5 8af uk tel 44 020 7848 0240 fax 44 020 7701 0167
0.24103056.11823327.html.plaintext.txt	2	institute psychiatry de crespigny park denmark hill london se5 8af uk tel 44 020 7848 0240 fax 44 020 7701 0167
0.24103056.11823327.html.plaintext.txt	3	background concept vascular dementia long history usefulness diagnostic category called question
0.24103056.11823327.html.plaintext.txt	4	aims evaluate vascular disease risk factor dementia interface cerebrovascular pathology alzheimers disease
0.24103056.11823327.html.plaintext.txt	5	method literature topic selectively reviewed synthesised
0.24103056.11823327.html.plaintext.txt	6	results risk factors cerebrovascular disease also risk factors dementia however course dementia developed appears frequently determined alzheimers disease
0.24103056.11823327.html.plaintext.txt	7	results risk factors cerebrovascular disease also risk factors dementia however course dementia developed appears frequently determined alzheimers disease
0.24103056.11823327.html.plaintext.txt	8	conclusions public health measure modification vascular risk represents potentially powerful means prevent dementia delaying onset however effect progression dementia developed yet established traditional view vascular dementia alzheimers disease distinguishable conditions becoming steadily less tenable
0.24103056.11823327.html.plaintext.txt	9	conclusions public health measure modification vascular risk represents potentially powerful means prevent dementia delaying onset however effect progression dementia developed yet established traditional view vascular dementia alzheimers disease distinguishable conditions becoming steadily less tenable
0.24103056.11823327.html.plaintext.txt	10	upon time around first half last century late onset dementia viewed essentially homogeneous condition main underlying cause assumed atherosclerosis pathological substrate old age pioneering work around 1960s early 1970s challenged assumption establishing importance alzheimer pathological changes majority cases however multiple cerebral infarctions also appeared underlie substantial proportion led division dementia two conditions alzheimers disease multi infarct dementia system persisted day coming increasing criticism particularly wish investigate vascular disease risk factor dementia following sections current status future directions vascular dementia considered diagnostic category heading broad field research
0.24103056.11823327.html.plaintext.txt	11	upon time around first half last century late onset dementia viewed essentially homogeneous condition main underlying cause assumed atherosclerosis pathological substrate old age pioneering work around 1960s early 1970s challenged assumption establishing importance alzheimer pathological changes majority cases however multiple cerebral infarctions also appeared underlie substantial proportion led division dementia two conditions alzheimers disease multi infarct dementia system persisted day coming increasing criticism particularly wish investigate vascular disease risk factor dementia following sections current status future directions vascular dementia considered diagnostic category heading broad field research
0.24103056.11823327.html.plaintext.txt	12	research diagnostic criteria treat alzheimers disease diagnosis exclusion mckhann et al 1984 system may useful examining issues relating disorder pure entity however may also miss potentially important influences factors vascular disease excluded definition addition begun excluding major vascular disease clinical stroke multiple cerebral infarctions computed tomographic imaging studies use diagnostic system consider evidence subtle subclinical disease white matter abnormalities seen magnetic resonance imaging increasingly sophisticated measurements cerebrovascular disease vivo raise question exclusion criteria stop detectable levels vascular disease continue excluded pure alzheimers disease group become progressively smaller defining increasingly select group persons whatever reason remained free vascular disease old age question course level vascular disease may cause dementia cannot answered using criteria assume cause
0.24103056.11823327.html.plaintext.txt	13	research diagnostic criteria treat alzheimers disease diagnosis exclusion mckhann et al 1984 system may useful examining issues relating disorder pure entity however may also miss potentially important influences factors vascular disease excluded definition addition begun excluding major vascular disease clinical stroke multiple cerebral infarctions computed tomographic imaging studies use diagnostic system consider evidence subtle subclinical disease white matter abnormalities seen magnetic resonance imaging increasingly sophisticated measurements cerebrovascular disease vivo raise question exclusion criteria stop detectable levels vascular disease continue excluded pure alzheimers disease group become progressively smaller defining increasingly select group persons whatever reason remained free vascular disease old age question course level vascular disease may cause dementia cannot answered using criteria assume cause
0.24103056.11823327.html.plaintext.txt	14	major problem concept multi infarct dementia diagnostic criteria tried thing alzheimers disease define pure entity however alzheimers disease least reasonably well defined pathological basis true dementia related cerebrovascular disease vascular dementia subsumed multi infarct dementia term recognition heterogeneity large numbers subtypes subsequently proposed konno et al 1997 range syndromes dementia appears resulted small discrete strategic infarctions bilateral thalamic infarction lesions angular gyrus dementia associated diffuse cerebrovascular disease ischaemic haemorrhagic cortical subcortical brun 2000 diffuse disease obviously exists across spectrum severity advancing age increasingly likely comorbid alzheimers disease raising questions whether two distinguished diagnostic system additional obstacle research term vascular dementia makes assumptions causation therefore limited use comes investigating potential causes would considered particularly noteworthy study report people stroke likely hypertension diabetes similarly would surprising found higher mortality higher levels depression problem vascular dementia term comparisons alzheimers disease control groups inevitably comparisons populations different rates cerebrovascular disease impossible conclude related cerebrovascular disease related particular dementia syndrome
0.24103056.11823327.html.plaintext.txt	15	major problem concept multi infarct dementia diagnostic criteria tried thing alzheimers disease define pure entity however alzheimers disease least reasonably well defined pathological basis true dementia related cerebrovascular disease vascular dementia subsumed multi infarct dementia term recognition heterogeneity large numbers subtypes subsequently proposed konno et al 1997 range syndromes dementia appears resulted small discrete strategic infarctions bilateral thalamic infarction lesions angular gyrus dementia associated diffuse cerebrovascular disease ischaemic haemorrhagic cortical subcortical brun 2000 diffuse disease obviously exists across spectrum severity advancing age increasingly likely comorbid alzheimers disease raising questions whether two distinguished diagnostic system additional obstacle research term vascular dementia makes assumptions causation therefore limited use comes investigating potential causes would considered particularly noteworthy study report people stroke likely hypertension diabetes similarly would surprising found higher mortality higher levels depression problem vascular dementia term comparisons alzheimers disease control groups inevitably comparisons populations different rates cerebrovascular disease impossible conclude related cerebrovascular disease related particular dementia syndrome
0.24103056.11823327.html.plaintext.txt	16	perhaps preferable consider vascular dementia series questions rather diagnosis vascular disease cause dementia type types dementia cause
0.24103056.11823327.html.plaintext.txt	17	perhaps preferable consider vascular dementia series questions rather diagnosis vascular disease cause dementia type types dementia cause
0.24103056.11823327.html.plaintext.txt	18	vascular disease cause dementia
0.24103056.11823327.html.plaintext.txt	19	systems dementia classification major obstacle investigating question previously discussed another problem age groups dementia common contain extent healthy survivors respect vascular disease also people conditions together higher mortality therefore less likely identified cross sectional prospective studies
0.24103056.11823327.html.plaintext.txt	20	systems dementia classification major obstacle investigating question previously discussed another problem age groups dementia common contain extent healthy survivors respect vascular disease also people conditions together higher mortality therefore less likely identified cross sectional prospective studies
0.24103056.11823327.html.plaintext.txt	21	particularly high rates dementia observed following clinical stroke approximately nine fold increase risk first year followed smaller two fold raised annual risk found persist least 25 years later kokmen et al 1996 vascular risk factors hypertension diabetes hypercholesterolaemia also established risk factors dementia large prospective studies stewart 1998 early reports smoking might protective factor least alzheimers disease confirmed rigorously designed investigations anything report raised risk subtypes dementia smokers ott et al 1998 important issue arising studies concerns stage cognitive decline factors effect raised blood pressure mid life instance strong risk factor later cognitive impairment elias et al 1993 however blood pressure later life tends lower association dementia skoog et al 1996 therefore hypertension appears exert effect early stage cognitive decline association may longer apparent time cognitive function deteriorated sufficiently classified dementia pattern described raised cholesterol concentrations notkola et al 1998 important potential implications preventive therapeutic intervention
0.24103056.11823327.html.plaintext.txt	22	particularly high rates dementia observed following clinical stroke approximately nine fold increase risk first year followed smaller two fold raised annual risk found persist least 25 years later kokmen et al 1996 vascular risk factors hypertension diabetes hypercholesterolaemia also established risk factors dementia large prospective studies stewart 1998 early reports smoking might protective factor least alzheimers disease confirmed rigorously designed investigations anything report raised risk subtypes dementia smokers ott et al 1998 important issue arising studies concerns stage cognitive decline factors effect raised blood pressure mid life instance strong risk factor later cognitive impairment elias et al 1993 however blood pressure later life tends lower association dementia skoog et al 1996 therefore hypertension appears exert effect early stage cognitive decline association may longer apparent time cognitive function deteriorated sufficiently classified dementia pattern described raised cholesterol concentrations notkola et al 1998 important potential implications preventive therapeutic intervention
0.24103056.11823327.html.plaintext.txt	23	type dementia cause
0.24103056.11823327.html.plaintext.txt	24	traditional diagnostic criteria hampered investigation question increasing body epidemiological evidence suggests vascular risk factors hypertension diabetes hyperlipidaemia risk factors development vascular dementia also alzheimers disease stewart 1998 community based research criticised neuroimaging routinely used diagnostic assessment subclinical levels cerebrovascular disease may missed mixed dementia misidentified alzheimers disease issue however consideration mechanisms vascular risk factors associated dementia rather one arbitrarily defined diagnostic categories post stroke studies found dementia appears follow alzheimers disease like course majority cases kokmen et al 1996 approximately 10 people post stroke dementia gradually deteriorating cognitive function stroke occurred pohjasvaara et al 1999 since alzheimers disease long latency period assumed substantial proportion may subclinical disease
0.24103056.11823327.html.plaintext.txt	25	traditional diagnostic criteria hampered investigation question increasing body epidemiological evidence suggests vascular risk factors hypertension diabetes hyperlipidaemia risk factors development vascular dementia also alzheimers disease stewart 1998 community based research criticised neuroimaging routinely used diagnostic assessment subclinical levels cerebrovascular disease may missed mixed dementia misidentified alzheimers disease issue however consideration mechanisms vascular risk factors associated dementia rather one arbitrarily defined diagnostic categories post stroke studies found dementia appears follow alzheimers disease like course majority cases kokmen et al 1996 approximately 10 people post stroke dementia gradually deteriorating cognitive function stroke occurred pohjasvaara et al 1999 since alzheimers disease long latency period assumed substantial proportion may subclinical disease
0.24103056.11823327.html.plaintext.txt	26	becoming increasingly apparent dementia associated vascular disease frequently resembles alzheimers disease clinical course many cases obviously explained multiple infarction mechanism one possibility vascular processes cause gradually progressive dementia syndrome however recent pathological studies suggested isolated cerebrovascular disease ie alzheimer lesions rarely found association dementia hulette et al 1997 findings contrast early post mortem series although borne mind people dementia late 1960s would expected display much florid severe cerebrovascular disease next question whether vascular disease may directly cause drive alzheimers disease processes many potential mechanisms exist proposed vascular induction alzheimers disease including amyloid deposition secondary ischaemia peri infarct inflammation microglial activation abnormal protein glycation may provide link diabetes alzheimers disease furthermore growing appreciation cerebrovascular pathology alzheimers disease vascular amyloid deposition microangiopathy apolipoprotein e apoe genotype may also provide potential explanation association however although apoe 4 variant associated increased vascular risk neither lipid levels vascular disease found mediating factors 4 risk alzheimers disease prince et al 2000
0.24103056.11823327.html.plaintext.txt	27	becoming increasingly apparent dementia associated vascular disease frequently resembles alzheimers disease clinical course many cases obviously explained multiple infarction mechanism one possibility vascular processes cause gradually progressive dementia syndrome however recent pathological studies suggested isolated cerebrovascular disease ie alzheimer lesions rarely found association dementia hulette et al 1997 findings contrast early post mortem series although borne mind people dementia late 1960s would expected display much florid severe cerebrovascular disease next question whether vascular disease may directly cause drive alzheimers disease processes many potential mechanisms exist proposed vascular induction alzheimers disease including amyloid deposition secondary ischaemia peri infarct inflammation microglial activation abnormal protein glycation may provide link diabetes alzheimers disease furthermore growing appreciation cerebrovascular pathology alzheimers disease vascular amyloid deposition microangiopathy apolipoprotein e apoe genotype may also provide potential explanation association however although apoe 4 variant associated increased vascular risk neither lipid levels vascular disease found mediating factors 4 risk alzheimers disease prince et al 2000
0.24103056.11823327.html.plaintext.txt	28	although many feasible mechanisms proposed direct links vascular alzheimers disease processes pathological evidence far suggests interact principally clinical effects nun study found direct association cerebrovascular disease level alzheimer pathology instead found less alzheimer pathology required produce dementia cerebrovascular disease also present snowdon et al 1997 one possible explanation memory impairment secondary hippocampal pathology alzheimers disease likely manifest clinical dementia also impairment executive function secondary vascular subcortical pathology executive function impairment important although frequently unmeasured factor associated memory decline decline executive function alone important potential consequence cerebrovascular disease suggested dementia syndrome right royall 2000
0.24103056.11823327.html.plaintext.txt	29	although many feasible mechanisms proposed direct links vascular alzheimers disease processes pathological evidence far suggests interact principally clinical effects nun study found direct association cerebrovascular disease level alzheimer pathology instead found less alzheimer pathology required produce dementia cerebrovascular disease also present snowdon et al 1997 one possible explanation memory impairment secondary hippocampal pathology alzheimers disease likely manifest clinical dementia also impairment executive function secondary vascular subcortical pathology executive function impairment important although frequently unmeasured factor associated memory decline decline executive function alone important potential consequence cerebrovascular disease suggested dementia syndrome right royall 2000
0.24103056.11823327.html.plaintext.txt	30	considering length time vascular disease accepted common potentially reversible risk factor dementia evidence interventions modify risk woefully scant summarised table 1 likely success intervention depends crucially mechanism association particular interest clinicians extent patients dementia may benefit treatment vascular disease risk factors however optimally designed trial interventions treatment vascular risk factors may impact cognitive decline preventing stroke increasing evidence suggests may upper age limit stroke prevention staessen et al 2000 addition would benefit vascular disease accelerating progression alzheimer lesions hand vascular disease predominantly accelerates age onset alzheimers disease treatment directed alzheimers disease rather vascular component dementia developed issue become particularly important licensing pharmacological agents use alzheimers disease stroke continues considered exclusion criterion large number people alzheimers disease fail receive appropriate treatment comorbid disease whatever lies ahead treatment dementia associated cerebro vascular disease potential prevention likely substantial since vascular risk factors high prevalence rates modest reduction vascular risk across population could therefore expected result large reduction future cases dementia delaying clinical onset supporting preliminary findings large systolic hypertension europe syst eur trial antihypertensive treatment older people suggested 50 reduction incident dementia principally alzheimers disease occurring treated calcium channel blocker compared placebo forette et al 1998
0.24103056.11823327.html.plaintext.txt	31	considering length time vascular disease accepted common potentially reversible risk factor dementia evidence interventions modify risk woefully scant summarised table 1 likely success intervention depends crucially mechanism association particular interest clinicians extent patients dementia may benefit treatment vascular disease risk factors however optimally designed trial interventions treatment vascular risk factors may impact cognitive decline preventing stroke increasing evidence suggests may upper age limit stroke prevention staessen et al 2000 addition would benefit vascular disease accelerating progression alzheimer lesions hand vascular disease predominantly accelerates age onset alzheimers disease treatment directed alzheimers disease rather vascular component dementia developed issue become particularly important licensing pharmacological agents use alzheimers disease stroke continues considered exclusion criterion large number people alzheimers disease fail receive appropriate treatment comorbid disease whatever lies ahead treatment dementia associated cerebro vascular disease potential prevention likely substantial since vascular risk factors high prevalence rates modest reduction vascular risk across population could therefore expected result large reduction future cases dementia delaying clinical onset supporting preliminary findings large systolic hypertension europe syst eur trial antihypertensive treatment older people suggested 50 reduction incident dementia principally alzheimers disease occurring treated calcium channel blocker compared placebo forette et al 1998
0.24103056.11823327.html.plaintext.txt	32	view table table 1 pathways association vascular disease dementia implications respect preventive therapeutic interventions
0.24103056.11823327.html.plaintext.txt	33	investigation mechanisms underlying links vascular alzheimer pathological processes likely provide important avenues risk modification addition evidence adequately designed therapeutic preventive trials even negative likely provide useful information regarding underlying mechanisms may well become increasingly apparent dementia late stage considering useful intervention one challenge develop public health strategies affect large populations reducing vascular risk earlier life aim decreasing burden dementia generation 10 20 years later however clinical standpoint directed towards individual rather population level risk also need move towards identifying cognitive decline much earlier stage dementia particular regard vascular disease focus memory decline influenced alzheimers disease need shift towards appreciation executive function impairment bowler hachinski 2000
0.24103056.11823327.html.plaintext.txt	34	investigation mechanisms underlying links vascular alzheimer pathological processes likely provide important avenues risk modification addition evidence adequately designed therapeutic preventive trials even negative likely provide useful information regarding underlying mechanisms may well become increasingly apparent dementia late stage considering useful intervention one challenge develop public health strategies affect large populations reducing vascular risk earlier life aim decreasing burden dementia generation 10 20 years later however clinical standpoint directed towards individual rather population level risk also need move towards identifying cognitive decline much earlier stage dementia particular regard vascular disease focus memory decline influenced alzheimers disease need shift towards appreciation executive function impairment bowler hachinski 2000
0.24103056.11823327.html.plaintext.txt	35	therefore vascular dementia certainly convenient subject heading rapidly accelerating field research less clear whether retains usefulness diagnosis vascular dementia implies primary cause cerebrovascular disease linked specific consequence distinguishable dementia syndrome however increasing evidence suggests dementia associated vascular disease involves broad spectrum manifestations strategic infarct syndromes alzheimers disease addition although vascular disease powerful risk factor dementia questionable often actually sole cause dementia absence underlying vulnerability comorbid disease dementia research suffered common areas epidemiology simplistic conceptual framework risk factor outcome relationships increasingly evident many potential factors operating across entire life course possibly extending back previous generations may influence mediate others effects table 2 designing appropriate studies systems analysis take account multiple influences interactions likely provide major challenge future research
0.24103056.11823327.html.plaintext.txt	36	therefore vascular dementia certainly convenient subject heading rapidly accelerating field research less clear whether retains usefulness diagnosis vascular dementia implies primary cause cerebrovascular disease linked specific consequence distinguishable dementia syndrome however increasing evidence suggests dementia associated vascular disease involves broad spectrum manifestations strategic infarct syndromes alzheimers disease addition although vascular disease powerful risk factor dementia questionable often actually sole cause dementia absence underlying vulnerability comorbid disease dementia research suffered common areas epidemiology simplistic conceptual framework risk factor outcome relationships increasingly evident many potential factors operating across entire life course possibly extending back previous generations may influence mediate others effects table 2 designing appropriate studies systems analysis take account multiple influences interactions likely provide major challenge future research
0.24103056.11823327.html.plaintext.txt	37	view table table 2 life course model aetiology cognitive decline dementia
0.24103056.11823327.html.plaintext.txt	38	meantime done vascular dementia recent editorial suggested rather tinkering existing criteria discarded replaced wholesale bowler hachinski 2000 certain syndromes reasonably considered diagnoses example dementia due strategic infarcts genetic disorders cadasil cerebral autosomal dominant arteriopathy subcortical infarcts leucoencephalopathy however majority vascular dementia syndromes arising later life although may manifest pure disorders questionable whether valid distinctions truly drawn sub categories vascular dementia alzheimers disease result clinical research diagnostic criteria vascular dementia involve high degree subjective judgement skoog aevarsson 2000 leading inevitably poor agreement raters lopez et al 1994 different diagnostic instruments chui et al 2000 depression feel need define life event depression poor physical health depression rather direct treatment symptoms holding mind formulation possible underlying causes attempt modify potential maintaining factors risk factors recurrence perhaps may lessons learned cognitive impairment dementia complex picture overlapping interacting pathological entities one challenges rewards health care older age groups enthuse students trainees diagnostic system attempts separate processes artificially pure diagnoses us treat favours
0.24103056.11823327.html.plaintext.txt	39	meantime done vascular dementia recent editorial suggested rather tinkering existing criteria discarded replaced wholesale bowler hachinski 2000 certain syndromes reasonably considered diagnoses example dementia due strategic infarcts genetic disorders cadasil cerebral autosomal dominant arteriopathy subcortical infarcts leucoencephalopathy however majority vascular dementia syndromes arising later life although may manifest pure disorders questionable whether valid distinctions truly drawn sub categories vascular dementia alzheimers disease result clinical research diagnostic criteria vascular dementia involve high degree subjective judgement skoog aevarsson 2000 leading inevitably poor agreement raters lopez et al 1994 different diagnostic instruments chui et al 2000 depression feel need define life event depression poor physical health depression rather direct treatment symptoms holding mind formulation possible underlying causes attempt modify potential maintaining factors risk factors recurrence perhaps may lessons learned cognitive impairment dementia complex picture overlapping interacting pathological entities one challenges rewards health care older age groups enthuse students trainees diagnostic system attempts separate processes artificially pure diagnoses us treat favours
0.24103056.11823327.html.plaintext.txt	40	clinical implications limitations
0.24103056.11823327.html.plaintext.txt	41	clinical implications modification vascular risk status mid life likely important means reducing subsequent risk dementia population evidence lacking effect course dementia developed usefulness vascular dementia diagnostic category questionable since involves high degree subjective judgement subsumes large number potentially heterogeneous conditions overlaps considerably alzheimers disease current system classifying dementia mutually exclusive subtypes poorly reflects mixed disease older age groups become important issue since diagnoses determine eligibility pharmacological intervention
0.24103056.11823327.html.plaintext.txt	42	clinical implications modification vascular risk status mid life likely important means reducing subsequent risk dementia population evidence lacking effect course dementia developed usefulness vascular dementia diagnostic category questionable since involves high degree subjective judgement subsumes large number potentially heterogeneous conditions overlaps considerably alzheimers disease current system classifying dementia mutually exclusive subtypes poorly reflects mixed disease older age groups become important issue since diagnoses determine eligibility pharmacological intervention
0.24103056.11823327.html.plaintext.txt	43	limitations review literature selective limited review looks relationship vascular disease dementia population level rather specific discrete syndromes within vascular dementia focus review relationship cerebrovascular disease alzheimers disease two overlapping disorders take account comorbid pathology
0.24103056.11823327.html.plaintext.txt	44	limitations review literature selective limited review looks relationship vascular disease dementia population level rather specific discrete syndromes within vascular dementia focus review relationship cerebrovascular disease alzheimers disease two overlapping disorders take account comorbid pathology
0.24103056.11823327.html.plaintext.txt	45	brun 2000 neuropathology vascular dementia cerebrovascular disease dementia pathology neuropsychiatry management eds e chiu l gustafson d ames et al pp 69 76 london martin dunitz
0.24103056.11823327.html.plaintext.txt	46	stewart r 1998 cardiovascular factors alzheimers disease journal neurology neurosurgery psychiatry 65 143 147free full text
0.24103056.11823327.html.plaintext.txt	47	received publication march 15 2000 revision received april 26 2001 accepted publication april 27 2001
0.24103056.11823327.html.plaintext.txt	48	received publication march 15 2000 revision received april 26 2001 accepted publication april 27 2001
0.24103056.11823327.html.plaintext.txt	49	highlights issue elizabeth walsh bjp 2002 180 0 full text
0.24103056.11823327.html.plaintext.txt	50	old age psychiatry alistair burns ian g mckeith bjp 2002 180 97 98 full text
0.2476838.9328480.html.plaintext.txt	0	distortion allelic expression apolipoprotein e alzheimers disease
0.2476838.9328480.html.plaintext.txt	1	jean charles lambert12 jordi perez tur13 marie joelle dupire1 douglas galasko4 david mann5 philippe amouyel2 john hardy3 andre delacourte1 marie christine chartier harlin12
0.2476838.9328480.html.plaintext.txt	2	1inserm unite 422 place de verdun 59045 lille cedex france 2inserm cjf95 05 institut pasteur de lille 1 rue de calmette 59019 lille cedex france 3birdsall building mayo clinic jacksonville 4500 san pablo road jacksonville fl 32224 usa 4ucsd medical centre pulman ambulatory care centre 9350 campus point drive la jolla ca 92037 usa 5department pathological sciences stopford building university manchester oxford road manchester m13 9pt uk
0.2476838.9328480.html.plaintext.txt	3	received july 25 1997 revised accepted august 2 1997
0.2476838.9328480.html.plaintext.txt	4	apoe epsis4 allele strong genetic susceptibility factor alzheimers disease interaction biological factors may modulate effect apoe isoforms however previous work suggested genetic variability within apoe locus influencing effect epsis4 allele may exist variability could modify expression apoe gene particular level expression apoe alleles could important determinant disease pathogenesis test hypothesis examined levels expression apoe heterozygotes ad controls using new method semi quantitation report relative epsis4 mrna expression increased ad compared controls suggest genetic variability neural expression apoe contributes disease risk introduction
0.2476838.9328480.html.plaintext.txt	5	apoe epsis4 allele strong genetic susceptibility factor alzheimers disease interaction biological factors may modulate effect apoe isoforms however previous work suggested genetic variability within apoe locus influencing effect epsis4 allele may exist variability could modify expression apoe gene particular level expression apoe alleles could important determinant disease pathogenesis test hypothesis examined levels expression apoe heterozygotes ad controls using new method semi quantitation report relative epsis4 mrna expression increased ad compared controls suggest genetic variability neural expression apoe contributes disease risk introduction
0.2476838.9328480.html.plaintext.txt	6	epsis4 allele apoe gene major risk factor late onset alzheimers disease load 1 also implicated risk factor early onset disease populations 23 previous studies described epsis4 homozygotes higher risk developing disease epsis3epsis4 heterozygotes however individuals bearing one two epsis4 alleles inevitably develop disease detailed genetic analysis around apoe locus suggested existence genetic variability region could contribute disease risk 4 two possible explanations observations another genetically variable locus vicinity apoe gene involved pathogenesis disease ii genetic variability control expression apoe gene 4
0.2476838.9328480.html.plaintext.txt	7	epsis4 allele apoe gene major risk factor late onset alzheimers disease load 1 also implicated risk factor early onset disease populations 23 previous studies described epsis4 homozygotes higher risk developing disease epsis3epsis4 heterozygotes however individuals bearing one two epsis4 alleles inevitably develop disease detailed genetic analysis around apoe locus suggested existence genetic variability region could contribute disease risk 4 two possible explanations observations another genetically variable locus vicinity apoe gene involved pathogenesis disease ii genetic variability control expression apoe gene 4
0.2476838.9328480.html.plaintext.txt	8	little examination mrna expression apoe ad 56 available evidence suggests apoe expression increased neuronal damage 78 bulk expression occurs astrocytes 5 expression believed part compensatory mechanism aimed aiding reafferentation reactive synaptogenesis 9 studies examined expression apoe protein ad cases controls relative apoe genotype 910 bertrand et al suggested amount apoe protein could inversely correlated number epsis4 alleles carried subjects higher levels observed epsis3 homozygotes lower epsis4 homozygotes intermediate levels epsis3epsis4 heterozygotes 10
0.2476838.9328480.html.plaintext.txt	9	little examination mrna expression apoe ad 56 available evidence suggests apoe expression increased neuronal damage 78 bulk expression occurs astrocytes 5 expression believed part compensatory mechanism aimed aiding reafferentation reactive synaptogenesis 9 studies examined expression apoe protein ad cases controls relative apoe genotype 910 bertrand et al suggested amount apoe protein could inversely correlated number epsis4 alleles carried subjects higher levels observed epsis3 homozygotes lower epsis4 homozygotes intermediate levels epsis3epsis4 heterozygotes 10
0.2476838.9328480.html.plaintext.txt	10	hypothesised since epsis4 homozygotes higher risk developing disease epsis3epsis4 heterozygotes high proportion individuals latter genotype reach greater age without developing ad likely explanation genetic variability neural expression apoe locus epsis3epsis4 heterozygote individuals high epsis4 expressors andor low epsis3 expressors likely develop ad individuals high epsis3 expressors andor low epsis4 expressors
0.2476838.9328480.html.plaintext.txt	11	identification apoe allele transcription products easily achieved rt pcr using restriction fragment length polymorphism developed semi quantitative assay measure allelic expression apoe mrna rt pcr using silver staining 11 method quantitation applied brains heterozygote subjects collected various centres used assess percentage epsis4 mrna expression epsis3epsis4 epsis2epsis4 subjects epsis2 mrna expression epsis2epsis3 individuals carried ad cases controls results
0.2476838.9328480.html.plaintext.txt	12	identification apoe allele transcription products easily achieved rt pcr using restriction fragment length polymorphism developed semi quantitative assay measure allelic expression apoe mrna rt pcr using silver staining 11 method quantitation applied brains heterozygote subjects collected various centres used assess percentage epsis4 mrna expression epsis3epsis4 epsis2epsis4 subjects epsis2 mrna expression epsis2epsis3 individuals carried ad cases controls results
0.2476838.9328480.html.plaintext.txt	13	selected series epsis3epsis4 epsis2epsis4 epsis2epsis3 ad cases n 14 controls n 12 order measure relative level expression apoe allele frontal cortex fig 1 observed epsis3 mrna expression consistently greater epsis4 mrna expression cases fig 2 addition clear consistent difference epsis4 allelic expression ratio ad cases controls fig 2 ad cases showing higher relative expression epsis4 mrna controls 344 plus minus 26 versus 226 plus minus 18 respectively p 0001 mann whitney test regarding heterozygous genotypes small size group prevented us reaching definite conclusion nevertheless trend towards situation observed epsis3epsis4 group could noted increase expression epsis4 allele epsis2epsis4 group 426 plus minus 37 ad cases versus 289 plus minus 12 control whereas nothing apparent epsis2epsis3 group 390 plus minus 14 ad case versus 458 plus minus 43 controls furthermore difference allelic expression ratio epsis2epsis4 epsis3epsis4 ad cases observed since epsis2epsis4 patients showed 125 fold increase epsis4 allele ratio p 001 mann whitney test
0.2476838.9328480.html.plaintext.txt	14	figure 1 semi quantitation epsis4 allele ratio control case final epsis4 allele ratio calculated data 2142
0.2476838.9328480.html.plaintext.txt	15	figure 1 semi quantitation epsis4 allele ratio control case final epsis4 allele ratio calculated data 2142
0.2476838.9328480.html.plaintext.txt	16	figure 2 differential expression apoe mrna three heterozygote genotypes alzheimers disease cases controls epsis2 mrna percentage measured epsis2epsis3 population epsis4 mrna percentage epsis3epsis4 epsis2epsis4 population average level expression indicated bold line category brain sample rt pcr semi quantitation repeated three times
0.2476838.9328480.html.plaintext.txt	17	figure 2 differential expression apoe mrna three heterozygote genotypes alzheimers disease cases controls epsis2 mrna percentage measured epsis2epsis3 population epsis4 mrna percentage epsis3epsis4 epsis2epsis4 population average level expression indicated bold line category brain sample rt pcr semi quantitation repeated three times
0.2476838.9328480.html.plaintext.txt	18	important note measurement ratio expression two alleles heterozygotes likely much robust measurement determination absolute levels mrna expression tissue since latter profoundly affected post mortem delay agonal state cell population density
0.2476838.9328480.html.plaintext.txt	19	seen figure 2 level expression epsis3 allele consistently higher epsis4 allele ad group well control group data suggest either differential stability different mrna species genetic variability expression two alleles disequilibrium coding polymorphism however addition clear consistent difference epsis4 allelic expression ratio ad cases controls results consistent notion part least genetic risk developing ad encoded apoe locus relates expression protein brain would seem heterozygote individuals express relatively high proportion epsis4 allele greater risk developing disease expressing relatively low proportion observation different alleles apoe equally expressed may importance formulation hypotheses relating role apoe pathogenesis ad general present much speculation experimentation designed determine nature role different alleles apoe pathogenesis ad previously suggested e4 isoform may facilitate 12 limit 13 amyloid substance deposition isoform would protect oxidative stress conversely e2 isoform 14 finally suggested e2 e3 isoforms may prevent aggregation tau protein e4 isoform may prevent paired helical filament formation 15 however hypotheses based premise apoe allele isoforms equally expressed present similar concentrations brain isoform specific differences could enhanced different representation isoform individual
0.2476838.9328480.html.plaintext.txt	20	seen figure 2 level expression epsis3 allele consistently higher epsis4 allele ad group well control group data suggest either differential stability different mrna species genetic variability expression two alleles disequilibrium coding polymorphism however addition clear consistent difference epsis4 allelic expression ratio ad cases controls results consistent notion part least genetic risk developing ad encoded apoe locus relates expression protein brain would seem heterozygote individuals express relatively high proportion epsis4 allele greater risk developing disease expressing relatively low proportion observation different alleles apoe equally expressed may importance formulation hypotheses relating role apoe pathogenesis ad general present much speculation experimentation designed determine nature role different alleles apoe pathogenesis ad previously suggested e4 isoform may facilitate 12 limit 13 amyloid substance deposition isoform would protect oxidative stress conversely e2 isoform 14 finally suggested e2 e3 isoforms may prevent aggregation tau protein e4 isoform may prevent paired helical filament formation 15 however hypotheses based premise apoe allele isoforms equally expressed present similar concentrations brain isoform specific differences could enhanced different representation isoform individual
0.2476838.9328480.html.plaintext.txt	21	date seems difficult link apoe mrna apoe protein levels several studies explored issue reporting contradictory findings brain 1016 cerebrospinal fluid 1718 plasma 19 even apoe level tested according apoe genotype none previous studies able determine relative ratio different isoforms thus results comparable development isoform specific monoclonal antibodies would help determine whether variation observed population also present protein level 20
0.2476838.9328480.html.plaintext.txt	22	date seems difficult link apoe mrna apoe protein levels several studies explored issue reporting contradictory findings brain 1016 cerebrospinal fluid 1718 plasma 19 even apoe level tested according apoe genotype none previous studies able determine relative ratio different isoforms thus results comparable development isoform specific monoclonal antibodies would help determine whether variation observed population also present protein level 20
0.2476838.9328480.html.plaintext.txt	23	two major findings work first expression epsis3 allele consistently higher expression epsis4 allele second expression epsis4 allele beyond certain level seems greatly influence vulnerability individual alzheimers disease
0.2476838.9328480.html.plaintext.txt	24	two major findings work first expression epsis3 allele consistently higher expression epsis4 allele second expression epsis4 allele beyond certain level seems greatly influence vulnerability individual alzheimers disease
0.2476838.9328480.html.plaintext.txt	25	interesting note apoe regulated consequence insult poirier et al showed increase level expression apoe mrna rat lesioning cerebral cortex 6 similarly diedrich et al showed apoe mrna increased ad brains 5 together results support event may lead increase apoe mrna parallel distortion allelic expression distortion allelic expression may specific brain possibly restricted certain areas 21 suggests neural genetic susceptibility ad associated apoe gene
0.2476838.9328480.html.plaintext.txt	26	interestingly templeton reached similar conclusion using cladistic analysis previously reported genetic data 4 using haplotype data markers surrounding apoe locus including apoe polymorphism templeton showed coding polymorphism apoe gene sufficient explain increased risk ad 22 data suggest influence non coding polymorphism apoe expression may supply rest answer materials methods rna extraction
0.2476838.9328480.html.plaintext.txt	27	interestingly templeton reached similar conclusion using cladistic analysis previously reported genetic data 4 using haplotype data markers surrounding apoe locus including apoe polymorphism templeton showed coding polymorphism apoe gene sufficient explain increased risk ad 22 data suggest influence non coding polymorphism apoe expression may supply rest answer materials methods rna extraction
0.2476838.9328480.html.plaintext.txt	28	fourteen late onset ad cases caucasian origin mean age 741 plus minus 118 years five male nine female 12 controls mean age 830 plus minus 106 years five male seven female selected function apoe genotype 23 mean age sampling 756 plus minus 88 years ad cases genotyped epsis3epsis4 776 plus minus 110 years controls genotyped epsis3epsis4 diagnoses confirmed neuropathological examination
0.2476838.9328480.html.plaintext.txt	29	total rna extraction performed frontal lobe samples described gilmour et al 24 digested dnase eurogentec dna contamination observed dnase digestion detected pcr digested product rt pcr amplification apoe mrnas
0.2476838.9328480.html.plaintext.txt	30	total rna extraction performed frontal lobe samples described gilmour et al 24 digested dnase eurogentec dna contamination observed dnase digestion detected pcr digested product rt pcr amplification apoe mrnas
0.2476838.9328480.html.plaintext.txt	31	rt reaction performed 1 h 30 min 37 degrees c using f4 primer 5prime acagaattcgccccggcctggta 3prime 50 pmol 1 mug total rna template m mlv reverse transcriptase following conditions described supplier gibcobrl pcr step carried f6 primer 5prime taagcttggcacggctgtccaagga 3prime 50 pmol final volume 10 mul 30 cycles 1 min 94 degrees c 1 min 58 degrees c 1 min 72 degrees c cycle remain linear range reaction briefly pcr performed total volume 25 mul containing 125 u taq dna polymerase 02 mm dntp 4 mm dtt 01 mm mgcl2 004 triton x 100 10 vv glycerol using whole rt reaction template electrophoresis
0.2476838.9328480.html.plaintext.txt	32	rt reaction performed 1 h 30 min 37 degrees c using f4 primer 5prime acagaattcgccccggcctggta 3prime 50 pmol 1 mug total rna template m mlv reverse transcriptase following conditions described supplier gibcobrl pcr step carried f6 primer 5prime taagcttggcacggctgtccaagga 3prime 50 pmol final volume 10 mul 30 cycles 1 min 94 degrees c 1 min 58 degrees c 1 min 72 degrees c cycle remain linear range reaction briefly pcr performed total volume 25 mul containing 125 u taq dna polymerase 02 mm dntp 4 mm dtt 01 mm mgcl2 004 triton x 100 10 vv glycerol using whole rt reaction template electrophoresis
0.2476838.9328480.html.plaintext.txt	33	rt pcr dna digested 12 u cfoi endonuclease promega dna fragments resolved 8 polyacrylamide gel acrylamidebisacrylamide 191 4 h 12 vcm range 6 02 mul rt pcr product loaded silver staining
0.2476838.9328480.html.plaintext.txt	34	gel fixed 90 min 10 vv ethanol 05 vv acetic acid two washings deionised water gel placed silver nitrate solution 1 mgml 25 min gel washed twice deionised water dna polymorphism fragments stained 30 min 0037 formaldehyde vv hydroxyde nitrate 15 mgml finally reaction stopped sodium carbonate solution 15 mgml developer silver nitrate solutions prepared extemporaneously gel digitalised sharp jx 325 high resolution colour scanner fragment intensity measured using image master software pharmacia appropriate background subtract allele quantitation
0.2476838.9328480.html.plaintext.txt	35	percentage epsis4 allele calculated equation described ref 11
0.2476838.9328480.html.plaintext.txt	36	roman n o sup epsilon roman 4 m r n roman n o sup epsilon roman 4 m r n roman n o sup epsilon roman 2 o r epsilon roman 3 m r n roman alpha sup prime epsilon roman 4 m r n roman alpha sup prime epsilon roman 4 m r n alpha sup prime epsilon roman 2 o r epsilon roman 3 m r n
0.2476838.9328480.html.plaintext.txt	37	noepsis4 mrna noepsis3 mrna initial number epsis3 epsis4 mrnas alphaprimeepsis4 mrna alphaprimeepsis2 epsis3 mrna coefficients allowing silver staining phenomenon saturation due staining integrated normalised coefficient proportionality correcting length difference restriction fragments digestion cfoi epsis3 epsis2 epsis4 alleles characterised 91 83 72 bp fragments respectively coefficient therefore calculated 9172 epsis3epsis4 individuals 8372 epsis2epsis4 individuals 9183 epsis2epsis3 population
0.2476838.9328480.html.plaintext.txt	38	noepsis4 mrna noepsis3 mrna initial number epsis3 epsis4 mrnas alphaprimeepsis4 mrna alphaprimeepsis2 epsis3 mrna coefficients allowing silver staining phenomenon saturation due staining integrated normalised coefficient proportionality correcting length difference restriction fragments digestion cfoi epsis3 epsis2 epsis4 alleles characterised 91 83 72 bp fragments respectively coefficient therefore calculated 9172 epsis3epsis4 individuals 8372 epsis2epsis4 individuals 9183 epsis2epsis3 population
0.2476838.9328480.html.plaintext.txt	39	epsis2 epsis3 alleles give restriction length fragment 91 bp aodepsis2 mrna odepsis3 mrna od91 bp
0.2476838.9328480.html.plaintext.txt	40	initial epsis2 allele percentage epsis2epsis3 population calculated
0.2476838.9328480.html.plaintext.txt	41	roman n o sup epsilon roman 2 m r n roman n o sup epsilon roman 2 m r n roman n o sup epsilon roman 3 m r n roman alpha sup roman prime epsilon roman 2 m r n alpha prime sup 9 1 roman b p
0.2476838.9328480.html.plaintext.txt	42	details calculations modelling method described ref 11 tested viability approach apoe alleles using genomic dna template different parameters initial concentrations dna template initial percentage allele compared another 11
0.2476838.9328480.html.plaintext.txt	43	linear regressions necessary perform ratio percentage mann whitney u test performed using sas software release 604 sas institute inc cary nc usa references 1 saunders strittmatter wj schmechel d st george hyslop ph pericak vance ma joo sh rosi bl gusella jf crapper maclachlan dr alberts mj hulette c crain b goldgaber d roses ad 1993 association apolipoprotein e allele epsis4 late onset familial sporadic alzheimers disease neurology 43 1467 1472 medline abstract
0.2476838.9328480.html.plaintext.txt	44	correspondence addressed inserm cjf95 05 institut pasteur de lille 1 rue de calmette 59019 lille cedex france tel 33 3 20 87 72 28 fax 33 3 20 87 78 94 email marie christinechartier harlinpasteur lillefr page maintained oup admin last updated sat oct 18 134119 bst 1997 part oup journals world wide web service copyright oxford university press 1997
0.2476838.9328480.html.plaintext.txt	45	correspondence addressed inserm cjf95 05 institut pasteur de lille 1 rue de calmette 59019 lille cedex france tel 33 3 20 87 72 28 fax 33 3 20 87 78 94 email marie christinechartier harlinpasteur lillefr page maintained oup admin last updated sat oct 18 134119 bst 1997 part oup journals world wide web service copyright oxford university press 1997
0.24991155.16154999.html.plaintext.txt	0	amyloid protein degraded cellular angiotensin converting enzyme ace elevated ace inhibitor matthew l hemming dennis j selkoe1
0.24991155.16154999.html.plaintext.txt	1	center neurologic diseases brigham womens hospital harvard medical school boston massachusetts 02115
0.24991155.16154999.html.plaintext.txt	2	received publication august 2 2005 revised form september 8 2005
0.24991155.16154999.html.plaintext.txt	3	abstract top abstract introduction materials methods results discussion references human genetic data associated angiotensin converting enzyme ace alzheimer disease ad purified ace reported cleave synthetic amyloid protein vitro whether deficiency ace activity arising genetic alteration pharmacological inhibition decrease degradation allow accumulation intact cells unknown cloned ace human neuroblastoma cells showed posttranslational processing enzymatic activity typical endogenous protease cellular expression ace promoted degradation naturally secreted a40 a42 leading significant clearance species using site directed mutagenesis determined active sites within ace contribute clearance ace construct bearing mutations catalytic domain effect levels pharmacological inhibition ace widely prescribed drug captopril promoted accumulation cell derived media amyloid precursor protein expressing cells together results show ace lower levels secreted living cells effect blocked inhibiting proteases activity ace inhibitor work combined genetic studies supports hypothesis ace may modulate susceptibility progression ad via degradation data encourage analyses ace gene disease association raise question whether currently prescribed ace inhibitors could elevate cerebral levels humans
0.24991155.16154999.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references human genetic data associated angiotensin converting enzyme ace alzheimer disease ad purified ace reported cleave synthetic amyloid protein vitro whether deficiency ace activity arising genetic alteration pharmacological inhibition decrease degradation allow accumulation intact cells unknown cloned ace human neuroblastoma cells showed posttranslational processing enzymatic activity typical endogenous protease cellular expression ace promoted degradation naturally secreted a40 a42 leading significant clearance species using site directed mutagenesis determined active sites within ace contribute clearance ace construct bearing mutations catalytic domain effect levels pharmacological inhibition ace widely prescribed drug captopril promoted accumulation cell derived media amyloid precursor protein expressing cells together results show ace lower levels secreted living cells effect blocked inhibiting proteases activity ace inhibitor work combined genetic studies supports hypothesis ace may modulate susceptibility progression ad via degradation data encourage analyses ace gene disease association raise question whether currently prescribed ace inhibitors could elevate cerebral levels humans
0.24991155.16154999.html.plaintext.txt	5	introduction top abstract introduction materials methods results discussion references early pathogenically important feature alzheimer disease ad2 progressive accumulation deposition amyloid protein brain regions serving memory cognition biochemical cell biological animal modeling genetic emerging clinical data suggest upstream initiator disease process associated neuropathology 1 4 although proven disease modifying treatments currently available recent efforts treat ad focused decreasing production enhancing clearance brain one little studied approach clearance augmenting degradation peptide various proteases expressed brain thus far metalloproteases neprilysin nep 5 insulin degrading enzyme ide 6 endothelin converting enzymes 1 2 7 implicated degrading proteases mammalian brain serine protease plasmin implicated degradation vitro 8 although genetic plasmin deficiency promote accumulation murine vivo 9 supporting role therapeutic regulation degrading proteases overexpression ide nep murine model ad decreased cerebral levels produced significant attenuation associated neuropathology 10
0.24991155.16154999.html.plaintext.txt	6	introduction top abstract introduction materials methods results discussion references early pathogenically important feature alzheimer disease ad2 progressive accumulation deposition amyloid protein brain regions serving memory cognition biochemical cell biological animal modeling genetic emerging clinical data suggest upstream initiator disease process associated neuropathology 1 4 although proven disease modifying treatments currently available recent efforts treat ad focused decreasing production enhancing clearance brain one little studied approach clearance augmenting degradation peptide various proteases expressed brain thus far metalloproteases neprilysin nep 5 insulin degrading enzyme ide 6 endothelin converting enzymes 1 2 7 implicated degrading proteases mammalian brain serine protease plasmin implicated degradation vitro 8 although genetic plasmin deficiency promote accumulation murine vivo 9 supporting role therapeutic regulation degrading proteases overexpression ide nep murine model ad decreased cerebral levels produced significant attenuation associated neuropathology 10
0.24991155.16154999.html.plaintext.txt	7	somatic angiotensin converting enzyme ace zinc metalloprotease containing two homologous regions termed n c domains proteolytically active 11 ace single transmembrane domain cleaved cell surface low rate resulting secretion ectodomain media cultured cells plasma 12 13 ace intensively characterized role regulation blood pressure cleaving angiotensin angiotensin ii inactivating bradykinin 14 function ace modulated pharmacologically ace inhibitors bind competitively active site zinc prevent substrate hydrolysis commonly prescribed class drugs used treatment hypertension disorders addition regulating vasoactive peptides ace shows broad substrate specificity including several neuropeptides able metabolize substrates using exopeptidase endopeptidase activities 15 interestingly despite homology n c domains display differential capacity degrade substrates inhibited selectively certain ace inhibitors 16 17 recently ace found participate c jun n terminal kinase signal transduction pathway apparently independently proteolytic function 18
0.24991155.16154999.html.plaintext.txt	8	somatic angiotensin converting enzyme ace zinc metalloprotease containing two homologous regions termed n c domains proteolytically active 11 ace single transmembrane domain cleaved cell surface low rate resulting secretion ectodomain media cultured cells plasma 12 13 ace intensively characterized role regulation blood pressure cleaving angiotensin angiotensin ii inactivating bradykinin 14 function ace modulated pharmacologically ace inhibitors bind competitively active site zinc prevent substrate hydrolysis commonly prescribed class drugs used treatment hypertension disorders addition regulating vasoactive peptides ace shows broad substrate specificity including several neuropeptides able metabolize substrates using exopeptidase endopeptidase activities 15 interestingly despite homology n c domains display differential capacity degrade substrates inhibited selectively certain ace inhibitors 16 17 recently ace found participate c jun n terminal kinase signal transduction pathway apparently independently proteolytic function 18
0.24991155.16154999.html.plaintext.txt	9	potential relationship ace ad first suggested human genetic studies reported insertion ideletion d polymorphism within intron 16 ace gene associates ad 19 specifically allele associated increased risk ad whereas d allele associated protection 20 21 potential mechanistic relevance inheritance d allele associated increased plasma ace levels 22 regarding disease specificity allele found associate positively ad vascular dementia vascular pathology 23 24 ii genotype also linked smaller volumes hippocampus amygdala 24 importantly post mortem analyses ad patients determined ii genotype trend toward increased brain a42 load compared dd genotype 25 single nucleotide polymorphisms ace gene also shown associate ad decrease prevalence ad susceptible genotype increased age consistent modulation longevity 26
0.24991155.16154999.html.plaintext.txt	10	potential relationship ace ad first suggested human genetic studies reported insertion ideletion d polymorphism within intron 16 ace gene associates ad 19 specifically allele associated increased risk ad whereas d allele associated protection 20 21 potential mechanistic relevance inheritance d allele associated increased plasma ace levels 22 regarding disease specificity allele found associate positively ad vascular dementia vascular pathology 23 24 ii genotype also linked smaller volumes hippocampus amygdala 24 importantly post mortem analyses ad patients determined ii genotype trend toward increased brain a42 load compared dd genotype 25 single nucleotide polymorphisms ace gene also shown associate ad decrease prevalence ad susceptible genotype increased age consistent modulation longevity 26
0.24991155.16154999.html.plaintext.txt	11	post mortem studies patients ad found elevated levels ace temporal cortex specifically within pyramidal cortical neurons 27 28 well significantly increased ace activity medial hippocampus parahippocampal gyrus frontal cortex caudate nucleus 29 mechanistic link ace ad suggested affinity purified ace shown degrade synthetic 1 40 asp7 ser8 bond vitro producing truncated 33 residue peptide exhibited decreased aggregation cytotoxic potential 30
0.24991155.16154999.html.plaintext.txt	12	post mortem studies patients ad found elevated levels ace temporal cortex specifically within pyramidal cortical neurons 27 28 well significantly increased ace activity medial hippocampus parahippocampal gyrus frontal cortex caudate nucleus 29 mechanistic link ace ad suggested affinity purified ace shown degrade synthetic 1 40 asp7 ser8 bond vitro producing truncated 33 residue peptide exhibited decreased aggregation cytotoxic potential 30
0.24991155.16154999.html.plaintext.txt	13	plausible interpretation genetic neuropathological biochemical findings ace implicated ad via direct proteolysis peptide modulating levels within brain hypothesis suggests reduced ace activity either genetic mechanisms chronic pharmacological inhibition could increase cerebral levels a40 andor a42 thus presumably increase risk developing ad andor contribute progression address hypothesis intact living cells cloned characterized human neural ace determined role clearance secreted awe demonstrate ace promotes clearance naturally produced a40 a42 leads secondary degradation species using site directed mutagenesis context full length enzyme show n c domains ace capable promoting degradation similar capacity finally demonstrate treatment secreting cells commonly prescribed ace inhibitor prevents ace mediated clearance results accumulation peptide
0.24991155.16154999.html.plaintext.txt	14	plausible interpretation genetic neuropathological biochemical findings ace implicated ad via direct proteolysis peptide modulating levels within brain hypothesis suggests reduced ace activity either genetic mechanisms chronic pharmacological inhibition could increase cerebral levels a40 andor a42 thus presumably increase risk developing ad andor contribute progression address hypothesis intact living cells cloned characterized human neural ace determined role clearance secreted awe demonstrate ace promotes clearance naturally produced a40 a42 leads secondary degradation species using site directed mutagenesis context full length enzyme show n c domains ace capable promoting degradation similar capacity finally demonstrate treatment secreting cells commonly prescribed ace inhibitor prevents ace mediated clearance results accumulation peptide
0.24991155.16154999.html.plaintext.txt	15	materials methods top abstract introduction materials methods results discussion references cloning ace creation active site mutants 40 kb ace cdna obtained reverse transcription pcr rna isolated human neuroblastoma cell line sk n sh 5 3 end primers used amplify sequence 5 ggaagcttgccgagcaccgcgcaccgc 3 5 cagtgttcccatcccagtct 3 respectively coding region contains full length ace protein including signal peptide n c catalytic domains transmembrane domain cytoplasmic c terminus fig 1b neurally derived ace cdna cloned pcdna5frt expression vector confirmed dna sequencing identical reported human ace cdna sequence full length ace cdna used template oligonucleotide directed mutagenesis quikchange xl site directed mutagenesis kit stratagene generate catalytically inactive ace constructs two ace zinc metalloprotease active site glutamates amino acids 362 c domain 960 n domain changed aspartates using following primers e362d 5 ccacagtgcaccatgacatgggccatatacag 3 forward 5 actgtatatggcccatgtcatggtgcactgtgg 3 reverse e960d 5 ggcccaccacgacatgggccacatc 3 forward 5 gatgtggcccatgtcgtggtgggcc 3 reverse mutant constructs cloned pcdna5frt screened dna sequencing ensure mutations occurred four constructs thus generated n domain mutant c domain mutant combined n c domain mutant wild type enzyme expression plasmids characterized restriction digestion dna sequencing entire ace cdna ha tagged ide construct pcdna5frt vector previously described 31
0.24991155.16154999.html.plaintext.txt	16	materials methods top abstract introduction materials methods results discussion references cloning ace creation active site mutants 40 kb ace cdna obtained reverse transcription pcr rna isolated human neuroblastoma cell line sk n sh 5 3 end primers used amplify sequence 5 ggaagcttgccgagcaccgcgcaccgc 3 5 cagtgttcccatcccagtct 3 respectively coding region contains full length ace protein including signal peptide n c catalytic domains transmembrane domain cytoplasmic c terminus fig 1b neurally derived ace cdna cloned pcdna5frt expression vector confirmed dna sequencing identical reported human ace cdna sequence full length ace cdna used template oligonucleotide directed mutagenesis quikchange xl site directed mutagenesis kit stratagene generate catalytically inactive ace constructs two ace zinc metalloprotease active site glutamates amino acids 362 c domain 960 n domain changed aspartates using following primers e362d 5 ccacagtgcaccatgacatgggccatatacag 3 forward 5 actgtatatggcccatgtcatggtgcactgtgg 3 reverse e960d 5 ggcccaccacgacatgggccacatc 3 forward 5 gatgtggcccatgtcgtggtgggcc 3 reverse mutant constructs cloned pcdna5frt screened dna sequencing ensure mutations occurred four constructs thus generated n domain mutant c domain mutant combined n c domain mutant wild type enzyme expression plasmids characterized restriction digestion dna sequencing entire ace cdna ha tagged ide construct pcdna5frt vector previously described 31
0.24991155.16154999.html.plaintext.txt	17	cell culture chinese hamster ovary cho human embryonic kidney 293 hek293 cells grown dulbeccos modified eagles medium containing 10 fetal bovine serum 2 mm l glutamine 100 microgml penicillin 100 microgml streptomycin hek293 cells stably expressing app695 bearing k595nm596l swedish ad causing mutation 32 selected medium containing 200 microgml g418 cho cells stably transfected app751 v717f ad causing mutation pfrtlaczeo construct enabling flp intm invitrogen competence grown 200 microgml g418 100 microgml zeocin successful genomic recombination pcdna5frt constructs occurred flp host cells lost zeocin resistance selected 350 microgml hygromycin b effects capoten captopril sigma assayed 24 h preincubation cells drug followed 18 h conditioning period cells grown serum free dulbeccos modified eagles medium invitrogen captopril
0.24991155.16154999.html.plaintext.txt	18	cell culture chinese hamster ovary cho human embryonic kidney 293 hek293 cells grown dulbeccos modified eagles medium containing 10 fetal bovine serum 2 mm l glutamine 100 microgml penicillin 100 microgml streptomycin hek293 cells stably expressing app695 bearing k595nm596l swedish ad causing mutation 32 selected medium containing 200 microgml g418 cho cells stably transfected app751 v717f ad causing mutation pfrtlaczeo construct enabling flp intm invitrogen competence grown 200 microgml g418 100 microgml zeocin successful genomic recombination pcdna5frt constructs occurred flp host cells lost zeocin resistance selected 350 microgml hygromycin b effects capoten captopril sigma assayed 24 h preincubation cells drug followed 18 h conditioning period cells grown serum free dulbeccos modified eagles medium invitrogen captopril
0.24991155.16154999.html.plaintext.txt	19	expression cloned constructs cho hek293 cells transient transfections cho hek293 cell lines performed using geneporter 2 gts expression assayed 24 42 h posttransfection cho cell lines stably expressing app751 v717f mutation either empty vector ace mutant ace constructs generated using flp intm system invitrogen allowed stable integration construct genomic locus single cell line
0.24991155.16154999.html.plaintext.txt	20	expression cloned constructs cho hek293 cells transient transfections cho hek293 cell lines performed using geneporter 2 gts expression assayed 24 42 h posttransfection cho cell lines stably expressing app751 v717f mutation either empty vector ace mutant ace constructs generated using flp intm system invitrogen allowed stable integration construct genomic locus single cell line
0.24991155.16154999.html.plaintext.txt	21	immunoblotting cells tissue lysed 50 mm tris hcl ph 74 150 mm nacl 1 nonidet p 40 protease inhibitor mixture roche applied science 2 mm 110 phenanthroline 5 mm edta extracts centrifuged 1000 x g 10 min remove nuclei protein concentrations determined using bicinchoninic acid based assay pierce samples subject sds page western blotting ace detected using polyclonal antibody raised amino acids 1 170 human ace sc 20791 santa cruz biotechnology inc full length human app detected using 8e5 reactive app 444 592 app695 gift p seubert app c99 c83 c terminal fragments detected using polyclonal antibody c9 specific residues 676 695 app695 total cellular ide detected using polyclonal ide 1 raised amino acids 62 73 human ide 33 ha tagged ide detected using anti ha monoclonal 3f10 roche applied science deglycosylation performed using peptide n glycosidase f remove n linked sugars mixture o deglycosylating enzymes sialidase o glycanase 1 4 galactosidase n acetylglucosaminidase prozyme western blots probed anti mouse anti rat anti rabbit secondary antibodies conjugated alexa fluor 680 molecular probes inc eugene irdye 800 rockland immunochemicals blots detected bands sized quantified using odyssey infrared imaging system li cor
0.24991155.16154999.html.plaintext.txt	22	immunoblotting cells tissue lysed 50 mm tris hcl ph 74 150 mm nacl 1 nonidet p 40 protease inhibitor mixture roche applied science 2 mm 110 phenanthroline 5 mm edta extracts centrifuged 1000 x g 10 min remove nuclei protein concentrations determined using bicinchoninic acid based assay pierce samples subject sds page western blotting ace detected using polyclonal antibody raised amino acids 1 170 human ace sc 20791 santa cruz biotechnology inc full length human app detected using 8e5 reactive app 444 592 app695 gift p seubert app c99 c83 c terminal fragments detected using polyclonal antibody c9 specific residues 676 695 app695 total cellular ide detected using polyclonal ide 1 raised amino acids 62 73 human ide 33 ha tagged ide detected using anti ha monoclonal 3f10 roche applied science deglycosylation performed using peptide n glycosidase f remove n linked sugars mixture o deglycosylating enzymes sialidase o glycanase 1 4 galactosidase n acetylglucosaminidase prozyme western blots probed anti mouse anti rat anti rabbit secondary antibodies conjugated alexa fluor 680 molecular probes inc eugene irdye 800 rockland immunochemicals blots detected bands sized quantified using odyssey infrared imaging system li cor
0.24991155.16154999.html.plaintext.txt	23	ace activity assay ace proteolytic activity assayed using substrate hippuryl l histidyl l leucine hip leu sigma described previously 34 several modifications cells lysed 50 mm tris ph 74 containing 05 nonidet p 40 nuclei cell debris pelleted 1000 x g 10 min assay ace activity 25 microg cell lysate incubated 1 mm hip leu 04 m sodium borate buffer ph 83 03 m nacl total volume 35 microl 5 60 min 37 degrees c assaying samples captopril 15 min preincubation drug performed 4 degrees c substrate addition time 0 values calculated addition edta final concentration 10 mm prior addition hip leu enzymatic reactions terminated addition edta 10 mm final concentration samples developed first addition 150 microl 034 m naoh followed 10 min room temperature incubation 20 microl 20 mgml o phthaldialdehyde sigma reaction terminated acidification 50 microl 3 n hcl fluorescence liberated o phthaldialdehyde modified leu assayed 96 well plate format using victor2 multilabel plate reader excitation 355 emission 535 perkinelmer life sciences 100 degradation defined maximal fluorescence signal achieved digestion 1 mm hip leu 25 microg ace transfected cell lysate 60 min
0.24991155.16154999.html.plaintext.txt	24	ace activity assay ace proteolytic activity assayed using substrate hippuryl l histidyl l leucine hip leu sigma described previously 34 several modifications cells lysed 50 mm tris ph 74 containing 05 nonidet p 40 nuclei cell debris pelleted 1000 x g 10 min assay ace activity 25 microg cell lysate incubated 1 mm hip leu 04 m sodium borate buffer ph 83 03 m nacl total volume 35 microl 5 60 min 37 degrees c assaying samples captopril 15 min preincubation drug performed 4 degrees c substrate addition time 0 values calculated addition edta final concentration 10 mm prior addition hip leu enzymatic reactions terminated addition edta 10 mm final concentration samples developed first addition 150 microl 034 m naoh followed 10 min room temperature incubation 20 microl 20 mgml o phthaldialdehyde sigma reaction terminated acidification 50 microl 3 n hcl fluorescence liberated o phthaldialdehyde modified leu assayed 96 well plate format using victor2 multilabel plate reader excitation 355 emission 535 perkinelmer life sciences 100 degradation defined maximal fluorescence signal achieved digestion 1 mm hip leu 25 microg ace transfected cell lysate 60 min
0.24991155.16154999.html.plaintext.txt	25	enzyme linked immunosorbant assay conditioned medium samples harvested removing cellular debris centrifugation 700 x g 10 min protease inhibitors added final concentration 5 microgml leupeptin 5 microgml aprotinin 2 microgml pepstatin 2 mm 110 phenanthroline 5 mm edta elisas performed previously described 35 following modifications 96 well elisa plates costar coated 35 microgml capture antibody 1 40 1 42 measured capturing antibodies specific c terminal 40 2g3 42 21f12 residues captured detected 01 microgml biotinylated 3d6 specific residues 1 5 n terminus elisas measuring x 40 x 42 forms captured identically 2g3 21f12 detected 01 microgml biotinylated 266 specific residues 13 28 total measured capture antibody 266 detection 01 microgml biotinylated 3d6 antibodies gift elan pharmaceuticals san francisco ca elisa development accomplished incubating bound biotinylated detection antibody avidin horseradish peroxidase vector followed tetramethylbenzidine elisa pierce plates washed three times 1 min incubation tris buffered saline 005 tween 20
0.24991155.16154999.html.plaintext.txt	26	enzyme linked immunosorbant assay conditioned medium samples harvested removing cellular debris centrifugation 700 x g 10 min protease inhibitors added final concentration 5 microgml leupeptin 5 microgml aprotinin 2 microgml pepstatin 2 mm 110 phenanthroline 5 mm edta elisas performed previously described 35 following modifications 96 well elisa plates costar coated 35 microgml capture antibody 1 40 1 42 measured capturing antibodies specific c terminal 40 2g3 42 21f12 residues captured detected 01 microgml biotinylated 3d6 specific residues 1 5 n terminus elisas measuring x 40 x 42 forms captured identically 2g3 21f12 detected 01 microgml biotinylated 266 specific residues 13 28 total measured capture antibody 266 detection 01 microgml biotinylated 3d6 antibodies gift elan pharmaceuticals san francisco ca elisa development accomplished incubating bound biotinylated detection antibody avidin horseradish peroxidase vector followed tetramethylbenzidine elisa pierce plates washed three times 1 min incubation tris buffered saline 005 tween 20
0.24991155.16154999.html.plaintext.txt	27	statistical analyses data analyzed using one way analysis variance tukeys post hoc comparison two way analysis variance bonferroni post hoc comparison appropriate calculated comparisons p 005 considered significant
0.24991155.16154999.html.plaintext.txt	28	statistical analyses data analyzed using one way analysis variance tukeys post hoc comparison two way analysis variance bonferroni post hoc comparison appropriate calculated comparisons p 005 considered significant
0.24991155.16154999.html.plaintext.txt	29	results top abstract introduction materials methods results discussion references expression characterization transfected human ace determine regional distribution ace within brain first dissected several murine brain peripheral tissues assess relative ace content particularly ad relevant brain regions previously reported found ace highly expressed kidney lung absent liver 36 brain observed similar expression ace protein cerebral cortex hippocampus cerebellum basal gangliabrainstem fig 1a ace brain regions found electrophorese two distinct bands consisting typical full length 180 kda species higher molecular weight species latter reported arise alternative glycosylation ace brain 37
0.24991155.16154999.html.plaintext.txt	30	results top abstract introduction materials methods results discussion references expression characterization transfected human ace determine regional distribution ace within brain first dissected several murine brain peripheral tissues assess relative ace content particularly ad relevant brain regions previously reported found ace highly expressed kidney lung absent liver 36 brain observed similar expression ace protein cerebral cortex hippocampus cerebellum basal gangliabrainstem fig 1a ace brain regions found electrophorese two distinct bands consisting typical full length 180 kda species higher molecular weight species latter reported arise alternative glycosylation ace brain 37
0.24991155.16154999.html.plaintext.txt	31	characterize ace cellular level cloned full length 40 kb cdna human neuroblastoma cell line sk n sh ace cdna cloned mammalian expression vector pcdna5frt shown conform reported human ace sequence restriction mapping dna sequencing transient transfection ace construct cho hek293 cells yielded indistinguishable results assays performed fig 2 neither cell line expressed detectable endogenous levels ace protein western blotting although ace mrna detected hek293 cells reverse transcription pcr data shown
0.24991155.16154999.html.plaintext.txt	32	characterize ace cellular level cloned full length 40 kb cdna human neuroblastoma cell line sk n sh ace cdna cloned mammalian expression vector pcdna5frt shown conform reported human ace sequence restriction mapping dna sequencing transient transfection ace construct cho hek293 cells yielded indistinguishable results assays performed fig 2 neither cell line expressed detectable endogenous levels ace protein western blotting although ace mrna detected hek293 cells reverse transcription pcr data shown
0.24991155.16154999.html.plaintext.txt	33	ace predicted contain 17 n type glycosylation sites o type glycosylation sites determine whether transfected ace protein processed similarly tissue derived ace compared glycosylation patterns mouse kidney tissue ace ace transfected either cho hek293 cells expected deglycosylation several enzymes specific o linked sugars produced shift ace size whereas removal n linked modifications yielded shift ace protein 182 154 kda fig 2a ace known secreted vivo vitro cell surface low levels secretase dependent manner 38 concentration conditioned medium hek293 cho cells transiently transfected ace cdna found contain low levels ace protein whereas control cells transfected empty vector corresponding signal fig 2b
0.24991155.16154999.html.plaintext.txt	34	ace predicted contain 17 n type glycosylation sites o type glycosylation sites determine whether transfected ace protein processed similarly tissue derived ace compared glycosylation patterns mouse kidney tissue ace ace transfected either cho hek293 cells expected deglycosylation several enzymes specific o linked sugars produced shift ace size whereas removal n linked modifications yielded shift ace protein 182 154 kda fig 2a ace known secreted vivo vitro cell surface low levels secretase dependent manner 38 concentration conditioned medium hek293 cho cells transiently transfected ace cdna found contain low levels ace protein whereas control cells transfected empty vector corresponding signal fig 2b
0.24991155.16154999.html.plaintext.txt	35	view larger version 37k figure 1 brain distribution schematic diagram angiotensin converting enzyme 20 microg murine tissue homogenates designated brain regions well peripheral tissues known lack highly express ace probed western blotting ace specific antibody note brain ace occurs doublet arising alternate glycosylation asterisk indicates nonspecific band detected liver previously reported 46 b schematic representation human full length ace protein wild type enzyme contains signal peptide sp two homologous catalytic domains gray boxes single transmembrane segment tm small c terminal cytoplasmic tail metalloprotease catalytic sequence domain indicated corresponding amino acid numbering first n terminal residue mature protein
0.24991155.16154999.html.plaintext.txt	36	view larger version 37k figure 1 brain distribution schematic diagram angiotensin converting enzyme 20 microg murine tissue homogenates designated brain regions well peripheral tissues known lack highly express ace probed western blotting ace specific antibody note brain ace occurs doublet arising alternate glycosylation asterisk indicates nonspecific band detected liver previously reported 46 b schematic representation human full length ace protein wild type enzyme contains signal peptide sp two homologous catalytic domains gray boxes single transmembrane segment tm small c terminal cytoplasmic tail metalloprotease catalytic sequence domain indicated corresponding amino acid numbering first n terminal residue mature protein
0.24991155.16154999.html.plaintext.txt	37	determine whether transfected ace enzymatically active incubated lysates cells transiently transfected ace empty vector commonly used synthetic ace substrate hip leu standard assay conditions 1 mm substrate 25 microg cell lysate 04 m sodium borate buffer 03 m nacl ph 83 30 min 37 degrees c lysates cells transfected ace exhibited robust degradation hip leu completely blocked 1 microm concentration competitive ace inhibitor captopril contrast lysates cells transfected empty vector detectable ace activity fig 2c taken together results demonstrate cloned transfected ace construct processed similarly tissue ace retains proteolytic activity sensitivity ace inhibitors
0.24991155.16154999.html.plaintext.txt	38	transiently expressed ace promotes clearance secondary degradation determine whether ace modulate levels intact living cells transiently transfected equal dna amounts plasmids encoding either empty vector ide ace pcdna5frt hek293 cells stably expressing human app695 bearing swedish ad causing mutation measured levels resulting conditioned medium transfection ha tagged ide served positive control proteolysis since shown lower cultured cells 6 39 using elisa specific 1 40 1 42 ide found reduce cell derived levels 55 47 respectively control cells transfected empty vector p 0001 comparisons transfections ace yielded similar results reducing 1 42 levels 70 1 42 levels 61 control p 005 1 40 p 001 1 42 fig 3a thus ace ide transfected cells significantly reduced levels principal species compared control significantly different
0.24991155.16154999.html.plaintext.txt	39	transiently expressed ace promotes clearance secondary degradation determine whether ace modulate levels intact living cells transiently transfected equal dna amounts plasmids encoding either empty vector ide ace pcdna5frt hek293 cells stably expressing human app695 bearing swedish ad causing mutation measured levels resulting conditioned medium transfection ha tagged ide served positive control proteolysis since shown lower cultured cells 6 39 using elisa specific 1 40 1 42 ide found reduce cell derived levels 55 47 respectively control cells transfected empty vector p 0001 comparisons transfections ace yielded similar results reducing 1 42 levels 70 1 42 levels 61 control p 005 1 40 p 001 1 42 fig 3a thus ace ide transfected cells significantly reduced levels principal species compared control significantly different
0.24991155.16154999.html.plaintext.txt	40	view larger version 26k figure 2 characterization processing enzymatic activity cloned human ace lysates mouse kidney cho cells transiently transfected ace cdna construct subjected deglycosylation enzymes specific n o linked sugars subject western blot analysis ace specific antibody asterisk indicates calculated molecular weight deglycosylated band b conditioned medium cho cells transiently transfected ace empty vector concentrated analyzed western blot reflecting low rate ace ectodomain secretion sace previously reported 12 c ace enzymatic activity measured incubating 25 microg lysate hek293 cells transfected indicated constructs 1 mm substrate hip leu 30 min 37 degrees c 100 degradation defined maximal fluorescence produced 60 min substrate incubation 25 microg lysate cells transfected ace cdna values c represent means plus minus se obtained four independent experiments blot b representative least four independent experiments deglycosylation secretion enzymatic activity assays identical transfected cho hek293 cell lines
0.24991155.16154999.html.plaintext.txt	41	view larger version 26k figure 2 characterization processing enzymatic activity cloned human ace lysates mouse kidney cho cells transiently transfected ace cdna construct subjected deglycosylation enzymes specific n o linked sugars subject western blot analysis ace specific antibody asterisk indicates calculated molecular weight deglycosylated band b conditioned medium cho cells transiently transfected ace empty vector concentrated analyzed western blot reflecting low rate ace ectodomain secretion sace previously reported 12 c ace enzymatic activity measured incubating 25 microg lysate hek293 cells transfected indicated constructs 1 mm substrate hip leu 30 min 37 degrees c 100 degradation defined maximal fluorescence produced 60 min substrate incubation 25 microg lysate cells transfected ace cdna values c represent means plus minus se obtained four independent experiments blot b representative least four independent experiments deglycosylation secretion enzymatic activity assays identical transfected cho hek293 cell lines
0.24991155.16154999.html.plaintext.txt	42	ace shown cleave asp7 ser8 vitro 30 hypothesized remaining fragment beginning ser8 might either accumulate undergo secondary degradation cellular context discriminate possibilities used elisa specific internal residues 13 28 capture either 40 42 c termini detection measured species denoted x 40 x 42 found ide decrease x 40 levels 78 x 42 levels 68 control cells p 005 x 40 p 0001 x 42 ace mirrored reduction x 40 decreased 79 x 42 decreased 71 controls p 005 x 40 p 0001 x 42 fig 3b x 40 x 42 values ide ace significantly different control different thus human cell line transfected human cdnas encoding app either ide ace levels significantly reduced cell derived ace transfected cells showed greater secondary degradation peptide reported vitro 30 result suggests ace degrades additional sites cellular context andor species cleaved ace subsequently degraded cellular proteases transfection efficiency assayed western blot analysis fig 3c whereas transfected constructs resulted robust expression total ide levels increased 25 fold endogenous ide fig 3c bottom panel contrast detectable endogenous ace expressed hek293 cells fig 3c top panel
0.24991155.16154999.html.plaintext.txt	43	ace shown cleave asp7 ser8 vitro 30 hypothesized remaining fragment beginning ser8 might either accumulate undergo secondary degradation cellular context discriminate possibilities used elisa specific internal residues 13 28 capture either 40 42 c termini detection measured species denoted x 40 x 42 found ide decrease x 40 levels 78 x 42 levels 68 control cells p 005 x 40 p 0001 x 42 ace mirrored reduction x 40 decreased 79 x 42 decreased 71 controls p 005 x 40 p 0001 x 42 fig 3b x 40 x 42 values ide ace significantly different control different thus human cell line transfected human cdnas encoding app either ide ace levels significantly reduced cell derived ace transfected cells showed greater secondary degradation peptide reported vitro 30 result suggests ace degrades additional sites cellular context andor species cleaved ace subsequently degraded cellular proteases transfection efficiency assayed western blot analysis fig 3c whereas transfected constructs resulted robust expression total ide levels increased 25 fold endogenous ide fig 3c bottom panel contrast detectable endogenous ace expressed hek293 cells fig 3c top panel
0.24991155.16154999.html.plaintext.txt	44	generation catalytically inactive ace mutants ace contains two homologous catalytic regions termed n c domains containing canonical zinc metalloprotease active site fig 1b determine active site mediates clearance generated three ace mutant constructs two containing one functional catalytic domain one catalytically inactive enzyme bearing mutations sites mutations made site directed mutagenesis change active site sequence hemgh hdmgh conservative mutation previously shown inactivate ace proteolysis 11 c domain inactivated mutating ace glutamate residue 362 aspartate termed e362d n domain similarly mutated changing glutamate residue 960 aspartate termed e960d singly mutated constructs combined restriction digestion ligation form catalytically inactive double mutant e362de960d construct analyzed restriction digestion dna sequencing ensure mutations made outside produced site directed mutagenesis cloned pcdna5frt achieve identical levels cellular expression
0.24991155.16154999.html.plaintext.txt	45	cho cell line stably expressing human app751 bearing ad causing v717f mutation flp acceptor locus used make stable cell lines expressing wild type ace wtace e362d e960d e362de960d empty vector thus stable cell line contained app well one transfected constructs integrated genomic locus site directed recombination pcdna5frt vector cell lines designated app x x integrated construct resulting ace stable lines produced identical levels wtace mutant ace proteins well indistinguishable levels human app fig 4a notably app empty vector line expressed estimated 11 higher level app four app ace lines fig 4a middle panel presumably result modest cytomegalovirus promoter competition app ace constructs
0.24991155.16154999.html.plaintext.txt	46	cho cell line stably expressing human app751 bearing ad causing v717f mutation flp acceptor locus used make stable cell lines expressing wild type ace wtace e362d e960d e362de960d empty vector thus stable cell line contained app well one transfected constructs integrated genomic locus site directed recombination pcdna5frt vector cell lines designated app x x integrated construct resulting ace stable lines produced identical levels wtace mutant ace proteins well indistinguishable levels human app fig 4a notably app empty vector line expressed estimated 11 higher level app four app ace lines fig 4a middle panel presumably result modest cytomegalovirus promoter competition app ace constructs
0.24991155.16154999.html.plaintext.txt	47	e362d e960d e362de960d mutant proteins posttranslationally modified secreted similar levels wtace protein fig 4 b canonical enzymatic activity mutant constructs confirmed degradation substrate hip leu fig 4c wtace e362d proteins found degrade substrate similar rates whereas e960d far reduced efficiency hydrolysis conforming published kinetic parameters active site hip leu 11 enzymatically inactive e362de960d wtace protein incubated 1 microm captopril produced detectable degradation product fig 4c
0.24991155.16154999.html.plaintext.txt	48	view larger version 30k figure 3 transfected human ace promotes clearance secondary degradation cell derived human a40 a42 hek293 cells stably transfected human app695 bearing ad causing swedish mutation transiently transfected empty vector well characterized degrading protease ide ace media conditioned cells 18 h levels determined elisa specific intact species beginning residue 1 ending either residue 40 solid barsor 42 hatched bars elisa specific middle region peptide residues 13 28 denoted x either residue 40 solid bars 42 hatched bars b data represent means plus minus se 6 8 independent experiments measured duplicate values normalized empty vector allow combination data sets compared empty vector p 005 p 001 p 0001 c immunoblots transient transfections hek293 cells ace ide panels indicate total cellular expression protein whereas ha ide panel indicates expression tagged ide construct immunoblot representative least four independent experiments
0.24991155.16154999.html.plaintext.txt	49	view larger version 30k figure 3 transfected human ace promotes clearance secondary degradation cell derived human a40 a42 hek293 cells stably transfected human app695 bearing ad causing swedish mutation transiently transfected empty vector well characterized degrading protease ide ace media conditioned cells 18 h levels determined elisa specific intact species beginning residue 1 ending either residue 40 solid barsor 42 hatched bars elisa specific middle region peptide residues 13 28 denoted x either residue 40 solid bars 42 hatched bars b data represent means plus minus se 6 8 independent experiments measured duplicate values normalized empty vector allow combination data sets compared empty vector p 005 p 001 p 0001 c immunoblots transient transfections hek293 cells ace ide panels indicate total cellular expression protein whereas ha ide panel indicates expression tagged ide construct immunoblot representative least four independent experiments
0.24991155.16154999.html.plaintext.txt	50	n c domains ace promote degradation determine effects ace active site levels conditioned medium doubly stable line analyzed total content elisa normalizing values app empty vector condition app content significant difference levels app empty vector catalytically inactive app e362de960d n c catalytic domains ace found decrease cell derived levels quantitatively similar degree wtace e362d reduced levels 52 e960d 43 wtace 34 app empty vector condition fig 4d single mutants wtace enzymes significantly different app empty vector p 0001 significantly different differences content could ascribed ace enzyme altering levels secretase generated app c terminal fragments since c99 c83 significantly changed compared app empty vector fig 4a bottom panel thus using conservative mutations inactivate ace catalytic domains experiments demonstrate n c domains capable mediating clearance naturally produced cell derived intact cells
0.24991155.16154999.html.plaintext.txt	51	n c domains ace promote degradation determine effects ace active site levels conditioned medium doubly stable line analyzed total content elisa normalizing values app empty vector condition app content significant difference levels app empty vector catalytically inactive app e362de960d n c catalytic domains ace found decrease cell derived levels quantitatively similar degree wtace e362d reduced levels 52 e960d 43 wtace 34 app empty vector condition fig 4d single mutants wtace enzymes significantly different app empty vector p 0001 significantly different differences content could ascribed ace enzyme altering levels secretase generated app c terminal fragments since c99 c83 significantly changed compared app empty vector fig 4a bottom panel thus using conservative mutations inactivate ace catalytic domains experiments demonstrate n c domains capable mediating clearance naturally produced cell derived intact cells
0.24991155.16154999.html.plaintext.txt	52	levels increased ace inhibition determine whether decreasing ace activity small molecule inhibitor could elevate cell derived levels preincubated cells 24 h presence prototypical ace inhibitor captopril conditioned media 18 h presence drug increasing doses captopril tested resulting conditioned media analyzed elisa total content values normalized cell line drug treatment captopril found significant effect levels catalytically inactive app e362de960d cell line expected contrast captopril treated app wtace cells accumulated nearly 2 fold untreated cells drug concentrations 1 microm p 001 01 microm captopril lowest concentration tested levels elevated 15 fold app wtace cells compared cell line without drug p 005 results demonstrate widely prescribed ace inhibitor promote accumulation natural cell derived blocking ace proteolytic activity
0.24991155.16154999.html.plaintext.txt	53	levels increased ace inhibition determine whether decreasing ace activity small molecule inhibitor could elevate cell derived levels preincubated cells 24 h presence prototypical ace inhibitor captopril conditioned media 18 h presence drug increasing doses captopril tested resulting conditioned media analyzed elisa total content values normalized cell line drug treatment captopril found significant effect levels catalytically inactive app e362de960d cell line expected contrast captopril treated app wtace cells accumulated nearly 2 fold untreated cells drug concentrations 1 microm p 001 01 microm captopril lowest concentration tested levels elevated 15 fold app wtace cells compared cell line without drug p 005 results demonstrate widely prescribed ace inhibitor promote accumulation natural cell derived blocking ace proteolytic activity
0.24991155.16154999.html.plaintext.txt	54	discussion top abstract introduction materials methods results discussion references experiments demonstrate ace expression leads cleavage amyloid protein cellular context ace promotes degradation naturally produced a40 a42 investigating role n c domains ace clearance site directed mutagenesis used conservative inactivating mutation ace metalloprotease active site found domains responsible clearance data support role putative signal transduction mechanism ace 18 lowering since overexpressing proteolytically inactive form ace produced change levels compared vector alone finally show captopril widely prescribed ace inhibitor promotes accumulation media cells expressing human app ace
0.24991155.16154999.html.plaintext.txt	55	discussion top abstract introduction materials methods results discussion references experiments demonstrate ace expression leads cleavage amyloid protein cellular context ace promotes degradation naturally produced a40 a42 investigating role n c domains ace clearance site directed mutagenesis used conservative inactivating mutation ace metalloprotease active site found domains responsible clearance data support role putative signal transduction mechanism ace 18 lowering since overexpressing proteolytically inactive form ace produced change levels compared vector alone finally show captopril widely prescribed ace inhibitor promotes accumulation media cells expressing human app ace
0.24991155.16154999.html.plaintext.txt	56	reported recently n domain ace c domain responsible degradation synthetic a40 vitro 40 study ace catalytic domains cloned isolation producing recombinant truncation proteins bearing one ace active site contrast find n c domains ace able degrade naturally produced cellular context studies used conservative mutations inactivate catalytic domain molecule conserving overall structure sequence full length protein possible c domain able degrade intact cells vitro evidence catalytic domain ace regulates activity 41 suggesting full length protein required normal substrate recognition degradation c domain expressed outside context full length enzyme may retain tertiary structure required degrade larger substrates whereas much smaller substrates still processed 40 unlikely incomplete inactivation n domain e362d mutant enzyme could account observed decrease domains inactivated e362de960d ace construct observe change levels compared empty vector control
0.24991155.16154999.html.plaintext.txt	57	reported recently n domain ace c domain responsible degradation synthetic a40 vitro 40 study ace catalytic domains cloned isolation producing recombinant truncation proteins bearing one ace active site contrast find n c domains ace able degrade naturally produced cellular context studies used conservative mutations inactivate catalytic domain molecule conserving overall structure sequence full length protein possible c domain able degrade intact cells vitro evidence catalytic domain ace regulates activity 41 suggesting full length protein required normal substrate recognition degradation c domain expressed outside context full length enzyme may retain tertiary structure required degrade larger substrates whereas much smaller substrates still processed 40 unlikely incomplete inactivation n domain e362d mutant enzyme could account observed decrease domains inactivated e362de960d ace construct observe change levels compared empty vector control
0.24991155.16154999.html.plaintext.txt	58	view larger version 41k figure 4 cell derived degraded n c domains ace elevated ace inhibition cho cells stably transfected human app751 bearing v717f ad causing missense mutation either empty vector human wild type ace indicated ace mutant constructs immunoblots showing expression ace app app c terminal fragments stable cell lines note slightly higher expression human app happ app empty vector line resulting presumably modest cytomegalovirus promoter competition app ace constructs immunoblots representative least four independent determinations b conditioned medium stable lines concentrated probed presence secreted ace sace protein c ace activity assay incubating 25 microg cell lysate 1 mm hip leu indicated time points 37 degrees c values represent means plus minus se obtained 3 5 independent experiments d cell lines conditioned 18 h media harvested probed elisa total content due elevated app expression values app empty vector condition normalized app expression app ace doubly stable lines data represent means plus minus se seven independent experiments measured duplicate values normalized app empty vector allow combination data sets p 0001 compared empty vector e fold change content conditioned medium app wtace app e362de960d cell lines 24 h pretreatment 18 h conditioning presence captopril data point normalized untreated cells 0 microm captopril doubly transfected cell line data represent means plus minus se four independent experiments measured duplicate ace compared e362de960d dose p 005 p 001 p 0001
0.24991155.16154999.html.plaintext.txt	59	view larger version 41k figure 4 cell derived degraded n c domains ace elevated ace inhibition cho cells stably transfected human app751 bearing v717f ad causing missense mutation either empty vector human wild type ace indicated ace mutant constructs immunoblots showing expression ace app app c terminal fragments stable cell lines note slightly higher expression human app happ app empty vector line resulting presumably modest cytomegalovirus promoter competition app ace constructs immunoblots representative least four independent determinations b conditioned medium stable lines concentrated probed presence secreted ace sace protein c ace activity assay incubating 25 microg cell lysate 1 mm hip leu indicated time points 37 degrees c values represent means plus minus se obtained 3 5 independent experiments d cell lines conditioned 18 h media harvested probed elisa total content due elevated app expression values app empty vector condition normalized app expression app ace doubly stable lines data represent means plus minus se seven independent experiments measured duplicate values normalized app empty vector allow combination data sets p 0001 compared empty vector e fold change content conditioned medium app wtace app e362de960d cell lines 24 h pretreatment 18 h conditioning presence captopril data point normalized untreated cells 0 microm captopril doubly transfected cell line data represent means plus minus se four independent experiments measured duplicate ace compared e362de960d dose p 005 p 001 p 0001
0.24991155.16154999.html.plaintext.txt	60	growing genetic evidence suggests ace potential risk factor ad writing approximately 40 published studies examined relationship majority finding significant association ace genotype ad post mortem analysis ad brain tissue shown significant elevation ace protein compared control 28 perhaps representing regulation clearance mechanism interestingly initiation ace mediated signal transduction substrates shown regulate enzymes expression via c jun n terminal kinase pathway 18 42 feedback system provides hypothetical mechanism ace could modulate expression depending levels substrate leading elevated levels ace ad cortex
0.24991155.16154999.html.plaintext.txt	61	growing genetic evidence suggests ace potential risk factor ad writing approximately 40 published studies examined relationship majority finding significant association ace genotype ad post mortem analysis ad brain tissue shown significant elevation ace protein compared control 28 perhaps representing regulation clearance mechanism interestingly initiation ace mediated signal transduction substrates shown regulate enzymes expression via c jun n terminal kinase pathway 18 42 feedback system provides hypothetical mechanism ace could modulate expression depending levels substrate leading elevated levels ace ad cortex
0.24991155.16154999.html.plaintext.txt	62	observation ace inhibition cells expressing human app ace promotes accumulation secreted may bear clinical relevance given neurons produce app ace neuronal ace regulated ad 27 hypothesize chronic pharmacological inhibition ace could increase levels brain reducing ace dependent proteolysis studies yet examined consequence chronic ace inhibition levels brain plasma humans clinical trials ace inhibitors analyzed effects cognitive decline ad subjects results date inconclusive 43 45
0.24991155.16154999.html.plaintext.txt	63	observation ace inhibition cells expressing human app ace promotes accumulation secreted may bear clinical relevance given neurons produce app ace neuronal ace regulated ad 27 hypothesize chronic pharmacological inhibition ace could increase levels brain reducing ace dependent proteolysis studies yet examined consequence chronic ace inhibition levels brain plasma humans clinical trials ace inhibitors analyzed effects cognitive decline ad subjects results date inconclusive 43 45
0.24991155.16154999.html.plaintext.txt	64	studies effects ace deficiency overexpression metabolism vivo reported studies may problematic interpretation endogenous murine amino acid differences human peptide immediately surrounding putative site cleavage ace could affect properties substrate future vivo studies examine ace inhibition deficiency overexpression mice expressing human app may instructive regarding role ace alzheimer disease
0.24991155.16154999.html.plaintext.txt	65	studies effects ace deficiency overexpression metabolism vivo reported studies may problematic interpretation endogenous murine amino acid differences human peptide immediately surrounding putative site cleavage ace could affect properties substrate future vivo studies examine ace inhibition deficiency overexpression mice expressing human app may instructive regarding role ace alzheimer disease
0.24991155.16154999.html.plaintext.txt	66	context new findings earlier studies reviewed hypothesize decreased activity ace aged human brain originating either genetic polymorphisms pharmacological inhibition may promote accumulation thus modulate likelihood development alzheimer disease andor neuropathological severity findings suggest need analyses biological effects ace genetic deficiency ace pharmacological inhibition experimental models ad large human population currently experiencing chronic ace inhibition
0.24991155.16154999.html.plaintext.txt	67	context new findings earlier studies reviewed hypothesize decreased activity ace aged human brain originating either genetic polymorphisms pharmacological inhibition may promote accumulation thus modulate likelihood development alzheimer disease andor neuropathological severity findings suggest need analyses biological effects ace genetic deficiency ace pharmacological inhibition experimental models ad large human population currently experiencing chronic ace inhibition
0.24991155.16154999.html.plaintext.txt	68	footnotes work supported national institutes health grant ag12749 d j predoctoral fellowship harvard center neurodegeneration repair m l h costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.24991155.16154999.html.plaintext.txt	69	1 correspondence addressed harvard institutes medicine 730 77 ave louis pasteur boston ma 02115 tel 617 525 5200 fax 617 525 5252 e mail dselkoeatricsbwhharvardedu u d
0.24991155.16154999.html.plaintext.txt	70	1 correspondence addressed harvard institutes medicine 730 77 ave louis pasteur boston ma 02115 tel 617 525 5200 fax 617 525 5252 e mail dselkoeatricsbwhharvardedu u d
0.24991155.16154999.html.plaintext.txt	71	2 abbreviations used ad alzheimer disease ace angiotensin converting enzyme app amyloid precursor protein cho chinese hamster ovary hek293 human embryonic kidney 293 amyloid protein ide insulin degrading enzyme nep neprilysin elisa enzyme linked immunosorbant assay hip leu hippuryl l histidyl l leucine ace insertion d ace deletion wtace wild type ace ha hemagglutinin
0.24991155.16154999.html.plaintext.txt	72	acknowledgments thank w farris m lavoie young g shankar b zheng rappley technical advice discussions d walsh providing cho cell line stably transfected pfrtlaczeo vector flp system especially thank l lou r w hemming n l hemming support encouragement
0.24991155.16154999.html.plaintext.txt	73	references top abstract introduction materials methods results discussion references gilman koller m black r jenkins l griffith g fox n c eisner l kirby l rovira m b forette f orgogozo j m 2005 neurology 64 1553 1562abstractfree full text selkoe d j 2004 ann intern med 140 627 638free full text walsh d m selkoe d j 2004 neuron 44 181 193crossrefmedline order article via infotrieve hock c konietzko u streffer j r tracy j signorell muller tillmanns b lemke u henke k moritz e garcia e wollmer m umbricht d deq uervain d j hofmann m maddalena papassotiropoulos nitsch r m 2003 neuron 38 547 554crossrefmedline order article via infotrieve iwata n tsubuki takaki y shirotani k lu b gerard n p gerard c hama e lee h j saido c 2001 science 292 1550 1552abstractfree full text farris w mansourian chang y lindsley l eckman e frosch m p eckman c b tanzi r e selkoe d j guenette 2003 proc natl acad sci u 100 4162 4167abstractfree full text eckman e watson m marlow l sambamurti k eckman c b 2003 j biol chem 278 2081 2084abstractfree full text tucker h m kihiko m caldwell j n wright kawarabayashi price d walker d scheff mcgillis j p rydel r e estus 2000 j neurosci 20 3937 3946abstractfree full text tucker h m simpson j kihiko ehmann m younkin l h mcgillis j p younkin g degen j l estus 2004 neurosci lett 368 285 289crossrefmedline order article via infotrieve leissring m farris w chang y walsh d m wu x sun x frosch m p selkoe d j 2003 neuron 40 1087 1093crossrefmedline order article via infotrieve wei l alhenc gelas f corvol p clauser e 1991 j biol chem 266 9002 9008abstractfree full text beldent v michaud wei l chauvet m corvol p 1993 j biol chem 268 26428 26434abstractfree full text balyasnikova v karran e h albrecht r f ii danilov m 2002 biochem j 362 585 595crossrefmedline order article via infotrieve coates d 2003 int j biochem cell biol 35 769 773crossrefmedline order article via infotrieve skidgel r erdos e g 1987 clin exp hypertens 9 243 259medline order article via infotrieve michaud williams chauvet m corvol p 1997 mol pharmacol 51 1070 1076abstractfree full text wei l clauser e alhenc gelas f corvol p 1992 j biol chem 267 13398 13405abstractfree full text kohlstedt k brandes r p muller esterl w busse r fleming 2004 circ res 94 60 67abstractfree full text kehoe p g russ c mcilory williams h holmans p holmes c liolitsa d vahidassr d powell j mcgleenon b liddell m plomin r dynan k williams n neal j cairns n j wilcock g passmore p lovestone williams j owen m j 1999 nat genet 21 71 72crossrefmedline order article via infotrieve elkins j douglas v c johnston c 2004 neurology 62 363 368abstractfree full text lehmann d j cortina borja m warden d r smith d sleegers k prince j van duijn c m kehoe p g 2005 j epidemiol 162 305 317abstractfree full text rigat b hubert c alhenc gelas f cambien f corvol p soubrier f 1990 j clin invest 86 1343 1346medline order article via infotrieve kolsch h jessen f freymann n kreis m hentschel f maier w heun r 2005 neurosci lett 377 37 39crossrefmedline order article via infotrieve sleegers k den heijer van dijk e j hofman bertoli avella m koudstaal p j breteler m m van duijn c m 2005 neurobiol aging 26 1153 1159crossrefmedline order article via infotrieve lendon c l thaker u harris j m mcdonagh m lambert j c chartier harlin m c iwatsubo pickering brown m mann d m 2002 neurosci lett 328 314 318crossrefmedline order article via infotrieve katzov h bennet m kehoe p wiman b gatz m blennow k lenhard b pedersen n l de faire u prince j 2004 hum mol genet 13 2647 2657abstractfree full text savaskan e hock c olivieri g bruttel rosenberg c hulette c muller spahn f 2001 neurobiol aging 22 541 546crossrefmedline order article via infotrieve barnes n m cheng c h costall b naylor r j williams j wischik c m 1991 eur j pharmacol 200 289 292crossrefmedline order article via infotrieve arregui perry e k rossor m tomlinson b e 1982 j neurochem 38 1490 1492medline order article via infotrieve hu j igarashi kamata m nakagawa h 2001 j biol chem 276 47863 47868abstractfree full text leissring m farris w wu x christodoulou d c haigis m c guarente l selkoe d j 2004 biochem j 383 439 446crossrefmedline order article via infotrieve citron m oltersdorf haass c mcconlogue l hung y seubert p vigo pelfrey c lieberburg selkoe d j 1992 nature 360 672 674crossrefmedline order article via infotrieve vekrellis k ye z qiu w q walsh d hartley d chesneau v rosner m r selkoe d j 2000 j neurosci 20 1657 1665abstractfree full text santos r krieger e m greene l j 1985 hypertension 7 244 252abstractfree full text johnson wood k lee m motter r hu k gordon g barbour r khan k gordon m tan h games d lieberburg schenk d seubert p mcconlogue l 1997 proc natl acad sci u 94 1550 1555abstractfree full text fuchs xiao h d cole j m adams j w frenzel k michaud zhao h keshelava g capecchi m r corvol p bernstein k e 2004 j biol chem 279 15946 15953abstractfree full text hooper n m turner j 1987 biochem j 241 625 633medline order article via infotrieve woodman z l oppong y cook hooper n m schwager l brandt w f ehlers m r sturrock e d 2000 biochem j 347 711 718crossrefmedline order article via infotrieve farris w leissring m hemming m l chang y selkoe d j 2005 biochemistry 44 6513 6525crossrefmedline order article via infotrieve oba r igarashi kamata m nagata k takano nakagawa h 2005 eur j neurosci 21 733 740crossrefmedline order article via infotrieve binevski p v sizova e pozdnev v f kost o 2003 febs lett 550 84 88crossrefmedline order article via infotrieve kohlstedt k busse r fleming 2005 hypertension 45 126 132abstractfree full text ohrui tomita n sato nakagawa matsui maruyama m niwa k arai h sasaki h 2004 neurology 63 1324 1325free full text knopman d 2004 neurology 63 1145free full text birkenhager w h forette f staessen j 2004 curr opin nephrol hypertens 13 225 230medline order article via infotrieve cole j quach du l sundaram k corvol p capecchi m r bernstein k e 2002 circ res 90 87 92abstractfree full text
0.2581098.12411259.html.plaintext.txt	0	brain ageing dementia makes difference lawrence j whalley frcpsych
0.2581098.12411259.html.plaintext.txt	1	university aberdeen clinical research centre royal cornhill hospital aberdeen ab25 2zh uk
0.2581098.12411259.html.plaintext.txt	2	correspondence tel 01224 55747 e mail ljwhalleyatabdnacuk
0.2581098.12411259.html.plaintext.txt	3	boundaries non pathological brain ageing dementias unclear contentious neuropathological examination detect occasional individuals microscopic features typical late onset alzheimers disease present yet clinical history dementia absent occasions converse seems true individuals seriously disabled life dementia show death mild pathological features alzheimers disease observations type although often made experienced neuropathologists widely discussed molecular neurobiologists among assumption largely prevailed alzheimers disease well validated nosological entity discontinuous ageing discrete molecular pathology reasoning extends repeated proposition understanding pathogenesis amyloid deposition provide sound sufficient basis develop novel therapies alzheimers disease selkoe 1999
0.2581098.12411259.html.plaintext.txt	4	boundaries non pathological brain ageing dementias unclear contentious neuropathological examination detect occasional individuals microscopic features typical late onset alzheimers disease present yet clinical history dementia absent occasions converse seems true individuals seriously disabled life dementia show death mild pathological features alzheimers disease observations type although often made experienced neuropathologists widely discussed molecular neurobiologists among assumption largely prevailed alzheimers disease well validated nosological entity discontinuous ageing discrete molecular pathology reasoning extends repeated proposition understanding pathogenesis amyloid deposition provide sound sufficient basis develop novel therapies alzheimers disease selkoe 1999
0.2581098.12411259.html.plaintext.txt	5	findings medical research council cognitive function ageing study mrc cfas challenge assumptions least two fronts first encourage dementia researchers re examine basis belief valid boundaries non pathological normal ageing absence dementia dementias second suggest central role often assigned amyloid deposition requires review longitudinal follow studies mrc cfas raise important issues nature phenomena explained editorial considers early contributions brain development influences cognitive decline later life turn approach requires deeper understanding yet available brain mechanisms processes affected ageing
0.2581098.12411259.html.plaintext.txt	6	findings medical research council cognitive function ageing study mrc cfas challenge assumptions least two fronts first encourage dementia researchers re examine basis belief valid boundaries non pathological normal ageing absence dementia dementias second suggest central role often assigned amyloid deposition requires review longitudinal follow studies mrc cfas raise important issues nature phenomena explained editorial considers early contributions brain development influences cognitive decline later life turn approach requires deeper understanding yet available brain mechanisms processes affected ageing
0.2581098.12411259.html.plaintext.txt	7	margaret esiri colleagues esiri et al 2001 described large community based neuropathological study distinction dementia brain ageing absence dementia shortage data impossible accept validity contemporary neuropathological criteria dementia definitions boundary existed dementias normal ageing study showed 209 old people weighted contain 100 people met clinical criteria dementia death majority showed mixed alzheimer vascular pathologies postmortem examination brains dementia non dementia subjects overlapped neuritic diffuse plaque density single pathological criterion reliably distinguished groups coexistent vascular lesions provide sufficient explanation presence dementia encourage view interactions alzheimer vascular pathologies may critical determinants progression clinical dementia
0.2581098.12411259.html.plaintext.txt	8	margaret esiri colleagues esiri et al 2001 described large community based neuropathological study distinction dementia brain ageing absence dementia shortage data impossible accept validity contemporary neuropathological criteria dementia definitions boundary existed dementias normal ageing study showed 209 old people weighted contain 100 people met clinical criteria dementia death majority showed mixed alzheimer vascular pathologies postmortem examination brains dementia non dementia subjects overlapped neuritic diffuse plaque density single pathological criterion reliably distinguished groups coexistent vascular lesions provide sufficient explanation presence dementia encourage view interactions alzheimer vascular pathologies may critical determinants progression clinical dementia
0.2581098.12411259.html.plaintext.txt	9	mrc cfas data provide strongest evidence yet relationship normal brain ageing dementias best represented continuum also much weaken pivotal position claimed amyloid deposition pathogenesis alzheimers disease without inclusion factor factors amyloid cascade hypothesis alzheimers disease longer tenable mrc cfas programme may yet identify factors sample size doubled improved descriptions quantifications vascular lesions possible begin disentangle pathological processes contribute clinical presentations dementia critically establish true relationships age
0.2581098.12411259.html.plaintext.txt	10	mrc cfas data provide strongest evidence yet relationship normal brain ageing dementias best represented continuum also much weaken pivotal position claimed amyloid deposition pathogenesis alzheimers disease without inclusion factor factors amyloid cascade hypothesis alzheimers disease longer tenable mrc cfas programme may yet identify factors sample size doubled improved descriptions quantifications vascular lesions possible begin disentangle pathological processes contribute clinical presentations dementia critically establish true relationships age
0.2581098.12411259.html.plaintext.txt	11	rate cognitive change caseness
0.2581098.12411259.html.plaintext.txt	12	longitudinal psychological studies cognitive ageing identify single point transition normal ageing dementia several cognitive domains used predict later onset dementia cognitive decline typically non uniform across domains exception early memory impairment largely inclusion among criteria dementia chen et al 2001 presymptomatic patterns cognitive decline reliably distinguished normal variation cognitive function late life almost half attributable original childhood iq deary 2000
0.2581098.12411259.html.plaintext.txt	13	longitudinal psychological studies cognitive ageing identify single point transition normal ageing dementia several cognitive domains used predict later onset dementia cognitive decline typically non uniform across domains exception early memory impairment largely inclusion among criteria dementia chen et al 2001 presymptomatic patterns cognitive decline reliably distinguished normal variation cognitive function late life almost half attributable original childhood iq deary 2000
0.2581098.12411259.html.plaintext.txt	14	psychologists psychiatrists alike familiar problems type comfortable search antecedents may extend earlier developmental epochs links increased late life dementia risk lower educational attainment suggest association dementia childhood iq reported whalley et al 2000 explanations associations type complex mutually exclusive least strong intergenerational lifelong continuities material advantage award entry safer healthier environment mentally able youngster usual concept mature brain possesses sufficient reserve redundancy withstand age related pathologies described esiri et al 2001 reserve determined early life experiences belief childhood educational attainment mental ability could determine threshold brain ageing dementia pathology must sufficient exceed cause dementia supported data reported whalley et al 2000 association lower childhood iq dementia confined late onset cases marked presenting age 72 years
0.2581098.12411259.html.plaintext.txt	15	psychologists psychiatrists alike familiar problems type comfortable search antecedents may extend earlier developmental epochs links increased late life dementia risk lower educational attainment suggest association dementia childhood iq reported whalley et al 2000 explanations associations type complex mutually exclusive least strong intergenerational lifelong continuities material advantage award entry safer healthier environment mentally able youngster usual concept mature brain possesses sufficient reserve redundancy withstand age related pathologies described esiri et al 2001 reserve determined early life experiences belief childhood educational attainment mental ability could determine threshold brain ageing dementia pathology must sufficient exceed cause dementia supported data reported whalley et al 2000 association lower childhood iq dementia confined late onset cases marked presenting age 72 years
0.2581098.12411259.html.plaintext.txt	16	mrc cfas programme represents successful application epidemiological neuropathological methods study distinctions clinical cases non cases ages disease onset occur usual contemporary approach age related disease disease interest case dementia defined present absent contrasts second potentially powerful research method investigates rate change premorbid characteristics specified age interval national institute aging working group aging genetic epidemiology 2001 risk factors dementia examined simply contributing duration survival becoming case dementia possible determinants rate timing change parameters believed closely linked pathogenesis dementia
0.2581098.12411259.html.plaintext.txt	17	mrc cfas programme represents successful application epidemiological neuropathological methods study distinctions clinical cases non cases ages disease onset occur usual contemporary approach age related disease disease interest case dementia defined present absent contrasts second potentially powerful research method investigates rate change premorbid characteristics specified age interval national institute aging working group aging genetic epidemiology 2001 risk factors dementia examined simply contributing duration survival becoming case dementia possible determinants rate timing change parameters believed closely linked pathogenesis dementia
0.2581098.12411259.html.plaintext.txt	18	age related abnormalities glucose metabolism one hypothetical parameters diabetes mellitus risk factor stroke possible risk factor alzheimers disease vascular dementia luchsinger et al 2001 matureonset type 2 diabetes also associated cardiovascular risk factors include hypertension hyperlipidaemia may cause accelerate unrecognised progressive cerebrovascular disease least two plausible biological mechanisms link enduring age related abnormalities glucose metabolism neuronal death formation advanced glycation end products ages hyperinsulinaemia separate strands evidence link foetal growth adult hypertension impaired glucose tolerance age 64 years hales et al 1991 taken together observations advocate longitudinal studies individual differences glucose metabolism age related cognitive variation studies type extend across life span subsumed title life course approaches late onset dementia dementia associated traits sometimes suggest parallel experimental routes better understanding mechanisms age related cognitive impairment strachan et al 1997
0.2581098.12411259.html.plaintext.txt	19	age related abnormalities glucose metabolism one hypothetical parameters diabetes mellitus risk factor stroke possible risk factor alzheimers disease vascular dementia luchsinger et al 2001 matureonset type 2 diabetes also associated cardiovascular risk factors include hypertension hyperlipidaemia may cause accelerate unrecognised progressive cerebrovascular disease least two plausible biological mechanisms link enduring age related abnormalities glucose metabolism neuronal death formation advanced glycation end products ages hyperinsulinaemia separate strands evidence link foetal growth adult hypertension impaired glucose tolerance age 64 years hales et al 1991 taken together observations advocate longitudinal studies individual differences glucose metabolism age related cognitive variation studies type extend across life span subsumed title life course approaches late onset dementia dementia associated traits sometimes suggest parallel experimental routes better understanding mechanisms age related cognitive impairment strachan et al 1997
0.2581098.12411259.html.plaintext.txt	20	explanations associations suboptimal foetal infant growth late onset disease include failure acquire lasting control complex central regulatory systems brain development foetal nutritional hormonal environments also important critical roles expression specific genes dauncey et al 2001 major differences foetal infant nutritional environment induce large differences expression hormonal receptor isoforms may provide means whereby dietary micro nutrients affect cognitive functions across life span nutritional influences apparently diverse contributions folate vitamin b12 neurodevelopment greater age related cognitive impairment linked dietary plasma folate concentrations miller 2000 duthie et al 2002
0.2581098.12411259.html.plaintext.txt	21	explanations associations suboptimal foetal infant growth late onset disease include failure acquire lasting control complex central regulatory systems brain development foetal nutritional hormonal environments also important critical roles expression specific genes dauncey et al 2001 major differences foetal infant nutritional environment induce large differences expression hormonal receptor isoforms may provide means whereby dietary micro nutrients affect cognitive functions across life span nutritional influences apparently diverse contributions folate vitamin b12 neurodevelopment greater age related cognitive impairment linked dietary plasma folate concentrations miller 2000 duthie et al 2002
0.2581098.12411259.html.plaintext.txt	22	diversity timing nature single nutritional influences represents important obstacle taking life course approach understanding dementia obscure best route elucidate molecular mechanisms early nutritional experience affects neurodevelopment later cognitive performance example observational studies late life suggest hyperhomocysteinaemia attributed reduced transformation homocysteine methionine folate vitamin b12 possible risk factor cerebrovascular disease miller 2000 dementia seshadri et al 2002 polymorphisms gene encoding methylenetetrahydrofolate reductase mthfr enzyme essential folate metabolism therefore possible susceptibility factors age related cognitive decline however possess potential influence brain metabolism throughout life similar critiques made studies interactions genes early nutrition may specific influences peripheral insulin sensitivity neuro development factors might influence synaptogenesis late life
0.2581098.12411259.html.plaintext.txt	23	diversity timing nature single nutritional influences represents important obstacle taking life course approach understanding dementia obscure best route elucidate molecular mechanisms early nutritional experience affects neurodevelopment later cognitive performance example observational studies late life suggest hyperhomocysteinaemia attributed reduced transformation homocysteine methionine folate vitamin b12 possible risk factor cerebrovascular disease miller 2000 dementia seshadri et al 2002 polymorphisms gene encoding methylenetetrahydrofolate reductase mthfr enzyme essential folate metabolism therefore possible susceptibility factors age related cognitive decline however possess potential influence brain metabolism throughout life similar critiques made studies interactions genes early nutrition may specific influences peripheral insulin sensitivity neuro development factors might influence synaptogenesis late life
0.2581098.12411259.html.plaintext.txt	24	brain ageing cognitive decline
0.2581098.12411259.html.plaintext.txt	25	association brain ageing age related cognitive decline uncertain largely ageing studies beginning brain ageing yet linked informatively known neurobiological basis cognitive decline higher brain functions comprise abilities like language learning memory planning abstract reasoning self awareness impaired age related cognitive decline progresses dementia neural foundations higher functions supported complex organisation synaptic connections one current paradigm attaches central role modulation synaptic functions enduring majority especially brain areas serving higher functions require constant remodelling respond optimally environmental demands
0.2581098.12411259.html.plaintext.txt	26	association brain ageing age related cognitive decline uncertain largely ageing studies beginning brain ageing yet linked informatively known neurobiological basis cognitive decline higher brain functions comprise abilities like language learning memory planning abstract reasoning self awareness impaired age related cognitive decline progresses dementia neural foundations higher functions supported complex organisation synaptic connections one current paradigm attaches central role modulation synaptic functions enduring majority especially brain areas serving higher functions require constant remodelling respond optimally environmental demands
0.2581098.12411259.html.plaintext.txt	27	brain areas provide higher functions appear susceptible effects ageing alzheimers disease one disease model progression age related cognitive decline dementia best represented reversal corticogenesis arendt 2001 develop models requires better understanding ageing processes available biological components ageing certainly involve complex interplay intrinsic mostly genetic extrinsic mostly environmental factors recent progress encourages optimism small number highly conserved genes affect life span similarly small number metabolic processes view contrasts previous degenerative position held biological ageing haphazard amenable study generation metabolites oxygen termed reactive oxygen species ros important cause oxidative stress ros intimately involved biology ageing finkel holbrook 2000 parallels ageing altered metabolic states induced lower organisms adverse circumstances surprisingly similar yeasts nematodes fruit flies mammals guarente kenyon 2000 permit postponement reproduction unfavourable environmental conditions control expression genes protect ros damage genes involved insulin signalling finch ruvkun 2001 reduced expression ageing genes involved insulin like receptor signalling extends life span may specific property neurons boulianne 2001
0.2581098.12411259.html.plaintext.txt	28	brain areas provide higher functions appear susceptible effects ageing alzheimers disease one disease model progression age related cognitive decline dementia best represented reversal corticogenesis arendt 2001 develop models requires better understanding ageing processes available biological components ageing certainly involve complex interplay intrinsic mostly genetic extrinsic mostly environmental factors recent progress encourages optimism small number highly conserved genes affect life span similarly small number metabolic processes view contrasts previous degenerative position held biological ageing haphazard amenable study generation metabolites oxygen termed reactive oxygen species ros important cause oxidative stress ros intimately involved biology ageing finkel holbrook 2000 parallels ageing altered metabolic states induced lower organisms adverse circumstances surprisingly similar yeasts nematodes fruit flies mammals guarente kenyon 2000 permit postponement reproduction unfavourable environmental conditions control expression genes protect ros damage genes involved insulin signalling finch ruvkun 2001 reduced expression ageing genes involved insulin like receptor signalling extends life span may specific property neurons boulianne 2001
0.2581098.12411259.html.plaintext.txt	29	extrinsic contributions brain ageing poorly understood lag way behind elegant scientific studies intrinsic components acquired defences ros damage largely derived dietary antioxidants oppose ros production ros defences falter additional burdens placed brains capacity maintain structural integrity often threatened increased peroxidation neuronal lipid membranes oxidative damage dna large regulatory molecules whalley 2001 terminally differentiated cells neurons cannot dispose dna damage cell division must rely dna repair enzymes type damage may compromise performance neuronal sub populations provide higher mental functions also impair capacity make good compensate performance decrements
0.2581098.12411259.html.plaintext.txt	30	extrinsic contributions brain ageing poorly understood lag way behind elegant scientific studies intrinsic components acquired defences ros damage largely derived dietary antioxidants oppose ros production ros defences falter additional burdens placed brains capacity maintain structural integrity often threatened increased peroxidation neuronal lipid membranes oxidative damage dna large regulatory molecules whalley 2001 terminally differentiated cells neurons cannot dispose dna damage cell division must rely dna repair enzymes type damage may compromise performance neuronal sub populations provide higher mental functions also impair capacity make good compensate performance decrements
0.2581098.12411259.html.plaintext.txt	31	arendt 2001 summarised much available evidence support hypothesis age related cognitive decline alzheimers disease best understood progressive failure synaptic remodelling view much compelling evidence accept first abnormal dendritic sprouting occurs alzheimers disease second morphoregulatory molecules involved neurodevelopment re emerge part alzheimer molecular pathology suggests example conserved functions amyloid precursor protein app presenilins apolipoprotein e implicated alzheimers disease key roles morphoregulatory molecules synaptic formation turnover stabilisation preferentially expressed adult brain areas retain capacity modify synaptic function morphogenesis neurons enormous relevance understanding neurodevelopment differential survival cell types arendt 2001 extends significance late life first argues molecular processes underpin functional sculpting used immature brain self organise acquisition higher functions language second identifies among detritus dementia features imply reactivation brain self organising molecular machinery arendts view reactivation triggers cascade events results eventually selective loss cortical neurons
0.2581098.12411259.html.plaintext.txt	32	arendt 2001 summarised much available evidence support hypothesis age related cognitive decline alzheimers disease best understood progressive failure synaptic remodelling view much compelling evidence accept first abnormal dendritic sprouting occurs alzheimers disease second morphoregulatory molecules involved neurodevelopment re emerge part alzheimer molecular pathology suggests example conserved functions amyloid precursor protein app presenilins apolipoprotein e implicated alzheimers disease key roles morphoregulatory molecules synaptic formation turnover stabilisation preferentially expressed adult brain areas retain capacity modify synaptic function morphogenesis neurons enormous relevance understanding neurodevelopment differential survival cell types arendt 2001 extends significance late life first argues molecular processes underpin functional sculpting used immature brain self organise acquisition higher functions language second identifies among detritus dementia features imply reactivation brain self organising molecular machinery arendts view reactivation triggers cascade events results eventually selective loss cortical neurons
0.2581098.12411259.html.plaintext.txt	33	model arendt 2001 adds lifelong accumulation noxious influences brain function sources diverse malnutrition neurotoxins cerebrovascular disease age related endogenous oxidative damage neurons summarised stresses brain adaptive mechanisms gradual pervasive result jeopardise high investment made neurons retain capacity synaptic remodelling completion brain maturation missing arendts model mechanisms account individual gender differences rate change traits associated dementia dilemma familiar developmental neuroscientists strong likeness current research problems molecular genetics cognition plomin craig 2001 potentially hormonal genetic contributions synaptic remodelling could relevant example evidence oestrogens induce synapse formation rat hippocampus induction dependent apolipoprotein e stone et al 1998 diversity efficiency self organisation may contribute variation childhood mental ability differences may extend late life leading divergence brain ageing dementia
0.2581098.12411259.html.plaintext.txt	34	model arendt 2001 adds lifelong accumulation noxious influences brain function sources diverse malnutrition neurotoxins cerebrovascular disease age related endogenous oxidative damage neurons summarised stresses brain adaptive mechanisms gradual pervasive result jeopardise high investment made neurons retain capacity synaptic remodelling completion brain maturation missing arendts model mechanisms account individual gender differences rate change traits associated dementia dilemma familiar developmental neuroscientists strong likeness current research problems molecular genetics cognition plomin craig 2001 potentially hormonal genetic contributions synaptic remodelling could relevant example evidence oestrogens induce synapse formation rat hippocampus induction dependent apolipoprotein e stone et al 1998 diversity efficiency self organisation may contribute variation childhood mental ability differences may extend late life leading divergence brain ageing dementia
0.2581098.12411259.html.plaintext.txt	35	understanding individual differences age related cognitive decline beset difficulty neuropathological evidence hypothetical discontinuity normal ageing dementia lacking best available evidence suggests boundary detection sources variation rate cognitive decline requires considerable investment longitudinal population based studies mrc cfas findings outcome longitudinal study continue informative many years quite rightly study focused dementia outcomes age interval risk dementia high
0.2581098.12411259.html.plaintext.txt	36	understanding individual differences age related cognitive decline beset difficulty neuropathological evidence hypothetical discontinuity normal ageing dementia lacking best available evidence suggests boundary detection sources variation rate cognitive decline requires considerable investment longitudinal population based studies mrc cfas findings outcome longitudinal study continue informative many years quite rightly study focused dementia outcomes age interval risk dementia high
0.2581098.12411259.html.plaintext.txt	37	problem boundary brain ageing dementia remains demand detailed attention analysis current longitudinal databases future research design clarification seems certain recommendations national institute aging working group aging genetic epidemiology 2001 come influence brain ageing research goals practice precise tools molecular biology applied phenomena ageing boundaries may brought focus far seems boundaries clinical data suggested ultimate research goal postpone perhaps even prevent dementia research type certain inform timing successful intervention
0.2581098.12411259.html.plaintext.txt	38	problem boundary brain ageing dementia remains demand detailed attention analysis current longitudinal databases future research design clarification seems certain recommendations national institute aging working group aging genetic epidemiology 2001 come influence brain ageing research goals practice precise tools molecular biology applied phenomena ageing boundaries may brought focus far seems boundaries clinical data suggested ultimate research goal postpone perhaps even prevent dementia research type certain inform timing successful intervention
0.2581098.12411259.html.plaintext.txt	39	arendt 2001 alzheimers disease disorder mechanisms underlying structural brain self organization neuroscience 102 723 765crossrefmedline
0.2581098.12411259.html.plaintext.txt	40	national institute aging working group aging genetic epidemiology 2001 genetic epidemiologic studies age specified traits american journal epidemiology 152 1003 1008abstractfree full text
0.2581098.12411259.html.plaintext.txt	41	national institute aging working group aging genetic epidemiology 2001 genetic epidemiologic studies age specified traits american journal epidemiology 152 1003 1008abstractfree full text
0.2581098.12411259.html.plaintext.txt	42	received publication december 17 2001 revision received april 12 2002 accepted publication april 12 2002
0.2581098.12411259.html.plaintext.txt	43	received publication december 17 2001 revision received april 12 2002 accepted publication april 12 2002
0.2582762.9751483.html.plaintext.txt	0	regulation multicatalytic enzyme activity insulin insulin degrading enzyme1 frederick g hamel robert g bennett william c duckworth
0.2582762.9751483.html.plaintext.txt	1	veterans affairs medical center departments medicine pharmacology fgh biochemistry molecular biology rgb wcd university nebraska medical center omaha nebraska 68198 3020
0.2582762.9751483.html.plaintext.txt	2	address correspondence requests reprints william c duckworth md university nebraska medical center 600 south 42nd street omaha nebraska 68198 3020
0.2582762.9751483.html.plaintext.txt	3	abstract top abstract introduction materials methods results discussion references insulin degrading enzyme ide plays important role cellular metabolism insulin recent studies also suggested regulatory role protein controlling activity cytoplasmic protein complexes including proteasome multicatalytic proteinase mcp glucocorticoid androgen receptors binding ide complexes increases activity whereas addition substrates ide inhibits activity provides potential mechanism action internalized insulin ide substrates control protein turnover examine interactions partially purified ide mcp complex treated edta egta activity measured absence presence various divalent cations ca2 mn2 co2 zn2 insulin edta treatment reduced mcp activity eliminated effect insulin complex divalent cations partially completely restored mcp activity restore effect insulin egta treatment lesser effect mcp activity abolished insulin inhibition activity divalent cations restored insulin effect inhibitors ide also blocked insulin effect mcp activity treatment sds findings suggest conformational changes complex may play role insulin control mcp activity
0.2582762.9751483.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references insulin degrading enzyme ide plays important role cellular metabolism insulin recent studies also suggested regulatory role protein controlling activity cytoplasmic protein complexes including proteasome multicatalytic proteinase mcp glucocorticoid androgen receptors binding ide complexes increases activity whereas addition substrates ide inhibits activity provides potential mechanism action internalized insulin ide substrates control protein turnover examine interactions partially purified ide mcp complex treated edta egta activity measured absence presence various divalent cations ca2 mn2 co2 zn2 insulin edta treatment reduced mcp activity eliminated effect insulin complex divalent cations partially completely restored mcp activity restore effect insulin egta treatment lesser effect mcp activity abolished insulin inhibition activity divalent cations restored insulin effect inhibitors ide also blocked insulin effect mcp activity treatment sds findings suggest conformational changes complex may play role insulin control mcp activity
0.2582762.9751483.html.plaintext.txt	5	introduction top abstract introduction materials methods results discussion references insulin degrading enzyme ide ec 342456 intracellular protein binding regulatory degradative functions vitro characteristic function proteolytic activity relatively high specificity insulin thus leading name 1 although insulin substrate highest affinity ide also degrades number peptides hormones including glucagon 2 insulin like growth factor ii 3 atrial natriuretic peptide 4 transforming growth factor 5 general proteinase degrade wide variety similarly sized peptides specific amino acid sequence required proteolysis 2 findings led conclusion ide recognizes three dimensional structure binding degradation 5 6 requirement specific ligand structure reflected binding properties ide protein binds proinsulin insulin like growth factor epidermal growth factor high affinities little degrading activity toward 7 fact ide first identified drosophila binding properties considered new intracellular growth factor receptor 8
0.2582762.9751483.html.plaintext.txt	6	regulatory properties ide relatively new finding ide associates activates cytosolic glucocorticoid androgen receptors 9 10 ide also complexes proteasome regulates activity 11 substrates bind ide including insulin various growth factors inhibit proteasome activity ide complexed multicatalytic proteinase mcp separation two proteins 12 13 furthermore insulin inhibits proteasome activity toward artificial substrate intact cells 14 led hypothesis intracellular actions insulin growth factors cellular protein turnover due interactions ide inhibition proteolysis proteasome
0.2582762.9751483.html.plaintext.txt	7	regulatory properties ide relatively new finding ide associates activates cytosolic glucocorticoid androgen receptors 9 10 ide also complexes proteasome regulates activity 11 substrates bind ide including insulin various growth factors inhibit proteasome activity ide complexed multicatalytic proteinase mcp separation two proteins 12 13 furthermore insulin inhibits proteasome activity toward artificial substrate intact cells 14 led hypothesis intracellular actions insulin growth factors cellular protein turnover due interactions ide inhibition proteolysis proteasome
0.2582762.9751483.html.plaintext.txt	8	ide metalloenzyme containing zn2 possibly mn2 15 degradative activity requires one divalent cations 7 addition zn2 mn2 ca2 shown affect degradative activity ide vitro intact cells 16 17 ca2 divalent cations implicated activities insulin 18 present study directed examination ide binding regulatory degradative functions special emphasis effect metals
0.2582762.9751483.html.plaintext.txt	9	ide metalloenzyme containing zn2 possibly mn2 15 degradative activity requires one divalent cations 7 addition zn2 mn2 ca2 shown affect degradative activity ide vitro intact cells 16 17 ca2 divalent cations implicated activities insulin 18 present study directed examination ide binding regulatory degradative functions special emphasis effect metals
0.2582762.9751483.html.plaintext.txt	10	materials methods top abstract introduction materials methods results discussion references 125iiodoinsulin specifically labeled tyra14 provided dr bruce frank eli lilly research laboratory indianapolis 19 crystalline porcine insulin provided dr ronald chance eli lilly research laboratory enzyme grade ammonium sulfate purchased icn biomedicals costa mesa ca succinyl leu leu val tyr 7 amino 4 methylcoumarin llvy boc leu ser thr arg 7 amino 4 methylcoumarin lstr cbz leu leu glu ss napthylamide lle purchased sigma st louis mo chemicals reagent grade better enzyme preparation used partially purified ammonium sulfate fractionation 20 enzyme dialyzed overnight least 20 vol sodium acetate ph 62 addition 1 mm edta 1 mm egta three changes egta specific ca2 edta egta binding ca2 25 times tightly 21 conversely edta binds divalent cations including zn2 mn2 co2 10 10000 times tightly egta acetate salts divalent cations added concentrations indicated
0.2582762.9751483.html.plaintext.txt	11	materials methods top abstract introduction materials methods results discussion references 125iiodoinsulin specifically labeled tyra14 provided dr bruce frank eli lilly research laboratory indianapolis 19 crystalline porcine insulin provided dr ronald chance eli lilly research laboratory enzyme grade ammonium sulfate purchased icn biomedicals costa mesa ca succinyl leu leu val tyr 7 amino 4 methylcoumarin llvy boc leu ser thr arg 7 amino 4 methylcoumarin lstr cbz leu leu glu ss napthylamide lle purchased sigma st louis mo chemicals reagent grade better enzyme preparation used partially purified ammonium sulfate fractionation 20 enzyme dialyzed overnight least 20 vol sodium acetate ph 62 addition 1 mm edta 1 mm egta three changes egta specific ca2 edta egta binding ca2 25 times tightly 21 conversely edta binds divalent cations including zn2 mn2 co2 10 10000 times tightly egta acetate salts divalent cations added concentrations indicated
0.2582762.9751483.html.plaintext.txt	12	measurement degradative activity insulin degradation measured trichloroacetic acid precipitation 22 expressed percent soluble per 15 min degradations llvy lstr lle measured incubating enzyme sample 13 microm fluorogenic peptide 01 m tris buffer ph 75 assay volume 1 ml 60 min 37 c metabolic shaker 12 inhibitors activators included concentrations indicated reaction stopped addition 02 ml ethanol ice increase fluorescence measured fluorometer excitation emission wavelengths 390 440 nm llvy lstr 335 410 nm lle data expressed change fluorescence units per 60 min normalized respect activity untreated uninhibited enzyme
0.2582762.9751483.html.plaintext.txt	13	measurement degradative activity insulin degradation measured trichloroacetic acid precipitation 22 expressed percent soluble per 15 min degradations llvy lstr lle measured incubating enzyme sample 13 microm fluorogenic peptide 01 m tris buffer ph 75 assay volume 1 ml 60 min 37 c metabolic shaker 12 inhibitors activators included concentrations indicated reaction stopped addition 02 ml ethanol ice increase fluorescence measured fluorometer excitation emission wavelengths 390 440 nm llvy lstr 335 410 nm lle data expressed change fluorescence units per 60 min normalized respect activity untreated uninhibited enzyme
0.2582762.9751483.html.plaintext.txt	14	results top abstract introduction materials methods results discussion references insulin degradation ide reduced treatment edta fig 1 ca2 restores insulin degradative activity edta treated ide concentrations low 10 6 m high ca2 concentrations 10 3 m activity increased untreated enzyme fig 1
0.2582762.9751483.html.plaintext.txt	15	view larger version 14k figure 1 restoration ca2 edta inhibited insulin degrading enzyme edta treatment ide inhibits enzyme almost half readdition ca2 restores activity even increases 10 3 m values mean plus minus sem ide activity expressed percentage ide without edta treatment
0.2582762.9751483.html.plaintext.txt	16	view larger version 14k figure 1 restoration ca2 edta inhibited insulin degrading enzyme edta treatment ide inhibits enzyme almost half readdition ca2 restores activity even increases 10 3 m values mean plus minus sem ide activity expressed percentage ide without edta treatment
0.2582762.9751483.html.plaintext.txt	17	regulatory function ide also affected edta figure 2a shows insulin inhibits llvy degradation untreated ide mcp complex addition ca2 slightly increases activity untreated complex alter effect insulin edta treatment ide mcp complex decreases chymotrypsin like activity mcp reflected decreased degradation llvy fig 2b addition 10 5 10 3 m ca2 restores llvy degradation insulin effect although wide variability results seen
0.2582762.9751483.html.plaintext.txt	18	regulatory function ide also affected edta figure 2a shows insulin inhibits llvy degradation untreated ide mcp complex addition ca2 slightly increases activity untreated complex alter effect insulin edta treatment ide mcp complex decreases chymotrypsin like activity mcp reflected decreased degradation llvy fig 2b addition 10 5 10 3 m ca2 restores llvy degradation insulin effect although wide variability results seen
0.2582762.9751483.html.plaintext.txt	19	view larger version 13k figure 2 effect ca2 readdition mcp edta treated mcp egta treated mcp addition ca2 slight stimulatory effect llvy degradation effect insulin inhibition b edta treatment reduces llvy activity 60 eliminates response insulin calcium addition reactivates llvy degradation restore insulin sensitivity c egta treatment reduces llvy activity essentially eliminates response insulin calcium addition restores degrading activity response insulin values shown mean plus minus sem llvy activity expressed percentage untreated enzyme
0.2582762.9751483.html.plaintext.txt	20	view larger version 13k figure 2 effect ca2 readdition mcp edta treated mcp egta treated mcp addition ca2 slight stimulatory effect llvy degradation effect insulin inhibition b edta treatment reduces llvy activity 60 eliminates response insulin calcium addition reactivates llvy degradation restore insulin sensitivity c egta treatment reduces llvy activity essentially eliminates response insulin calcium addition restores degrading activity response insulin values shown mean plus minus sem llvy activity expressed percentage untreated enzyme
0.2582762.9751483.html.plaintext.txt	21	evidence ide contains one divalent cation 15 tightly bound zn2 easily dissociable mn2 different cations may different effects ide activities thus effect different chelator egta examined fig 2c llvy degradation decreased slight effect insulin ca2 however restored llvy degradative activity effect insulin
0.2582762.9751483.html.plaintext.txt	22	evidence ide contains one divalent cation 15 tightly bound zn2 easily dissociable mn2 different cations may different effects ide activities thus effect different chelator egta examined fig 2c llvy degradation decreased slight effect insulin ca2 however restored llvy degradative activity effect insulin
0.2582762.9751483.html.plaintext.txt	23	similar studies edta egta treated ide mcp complex performed readdition cations zn2 mn2 co2 alter ide degradative activity figs 3 4 effects ca2 shown comparison metals variable effects restoring mcp activity edta treated complex none restores insulin effect however zn2 ca2 co2 restore regulatory function ide mcp activity egta treated material manganese appeared restore insulin sensitivity reach statistical significance p 0066 one tailed test
0.2582762.9751483.html.plaintext.txt	24	view larger version 17k figure 3 effect edta treatment metal readdition llvy degrading activity inhibition insulin graph shows activity ide mcp complex toward llvy various treatments without open bars closed bars addition 1 microm insulin partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate 1 mm edta readdition various metals values shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added metal chloride concentrations used maximally restored ide activity toward radiolabeled insulin follows zn2 10 6 m ca2 10 3 m mn2 5 x 10 6 m co2 10 5 m
0.2582762.9751483.html.plaintext.txt	25	view larger version 17k figure 3 effect edta treatment metal readdition llvy degrading activity inhibition insulin graph shows activity ide mcp complex toward llvy various treatments without open bars closed bars addition 1 microm insulin partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate 1 mm edta readdition various metals values shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added metal chloride concentrations used maximally restored ide activity toward radiolabeled insulin follows zn2 10 6 m ca2 10 3 m mn2 5 x 10 6 m co2 10 5 m
0.2582762.9751483.html.plaintext.txt	26	view larger version 19k figure 4 effect egta treatment metal readdition llvy degrading activity inhibition insulin graph shows activity ide mcp complex toward llvy various treatments without open bars closed bars addition 1 microm insulin partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate 1 mm egta readdition various metals values shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added egta treatment little effect insulin degrading activities metal concentrations used used edta treated enzyme zn2 10 6 m ca2 10 3 m mn2 5 x 10 6 m co2 10 5 m
0.2582762.9751483.html.plaintext.txt	27	view larger version 19k figure 4 effect egta treatment metal readdition llvy degrading activity inhibition insulin graph shows activity ide mcp complex toward llvy various treatments without open bars closed bars addition 1 microm insulin partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate 1 mm egta readdition various metals values shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added egta treatment little effect insulin degrading activities metal concentrations used used edta treated enzyme zn2 10 6 m ca2 10 3 m mn2 5 x 10 6 m co2 10 5 m
0.2582762.9751483.html.plaintext.txt	28	mcp multiple catalytic sites insulin ide regulate trypsin like lstr degradation well chymotrypsin like llvy degradation activity edta treatment dramatically decreases lstr degradation eliminates insulin effect fig 5 readdition divalent cations ca2 co2 restores degrading activity insulin effect egta treatment reduces lstr activity change achieve significance remove insulin inhibition mcp activity fig 6
0.2582762.9751483.html.plaintext.txt	29	mcp multiple catalytic sites insulin ide regulate trypsin like lstr degradation well chymotrypsin like llvy degradation activity edta treatment dramatically decreases lstr degradation eliminates insulin effect fig 5 readdition divalent cations ca2 co2 restores degrading activity insulin effect egta treatment reduces lstr activity change achieve significance remove insulin inhibition mcp activity fig 6
0.2582762.9751483.html.plaintext.txt	30	view larger version 17k figure 5 effects edta treatment metal readdition lstr degrading activity inhibition insulin see fig 3 details
0.2582762.9751483.html.plaintext.txt	31	view larger version 17k figure 5 effects edta treatment metal readdition lstr degrading activity inhibition insulin see fig 3 details
0.2582762.9751483.html.plaintext.txt	32	view larger version 20k figure 6 effects egta treatment metal readdition lstr degrading activity inhibition insulin see fig 4 details
0.2582762.9751483.html.plaintext.txt	33	view larger version 20k figure 6 effects egta treatment metal readdition lstr degrading activity inhibition insulin see fig 4 details
0.2582762.9751483.html.plaintext.txt	34	data figs 2 6 support role easily dissociable divalent cation essential insulin effect complex egta effects edta treatment however results profound alterations perhaps due partial removal tightly bound cation subsequent conformational changes simple addition individual cations restore functional control complex insulin
0.2582762.9751483.html.plaintext.txt	35	explore regulatory role ide control mcp selected inhibitors examined table 1 metalloproteinase inhibitor 110 phenanthroline inhibited ide abolished insulin effect llvy degradation similar edta n ethylmaleimide bacitracin known inhibitors ide also blocked effect insulin phenylmethylsulfonylfluoride low concentrations appreciable effect
0.2582762.9751483.html.plaintext.txt	36	explore regulatory role ide control mcp selected inhibitors examined table 1 metalloproteinase inhibitor 110 phenanthroline inhibited ide abolished insulin effect llvy degradation similar edta n ethylmaleimide bacitracin known inhibitors ide also blocked effect insulin phenylmethylsulfonylfluoride low concentrations appreciable effect
0.2582762.9751483.html.plaintext.txt	37	view table table 1 effects various inhibitors ide mcp complex
0.2582762.9751483.html.plaintext.txt	38	table 2 compares effects inhibitors ide proteolytic activity ide mcp complex purified mcp phenanthroline n ethylmaleimide bacitracin inhibit llvy degradation mcp complexed ide agents ineffective purified mcp findings support regulatory activating effect ide mcp activity
0.2582762.9751483.html.plaintext.txt	39	table 2 compares effects inhibitors ide proteolytic activity ide mcp complex purified mcp phenanthroline n ethylmaleimide bacitracin inhibit llvy degradation mcp complexed ide agents ineffective purified mcp findings support regulatory activating effect ide mcp activity
0.2582762.9751483.html.plaintext.txt	40	view table table 2 effects inhibitors ide mcp activity
0.2582762.9751483.html.plaintext.txt	41	importance activation mcp ide supported effect removal ide purification reported previously 11 12 ide mcp llvy degradation copurify various standard affinity procedures separated ion exchange columns ide mcp complex purified ammonium sulfate fractionation diethylaminoethyl batch separation phenyl sepharose p200 chromatofocusing preparation chromatographed mono q hplc column llvy degrading activity eluting sharp symmetrical peak shown recovery llvy degrading activity ion exchange column 002 specific activity decreased 62 11 fluorescent units per microg proteinh
0.2582762.9751483.html.plaintext.txt	42	importance activation mcp ide supported effect removal ide purification reported previously 11 12 ide mcp llvy degradation copurify various standard affinity procedures separated ion exchange columns ide mcp complex purified ammonium sulfate fractionation diethylaminoethyl batch separation phenyl sepharose p200 chromatofocusing preparation chromatographed mono q hplc column llvy degrading activity eluting sharp symmetrical peak shown recovery llvy degrading activity ion exchange column 002 specific activity decreased 62 11 fluorescent units per microg proteinh
0.2582762.9751483.html.plaintext.txt	43	ide control mcp activity may due conformational change mcp enzyme responsive reagents alter conformation 23 sds low concentrations increases activity higher concentrations inhibiting 24 explore dose response curves sds performed ide mcp complex without insulin effects llvy lstr lle activities examined fig 7 llvy degrading activity stimulated sds concentrations 0015 0030 insulin inhibited llvy lstr lle degradation absence sds effect even slight stimulatory effect presence sds
0.2582762.9751483.html.plaintext.txt	44	ide control mcp activity may due conformational change mcp enzyme responsive reagents alter conformation 23 sds low concentrations increases activity higher concentrations inhibiting 24 explore dose response curves sds performed ide mcp complex without insulin effects llvy lstr lle activities examined fig 7 llvy degrading activity stimulated sds concentrations 0015 0030 insulin inhibited llvy lstr lle degradation absence sds effect even slight stimulatory effect presence sds
0.2582762.9751483.html.plaintext.txt	45	view larger version 16k figure 7 insulin effect peptide degradation sds activated multicatalytic proteinase enzyme ammonium sulfate purified complex incubated increasing concentrations sds 0 0035 wtvol presence absence 1 microm insulin degradation peptides expressed fluorescence liberated arbitrary units per 60 min lle degradation expressed thousands
0.2582762.9751483.html.plaintext.txt	46	view larger version 16k figure 7 insulin effect peptide degradation sds activated multicatalytic proteinase enzyme ammonium sulfate purified complex incubated increasing concentrations sds 0 0035 wtvol presence absence 1 microm insulin degradation peptides expressed fluorescence liberated arbitrary units per 60 min lle degradation expressed thousands
0.2582762.9751483.html.plaintext.txt	47	determine insulin effect complex could restored ide mcp activated sds sds removed table 3 degradation llvy monitored continuously insulin added achieve sequential concentrations 10 9 10 8 10 6 m seen mcp activity inhibited insulin concentrations removal sds
0.2582762.9751483.html.plaintext.txt	48	determine insulin effect complex could restored ide mcp activated sds sds removed table 3 degradation llvy monitored continuously insulin added achieve sequential concentrations 10 9 10 8 10 6 m seen mcp activity inhibited insulin concentrations removal sds
0.2582762.9751483.html.plaintext.txt	49	view table table 3 effect insulin mcp treatment removal sds
0.2582762.9751483.html.plaintext.txt	50	discussion top abstract introduction materials methods results discussion references although role ide cellular insulin metabolism firmly established 7 many factors mitigate sole physiological activity enzyme although insulin sensitive tissues contain enzyme also found noninsulin sensitive tissues multiple subcellular compartments ide found peroxisomes 25 26 27 cytosol 7 endosomes 28 plasma membranes 29 cellular content ide developmentally regulated ide implicated cellular differentiation 26 30 31 32 growth factor binding 30 diverse properties become less confusing ide recognized multifunctional protein complex variety subcellular components proteasome steroid receptor peroxisomes alter activities complexes
0.2582762.9751483.html.plaintext.txt	51	discussion top abstract introduction materials methods results discussion references although role ide cellular insulin metabolism firmly established 7 many factors mitigate sole physiological activity enzyme although insulin sensitive tissues contain enzyme also found noninsulin sensitive tissues multiple subcellular compartments ide found peroxisomes 25 26 27 cytosol 7 endosomes 28 plasma membranes 29 cellular content ide developmentally regulated ide implicated cellular differentiation 26 30 31 32 growth factor binding 30 diverse properties become less confusing ide recognized multifunctional protein complex variety subcellular components proteasome steroid receptor peroxisomes alter activities complexes
0.2582762.9751483.html.plaintext.txt	52	stimulatory effects ide proteasomes glucocorticoid androgen receptors established present previous reports 9 12 mechanism reversible nature activation argues proteolytic activation complex ide possibilities include conformational changes complex ide degradation ligand proteolytic products generated ide combination
0.2582762.9751483.html.plaintext.txt	53	stimulatory effects ide proteasomes glucocorticoid androgen receptors established present previous reports 9 12 mechanism reversible nature activation argues proteolytic activation complex ide possibilities include conformational changes complex ide degradation ligand proteolytic products generated ide combination
0.2582762.9751483.html.plaintext.txt	54	present study provides evidence divalent cations involved activity control ide mcp complex treatment partially purified enzyme edta significantly reduced activity ide restored addition ca2 little 10 6 m effect presumably mediated removal zn2 found active site ide required activity treatment also reduces chymotrypsin like trypsin like activities proteasome eliminates ability insulin inhibit activities addition ca2 co2 restores chymotrypsin like trypsin like activities fails restore insulin responsiveness zn2 mn2 show relatively little effect
0.2582762.9751483.html.plaintext.txt	55	present study provides evidence divalent cations involved activity control ide mcp complex treatment partially purified enzyme edta significantly reduced activity ide restored addition ca2 little 10 6 m effect presumably mediated removal zn2 found active site ide required activity treatment also reduces chymotrypsin like trypsin like activities proteasome eliminates ability insulin inhibit activities addition ca2 co2 restores chymotrypsin like trypsin like activities fails restore insulin responsiveness zn2 mn2 show relatively little effect
0.2582762.9751483.html.plaintext.txt	56	also examined effect egta complex egta slightly higher affinity 25 times ca2 edta 10 10000 times less affinity cations including zn2 21 conditions experiments egta effect ide activity data shown reduce chymotrypsin like activity proteasome effectively eliminated insulin effect similar reduction seen trypsin like activity although reach statistical significance insulin ability inhibit restored cations ca2 co2 data suggest two metals involved complex reported previously 15
0.2582762.9751483.html.plaintext.txt	57	also examined effect egta complex egta slightly higher affinity 25 times ca2 edta 10 10000 times less affinity cations including zn2 21 conditions experiments egta effect ide activity data shown reduce chymotrypsin like activity proteasome effectively eliminated insulin effect similar reduction seen trypsin like activity although reach statistical significance insulin ability inhibit restored cations ca2 co2 data suggest two metals involved complex reported previously 15
0.2582762.9751483.html.plaintext.txt	58	propose one metal zinc tightly bound ide essential activity possibly mn2 ca2 loosely bound required productive interaction ide proteasome edta chelate tightly bound zn2 loosely bound metal associated complex inhibits ide thereby lessening stimulatory effect proteasome loss zn2 molecule causes conformational change ide dissociating proteasome disrupting ability insulin alter proteasome activity readdition divalent cation restores ide activity longer part complex ide cannot alter proteasome function however egta effects loosely bound metal disrupts ide ability affect chymotrypsin like activity cause ide dissociate complex thus addition cations restore insulin sensitivity
0.2582762.9751483.html.plaintext.txt	59	propose one metal zinc tightly bound ide essential activity possibly mn2 ca2 loosely bound required productive interaction ide proteasome edta chelate tightly bound zn2 loosely bound metal associated complex inhibits ide thereby lessening stimulatory effect proteasome loss zn2 molecule causes conformational change ide dissociating proteasome disrupting ability insulin alter proteasome activity readdition divalent cation restores ide activity longer part complex ide cannot alter proteasome function however egta effects loosely bound metal disrupts ide ability affect chymotrypsin like activity cause ide dissociate complex thus addition cations restore insulin sensitivity
0.2582762.9751483.html.plaintext.txt	60	fact ide must active complex proteasome mediate regulatory effects supported data presented tables 1 2 agents inhibit ide lessen proteasome activity effectively eliminate insulin inhibitory effect
0.2582762.9751483.html.plaintext.txt	61	fact ide must active complex proteasome mediate regulatory effects supported data presented tables 1 2 agents inhibit ide lessen proteasome activity effectively eliminate insulin inhibitory effect
0.2582762.9751483.html.plaintext.txt	62	finally studied ide proteasome interactions using sds shown alter proteasome conformation shown fig 7 chymotrypsin trypsin like activities proteasome insulin sensitive absence sds lose sensitivity considerable activity 0005 sds presumably due sds altering interaction ide proteasome higher concentrations sds alters conformation proteasome stimulates chymotrypsin like peptidyl glutamyl degrading activities however high concentrations ide still unable interact proteasomes insulin inhibit effect reversible
0.2582762.9751483.html.plaintext.txt	63	data presented characterize support idea ide serve regulator proteasome metal ions play important roles interaction first ide metalloproteinase must active insulin inhibitory effect second loosely bound divalent cation required ide mediate effects changes protein conformation important illustrated loss activity ide active site metal removed changes activity induced sds
0.2582762.9751483.html.plaintext.txt	64	data presented characterize support idea ide serve regulator proteasome metal ions play important roles interaction first ide metalloproteinase must active insulin inhibitory effect second loosely bound divalent cation required ide mediate effects changes protein conformation important illustrated loss activity ide active site metal removed changes activity induced sds
0.2582762.9751483.html.plaintext.txt	65	physiological effect insulin inhibit cellular protein degradation greater effects catabolic states eg starvation diabetes traumatic stress cell survival requires continued protein turnover would expected insulin could totally inhibit mcp activity completely block protein degradation rather ide mcp interaction may serve activator basal cellular protein degradation analogous activation glucocorticoid androgen receptors ide 9 insulin substrates acting inhibit stimulated process thus selective effects cellular protein degradation insulin sensitive cells control insulin ide interactions mcp comprises relatively large proportion protein many cells 1 ide although expressed high levels tissues 33 present sufficient quantities tissues universal regulator mcp activities results show insulin substantially inhibits two activities mcp chymotrypsin trypsin like activities proteasome may many five different proteolytic activities 34 also remains determined whether degradation ubiquitinylated proteins inhibited insulin ide
0.2582762.9751483.html.plaintext.txt	66	although widely appreciated many studies shown biological activity intracellular insulin 35 36 alterations insulin activity inhibition cellular insulin processing 37 38 recent studies provided potential mechanism previously unexplained observations scheme ide portion complex acts intracellular receptor insulin possibly growth factors insulin ide interaction alters activity protein complex ie mcp glucocorticoid receptor androgen receptor perhaps others contributes biological actions insulin insulin effect mcp prevented altering activity ide although speculative cellular activity regulated ide complexes may affected cellular redox state divalent cation distribution due changes ide alterations insulin action associated ion flux redistribution redox state effects could explained part regulatory effects ide studies required
0.2582762.9751483.html.plaintext.txt	67	although widely appreciated many studies shown biological activity intracellular insulin 35 36 alterations insulin activity inhibition cellular insulin processing 37 38 recent studies provided potential mechanism previously unexplained observations scheme ide portion complex acts intracellular receptor insulin possibly growth factors insulin ide interaction alters activity protein complex ie mcp glucocorticoid receptor androgen receptor perhaps others contributes biological actions insulin insulin effect mcp prevented altering activity ide although speculative cellular activity regulated ide complexes may affected cellular redox state divalent cation distribution due changes ide alterations insulin action associated ion flux redistribution redox state effects could explained part regulatory effects ide studies required
0.2582762.9751483.html.plaintext.txt	68	acknowledgments authors thank janet corr preparation manuscript
0.2582762.9751483.html.plaintext.txt	69	footnotes 1 work supported department veterans affairs research service bly memorial research fund
0.2582762.9751483.html.plaintext.txt	70	references top abstract introduction materials methods results discussion references duckworth wc hamel fg bennett rg ryan mp roth ra 1990 human red blood cell insulin degrading enzyme rat skeletal muscle insulin protease share antigenic sites generate identical products insulin j biol chem 2652984 2987abstractfree full text authier f posner bi bergeron jjm 1996 insulin degrading enzyme clin invest med 19149 160medline roth ra mesirow ml yokono k baba 1984 degradation insulin like growth factors ii human insulin degrading enzyme endocr res 10101 112medline muller d baumeister h buck f richter d 1991 atrial natriuretic peptide anp high affinity substrate rat insulin degrading enzyme eur j biochem 202285 292abstract hamel fg gehm bd rosner rg duckworth wc 1997 identification cleavage sites transforming growth factor insulin degrading enzymes biochim biophys acta 1338207 214medline duckworth wc hamel fg peavy de liepnieks jj ryan mp hermodson ma frank bh 1988 degradation products insulin generated hepatocytes insulin protease j biol chem 2631826 1833abstractfree full text duckworth wc 1988 insulin degradation mechanisms products significance endocr rev 9319 345abstract garcia jv stoppelli mp thompson kl decker sj rosner mr 1987 characterization drosophila protein binds epidermal growth factor insulin related growth factors j cell biol 105449 456abstract kupfer marschke k wilson e french f 1993 receptor accessory factor enhances specific dna binding androgen glucocorticoid receptors j biol chem 26817519 17527abstractfree full text kupfer sr wilson em french fs 1994 androgen glucocorticoid receptors interact insulin degrading enzyme j biol chem 26920622 20628abstractfree full text bennett rg hamel fg duckworth wc 1994 identification isolation cytosolic proteolytic complex containing insulin degrading enzyme multicatalytic proteinase biochem biophys res commun 2021047 1053crossrefmedline duckworth wc bennett rg hamel fg 1994 direct inhibitory effect insulin cytosolic proteolytic complex containing insulin degrading enzyme multicatalytic proteinase j biol chem 26924575 24580abstractfree full text bennett rg hamel fg duckworth wc 1997 characterization insulin inhibition peptidolytic activities insulin degrading enzyme proteasome complex diabetes 46197 203abstract hamel f bennett r harmon k duckworth w 1997 insulin inhibition proteasome activity intact cells biochem biophys res commun 234671 674crossrefmedline ebrahim hamel fg bennett rg duckworth wc 1991 identification metal associated insulin degrading enzyme biochem biophys res commun 1811398 1406medline ryan mp duckworth wc 1983 partial characterization endogenous inhibitor calcium dependent form insulin protease biochem biophys res commun 116195 203medline ryan mp gifford jd solomon ss duckworth wc 1985 calcium dependence insulin degradation rat skeletal muscle endocrinology 1171693 1698abstract pershadsingh h shade d delfert d mcdonald j 1987 chelation intracellular calcium blocks insulin action adipocyte proc natl acad sci usa 841025 1029abstract frank bh peavy de hooker cs duckworth wc 1983 receptor binding properties monoiodotyrosyl insulin isomers purified high performance liquid chromatography diabetes 32705 711medline duckworth w heinemann m kitabchi 1972 purification insulin specific protease affinity chromatography proc natl acad sci usa 693698 3702abstract blanchard j 1984 buffers enzymes methods enzymol 104404 414medline duckworth w heinemann m kitabchi 1975 proteolytic degradation insulin glucagon biochim biophys acta 377421 430medline saitoh y yokusawa h ishii 1989 sodium dodecyl sulfate induced conformational enzymatic changes multicatalytic proteinase biochem biophys res commun 162334 339medline arribas j castano j 1990 kinetic studies differential effect detergents peptidase activities multicatalytic proteinase rat liver j biol chem 26513969 13973abstractfree full text authier f bergeron jj ou wj rachubinski ra posner bi walton pa 1995 degradation cleaved leader peptide thiolase peroxisomal proteinase proc natl acad sci usa 923859 3863abstractfree full text kuo wl gehm bd rosner mr li w keller g 1994 inducible expression cellular localization insulin degrading enzyme stably transfected cell line j biol chem 26922599 22606abstractfree full text rabkin r birn h shi j roth r christensen e 1992 insulin degrading enzyme ide renal proximal tubules diabetes 4115a hamel fg mahoney mj duckworth wc 1991 degradation intraendosomal insulin insulin degrading enzyme without acidification diabetes 40436 443abstract roth r mesirow m cassell d yokono k baba 1985 characterization insulin degrading enzyme cultured human lymphocytes diabetes res clin pract 131 39medline gehm bd rosner mr 1991 regulation insulin epidermal growth factor transforming growth factor levels growth factor degrading enzymes endocrinology 1281603 1609abstract kayalar c wong wt hendrickson l 1990 differentiation bc3h1 primary skeletal muscle cells activity endogenous insulin degrading enzyme inhibited metalloendoprotease inhibitors j cell biochem 44137 151medline kayalar c wong w 1989 metalloendoprotease inhibitors block differentiation l6 myoblasts inhibit insulin degradation endogenous insulin degrading enzyme j biol chem 2648928 8934abstractfree full text kuo wl montag ag rosner mr 1993 insulin degrading enzyme differentially expressed developmentally regulated various rat tissues endocrinology 132604 611abstract rivett 1989 multicatalytic proteinase mammalian cells arch biochem biophys 2681 8medline hofmann ca lotan rm ku ww oeltmann tn 1983 insulin ricin b hybrid molecules mediate insulin associated effect cells bind insulin j biol chem 25811774 11779abstractfree full text miller ds 1988 stimulation rna protein synthesis intracellular insulin science 240506 509medline draznin b trowbridge m 1982 inhibition intracellular proteolysis insulin isolated rat hepatocytes possible role internalized hormone j biol chem 25711988 11993abstractfree full text peavy de edmondson jw duckworth wc 1984 selective effects inhibitors hormone processing insulin action isolated hepatocytes endocrinology 114753 760abstract
0.2582762.9751483.html.plaintext.txt	71	references top abstract introduction materials methods results discussion references duckworth wc hamel fg bennett rg ryan mp roth ra 1990 human red blood cell insulin degrading enzyme rat skeletal muscle insulin protease share antigenic sites generate identical products insulin j biol chem 2652984 2987abstractfree full text authier f posner bi bergeron jjm 1996 insulin degrading enzyme clin invest med 19149 160medline roth ra mesirow ml yokono k baba 1984 degradation insulin like growth factors ii human insulin degrading enzyme endocr res 10101 112medline muller d baumeister h buck f richter d 1991 atrial natriuretic peptide anp high affinity substrate rat insulin degrading enzyme eur j biochem 202285 292abstract hamel fg gehm bd rosner rg duckworth wc 1997 identification cleavage sites transforming growth factor insulin degrading enzymes biochim biophys acta 1338207 214medline duckworth wc hamel fg peavy de liepnieks jj ryan mp hermodson ma frank bh 1988 degradation products insulin generated hepatocytes insulin protease j biol chem 2631826 1833abstractfree full text duckworth wc 1988 insulin degradation mechanisms products significance endocr rev 9319 345abstract garcia jv stoppelli mp thompson kl decker sj rosner mr 1987 characterization drosophila protein binds epidermal growth factor insulin related growth factors j cell biol 105449 456abstract kupfer marschke k wilson e french f 1993 receptor accessory factor enhances specific dna binding androgen glucocorticoid receptors j biol chem 26817519 17527abstractfree full text kupfer sr wilson em french fs 1994 androgen glucocorticoid receptors interact insulin degrading enzyme j biol chem 26920622 20628abstractfree full text bennett rg hamel fg duckworth wc 1994 identification isolation cytosolic proteolytic complex containing insulin degrading enzyme multicatalytic proteinase biochem biophys res commun 2021047 1053crossrefmedline duckworth wc bennett rg hamel fg 1994 direct inhibitory effect insulin cytosolic proteolytic complex containing insulin degrading enzyme multicatalytic proteinase j biol chem 26924575 24580abstractfree full text bennett rg hamel fg duckworth wc 1997 characterization insulin inhibition peptidolytic activities insulin degrading enzyme proteasome complex diabetes 46197 203abstract hamel f bennett r harmon k duckworth w 1997 insulin inhibition proteasome activity intact cells biochem biophys res commun 234671 674crossrefmedline ebrahim hamel fg bennett rg duckworth wc 1991 identification metal associated insulin degrading enzyme biochem biophys res commun 1811398 1406medline ryan mp duckworth wc 1983 partial characterization endogenous inhibitor calcium dependent form insulin protease biochem biophys res commun 116195 203medline ryan mp gifford jd solomon ss duckworth wc 1985 calcium dependence insulin degradation rat skeletal muscle endocrinology 1171693 1698abstract pershadsingh h shade d delfert d mcdonald j 1987 chelation intracellular calcium blocks insulin action adipocyte proc natl acad sci usa 841025 1029abstract frank bh peavy de hooker cs duckworth wc 1983 receptor binding properties monoiodotyrosyl insulin isomers purified high performance liquid chromatography diabetes 32705 711medline duckworth w heinemann m kitabchi 1972 purification insulin specific protease affinity chromatography proc natl acad sci usa 693698 3702abstract blanchard j 1984 buffers enzymes methods enzymol 104404 414medline duckworth w heinemann m kitabchi 1975 proteolytic degradation insulin glucagon biochim biophys acta 377421 430medline saitoh y yokusawa h ishii 1989 sodium dodecyl sulfate induced conformational enzymatic changes multicatalytic proteinase biochem biophys res commun 162334 339medline arribas j castano j 1990 kinetic studies differential effect detergents peptidase activities multicatalytic proteinase rat liver j biol chem 26513969 13973abstractfree full text authier f bergeron jj ou wj rachubinski ra posner bi walton pa 1995 degradation cleaved leader peptide thiolase peroxisomal proteinase proc natl acad sci usa 923859 3863abstractfree full text kuo wl gehm bd rosner mr li w keller g 1994 inducible expression cellular localization insulin degrading enzyme stably transfected cell line j biol chem 26922599 22606abstractfree full text rabkin r birn h shi j roth r christensen e 1992 insulin degrading enzyme ide renal proximal tubules diabetes 4115a hamel fg mahoney mj duckworth wc 1991 degradation intraendosomal insulin insulin degrading enzyme without acidification diabetes 40436 443abstract roth r mesirow m cassell d yokono k baba 1985 characterization insulin degrading enzyme cultured human lymphocytes diabetes res clin pract 131 39medline gehm bd rosner mr 1991 regulation insulin epidermal growth factor transforming growth factor levels growth factor degrading enzymes endocrinology 1281603 1609abstract kayalar c wong wt hendrickson l 1990 differentiation bc3h1 primary skeletal muscle cells activity endogenous insulin degrading enzyme inhibited metalloendoprotease inhibitors j cell biochem 44137 151medline kayalar c wong w 1989 metalloendoprotease inhibitors block differentiation l6 myoblasts inhibit insulin degradation endogenous insulin degrading enzyme j biol chem 2648928 8934abstractfree full text kuo wl montag ag rosner mr 1993 insulin degrading enzyme differentially expressed developmentally regulated various rat tissues endocrinology 132604 611abstract rivett 1989 multicatalytic proteinase mammalian cells arch biochem biophys 2681 8medline hofmann ca lotan rm ku ww oeltmann tn 1983 insulin ricin b hybrid molecules mediate insulin associated effect cells bind insulin j biol chem 25811774 11779abstractfree full text miller ds 1988 stimulation rna protein synthesis intracellular insulin science 240506 509medline draznin b trowbridge m 1982 inhibition intracellular proteolysis insulin isolated rat hepatocytes possible role internalized hormone j biol chem 25711988 11993abstractfree full text peavy de edmondson jw duckworth wc 1984 selective effects inhibitors hormone processing insulin action isolated hepatocytes endocrinology 114753 760abstract
0.26019153.11581097.html.plaintext.txt	0	diabetes mellitus risk alzheimers disease dementia stroke multiethnic cohort
0.26019153.11581097.html.plaintext.txt	1	jose luchsinger12 ming xin tang13 yaakov stern145 steven shea26 richard mayeux14 7
0.26019153.11581097.html.plaintext.txt	2	1 taub institute research alzheimers disease aging brain columbia university new york ny 2 division general medicine department medicine college physicians surgeons columbia university new york ny 3 division biostatistics joseph p mailman school public health columbia university new york ny 4 gertrude h sergievsky center columbia university new york ny 5 department psychiatry college physicians surgeons columbia university new york ny 6 division epidemiology joseph p mailman school public health columbia university new york ny 7 department neurology college physicians surgeons columbia university new york ny
0.26019153.11581097.html.plaintext.txt	3	1 taub institute research alzheimers disease aging brain columbia university new york ny 2 division general medicine department medicine college physicians surgeons columbia university new york ny 3 division biostatistics joseph p mailman school public health columbia university new york ny 4 gertrude h sergievsky center columbia university new york ny 5 department psychiatry college physicians surgeons columbia university new york ny 6 division epidemiology joseph p mailman school public health columbia university new york ny 7 department neurology college physicians surgeons columbia university new york ny
0.26019153.11581097.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references research relation diabetes mellitus dementia produced conflicting results relation investigated among blacks hispanics study cox proportional hazards models used analyze longitudinal data 1262 elderly subjects without dementia baseline 1991 1996 followed average 43 years 1992 1997 outcomes incident alzheimers disease dementia associated stroke prevalence diabetes 20 baseline adjusted relative risk alzheimers disease among persons diabetes compared without diabetes 13 95 confidence interval ci 08 19 adjusted relative risk composite outcome alzheimers disease cognitive impairment without dementia without stroke subjects diabetes 16 95 ci 12 21 adjusted relative risk stroke associated dementia persons diabetes 34 95 ci 17 69 among blacks hispanics approximately one third risk stroke associated dementia attributable diabetes 33 95 ci 31 36 36 95 ci 33 37 respectively compared 17 95 ci 13 22 among whites finding association diabetes composite outcome alzheimers disease cognitive impairment without dementia without stroke consistent prior reports modest relation diabetes alzheimers disease
0.26019153.11581097.html.plaintext.txt	5	abstract top abstract introduction materials methods results discussion references research relation diabetes mellitus dementia produced conflicting results relation investigated among blacks hispanics study cox proportional hazards models used analyze longitudinal data 1262 elderly subjects without dementia baseline 1991 1996 followed average 43 years 1992 1997 outcomes incident alzheimers disease dementia associated stroke prevalence diabetes 20 baseline adjusted relative risk alzheimers disease among persons diabetes compared without diabetes 13 95 confidence interval ci 08 19 adjusted relative risk composite outcome alzheimers disease cognitive impairment without dementia without stroke subjects diabetes 16 95 ci 12 21 adjusted relative risk stroke associated dementia persons diabetes 34 95 ci 17 69 among blacks hispanics approximately one third risk stroke associated dementia attributable diabetes 33 95 ci 31 36 36 95 ci 33 37 respectively compared 17 95 ci 13 22 among whites finding association diabetes composite outcome alzheimers disease cognitive impairment without dementia without stroke consistent prior reports modest relation diabetes alzheimers disease
0.26019153.11581097.html.plaintext.txt	6	alzheimer disease dementia diabetes mellitus survival analysis
0.26019153.11581097.html.plaintext.txt	7	abbreviations ci confidence interval nincds adrda national institute neurological communicative disorders stroke alzheimers disease related disorders association ninds airen national institute neurological disorders stroke association internationale pour la recherche et lenseignement en neurosciences
0.26019153.11581097.html.plaintext.txt	8	introduction top abstract introduction materials methods results discussion references dementia diabetes mellitus two prevalent problems elderly 10 percent people age 65 years develop dementia prevalence dementia increases 50 percent people age 85 1 2 10 percent elderly suffer diabetes prevalence increasing 3 4 dementia diabetes common among blacks hispanics 3 7 differences predictive ability known risk factors dementia across ethnic groups 5 8 12
0.26019153.11581097.html.plaintext.txt	9	introduction top abstract introduction materials methods results discussion references dementia diabetes mellitus two prevalent problems elderly 10 percent people age 65 years develop dementia prevalence dementia increases 50 percent people age 85 1 2 10 percent elderly suffer diabetes prevalence increasing 3 4 dementia diabetes common among blacks hispanics 3 7 differences predictive ability known risk factors dementia across ethnic groups 5 8 12
0.26019153.11581097.html.plaintext.txt	10	association diabetes vascular dementia may depend presence subclinical cerebrovascular disease frank stroke 13 15 may mediated traditional cardiovascular disease risk factors specifically hyperlipidemia hypertension 16 18 relation diabetes alzheimers disease less obvious although role glycated end products pathogenesis alzheimers disease hypothesized 19 20
0.26019153.11581097.html.plaintext.txt	11	association diabetes vascular dementia may depend presence subclinical cerebrovascular disease frank stroke 13 15 may mediated traditional cardiovascular disease risk factors specifically hyperlipidemia hypertension 16 18 relation diabetes alzheimers disease less obvious although role glycated end products pathogenesis alzheimers disease hypothesized 19 20
0.26019153.11581097.html.plaintext.txt	12	several longitudinal studies demonstrated association history diabetes cognitive deficits 21 22 dementia 23 26 finding associa tion diabetes alzheimers disease inconsistent two reports rotterdam study showed relation diabetes alzheimers disease relative risks 13 95 percent confidence interval ci 10 19 19 95 percent ci 13 28 23 26 relative risk alzheimers disease among subjects treated insulin higher among subjects treated oral hypoglycemic agents compared subjects without diabetes one studies 23 recent report cohort risk alzheimers disease elevated among diabetic subjects treated insulin risk elevated among subjects treated oral hypoglycemic agents 26 one study rochester minnesota 24 reported doubling risk alzheimers disease among men diabetes compared men without diabetes relative risk 23 95 percent ci 16 33 non statistically significant increased risk among women relative risk 137 95 percent ci 09 20 another study british cohort also reported higher risk alzheimers disease among subjects diabetes compared subjects without relative risk 14 95 percent ci 11 170 25 studies relative risk alzheimers disease lower overall dementia vascular dementia risk attenuated cases stroke excluded
0.26019153.11581097.html.plaintext.txt	13	several longitudinal studies demonstrated association history diabetes cognitive deficits 21 22 dementia 23 26 finding associa tion diabetes alzheimers disease inconsistent two reports rotterdam study showed relation diabetes alzheimers disease relative risks 13 95 percent confidence interval ci 10 19 19 95 percent ci 13 28 23 26 relative risk alzheimers disease among subjects treated insulin higher among subjects treated oral hypoglycemic agents compared subjects without diabetes one studies 23 recent report cohort risk alzheimers disease elevated among diabetic subjects treated insulin risk elevated among subjects treated oral hypoglycemic agents 26 one study rochester minnesota 24 reported doubling risk alzheimers disease among men diabetes compared men without diabetes relative risk 23 95 percent ci 16 33 non statistically significant increased risk among women relative risk 137 95 percent ci 09 20 another study british cohort also reported higher risk alzheimers disease among subjects diabetes compared subjects without relative risk 14 95 percent ci 11 170 25 studies relative risk alzheimers disease lower overall dementia vascular dementia risk attenuated cases stroke excluded
0.26019153.11581097.html.plaintext.txt	14	incidence vascular dementia varies considerably depending criteria used 27 cases vascular dementia classified alzheimers disease finding weak relation diabetes alzheimers disease may due misclassification one study used sensitive criteria detection vascular dementia found association diabetes alzheimers disease relative risks alzheimers disease subjects diabetes compared subjects without diabetes 098 95 percent ci 048 199 10 95 percent ci 058 172 researchers considered 25 year history diabetes 15 year history diabetes respectively 28 thus finding relation diabetes dementia specifically alzheimers disease vascular dementia may depend criteria used define vascular dementia accuracy diagnostic procedures employed none previous studies examining relation diabetes dementia included large numbers blacks hispanics
0.26019153.11581097.html.plaintext.txt	15	incidence vascular dementia varies considerably depending criteria used 27 cases vascular dementia classified alzheimers disease finding weak relation diabetes alzheimers disease may due misclassification one study used sensitive criteria detection vascular dementia found association diabetes alzheimers disease relative risks alzheimers disease subjects diabetes compared subjects without diabetes 098 95 percent ci 048 199 10 95 percent ci 058 172 researchers considered 25 year history diabetes 15 year history diabetes respectively 28 thus finding relation diabetes dementia specifically alzheimers disease vascular dementia may depend criteria used define vascular dementia accuracy diagnostic procedures employed none previous studies examining relation diabetes dementia included large numbers blacks hispanics
0.26019153.11581097.html.plaintext.txt	16	objective study clarify association diabetes different types dementia prevalence diabetes blacks hispanics higher whites 3 4 also examined whether difference could account higher risk dementia reported non whites 5 7
0.26019153.11581097.html.plaintext.txt	17	objective study clarify association diabetes different types dementia prevalence diabetes blacks hispanics higher whites 3 4 also examined whether difference could account higher risk dementia reported non whites 5 7
0.26019153.11581097.html.plaintext.txt	18	materials methods top abstract introduction materials methods results discussion references study population participants washington heights inwood columbia aging project cohort drawn random sampling healthy medicare beneficiaries aged 65 years residing within geographically defined area northern manhattan new york city sampling procedures described elsewhere 5 subject underwent person structured interview health function time study entry followed completion standard medical history physical neurologic examinations battery neuropsychological tests 29 subjects recruited 1991 1996 followed annually evaluations used baseline repeated follow subjects followed average 43 years 1992 1997 persons completed least 1 year follow included analysis 2126 persons underwent baseline assessment 327 persons excluded prevalent dementia 537 persons available follow 141 died 396 refused follow moved 537 excluded persons slightly older analytical sample mean age 78 years vs 75 years similar regard gender ethnic distributions lower prevalence diabetes 14 percent vs 20 percent final sample comprised 1262 subjects
0.26019153.11581097.html.plaintext.txt	19	materials methods top abstract introduction materials methods results discussion references study population participants washington heights inwood columbia aging project cohort drawn random sampling healthy medicare beneficiaries aged 65 years residing within geographically defined area northern manhattan new york city sampling procedures described elsewhere 5 subject underwent person structured interview health function time study entry followed completion standard medical history physical neurologic examinations battery neuropsychological tests 29 subjects recruited 1991 1996 followed annually evaluations used baseline repeated follow subjects followed average 43 years 1992 1997 persons completed least 1 year follow included analysis 2126 persons underwent baseline assessment 327 persons excluded prevalent dementia 537 persons available follow 141 died 396 refused follow moved 537 excluded persons slightly older analytical sample mean age 78 years vs 75 years similar regard gender ethnic distributions lower prevalence diabetes 14 percent vs 20 percent final sample comprised 1262 subjects
0.26019153.11581097.html.plaintext.txt	20	diagnosis dementia cognitive impairment diagnosis dementia assignment specific cause made group neurologists psychiatrists neuropsychologists consensus basis information gathered initial visit follow visits dementia diagnosis based criteria diagnostic statistical manual mental disorders fourth edition 30 required evidence cognitive deficits neuropsychological test battery well evidence impairment social occupational functioning clinical dementia rating 05 31 diagnosis alzheimers disease based criteria national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda 32 diagnosis dementia associated stroke hereafter called stroke associated dementia made subjects dementia stroke judged main cause dementia based evidence focal effects stroke temporal relation dementia brain imaging available 85 percent cases stroke remainder world health organization criteria used define stroke 33 subjects without dementia history stroke baseline examination included analyses diagnosis cognitive impairment without dementia hereafter called nondementia cognitive impairment made neuropsychological testing detected memory impairment one standard deviation lower normal subjects age individual reported impairment mild impairment social occupational activities clinical dementia rating 05 30
0.26019153.11581097.html.plaintext.txt	21	diagnosis dementia cognitive impairment diagnosis dementia assignment specific cause made group neurologists psychiatrists neuropsychologists consensus basis information gathered initial visit follow visits dementia diagnosis based criteria diagnostic statistical manual mental disorders fourth edition 30 required evidence cognitive deficits neuropsychological test battery well evidence impairment social occupational functioning clinical dementia rating 05 31 diagnosis alzheimers disease based criteria national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda 32 diagnosis dementia associated stroke hereafter called stroke associated dementia made subjects dementia stroke judged main cause dementia based evidence focal effects stroke temporal relation dementia brain imaging available 85 percent cases stroke remainder world health organization criteria used define stroke 33 subjects without dementia history stroke baseline examination included analyses diagnosis cognitive impairment without dementia hereafter called nondementia cognitive impairment made neuropsychological testing detected memory impairment one standard deviation lower normal subjects age individual reported impairment mild impairment social occupational activities clinical dementia rating 05 30
0.26019153.11581097.html.plaintext.txt	22	diagnosis diabetes covariates presence diabetes based reported use insulin oral hypoglycemic agents clinical history diabetes hypertension heart disease smoking based self report clinical history ethnic group based self report using format 1990 us census 34 individuals asked whether hispanic origin subjects assigned one three ethnic groups non hispanic black hispanic non hispanic white years education obtained self report apolipoprotein e genotyping obtained amplification genomic dna polymerase chain reaction subjected cfoi restriction analysis using apolipoprotein e primers conditions similar described hixson vernier 35 fasting plasma total cholesterol triglyceride levels determined initial assessment using standard enzymatic techniques high density lipoprotein cholesterol determined precipitation apolipoprotein b containing lipoproteins phosphotungstic acid 36 low density lipoprotein cholesterol levels calculated using formula friedewald et al 37
0.26019153.11581097.html.plaintext.txt	23	diagnosis diabetes covariates presence diabetes based reported use insulin oral hypoglycemic agents clinical history diabetes hypertension heart disease smoking based self report clinical history ethnic group based self report using format 1990 us census 34 individuals asked whether hispanic origin subjects assigned one three ethnic groups non hispanic black hispanic non hispanic white years education obtained self report apolipoprotein e genotyping obtained amplification genomic dna polymerase chain reaction subjected cfoi restriction analysis using apolipoprotein e primers conditions similar described hixson vernier 35 fasting plasma total cholesterol triglyceride levels determined initial assessment using standard enzymatic techniques high density lipoprotein cholesterol determined precipitation apolipoprotein b containing lipoproteins phosphotungstic acid 36 low density lipoprotein cholesterol levels calculated using formula friedewald et al 37
0.26019153.11581097.html.plaintext.txt	24	data analysis prevalences diabetes covariates compared subjects without alzheimers disease subjects without stroke associated dementia continuous variables compared analysis variance categorical variables compared 2 test cox proportional hazards modeling used multivariate analyses time event variable age onset dementia models stratified year entry cohort order control period effects recommended longitudinal studies 38 one model outcome mentioned covariates treated time constant covariates using baseline values 26 255 subjects diabetes diagnosis made baseline persons treated diabetes baseline additional analysis carried treating diabetes time dependent covariate taking account date reporting diabetes diagnosis analysis conducted examine definition diabetes baseline vs follow affected analysis similar analysis carried treating variables time dependent covariates beginning exposure used beginning observation later 26 subjects diagnosed diabetes baseline compare results time constant covariate model subjects without outcome censored time last follow visit subjects type dementia different one considered specific model censored time onset dementia example alzheimers disease examined outcome persons stroke associated dementia censored time dementia onset additional analyses performed using nondementia cognitive impairment without stroke nondementia cognitive impairment stroke outcomes persons nondementia cognitive impairment baseline excluded
0.26019153.11581097.html.plaintext.txt	25	data analysis prevalences diabetes covariates compared subjects without alzheimers disease subjects without stroke associated dementia continuous variables compared analysis variance categorical variables compared 2 test cox proportional hazards modeling used multivariate analyses time event variable age onset dementia models stratified year entry cohort order control period effects recommended longitudinal studies 38 one model outcome mentioned covariates treated time constant covariates using baseline values 26 255 subjects diabetes diagnosis made baseline persons treated diabetes baseline additional analysis carried treating diabetes time dependent covariate taking account date reporting diabetes diagnosis analysis conducted examine definition diabetes baseline vs follow affected analysis similar analysis carried treating variables time dependent covariates beginning exposure used beginning observation later 26 subjects diagnosed diabetes baseline compare results time constant covariate model subjects without outcome censored time last follow visit subjects type dementia different one considered specific model censored time onset dementia example alzheimers disease examined outcome persons stroke associated dementia censored time dementia onset additional analyses performed using nondementia cognitive impairment without stroke nondementia cognitive impairment stroke outcomes persons nondementia cognitive impairment baseline excluded
0.26019153.11581097.html.plaintext.txt	26	population attributable risk par diabetes relation dementia calculated ethnic group using formula par prhr 11 prhr 1 hr adjusted hazard ratio obtained multivariate models pr prevalence diabetes ethnic group cohort 95 percent confidence intervals calculated population attributable risk using methods described prospective studies 39 sas windows version 7 sas institute inc cary north carolina used analyses
0.26019153.11581097.html.plaintext.txt	27	population attributable risk par diabetes relation dementia calculated ethnic group using formula par prhr 11 prhr 1 hr adjusted hazard ratio obtained multivariate models pr prevalence diabetes ethnic group cohort 95 percent confidence intervals calculated population attributable risk using methods described prospective studies 39 sas windows version 7 sas institute inc cary north carolina used analyses
0.26019153.11581097.html.plaintext.txt	28	results top abstract introduction materials methods results discussion references mean age cohort 756 years standard deviation 59 689 percent subjects women forty five percent subjects hispanic 32 percent black prevalence diabetes 96 percent whites 212 percent blacks 241 percent hispanics 213 incident cases dementia cohort 157 cases 74 percent due alzheimers disease 36 cases 17 percent due stroke 20 cases 9 percent due causes incidence dementia 14 per 1000 person years whites 33 cases 23 alzheimers disease four stroke associated dementia six 24 per 1000 person years blacks 80 cases 62 alzheimers disease 14 stroke associated dementia four 23 per 1000 person years hispanics 100 cases 72 alzheimers disease 18 stroke associated dementia 10
0.26019153.11581097.html.plaintext.txt	29	table 1 shows comparison characteristics subjects sample subjects alzheimers disease stroke associated dementia nondementia cognitive impairment without stroke nondementia cognitive impairment stroke persons alzheimers disease older fewer years education higher proportion blacks higher prevalence heart disease persons without alzheimers disease persons stroke associated dementia older higher prevalence diabetes higher level low density lipoprotein cholesterol higher prevalence hypertension higher prevalence heart disease persons without stroke associated dementia exclusion 174 cases nondementia cognitive impairment baseline 1088 persons left analysis nondementia cognitive impairment persons nondementia cognitive impairment without stroke older fewer years education higher proportion ever smokers higher proportion hispanics persons without persons nondementia cognitive impairment stroke higher prevalence hypertension heart disease persons without
0.26019153.11581097.html.plaintext.txt	30	table 1 shows comparison characteristics subjects sample subjects alzheimers disease stroke associated dementia nondementia cognitive impairment without stroke nondementia cognitive impairment stroke persons alzheimers disease older fewer years education higher proportion blacks higher prevalence heart disease persons without alzheimers disease persons stroke associated dementia older higher prevalence diabetes higher level low density lipoprotein cholesterol higher prevalence hypertension higher prevalence heart disease persons without stroke associated dementia exclusion 174 cases nondementia cognitive impairment baseline 1088 persons left analysis nondementia cognitive impairment persons nondementia cognitive impairment without stroke older fewer years education higher proportion ever smokers higher proportion hispanics persons without persons nondementia cognitive impairment stroke higher prevalence hypertension heart disease persons without
0.26019153.11581097.html.plaintext.txt	31	view table table 1 characteristics subjects baseline washington heights inwood columbia aging project new york city 1991 1996
0.26019153.11581097.html.plaintext.txt	32	multivariate adjusted hazard ratio alzheimers disease relation diabetes compared absence diabetes 13 95 percent ci 08 19 hazard ratio stroke associated dementia relation diabetes 34 95 percent ci 17 69 table 2 population attributable risk diabetes relation stroke associated dementia 36 percent 95 percent ci 33 37 among hispanics 33 percent 95 percent ci 31 36 among non hispanic blacks 17 percent 95 percent ci 13 22 among non hispanic whites
0.26019153.11581097.html.plaintext.txt	33	view table table 2 hazard ratios dementia cognitive impairment persons diabetes mellitus compared persons without diabetes washington heights inwood columbia aging project new york city 1992 1997
0.26019153.11581097.html.plaintext.txt	34	hazard ratio nondementia cognitive impairment without stroke persons diabetes compared persons without diabetes 13 95 percent ci 08 19 hazard ratio nondementia cognitive impairment stroke relation diabetes 16 95 percent ci 06 44 table 2 persons nondementia cognitive impairment increased risk developing alzheimers disease compared persons without nondementia cognitive impairment 40 therefore conducted analysis examining relation diabetes composite outcome alzheimers disease nondementia cognitive impairment without stroke hazard ratio composite outcome relation diabetes compared absence diabetes 16 95 percent ci 12 21
0.26019153.11581097.html.plaintext.txt	35	performed subgroup analysis examining relation diabetes stroke associated dementia 184 persons stroke estimate effect diabetes independent stroke adjusted hazard ratio stroke associated dementia relation diabetes compared absence diabetes 18 95 percent ci 08 41
0.26019153.11581097.html.plaintext.txt	36	performed subgroup analysis examining relation diabetes stroke associated dementia 184 persons stroke estimate effect diabetes independent stroke adjusted hazard ratio stroke associated dementia relation diabetes compared absence diabetes 18 95 percent ci 08 41
0.26019153.11581097.html.plaintext.txt	37	performed another analysis reclassifying 19 cases alzheimers disease stroke cases stroke associated dementia hazard ratio alzheimers disease relation diabetes compared absence diabetes unchanged relative risk 13 95 percent ci 083 194 hazard ratio alzheimers disease relation diabetes also remained unchanged excluded cases stroke analysis
0.26019153.11581097.html.plaintext.txt	38	performed additional analysis examining effect diabetes treatment relation diabetes alzheimers disease previous studies reported increased risk alzheimers disease among subjects treated insulin smaller increase increase risk among subjects using oral hypoglycemic agents comparison subjects without diabetes 23 26 models built including dummy variables insulin oral hypoglycemic agents subjects without diabetes used reference group hazard ratio alzheimers disease relation diabetes compared absence diabetes 14 95 percent ci 061 324 persons reporting insulin use 12 95 percent ci 066 20 persons reporting use oral hypoglycemic agents hazard ratio stroke associated dementia among insulin using subjects diabetes 39 95 percent ci 129 1156 hazard ratio among diabetic subjects using oral hypoglycemic agents 26 95 percent ci 100 653 hazard ratios composite outcome alzheimers disease nondementia cognitive impairment without stroke among subjects using insulin subjects using oral hypoglycemic agents compared subjects without diabetes materially different hazard ratio subjects diabetes
0.26019153.11581097.html.plaintext.txt	39	performed additional analysis examining effect diabetes treatment relation diabetes alzheimers disease previous studies reported increased risk alzheimers disease among subjects treated insulin smaller increase increase risk among subjects using oral hypoglycemic agents comparison subjects without diabetes 23 26 models built including dummy variables insulin oral hypoglycemic agents subjects without diabetes used reference group hazard ratio alzheimers disease relation diabetes compared absence diabetes 14 95 percent ci 061 324 persons reporting insulin use 12 95 percent ci 066 20 persons reporting use oral hypoglycemic agents hazard ratio stroke associated dementia among insulin using subjects diabetes 39 95 percent ci 129 1156 hazard ratio among diabetic subjects using oral hypoglycemic agents 26 95 percent ci 100 653 hazard ratios composite outcome alzheimers disease nondementia cognitive impairment without stroke among subjects using insulin subjects using oral hypoglycemic agents compared subjects without diabetes materially different hazard ratio subjects diabetes
0.26019153.11581097.html.plaintext.txt	40	models covariates hypertension diabetes treated time constant covariates assume lifetime exposure may thereby overestimated exposure therefore also fitted models specifying covariates time dependent covariates beginning exposure set beginning observation 255 subjects diabetes cohort 26 diagnosis diabetes made baseline examination thus fitted another model time dependent covariates taking account time diabetes diagnosis 26 subjects hazard ratios two models using time dependent covariates close main models
0.26019153.11581097.html.plaintext.txt	41	models covariates hypertension diabetes treated time constant covariates assume lifetime exposure may thereby overestimated exposure therefore also fitted models specifying covariates time dependent covariates beginning exposure set beginning observation 255 subjects diabetes cohort 26 diagnosis diabetes made baseline examination thus fitted another model time dependent covariates taking account time diabetes diagnosis 26 subjects hazard ratios two models using time dependent covariates close main models
0.26019153.11581097.html.plaintext.txt	42	discussion top abstract introduction materials methods results discussion references longitudinal data 1262 subjects multiethnic community cohort 43 years follow diabetes related stroke associated dementia hazard ratio 34 95 percent ci 170 691 composite outcome alzheimers disease cognitive deficit without dementia without stroke hazard ratio 16 95 percent ci 121 210 association diabetes incident alzheimers disease statistically significant hazard ratio 13 95 percent ci 084 188 relations diabetes nondementia cognitive impairment without stroke paralleled relations diabetes stroke associated dementia alzheimers disease respectively population attributable risk diabetes relation stroke associated dementia varied ethnic group approximately twice great hispanics blacks whites
0.26019153.11581097.html.plaintext.txt	43	discussion top abstract introduction materials methods results discussion references longitudinal data 1262 subjects multiethnic community cohort 43 years follow diabetes related stroke associated dementia hazard ratio 34 95 percent ci 170 691 composite outcome alzheimers disease cognitive deficit without dementia without stroke hazard ratio 16 95 percent ci 121 210 association diabetes incident alzheimers disease statistically significant hazard ratio 13 95 percent ci 084 188 relations diabetes nondementia cognitive impairment without stroke paralleled relations diabetes stroke associated dementia alzheimers disease respectively population attributable risk diabetes relation stroke associated dementia varied ethnic group approximately twice great hispanics blacks whites
0.26019153.11581097.html.plaintext.txt	44	risk vascular dementia increases greatly stroke 13 14 may caused large small vessel disease 18 41 associated diabetes likely diabetes affects risk vascular dementia partly contributing dyslipidemia hypertension hyperlipidemia hypertension reported investigators associated vascular dementia 17 41 43 associations also present data strong though statistically nonsignificant hazard ratio stroke associated dementia diabetic persons compared nondiabetic persons among subjects stroke hazard ratio 18 95 percent ci 08 41 suggests diabetes contributes risk stroke associated dementia additional mechanisms one mechanism proposed diabetes related impairment cerebral vasoreactivity accompanying changes blood flow 44 45
0.26019153.11581097.html.plaintext.txt	45	risk vascular dementia increases greatly stroke 13 14 may caused large small vessel disease 18 41 associated diabetes likely diabetes affects risk vascular dementia partly contributing dyslipidemia hypertension hyperlipidemia hypertension reported investigators associated vascular dementia 17 41 43 associations also present data strong though statistically nonsignificant hazard ratio stroke associated dementia diabetic persons compared nondiabetic persons among subjects stroke hazard ratio 18 95 percent ci 08 41 suggests diabetes contributes risk stroke associated dementia additional mechanisms one mechanism proposed diabetes related impairment cerebral vasoreactivity accompanying changes blood flow 44 45
0.26019153.11581097.html.plaintext.txt	46	mechanisms underlying possible association diabetes alzheimers disease remain unclear one possibility production glycation end products 19 20 however reductions plasma amyloid precursor protein reported elevation plasma levels glucose insulin 46 insulin reported decrease ss amyloid neurotoxicity vitro 47 findings raise possibility hyperinsulinemia one characteristics type ii diabetes may decrease deposition amyloid protein brain key step pathogenesis alzheimers disease 48 53 mechanisms underlying weak relation diabetes alzheimers disease remain clarified
0.26019153.11581097.html.plaintext.txt	47	mechanisms underlying possible association diabetes alzheimers disease remain unclear one possibility production glycation end products 19 20 however reductions plasma amyloid precursor protein reported elevation plasma levels glucose insulin 46 insulin reported decrease ss amyloid neurotoxicity vitro 47 findings raise possibility hyperinsulinemia one characteristics type ii diabetes may decrease deposition amyloid protein brain key step pathogenesis alzheimers disease 48 53 mechanisms underlying weak relation diabetes alzheimers disease remain clarified
0.26019153.11581097.html.plaintext.txt	48	three longitudinal studies reported increased risk dementia including alzheimers disease among persons diabetes 23 26 two studies used nincds adrda criteria diagnosis alzheimers disease 23 25 26 one showed risk alzheimers disease lower risk overall dementia persons diabetes 25 showed risk alzheimers disease subjects decreased excluding subjects stroke although risk remained significant 26 third study used criteria diagnostic statistical manual mental disorders third edition revised diagnosis dementia based medical record review autopsy data 24 studies limited ability detect vascular dementia definition vascular dementia controversial depending criteria used incidence vascular dementia vary severalfold 27 cases stroke associated dementia misclassified cases alzheimers disease risk factors stroke associated dementia appear predict alzheimers disease one study used nincds adrda criteria diagnosis alzheimers disease criteria california state alzheimers disease diagnostic treatment centers diagnosis vascular dementia found relation diabetes vascular dementia alzheimers disease 28
0.26019153.11581097.html.plaintext.txt	49	three longitudinal studies reported increased risk dementia including alzheimers disease among persons diabetes 23 26 two studies used nincds adrda criteria diagnosis alzheimers disease 23 25 26 one showed risk alzheimers disease lower risk overall dementia persons diabetes 25 showed risk alzheimers disease subjects decreased excluding subjects stroke although risk remained significant 26 third study used criteria diagnostic statistical manual mental disorders third edition revised diagnosis dementia based medical record review autopsy data 24 studies limited ability detect vascular dementia definition vascular dementia controversial depending criteria used incidence vascular dementia vary severalfold 27 cases stroke associated dementia misclassified cases alzheimers disease risk factors stroke associated dementia appear predict alzheimers disease one study used nincds adrda criteria diagnosis alzheimers disease criteria california state alzheimers disease diagnostic treatment centers diagnosis vascular dementia found relation diabetes vascular dementia alzheimers disease 28
0.26019153.11581097.html.plaintext.txt	50	criteria california alzheimers disease diagnostic treatment centers sensitive diagnosis vascular dementia 27 would therefore classify fewer cases stroke associated dementia cases alzheimers disease thus appears relation diabetes alzheimers disease sensitive criteria used define vascular dementia addressed issue reclassifying subjects alzheimers disease also stroke subjects stroke associated dementia including cases temporal relation dementia stroke unclear hazard ratios analysis remained essentially unchanged criteria diagnosis stroke associated dementia used last analysis consistent national institute neurological disorders stroke association internationale pour la recherche et lenseignement en neurosciences ninds airen 54 ninds airen criteria sensitive detection vascular dementia california criteria used study found relation diabetes alzheimers disease 27 however misclassification cases stroke associated dementia cases alzheimers disease unlikely explanation finding relation diabetes alzheimers disease results unchanged exclusion stroke cases analyses reclassification dementia subtypes described finding slightly greater risk alzheimers disease among subjects using insulin among using oral hypoglycemic agents consistent findings rotterdam study 23 26 may reflect possibility diabetic subjects used insulin severe prolonged diabetes
0.26019153.11581097.html.plaintext.txt	51	criteria california alzheimers disease diagnostic treatment centers sensitive diagnosis vascular dementia 27 would therefore classify fewer cases stroke associated dementia cases alzheimers disease thus appears relation diabetes alzheimers disease sensitive criteria used define vascular dementia addressed issue reclassifying subjects alzheimers disease also stroke subjects stroke associated dementia including cases temporal relation dementia stroke unclear hazard ratios analysis remained essentially unchanged criteria diagnosis stroke associated dementia used last analysis consistent national institute neurological disorders stroke association internationale pour la recherche et lenseignement en neurosciences ninds airen 54 ninds airen criteria sensitive detection vascular dementia california criteria used study found relation diabetes alzheimers disease 27 however misclassification cases stroke associated dementia cases alzheimers disease unlikely explanation finding relation diabetes alzheimers disease results unchanged exclusion stroke cases analyses reclassification dementia subtypes described finding slightly greater risk alzheimers disease among subjects using insulin among using oral hypoglycemic agents consistent findings rotterdam study 23 26 may reflect possibility diabetic subjects used insulin severe prolonged diabetes
0.26019153.11581097.html.plaintext.txt	52	performed additional analyses using nondementia cognitive impairment outcome analyses yielded results similar dementia inconsistent reports association diabetes cognitive impairment 21 22 55 subjects cognitive deficits functional disability determined higher risk dementia 40 thus association diabetes cognitive impairment would expected similar diabetes dementia findings nondementia cognitive impairment support results main analyses
0.26019153.11581097.html.plaintext.txt	53	performed additional analyses using nondementia cognitive impairment outcome analyses yielded results similar dementia inconsistent reports association diabetes cognitive impairment 21 22 55 subjects cognitive deficits functional disability determined higher risk dementia 40 thus association diabetes cognitive impairment would expected similar diabetes dementia findings nondementia cognitive impairment support results main analyses
0.26019153.11581097.html.plaintext.txt	54	one explanation finding nonsignificant weak association diabetes alzheimers disease may relation truly exists study lacked statistical power detect analysis using composite outcome alzheimers disease nondementia cognitive impairment without stroke showing statistically significant association diabetes compared absence diabetes hazard ratio 16 95 percent ci 121 210 consistent interpretation another possible explanation nonsignificant finding misclassification error diabetes alzheimers disease may diluted relation diabetes alzheimers disease self reported diabetes used study almost certainly underestimated true prevalence diabetes true prevalence reported twice prevalence self reported disease subjects undiagnosed diabetes considered 3
0.26019153.11581097.html.plaintext.txt	55	one explanation finding nonsignificant weak association diabetes alzheimers disease may relation truly exists study lacked statistical power detect analysis using composite outcome alzheimers disease nondementia cognitive impairment without stroke showing statistically significant association diabetes compared absence diabetes hazard ratio 16 95 percent ci 121 210 consistent interpretation another possible explanation nonsignificant finding misclassification error diabetes alzheimers disease may diluted relation diabetes alzheimers disease self reported diabetes used study almost certainly underestimated true prevalence diabetes true prevalence reported twice prevalence self reported disease subjects undiagnosed diabetes considered 3
0.26019153.11581097.html.plaintext.txt	56	study important strengths longitudinal study nondemented elderly subjects three ethnic groups used standardized procedures diagnosis dementia subtypes prospective fashion main limitations study lack data duration diabetes severity diabetes presence undiagnosed diabetes multivariate models assumed lifetime duration exposure could resulted error measurement exposures diabetes lipid levels hypertension however noted appreciably affect hazard ratios diabetes relation alzheimers disease stroke associated dementia
0.26019153.11581097.html.plaintext.txt	57	study important strengths longitudinal study nondemented elderly subjects three ethnic groups used standardized procedures diagnosis dementia subtypes prospective fashion main limitations study lack data duration diabetes severity diabetes presence undiagnosed diabetes multivariate models assumed lifetime duration exposure could resulted error measurement exposures diabetes lipid levels hypertension however noted appreciably affect hazard ratios diabetes relation alzheimers disease stroke associated dementia
0.26019153.11581097.html.plaintext.txt	58	findings study support previous longitudinal studies reported weak association diabetes alzheimers disease strong association diabetes stroke associated dementia extend observations minority population groups population attributable risk diabetes relation stroke associated dementia significantly greater blacks hispanics whites
0.26019153.11581097.html.plaintext.txt	59	findings study support previous longitudinal studies reported weak association diabetes alzheimers disease strong association diabetes stroke associated dementia extend observations minority population groups population attributable risk diabetes relation stroke associated dementia significantly greater blacks hispanics whites
0.26019153.11581097.html.plaintext.txt	60	acknowledgments support work provided grants national institute aging ag07232 ag08702 charles robertson memorial gift fund research alzheimers disease blanchette hooker rockefeller foundation
0.26019153.11581097.html.plaintext.txt	61	acknowledgments support work provided grants national institute aging ag07232 ag08702 charles robertson memorial gift fund research alzheimers disease blanchette hooker rockefeller foundation
0.26019153.11581097.html.plaintext.txt	62	notes reprint requests dr richard mayeux gertrude h sergievsky center ph 19 columbia university 630 west 168th street new york ny 10032 e mail rpm2atcolumbiaedurpm2columbiaedu
0.26019153.11581097.html.plaintext.txt	63	references top abstract introduction materials methods results discussion references evans da funkenstein hh albert ms et al prevalence alzheimers disease community population older persons higher previously reported jama 19892622551 6abstract geldmacher ds whitehouse pj evaluation dementia n engl j med 1996335330 6free full text harris mi flegal km cowie cc et al prevalence diabetes impaired fasting glucose impaired glucose tolerance us adults third national health nutrition examination survey 1988 1994 diabetes care 199821518 24abstract harris mi diabetes america epidemiology scope problem diabetes care 199821suppl 3c11 14isimedline tang m stern y marder k et al apoe 4 allele risk alzheimers disease among african americans whites hispanics jama 1998279751 5abstractfree full text gurland b wilder d lantigua r et al relative rates dementia multiple case definitions 2 prevalence periods 3 cultural groups j geriatr psychiatry 199536 12isi gurland bj wilder de lantigua r et al differences rates dementia ethnoracial groups martin lg soldo bj eds racial ethnic difference health older americans washington dc national academy press 1997 232 68 mayeux r stern y ottman r et al apolipoprotein 4 allele patients alzheimers disease ann neurol 199334752 4isimedline maestre g ottman r stern y et al apolipoprotein e alzheimers disease ethnic variation genotypic risks ann neurol 199537254 9isimedline tang m x maestre g tsai w y et al relative risk alzheimers disease age onset base apoe genotypes among elderly african americans caucasians hispanics new york city j hum genet 199658554 74 sahota yang m gao et al apolipoprotein e associated risk alzheimers disease african american population genotype dependent ann neurol 199742659 61isimedline osuntukun bo sahota ogunniyi ao et al lack association apolipoprotein e 4 alzheimers disease elderly nigerians ann neurol 199538463 5isimedline tatemichi tk desmond dw mayeux r et al dementia stroke baseline frequency risks clinical features hospitalized cohort neurology 1992421185 93abstract tatemichi tk paik m bagiella e et al risk dementia stroke hospitalized cohort results longitudinal study neurology 1994441885 91abstract esiri mm wilcock gk morris jh neuropathological assessment lesions significance vascular dementia j neurol neurosurg psychiatry 199763749 53abstractfree full text moroney jt tang m berglund l et al low density lipoprotein cholesterol risk dementia stroke jama 1999282254 60abstractfree full text gorelick pb status risk factors dementia associated stroke stroke 199728459 63abstractfree full text oleary dh polak jf kronmal r et al distribution correlates sonographically detected carotid artery disease cardiovascular health study cardiovascular health study collaborative group stroke 1992231752 60abstract sasaki n fukatsu r tsusuki k et al advanced glycation end products alzheimers disease neurodegenerative diseases j pathol 19981531149 55abstractfree full text smith ma sayre lm perry g diabetes alzheimers disease glycation biochemical link letter diabetologia 199639247medline elias pk elias mf dagostino rb et al niddm blood pressure risk factors poor cognitive performance framingham study diabetes care 1997201388 95abstract gregg ew yaffe k cauley ja et al diabetes associated cognitive impairment cognitive decline among older women arch intern med 2000160174 80abstractfree full text ott stolk rp hoffman et al association diabetes mellitus dementia rotterdam study diabetologia 1996391392 7isimedline leibson cl rocca wa hanson va et al risk dementia among persons diabetes mellitus population based cohort study j epidemiol 1997145301 8abstract brayne c gill c huppert fa et al vascular risks incident dementia results cohort study old dement geriatr cogn disord 19989175 80isimedline ott stolk rp van harskamp f et al diabetes mellitus risk dementia rotterdam study neurology 1999531937 42abstractfree full text chui hc mack w jackson e et al clinical criteria diagnosis vascular dementia multicenter study comparability interrater reliability arch neurol 200057191 6abstractfree full text curb jd rodriguez bl abbott rd et al longitudinal association vascular alzheimers dementias diabetes glucose tolerance neurology 199952971 5abstractfree full text stern y andrews h pittman j et al diagnosis dementia heterogeneous population development neuropsychological paradigm quantified correction education arch neurol 199249453 60abstract american psychiatric association diagnostic statistical manual mental disorders fourth edition dsm iv washington dc american psychiatric association 1994143 7 hughes cp berg l danzinger w et al new clinical scale staging dementia br j psychiatry 1982140566 72abstract mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract world health organization icd 10 classification mental behavioral disorders diagnostic criteria research geneva switzerland world health organization 199336 40 bureau census 1990 census population housing summary tape file 1 technical documentation stf 1a database computer diskette washington dc bureau census us department commerce 1991 hixson j vernier d restriction isotyping human lipoprotein e gene amplification cleavage hhai j lipid res 199131545 8abstract lopes virella mf stone p ellis et al cholesterol determination high density lipoproteins separated three different methods clin chem 197723882 4abstractfree full text friedewald wt levy ri frederickson ds estimation concentration low density lipoprotein cholesterol plasma without use preparative ultracentrifuge clin chem 197218499 502abstractfree full text korn el graubard bi midthune d time event analysis longitudinal follow survey choice time scale j epidemiol 199714572 80abstract kahn ha sempos ct statistical methods epidemiology new york ny oxford university press 198972 84 ritchie k touchon j mild cognitive impairment conceptual basis current nosological status lancet 2000355225 8isimedline mast h thompson jl lee sh et al hypertension diabetes mellitus determinants multiple lacunar infarcts stroke 19952630 3abstractfree full text tatemichi tk desmond dw paik m et al clinical determinants dementia related stroke ann neurol 199333568 75isimedline desmond dw tatemichi tk paik m et al risk factors cerebrovascular disease correlates cognitive function stroke free cohort arch neurol 199350162 6abstract albert sg gomez cr russell et al cerebral ophthalmic artery hemodynamic responses diabetes mellitus diabetes care 199316476 82abstract fulesdi b limburg m bereczki d et al impairment cerebrovascular reactivity long term type 1 diabetes diabetes 1997461840 5abstract boyt aa taddei k hallmayer j et al effect insulin glucose plasma concentration alzheimers amyloid precursor protein neuroscience 200095727 34isimedline takadera sakura n mohri et al toxic effects beta amyloid peptide beta 22 35 hippocampal neuron prevention neuroscience 199316141 4 ko l sheu kr blass jp inmunohistochemical colocalization amyloid precursor protein cerebrovascular amyloid alzheimers disease j pathol 1991139523 33abstract martins rn robinson pj chleboun jp et al molecular pathology amyloid deposition alzheimers disease mol neurobiol 19915389 98isimedline masters cl multhaup g simms g et al neuronal origin cerebral amyloid neurofibrillary tangles alzheimers disease contain protein amyloid plaque cores blood vessels eur mol biol org 198542757 63abstract masters cl simms g weinman na et al amyloid plaque core protein alzheimers disease downs syndrome proc natl acad sci u 1985824245 9abstract murphy m molecular pathogenesis alzheimers disease clinical prospects lancet 19923401512 15isimedline naslund j haroutunian v mohs r et al correlation elevated levels amyloid ss peptide brain cognitive decline jama 20002831571 7abstractfree full text roman gc tatemichi tk erkinjuntti et al vascular dementia diagnostic criteria research studies report ninds airen international workshop neurology 199343 250 60abstract vanhanen m kuusisto j koivisto k et al type 2 diabetes cognitive function non demented population acta neurol scand 199910097 101isimedline received publication august 18 2000 accepted publication april 16 2001
0.26019153.11581097.html.plaintext.txt	64	references top abstract introduction materials methods results discussion references evans da funkenstein hh albert ms et al prevalence alzheimers disease community population older persons higher previously reported jama 19892622551 6abstract geldmacher ds whitehouse pj evaluation dementia n engl j med 1996335330 6free full text harris mi flegal km cowie cc et al prevalence diabetes impaired fasting glucose impaired glucose tolerance us adults third national health nutrition examination survey 1988 1994 diabetes care 199821518 24abstract harris mi diabetes america epidemiology scope problem diabetes care 199821suppl 3c11 14isimedline tang m stern y marder k et al apoe 4 allele risk alzheimers disease among african americans whites hispanics jama 1998279751 5abstractfree full text gurland b wilder d lantigua r et al relative rates dementia multiple case definitions 2 prevalence periods 3 cultural groups j geriatr psychiatry 199536 12isi gurland bj wilder de lantigua r et al differences rates dementia ethnoracial groups martin lg soldo bj eds racial ethnic difference health older americans washington dc national academy press 1997 232 68 mayeux r stern y ottman r et al apolipoprotein 4 allele patients alzheimers disease ann neurol 199334752 4isimedline maestre g ottman r stern y et al apolipoprotein e alzheimers disease ethnic variation genotypic risks ann neurol 199537254 9isimedline tang m x maestre g tsai w y et al relative risk alzheimers disease age onset base apoe genotypes among elderly african americans caucasians hispanics new york city j hum genet 199658554 74 sahota yang m gao et al apolipoprotein e associated risk alzheimers disease african american population genotype dependent ann neurol 199742659 61isimedline osuntukun bo sahota ogunniyi ao et al lack association apolipoprotein e 4 alzheimers disease elderly nigerians ann neurol 199538463 5isimedline tatemichi tk desmond dw mayeux r et al dementia stroke baseline frequency risks clinical features hospitalized cohort neurology 1992421185 93abstract tatemichi tk paik m bagiella e et al risk dementia stroke hospitalized cohort results longitudinal study neurology 1994441885 91abstract esiri mm wilcock gk morris jh neuropathological assessment lesions significance vascular dementia j neurol neurosurg psychiatry 199763749 53abstractfree full text moroney jt tang m berglund l et al low density lipoprotein cholesterol risk dementia stroke jama 1999282254 60abstractfree full text gorelick pb status risk factors dementia associated stroke stroke 199728459 63abstractfree full text oleary dh polak jf kronmal r et al distribution correlates sonographically detected carotid artery disease cardiovascular health study cardiovascular health study collaborative group stroke 1992231752 60abstract sasaki n fukatsu r tsusuki k et al advanced glycation end products alzheimers disease neurodegenerative diseases j pathol 19981531149 55abstractfree full text smith ma sayre lm perry g diabetes alzheimers disease glycation biochemical link letter diabetologia 199639247medline elias pk elias mf dagostino rb et al niddm blood pressure risk factors poor cognitive performance framingham study diabetes care 1997201388 95abstract gregg ew yaffe k cauley ja et al diabetes associated cognitive impairment cognitive decline among older women arch intern med 2000160174 80abstractfree full text ott stolk rp hoffman et al association diabetes mellitus dementia rotterdam study diabetologia 1996391392 7isimedline leibson cl rocca wa hanson va et al risk dementia among persons diabetes mellitus population based cohort study j epidemiol 1997145301 8abstract brayne c gill c huppert fa et al vascular risks incident dementia results cohort study old dement geriatr cogn disord 19989175 80isimedline ott stolk rp van harskamp f et al diabetes mellitus risk dementia rotterdam study neurology 1999531937 42abstractfree full text chui hc mack w jackson e et al clinical criteria diagnosis vascular dementia multicenter study comparability interrater reliability arch neurol 200057191 6abstractfree full text curb jd rodriguez bl abbott rd et al longitudinal association vascular alzheimers dementias diabetes glucose tolerance neurology 199952971 5abstractfree full text stern y andrews h pittman j et al diagnosis dementia heterogeneous population development neuropsychological paradigm quantified correction education arch neurol 199249453 60abstract american psychiatric association diagnostic statistical manual mental disorders fourth edition dsm iv washington dc american psychiatric association 1994143 7 hughes cp berg l danzinger w et al new clinical scale staging dementia br j psychiatry 1982140566 72abstract mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract world health organization icd 10 classification mental behavioral disorders diagnostic criteria research geneva switzerland world health organization 199336 40 bureau census 1990 census population housing summary tape file 1 technical documentation stf 1a database computer diskette washington dc bureau census us department commerce 1991 hixson j vernier d restriction isotyping human lipoprotein e gene amplification cleavage hhai j lipid res 199131545 8abstract lopes virella mf stone p ellis et al cholesterol determination high density lipoproteins separated three different methods clin chem 197723882 4abstractfree full text friedewald wt levy ri frederickson ds estimation concentration low density lipoprotein cholesterol plasma without use preparative ultracentrifuge clin chem 197218499 502abstractfree full text korn el graubard bi midthune d time event analysis longitudinal follow survey choice time scale j epidemiol 199714572 80abstract kahn ha sempos ct statistical methods epidemiology new york ny oxford university press 198972 84 ritchie k touchon j mild cognitive impairment conceptual basis current nosological status lancet 2000355225 8isimedline mast h thompson jl lee sh et al hypertension diabetes mellitus determinants multiple lacunar infarcts stroke 19952630 3abstractfree full text tatemichi tk desmond dw paik m et al clinical determinants dementia related stroke ann neurol 199333568 75isimedline desmond dw tatemichi tk paik m et al risk factors cerebrovascular disease correlates cognitive function stroke free cohort arch neurol 199350162 6abstract albert sg gomez cr russell et al cerebral ophthalmic artery hemodynamic responses diabetes mellitus diabetes care 199316476 82abstract fulesdi b limburg m bereczki d et al impairment cerebrovascular reactivity long term type 1 diabetes diabetes 1997461840 5abstract boyt aa taddei k hallmayer j et al effect insulin glucose plasma concentration alzheimers amyloid precursor protein neuroscience 200095727 34isimedline takadera sakura n mohri et al toxic effects beta amyloid peptide beta 22 35 hippocampal neuron prevention neuroscience 199316141 4 ko l sheu kr blass jp inmunohistochemical colocalization amyloid precursor protein cerebrovascular amyloid alzheimers disease j pathol 1991139523 33abstract martins rn robinson pj chleboun jp et al molecular pathology amyloid deposition alzheimers disease mol neurobiol 19915389 98isimedline masters cl multhaup g simms g et al neuronal origin cerebral amyloid neurofibrillary tangles alzheimers disease contain protein amyloid plaque cores blood vessels eur mol biol org 198542757 63abstract masters cl simms g weinman na et al amyloid plaque core protein alzheimers disease downs syndrome proc natl acad sci u 1985824245 9abstract murphy m molecular pathogenesis alzheimers disease clinical prospects lancet 19923401512 15isimedline naslund j haroutunian v mohs r et al correlation elevated levels amyloid ss peptide brain cognitive decline jama 20002831571 7abstractfree full text roman gc tatemichi tk erkinjuntti et al vascular dementia diagnostic criteria research studies report ninds airen international workshop neurology 199343 250 60abstract vanhanen m kuusisto j koivisto k et al type 2 diabetes cognitive function non demented population acta neurol scand 199910097 101isimedline received publication august 18 2000 accepted publication april 16 2001
0.26308063.11581098.html.plaintext.txt	0	mortality dementia results french prospective community based cohort
0.26308063.11581098.html.plaintext.txt	1	inserm u 330 universite de bordeaux ii bordeaux france
0.26308063.11581098.html.plaintext.txt	2	abstract top abstract introduction materials methods results discussion references despite magnitude problem little known duration dementia survival risk factors mortality dementia impact dementia risk death investigated using personnes agees quid paquid prospective population based cohort study 1988 1998 statistical models dealing interval censoring performed among 3675 participants aged 65 years older initially nondemented 2923 followed 8 years 281 persons incident dementia actively diagnosed mean age onset dementia 823 years total population relative risk dying developing dementia estimated 182 95 confidence interval ci 177 268 adjusted sociodemographic variables comorbidity deaths cerebrovascular diseases respiratory diseases particularly increased among persons dementia compared without median survival time persons dementia estimated 45 years women dementia longer survival men dementia particularly alzheimer type dementia relative risk 047 95 ci 027 083 educational level significantly associated survival persons dementia results provide evidence malignancy dementia challenge 21st century
0.26308063.11581098.html.plaintext.txt	3	abstract top abstract introduction materials methods results discussion references despite magnitude problem little known duration dementia survival risk factors mortality dementia impact dementia risk death investigated using personnes agees quid paquid prospective population based cohort study 1988 1998 statistical models dealing interval censoring performed among 3675 participants aged 65 years older initially nondemented 2923 followed 8 years 281 persons incident dementia actively diagnosed mean age onset dementia 823 years total population relative risk dying developing dementia estimated 182 95 confidence interval ci 177 268 adjusted sociodemographic variables comorbidity deaths cerebrovascular diseases respiratory diseases particularly increased among persons dementia compared without median survival time persons dementia estimated 45 years women dementia longer survival men dementia particularly alzheimer type dementia relative risk 047 95 ci 027 083 educational level significantly associated survival persons dementia results provide evidence malignancy dementia challenge 21st century
0.26308063.11581098.html.plaintext.txt	4	alzheimer disease dementia mortality prognosis
0.26308063.11581098.html.plaintext.txt	5	abbreviations cep certificat detudes primaires ci confidence interval dsm iii r diagnostic statistical manual mental disorders third edition revised paquid personnes agees quid rr relative risk
0.26308063.11581098.html.plaintext.txt	6	introduction top abstract introduction materials methods results discussion references major public health problems duration disease key factor dementia family practitioner society despite magnitude problem knowledge serious dementia consequences population remains imprecise dementia major source disability population 1 precise knowledge survival dementia useful family practitioner decide manage patient society survival time persons dementia affects burden due therefore health policy decision makers need precise data survival dementia health care planning
0.26308063.11581098.html.plaintext.txt	7	introduction top abstract introduction materials methods results discussion references major public health problems duration disease key factor dementia family practitioner society despite magnitude problem knowledge serious dementia consequences population remains imprecise dementia major source disability population 1 precise knowledge survival dementia useful family practitioner decide manage patient society survival time persons dementia affects burden due therefore health policy decision makers need precise data survival dementia health care planning
0.26308063.11581098.html.plaintext.txt	8	100 studies carried survival dementia found increased risk dying among persons dementia compared without however data often obtained community based studies selected groups institutions clinical settings cannot applied general population indeed review literature van dijk et al 2 found survival conditioned reference population lower survival studies conducted institution community based studies addition even among community based studies 2 year survival found vary 37 percent 86 percent probably depending study designs 2 majority studies conducted community based samples 3 11 based prevalent cases onset disease known onset dementia insidious progressive thus cannot determined exactly onset often considered either time first symptoms disease time first consultation however earlier one sees patient onset precise estimation onset thus onset estimated precisely incident prevalent cases
0.26308063.11581098.html.plaintext.txt	9	100 studies carried survival dementia found increased risk dying among persons dementia compared without however data often obtained community based studies selected groups institutions clinical settings cannot applied general population indeed review literature van dijk et al 2 found survival conditioned reference population lower survival studies conducted institution community based studies addition even among community based studies 2 year survival found vary 37 percent 86 percent probably depending study designs 2 majority studies conducted community based samples 3 11 based prevalent cases onset disease known onset dementia insidious progressive thus cannot determined exactly onset often considered either time first symptoms disease time first consultation however earlier one sees patient onset precise estimation onset thus onset estimated precisely incident prevalent cases
0.26308063.11581098.html.plaintext.txt	10	community based studies used incident cases dementia 12 14 dementia cases actively screened one 14 active detection dementia makes possible take account cases undiagnosed practitioner scenario frequent france 15 recent study sweden based kungsholmen project 14 risk death among alzheimers disease cases estimated 20 compared nondemented persons however latter study onset disease considered time diagnosis statistical analyses take account problem interval censoring cohort studies participants followed continually receive repeated cross sectional screenings time intervals could bias results particularly lack accuracy determination disease onset
0.26308063.11581098.html.plaintext.txt	11	community based studies used incident cases dementia 12 14 dementia cases actively screened one 14 active detection dementia makes possible take account cases undiagnosed practitioner scenario frequent france 15 recent study sweden based kungsholmen project 14 risk death among alzheimers disease cases estimated 20 compared nondemented persons however latter study onset disease considered time diagnosis statistical analyses take account problem interval censoring cohort studies participants followed continually receive repeated cross sectional screenings time intervals could bias results particularly lack accuracy determination disease onset
0.26308063.11581098.html.plaintext.txt	12	aim paper evaluate survival risk factors mortality dementia quantify impact dementia total mortality using statistical models dealing interval censoring french prospective population based cohort active search incident cases dementia follow screening
0.26308063.11581098.html.plaintext.txt	13	materials methods top abstract introduction materials methods results discussion references study population information study gathered personnes agees quid paquid cohort paquid research program prospective cohort study representative sample community residents aged 65 years living southwestern france departments gironde dordogne cohort began 1988 three criteria met inclusion least 65 years age december 31 1987 living home time initial data collection phase give written informed consent participate study sample randomly chosen electoral rolls french citizen except guardianship register three step procedure stratification size urban unit age sex used among 5554 persons selected 3777 68 percent agreed participate study 3777 participants 2792 gironde 985 dordogne representative age sex distribution elderly area 15 nonresponders differ responders age gender educational level general methodology paquid study described previously 16 ethical review committee approved paquid study
0.26308063.11581098.html.plaintext.txt	14	materials methods top abstract introduction materials methods results discussion references study population information study gathered personnes agees quid paquid cohort paquid research program prospective cohort study representative sample community residents aged 65 years living southwestern france departments gironde dordogne cohort began 1988 three criteria met inclusion least 65 years age december 31 1987 living home time initial data collection phase give written informed consent participate study sample randomly chosen electoral rolls french citizen except guardianship register three step procedure stratification size urban unit age sex used among 5554 persons selected 3777 68 percent agreed participate study 3777 participants 2792 gironde 985 dordogne representative age sex distribution elderly area 15 nonresponders differ responders age gender educational level general methodology paquid study described previously 16 ethical review committee approved paquid study
0.26308063.11581098.html.plaintext.txt	15	data collection data collected means questionnaire administered home trained psychologists initial interview included items sociodemographic characteristics objective subjective physical health functional assessment depressive symptomatology battery neuropsychological tests including evaluation global mental status mini mental state examination 17 physical health evaluated self reported diseases symptoms treated diabetes history heart disease stroke hypertension dyspnea considered variable comorbidity created participants reported history least one diseases symptoms functional status evaluated using activities daily living scale excluding item maintaining continence 18 participants needed help least one five activities classified disabled
0.26308063.11581098.html.plaintext.txt	16	data collection data collected means questionnaire administered home trained psychologists initial interview included items sociodemographic characteristics objective subjective physical health functional assessment depressive symptomatology battery neuropsychological tests including evaluation global mental status mini mental state examination 17 physical health evaluated self reported diseases symptoms treated diabetes history heart disease stroke hypertension dyspnea considered variable comorbidity created participants reported history least one diseases symptoms functional status evaluated using activities daily living scale excluding item maintaining continence 18 participants needed help least one five activities classified disabled
0.26308063.11581098.html.plaintext.txt	17	initial interview participants followed baseline procedure 1 3 5 8 years gironde 3 5 8 years dordogne
0.26308063.11581098.html.plaintext.txt	18	data vital status collected throughout follow dates causes death collected death certificates way national registry mortality statistics causes death classified according international classification diseases ninth revision 19 cancer codes 140 208 230 239 cardiovascular diseases excluding cerebrovascular diseases codes 390 427 440 455 cerebrovascular disease codes 430 438 respiratory disease codes 460 511
0.26308063.11581098.html.plaintext.txt	19	data vital status collected throughout follow dates causes death collected death certificates way national registry mortality statistics causes death classified according international classification diseases ninth revision 19 cancer codes 140 208 230 239 cardiovascular diseases excluding cerebrovascular diseases codes 390 427 440 455 cerebrovascular disease codes 430 438 respiratory disease codes 460 511
0.26308063.11581098.html.plaintext.txt	20	diagnosis dementia baseline intellectual functioning examined series psychometric tests shown among sensitive assessing cognitive decline elderly persons psychologists systematically filled standardized questionnaire designed obtain memory impairment b impairment least one cognitive function c interference social professional life criteria dementia according diagnostic statistical manual mental disorders third edition revised dsm iii r 20 second stage participants met dsm iii r criteria seen senior neurologist confirmed completed dsm iii r criteria dementia filled national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda criteria alzheimers disease 21 hachinski score vascular dementia 22 document dementia diagnosis etiology probable possible alzheimers disease vascular dementia alzheimers disease cerebrovascular disease types dementia informant consulted neurologist available ancillary information considered including medical charts brain imaging available finally consensus meeting allowed us definitely classify case comparable procedures screening dementia usually used cohort studies 23 diagnosis incident dementia cases followed procedure follow assessment baseline screening order increase screening sensitivity another criterion added qualify neurologic examination participants selected stage met b c dsm iii r criteria dementia lost three points mini mental state examination score
0.26308063.11581098.html.plaintext.txt	21	diagnosis dementia baseline intellectual functioning examined series psychometric tests shown among sensitive assessing cognitive decline elderly persons psychologists systematically filled standardized questionnaire designed obtain memory impairment b impairment least one cognitive function c interference social professional life criteria dementia according diagnostic statistical manual mental disorders third edition revised dsm iii r 20 second stage participants met dsm iii r criteria seen senior neurologist confirmed completed dsm iii r criteria dementia filled national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda criteria alzheimers disease 21 hachinski score vascular dementia 22 document dementia diagnosis etiology probable possible alzheimers disease vascular dementia alzheimers disease cerebrovascular disease types dementia informant consulted neurologist available ancillary information considered including medical charts brain imaging available finally consensus meeting allowed us definitely classify case comparable procedures screening dementia usually used cohort studies 23 diagnosis incident dementia cases followed procedure follow assessment baseline screening order increase screening sensitivity another criterion added qualify neurologic examination participants selected stage met b c dsm iii r criteria dementia lost three points mini mental state examination score
0.26308063.11581098.html.plaintext.txt	22	statistical analysis mortality dementia analyzed according age sex educational level educational level divided two categories least primary school level validated diploma certificat detudes primaires cep versus diploma 24 analyses performed dementia due causes alzheimers disease
0.26308063.11581098.html.plaintext.txt	23	statistical analysis mortality dementia analyzed according age sex educational level educational level divided two categories least primary school level validated diploma certificat detudes primaires cep versus diploma 24 analyses performed dementia due causes alzheimers disease
0.26308063.11581098.html.plaintext.txt	24	first impact mortality dementia general population considered comparing mortality among persons incident dementia without partitioning competing causes death analyzed mortality dementia among persons incident dementia 1 quantify impact dementia total mortality performed cox model delayed entry time scale age participants 25 taking occurrence dementia time dependent variable considering age onset dementia middle interval last follow without dementia first follow dementia relative risks death dementia alzheimers disease provided 95 percent confidence intervals relative risks competing causes death provided 2 mortality among persons incident dementia onset clinical stage death analyzed using multistate approach semi markov model performed statistical model dealing interval censoring common problem cohort studies indeed paquid study participants followed continuously cross sectional screenings discrete times thus onset disease known exactly information available onset occurred two follow times therefore used semi markov model includes two transitions first transition represents age specific incidence rates dementia second transition represents mortality rates persons dementia model uses information incidence data people cohort fact time onset dementia known taken account penalized likelihood approach 26
0.26308063.11581098.html.plaintext.txt	25	first impact mortality dementia general population considered comparing mortality among persons incident dementia without partitioning competing causes death analyzed mortality dementia among persons incident dementia 1 quantify impact dementia total mortality performed cox model delayed entry time scale age participants 25 taking occurrence dementia time dependent variable considering age onset dementia middle interval last follow without dementia first follow dementia relative risks death dementia alzheimers disease provided 95 percent confidence intervals relative risks competing causes death provided 2 mortality among persons incident dementia onset clinical stage death analyzed using multistate approach semi markov model performed statistical model dealing interval censoring common problem cohort studies indeed paquid study participants followed continuously cross sectional screenings discrete times thus onset disease known exactly information available onset occurred two follow times therefore used semi markov model includes two transitions first transition represents age specific incidence rates dementia second transition represents mortality rates persons dementia model uses information incidence data people cohort fact time onset dementia known taken account penalized likelihood approach 26
0.26308063.11581098.html.plaintext.txt	26	results top abstract introduction materials methods results discussion references description baseline 3777 participants included cohort among 102 already dementia excluded among 3675 initially without dementia least one complete follow examination performed 2923 795 percent 752 205 percent remaining participants participate follow died n 413 112 percent refused follow screenings n 335 91 percent participants lost follow n 4 01 percent description participants follow according sociodemographic characteristics given table 1
0.26308063.11581098.html.plaintext.txt	27	results top abstract introduction materials methods results discussion references description baseline 3777 participants included cohort among 102 already dementia excluded among 3675 initially without dementia least one complete follow examination performed 2923 795 percent 752 205 percent remaining participants participate follow died n 413 112 percent refused follow screenings n 335 91 percent participants lost follow n 4 01 percent description participants follow according sociodemographic characteristics given table 1
0.26308063.11581098.html.plaintext.txt	28	view table table 1 distribution participants interviewed follow according diagnosis dementia sociodemographic characteristics paquid cohort france 1988 1998
0.26308063.11581098.html.plaintext.txt	29	2923 reevaluated participants included 1705 583 percent women 1375 47 percent participants aged 75 years older mean delay two follow evaluations 22 years follow 281 participants developed incident dementia including 189 alzheimer type dementia 70 vascular mixed dementia 22 types dementia persons incident dementia included 183 651 percent women mean age onset dementia 80 standard deviation 59 years among men 835 standard deviation 61 years among women
0.26308063.11581098.html.plaintext.txt	30	2923 reevaluated participants included 1705 583 percent women 1375 47 percent participants aged 75 years older mean delay two follow evaluations 22 years follow 281 participants developed incident dementia including 189 alzheimer type dementia 70 vascular mixed dementia 22 types dementia persons incident dementia included 183 651 percent women mean age onset dementia 80 standard deviation 59 years among men 835 standard deviation 61 years among women
0.26308063.11581098.html.plaintext.txt	31	end study 391 percent persons dementia died versus 222 percent among without persons dementia died cardiovascular pathology 200 percent stroke 127 percent cancer 127 percent respiratory pathology 100 percent symptoms signs ill defined conditions including senile dementia 109 percent proportions respectively 323 percent 92 percent 246 percent 64 percent 72 percent persons without dementia
0.26308063.11581098.html.plaintext.txt	32	impact dementia mortality impact dementia total mortality analyzed using cox proportional hazards model delayed entry adjusted sex educational level index comorbidity baseline dependency activities daily living scale comparing participants dementia without total population relative risk dying developing dementia estimated 180 95 percent confidence interval ci 146 221 alzheimers disease risk 172 95 percent ci 134 221 however significant interaction dementia age relative risk rr 095 95 percent ci 092 098 lower impact dementia mortality increasing age relative risk dying dementia estimated 159 95 percent ci 126 201 among participants aged 75 years older 137 95 percent ci 091 204 among participants aged 85 years older risks similar men women
0.26308063.11581098.html.plaintext.txt	33	impact dementia mortality impact dementia total mortality analyzed using cox proportional hazards model delayed entry adjusted sex educational level index comorbidity baseline dependency activities daily living scale comparing participants dementia without total population relative risk dying developing dementia estimated 180 95 percent confidence interval ci 146 221 alzheimers disease risk 172 95 percent ci 134 221 however significant interaction dementia age relative risk rr 095 95 percent ci 092 098 lower impact dementia mortality increasing age relative risk dying dementia estimated 159 95 percent ci 126 201 among participants aged 75 years older 137 95 percent ci 091 204 among participants aged 85 years older risks similar men women
0.26308063.11581098.html.plaintext.txt	34	according causes death relative risks significantly increased cancer rr 122 95 percent ci 070 213 cardiovascular disease rr 112 95 percent ci 072 175 among persons dementia whereas relative risk 229 95 percent ci 126 417 cerebrovascular disease 278 95 percent ci 140 551 respiratory disease tendency alzheimers disease increased risk respiratory disease rr 282 95 percent ci 130 617 risk cerebrovascular disease reach significance rr 166 95 percent ci 075 369
0.26308063.11581098.html.plaintext.txt	35	survival dementia risk factors median survival time onset disease estimated 45 years among persons incident dementia model provides results age dementia onset chose provide results persons developing dementia 75 85 years median times survival according risk factors summarized table 2 whatever age onset dementia median times survival higher among women among men among persons alzheimers disease protective effect female sex risk dying adjusted educational level comorbidity activities daily living scale dependency time diagnosis rr 047 95 percent ci 027 083 tendency dementia causes although relative risk reach statistical significance rr 070 95 percent ci 046 108
0.26308063.11581098.html.plaintext.txt	36	survival dementia risk factors median survival time onset disease estimated 45 years among persons incident dementia model provides results age dementia onset chose provide results persons developing dementia 75 85 years median times survival according risk factors summarized table 2 whatever age onset dementia median times survival higher among women among men among persons alzheimers disease protective effect female sex risk dying adjusted educational level comorbidity activities daily living scale dependency time diagnosis rr 047 95 percent ci 027 083 tendency dementia causes although relative risk reach statistical significance rr 070 95 percent ci 046 108
0.26308063.11581098.html.plaintext.txt	37	view table table 2 median times survival persons dementia alzheimers disease according sex educational level paquid cohort france 1988 1998
0.26308063.11581098.html.plaintext.txt	38	dementia alzheimers disease median survival time shorter participants cep without dementia began 75 years difference survival observed according cep 85 years table 2 educational level significantly influence survival among persons dementia relative risk dying participants without cep estimated 100 95 percent ci 068 146 dementia 088 95 percent ci 054 142 alzheimers disease adjustment sex comorbidity activities daily living scale dependency time diagnosis modify relative risks 111 dementia 100 alzheimers disease
0.26308063.11581098.html.plaintext.txt	39	dementia alzheimers disease median survival time shorter participants cep without dementia began 75 years difference survival observed according cep 85 years table 2 educational level significantly influence survival among persons dementia relative risk dying participants without cep estimated 100 95 percent ci 068 146 dementia 088 95 percent ci 054 142 alzheimers disease adjustment sex comorbidity activities daily living scale dependency time diagnosis modify relative risks 111 dementia 100 alzheimers disease
0.26308063.11581098.html.plaintext.txt	40	although effect sex educational level seemed differ according age dementia onset significant interaction found either age sex rr 101 95 percent ci 092 110 age cep rr 101 95 percent ci 094 108
0.26308063.11581098.html.plaintext.txt	41	discussion top abstract introduction materials methods results discussion references follow 281 persons incident dementia allowed us accurately define mortality dementia general population median survival dementia 45 years survival longer women compared men particularly alzheimers disease however educational level significantly modify survival dementia relative risk dying estimated 18 persons dementia compared without among persons dementia risks dying cerebrovascular respiratory diseases particularly increased
0.26308063.11581098.html.plaintext.txt	42	discussion top abstract introduction materials methods results discussion references follow 281 persons incident dementia allowed us accurately define mortality dementia general population median survival dementia 45 years survival longer women compared men particularly alzheimers disease however educational level significantly modify survival dementia relative risk dying estimated 18 persons dementia compared without among persons dementia risks dying cerebrovascular respiratory diseases particularly increased
0.26308063.11581098.html.plaintext.txt	43	studying mortality dementia general population raises special difficulties first one needs conduct study community dementia diagnosed hospital nursing home setting representative cases general population second dementia actively screened widely underdiagnosed population 15 27 third necessary use incident cases dementia disease onset better known finally incident cases dementia followed long time observe death methodological difficulties previous studies investigated mortality dementia community using incident cases dementia 12 14 even studies onset disease difficult assess indeed unless participants screened dementia continuously onset dementia always imprecise clearly insidious onset also interval censoring last time participant considered dementia free first time diagnosed dementia thus onset estimated even incident cases dementia paquid study opportunity analyze actively screened incident cases dementia prospectively followed several years addition applied statistical models taking account fact disease onset known precisely
0.26308063.11581098.html.plaintext.txt	44	studying mortality dementia general population raises special difficulties first one needs conduct study community dementia diagnosed hospital nursing home setting representative cases general population second dementia actively screened widely underdiagnosed population 15 27 third necessary use incident cases dementia disease onset better known finally incident cases dementia followed long time observe death methodological difficulties previous studies investigated mortality dementia community using incident cases dementia 12 14 even studies onset disease difficult assess indeed unless participants screened dementia continuously onset dementia always imprecise clearly insidious onset also interval censoring last time participant considered dementia free first time diagnosed dementia thus onset estimated even incident cases dementia paquid study opportunity analyze actively screened incident cases dementia prospectively followed several years addition applied statistical models taking account fact disease onset known precisely
0.26308063.11581098.html.plaintext.txt	45	several methodological issues may influenced results twenty percent participants cohort never reevaluated among large part 55 percent died follow others refused follow examinations participants refused follow examinations could higher risk developing dementia thus nonresponse could lead underestimation incidence dementia however could bias prognosis group persons dementia mortality among persons dementia refused follow differed mortality among persons dementia evaluated unlikely
0.26308063.11581098.html.plaintext.txt	46	several methodological issues may influenced results twenty percent participants cohort never reevaluated among large part 55 percent died follow others refused follow examinations participants refused follow examinations could higher risk developing dementia thus nonresponse could lead underestimation incidence dementia however could bias prognosis group persons dementia mortality among persons dementia refused follow differed mortality among persons dementia evaluated unlikely
0.26308063.11581098.html.plaintext.txt	47	participants short survival onset dementia occurred two follow ups died rapidly onset cannot diagnosed cohort thus included survival analysis persons incident dementia studies could overestimate survival time dementia however specific illness death model dealing interval censoring taking account cases dementia short survival could establish extent survival overestimated model developed
0.26308063.11581098.html.plaintext.txt	48	participants short survival onset dementia occurred two follow ups died rapidly onset cannot diagnosed cohort thus included survival analysis persons incident dementia studies could overestimate survival time dementia however specific illness death model dealing interval censoring taking account cases dementia short survival could establish extent survival overestimated model developed
0.26308063.11581098.html.plaintext.txt	49	another methodological problem due difficulties diagnosis dementia subgroups persons particularly old people persons living institution illiterate deaf depressive persons lead either false diagnosis dementia delay diagnosis among persons could bias survival among persons incident dementia
0.26308063.11581098.html.plaintext.txt	50	another methodological problem due difficulties diagnosis dementia subgroups persons particularly old people persons living institution illiterate deaf depressive persons lead either false diagnosis dementia delay diagnosis among persons could bias survival among persons incident dementia
0.26308063.11581098.html.plaintext.txt	51	demonstrate possible bias problem interval censoring taken account results three state approach compared using standard models kaplan meier curves describe survival among incident participants dementia cox models delayed entry analyze effect sex educational level risk mortality among standard models onset dementia considered middle interval last follow without dementia first follow although differences two models slight median survival developing dementia 2 months longer standard models three state approach larger interval two follow evaluations greater overestimation survival addition using standard models tended increase effect risk factors mortality among persons dementia also slightly underestimate confidence intervals particularly visible effect sex led erroneous significant factors
0.26308063.11581098.html.plaintext.txt	52	demonstrate possible bias problem interval censoring taken account results three state approach compared using standard models kaplan meier curves describe survival among incident participants dementia cox models delayed entry analyze effect sex educational level risk mortality among standard models onset dementia considered middle interval last follow without dementia first follow although differences two models slight median survival developing dementia 2 months longer standard models three state approach larger interval two follow evaluations greater overestimation survival addition using standard models tended increase effect risk factors mortality among persons dementia also slightly underestimate confidence intervals particularly visible effect sex led erroneous significant factors
0.26308063.11581098.html.plaintext.txt	53	impact dementia mortality three state approach used describe mortality among persons dementia takes account fact time disease onset known could applied evaluate impact dementia mortality among general population indeed cannot estimate date onset participant cohort however although estimation onset dementia prime importance describe survival dementia affect time survival several years depending number years two follow evaluations estimation less important evaluation impact dementia mortality age participant time scale model
0.26308063.11581098.html.plaintext.txt	54	impact dementia mortality three state approach used describe mortality among persons dementia takes account fact time disease onset known could applied evaluate impact dementia mortality among general population indeed cannot estimate date onset participant cohort however although estimation onset dementia prime importance describe survival dementia affect time survival several years depending number years two follow evaluations estimation less important evaluation impact dementia mortality age participant time scale model
0.26308063.11581098.html.plaintext.txt	55	relative risks dying study estimated 18 dementia 17 alzheimers disease decreased age results agreement slightly lower found previous community based studies ranging 14 41 alzheimers disease 19 30 dementia 4 7 12 14 28 even higher rr 96 among younger participants 11 28 explained inclusion incident rather prevalent cases dementia study fact took account morbidity evaluating risk death
0.26308063.11581098.html.plaintext.txt	56	two causes death particularly increased among persons dementia cerebrovascular respiratory diseases increase death cerebrovascular diseases essentially due vascular dementia however even among persons alzheimers disease trend increased risk cerebrovascular diseases concordant implication vascular mechanisms alzheimer pathology 29 death due respiratory diseases already found important cause death among alzheimers persons 30 31 also increased persons dementia alzheimers disease compared without dementia
0.26308063.11581098.html.plaintext.txt	57	two causes death particularly increased among persons dementia cerebrovascular respiratory diseases increase death cerebrovascular diseases essentially due vascular dementia however even among persons alzheimers disease trend increased risk cerebrovascular diseases concordant implication vascular mechanisms alzheimer pathology 29 death due respiratory diseases already found important cause death among alzheimers persons 30 31 also increased persons dementia alzheimers disease compared without dementia
0.26308063.11581098.html.plaintext.txt	58	survival among persons dementia general population median duration survival among persons dementia dependent sex age participants median survival times observed study longer reported previous studies prevalent cases community 3 5 7 10 even studies incident cases 14 incident cases considered leads automatically longer survival however clinical studies alzheimer center studies reported median survival times long longer 32 34 6 year survival several explanations may account longer survival first persons referred clinical settings memory probably interested health others may less medical comorbidity second treatment management persons dementia present clinical settings could increase survival finally mean age patients clinical settings often lower community based studies
0.26308063.11581098.html.plaintext.txt	59	survival among persons dementia general population median duration survival among persons dementia dependent sex age participants median survival times observed study longer reported previous studies prevalent cases community 3 5 7 10 even studies incident cases 14 incident cases considered leads automatically longer survival however clinical studies alzheimer center studies reported median survival times long longer 32 34 6 year survival several explanations may account longer survival first persons referred clinical settings memory probably interested health others may less medical comorbidity second treatment management persons dementia present clinical settings could increase survival finally mean age patients clinical settings often lower community based studies
0.26308063.11581098.html.plaintext.txt	60	effect sex survival protective effect female sex observed study particularly alzheimers disease concordant results several studies done different methodologies 7 8 14 33 35 37 general population women dementia lower risk mortality men although interaction age sex risk dying among persons dementia significant effect sex seemed decrease age greater difference women men 75 years 85 years results concordant observed kungsholmen project sex affected survival among persons dementia 85 years 14 factors explain longer survival among women general population could remain unchanged course disease trials currently progress test hypothesis estrogen replacement therapy could affect progression alzheimers disease however paquid study women taken therapy cannot explain longer survival women dementia sample
0.26308063.11581098.html.plaintext.txt	61	effect sex survival protective effect female sex observed study particularly alzheimers disease concordant results several studies done different methodologies 7 8 14 33 35 37 general population women dementia lower risk mortality men although interaction age sex risk dying among persons dementia significant effect sex seemed decrease age greater difference women men 75 years 85 years results concordant observed kungsholmen project sex affected survival among persons dementia 85 years 14 factors explain longer survival among women general population could remain unchanged course disease trials currently progress test hypothesis estrogen replacement therapy could affect progression alzheimers disease however paquid study women taken therapy cannot explain longer survival women dementia sample
0.26308063.11581098.html.plaintext.txt	62	effect education survival effect educational level survival dementia low study observed among participants developed dementia youngest age previous results concerning relation education mortality among persons dementia controversial authors found increased risk mortality associated high educational level 9 38 whereas others replicated findings 10 even found opposite 37 hypothesis brain reserve capacity according development cerebral lesions alzheimers disease time diagnosis advanced among highly educated people others proposed explain association high educational level increased risk mortality 9 39 also observed tendency although slight nonsignificant lower survival persons dementia cep among youngest possible bias detecting dementia according educational level cannot excluded indeed participants low educational level low premorbid cognitive performances thus could detected earlier highly educated participants however bias probably reduced taking account dsm iii r criteria also loss mini mental state examination score screening procedure
0.26308063.11581098.html.plaintext.txt	63	effect education survival effect educational level survival dementia low study observed among participants developed dementia youngest age previous results concerning relation education mortality among persons dementia controversial authors found increased risk mortality associated high educational level 9 38 whereas others replicated findings 10 even found opposite 37 hypothesis brain reserve capacity according development cerebral lesions alzheimers disease time diagnosis advanced among highly educated people others proposed explain association high educational level increased risk mortality 9 39 also observed tendency although slight nonsignificant lower survival persons dementia cep among youngest possible bias detecting dementia according educational level cannot excluded indeed participants low educational level low premorbid cognitive performances thus could detected earlier highly educated participants however bias probably reduced taking account dsm iii r criteria also loss mini mental state examination score screening procedure
0.26308063.11581098.html.plaintext.txt	64	conclusion data provide evidence malignancy dementia strong predictor death short survival time disease onset high risk dying associated future data survival dementia make possible evaluate whether development medical social therapies dementia leads increased survival persons pathology
0.26308063.11581098.html.plaintext.txt	65	conclusion data provide evidence malignancy dementia strong predictor death short survival time disease onset high risk dying associated future data survival dementia make possible evaluate whether development medical social therapies dementia leads increased survival persons pathology
0.26308063.11581098.html.plaintext.txt	66	acknowledgments study supported grants fondation de france novartis pharma axa insurance group caisse nationale dassurance maladie caisse primaire dassurance maladie de dordogne conseil general de la dordogne conseil general de la gironde conseil regional daquitaine danone ministere de la recherche et de la technologie mutualite sociale agricole de gironde et dordogne mutuelle generale de leducation nationale societe pechiney 2010 media caisse de retraite interentreprise capimmec institut du cerveau direction regionale des affaires sanitaires et sociales daquitaine
0.26308063.11581098.html.plaintext.txt	67	notes correspondence dr catherine helmer case 11 inserm u 330 universite de bordeaux ii 146 rue leo saignat 33076 bordeaux cedex france e mail catherinehelmeratispedu bordeaux2fr u d
0.26308063.11581098.html.plaintext.txt	68	notes correspondence dr catherine helmer case 11 inserm u 330 universite de bordeaux ii 146 rue leo saignat 33076 bordeaux cedex france e mail catherinehelmeratispedu bordeaux2fr u d
0.26308063.11581098.html.plaintext.txt	69	references top abstract introduction materials methods results discussion references aguero torres h fratiglioni l guo z et al dementia major cause functional dependence elderly 3 year follow data population based study j public health 1998101452 6 van dijk ptm dippel dwj habbema jfd survival patients dementia j geriatr soc 199139603 10isimedline molsa pk marttila rj rinne uk survival cause death alzheimers disease multi infarct dementia acta neurol scand 198674103 7isimedline evans da smith la scherr pa et al risk death alzheimers disease community population older persons j epidemiol 1991134403 12abstract heeren tj van hemert rooymans hgm community based study survival dementia acta psychiatr scand 199285415 18isimedline tsuji minami y fukao et al dementia physical disability competing risks mortality community based sample elderly japanese tohoku j exp med 199517699 107isimedline jagger c clarke m stone predictors survival alzheimers disease community based study psychol med 199525171 7isimedline molsa pk marttila rj rinne uk long term survival predictors mortality alzheimers disease multi infarct dementia acta neurol scand 199591159 64isimedline stern y tang mx denaro j et al increased risk mortality alzheimers disease patients advanced educational occupational attainment ann neurol 199537590 5isimedline geerlings mi deeg djh schmand b et al increased risk mortality alzheimers disease patients higher education replication study neurology 199749798 802abstract ostbye hill g steenhuis r mortality elderly canadians without dementia 5 year follow neurology 199953521 6abstractfree full text aronson mk ooi wl geva dl et al dementia age dependent incidence prevalence mortality old old arch intern med 1991151989 92abstract bowen jd malter ad sheppard l et al predictors mortality patients diagnosed probable alzheimers disease neurology 199647433 9abstract aguero torres h fratiglioni l guo z et al mortality dementia advanced age 5 year follow study incident dementia cases j clin epidemiol 199952737 43isimedline dartigues j f gagnon m michel p et al le programme de recherche paquid sur lepidemiologie de la demence methodologie et resultats initiaux french rev neurol 1991147225 30medline dartigues j f gagnon m letenneur l et al principal lifetime occupation cognitive impairment french elderly cohort j epidemiol 1992135981 8abstract folstein mf folstein se mchugh pr mini mental state practical method grading cognitive state patients clinician j psychiatr res 197512189 98isimedline katz downs td cash hr et al progress development index adl gerontologist 19701020 30isimedline health care financing administration international classification diseases ninth revision clinical modification washington dc government printing office 1980 dhhs publication phs 80 1260 american psychiatric association diagnostic statistical manual mental disorders dsm iiir 3rd ed rev washington dc american psychiatric association 1987 mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract hachinski vc iliff ld zilhka f et al cerebral blood flow dementia arch neurol 197532632 7abstract launer lj andersen k dewey et al rates risk factors dementia alzheimers disease results eurodem pooled analyses neurology 19995278 84abstractfree full text letenneur l gilleron v commenges d et al sex educational level independent predictors dementia alzheimers disease incidence data paquid project j neurol neurosurg psychiatry 199966177 83abstractfree full text commenges d letenneur l joly p et al modelling age specific risk application dementia stat med 1998171973 88isimedline joly p commenges d penalized likelihood approach progressive three state model censored truncated data application aids biometrics 199955887 90isimedline ross gw abbott rd petrovitch h et al frequency characteristics silent dementia among elderly japanese american men jama 1997277800 5abstract katzman r hill lr yu esh et al malignancy dementia predictors mortality clinically diagnosed dementia population survey shanghai china arch neurol 1994511220 5abstract hofman ott breteler mmb et al atherosclerosis apolipoprotein e prevalence dementia alzheimers disease rotterdam study lancet 1997349151 4isimedline burns jacoby r luthert p et al cause death alzheimers disease age ageing 199019341 4abstract olichney jm hofstetter cr galasko d et al death certificate reporting dementia mortality alzheimers disease research center cohort j geriatr soc 199543890 3isimedline beard cm kokmen e obrien pc et al patients alzheimers disease surviving longer recent years neurology 1994441869 71abstract heyman peterson b fillenbaum g et al consortium establish registry alzheimers disease cerad part xiv demographic clinical predictors survival patients alzheimers disease neurology 199646656 60abstract claus jj walstra gjm bossuyt pm et al simple test copying ability sex define survival patients early alzheimers disease psychol med 199929485 9isimedline burns lewis g jacoby r et al factors affecting survival alzheimers disease psychol med 199121363 70isimedline gambassi g landi f lapane k et al predictors mortality patients alzheimers disease living nursing homes j neurol neurosurg psychiatry 19996759 65abstractfree full text aguero torres h fratiglioni l guo z et al prognostic factors old demented adults seven year follow population based survey stockholm j geriatr soc 199846444 52isimedline geerlings mi deeg djh penninx wjh et al cognitive reserve mortality dementia role cognition functional ability depression psychol med 1999291219 26isimedline stern y albert tang m et al rate memory decline ad related education occupation cognitive reserve neurology 1999531942 7abstractfree full text received publication july 10 2000 accepted publication april 20 2001
0.26308063.11581098.html.plaintext.txt	70	references top abstract introduction materials methods results discussion references aguero torres h fratiglioni l guo z et al dementia major cause functional dependence elderly 3 year follow data population based study j public health 1998101452 6 van dijk ptm dippel dwj habbema jfd survival patients dementia j geriatr soc 199139603 10isimedline molsa pk marttila rj rinne uk survival cause death alzheimers disease multi infarct dementia acta neurol scand 198674103 7isimedline evans da smith la scherr pa et al risk death alzheimers disease community population older persons j epidemiol 1991134403 12abstract heeren tj van hemert rooymans hgm community based study survival dementia acta psychiatr scand 199285415 18isimedline tsuji minami y fukao et al dementia physical disability competing risks mortality community based sample elderly japanese tohoku j exp med 199517699 107isimedline jagger c clarke m stone predictors survival alzheimers disease community based study psychol med 199525171 7isimedline molsa pk marttila rj rinne uk long term survival predictors mortality alzheimers disease multi infarct dementia acta neurol scand 199591159 64isimedline stern y tang mx denaro j et al increased risk mortality alzheimers disease patients advanced educational occupational attainment ann neurol 199537590 5isimedline geerlings mi deeg djh schmand b et al increased risk mortality alzheimers disease patients higher education replication study neurology 199749798 802abstract ostbye hill g steenhuis r mortality elderly canadians without dementia 5 year follow neurology 199953521 6abstractfree full text aronson mk ooi wl geva dl et al dementia age dependent incidence prevalence mortality old old arch intern med 1991151989 92abstract bowen jd malter ad sheppard l et al predictors mortality patients diagnosed probable alzheimers disease neurology 199647433 9abstract aguero torres h fratiglioni l guo z et al mortality dementia advanced age 5 year follow study incident dementia cases j clin epidemiol 199952737 43isimedline dartigues j f gagnon m michel p et al le programme de recherche paquid sur lepidemiologie de la demence methodologie et resultats initiaux french rev neurol 1991147225 30medline dartigues j f gagnon m letenneur l et al principal lifetime occupation cognitive impairment french elderly cohort j epidemiol 1992135981 8abstract folstein mf folstein se mchugh pr mini mental state practical method grading cognitive state patients clinician j psychiatr res 197512189 98isimedline katz downs td cash hr et al progress development index adl gerontologist 19701020 30isimedline health care financing administration international classification diseases ninth revision clinical modification washington dc government printing office 1980 dhhs publication phs 80 1260 american psychiatric association diagnostic statistical manual mental disorders dsm iiir 3rd ed rev washington dc american psychiatric association 1987 mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract hachinski vc iliff ld zilhka f et al cerebral blood flow dementia arch neurol 197532632 7abstract launer lj andersen k dewey et al rates risk factors dementia alzheimers disease results eurodem pooled analyses neurology 19995278 84abstractfree full text letenneur l gilleron v commenges d et al sex educational level independent predictors dementia alzheimers disease incidence data paquid project j neurol neurosurg psychiatry 199966177 83abstractfree full text commenges d letenneur l joly p et al modelling age specific risk application dementia stat med 1998171973 88isimedline joly p commenges d penalized likelihood approach progressive three state model censored truncated data application aids biometrics 199955887 90isimedline ross gw abbott rd petrovitch h et al frequency characteristics silent dementia among elderly japanese american men jama 1997277800 5abstract katzman r hill lr yu esh et al malignancy dementia predictors mortality clinically diagnosed dementia population survey shanghai china arch neurol 1994511220 5abstract hofman ott breteler mmb et al atherosclerosis apolipoprotein e prevalence dementia alzheimers disease rotterdam study lancet 1997349151 4isimedline burns jacoby r luthert p et al cause death alzheimers disease age ageing 199019341 4abstract olichney jm hofstetter cr galasko d et al death certificate reporting dementia mortality alzheimers disease research center cohort j geriatr soc 199543890 3isimedline beard cm kokmen e obrien pc et al patients alzheimers disease surviving longer recent years neurology 1994441869 71abstract heyman peterson b fillenbaum g et al consortium establish registry alzheimers disease cerad part xiv demographic clinical predictors survival patients alzheimers disease neurology 199646656 60abstract claus jj walstra gjm bossuyt pm et al simple test copying ability sex define survival patients early alzheimers disease psychol med 199929485 9isimedline burns lewis g jacoby r et al factors affecting survival alzheimers disease psychol med 199121363 70isimedline gambassi g landi f lapane k et al predictors mortality patients alzheimers disease living nursing homes j neurol neurosurg psychiatry 19996759 65abstractfree full text aguero torres h fratiglioni l guo z et al prognostic factors old demented adults seven year follow population based survey stockholm j geriatr soc 199846444 52isimedline geerlings mi deeg djh penninx wjh et al cognitive reserve mortality dementia role cognition functional ability depression psychol med 1999291219 26isimedline stern y albert tang m et al rate memory decline ad related education occupation cognitive reserve neurology 1999531942 7abstractfree full text received publication july 10 2000 accepted publication april 20 2001
0.2649917.9811940.html.plaintext.txt	0	genetic association alpha2 macroglobulin val1000ile polymorphism alzheimers disease
0.2649917.9811940.html.plaintext.txt	1	alzheimer research unit neurology service massachusetts general hospital 149 13th street cny 6405 charlestown ma 02129 usa 1university hamburg hamburg germany 2irccs giovanni de dio fbf brescia italy 3university basel basel switzerland
0.2649917.9811940.html.plaintext.txt	2	alzheimer research unit neurology service massachusetts general hospital 149 13th street cny 6405 charlestown ma 02129 usa 1university hamburg hamburg germany 2irccs giovanni de dio fbf brescia italy 3university basel basel switzerland
0.2649917.9811940.html.plaintext.txt	3	received july 2 1998 revised accepted august 20 1998
0.2649917.9811940.html.plaintext.txt	4	alpha2 macroglobulin a2m proteinase inhibitor found association senile plaques sp alzheimers disease ad a2m implicated biochemically binding degradation amyloid beta abeta protein accumulates sp studied relationship alzheimers disease common a2m polymorphism val1000 gtcile1000 atc occurs near thiolester active site molecule initial exploratory data set 90 controls 171 alzheimers disease noted increased frequency gg genotype 007 012 therefore tested hypothesis gg genotype represented alzheimers disease additional independent data set group 359 controls 566 alzheimers disease patients hypothesis testing cohort gg genotype increased 007 controls 012 alzheimers disease p 005 fishers exact test odds ratio alzheimers disease associated gg genotype 177 116 270 p 001 combination apoe4 968 95 ci 391 240 p 0001 presence g allele associated increase abeta burden small series a2m receptor a2m rlrp multifunctional receptor whose ligands include apolipoprotein e amyloid precursor protein four proteins genetically linked alzheimers disease suggesting may participate common disease pathway
0.2649917.9811940.html.plaintext.txt	5	alpha2 macroglobulin a2m proteinase inhibitor found association senile plaques sp alzheimers disease ad a2m implicated biochemically binding degradation amyloid beta abeta protein accumulates sp studied relationship alzheimers disease common a2m polymorphism val1000 gtcile1000 atc occurs near thiolester active site molecule initial exploratory data set 90 controls 171 alzheimers disease noted increased frequency gg genotype 007 012 therefore tested hypothesis gg genotype represented alzheimers disease additional independent data set group 359 controls 566 alzheimers disease patients hypothesis testing cohort gg genotype increased 007 controls 012 alzheimers disease p 005 fishers exact test odds ratio alzheimers disease associated gg genotype 177 116 270 p 001 combination apoe4 968 95 ci 391 240 p 0001 presence g allele associated increase abeta burden small series a2m receptor a2m rlrp multifunctional receptor whose ligands include apolipoprotein e amyloid precursor protein four proteins genetically linked alzheimers disease suggesting may participate common disease pathway
0.2649917.9811940.html.plaintext.txt	6	alpha2 macroglobulin a2m proteinase inhibitor inhibits proteinases classes steric trapping mechanism tetrameric a2m structure undergoes conformational change upon cleavage peptide bond bait region proteinase conformational change traps proteinase a2m implicated several pathophysiological processes alzheimers disease a2m immunostains senile plaques sp 1 3 binds amyloid beta protein abeta 1 42 high affinity apparent kd 10 nm 4 moreover recent data suggest serine proteinase a2m complex degrade abeta 5 trypsin activated a2m efficiently degrades abeta vitro prevents vitro formation thioflavin positive abeta fibrils well abeta induced toxicity cultured human cortical neuronal cells 6
0.2649917.9811940.html.plaintext.txt	7	alpha2 macroglobulin a2m proteinase inhibitor inhibits proteinases classes steric trapping mechanism tetrameric a2m structure undergoes conformational change upon cleavage peptide bond bait region proteinase conformational change traps proteinase a2m implicated several pathophysiological processes alzheimers disease a2m immunostains senile plaques sp 1 3 binds amyloid beta protein abeta 1 42 high affinity apparent kd 10 nm 4 moreover recent data suggest serine proteinase a2m complex degrade abeta 5 trypsin activated a2m efficiently degrades abeta vitro prevents vitro formation thioflavin positive abeta fibrils well abeta induced toxicity cultured human cortical neuronal cells 6
0.2649917.9811940.html.plaintext.txt	8	activated a2m cleared a2m rlow density lipoprotein receptor related protein a2m rlrp a2m rlrp multifunctional receptor interestingly also primary neuronal apolipoprotein e apoe receptor 78 lrp also binds clears kunitz proteinase inhibitor containing isoforms amyloid precursor protein app 9 thus a2m potentially impacts apoe app metabolism brain
0.2649917.9811940.html.plaintext.txt	9	activated a2m cleared a2m rlow density lipoprotein receptor related protein a2m rlrp a2m rlrp multifunctional receptor interestingly also primary neuronal apolipoprotein e apoe receptor 78 lrp also binds clears kunitz proteinase inhibitor containing isoforms amyloid precursor protein app 9 thus a2m potentially impacts apoe app metabolism brain
0.2649917.9811940.html.plaintext.txt	10	biological links alzheimers disease studied possible association previously reported polymorphism a2m gene alzheimers disease poller et al 10 screened 30 normal 30 pulmonary disease patients a2m polymorphisms near active site reported three a2m polymorphisms common occurred 25 amino acids downstream thiolester site interchanging val1000 gtc ile1000 atc 10 numbering based cdna sequence includes 24 amino acid signal peptide corresponds valile976 mature protein allele frequencies 60 probands 03 gtc 07 atc difference a2m serum levels associated two alleles polymorphism especially interesting potential biologically relevant function a2m proteinase inhibitor occurs near thiolester active site molecule
0.2649917.9811940.html.plaintext.txt	11	initial exploratory experiment tested possibility less common form a2m g allele would associated alzheimers disease potential error due multiple hypothesis testing planned use initial data set exploratory data set intent formulate specific hypotheses would tested formally second independent data set genotyped 90 non alzheimers individuals either undergone screening tests blessed dementia scale 11 whose dna isolated autopsy material demonstrated alzheimers disease 171 individuals either clinical diagnosis alzheimers disease neuropathologically proven alzheimers disease table 1 genotypes determined pcr amplification dna restriction enzyme digestion fig 1 control series g allele frequency 028 six 90 individuals contained gg genotype 0067 alzheimers disease set g allele frequency 032 noticed gg genotype frequency increased alzheimers group 012 table 1 results suggest possible influence a2m polymorphism genetic risk factor alzheimers disease
0.2649917.9811940.html.plaintext.txt	12	initial exploratory experiment tested possibility less common form a2m g allele would associated alzheimers disease potential error due multiple hypothesis testing planned use initial data set exploratory data set intent formulate specific hypotheses would tested formally second independent data set genotyped 90 non alzheimers individuals either undergone screening tests blessed dementia scale 11 whose dna isolated autopsy material demonstrated alzheimers disease 171 individuals either clinical diagnosis alzheimers disease neuropathologically proven alzheimers disease table 1 genotypes determined pcr amplification dna restriction enzyme digestion fig 1 control series g allele frequency 028 six 90 individuals contained gg genotype 0067 alzheimers disease set g allele frequency 032 noticed gg genotype frequency increased alzheimers group 012 table 1 results suggest possible influence a2m polymorphism genetic risk factor alzheimers disease
0.2649917.9811940.html.plaintext.txt	13	figure 1 electrophoresis pattern restriction digest demonstrating bands representing g 532 bp alleles 429 bp
0.2649917.9811940.html.plaintext.txt	14	table 1 representation a2m gg genotype alzheimers disease n g allele gg genotype exploratory data set control 90 028 007 ad 171 032 012 hypothesis testing data set control 359 032 007 ad 566 034 012a combined data set total control 449 032 007 ad 737 034 012b ap 005 bp 001
0.2649917.9811940.html.plaintext.txt	15	formally test hypothesis gg genotype a2m represented alzheimers disease collected genotyped additional independent groups patients controls power analysis showed 500 alzheimers disease control individuals would necessary 80 chance showing difference genotype frequencies 007 012 therefore collected cases controls several sites order approximate number samples second data set consisted individuals met criteria alzheimers disease control hypothesis generating set derived sporadic alzheimers disease patients massachusetts three european centers probands multicenter us study sib pairs small families results second data set supported hypothesis gg genotype frequencies 007 controls 012 alzheimers disease p 005 fishers exact test table 1 g allele represented data set control 032 alzheimers disease 034 difference age onset gg non gg found second data set multivariate analysis showed site collection influence genotype frequencies also compared rate controls subset 387 clinic based alzheimers disease cases gg frequency 114 p 006 subset 179 familial alzheimers disease samples gg frequency 127 p 0056 found essentially equal representation gg data support association gg genotype alzheimers disease
0.2649917.9811940.html.plaintext.txt	16	formally test hypothesis gg genotype a2m represented alzheimers disease collected genotyped additional independent groups patients controls power analysis showed 500 alzheimers disease control individuals would necessary 80 chance showing difference genotype frequencies 007 012 therefore collected cases controls several sites order approximate number samples second data set consisted individuals met criteria alzheimers disease control hypothesis generating set derived sporadic alzheimers disease patients massachusetts three european centers probands multicenter us study sib pairs small families results second data set supported hypothesis gg genotype frequencies 007 controls 012 alzheimers disease p 005 fishers exact test table 1 g allele represented data set control 032 alzheimers disease 034 difference age onset gg non gg found second data set multivariate analysis showed site collection influence genotype frequencies also compared rate controls subset 387 clinic based alzheimers disease cases gg frequency 114 p 006 subset 179 familial alzheimers disease samples gg frequency 127 p 0056 found essentially equal representation gg data support association gg genotype alzheimers disease
0.2649917.9811940.html.plaintext.txt	17	carried series exploratory analyses using pooled data individuals 737 alzheimers disease patients 449 controls gg genotype present 119 alzheimer patients 73 controls p 001 fishers exact test genotype frequency controls consistent hardy weinberg equilibrium age onset different alzheimers disease patients gg 700 plus minus 92 mean plus minus sd non gg carriers 706 plus minus 91 multivariate logistic model controlled presence apoe4 allele gender showed odds ratio 188 95 ci 120 295 p 001 presence a2m gg genotype presence apoe4 model associated odds ratio 421 95 ci 320 555 p 0001 odds ratio combination gg apoe4 968 95 ci 391 240 p 0001 relative neither risk factor explore whether gg mediated risk influenced presence absence apoe4 stratified sample presence absence apoe4 similar representations gg genotype seen strata without apoe4 suggesting effects two risk factors independent multivariate analysis interaction gg genotype either apoe4 gender demonstrated interactions p 05 interaction terms analysis based mantel haenszel estimator suggested heterogeneity odds ratios strata without apoe4 p 05 consistent absence interaction a2m apoe4 logistic regression model
0.2649917.9811940.html.plaintext.txt	18	carried series exploratory analyses using pooled data individuals 737 alzheimers disease patients 449 controls gg genotype present 119 alzheimer patients 73 controls p 001 fishers exact test genotype frequency controls consistent hardy weinberg equilibrium age onset different alzheimers disease patients gg 700 plus minus 92 mean plus minus sd non gg carriers 706 plus minus 91 multivariate logistic model controlled presence apoe4 allele gender showed odds ratio 188 95 ci 120 295 p 001 presence a2m gg genotype presence apoe4 model associated odds ratio 421 95 ci 320 555 p 0001 odds ratio combination gg apoe4 968 95 ci 391 240 p 0001 relative neither risk factor explore whether gg mediated risk influenced presence absence apoe4 stratified sample presence absence apoe4 similar representations gg genotype seen strata without apoe4 suggesting effects two risk factors independent multivariate analysis interaction gg genotype either apoe4 gender demonstrated interactions p 05 interaction terms analysis based mantel haenszel estimator suggested heterogeneity odds ratios strata without apoe4 p 05 consistent absence interaction a2m apoe4 logistic regression model
0.2649917.9811940.html.plaintext.txt	19	next turned attention possible biological effects inheritance a2m gg genotype previous studies a2m immunohistochemistry alzheimer brain suggested sp different cases stained varying intensity 3 explored possibility variability due different genotypes immunostaining eight alzheimers disease cases known gg aa genotype instances a2m immunoreactivity present robustly sp astrocytes neurons qualitative differences observed genotype groups
0.2649917.9811940.html.plaintext.txt	20	next turned attention possible biological effects inheritance a2m gg genotype previous studies a2m immunohistochemistry alzheimer brain suggested sp different cases stained varying intensity 3 explored possibility variability due different genotypes immunostaining eight alzheimers disease cases known gg aa genotype instances a2m immunoreactivity present robustly sp astrocytes neurons qualitative differences observed genotype groups
0.2649917.9811940.html.plaintext.txt	21	also explored effect inheritance a2m gg genotype neuropathological phenotype alzheimers disease table 2 previously used stereological techniques quantitative image analysis measure amount abeta present amyloid burden neocortical association area surrounding superior temporal sulcus number neurofibrillary tangles present region 12 thirty one previously analyzed alzheimers disease cases a2m genotyped selected analysis initial inspection data suggested increase abeta individuals ag gg difference two groups statistically significant increase abeta deposition seen comparing g containing cases non g containing cases 88 plus minus 28 versus 66 plus minus 19 p 003 unpaired test effect appears primarily due presence least one g allele difference ag gg genotypes observed although sample size limits power comparison statistically significant differences neurofibrillary tangle number g alleles suggesting specific effect abeta deposition
0.2649917.9811940.html.plaintext.txt	22	also explored effect inheritance a2m gg genotype neuropathological phenotype alzheimers disease table 2 previously used stereological techniques quantitative image analysis measure amount abeta present amyloid burden neocortical association area surrounding superior temporal sulcus number neurofibrillary tangles present region 12 thirty one previously analyzed alzheimers disease cases a2m genotyped selected analysis initial inspection data suggested increase abeta individuals ag gg difference two groups statistically significant increase abeta deposition seen comparing g containing cases non g containing cases 88 plus minus 28 versus 66 plus minus 19 p 003 unpaired test effect appears primarily due presence least one g allele difference ag gg genotypes observed although sample size limits power comparison statistically significant differences neurofibrillary tangle number g alleles suggesting specific effect abeta deposition
0.2649917.9811940.html.plaintext.txt	23	table 2 neuropathological correlates a2m genotype genotype n amyloid burden neurofibrillary tangles x 103 aa 10 66 plus minus 19a 69 plus minus 42 ag gg 21 88 plus minus 28b 90 plus minus 50c amean plus minus sd bp 003 test cn 17 measurement discussion
0.2649917.9811940.html.plaintext.txt	24	exploratory studies genetic risk factors run risk type errors large number hypotheses either explicitly implicitly tested alternatively type ii errors occur sample size insufficient order overcome difficulties inherent exploratory studies genetic risk factors used independent data sets first generate test hypothesis gg genotype associated alzheimers disease two separate control populations gave identical genotype frequencies hypothesis testing data set made two groups sporadic ad probands multicenter study alzheimers disease sib pairs small families gave essentially identical genotype frequencies representation gg genotype a2m gg effect dependent apoe genotype effect additive substantial odds ratio gg presence apoe4 allele showed almost 10 fold increased risk power analysis using size effect observed combined data set using 500 samples suggests group size 578 controls 578 alzheimers disease patients would necessary alpha 005 beta 80 hypothesis gg genotype increased 007 012 alzheimers disease
0.2649917.9811940.html.plaintext.txt	25	exploratory studies genetic risk factors run risk type errors large number hypotheses either explicitly implicitly tested alternatively type ii errors occur sample size insufficient order overcome difficulties inherent exploratory studies genetic risk factors used independent data sets first generate test hypothesis gg genotype associated alzheimers disease two separate control populations gave identical genotype frequencies hypothesis testing data set made two groups sporadic ad probands multicenter study alzheimers disease sib pairs small families gave essentially identical genotype frequencies representation gg genotype a2m gg effect dependent apoe genotype effect additive substantial odds ratio gg presence apoe4 allele showed almost 10 fold increased risk power analysis using size effect observed combined data set using 500 samples suggests group size 578 controls 578 alzheimers disease patients would necessary alpha 005 beta 80 hypothesis gg genotype increased 007 012 alzheimers disease
0.2649917.9811940.html.plaintext.txt	26	association gg a2m genotype risk factor alzheimers disease leads several interesting mechanistic interpretations previous data shown a2m immunostains sp implicated a2m amyloid precursor protein metabolism 13 well possible interactions binding abeta 4 mediation degradation abeta 56 a2m abeta complexes undergo endocytosis via a2m rlrp receptor 14 a2m associates abeta prevents fibril formation 15 addition a2m viewed subacute phase reactive molecule potent proteinase inhibitor might participate inflammatory response alzheimer brain interestingly a2m also implicated trophic factor possibly result binding transporting number polypeptide growth factors cytokines 16 like apoe a2m may serve binding protein targeting various bioactive molecules site action clearing 3 finally fact apoe app two ligands a2m rlrp receptor clearly involved pathophysiology alzheimers disease support plausibility idea a2m polymorphism might contribute risk alzheimers disease fact polymorphism a2m rlrp recently reported two studies show genetic association alzheimers disease 1718
0.2649917.9811940.html.plaintext.txt	27	association gg a2m genotype risk factor alzheimers disease leads several interesting mechanistic interpretations previous data shown a2m immunostains sp implicated a2m amyloid precursor protein metabolism 13 well possible interactions binding abeta 4 mediation degradation abeta 56 a2m abeta complexes undergo endocytosis via a2m rlrp receptor 14 a2m associates abeta prevents fibril formation 15 addition a2m viewed subacute phase reactive molecule potent proteinase inhibitor might participate inflammatory response alzheimer brain interestingly a2m also implicated trophic factor possibly result binding transporting number polypeptide growth factors cytokines 16 like apoe a2m may serve binding protein targeting various bioactive molecules site action clearing 3 finally fact apoe app two ligands a2m rlrp receptor clearly involved pathophysiology alzheimers disease support plausibility idea a2m polymorphism might contribute risk alzheimers disease fact polymorphism a2m rlrp recently reported two studies show genetic association alzheimers disease 1718
0.2649917.9811940.html.plaintext.txt	28	although strong biological rationale involvement a2m polymorphism alzheimers disease possibility remains genetic association observe reflects linkage another mutation polymorphism either a2m gene nearby gene chromosome 12 a2m gene resides 25 cm distal marker d12s1042 yielded maximal lod score recent linkage study suggesting chromosome 12 contains alzheimer risk factor 19 however likelihood a2m risk factor supported results recent separate study observed association intronic 5prime splice site exon 18 pentanucleotide deletion allele 2 within a2m gene alzheimers disease sibship analysis alzheimers disease sib pairs small alzheimers disease families 20 current results extend observation showing linkage missense mutation case control sample rather family based association currently studying two a2m polymorphisms relate one another preliminary results consistent hypothesis act independent risk factors initial study group evaluated polymorphisms suggests g allele inherited 1 allele 70 g chromosomes examined 35 gg individuals 97 allele 1 3 allele 2 compared allele 2 frequency 15 p 0005 chi2 analysis yates correction
0.2649917.9811940.html.plaintext.txt	29	although strong biological rationale involvement a2m polymorphism alzheimers disease possibility remains genetic association observe reflects linkage another mutation polymorphism either a2m gene nearby gene chromosome 12 a2m gene resides 25 cm distal marker d12s1042 yielded maximal lod score recent linkage study suggesting chromosome 12 contains alzheimer risk factor 19 however likelihood a2m risk factor supported results recent separate study observed association intronic 5prime splice site exon 18 pentanucleotide deletion allele 2 within a2m gene alzheimers disease sibship analysis alzheimers disease sib pairs small alzheimers disease families 20 current results extend observation showing linkage missense mutation case control sample rather family based association currently studying two a2m polymorphisms relate one another preliminary results consistent hypothesis act independent risk factors initial study group evaluated polymorphisms suggests g allele inherited 1 allele 70 g chromosomes examined 35 gg individuals 97 allele 1 3 allele 2 compared allele 2 frequency 15 p 0005 chi2 analysis yates correction
0.2649917.9811940.html.plaintext.txt	30	taken together believe polymorphisms a2m gene may contribute risk alzheimers disease moreover data focus attention mechanisms pathophysiology impact a2m rlrp ligands including clearance mechanisms mediated a2m rlrp 714 suggest a2m rlrp ligands may candidate alzheimers disease genes well
0.2649917.9811940.html.plaintext.txt	31	taken together believe polymorphisms a2m gene may contribute risk alzheimers disease moreover data focus attention mechanisms pathophysiology impact a2m rlrp ligands including clearance mechanisms mediated a2m rlrp 714 suggest a2m rlrp ligands may candidate alzheimers disease genes well
0.2649917.9811940.html.plaintext.txt	32	initial hypothesis generating data set established 171 alzheimers disease patients clinical history probable alzheimers disease 90 age compatible control individuals primarily spouses patients second hypothesis testing data set collected several sources attempt approximate 500 patients controls estimated power analysis adequately test hypothesis gg genotype represented alzheimers disease individuals included additional cases 380 sporadic alzheimer disease 337 controls matched site primarily cognitively tested spouses collected massachusetts general hospital memory disorder unit consortium european centers university hamburg germany university basel switzerland cuore fatebenefratelli hospital brescia italy 179 probands multicenter study alzheimer disease sib pairs small alzheimers disease families 21
0.2649917.9811940.html.plaintext.txt	33	initial hypothesis generating data set established 171 alzheimers disease patients clinical history probable alzheimers disease 90 age compatible control individuals primarily spouses patients second hypothesis testing data set collected several sources attempt approximate 500 patients controls estimated power analysis adequately test hypothesis gg genotype represented alzheimers disease individuals included additional cases 380 sporadic alzheimer disease 337 controls matched site primarily cognitively tested spouses collected massachusetts general hospital memory disorder unit consortium european centers university hamburg germany university basel switzerland cuore fatebenefratelli hospital brescia italy 179 probands multicenter study alzheimer disease sib pairs small alzheimers disease families 21
0.2649917.9811940.html.plaintext.txt	34	genomic dna isolated brain tissue blood amplified pcr presence oligonucleotide sense primer c23 5prime atc cct gaa act gcc acc aa 3prime antisense primer as24 5prime gta act gaa acc tac tgg aa 3prime 10 mm tris hc1 50 mm kc1 ph 83 15 mm mgc12 5 mm dntps 5 pmol primer 125 u taq dna polymerase pcr carried touchdown procedure stepped annealing temperature increase primer specificity follows one cycle 94 degrees c 5 min four cycles 94 degrees c 30 65 degrees c 30 72 degrees c 1 min four cycles 94 degrees c 30 62 degrees c 30 72 degrees c 1 min four cycles 94 degrees c 30 59 degrees c 30 72 degrees c 1 min 20 cycles 94 degrees c 30 56 degrees c 30 72 degrees c 1 min one cycle 72 degrees c 5 min
0.2649917.9811940.html.plaintext.txt	35	reaction mixture mboi added amplified product 615 bp digestion carried 37 degrees c 3 h producing fragments 532 g allele 429 bp allele digested product loaded onto 2 agarose gel treated ethidium bromide 0005 electrophoresed 2 h constant voltage 150 v sufficient separate digested product 532 429 bp bands distinguished electrophoresis dna fragments visualized uv illumination using bio rad gel doc system incomplete digestion monitored continued presence 615 bp product
0.2649917.9811940.html.plaintext.txt	36	reaction mixture mboi added amplified product 615 bp digestion carried 37 degrees c 3 h producing fragments 532 g allele 429 bp allele digested product loaded onto 2 agarose gel treated ethidium bromide 0005 electrophoresed 2 h constant voltage 150 v sufficient separate digested product 532 429 bp bands distinguished electrophoresis dna fragments visualized uv illumination using bio rad gel doc system incomplete digestion monitored continued presence 615 bp product
0.2649917.9811940.html.plaintext.txt	37	immunohistochemical analysis used anti a2m antibody 1500 zymed goat cy3 linked secondary antibody jackson immunoresearch used visualize immunostaining instances double immunofluorescence carried abeta counterstain antibody 10d5 courtesy dr d schenk athena neurosciences using bodipy fluorescein linked secondary antibody molecular probes second fluorochrome quantitative neuropathological techniques measuring abeta burden neurofibrillary tangles number superior temporal sulcus area previously published 12
0.2649917.9811940.html.plaintext.txt	38	immunohistochemical analysis used anti a2m antibody 1500 zymed goat cy3 linked secondary antibody jackson immunoresearch used visualize immunostaining instances double immunofluorescence carried abeta counterstain antibody 10d5 courtesy dr d schenk athena neurosciences using bodipy fluorescein linked secondary antibody molecular probes second fluorochrome quantitative neuropathological techniques measuring abeta burden neurofibrillary tangles number superior temporal sulcus area previously published 12
0.2649917.9811940.html.plaintext.txt	39	comparisons a2m allele frequency proportion chromosomes allele present genotype frequency proportion individuals genotype performed 2 x 2 tables using fishers exact test significance age onset alzheimers disease normally distributed compared test multivariate analysis odds alzheimers disease performed logistic regression apoe genotype coded according presence absence apoe4 similar results obtained group apoe4 coded separately heterozygotes homozygotes allele odds ratios presented 95 confidence intervals cis analyses performed stata software college park tx significance tests two tailed
0.2649917.9811940.html.plaintext.txt	40	comparisons a2m allele frequency proportion chromosomes allele present genotype frequency proportion individuals genotype performed 2 x 2 tables using fishers exact test significance age onset alzheimers disease normally distributed compared test multivariate analysis odds alzheimers disease performed logistic regression apoe genotype coded according presence absence apoe4 similar results obtained group apoe4 coded separately heterozygotes homozygotes allele odds ratios presented 95 confidence intervals cis analyses performed stata software college park tx significance tests two tailed
0.2649917.9811940.html.plaintext.txt	41	thank c maschke technical assistance thank massachusetts alzheimers research center ag05134 brain bank dr et hedley whyte neuropathological specimens additional neurological pathological specimens obtained brain tissue research center mhns 31862 work supported nih grants ag12406 ag08487
0.2649917.9811940.html.plaintext.txt	42	correspondence addressed tel 1 617 726 2299 fax 1 617 726 5677 email bhymanhelixmghharvardedu page run oxford university press great clarendon street oxford ox2 6dp part oup journals comments feedback www adminatoupcouk u d last modification 12 nov 1998 copyright oxford university press 1998
0.2649917.9811940.html.plaintext.txt	43	correspondence addressed tel 1 617 726 2299 fax 1 617 726 5677 email bhymanhelixmghharvardedu page run oxford university press great clarendon street oxford ox2 6dp part oup journals comments feedback www adminatoupcouk u d last modification 12 nov 1998 copyright oxford university press 1998
0.2674377.16162502.html.plaintext.txt	0	resveratrol promotes clearance alzheimers disease amyloid peptides philippe marambaud1 haitian zhao peter davies
0.2674377.16162502.html.plaintext.txt	1	litwin zucker research center study alzheimers disease memory disorders north shore long island jewish institute medical research manhasset new york 11030
0.2674377.16162502.html.plaintext.txt	2	received publication july 27 2005 revised form september 12 2005
0.2674377.16162502.html.plaintext.txt	3	abstract top abstract introduction experimental procedures results discussion references several epidemiological studies indicate moderate consumption wine associated lower incidence alzheimers disease wine enriched antioxidant compounds potential neuroprotective activities however exact molecular mechanisms involved beneficial effects wine intake neurodegenerative process alzheimers disease brain remain clearly defined show resveratrol trans 345 trihydroxystilbene naturally occurring polyphenol mainly found grapes red wine markedly lowers levels secreted intracellular amyloid peptides produced different cell lines resveratrol inhibit production effect producing enzymes secretases promotes instead intracellular degradation via mechanism involves proteasome indeed resveratrol induced decrease could prevented several selective proteasome inhibitors sirna directed silencing proteasome subunit 5 findings demonstrate proteasome dependent anti amyloidogenic activity resveratrol suggest natural compound therapeutic potential alzheimers disease
0.2674377.16162502.html.plaintext.txt	4	abstract top abstract introduction experimental procedures results discussion references several epidemiological studies indicate moderate consumption wine associated lower incidence alzheimers disease wine enriched antioxidant compounds potential neuroprotective activities however exact molecular mechanisms involved beneficial effects wine intake neurodegenerative process alzheimers disease brain remain clearly defined show resveratrol trans 345 trihydroxystilbene naturally occurring polyphenol mainly found grapes red wine markedly lowers levels secreted intracellular amyloid peptides produced different cell lines resveratrol inhibit production effect producing enzymes secretases promotes instead intracellular degradation via mechanism involves proteasome indeed resveratrol induced decrease could prevented several selective proteasome inhibitors sirna directed silencing proteasome subunit 5 findings demonstrate proteasome dependent anti amyloidogenic activity resveratrol suggest natural compound therapeutic potential alzheimers disease
0.2674377.16162502.html.plaintext.txt	5	introduction top abstract introduction experimental procedures results discussion references alzheimers disease ad2 progressive neurodegenerative disorder leading common form dementia compelling evidence supports central role pathogenesis disease 1 core component senile plaque classical lesion found neocortex hippocampus ad brains excessive production highly insoluble 42 amino acid long a42 peptide almost invariably observed presence mutations three genes linked early onset autosomal dominant familial forms ad 2
0.2674377.16162502.html.plaintext.txt	6	introduction top abstract introduction experimental procedures results discussion references alzheimers disease ad2 progressive neurodegenerative disorder leading common form dementia compelling evidence supports central role pathogenesis disease 1 core component senile plaque classical lesion found neocortex hippocampus ad brains excessive production highly insoluble 42 amino acid long a42 peptide almost invariably observed presence mutations three genes linked early onset autosomal dominant familial forms ad 2
0.2674377.16162502.html.plaintext.txt	7	amyloidogenic pathway amyloid precursor protein app cleaved aspartic protease secretasebace1 yield membrane anchored c terminal fragments c99 c89 c99 endoproteolyzed secretase proteolytic complex produce various peptides major cleavage takes place val 40 producing a40 alternative nonamyloidogenic pathway app endoproteolyzed within region secretase generate c terminal fragment c83 soluble n terminal fragment secreted app finally secretase mediated cleavage app allows intracellular release transcriptionally active app intracellular domain aid 3 aicd 4 6
0.2674377.16162502.html.plaintext.txt	8	amyloidogenic pathway amyloid precursor protein app cleaved aspartic protease secretasebace1 yield membrane anchored c terminal fragments c99 c89 c99 endoproteolyzed secretase proteolytic complex produce various peptides major cleavage takes place val 40 producing a40 alternative nonamyloidogenic pathway app endoproteolyzed within region secretase generate c terminal fragment c83 soluble n terminal fragment secreted app finally secretase mediated cleavage app allows intracellular release transcriptionally active app intracellular domain aid 3 aicd 4 6
0.2674377.16162502.html.plaintext.txt	9	epidemiological studies shown moderate wine intake reduces risk developing ad 7 10 resveratrol polyphenol occurs abundance grapes red wine suspected afford antioxidant neuroprotective properties therefore contribute beneficial effect wine consumption neurodegenerative process 11 13 report resveratrol potent anti amyloidogenic activity reducing levels produced different cell lines expressing wild type swedish mutant app695 show resveratrol acts promoting intracellular degradation mechanism implicates proteasome
0.2674377.16162502.html.plaintext.txt	10	epidemiological studies shown moderate wine intake reduces risk developing ad 7 10 resveratrol polyphenol occurs abundance grapes red wine suspected afford antioxidant neuroprotective properties therefore contribute beneficial effect wine consumption neurodegenerative process 11 13 report resveratrol potent anti amyloidogenic activity reducing levels produced different cell lines expressing wild type swedish mutant app695 show resveratrol acts promoting intracellular degradation mechanism implicates proteasome
0.2674377.16162502.html.plaintext.txt	11	experimental procedures top abstract introduction experimental procedures results discussion references materials antibodies quercetin catechin resveratrol piceatannol phosphoramidon thiorphan insulin n succinyl llvy 7 amido 4 methylcoumarin suc llvy amc suc aaf amc obtained sigma trimethoxy resveratrol tms trans 2345 tetramethoxystilbene cayman chemical l 685458 lactacystin z gpfl cho yu101 n acetyl ll norleucinal cho alln calbiochem purified human 20 proteasome biomol anti 1 17 6e10 anti 17 24 4g8 pure biotinylated antibodies signet anti app 66 81 22c11 antibody chemicon anti app c terminal domain r1 antibody provided dr p d mehta institute basic research developmental disabilities staten island ny polyclonal antibodies specific a40 fca3340 a42 fca3542 14 obtained dr f checler ipmc centre national de la recherche scientifique valbonne france anti n cadherin c32 anti catenin antibodies bd transduction laboratories anti 20 proteasome subunit 5 antibody abr affinity bioreagents polyclonal antibody directed subunits 5 7 1 5 5i 7 20 proteasome biomol anti tubulin antibody santa cruz biotechnology
0.2674377.16162502.html.plaintext.txt	12	experimental procedures top abstract introduction experimental procedures results discussion references materials antibodies quercetin catechin resveratrol piceatannol phosphoramidon thiorphan insulin n succinyl llvy 7 amido 4 methylcoumarin suc llvy amc suc aaf amc obtained sigma trimethoxy resveratrol tms trans 2345 tetramethoxystilbene cayman chemical l 685458 lactacystin z gpfl cho yu101 n acetyl ll norleucinal cho alln calbiochem purified human 20 proteasome biomol anti 1 17 6e10 anti 17 24 4g8 pure biotinylated antibodies signet anti app 66 81 22c11 antibody chemicon anti app c terminal domain r1 antibody provided dr p d mehta institute basic research developmental disabilities staten island ny polyclonal antibodies specific a40 fca3340 a42 fca3542 14 obtained dr f checler ipmc centre national de la recherche scientifique valbonne france anti n cadherin c32 anti catenin antibodies bd transduction laboratories anti 20 proteasome subunit 5 antibody abr affinity bioreagents polyclonal antibody directed subunits 5 7 1 5 5i 7 20 proteasome biomol anti tubulin antibody santa cruz biotechnology
0.2674377.16162502.html.plaintext.txt	13	cell lines transfections drug treatments hek293 cells stably transfected human app695 provided dr l dadamio albert einstein college medicine bronx ny n2a cells stably transfected wild type swedish mutant human app695 cdnas obtained dr n k robakis mount sinai school medicine new york ny app695 hek293 transfectants grown dulbeccos modified eagles medium plus 10 fetal bovine serum penicillin streptomycin 5 microgml puromycin app695 n2a cells maintained 11 dulbeccos modified eagles mediumopti mem supplemented 5 fetal bovine serum penicillin streptomycin 02 mgml g418 drug treatments cells treated confluence indicated concentrations incubation times medium changed treatments continued another 2 h allow secretion sirna directed silencing 200 pmol purified sirna directed proteasome subunit 5 smartpool dharmacon transfected 10 microl lipofectamine 2000 invitrogen app695 hek293 cells plated 35 mm dishes 48 h post transfection cells incubated absence presence 40 microm resveratrol another 24 h cells conditioned medium harvested analyzed western blotting wb proteasome activity assays described
0.2674377.16162502.html.plaintext.txt	14	western blotting cells washed phosphate buffered saline solubilized ice cold hepes buffer 25 mm hepes ph 74 150 mm nacl 1x complete protease inhibitor mixture roche applied science containing 1 sds ten micrograms extracts analyzed sds page total sa wb conditioned medium subjected 02 microm filtration twenty microliters medium electrophoresed 165 tris tricine gels transferred onto 02 microm nitrocellulose membranes membranes microwaved 5 min phosphate buffered saline blocked 5 fat free milk tbs incubated 6e10 11000 pierce superblock overnight 4 degrees c standard ecl detection procedure used
0.2674377.16162502.html.plaintext.txt	15	western blotting cells washed phosphate buffered saline solubilized ice cold hepes buffer 25 mm hepes ph 74 150 mm nacl 1x complete protease inhibitor mixture roche applied science containing 1 sds ten micrograms extracts analyzed sds page total sa wb conditioned medium subjected 02 microm filtration twenty microliters medium electrophoresed 165 tris tricine gels transferred onto 02 microm nitrocellulose membranes membranes microwaved 5 min phosphate buffered saline blocked 5 fat free milk tbs incubated 6e10 11000 pierce superblock overnight 4 degrees c standard ecl detection procedure used
0.2674377.16162502.html.plaintext.txt	16	immunoprecipitations ips cells solubilized ice cold ripa buffer 50 mm tris hcl ph 8 150 mm nacl 01 sds 1 nonidet p 40 05 sodium deoxycholate 1x complete five hundred micrograms cell extracts total intracellular ip 1 ml corresponding conditioned medium diluted 4x ripa buffer sa40 sa42 ips precleared protein protein g sepharose amersham biosciences 2 h 4 degrees c supernatants incubated overnight 4 degrees c 3 microl antibodies 4g8 total intracellular ip fca3340 sa40 ip fca3542 sa42 ip supernatants treated 2 h 4 degrees c protein sepharose polyclonal antibodies protein g sepharose monoclonal antibodies ips washed ice cold ripa buffer analyzed wb using 6e10 antibody described
0.2674377.16162502.html.plaintext.txt	17	enzyme linked immunosorbent assay elisa 6e10 capture antibody coated 2 microgml coating buffer 227 gliter k2hpo4 348 gliter kh2po4 ph 72 8 gliter nacl 0372 gliter edta 01 gliter nan3 96 well immunoassay plates 24 h 4 degrees c plates washed 005 tween 20 tbs ttbs blocked pierce tbs starting block buffer 1 h room temperature samples conditioned medium a1 40 standards biotinylated 4g8 reporter antibody 05 microgml 20 pierce superblock added plates incubated room temperature 2 h following washing ttbs streptavidin horseradish peroxidase southern biotech 025 microgml 20 superblock added wells 1 h room temperature fluorogenic substrate amplex ultra red molecular probes added plates incubated 15 min reaction products quantified using tecan genios pro plate reader 535 nm excitation 590 nm emission
0.2674377.16162502.html.plaintext.txt	18	enzymatic activity assays neprilysin nep activity assays intact cells incubated 37 degrees c 2 h opti mem containing 50 microm suc aaf amc absence presence 20 microm thiorphan cells homogenized protein concentrations determined using bradford assay bio rad chymotrypsin like activity endogenous proteasome determined solubilizing cells activity assay buffer 25 mm hepes ph 75 05 mm edta 005 nonidet p 40 0001 sds cell extracts 40 microg incubated 37 degrees c 2 h 100 microl activity assay buffer containing 50 microm suc llvy amc absence presence 10 microm alln purified proteasome activity assays 125 microgml purified human 20 proteasome incubated 37 degrees c 2 h 100 microl activity assay buffer containing 50 microm suc llvy amc release amc measured fluorescence spectrophotometry using wavelengths 340 nm excitation 535 nm emission tecan genios pro enzymatic activities expressed nmol amcminmg protein
0.2674377.16162502.html.plaintext.txt	19	enzymatic activity assays neprilysin nep activity assays intact cells incubated 37 degrees c 2 h opti mem containing 50 microm suc aaf amc absence presence 20 microm thiorphan cells homogenized protein concentrations determined using bradford assay bio rad chymotrypsin like activity endogenous proteasome determined solubilizing cells activity assay buffer 25 mm hepes ph 75 05 mm edta 005 nonidet p 40 0001 sds cell extracts 40 microg incubated 37 degrees c 2 h 100 microl activity assay buffer containing 50 microm suc llvy amc absence presence 10 microm alln purified proteasome activity assays 125 microgml purified human 20 proteasome incubated 37 degrees c 2 h 100 microl activity assay buffer containing 50 microm suc llvy amc release amc measured fluorescence spectrophotometry using wavelengths 340 nm excitation 535 nm emission tecan genios pro enzymatic activities expressed nmol amcminmg protein
0.2674377.16162502.html.plaintext.txt	20	view larger version 18k figure 1 structure quercetin catechin resveratrol
0.2674377.16162502.html.plaintext.txt	21	view larger version 18k figure 1 structure quercetin catechin resveratrol
0.2674377.16162502.html.plaintext.txt	22	view larger version 25k figure 2 effect resveratrol quercetin catechin levels app695 hek293 cells b cells treated 24 h indicated concentrations polyphenols dissolved me2so medium changed drug treatments continued another 2 h allow secretion total sa analyzed elisa wb b panel b sa40 b sa42 c total intracellular panel d total ia analyzed ip wb see experimental procedures full length app b panel e analyzed wb c cells treated different periods time indicated concentrations resveratrol total sa analyzed b final concentration me2so adjusted 004 vv conditions histogram shows mean plus minus sd 3 4 independent experiments western blots shown representative least three independent experiments
0.2674377.16162502.html.plaintext.txt	23	view larger version 25k figure 2 effect resveratrol quercetin catechin levels app695 hek293 cells b cells treated 24 h indicated concentrations polyphenols dissolved me2so medium changed drug treatments continued another 2 h allow secretion total sa analyzed elisa wb b panel b sa40 b sa42 c total intracellular panel d total ia analyzed ip wb see experimental procedures full length app b panel e analyzed wb c cells treated different periods time indicated concentrations resveratrol total sa analyzed b final concentration me2so adjusted 004 vv conditions histogram shows mean plus minus sd 3 4 independent experiments western blots shown representative least three independent experiments
0.2674377.16162502.html.plaintext.txt	24	view larger version 42k figure 3 effect resveratrol app processing n2a cells expressing wild type swedish app695 wild type app695 n2a cells treated 24 h increasing concentrations resveratrol 1 microm secretase inhibitor l 685458 first lane medium changed drug treatments continued another 2 h allow secretion total sa levels analyzed wb panel app c terminal fragments c99 c89 c83 panel b short film exposure panel c long film exposure app intracellular domain aicd panel d analyzed wb using r1 antibody full length app panel e secreted app sapp panel f probed antibodies 22c11 6e10 respectively b swedish app695 n2a cells treated resveratrol l 685458 described total sa analyzed western blots shown representative least three independent experiments
0.2674377.16162502.html.plaintext.txt	25	view larger version 42k figure 3 effect resveratrol app processing n2a cells expressing wild type swedish app695 wild type app695 n2a cells treated 24 h increasing concentrations resveratrol 1 microm secretase inhibitor l 685458 first lane medium changed drug treatments continued another 2 h allow secretion total sa levels analyzed wb panel app c terminal fragments c99 c89 c83 panel b short film exposure panel c long film exposure app intracellular domain aicd panel d analyzed wb using r1 antibody full length app panel e secreted app sapp panel f probed antibodies 22c11 6e10 respectively b swedish app695 n2a cells treated resveratrol l 685458 described total sa analyzed western blots shown representative least three independent experiments
0.2674377.16162502.html.plaintext.txt	26	vitro secretase assays vitro assays performed described previously 15 briefly cells resuspended 05 ml35 mm dish hypotonic buffer 10 mm mops ph 70 10 mm kcl homogenized ice postnuclear supernatant prepared centrifugation 1000 x g 15 min 4 degrees c crude membranes isolated postnuclear supernatant centrifugation 16000 x g 40 min 4 degrees c membranes resuspended 25 microlof assay buffer 150 mm sodium citrate ph 64 1x complete incubated 37 degrees c 4 h absence presence indicated drugs samples analyzed wb
0.2674377.16162502.html.plaintext.txt	27	vitro secretase assays vitro assays performed described previously 15 briefly cells resuspended 05 ml35 mm dish hypotonic buffer 10 mm mops ph 70 10 mm kcl homogenized ice postnuclear supernatant prepared centrifugation 1000 x g 15 min 4 degrees c crude membranes isolated postnuclear supernatant centrifugation 16000 x g 40 min 4 degrees c membranes resuspended 25 microlof assay buffer 150 mm sodium citrate ph 64 1x complete incubated 37 degrees c 4 h absence presence indicated drugs samples analyzed wb
0.2674377.16162502.html.plaintext.txt	28	results top abstract introduction experimental procedures results discussion references evidence increasing moderate wine intake reduces risk developing ad 7 10 sought determine whether three powerful antioxidant polyphenols found red wine resveratrol trans 345 trihydroxystilbene see fig 1 quercetin 33457 pentahydroxyflavone catechin trans 33457 pentahydroxyflavane modulate levels end treated app695 transfected hek293 cells increasing concentrations different polyphenols analyzed levels elisa wb total secreted fig 2 b panel including secreted a40 fig 2b panel b a42 fig 2b panel c markedly reduced 20 40 microm resveratrol 24 h incubation whereas quercetin catechin apparently ineffective concentrations fig 2 b panel concentration range resveratrol also reduced total intracellular fig 2b panel d resveratrol treatment lead intracellular accumulation fig 2b panel d concluded secretion impaired determine whether effect resveratrol time dependent app695 hek293 cells treated different periods time 10 20 microm polyphenol fig 2c shows although resveratrol affect levels 12 h incubation inhibitory effect levels gradually strengthened longer incubation periods 48 72 h
0.2674377.16162502.html.plaintext.txt	29	results top abstract introduction experimental procedures results discussion references evidence increasing moderate wine intake reduces risk developing ad 7 10 sought determine whether three powerful antioxidant polyphenols found red wine resveratrol trans 345 trihydroxystilbene see fig 1 quercetin 33457 pentahydroxyflavone catechin trans 33457 pentahydroxyflavane modulate levels end treated app695 transfected hek293 cells increasing concentrations different polyphenols analyzed levels elisa wb total secreted fig 2 b panel including secreted a40 fig 2b panel b a42 fig 2b panel c markedly reduced 20 40 microm resveratrol 24 h incubation whereas quercetin catechin apparently ineffective concentrations fig 2 b panel concentration range resveratrol also reduced total intracellular fig 2b panel d resveratrol treatment lead intracellular accumulation fig 2b panel d concluded secretion impaired determine whether effect resveratrol time dependent app695 hek293 cells treated different periods time 10 20 microm polyphenol fig 2c shows although resveratrol affect levels 12 h incubation inhibitory effect levels gradually strengthened longer incubation periods 48 72 h
0.2674377.16162502.html.plaintext.txt	30	view larger version 34k figure 4 resveratrol affect secretase activity vitro panel membrane preparations app695 hek293 cells see experimental procedures incubated vitro 4 degrees c lane 1 37 degrees c lanes 2 7 4 h absence presence indicated drugs total produced vitro analyzed wb 6e10 antibody panels b c membranes app695 hek293 cells treated culture 24 h absence presence indicated drugs incubated described total n cadherin derived c terminal fragments n cadctf1 n cadctf2 analyzed wb antibodies 6e10 panel b c32 panel c respectively
0.2674377.16162502.html.plaintext.txt	31	view larger version 34k figure 4 resveratrol affect secretase activity vitro panel membrane preparations app695 hek293 cells see experimental procedures incubated vitro 4 degrees c lane 1 37 degrees c lanes 2 7 4 h absence presence indicated drugs total produced vitro analyzed wb 6e10 antibody panels b c membranes app695 hek293 cells treated culture 24 h absence presence indicated drugs incubated described total n cadherin derived c terminal fragments n cadctf1 n cadctf2 analyzed wb antibodies 6e10 panel b c32 panel c respectively
0.2674377.16162502.html.plaintext.txt	32	exclude cell line specific effect also treated app695 transfected mouse neuroblastoma n2a cells resveratrol showed resveratrol inhibited total secreted concentration range another cell line fig 3a panel secreted produced n2a cells overexpressing app695 bearing familial ad swedish mutation also reduced similar treatments fig 3b determine whether resveratrol affects app metabolism monitored wb levels app holoprotein proteolytic fragments concentrations resveratrol neither affected full length app levels fig 2b panel e fig 3a panel e reduced secreted app immunoreactivity fig 3a panel f addition resveratrol affect steady state levels app c terminal fragments c99 c89 c83 fig 3a panels b c app intracellular domain aicd fig 3a panel d together data indicate resveratrol effect secretase mediated cleavages app stability app c terminal fragments therefore resveratrol affect app metabolism production
0.2674377.16162502.html.plaintext.txt	33	exclude cell line specific effect also treated app695 transfected mouse neuroblastoma n2a cells resveratrol showed resveratrol inhibited total secreted concentration range another cell line fig 3a panel secreted produced n2a cells overexpressing app695 bearing familial ad swedish mutation also reduced similar treatments fig 3b determine whether resveratrol affects app metabolism monitored wb levels app holoprotein proteolytic fragments concentrations resveratrol neither affected full length app levels fig 2b panel e fig 3a panel e reduced secreted app immunoreactivity fig 3a panel f addition resveratrol affect steady state levels app c terminal fragments c99 c89 c83 fig 3a panels b c app intracellular domain aicd fig 3a panel d together data indicate resveratrol effect secretase mediated cleavages app stability app c terminal fragments therefore resveratrol affect app metabolism production
0.2674377.16162502.html.plaintext.txt	34	confirm resveratrol inhibit secretase directly resveratrol used cell free assay designed produce vitro vitro assay membrane preparations isolated app695 hek293 cells incubated 37 degrees c 4 h absence presence increasing concentrations resveratrol production affected presence resveratrol vitro fig 4a however levels produced vitro membranes isolated cells treated culture polyphenol significantly reduced fig 4b indicating resveratrol promoted reduction without directly affecting secretases
0.2674377.16162502.html.plaintext.txt	35	confirm resveratrol inhibit secretase directly resveratrol used cell free assay designed produce vitro vitro assay membrane preparations isolated app695 hek293 cells incubated 37 degrees c 4 h absence presence increasing concentrations resveratrol production affected presence resveratrol vitro fig 4a however levels produced vitro membranes isolated cells treated culture polyphenol significantly reduced fig 4b indicating resveratrol promoted reduction without directly affecting secretases
0.2674377.16162502.html.plaintext.txt	36	view larger version 27k figure 5 proteasome inhibition prevents resveratrol mediated decrease app695 hek293 cells incubated 24 h increasing concentrations resveratrol thiorphan sensitive endoproteolytic activity nep activity determined intact cells described experimental procedures b app695 hek293 cells treated 24 h resveratrol 40 microm vehicle dimethyl sulfoxide dmso absence control presence phosphoramidon 50 microm thiorphan 20 microm insulin 10 microm lactacystin 2 microm z gpfl cho 25 microm yu101 1 microm total sa analyzed elisa described fig 2a c app695 hek293 cells transfected 5 sirnas buffer control treated 24 h resveratrol 40 microm vehicle dimethyl sulfoxide dmso cells harvested analyzed wb anti 5 antibody panel anti tubulin antibody panel c total sa panel b analyzed wb described fig 2b alln sensitive endoproteolytic activity proteasome activity determined described experimental procedures d purified human 20 proteasome incubated 30 min lactacystin 20 microm dimethyl sulfoxide resveratrol 40 microm proteasome activity monitored c e app695 hek293 cells treated 24 h dimethyl sulfoxide resveratrol 40 microm cells harvested analyzed wb anti 20 proteasome subunits antibody panel anti catenin antibody panel b five hundred nanograms purified human 20 proteasome analyzed wb panel last lane values mean plus minus sd 3 5 independent experiments p 005 p 001 students test
0.2674377.16162502.html.plaintext.txt	37	view larger version 27k figure 5 proteasome inhibition prevents resveratrol mediated decrease app695 hek293 cells incubated 24 h increasing concentrations resveratrol thiorphan sensitive endoproteolytic activity nep activity determined intact cells described experimental procedures b app695 hek293 cells treated 24 h resveratrol 40 microm vehicle dimethyl sulfoxide dmso absence control presence phosphoramidon 50 microm thiorphan 20 microm insulin 10 microm lactacystin 2 microm z gpfl cho 25 microm yu101 1 microm total sa analyzed elisa described fig 2a c app695 hek293 cells transfected 5 sirnas buffer control treated 24 h resveratrol 40 microm vehicle dimethyl sulfoxide dmso cells harvested analyzed wb anti 5 antibody panel anti tubulin antibody panel c total sa panel b analyzed wb described fig 2b alln sensitive endoproteolytic activity proteasome activity determined described experimental procedures d purified human 20 proteasome incubated 30 min lactacystin 20 microm dimethyl sulfoxide resveratrol 40 microm proteasome activity monitored c e app695 hek293 cells treated 24 h dimethyl sulfoxide resveratrol 40 microm cells harvested analyzed wb anti 20 proteasome subunits antibody panel anti catenin antibody panel b five hundred nanograms purified human 20 proteasome analyzed wb panel last lane values mean plus minus sd 3 5 independent experiments p 005 p 001 students test
0.2674377.16162502.html.plaintext.txt	38	secretase targets several type proteins including cell cell adhesion receptors e n cadherins 15 16 cleavage n cadherin secretase produces transcriptionally active intracellular fragment n cadctf2 proteolytic cleavage intermediate c terminal fragment n cadctf1 15 using similar cell free assay determined production n cadctf2 affected resveratrol treatment fig 4c confirming absence inhibitory effect resveratrol secretase activity together observation resveratrol affect levels app holoprotein c terminal proteolytic fragments data indicate resveratrol target producing activity rather promoted clearance
0.2674377.16162502.html.plaintext.txt	39	secretase targets several type proteins including cell cell adhesion receptors e n cadherins 15 16 cleavage n cadherin secretase produces transcriptionally active intracellular fragment n cadctf2 proteolytic cleavage intermediate c terminal fragment n cadctf1 15 using similar cell free assay determined production n cadctf2 affected resveratrol treatment fig 4c confirming absence inhibitory effect resveratrol secretase activity together observation resveratrol affect levels app holoprotein c terminal proteolytic fragments data indicate resveratrol target producing activity rather promoted clearance
0.2674377.16162502.html.plaintext.txt	40	based observations aimed determine whether resveratrol treatment promotes degradation peptides degraded vivo least four metalloendopeptidases nep endothelin converting enzyme 1 2 ece 1 2 insulin degrading enzyme ide 17 recent evidence indicates long term treatment resveratrol promotes nep activity sk n sh cells 18 using thiorphan sensitive enzymatic assays intact hek293 cells confirmed nep activity significantly increased upon resveratrol treatment fig 5a however inhibition nep phosphoramidon thiorphan app695 hek293 cells could prevent decrease levels triggered resveratrol fig 5b phosphoramidon also inhibits ece 1 2 concluded enzymatic activities also involved resveratrol mediated decrease pretreatment insulin acts competitive inhibitor ide rescue levels resveratrol treatment fig 5b thus resveratrol promote degradation nep ece 1 2 ide hek293 cells
0.2674377.16162502.html.plaintext.txt	41	based observations aimed determine whether resveratrol treatment promotes degradation peptides degraded vivo least four metalloendopeptidases nep endothelin converting enzyme 1 2 ece 1 2 insulin degrading enzyme ide 17 recent evidence indicates long term treatment resveratrol promotes nep activity sk n sh cells 18 using thiorphan sensitive enzymatic assays intact hek293 cells confirmed nep activity significantly increased upon resveratrol treatment fig 5a however inhibition nep phosphoramidon thiorphan app695 hek293 cells could prevent decrease levels triggered resveratrol fig 5b phosphoramidon also inhibits ece 1 2 concluded enzymatic activities also involved resveratrol mediated decrease pretreatment insulin acts competitive inhibitor ide rescue levels resveratrol treatment fig 5b thus resveratrol promote degradation nep ece 1 2 ide hek293 cells
0.2674377.16162502.html.plaintext.txt	42	converging evidence indicates resveratrol promotes proteasomal degradation specific subset proteins including cyclin d1 19 estrogen receptor 20 hypoxia inducible factor 1 21 proteasome shown modulate levels 22 asked whether proteasome inhibition rescues levels upon resveratrol treatment fig 5b shows treatments selective proteasome inhibitors lactacystin z gpfl cho yu101 significantly prevented resveratrol induced decrease confirm involvement proteasome anti amyloidogenic effect resveratrol sought regulate proteasome activity sirna directed silencing proteasome multicatalytic protease complex formed different subunits encoded several genes 23 yu101 highly selective chymotrypsin like activity proteasome 24 subunit 5 critical proteolytic activity 23 asked whether sirna directed silencing proteasome subunit 5 prevents resveratrol induced decrease transfection sirnas directed subunit 5 strongly decreased 5 protein expression fig 5c panel inhibited 60 chymotrypsin like activity proteasome fig 5c conditions observed strong inhibition resveratrol induced decrease fig 5c panel b
0.2674377.16162502.html.plaintext.txt	43	converging evidence indicates resveratrol promotes proteasomal degradation specific subset proteins including cyclin d1 19 estrogen receptor 20 hypoxia inducible factor 1 21 proteasome shown modulate levels 22 asked whether proteasome inhibition rescues levels upon resveratrol treatment fig 5b shows treatments selective proteasome inhibitors lactacystin z gpfl cho yu101 significantly prevented resveratrol induced decrease confirm involvement proteasome anti amyloidogenic effect resveratrol sought regulate proteasome activity sirna directed silencing proteasome multicatalytic protease complex formed different subunits encoded several genes 23 yu101 highly selective chymotrypsin like activity proteasome 24 subunit 5 critical proteolytic activity 23 asked whether sirna directed silencing proteasome subunit 5 prevents resveratrol induced decrease transfection sirnas directed subunit 5 strongly decreased 5 protein expression fig 5c panel inhibited 60 chymotrypsin like activity proteasome fig 5c conditions observed strong inhibition resveratrol induced decrease fig 5c panel b
0.2674377.16162502.html.plaintext.txt	44	view larger version 33k figure 6 effect resveratrol analogues levels app695 hek293 cells treated 24 h indicated concentrations resveratrol analogues dissolved me2so total sa analyzed fig 2b final concentration me2so adjusted 004 vv conditions histogram shows relative amounts total sa detected wb upper panel
0.2674377.16162502.html.plaintext.txt	45	view larger version 33k figure 6 effect resveratrol analogues levels app695 hek293 cells treated 24 h indicated concentrations resveratrol analogues dissolved me2so total sa analyzed fig 2b final concentration me2so adjusted 004 vv conditions histogram shows relative amounts total sa detected wb upper panel
0.2674377.16162502.html.plaintext.txt	46	investigated whether resveratrol directly stimulates proteasome activity fig 5d chymotrypsin like activity purified proteasome monitored upon vitro incubation resveratrol activity also assessed endogenous proteasome cell extracts treatment polyphenol cell cultures fig 5c significant effect resveratrol chymotrypsin like activity purified endogenous proteasome observed histograms fig 5 d c respectively resveratrol effectively reduced levels 24 h incubation also asked whether resveratrol modifies proteasome subunit transcription found resveratrol treatment markedly affect steady state levels several proteasome subunits hek293 cells fig 5c panel fig 5e panel together results demonstrate resveratrol promotes proteasome dependent intracellular degradation via mechanism increase total proteasome activity consistent conclusion levels catenin cytosolic protein degraded ubiquitin proteasome system 25 affected resveratrol hek293 cells fig 5e panel b
0.2674377.16162502.html.plaintext.txt	47	investigated anti amyloidogenic effect several resveratrol analogues three analogues tested piceatannol trans 3345 tetrahydroxystilbene contains additional hydroxyl group c 3 two methoxy analogues trimethoxy resveratrol trans 345 trimethoxystilbene tms interestingly three analogues able decrease levels fig 6 however compared resveratrol fig 2a piceatannol trimethoxy resveratrol less potent whereas tms comparable potency reducing amounts fig 6
0.2674377.16162502.html.plaintext.txt	48	investigated anti amyloidogenic effect several resveratrol analogues three analogues tested piceatannol trans 3345 tetrahydroxystilbene contains additional hydroxyl group c 3 two methoxy analogues trimethoxy resveratrol trans 345 trimethoxystilbene tms interestingly three analogues able decrease levels fig 6 however compared resveratrol fig 2a piceatannol trimethoxy resveratrol less potent whereas tms comparable potency reducing amounts fig 6
0.2674377.16162502.html.plaintext.txt	49	discussion top abstract introduction experimental procedures results discussion references data show resveratrol strongly reduces produced different cell lines expressing wild type swedish mutant app695 resveratrol acts promoting intracellular degradation amyloid peptide mechanism implicates proteasome pharmacological studies show none previously reported degrading metalloendopeptidases nep ece 1 2 ide involved clearance finally demonstrate anti amyloidogenic activity two methoxy analogues resveratrol trimethoxy resveratrol tms suggesting chemical modifications resveratrol done context improving potency stability bioavailability therefore therapeutic use
0.2674377.16162502.html.plaintext.txt	50	discussion top abstract introduction experimental procedures results discussion references data show resveratrol strongly reduces produced different cell lines expressing wild type swedish mutant app695 resveratrol acts promoting intracellular degradation amyloid peptide mechanism implicates proteasome pharmacological studies show none previously reported degrading metalloendopeptidases nep ece 1 2 ide involved clearance finally demonstrate anti amyloidogenic activity two methoxy analogues resveratrol trimethoxy resveratrol tms suggesting chemical modifications resveratrol done context improving potency stability bioavailability therefore therapeutic use
0.2674377.16162502.html.plaintext.txt	51	additional studies needed fully elucidate role proteasome mechanism intracellular clearance number possible functions proteasome regulation metabolism ascribed multicatalytic complex 22 proteasome targets degradation c99 three core components secretase complex presenilins aph 1 pen 2 22 suggesting proteasome activation may decrease levels reducing amounts c99 available altering secretase activity data show reduction c99 levels fig 3a panel c alteration secretase mediated cleavages app n cadherin upon resveratrol treatment figs 3 4 thus excluding possibility resveratrol lowers promoting proteasomal degradation c99 secretase components recent evidence also suggests degraded proteasome dependent endoplasmic reticulum er associated degradation 26 using cell free reconstitutions er derived brain microsomes schmitz et al 26 show translocate er cytosol directly degraded proteasome conceivable resveratrol promotes clearance mechanism however er represents small fraction total produced small pool produced er appears controlled er associated degradation unlikely severe reduction levels observed presence resveratrol entirely due increase clearance mechanism therefore hypothesize resveratrol may act indirectly selectively stimulating proteasomal degradation yet identified critical regulators clearance
0.2674377.16162502.html.plaintext.txt	52	additional studies needed fully elucidate role proteasome mechanism intracellular clearance number possible functions proteasome regulation metabolism ascribed multicatalytic complex 22 proteasome targets degradation c99 three core components secretase complex presenilins aph 1 pen 2 22 suggesting proteasome activation may decrease levels reducing amounts c99 available altering secretase activity data show reduction c99 levels fig 3a panel c alteration secretase mediated cleavages app n cadherin upon resveratrol treatment figs 3 4 thus excluding possibility resveratrol lowers promoting proteasomal degradation c99 secretase components recent evidence also suggests degraded proteasome dependent endoplasmic reticulum er associated degradation 26 using cell free reconstitutions er derived brain microsomes schmitz et al 26 show translocate er cytosol directly degraded proteasome conceivable resveratrol promotes clearance mechanism however er represents small fraction total produced small pool produced er appears controlled er associated degradation unlikely severe reduction levels observed presence resveratrol entirely due increase clearance mechanism therefore hypothesize resveratrol may act indirectly selectively stimulating proteasomal degradation yet identified critical regulators clearance
0.2674377.16162502.html.plaintext.txt	53	also important determine molecular targets resveratrol pathway clearance resveratrol interacts several proteins including members sirtuin family sirtuins evolutionarily conserved deacetylases important functions longevity 27 resveratrol found act potent activator human sirtuin sirt1 vitro yeast homologue sir2 vivo mechanism may extend life span yeast 28 moreover resveratrol sirt1 activation recently linked neuroprotective pathways models axonal degeneration 29 neuronal dysfunctions caused mutant polyglutamines 30 would therefore interest determine whether sirt1 involved resveratrol induced decrease
0.2674377.16162502.html.plaintext.txt	54	also important determine molecular targets resveratrol pathway clearance resveratrol interacts several proteins including members sirtuin family sirtuins evolutionarily conserved deacetylases important functions longevity 27 resveratrol found act potent activator human sirtuin sirt1 vitro yeast homologue sir2 vivo mechanism may extend life span yeast 28 moreover resveratrol sirt1 activation recently linked neuroprotective pathways models axonal degeneration 29 neuronal dysfunctions caused mutant polyglutamines 30 would therefore interest determine whether sirt1 involved resveratrol induced decrease
0.2674377.16162502.html.plaintext.txt	55	evidence compelling decrease proteasome activity occurs ad brains 31 32 unclear however whether decrease proteasome activity parallel increase levels proposed may lead proteasome inhibition 33 suggesting high levels ad brain may create vicious cycle inhibiting proteasome blocking degradation critical regulators clearance context data reveal important mechanism selective proteasome activation anti amyloidogenic effect resveratrol support therapeutic potential natural polyphenol
0.2674377.16162502.html.plaintext.txt	56	evidence compelling decrease proteasome activity occurs ad brains 31 32 unclear however whether decrease proteasome activity parallel increase levels proposed may lead proteasome inhibition 33 suggesting high levels ad brain may create vicious cycle inhibiting proteasome blocking degradation critical regulators clearance context data reveal important mechanism selective proteasome activation anti amyloidogenic effect resveratrol support therapeutic potential natural polyphenol
0.2674377.16162502.html.plaintext.txt	57	footnotes work supported national institute mental health grant 38623 grant american health assistance foundation costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.2674377.16162502.html.plaintext.txt	58	footnotes work supported national institute mental health grant 38623 grant american health assistance foundation costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.2674377.16162502.html.plaintext.txt	59	1 correspondence addressed litwin zucker research center study alzheimers disease memory disorders north shore long island jewish institute medical research 350 community dr manhasset ny 11030 tel 516 562 3492 e mail pmarambaataecomyuedu u d
0.2674377.16162502.html.plaintext.txt	60	2 abbreviations used ad alzheimers disease suc succinyl tms trans 2345 tetramethoxystilbene alln n acetyl ll norleucinal cho elisa enzyme linked immunosorbent assay ece endothelin converting enzyme ide insulin degrading enzyme amyloid app amyloid precursor protein amc amido 4 methylcoumarin tricine n 2 hydroxy 11 bishydroxymethylethylglycine wb western blotting ip immunoprecipitation nep neprilysin mops 4 morpholinepropanesulfonic acid er endoplasmic reticulum sirna small interfering rna tbs tris buffered saline sa secreted amyloid z benzyloxycarbonyl
0.2674377.16162502.html.plaintext.txt	61	acknowledgments thank drs f checler n k robakis l dadamio p d mehta generously providing us antibodies cdnas cell lines
0.2674377.16162502.html.plaintext.txt	62	references top abstract introduction experimental procedures results discussion references hardy j selkoe d j 2002 science 297 353 356abstractfree full text tanzi r e bertram l 2005 cell 120 545 555crossrefmedline order article via infotrieve passer b pellegrini l russo c siegel r m lenardo m j schettini g bachmann m tabaton m dadamio l 2000 j alzheimers dis 2 289 301medline order article via infotrieve checler f 1995 j neurochem 65 1431 1444medline order article via infotrieve annaert w de strooper b 2002 annu rev cell dev biol 18 25 51crossrefmedline order article via infotrieve marambaud p robakis n k 2005 genes brain behav 4 134 146crossrefmedline order article via infotrieve luchsinger j tang m x siddiqui m shea mayeux r 2004 j geriatr soc 52 540 546crossrefmedline order article via infotrieve lindsay j laurin d verreault r hebert r helliwell b hill g b mcdowell 2002 j epidemiol 156 445 453abstractfree full text orgogozo j m dartigues j f lafont letenneur l commenges d salamon r renaud breteler m b 1997 rev neurol paris 153 185 192medline order article via infotrieve truelsen thudium d gronbaek m 2002 neurology 59 1313 1319abstractfree full text savaskan e olivieri g meier f seifritz e wirz justice muller spahn f 2003 gerontology 49 380 383crossrefmedline order article via infotrieve jang j h surh y j 2003 free radic biol med 34 1100 1110crossrefmedline order article via infotrieve han y zheng w h bastianetto chabot j g quirion r 2004 br j pharmacol 141 997 1005crossrefmedline order article via infotrieve barelli h lebeau vizzavona j delaere p chevallier n drouot c marambaud p ancolio k buxbaum j d khorkova o heroux j sahasrabudhe martinez j warter j m mohr m checler f 1997 mol med 3 695 707medline order article via infotrieve marambaud p wen p h dutt shioi j takashima siman r robakis n k 2003 cell 114 635 645crossrefmedline order article via infotrieve marambaud p shioi j serban g georgakopoulos sarner nagy v baki l wen p efthimiopoulos shao z wisniewski robakis n k 2002 embo j 21 1948 1956abstractfree full text turner j fisk l nalivaeva n n 2004 ann n y acad sci 1035 1 20abstractfree full text melzig m f escher f 2002 pharmazie 57 556 558medline order article via infotrieve joe k liu h suzui m vural m e xiao d weinstein b 2002 clin cancer res 8 893 903abstractfree full text pozo guisado e lorenzo benayas m j fernandez salguero p m 2004 int j cancer 109 167 173crossrefmedline order article via infotrieve cao z fang j xia c shi x jiang b h 2004 clin cancer res 10 5253 5263abstractfree full text de vrij f m fischer d f van leeuwen f w hol e m 2004 prog neurobiol 74 249 270crossrefmedline order article via infotrieve orlowski m wilk 2000 arch biochem biophys 383 1 16crossrefmedline order article via infotrieve elofsson m splittgerber u myung j mohan r crews c m 1999 chem biol 6 811 822crossrefmedline order article via infotrieve aberle h bauer stappert j kispert kemler r 1997 embo j 16 3797 3804abstractfree full text schmitz schneider kummer m p herzog v 2004 traffic 5 89 101crossrefmedline order article via infotrieve guarente l 2001 trends genet 17 391 392crossrefmedline order article via infotrieve howitz k bitterman k j cohen h y lamming d w lavu wood j g zipkin r e chung p kisielewski zhang l l scherer b sinclair d 2003 nature 425 191 196crossrefmedline order article via infotrieve araki sasaki y milbrandt j 2004 science 305 1010 1013abstractfree full text parker j arango m abderrahmane lambert e tourette c catoire h neri c 2005 nat genet 37 349 350crossrefmedline order article via infotrieve keller j n hanni k b markesbery w r 2000 j neurochem 75 436 439crossrefmedline order article via infotrieve lopez salon m morelli l castano e m soto e f pasquini j m 2000 j neurosci res 62 302 31033co2 c 19708abstractfree full text article abstract full text pdf versions article 2804537377 recent m508246200v1 purchase article view shopping cart alert article cited alert correction posted citation map services email article friend similar articles journal similar articles pubmed alert new issues journal download citation manager copyright permissions google scholar articles marambaud p articles davies p pubmed pubmed citation articles marambaud p articles davies p
0.2674377.16162502.html.plaintext.txt	63	home help feedback subscriptions archive search table contents asbmb journals molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright 2005 american society biochemistry molecular biology
0.2710359.15003956.html.plaintext.txt	0	meta analysis association cathepsin d ala224val gene polymorphism risk alzheimer disease huge gene disease association review christos ntais1 anastasia polycarpou1 john p ioannidis123
0.2710359.15003956.html.plaintext.txt	1	1 clinical molecular epidemiology unit department hygiene epidemiology university ioannina school medicine ioannina greece 2 biomedical research institute foundation research technology hellas ioannina greece 3 institute clinical research health policy studies department medicine tufts new england medical center tufts university school medicine boston ma
0.2710359.15003956.html.plaintext.txt	2	1 clinical molecular epidemiology unit department hygiene epidemiology university ioannina school medicine ioannina greece 2 biomedical research institute foundation research technology hellas ioannina greece 3 institute clinical research health policy studies department medicine tufts new england medical center tufts university school medicine boston ma
0.2710359.15003956.html.plaintext.txt	3	received publication august 5 2003 accepted publication october 10 2003
0.2710359.15003956.html.plaintext.txt	4	abstract top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references c polymorphism exon 2 cathepsin d gene encoding cathepsin d ctsd implicated risk factor alzheimer disease authors performed meta analysis 14 studies 16 comparisons ctsd genotyping 3174 alzheimer disease cases 3298 controls overall random effects odds ratio versus c allele 117 95 confidence interval ci 095 144 study heterogeneity p 001 significant study heterogeneity evidence significant association first hypothesis generating study excluded calculations odds ratio 111 95 ci 091 135 p 029 summary odds ratio carriers versus noncarriers similar subjects carrying carrying apolipoprotein e 4 allele apoe4 increased susceptibility alzheimer disease conferred apoe4 carriage tended prominent presence allele random effects 607 95 ci 419 879 409 95 ci 315 531 carriers noncarriers respectively meta analysis shows ctsd polymorphism major risk factor alzheimer disease although small effect enhancement apoe4 effect cannot excluded
0.2710359.15003956.html.plaintext.txt	5	abstract top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references c polymorphism exon 2 cathepsin d gene encoding cathepsin d ctsd implicated risk factor alzheimer disease authors performed meta analysis 14 studies 16 comparisons ctsd genotyping 3174 alzheimer disease cases 3298 controls overall random effects odds ratio versus c allele 117 95 confidence interval ci 095 144 study heterogeneity p 001 significant study heterogeneity evidence significant association first hypothesis generating study excluded calculations odds ratio 111 95 ci 091 135 p 029 summary odds ratio carriers versus noncarriers similar subjects carrying carrying apolipoprotein e 4 allele apoe4 increased susceptibility alzheimer disease conferred apoe4 carriage tended prominent presence allele random effects 607 95 ci 419 879 409 95 ci 315 531 carriers noncarriers respectively meta analysis shows ctsd polymorphism major risk factor alzheimer disease although small effect enhancement apoe4 effect cannot excluded
0.2710359.15003956.html.plaintext.txt	6	alzheimer disease cathepsin d ctsd epidemiology genetics meta analysis polymorphism genetics
0.2710359.15003956.html.plaintext.txt	7	abbreviations abbreviations ci confidence interval odds ratio
0.2710359.15003956.html.plaintext.txt	8	introduction top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references editor note paper also available website human genome epidemiology network httpwwwcdcgovgenomicshugenetdefaulthtm
0.2710359.15003956.html.plaintext.txt	9	gene top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references cathepsin d intracellular acid protease exhibits beta secretase activity vitro implicated processing amyloid precursor protein tau protein 1 2 cathepsin d gene ctsd located short arm chromosome 11 11p155 consists nine exons synthesis beta amyloid peptide putative key event pathogenesis alzheimer disease beta amyloid derives precursor protein via proteolytic cleavage secretases therefore postulated variants genes coding enzymes involved proteolytic cleavage amyloid precursor protein degradation clearance beta amyloid central nervous system may potential risk factors alzheimer disease
0.2710359.15003956.html.plaintext.txt	10	gene top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references cathepsin d intracellular acid protease exhibits beta secretase activity vitro implicated processing amyloid precursor protein tau protein 1 2 cathepsin d gene ctsd located short arm chromosome 11 11p155 consists nine exons synthesis beta amyloid peptide putative key event pathogenesis alzheimer disease beta amyloid derives precursor protein via proteolytic cleavage secretases therefore postulated variants genes coding enzymes involved proteolytic cleavage amyloid precursor protein degradation clearance beta amyloid central nervous system may potential risk factors alzheimer disease
0.2710359.15003956.html.plaintext.txt	11	gene variants top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references ctsd gene contains polymorphic c transition site position 224 exon 2 polymorphism results ala38 val substitution cathepsin d profragment 3 polymorphism associated increased secretion altered intracellular maturation cathep sin d profragment one study 3 moreover allele associated 50 percent decrease beta amyloid peptide 1 42 levels cerebrospinal fluid patients alzheimer disease 4 finally polymorphism recently reported significantly associated general intelligence healthy elderly people 5
0.2710359.15003956.html.plaintext.txt	12	gene variants top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references ctsd gene contains polymorphic c transition site position 224 exon 2 polymorphism results ala38 val substitution cathepsin d profragment 3 polymorphism associated increased secretion altered intracellular maturation cathep sin d profragment one study 3 moreover allele associated 50 percent decrease beta amyloid peptide 1 42 levels cerebrospinal fluid patients alzheimer disease 4 finally polymorphism recently reported significantly associated general intelligence healthy elderly people 5
0.2710359.15003956.html.plaintext.txt	13	molecular epidemiologic studies presented seemingly contradictory results concerning potential role ctsd polymorphism alzheimer disease 6 19 also controversy whether polymorphism may interact apolipoprotein e 4 allele apoe4 best known genetic determinant sporadic alzhei mer disease 20 single studies may underpowered detect interactions even overall effects given amount accumulated data deemed important perform quantitative synthesis evidence using rigorous methods thus conducted comprehensive meta analysis available studies relating ctsd polymorphism risk alzheimer disease
0.2710359.15003956.html.plaintext.txt	14	molecular epidemiologic studies presented seemingly contradictory results concerning potential role ctsd polymorphism alzheimer disease 6 19 also controversy whether polymorphism may interact apolipoprotein e 4 allele apoe4 best known genetic determinant sporadic alzhei mer disease 20 single studies may underpowered detect interactions even overall effects given amount accumulated data deemed important perform quantitative synthesis evidence using rigorous methods thus conducted comprehensive meta analysis available studies relating ctsd polymorphism risk alzheimer disease
0.2710359.15003956.html.plaintext.txt	15	disease top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references alzheimer disease common cause progressive cognitive impairment elderly annual incidence approximately 1 percent 65 69 years increasing 40 percent elderly 85 years age 21 22 mutations amyloid precursor protein presenilin 1 presenilin 2 genes account 5 percent cases result autosomally dominant pattern expressed complete penetrance early manifestations 23 alzheimer disease probably slightly common females 24 proven postulated risk factors include head injury particular among males 25 well family history low income low education low occupational status depression exposure aluminum drinking water hypertension syndrome 26 27 conversely use nonsteroidal antiinflammatory drugs treat arthritis associated reduced risk alzhei mer disease estrogen use postmenopausal women 27 physical activity diets high levels vitamins b6 b12 folate red wine moderate quantities may protective 27 prevalence alzheimer disease varies considerably among different population groups 28 least dozens polymorphisms examined relation sporadic alzheimer disease published reviews available 23 29 among conclusive evidence several studies meta analysis thereof apoe4 strong risk factor developing alzheimer disease male female subjects early onset 65 years late onset disease 20 approximately fivefold increase odds developing alzheimer disease single studies also implicated polymorphisms important although reported odds ratios much smaller seen apoe4 attempts replication subsequent research conclusive meta analyses polymorphisms already appeared literature 30 35 suggest significant overall associations several polymorphisms including myeloperoxidase gene promoter polymorphism 30 intronic promoter region polymorphisms presenilin 1 late onset disease 31 insertion deletion polymorphism missense mutation alpha 2 macroglobulin gene 32 several polymorphisms protein tau gene 33 associations modest effect size odds ratios ors 130 135 claimed meta analyses low density lipoprotein receptor related protein gene exon 3 polymorphism 34 insertion deletion polymorphism angiotensin converting enzyme gene 35
0.2710359.15003956.html.plaintext.txt	16	disease top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references alzheimer disease common cause progressive cognitive impairment elderly annual incidence approximately 1 percent 65 69 years increasing 40 percent elderly 85 years age 21 22 mutations amyloid precursor protein presenilin 1 presenilin 2 genes account 5 percent cases result autosomally dominant pattern expressed complete penetrance early manifestations 23 alzheimer disease probably slightly common females 24 proven postulated risk factors include head injury particular among males 25 well family history low income low education low occupational status depression exposure aluminum drinking water hypertension syndrome 26 27 conversely use nonsteroidal antiinflammatory drugs treat arthritis associated reduced risk alzhei mer disease estrogen use postmenopausal women 27 physical activity diets high levels vitamins b6 b12 folate red wine moderate quantities may protective 27 prevalence alzheimer disease varies considerably among different population groups 28 least dozens polymorphisms examined relation sporadic alzheimer disease published reviews available 23 29 among conclusive evidence several studies meta analysis thereof apoe4 strong risk factor developing alzheimer disease male female subjects early onset 65 years late onset disease 20 approximately fivefold increase odds developing alzheimer disease single studies also implicated polymorphisms important although reported odds ratios much smaller seen apoe4 attempts replication subsequent research conclusive meta analyses polymorphisms already appeared literature 30 35 suggest significant overall associations several polymorphisms including myeloperoxidase gene promoter polymorphism 30 intronic promoter region polymorphisms presenilin 1 late onset disease 31 insertion deletion polymorphism missense mutation alpha 2 macroglobulin gene 32 several polymorphisms protein tau gene 33 associations modest effect size odds ratios ors 130 135 claimed meta analyses low density lipoprotein receptor related protein gene exon 3 polymorphism 34 insertion deletion polymorphism angiotensin converting enzyme gene 35
0.2710359.15003956.html.plaintext.txt	17	meta analysis methods top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references identification eligibility relevant studies considered studies examined association ctsd polymorphism alzheimer disease sources included medline embase january 1994 september 2003 search strategy based combinations alzheimer disease ctsd cathepsin d polymorphism allele genetics references retrieved articles also screened
0.2710359.15003956.html.plaintext.txt	18	meta analysis methods top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references identification eligibility relevant studies considered studies examined association ctsd polymorphism alzheimer disease sources included medline embase january 1994 september 2003 search strategy based combinations alzheimer disease ctsd cathepsin d polymorphism allele genetics references retrieved articles also screened
0.2710359.15003956.html.plaintext.txt	19	case control studies eligible determined distribution ctsd genotypes alzheimer disease cases regardless age onset concurrent control group dementia free subjects using molecular method genotyping cases alzheimer disease eligible regardless whether family history alzhei mer disease however excluded family based studies pedigrees several affected cases per family analysis based linkage considerations
0.2710359.15003956.html.plaintext.txt	20	case control studies eligible determined distribution ctsd genotypes alzheimer disease cases regardless age onset concurrent control group dementia free subjects using molecular method genotyping cases alzheimer disease eligible regardless whether family history alzhei mer disease however excluded family based studies pedigrees several affected cases per family analysis based linkage considerations
0.2710359.15003956.html.plaintext.txt	21	data extraction two investigators independently extracted data reached consensus items following information sought report authors journal year publication country origin selection characteristics alzheimer disease cases controls demographics ethnic group study population eligible genotyped cases controls number cases controls ctsd genotype studies including subjects different ethnic groups data extracted separately ethnicity whenever possible furthermore examined whether matching used whether specific mention blinding personnel performed genotyping clinical status subjects whether genotyping method validated
0.2710359.15003956.html.plaintext.txt	22	data extraction two investigators independently extracted data reached consensus items following information sought report authors journal year publication country origin selection characteristics alzheimer disease cases controls demographics ethnic group study population eligible genotyped cases controls number cases controls ctsd genotype studies including subjects different ethnic groups data extracted separately ethnicity whenever possible furthermore examined whether matching used whether specific mention blinding personnel performed genotyping clinical status subjects whether genotyping method validated
0.2710359.15003956.html.plaintext.txt	23	meta analysis primary analysis compared alzheimer disease cases controls contrast versus c alleles analysis aims detect overall differences also examined contrast extremes homozygotes tt versus cc finally examined contrast tt versus ct cc contrast ct tt versus cc contrasts correspond recessive dominant effects respectively allele
0.2710359.15003956.html.plaintext.txt	24	meta analysis primary analysis compared alzheimer disease cases controls contrast versus c alleles analysis aims detect overall differences also examined contrast extremes homozygotes tt versus cc finally examined contrast tt versus ct cc contrast ct tt versus cc contrasts correspond recessive dominant effects respectively allele
0.2710359.15003956.html.plaintext.txt	25	odds ratio used metric choice genetic contrast estimated study heterogeneity across eligible comparisons using chi square based q statistic 36 heterogeneity considered significant p 010 data combined using fixed effects mantel haenszel random effects dersimonian laird models 37 random effects incorporate estimate study variance tend provide wider confidence intervals results constituent studies differ among absence study heterogeneity two methods provide identical results random effects appropriate heterogeneity present 37
0.2710359.15003956.html.plaintext.txt	26	odds ratio used metric choice genetic contrast estimated study heterogeneity across eligible comparisons using chi square based q statistic 36 heterogeneity considered significant p 010 data combined using fixed effects mantel haenszel random effects dersimonian laird models 37 random effects incorporate estimate study variance tend provide wider confidence intervals results constituent studies differ among absence study heterogeneity two methods provide identical results random effects appropriate heterogeneity present 37
0.2710359.15003956.html.plaintext.txt	27	also performed cumulative meta analysis 38 recursive cumulative meta analysis 39 40 evaluate whether summary odds ratio versus c contrast changed time data accumulated whether strength association changed first hypothesis generating study excluded calculations 41 inverted funnel plots begg mazumdar publication bias diagnostic nonparametric correlation coefficient 42 evaluated whether magnitude observed association related variance study whether large studies gave different results compared smaller ones 43 finally evaluated whether summary results different analysis limited studies intensive efforts exclude alzheimer disease controls clearly performed neuropsychological testing controls
0.2710359.15003956.html.plaintext.txt	28	also performed cumulative meta analysis 38 recursive cumulative meta analysis 39 40 evaluate whether summary odds ratio versus c contrast changed time data accumulated whether strength association changed first hypothesis generating study excluded calculations 41 inverted funnel plots begg mazumdar publication bias diagnostic nonparametric correlation coefficient 42 evaluated whether magnitude observed association related variance study whether large studies gave different results compared smaller ones 43 finally evaluated whether summary results different analysis limited studies intensive efforts exclude alzheimer disease controls clearly performed neuropsychological testing controls
0.2710359.15003956.html.plaintext.txt	29	previous investigations alluded possibility allele may interact apoe4 allele conferring susceptibility alzheimer disease 7 9 thus also evaluated effect allele carriage risk alzheimer disease separately apoe4 positive apoe4 negative subjects moreover evaluated genetic effect conferred presence apoe4 separately subjects carrying allele carrying allele odds ratios combined fixed random effects models described data reported communicated primary investigators obtain information whenever possible
0.2710359.15003956.html.plaintext.txt	30	previous investigations alluded possibility allele may interact apoe4 allele conferring susceptibility alzheimer disease 7 9 thus also evaluated effect allele carriage risk alzheimer disease separately apoe4 positive apoe4 negative subjects moreover evaluated genetic effect conferred presence apoe4 separately subjects carrying allele carrying allele odds ratios combined fixed random effects models described data reported communicated primary investigators obtain information whenever possible
0.2710359.15003956.html.plaintext.txt	31	analyses performed spss 110 spss inc chicago illinois meta analyst joseph lau boston massachusetts software whenever 0 values 2 x 2 table added 05 four cells odds ratio could calculated p values two tailed
0.2710359.15003956.html.plaintext.txt	32	meta analysis results top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references eligible studies fourteen studies probing relation ctsd polymorphism alzheimer disease susceptibility identified 6 19 profiled table 1 two eligible studies 6 15 contained subjects two different ethnic groups total 16 separate comparisons considered considerable diversity ethnic groups eleven studies 6 15 19 selected alzheimer disease cases according criteria national institute neurological communicative disorders stroke alzheimer disease related disorders association nincds adrda two studies 16 18 selected alzhei mer disease cases according diagnostic statistical manual mental disorders dsm iiir dsm iv criteria one study 17 clarify exact criteria used diagnosis alzheimer disease five studies 13 17 also included autopsy confirmed alzheimer disease cases two studies 7 16 mentioned included cases family history alzheimer disease eight studies 9 14 18 19 specifically excluded patients remaining clarify background family history one study 6 mentioned 61 percent alzheimer disease cases late onset disease age onset 65 years five studies 8 12 14 19 specifically included late onset alzheimer disease cases one study 18 specifically excluded patients remaining clarify age onset controls diagnosis alzheimer disease amount additional screening general physical neurologic examination psychiatric interview neuropsychological testing blood cerebrospinal fluid studies computed tomography scan mini mental state examination score exclude alzheimer disease differed substantially across studies
0.2710359.15003956.html.plaintext.txt	33	meta analysis results top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references eligible studies fourteen studies probing relation ctsd polymorphism alzheimer disease susceptibility identified 6 19 profiled table 1 two eligible studies 6 15 contained subjects two different ethnic groups total 16 separate comparisons considered considerable diversity ethnic groups eleven studies 6 15 19 selected alzheimer disease cases according criteria national institute neurological communicative disorders stroke alzheimer disease related disorders association nincds adrda two studies 16 18 selected alzhei mer disease cases according diagnostic statistical manual mental disorders dsm iiir dsm iv criteria one study 17 clarify exact criteria used diagnosis alzheimer disease five studies 13 17 also included autopsy confirmed alzheimer disease cases two studies 7 16 mentioned included cases family history alzheimer disease eight studies 9 14 18 19 specifically excluded patients remaining clarify background family history one study 6 mentioned 61 percent alzheimer disease cases late onset disease age onset 65 years five studies 8 12 14 19 specifically included late onset alzheimer disease cases one study 18 specifically excluded patients remaining clarify age onset controls diagnosis alzheimer disease amount additional screening general physical neurologic examination psychiatric interview neuropsychological testing blood cerebrospinal fluid studies computed tomography scan mini mental state examination score exclude alzheimer disease differed substantially across studies
0.2710359.15003956.html.plaintext.txt	34	view table table 1 characteristics studies included meta analysis specific matching age described five studies 10 12 15 one study also matched sex 10 one study 7 specifically mentioned blinding personnel performed genotyping appropriate molecular methods genotyping used studies used polymerase chain reaction two studies 14 18 also used dynamic allele specific hybridization
0.2710359.15003956.html.plaintext.txt	35	meta analysis database eligible studies summarized table 2 included total 3175 cases alzheimer disease 3334 controls 3174 3298 respectively genotype data allele highly represented among controls american descent overall prevalence 86 percent 95 percent confidence interval ci 71 101 controls european 78 percent 95 percent ci 70 86 asian 09 percent 95 percent ci 03 15 descent significant heterogeneity prevalence rates allele even across control subjects european descent rate 143 percent among hispanic americans 104 percent italy 101 percent spain lower rates northern european countries 76 percent united kingdom 63 percent sweden 61 percent germany lowest prevalence rate 45 percent polish population overall prevalence tt homozygosity 03 percent 08 percent 02 percent control subjects american european asian descent respectively respective prevalence rates ct heterozygosity 166 percent 140 percent 15 percent respective rates cc homozygosity 831 percent 852 percent 983 percent distribution genotypes control groups consistent hardy weinberg equilibrium studies
0.2710359.15003956.html.plaintext.txt	36	meta analysis database eligible studies summarized table 2 included total 3175 cases alzheimer disease 3334 controls 3174 3298 respectively genotype data allele highly represented among controls american descent overall prevalence 86 percent 95 percent confidence interval ci 71 101 controls european 78 percent 95 percent ci 70 86 asian 09 percent 95 percent ci 03 15 descent significant heterogeneity prevalence rates allele even across control subjects european descent rate 143 percent among hispanic americans 104 percent italy 101 percent spain lower rates northern european countries 76 percent united kingdom 63 percent sweden 61 percent germany lowest prevalence rate 45 percent polish population overall prevalence tt homozygosity 03 percent 08 percent 02 percent control subjects american european asian descent respectively respective prevalence rates ct heterozygosity 166 percent 140 percent 15 percent respective rates cc homozygosity 831 percent 852 percent 983 percent distribution genotypes control groups consistent hardy weinberg equilibrium studies
0.2710359.15003956.html.plaintext.txt	37	view table table 2 distribution ctsd alleles among alzheimer disease cases controls included studies overall effects trend suggesting allele may confer increased susceptibility alzheimer disease figure 1 shown table 3 summary odds ratio 117 random effects p 014 significant heterogeneity among 16 study comparisons p 001 heterogeneity found evidence association tt genotype risk alzheimer disease relative cc genotype significant study heterogeneity evidence association alzhei mer disease discerned also recessive model examined effect trend association seen dominant model random effects 119 95 percent ci 097 147 p 010 study heterogeneity recessive model contrast significant heterogeneity p 005 still seen dominant model contrast subgroup analysis studies cases controls european descent yielded similar results 15 comparisons 11436 alleles 118 95 percent ci 096 146 p 012 p 001 heterogeneity
0.2710359.15003956.html.plaintext.txt	38	view larger version 26k figure 1 meta analysis effect allele versus c allele risk alzheimer disease comparison presented name first author year publication h signifies hispanic subjects j signifies japanese subjects comparison point estimate odds ratio accompanying 95 confidence interval ci shown represents summary random effects estimate comparison along respective 95 confidence interval values 1 denote increased risk alzheimer disease allele
0.2710359.15003956.html.plaintext.txt	39	view larger version 26k figure 1 meta analysis effect allele versus c allele risk alzheimer disease comparison presented name first author year publication h signifies hispanic subjects j signifies japanese subjects comparison point estimate odds ratio accompanying 95 confidence interval ci shown represents summary random effects estimate comparison along respective 95 confidence interval values 1 denote increased risk alzheimer disease allele
0.2710359.15003956.html.plaintext.txt	40	view table table 3 summary odds ratios various contrasts bias diagnostics cumulative meta analysis recursive cumulative meta analysis magnitude summary odds ratio stable time changed considerably per year apparent dissipation postulated effect random effects summary vs c 205 end 1999 141 end 2000 116 end 2001 114 end 2002 117 2003 excluding first hypothesis generating study 9 found summary odds ratio became 111 95 percent ci 091 135 p 029 significant study heterogeneity p 005 evidence association even comparison homozygotes tt vs cc 096 95 percent ci 048 190 p 091 study heterogeneity relation effect size variance study suggesting larger studies agreed results smaller studies analyses limited studies intensive efforts exclude alzheimer disease controls yielded similar results 11 comparisons 10382 alleles 122 95 percent ci 096 154 p 010 p 002 heterogeneity
0.2710359.15003956.html.plaintext.txt	41	interaction apoe genotype nine studies 7 9 11 14 16 18 obtained data ctsd apoe genotypes one study 8 separating male female subjects 10 comparisons became available
0.2710359.15003956.html.plaintext.txt	42	interaction apoe genotype nine studies 7 9 11 14 16 18 obtained data ctsd apoe genotypes one study 8 separating male female subjects 10 comparisons became available
0.2710359.15003956.html.plaintext.txt	43	nine comparative studies tended gave slightly inflated effect allele compared full meta analysis 14 comparisons summary random effects 123 vs 117 complete meta analysis thus inferences cautious among carriers high risk apoe4 allele allele carriers random effects odds ratio 138 95 percent ci 089 215 alzheimer disease compared subjects carrying allele among subjects carrying apoe4 allele respective odds ratio 113 95 percent ci 090 142 significant study heterogeneity apoe4 positive group p 007 two effect sizes overlapped widely
0.2710359.15003956.html.plaintext.txt	44	among carriers allele presence apoe4 increased risk alzheimer disease 607 fold 95 percent ci 419 879 study heterogeneity among subjects without allele presence apoe4 increased risk alzheimer disease 409 fold 95 percent ci 315 531 significant study heterogeneity p 001 two estimates overlapped widely individual studies overall typically odds ratios larger group allele carriers figure 2
0.2710359.15003956.html.plaintext.txt	45	view larger version 22k figure 2 meta analysis effect apoe4 allele carriers noncarriers risk alzheimer disease ad comparison presented name first author m signifies male subjects f signifies female subjects comparison point estimate odds ratio accompanying 95 confidence interval ci shown filled squares represent carriers open circles represent noncarriers represents summary random effects estimate comparison along respective 95 confidence interval papassotiropoulos 2 1 pertain following respective references 7 9
0.2710359.15003956.html.plaintext.txt	46	view larger version 22k figure 2 meta analysis effect apoe4 allele carriers noncarriers risk alzheimer disease ad comparison presented name first author m signifies male subjects f signifies female subjects comparison point estimate odds ratio accompanying 95 confidence interval ci shown filled squares represent carriers open circles represent noncarriers represents summary random effects estimate comparison along respective 95 confidence interval papassotiropoulos 2 1 pertain following respective references 7 9
0.2710359.15003956.html.plaintext.txt	47	discussion top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references meta analysis includes data 14 case control studies 6000 genotyped alzheimer disease cases controls proves ctsd polymorphism strong risk factor alzheimer disease current evidence cannot exclude allele ctsd polymorphism may increase modestly risk alzheimer disease significant heterogeneity results various studies however found bias might exist decreasing effect size data accumulated time moreover meta analysis also cannot exclude possibility presence ctsd allele may enhance increased susceptibility toward alzheimer disease conferred apoe4 however even true would pertain relatively small group subjects carry apoe4 ctsd alleles impact allele population level would small present
0.2710359.15003956.html.plaintext.txt	48	discussion top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references meta analysis includes data 14 case control studies 6000 genotyped alzheimer disease cases controls proves ctsd polymorphism strong risk factor alzheimer disease current evidence cannot exclude allele ctsd polymorphism may increase modestly risk alzheimer disease significant heterogeneity results various studies however found bias might exist decreasing effect size data accumulated time moreover meta analysis also cannot exclude possibility presence ctsd allele may enhance increased susceptibility toward alzheimer disease conferred apoe4 however even true would pertain relatively small group subjects carry apoe4 ctsd alleles impact allele population level would small present
0.2710359.15003956.html.plaintext.txt	49	meta analysis findings may interpreted postulated biologic context ctsd polymorphism cathepsin d intracellular acid protease beta secretase activity vitro 1 2 cleave amyloid precursor protein tau protein generate fragments intact microtubule binding domains 44 might play role pathogenesis paired helical filaments one study shown ctsd polymorphism associated increased secretion altered intracellular maturation procathepsin d 3 noted clear whether ctsd polymorphism functional consequences mature form enzyme although cannot exclude biologic effect ctsd polymorphism findings accordance results recent full genome scan showing significant linkage alzheimer disease short arm chromosome 11 region ctsd gene located 45 47
0.2710359.15003956.html.plaintext.txt	50	meta analysis findings may interpreted postulated biologic context ctsd polymorphism cathepsin d intracellular acid protease beta secretase activity vitro 1 2 cleave amyloid precursor protein tau protein generate fragments intact microtubule binding domains 44 might play role pathogenesis paired helical filaments one study shown ctsd polymorphism associated increased secretion altered intracellular maturation procathepsin d 3 noted clear whether ctsd polymorphism functional consequences mature form enzyme although cannot exclude biologic effect ctsd polymorphism findings accordance results recent full genome scan showing significant linkage alzheimer disease short arm chromosome 11 region ctsd gene located 45 47
0.2710359.15003956.html.plaintext.txt	51	attention given design individual studies results meta analyses may affected methodological problems potential biases designs constituent studies nondifferential misclassification errors may dilute strength observed association alzheimer disease cases generally selected according appropriate criteria however young control subjects may developed alzheimer disease older ages choice appropriate age window assessing postulated genetic risk factor alzheimer disease difficult studies younger subjects may suitable identifying risk factors result early onset alzhei mer disease conversely selection younger subjects may less appropriate influence postulated genetic risk factor important late onset alzhei mer disease
0.2710359.15003956.html.plaintext.txt	52	attention given design individual studies results meta analyses may affected methodological problems potential biases designs constituent studies nondifferential misclassification errors may dilute strength observed association alzheimer disease cases generally selected according appropriate criteria however young control subjects may developed alzheimer disease older ages choice appropriate age window assessing postulated genetic risk factor alzheimer disease difficult studies younger subjects may suitable identifying risk factors result early onset alzhei mer disease conversely selection younger subjects may less appropriate influence postulated genetic risk factor important late onset alzhei mer disease
0.2710359.15003956.html.plaintext.txt	53	subgroup effects effect modification eg differential effects genetic polymorphism early vs late onset alzheimer disease cases familial vs sporadic disease complex interactions genes may also need considered 48 analyses addressed interactions apoe4 major known genetic determinant alzhei mer disease interactions genetic environmental factors studied trend stronger effect apoe4 presence allele carriage interesting light data suggesting carriage may affect general intelligence 5 however subgroup interaction analyses interpreted cautiously since differences subgroups may occur chance 49 validation would require studies even larger sample sizes several thousand included meta analysis finally population stratification may theoretically affected results constituent studies meta analysis 50 since documented frequency allele varied considerably among different ethnic groups even among different ethnic groups european descent however studies strictly ethnically defined population stratification effect unlikely considerable magnitude
0.2710359.15003956.html.plaintext.txt	54	increasing prevalence alzheimer disease worldwide crucial identify genetic risk factors neurodegenerative disease thus list identified polymorphisms may influence risk alzheimer disease continuously expanding 23 29 reported associations candidate genes date remain nonreplicated least controversial subsequent investigation early small genetic association studies may come spurious findings 41 51 52 even genetic associations replicated usually major public health impact would lead screening recommendations 53 nevertheless knowledge could improve understanding pathogenesis complex diseases alzheimer disease
0.2710359.15003956.html.plaintext.txt	55	increasing prevalence alzheimer disease worldwide crucial identify genetic risk factors neurodegenerative disease thus list identified polymorphisms may influence risk alzheimer disease continuously expanding 23 29 reported associations candidate genes date remain nonreplicated least controversial subsequent investigation early small genetic association studies may come spurious findings 41 51 52 even genetic associations replicated usually major public health impact would lead screening recommendations 53 nevertheless knowledge could improve understanding pathogenesis complex diseases alzheimer disease
0.2710359.15003956.html.plaintext.txt	56	laboratory tests top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references methods used ctsd genotyping analyzed studies straightforward include polymerase chain reaction 9 dynamic allele specific hybridization 14 error rate due misclassification likely small future studies nevertheless ensure clearly report assessment genotyping performed blinded clinical status patient
0.2710359.15003956.html.plaintext.txt	57	laboratory tests top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references methods used ctsd genotyping analyzed studies straightforward include polymerase chain reaction 9 dynamic allele specific hybridization 14 error rate due misclassification likely small future studies nevertheless ensure clearly report assessment genotyping performed blinded clinical status patient
0.2710359.15003956.html.plaintext.txt	58	population testing top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references date population testing ctsd polymorphism based results meta analysis testing would indicated given currently available data
0.2710359.15003956.html.plaintext.txt	59	population testing top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references date population testing ctsd polymorphism based results meta analysis testing would indicated given currently available data
0.2710359.15003956.html.plaintext.txt	60	acknowledgments authors thank jonathan prince patrizia mecocci anthony j brookes providing additional data studies
0.2710359.15003956.html.plaintext.txt	61	acknowledgments authors thank jonathan prince patrizia mecocci anthony j brookes providing additional data studies
0.2710359.15003956.html.plaintext.txt	62	notes correspondence dr john p ioannidis department hygiene epidemiology university ioannina school medicine ioannina 45110 greece e mail jioannidatccuoigr u d
0.2710359.15003956.html.plaintext.txt	63	references top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references mcdermott jr gibson degradation alzheimer beta amyloid protein human cathepsin d neuroreport 199672163 6isimedline chevalier n vizzavona j marambaud p et al cathepsin d displays vitro beta secretase like specificity brain res 199775011 19crossrefisimedline touitou capony f brouillet jp et al missense polymorphism ct224 human cathepsin d pro fragment determined polymerase chain reaction single strand conformational polymorphism analysis possible consequences cancer cells eur j cancer 199430a390 4isimedline papassotiropoulos lewis hd bagli m et al cerebrospinal fluid levels ss amyloid42 patients alzheimer disease related exon 2 polymorphism cathepsin d gene neuroreport 2002131291 4crossrefisimedline payton holland f diggle p et al cathepsin d exon 2 polymorphism associated general intelligence healthy older population mol psychiatry 2003814 18crossrefisimedline crawford fc freeman mj schinka j et al genetic association cathepsin d alzheimer disease neurosci lett 200028961 5crossrefisimedline papassotiropoulos bagli m kurz et al genetic variation cathepsin d major risk factor alzheimer disease ann neurol 200047399 40330co2 5 105179 82crossrefisimedline papassotiropoulos bagli m feder o et al genetic polymorphism cathepsin d strongly associated risk developing sporadic alzheimer disease neurosci lett 1999262171 4crossrefisimedline mcilroy sp dynan kb mcgleenon bm et al cathepsin d gene exon 2 polymorphism sporadic alzheimer disease neurosci lett 1999273140 1crossrefisimedline mateo sanchez guerra m combarros o et al lack association cathepsin d genetic polymorphism alzheimer disease spanish sample j med genet 200211431 3crossrefisimedline ingegni nocentini g mariani e et al cathepsin d polymorphism italian elderly subjects sporadic late onset alzheimer disease dement geriatr cogn disord 200316151 5crossrefisimedline bhojak tj dekosky st ganguli m et al genetic polymorphisms cathespin d interleukin 6 genes risk alzheimer disease neurosci lett 200028821 4crossrefisimedline prince ja feuk l sawyer sl et al lack replication association findings complex disease analysis 15 polymorphisms prior candidate genes sporadic alzheimer disease eur j hum genet 20019437 44crossrefisimedline matsui morikawa y tojo m et al cathepsin d polymorphism associated alzheimer disease japanese ann neurol 200149544 5 bagnoli nacmias b tedde et al cathepsin d polymorphism italian sporadic familial alzheimer disease neurosci lett 2002328273 6crossrefisimedline bertram l guenette jones j et al evidence genetic association linkage cathepsin d ctsd exon 2 polymorphism alzheimer disease ann neurol 200149114 1630co2 m disease highlight problems complex disease analysis trends genet 200117407 13crossrefisimedline styczynska m religa d pfeffer et al simultaneous analysis five genetic risk factors polish patients alzheimer disease neurosci lett 200334499 102crossrefisimedline farrer la cupples la haines jl et al effects age sex ethnicity association apolipoprotein e genotype alzheimer disease meta analysis apoe alzheimer disease meta analysis consortium jama 19972781349 56abstract hebert le scherr pa beckett la et al age specific incidence alzheimer disease community population jama 19952731354 9abstract cummings jl cole g alzheimer disease jama 20022872335 8free full text st george hyslop ph molecular genetics alzheimer disease biol psychiatry 200047183 99crossrefisimedline gao hendrie hc hall ks et al relationships age sex incidence dementia alzheimer disease meta analysis arch gen psychiatry 199855809 15abstractfree full text fleminger oliver dl lovestone et al head injury risk factor alzheimer disease evidence 10 years partial replication j neurol neurosurg psychiatry 200374857 62abstractfree full text launer lj andersen k dewey et al rates risk factors dementia alzheimer disease neurology 19995278 84abstractfree full text mcdowell alzheimer disease insights epidemiology aging milano 200113143 62isimedline hendrie hc ogunniyi hall ks et al incidence dementia alzheimer disease 2 communities jama 2001285739 47abstractfree full text combarros o alvarez arcaya sanchez guerra m et al candidate gene association studies sporadic alzheimer disease dement geriatr cogn disord 20021441 54crossrefisimedline combarros o infante j llorca j et al myeloperoxidase gene alzheimer disease case control study meta analysis neurosci lett 200232633 6crossrefisimedline dermaut b roks g theuns j et al variable expression presenilin 1 major determinant risk late onset alzheimer disease j neurol 2001248935 9crossrefisimedline koster mn dermaut b cruts m et al 2 macroglobulin gene ad population based study meta analysis neurology 200055678 84abstractfree full text russ c powell jf zhao j et al microtubule associated protein tau gene alzheimer disease association study meta analysis neurosci lett 200131492 6crossrefisimedline sanchez guerra m combarros o infante j et al case control study meta analysis low density lipoprotein receptor related protein gene exon 3 polymorphism alzheimer disease neurosci lett 200131617 20crossrefisimedline kehoe pg katzov h feuk l et al haplotypes extending across ace associated alzheimer disease hum mol genet 200312859 67abstractfree full text lau j ioannidis jp schmid ch quantitative synthesis systematic reviews ann intern med 1997127820 6abstractfree full text petitti db meta analysis decision analysis cost effectiveness analysis new york ny oxford university press 1994 lau j antman em jimenez silva j et al cumulative meta analysis therapeutic trials myocardial infarction n engl j med 1992327248 54abstract ioannidis jp contopoulos ioannidis dg lau j recursive cumulative meta analysis diagnostic evolution total randomized evidence group individual patient data j clin epidemiol 199952281 91crossrefisimedline ioannidis j lau j evolution treatment effects time empirical insight recursive cumulative metaanalyses proc natl acad sci u 200198831 6abstractfree full text ioannidis jp ntzani ee trikalinos ta et al replication validity genetic association studies nat genet 200129306 9crossrefisimedline begg cb mazumdar m operating characteristics rank correlation test publication bias biometrics 1994501088 101isimedline ioannidis jp trikalinos ta ntzani ee et al genetic associations large versus small studies empirical assessment lancet 2003361567 71crossrefisimedline kenessey nacharaju p ko lw et al degradation tau lysosomal enzyme cathepsin d implication alzheimer neurofibrillary degeneration j neurochem 1997692026 38isimedline kehoe p wavrant de vrieze f crook r et al full genome scan late onset alzheimer disease hum mol genet 19998237 45abstractfree full text collins js perry rt watson b jr et al association haplotype tumor necrosis factor siblings late onset alzheimer disease nimh alzheimer disease genetics initiative j med genet 200096823 3033co2 9 12415 22abstractfree full text lehmann dj williams j mcbroom j et al using meta analysis explain diversity results genetic studies late onset alzheimer disease identify high risk subgroups neuroscience 2001108541 54crossrefisimedline oxman ad guyatt gh consumer guide subgroup analyses ann intern med 199211678 84isimedline cardon lr palmer lj population stratification spurious allelic association lancet 2003361598 604crossrefisimedline lohmueller ke pearce cl pike m et al meta analysis genetic association studies supports contribution common variants susceptibility common disease nat genet 200333177 82crossrefisimedline ioannidis jpa genetic associations false true trends mol med 20039135 8crossrefisimedline little j khoury mj bradley l et al human genome project complete develop handle pump j epidemiol 2003157667 73free full text
0.2710359.15003956.html.plaintext.txt	64	references top abstract introduction gene gene variants disease meta analysis methods meta analysis results discussion laboratory tests population testing references mcdermott jr gibson degradation alzheimer beta amyloid protein human cathepsin d neuroreport 199672163 6isimedline chevalier n vizzavona j marambaud p et al cathepsin d displays vitro beta secretase like specificity brain res 199775011 19crossrefisimedline touitou capony f brouillet jp et al missense polymorphism ct224 human cathepsin d pro fragment determined polymerase chain reaction single strand conformational polymorphism analysis possible consequences cancer cells eur j cancer 199430a390 4isimedline papassotiropoulos lewis hd bagli m et al cerebrospinal fluid levels ss amyloid42 patients alzheimer disease related exon 2 polymorphism cathepsin d gene neuroreport 2002131291 4crossrefisimedline payton holland f diggle p et al cathepsin d exon 2 polymorphism associated general intelligence healthy older population mol psychiatry 2003814 18crossrefisimedline crawford fc freeman mj schinka j et al genetic association cathepsin d alzheimer disease neurosci lett 200028961 5crossrefisimedline papassotiropoulos bagli m kurz et al genetic variation cathepsin d major risk factor alzheimer disease ann neurol 200047399 40330co2 5 105179 82crossrefisimedline papassotiropoulos bagli m feder o et al genetic polymorphism cathepsin d strongly associated risk developing sporadic alzheimer disease neurosci lett 1999262171 4crossrefisimedline mcilroy sp dynan kb mcgleenon bm et al cathepsin d gene exon 2 polymorphism sporadic alzheimer disease neurosci lett 1999273140 1crossrefisimedline mateo sanchez guerra m combarros o et al lack association cathepsin d genetic polymorphism alzheimer disease spanish sample j med genet 200211431 3crossrefisimedline ingegni nocentini g mariani e et al cathepsin d polymorphism italian elderly subjects sporadic late onset alzheimer disease dement geriatr cogn disord 200316151 5crossrefisimedline bhojak tj dekosky st ganguli m et al genetic polymorphisms cathespin d interleukin 6 genes risk alzheimer disease neurosci lett 200028821 4crossrefisimedline prince ja feuk l sawyer sl et al lack replication association findings complex disease analysis 15 polymorphisms prior candidate genes sporadic alzheimer disease eur j hum genet 20019437 44crossrefisimedline matsui morikawa y tojo m et al cathepsin d polymorphism associated alzheimer disease japanese ann neurol 200149544 5 bagnoli nacmias b tedde et al cathepsin d polymorphism italian sporadic familial alzheimer disease neurosci lett 2002328273 6crossrefisimedline bertram l guenette jones j et al evidence genetic association linkage cathepsin d ctsd exon 2 polymorphism alzheimer disease ann neurol 200149114 1630co2 m disease highlight problems complex disease analysis trends genet 200117407 13crossrefisimedline styczynska m religa d pfeffer et al simultaneous analysis five genetic risk factors polish patients alzheimer disease neurosci lett 200334499 102crossrefisimedline farrer la cupples la haines jl et al effects age sex ethnicity association apolipoprotein e genotype alzheimer disease meta analysis apoe alzheimer disease meta analysis consortium jama 19972781349 56abstract hebert le scherr pa beckett la et al age specific incidence alzheimer disease community population jama 19952731354 9abstract cummings jl cole g alzheimer disease jama 20022872335 8free full text st george hyslop ph molecular genetics alzheimer disease biol psychiatry 200047183 99crossrefisimedline gao hendrie hc hall ks et al relationships age sex incidence dementia alzheimer disease meta analysis arch gen psychiatry 199855809 15abstractfree full text fleminger oliver dl lovestone et al head injury risk factor alzheimer disease evidence 10 years partial replication j neurol neurosurg psychiatry 200374857 62abstractfree full text launer lj andersen k dewey et al rates risk factors dementia alzheimer disease neurology 19995278 84abstractfree full text mcdowell alzheimer disease insights epidemiology aging milano 200113143 62isimedline hendrie hc ogunniyi hall ks et al incidence dementia alzheimer disease 2 communities jama 2001285739 47abstractfree full text combarros o alvarez arcaya sanchez guerra m et al candidate gene association studies sporadic alzheimer disease dement geriatr cogn disord 20021441 54crossrefisimedline combarros o infante j llorca j et al myeloperoxidase gene alzheimer disease case control study meta analysis neurosci lett 200232633 6crossrefisimedline dermaut b roks g theuns j et al variable expression presenilin 1 major determinant risk late onset alzheimer disease j neurol 2001248935 9crossrefisimedline koster mn dermaut b cruts m et al 2 macroglobulin gene ad population based study meta analysis neurology 200055678 84abstractfree full text russ c powell jf zhao j et al microtubule associated protein tau gene alzheimer disease association study meta analysis neurosci lett 200131492 6crossrefisimedline sanchez guerra m combarros o infante j et al case control study meta analysis low density lipoprotein receptor related protein gene exon 3 polymorphism alzheimer disease neurosci lett 200131617 20crossrefisimedline kehoe pg katzov h feuk l et al haplotypes extending across ace associated alzheimer disease hum mol genet 200312859 67abstractfree full text lau j ioannidis jp schmid ch quantitative synthesis systematic reviews ann intern med 1997127820 6abstractfree full text petitti db meta analysis decision analysis cost effectiveness analysis new york ny oxford university press 1994 lau j antman em jimenez silva j et al cumulative meta analysis therapeutic trials myocardial infarction n engl j med 1992327248 54abstract ioannidis jp contopoulos ioannidis dg lau j recursive cumulative meta analysis diagnostic evolution total randomized evidence group individual patient data j clin epidemiol 199952281 91crossrefisimedline ioannidis j lau j evolution treatment effects time empirical insight recursive cumulative metaanalyses proc natl acad sci u 200198831 6abstractfree full text ioannidis jp ntzani ee trikalinos ta et al replication validity genetic association studies nat genet 200129306 9crossrefisimedline begg cb mazumdar m operating characteristics rank correlation test publication bias biometrics 1994501088 101isimedline ioannidis jp trikalinos ta ntzani ee et al genetic associations large versus small studies empirical assessment lancet 2003361567 71crossrefisimedline kenessey nacharaju p ko lw et al degradation tau lysosomal enzyme cathepsin d implication alzheimer neurofibrillary degeneration j neurochem 1997692026 38isimedline kehoe p wavrant de vrieze f crook r et al full genome scan late onset alzheimer disease hum mol genet 19998237 45abstractfree full text collins js perry rt watson b jr et al association haplotype tumor necrosis factor siblings late onset alzheimer disease nimh alzheimer disease genetics initiative j med genet 200096823 3033co2 9 12415 22abstractfree full text lehmann dj williams j mcbroom j et al using meta analysis explain diversity results genetic studies late onset alzheimer disease identify high risk subgroups neuroscience 2001108541 54crossrefisimedline oxman ad guyatt gh consumer guide subgroup analyses ann intern med 199211678 84isimedline cardon lr palmer lj population stratification spurious allelic association lancet 2003361598 604crossrefisimedline lohmueller ke pearce cl pike m et al meta analysis genetic association studies supports contribution common variants susceptibility common disease nat genet 200333177 82crossrefisimedline ioannidis jpa genetic associations false true trends mol med 20039135 8crossrefisimedline little j khoury mj bradley l et al human genome project complete develop handle pump j epidemiol 2003157667 73free full text
0.2731872.12196314.html.plaintext.txt	0	risk factors alzheimer disease prospective analysis canadian study health aging joan lindsay12 danielle laurin34 rene verreault34 rejean hebert5 barbara helliwell6 gerry b hill16 ian mcdowell1
0.2731872.12196314.html.plaintext.txt	1	1 department epidemiology community medicine faculty medicine university ottawa ottawa canada 2 surveillance risk assessment division health canada ottawa canada 3 laval university geriatric research unit beauport qc canada 4 department social preventive medicine laval university quebec qc canada 5 sherbrooke university geriatric institute sherbrooke qc canada 6 elisabeth bruyere health centre ottawa canada
0.2731872.12196314.html.plaintext.txt	2	1 department epidemiology community medicine faculty medicine university ottawa ottawa canada 2 surveillance risk assessment division health canada ottawa canada 3 laval university geriatric research unit beauport qc canada 4 department social preventive medicine laval university quebec qc canada 5 sherbrooke university geriatric institute sherbrooke qc canada 6 elisabeth bruyere health centre ottawa canada
0.2731872.12196314.html.plaintext.txt	3	received publication december 14 2001 accepted publication may 9 2002
0.2731872.12196314.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references prospective analysis risk factors alzheimer disease major objective canadian study health aging nationwide population based study 6434 eligible subjects aged 65 years older 1991 4615 alive 1996 participated follow study participants cognitively normal 1991 completed risk factor questionnaire cognitive status reassessed 5 years later using similar two phase procedure including screening interview followed clinical examination indicated analysis included 194 alzheimer disease cases 3894 cognitively normal controls increasing age fewer years education apolipoprotein e 4 allele significantly associated increased risk alzheimer disease use nonsteroidal anti inflammatory drugs wine consumption coffee consumption regular physical activity associated reduced risk alzheimer disease statistically significant association found family history dementia sex history depression estrogen replacement therapy head trauma antiperspirant antacid use smoking high blood pressure heart disease stroke protective associations warrant study particular regular physical activity could important component preventive strategy alzheimer disease many conditions
0.2731872.12196314.html.plaintext.txt	5	abstract top abstract introduction materials methods results discussion references prospective analysis risk factors alzheimer disease major objective canadian study health aging nationwide population based study 6434 eligible subjects aged 65 years older 1991 4615 alive 1996 participated follow study participants cognitively normal 1991 completed risk factor questionnaire cognitive status reassessed 5 years later using similar two phase procedure including screening interview followed clinical examination indicated analysis included 194 alzheimer disease cases 3894 cognitively normal controls increasing age fewer years education apolipoprotein e 4 allele significantly associated increased risk alzheimer disease use nonsteroidal anti inflammatory drugs wine consumption coffee consumption regular physical activity associated reduced risk alzheimer disease statistically significant association found family history dementia sex history depression estrogen replacement therapy head trauma antiperspirant antacid use smoking high blood pressure heart disease stroke protective associations warrant study particular regular physical activity could important component preventive strategy alzheimer disease many conditions
0.2731872.12196314.html.plaintext.txt	6	alzheimer disease anti inflammatory agents non steroidal apolipoproteins cohort studies education exercise risk factors wine
0.2731872.12196314.html.plaintext.txt	7	abbreviations abbreviations apoe apolipoprotein e apoe4 apolipoprotein e 4 allele ci confidence interval csha canadian study health aging eurodem european community concerted action epidemiology prevention dementia nsaids nonsteroidal anti inflammatory drugs odds ratio 3ms modified mini mental state
0.2731872.12196314.html.plaintext.txt	8	introduction top abstract introduction materials methods results discussion references dementia growing problem aging populations impact health services society increasing concern health policy makers service providers life expectancy increases particularly baby boom generation ages among canadians aged 65 years older alzheimer disease accounts almost two thirds prevalent cases dementia 1 majority epidemiologic studies risk factors alzheimer disease date retrospective case control studies compared prevalent alzheimer disease cases nondemented controls 2 retrospective studies subject methodological problems including survival bias recall bias addition collecting detailed exposure information difficult information must obtained proxies 3 risk protective factors alzheimer disease suggested prevalence studies family history dementia upheld prospective studies
0.2731872.12196314.html.plaintext.txt	9	introduction top abstract introduction materials methods results discussion references dementia growing problem aging populations impact health services society increasing concern health policy makers service providers life expectancy increases particularly baby boom generation ages among canadians aged 65 years older alzheimer disease accounts almost two thirds prevalent cases dementia 1 majority epidemiologic studies risk factors alzheimer disease date retrospective case control studies compared prevalent alzheimer disease cases nondemented controls 2 retrospective studies subject methodological problems including survival bias recall bias addition collecting detailed exposure information difficult information must obtained proxies 3 risk protective factors alzheimer disease suggested prevalence studies family history dementia upheld prospective studies
0.2731872.12196314.html.plaintext.txt	10	even though investigations using prospective designs reveal defined picture pathogenesis alzheimer disease results obtained far consistent european community concerted action epidemiology prevention dementia eurodem group associated smoking higher risk alzheimer disease 3 whereas studies observe significant relation smoking onset alzheimer disease 4 6 eurodem group also found female sex low educational level associated increased risks alzheimer disease conversely sex education reported risk factors incident alzheimer disease studies 7 8 methodological differences duration follow selection number study participants may account discrepancies
0.2731872.12196314.html.plaintext.txt	11	even though investigations using prospective designs reveal defined picture pathogenesis alzheimer disease results obtained far consistent european community concerted action epidemiology prevention dementia eurodem group associated smoking higher risk alzheimer disease 3 whereas studies observe significant relation smoking onset alzheimer disease 4 6 eurodem group also found female sex low educational level associated increased risks alzheimer disease conversely sex education reported risk factors incident alzheimer disease studies 7 8 methodological differences duration follow selection number study participants may account discrepancies
0.2731872.12196314.html.plaintext.txt	12	canadian study health aging csha large national multicenter longitudinal study dementia elderly people focusing prevalence 1 incidence 9 risk factors 10 12 part first phase csha 1 case control study conducted age family history dementia educational level arthritis use nonsteroidal anti inflammatory drugs nsaids significantly related alzheimer disease 10 report results prospective analysis risk factors incident cases late onset alzheimer disease based risk factor data collected csha 1 cognitively normal diagnosis incident alzheimer disease 5 years later csha 2
0.2731872.12196314.html.plaintext.txt	13	canadian study health aging csha large national multicenter longitudinal study dementia elderly people focusing prevalence 1 incidence 9 risk factors 10 12 part first phase csha 1 case control study conducted age family history dementia educational level arthritis use nonsteroidal anti inflammatory drugs nsaids significantly related alzheimer disease 10 report results prospective analysis risk factors incident cases late onset alzheimer disease based risk factor data collected csha 1 cognitively normal diagnosis incident alzheimer disease 5 years later csha 2
0.2731872.12196314.html.plaintext.txt	14	materials methods top abstract introduction materials methods results discussion references study methods described detail elsewhere 1 9 summarized eighteen field centers across canada participated national study coordinated jointly university ottawa health canada
0.2731872.12196314.html.plaintext.txt	15	materials methods top abstract introduction materials methods results discussion references study methods described detail elsewhere 1 9 summarized eighteen field centers across canada participated national study coordinated jointly university ottawa health canada
0.2731872.12196314.html.plaintext.txt	16	initial assessment csha 1 1991 1992 representative samples men women aged 65 years older drawn 36 urban surrounding rural areas 10 canadian provinces covered 10263 participants 9008 lived community 1255 resided institutions excluded analysis community interviewed health presence specific disorders limitations performing basic instrumental activities daily living based older americans resources services activities daily living scale 13 participants screened dementia using modified mini mental state 3ms examination 14 15 screened positive 3ms examination score 78100 random sample screened negative score 78 invited participate extensive clinical evaluation followed three stage protocol nurse first readministered 3ms examination collected information participant medical family history next physician conducted standardized physical neurologic examination finally participants deemed testable 3ms examination score 50 psychometrist administered series neuropsychological tests 16 interpreted later neuropsychologist
0.2731872.12196314.html.plaintext.txt	17	initial assessment csha 1 1991 1992 representative samples men women aged 65 years older drawn 36 urban surrounding rural areas 10 canadian provinces covered 10263 participants 9008 lived community 1255 resided institutions excluded analysis community interviewed health presence specific disorders limitations performing basic instrumental activities daily living based older americans resources services activities daily living scale 13 participants screened dementia using modified mini mental state 3ms examination 14 15 screened positive 3ms examination score 78100 random sample screened negative score 78 invited participate extensive clinical evaluation followed three stage protocol nurse first readministered 3ms examination collected information participant medical family history next physician conducted standardized physical neurologic examination finally participants deemed testable 3ms examination score 50 psychometrist administered series neuropsychological tests 16 interpreted later neuropsychologist
0.2731872.12196314.html.plaintext.txt	18	independent preliminary diagnoses made physician neuropsychologist followed case conference consensus diagnosis reached according diagnostic statistical manual mental disorders third edition revised criteria dementia 17 national institute neurological communicative disorders stroke alzheimer disease related disorders association nincds adrda criteria alzheimer disease 18 specific criteria cognitive impairment 19 vascular dementia 20 diagnoses comprised following categories cognitive impairment cognitive impairment dementia probable possible alzheimer disease vascular dementia specific dementia unclassifiable dementia
0.2731872.12196314.html.plaintext.txt	19	independent preliminary diagnoses made physician neuropsychologist followed case conference consensus diagnosis reached according diagnostic statistical manual mental disorders third edition revised criteria dementia 17 national institute neurological communicative disorders stroke alzheimer disease related disorders association nincds adrda criteria alzheimer disease 18 specific criteria cognitive impairment 19 vascular dementia 20 diagnoses comprised following categories cognitive impairment cognitive impairment dementia probable possible alzheimer disease vascular dementia specific dementia unclassifiable dementia
0.2731872.12196314.html.plaintext.txt	20	detailed information risk factors gathered self administered questionnaire completed csha 1 participants found cognitively normal basis either screening test clinical examination risk factor questionnaire covered sociodemographic characteristics occupational environmental exposures lifestyle smoking alcohol consumption intake selected food items regular exercise family medical history prior head injury without loss consciousness chronic diseases medication use participants asked whether engaged regular exercise yesno regular explicitly defined regular consumption beer wine spirits defined least week regular consumption tea coffee defined nearly every day
0.2731872.12196314.html.plaintext.txt	21	detailed information risk factors gathered self administered questionnaire completed csha 1 participants found cognitively normal basis either screening test clinical examination risk factor questionnaire covered sociodemographic characteristics occupational environmental exposures lifestyle smoking alcohol consumption intake selected food items regular exercise family medical history prior head injury without loss consciousness chronic diseases medication use participants asked whether engaged regular exercise yesno regular explicitly defined regular consumption beer wine spirits defined least week regular consumption tea coffee defined nearly every day
0.2731872.12196314.html.plaintext.txt	22	follow study csha 2 1996 1997 subjects could contacted agreed participate second wave study interviewed measure changes health status functioning average 5 years csha 1 participants took part diagnostic process one used csha 1 including screening test nurse evaluation clinical evaluation two diagnoses dementia made consensus conference one according criteria used csha 1 according recent diagnostic statistical manual mental disorders fourth edition criteria 21 alzheimer disease national institute neurological disorders stroke association internationale pour la recherche et l enseignement en neurosciences ninds airen criteria vascular dementia 22 recent criteria used define cases current analysis blood samples collected apolipoprotein e apoe allele status determined subsample subjects examined clinically 23
0.2731872.12196314.html.plaintext.txt	23	follow study csha 2 1996 1997 subjects could contacted agreed participate second wave study interviewed measure changes health status functioning average 5 years csha 1 participants took part diagnostic process one used csha 1 including screening test nurse evaluation clinical evaluation two diagnoses dementia made consensus conference one according criteria used csha 1 according recent diagnostic statistical manual mental disorders fourth edition criteria 21 alzheimer disease national institute neurological disorders stroke association internationale pour la recherche et l enseignement en neurosciences ninds airen criteria vascular dementia 22 recent criteria used define cases current analysis blood samples collected apolipoprotein e apoe allele status determined subsample subjects examined clinically 23
0.2731872.12196314.html.plaintext.txt	24	participants died follow study conducted date cause death obtained relevant provincial registrar vital statistics relative informant interviewed assess subject physical cognitive status 3 months prior death subjects died follow probability dementia estimated three different sources 9 1 mention dementia death certificates 2 information proxies diagnosis memory problems alzheimer disease senile dementia prior death 3 logistic regression model based analysis 71 people died within 2 5 months complete diagnostic evaluation estimating probability deceased person demented prior death estimates available 1022 decedents 872 percent procedure permit diagnosis type dementia decedents omitted main analysis secondary analysis conducted assess potential impact omitting decedents deaths classified due dementia included alzheimer disease cases deaths due dementia considered controls
0.2731872.12196314.html.plaintext.txt	25	participants died follow study conducted date cause death obtained relevant provincial registrar vital statistics relative informant interviewed assess subject physical cognitive status 3 months prior death subjects died follow probability dementia estimated three different sources 9 1 mention dementia death certificates 2 information proxies diagnosis memory problems alzheimer disease senile dementia prior death 3 logistic regression model based analysis 71 people died within 2 5 months complete diagnostic evaluation estimating probability deceased person demented prior death estimates available 1022 decedents 872 percent procedure permit diagnosis type dementia decedents omitted main analysis secondary analysis conducted assess potential impact omitting decedents deaths classified due dementia included alzheimer disease cases deaths due dementia considered controls
0.2731872.12196314.html.plaintext.txt	26	phases csha approved ethics review committees 18 participating study centers well coordinating center participants proxies provided informed consent component study however residents province newfoundland omitted prospective analysis 1996 legal interpretation province advance directives legislation prohibited use proxy consent persons unable give full informed consent participate research studies interpretation meant people dementia could provide consent clinical examination ie outcome measure could obtained therefore newfoundland participants excluded
0.2731872.12196314.html.plaintext.txt	27	phases csha approved ethics review committees 18 participating study centers well coordinating center participants proxies provided informed consent component study however residents province newfoundland omitted prospective analysis 1996 legal interpretation province advance directives legislation prohibited use proxy consent persons unable give full informed consent participate research studies interpretation meant people dementia could provide consent clinical examination ie outcome measure could obtained therefore newfoundland participants excluded
0.2731872.12196314.html.plaintext.txt	28	analysis analysis included participants living community csha 1 case control analysis conducted incident cases controls selected csha 2 included participants initial screening results negative csha 1 participants clinically diagnosed without 1 cognitive impairment dementia 2 dementia cases diagnosed probable possible alzheimer disease csha 2 comparisons made controls csha 2 remained without cognitive impairment dementia dementia according clinical evaluation screening test follow
0.2731872.12196314.html.plaintext.txt	29	analysis analysis included participants living community csha 1 case control analysis conducted incident cases controls selected csha 2 included participants initial screening results negative csha 1 participants clinically diagnosed without 1 cognitive impairment dementia 2 dementia cases diagnosed probable possible alzheimer disease csha 2 comparisons made controls csha 2 remained without cognitive impairment dementia dementia according clinical evaluation screening test follow
0.2731872.12196314.html.plaintext.txt	30	differences cases controls regarding means proportions compared using test chi square test respectively univariate multivariate logistic regression models used calculate crude adjusted odds ratios various risk factors rare disease assumption odds ratio considered valid estimate relative risk age sex education age education continuous variables 1 year increments introduced multivariate models potential confounders modification risk age sex apoe 4 allele apoe4 status examined using interaction terms
0.2731872.12196314.html.plaintext.txt	31	differences cases controls regarding means proportions compared using test chi square test respectively univariate multivariate logistic regression models used calculate crude adjusted odds ratios various risk factors rare disease assumption odds ratio considered valid estimate relative risk age sex education age education continuous variables 1 year increments introduced multivariate models potential confounders modification risk age sex apoe 4 allele apoe4 status examined using interaction terms
0.2731872.12196314.html.plaintext.txt	32	results top abstract introduction materials methods results discussion references community participants overall response rates screening interview clinical examination 883 percent 87 percent respectively 9 figure 1 shows categories ineligible study subjects excluded analysis leaving 194 cases 3894 controls apoe allele status available 613 subjects 98 cases 515 controls table 1 presents selected characteristics csha 1 cases controls decedents considered demented demented subjects refused participate data missing cases including decedents older subjects categories percentage female controls including decedents smaller living cases lower 3ms examination scores living cases controls somewhat fewer chronic conditions
0.2731872.12196314.html.plaintext.txt	33	results top abstract introduction materials methods results discussion references community participants overall response rates screening interview clinical examination 883 percent 87 percent respectively 9 figure 1 shows categories ineligible study subjects excluded analysis leaving 194 cases 3894 controls apoe allele status available 613 subjects 98 cases 515 controls table 1 presents selected characteristics csha 1 cases controls decedents considered demented demented subjects refused participate data missing cases including decedents older subjects categories percentage female controls including decedents smaller living cases lower 3ms examination scores living cases controls somewhat fewer chronic conditions
0.2731872.12196314.html.plaintext.txt	34	view larger version 23k figure 1 study sample analysis risk factors incident alzheimer disease canadian study health aging csha 1991 1992 csha 1 1996 1997 csha 2 clinical clinical examination cind cognitive impairment dementia
0.2731872.12196314.html.plaintext.txt	35	view larger version 23k figure 1 study sample analysis risk factors incident alzheimer disease canadian study health aging csha 1991 1992 csha 1 1996 1997 csha 2 clinical clinical examination cind cognitive impairment dementia
0.2731872.12196314.html.plaintext.txt	36	view table table 1 characteristics participants decedents subjects refused data missing risk factor analysis alzheimer disease canadian study health aging 1996 1997 using recent criteria diagnosing alzheimer disease resulted change status fewer 10 percent cases included analysis new criteria identified 116 incident cases probable alzheimer disease compared 107 cases old criteria used 78 cases possible alzheimer disease compared 74 results analyses conducted including cases probable alzheimer disease consistent results presented
0.2731872.12196314.html.plaintext.txt	37	demographic characteristics subjects summarized table 2 distributions age sex education across cases controls significantly different cases older controls median age range csha 2 screening 87 years range 69 105 vs 78 years range 70 100 cases also completed fewer years education median 10 vs 11 years table 2 also presents adjusted odds ratios age sex education expected advanced age strongly associated higher risk alzheimer disease controlled sex education age treated continuous variable risk alzheimer disease increased 23 percent 95 percent confidence interval ci 119 126 per additional year age age sex adjusted risk alzheimer disease lowest level education almost twice educated participants association observed sex risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	38	demographic characteristics subjects summarized table 2 distributions age sex education across cases controls significantly different cases older controls median age range csha 2 screening 87 years range 69 105 vs 78 years range 70 100 cases also completed fewer years education median 10 vs 11 years table 2 also presents adjusted odds ratios age sex education expected advanced age strongly associated higher risk alzheimer disease controlled sex education age treated continuous variable risk alzheimer disease increased 23 percent 95 percent confidence interval ci 119 126 per additional year age age sex adjusted risk alzheimer disease lowest level education almost twice educated participants association observed sex risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	39	view table table 2 distributions alzheimer disease risk estimates age sex education canadian study health aging 1996 1997 table 3 shows odds ratios selected putative risk factors adjustment age sex education family history alzheimer disease senile dementia associated late onset alzheimer disease participants least one apoe4 allele 328 times risk alzheimer disease compared two 3 alleles antecedent coexisting chronic conditions included risk factor questionnaire arthritis significantly related reduced risk alzheimer disease statistically significant relation observed alzheimer disease risk high blood pressure stroke heart disease depression head trauma diabetes thyroid condition cancer type stomach ulcer use nsaids reduced risk alzheimer disease 35 percent effect due mostly nonsalicylates inclusion nsaid use arthritis along age sex education model yielded similar odds ratio estimates factors remained protective alzheimer disease testing interaction nsaids arthritis significant p 010 association alzheimer disease antihypertensive agents antacids corticosteroids estrogen therapy found
0.2731872.12196314.html.plaintext.txt	40	view table table 3 association selected risk factors alzheimer disease canadian study health aging 1996 1997 table 4 shows age sex education adjusted risk estimates alzheimer disease lifestyle related variables 5 year follow smoking significantly associated alzheimer disease risk regular alcohol consumption associated reduced risk alzheimer disease particularly wine consumption reduced risk 50 percent variables observed significantly associated lower risk alzheimer disease daily coffee consumption regular physical activity 31 percent reductions association tea drinking antiperspirant use depression noted reported risk factors evidence found modification risk age sex apoe4 status furthermore relation risk alzheimer disease observed marital status parental age subject birth birth order occupational history exposure inks paints solvents rubbers glues pesticides fumigants radiation anesthetics family history syndrome mental retardation parkinson disease thyroid disease data shown
0.2731872.12196314.html.plaintext.txt	41	view table table 4 association specific lifestyle variables risk alzheimer disease canadian study health aging 1996 1997 table 5 presents estimates odds ratios selected risk factors decedents excluded addition deaths classified due dementia included alzheimer disease cases deaths due dementia included controls beneficial effect regular physical activity remained strong highly significant whereas associations arthritis nsaid use wine consumption coffee consumption remained 10 longer statistically significant
0.2731872.12196314.html.plaintext.txt	42	view table table 5 risk alzheimer disease 1991 1992 1996 1997 associated selected variables according original analysis assumption concerning decedents canada discussion top abstract introduction materials methods results discussion references csha large scale cohort study based representative nationwide sample canadian population aged 65 years older prospective nature analysis high response rates careful standardization screening clinical assessments thorough checking questionnaires well coding editing data constitute strengths study
0.2731872.12196314.html.plaintext.txt	43	found increasing age low educational level apoe4 allele associated increased risks incident alzheimer disease arthritis regular use nsaids wine consumption coffee consumption regular physical activity associated reduced risks note family history dementia smoking related risk alzheimer disease addition estrogen shown protective
0.2731872.12196314.html.plaintext.txt	44	found increasing age low educational level apoe4 allele associated increased risks incident alzheimer disease arthritis regular use nsaids wine consumption coffee consumption regular physical activity associated reduced risks note family history dementia smoking related risk alzheimer disease addition estrogen shown protective
0.2731872.12196314.html.plaintext.txt	45	however results subject potential limitations first eligible community subjects baseline risk factor questionnaire available 1172 182 percent died 5 year follow period included main analyses group decedents included proportionately men generally older less educated suffered frequently chronic diseases subjects completed follow exclusion participants may distorted results example subjects frequently exposed particular risk factor higher risk developing alzheimer disease results simulation included subjects died suggest although arthritis nsaid use wine consumption coffee consumption might potentially valid protective factors alzheimer disease bias due exclusion decedents follow might also partially explain associations
0.2731872.12196314.html.plaintext.txt	46	however results subject potential limitations first eligible community subjects baseline risk factor questionnaire available 1172 182 percent died 5 year follow period included main analyses group decedents included proportionately men generally older less educated suffered frequently chronic diseases subjects completed follow exclusion participants may distorted results example subjects frequently exposed particular risk factor higher risk developing alzheimer disease results simulation included subjects died suggest although arthritis nsaid use wine consumption coffee consumption might potentially valid protective factors alzheimer disease bias due exclusion decedents follow might also partially explain associations
0.2731872.12196314.html.plaintext.txt	47	another limitation analysis possibility bias assessing risk factor exposures spite prospective nature study results could explained least part preclinical cognitive decline yet detectable screening clinical evaluations csha 1 among subjects developed alzheimer disease csha 2 although cannot ruled explanation seems improbable view extensive screening clinical evaluation process used csha 1 diagnose cognitive impairment dementia well dementia along relatively long follow period nevertheless test possibility results reanalyzed excluding cases whose symptoms alzheimer disease reported proxies started within 2 years csha 1 end 1993 persistence protective effect alzheimer disease nsaids odds ratio 061 95 percent ci 040 097 wine 055 95 percent ci 030 103 coffee 069 95 percent ci 048 099 physical activity 066 95 percent ci 047 094 support hypothesis preclinical decline explains results
0.2731872.12196314.html.plaintext.txt	48	another limitation analysis possibility bias assessing risk factor exposures spite prospective nature study results could explained least part preclinical cognitive decline yet detectable screening clinical evaluations csha 1 among subjects developed alzheimer disease csha 2 although cannot ruled explanation seems improbable view extensive screening clinical evaluation process used csha 1 diagnose cognitive impairment dementia well dementia along relatively long follow period nevertheless test possibility results reanalyzed excluding cases whose symptoms alzheimer disease reported proxies started within 2 years csha 1 end 1993 persistence protective effect alzheimer disease nsaids odds ratio 061 95 percent ci 040 097 wine 055 95 percent ci 030 103 coffee 069 95 percent ci 048 099 physical activity 066 95 percent ci 047 094 support hypothesis preclinical decline explains results
0.2731872.12196314.html.plaintext.txt	49	since multiple comparisons performed possible statistically significant associations may occurred chance new associations found example protective effect coffee drinking replication studies needed determine validity association results generalizable populations largely european descent inclusion different ethnic groups living canada determined ability speak either english french
0.2731872.12196314.html.plaintext.txt	50	since multiple comparisons performed possible statistically significant associations may occurred chance new associations found example protective effect coffee drinking replication studies needed determine validity association results generalizable populations largely european descent inclusion different ethnic groups living canada determined ability speak either english french
0.2731872.12196314.html.plaintext.txt	51	family history dementia similar advancing age apoe4 allele frequently associated increased risk alzheimer disease generally considered definite risk factor 24 csha 1 case control study found increased risk alzheimer disease increased significantly two threefold family history dementia 10 however eurodem pooled data set 3 prospective analysis csha data find association contradictory findings might reflect misclassification information recall bias andor uncertainty information collected help informants retrospective investigations compared longitudinal studies case control study mayeux et al 25 observed relatives patients whose onset alzheimer disease began age 70 years older increased risk alzheimer disease whereas increased risk first degree relatives patients whose onset occurred prior age 70 years thus would seem reasonable observe association older cohort may surprising family history dementia associated alzheimer disease increased risk alzheimer disease observed subjects apoe4 allele since family history dementia believed potential indicator genetic factor however suggested apoe4 allele explain large part family history dementia 26 study 13 percent least one apoe4 allele reported parent dementia compared 10 percent 4 allele
0.2731872.12196314.html.plaintext.txt	52	family history dementia similar advancing age apoe4 allele frequently associated increased risk alzheimer disease generally considered definite risk factor 24 csha 1 case control study found increased risk alzheimer disease increased significantly two threefold family history dementia 10 however eurodem pooled data set 3 prospective analysis csha data find association contradictory findings might reflect misclassification information recall bias andor uncertainty information collected help informants retrospective investigations compared longitudinal studies case control study mayeux et al 25 observed relatives patients whose onset alzheimer disease began age 70 years older increased risk alzheimer disease whereas increased risk first degree relatives patients whose onset occurred prior age 70 years thus would seem reasonable observe association older cohort may surprising family history dementia associated alzheimer disease increased risk alzheimer disease observed subjects apoe4 allele since family history dementia believed potential indicator genetic factor however suggested apoe4 allele explain large part family history dementia 26 study 13 percent least one apoe4 allele reported parent dementia compared 10 percent 4 allele
0.2731872.12196314.html.plaintext.txt	53	association low educational level risk alzheimer disease consistent findings several retrospective prospective studies 3 10 27 29 large scale population based studies csha cases ascertained means two phase diagnostic procedure screening clinical examination cutpoint screening 3ms examination chosen achieve high sensitivity even though cutpoint could missed mild cases alzheimer disease people higher levels education could still perform well cognitive screening tests whether risk alzheimer disease associated less education corresponds artifact represents true risk factor still unclear explanations education effect include increased brain reserve 30 selection bias resulting selective attrition use two phase diagnostic procedure 27 31 confounding indicators socioeconomic status linked education diet lifestyle occupational history 32 33
0.2731872.12196314.html.plaintext.txt	54	association low educational level risk alzheimer disease consistent findings several retrospective prospective studies 3 10 27 29 large scale population based studies csha cases ascertained means two phase diagnostic procedure screening clinical examination cutpoint screening 3ms examination chosen achieve high sensitivity even though cutpoint could missed mild cases alzheimer disease people higher levels education could still perform well cognitive screening tests whether risk alzheimer disease associated less education corresponds artifact represents true risk factor still unclear explanations education effect include increased brain reserve 30 selection bias resulting selective attrition use two phase diagnostic procedure 27 31 confounding indicators socioeconomic status linked education diet lifestyle occupational history 32 33
0.2731872.12196314.html.plaintext.txt	55	present analysis supports hypothesis negative association nsaids risk alzheimer disease protective relation also found several population based case control studies including csha 1 analysis 34 least one longitudinal study supports protective effect anti inflammatory drugs alzheimer disease dementia 35 studies remain inconclusive 36 37
0.2731872.12196314.html.plaintext.txt	56	present analysis supports hypothesis negative association nsaids risk alzheimer disease protective relation also found several population based case control studies including csha 1 analysis 34 least one longitudinal study supports protective effect anti inflammatory drugs alzheimer disease dementia 35 studies remain inconclusive 36 37
0.2731872.12196314.html.plaintext.txt	57	regular wine consumption also associated reduced risk alzheimer disease results paquid study longitudinal study community residents showed similar negative relation wine consumption alzheimer disease 38 protective effect remained significant depth statistical analyses conducted 39 suggested specific substances wine alcoholic beverages could responsible positive effect nerve cells dementia 40
0.2731872.12196314.html.plaintext.txt	58	regular wine consumption also associated reduced risk alzheimer disease results paquid study longitudinal study community residents showed similar negative relation wine consumption alzheimer disease 38 protective effect remained significant depth statistical analyses conducted 39 suggested specific substances wine alcoholic beverages could responsible positive effect nerve cells dementia 40
0.2731872.12196314.html.plaintext.txt	59	analysis regular consumption coffee seemed protective alzheimer disease low coffee intake reported related mental disability 25 year follow 716 finnish men 41 without confirmation prospective studies alzheimer disease finding may due chance
0.2731872.12196314.html.plaintext.txt	60	analysis regular consumption coffee seemed protective alzheimer disease low coffee intake reported related mental disability 25 year follow 716 finnish men 41 without confirmation prospective studies alzheimer disease finding may due chance
0.2731872.12196314.html.plaintext.txt	61	potential protective effect regular physical activity risk alzheimer disease important represents modifiable lifestyle habit epidemiologic studies evaluated possible protective role regular physical activity risk cognitive impairment dementia elderly results inconsistent 7 42 however clinical trials exercise shown benefit cognitive function 43 44 recently regular physical activity found protective cognitive impairment well types dementia including alzheimer disease interaction sex reported suggesting greater protection women men 45
0.2731872.12196314.html.plaintext.txt	62	potential protective effect regular physical activity risk alzheimer disease important represents modifiable lifestyle habit epidemiologic studies evaluated possible protective role regular physical activity risk cognitive impairment dementia elderly results inconsistent 7 42 however clinical trials exercise shown benefit cognitive function 43 44 recently regular physical activity found protective cognitive impairment well types dementia including alzheimer disease interaction sex reported suggesting greater protection women men 45
0.2731872.12196314.html.plaintext.txt	63	conclusion large scale prospective study older age onset alzheimer disease confirmed frequently suggested etiologic hypotheses disease intriguing protective associations observed study warrant research preventive strategies alzheimer disease explored regular physical activity could represent novel safe preventive strategy alzheimer disease many conditions examined
0.2731872.12196314.html.plaintext.txt	64	conclusion large scale prospective study older age onset alzheimer disease confirmed frequently suggested etiologic hypotheses disease intriguing protective associations observed study warrant research preventive strategies alzheimer disease explored regular physical activity could represent novel safe preventive strategy alzheimer disease many conditions examined
0.2731872.12196314.html.plaintext.txt	65	acknowledgments data reported paper collected part csha study core study funded seniors independence research program national health research development program nhrdp health canada project 6606 3954 mc additional funding provided pfizer canada incorporated medical research councilpharmaceutical manufacturers association canada health activity program nhrdp project 6603 1417 302 r bayer incorporated british columbia health research foundation project 38 93 2 34 96 1 study coordinated university ottawa division aging seniors health canada dr rene verreault supported laval university chair geriatric research dr danielle laurin supported part national health phd fellowship provided nhrdp project 6605 5228 47 laval university chair geriatric research
0.2731872.12196314.html.plaintext.txt	66	acknowledgments data reported paper collected part csha study core study funded seniors independence research program national health research development program nhrdp health canada project 6606 3954 mc additional funding provided pfizer canada incorporated medical research councilpharmaceutical manufacturers association canada health activity program nhrdp project 6603 1417 302 r bayer incorporated british columbia health research foundation project 38 93 2 34 96 1 study coordinated university ottawa division aging seniors health canada dr rene verreault supported laval university chair geriatric research dr danielle laurin supported part national health phd fellowship provided nhrdp project 6605 5228 47 laval university chair geriatric research
0.2731872.12196314.html.plaintext.txt	67	authors grateful richard aylesworth louis rochette statistical assistance
0.2731872.12196314.html.plaintext.txt	68	notes reprint requests dr joan lindsay department epidemiology community medicine university ottawa 451 smyth road ottawa k1h 8m5 canada e mail joanlindsayathc scgcca u d
0.2731872.12196314.html.plaintext.txt	69	notes reprint requests dr joan lindsay department epidemiology community medicine university ottawa 451 smyth road ottawa k1h 8m5 canada e mail joanlindsayathc scgcca u d
0.2731872.12196314.html.plaintext.txt	70	references top abstract introduction materials methods results discussion references canadian study health aging study methods prevalence dementia cmaj 1994150899 913abstract van duijn cm epidemiology dementias recent developments new approaches j neurol neurosurg psychiatry 199660478 88isimedline launer lj andersen k dewey et al rates risk factors dementia alzheimer disease results eurodem pooled analyses neurology 19995278 84abstractfree full text hebert le scherr pa beckett la et al relation smoking alcohol consumption incident alzheimer disease j epidemiol 1992135347 55abstract wang hx fratiglioni l frisoni gb et al smoking occurrence alzheimer disease cross sectional longitudinal data population based study j epidemiol 1999149640 4abstract doll r peto r boreham j et al smoking dementia male british doctors prospective study bmj 20003201097 102abstractfree full text yoshitake kiyohara y kato et al incidence risk factors vascular dementia alzheimer disease defined elderly japanese population hisayama study neurology 1995451161 8abstract cobb jl wolf pa au r et al effect education incidence dementia alzheimer disease framingham study neurology 1995451707 12abstract canadian study health aging working group incidence dementia canada neurology 20005566 73abstractfree full text canadian study health aging risk factors alzheimer disease canada neurology 1994442073 80abstract lindsay j hebert r rockwood k canadian study health aging risk factors vascular dementia stroke 199728526 30abstractfree full text hebert r lindsay j verreault r et al vascular dementia incidence risk factors canadian study health aging stroke 2000311487 93abstractfree full text mcdowell newell c measuring health guide rating scales questionnaires 2nd ed new york ny oxford university press 1996 teng el chui hc modified mini mental state 3ms examination j clin psychiatry 198748314 18isimedline hebert r bravo g girouard d validation de l adaptation francaise du modified mini mental state 3ms french rev geriatrie 199217443 50 tuokko h kristjansson e miller j neuropsychological detection dementia overview neuropsychological component canadian study health aging j clin exp neuropsychol 199517352 73isimedline american psychiatric association diagnostic statistical manual mental disorders dsm iii r 3rd ed rev washington dc american psychiatric association 1987 mckhann g drachman d folstein m et al clinical diagnosis alzheimer disease report nincds adrda work group auspices department health human services task force alzheimer disease neurology 198434939 44abstract graham je rockwood k beattie bl et al prevalence severity cognitive impairment without dementia elderly population lancet 19973491793 6isimedline world health organization icd 10 classification mental behavioural disorders diagnostic criteria research geneva switzerland world health organization 1993 american psychiatric association diagnostic statistical manual mental disorders dsm iv 4th ed washington dc american psychiatric association 1994 roman gc tatemichi tk erkinjuntti et al vascular dementia diagnostic criteria research studies report ninds airen international workshop neurology 199343250 60abstract mcleod da arnott b gaudreault n et al comparison two methods routine accurate determination apolipoprotein e genotypes alzheimer rep 19981211 15isi fratiglioni l epidemiology alzheimer disease current possibilities prevention acta neurol scand suppl 199616533 40medline mayeux r ottman r tang mx et al genetic susceptibility head injury risk factors alzheimer disease among community dwelling elderly persons first degree relatives ann neurol 199333494 501isimedline danet brousseau richard f et al risk dementia parents probands without apolipoprotein e4 allele eva study j epidemiol community health 199953393 8abstract stern y gurland b tatemichi tk et al influence education occupation incidence alzheimer disease jama 19942711004 10abstract ott breteler mm van harskamp f et al prevalence alzheimer disease vascular dementia association education rotterdam study bmj 1995310970 3abstractfree full text letenneur l gilleron v commenges d et al sex educational level independent predictors dementia alzheimer disease incidence data paquid project j neurol neurosurg psychiatry 199966177 83abstractfree full text katzman r education prevalence dementia alzheimer disease neurology 19934313 20isimedline geerlings mi schmand b jonker c et al education incident alzheimer disease biased association due selective attrition use two step diagnostic procedure int j epidemiol 199928492 7abstract mortimer ja graves ab education socioeconomic determinants dementia alzheimer disease neurology 199343suppl 4s39 44abstract stern y alexander ge prohovnik et al relationship lifetime occupation parietal flow implications reserve alzheimer disease pathology neurology 19954555 60abstract mcgeer pl schulzer m mcgeer eg arthritis anti inflammatory agents possible protective factors alzheimer disease review 17 epidemiologic studies neurology 199647425 32abstract stewart wf kawas c corrada m et al risk alzheimer disease duration nsaid use neurology 199748626 32abstract veld ba launer lj hoes aw et al nsaids incident alzheimer disease rotterdam study neurobiol aging 199819607 11isimedline fourrier letenneur l begaud b et al nonsteroidal antiinflammatory drug use cognitive function elderly inconclusive results population based cohort study j clin epidemiol 1996491201 orgogozo jm dartigues jf lafont et al wine consumption dementia elderly prospective community study bordeaux area rev neurol paris 1997153185 92medline lemeshow letenneur l dartigues jf et al illustration analysis taking account complex survey considerations association wine consumption dementia paquid study j epidemiol 1998148298 306abstract tredici g miloso m nicolini g et al resveratrol map kinases neuronal cells might wine neuroprotectant drugs exp clin res 19992599 103isimedline lammi uk kivela sl nissinen et al mental disability among elderly men finland prevalence predictors correlates acta psychiatr scand 198980459 68isimedline broe ga creasey h jorm af et al health habits risk cognitive impairment dementia old age prospective study effects exercise smoking alcohol consumption aust n z j public health 199822621 3isimedline emery cf huppert fa schein rl relationships among age exercise health cognitive function british sample gerontologist 199535378 85abstract rogers rl meyer js mortel kf reaching retirement age physical activity sustains cerebral perfusion cognition j geriatr soc 199038123 8isimedline laurin d verreault r lindsay j et al physical activity risk cognitive impairment dementia elderly persons arch neurol 200158498 504abstractfree full text
0.28510132.11581121.html.plaintext.txt	0	nice guidelines treatment alzheimers disease evidence based medicine may discriminatory r stewart
0.28510132.11581121.html.plaintext.txt	1	institute psychiatry de crespigny park london se5 8af uk
0.28510132.11581121.html.plaintext.txt	2	arshad et al 2001 raise important concerns uk guidelines treatment alzheimers disease national institute clinical excellence nice 2001 may counterproductive patients learning disabilities potential discrimination means stop particular difficulty highlight central role mini mental state examination mmse instrument determining treatment eligibility response scores mmse strongly influenced previous education cross cultural validity poor guidelines therefore unhelpful people lower educational attainment growing numbers older people minority ethnic groups uk comorbid cerebrovascular disease also frequent people disadvantaged backgrounds particular minority ethnic groups african caribbean populations stewart et al 1999 reduces likelihood diagnosis alzheimers disease therefore eligibility anti cholinesterase treatment according standard diagnostic criteria mckhann et al 1984 despite growing evidence overlapping pathological processes dementia holmes et al 1999
0.28510132.11581121.html.plaintext.txt	3	arshad et al 2001 raise important concerns uk guidelines treatment alzheimers disease national institute clinical excellence nice 2001 may counterproductive patients learning disabilities potential discrimination means stop particular difficulty highlight central role mini mental state examination mmse instrument determining treatment eligibility response scores mmse strongly influenced previous education cross cultural validity poor guidelines therefore unhelpful people lower educational attainment growing numbers older people minority ethnic groups uk comorbid cerebrovascular disease also frequent people disadvantaged backgrounds particular minority ethnic groups african caribbean populations stewart et al 1999 reduces likelihood diagnosis alzheimers disease therefore eligibility anti cholinesterase treatment according standard diagnostic criteria mckhann et al 1984 despite growing evidence overlapping pathological processes dementia holmes et al 1999
0.28510132.11581121.html.plaintext.txt	4	sub populations represented clinical trial samples minority ethnic groups people lower educational attainment people learning disability people comorbid cerebrovascular disease best hoped considerably weaker evidence base might emerge years future time large numbers people may failed receive potentially beneficial treatment problem lie treatment guidelines applied level individuals services particular regarding groups alzheimers disease 26 year old cognitive screen andor 17 year old diagnostic criteria unhelpful evidence based medicine noble ideal however clinical practice restricted evidence base may amount institutionalised discrimination
0.28510132.11581121.html.plaintext.txt	5	sub populations represented clinical trial samples minority ethnic groups people lower educational attainment people learning disability people comorbid cerebrovascular disease best hoped considerably weaker evidence base might emerge years future time large numbers people may failed receive potentially beneficial treatment problem lie treatment guidelines applied level individuals services particular regarding groups alzheimers disease 26 year old cognitive screen andor 17 year old diagnostic criteria unhelpful evidence based medicine noble ideal however clinical practice restricted evidence base may amount institutionalised discrimination
0.28510132.11581121.html.plaintext.txt	6	national institute clinical excellence 2001 guidance use donepezil rivastigmine galantamine treatment alzheimers disease london nice
0.29024228.15781953.html.plaintext.txt	0	physical activity apoe genotype dementia risk findings cardiovascular health cognition study laura jean podewils1 eliseo guallar12 lewis h kuller3 linda p fried4 oscar l lopez5 michelle carlson6 constantine g lyketsos7
0.29024228.15781953.html.plaintext.txt	1	1 department epidemiology johns hopkins bloomberg school public health baltimore md 2 welch center prevention epidemiology clinical research johns hopkins medical institutions baltimore md 3 department epidemiology university pittsburgh graduate school public health pittsburgh pa 4 department medicine center aging health johns hopkins medical institutions baltimore md 5 department neurology university pittsburgh school medicine pittsburgh pa 6 department mental health center aging health johns hopkins medical institutions baltimore md 7 division geriatric psychiatry neuropsychiatry department psychiatry behavioral sciences johns hopkins medical institutions baltimore md
0.29024228.15781953.html.plaintext.txt	2	received publication january 26 2004 accepted publication november 15 2004
0.29024228.15781953.html.plaintext.txt	3	received publication january 26 2004 accepted publication november 15 2004
0.29024228.15781953.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references physical activity may help preserve cognitive function decrease dementia risk epidemiologic findings inconsistent authors conducted prospective study determine association physical activity risk dementia alzheimers disease vascular dementia us study population comprised 3375 men women aged 65 years older free dementia baseline participated cardiovascular health cognition study 1992 2000 leisure time energy expenditure activity index reflecting number different physical activities calculated analyses based cox proportional hazards models 480 incident cases dementia average 54 years follow multivariate adjustment participants highest quartile physical energy expenditure relative risk dementia 085 95 confidence interval 061 119 compared lowest quartile participants engaging 4 activities relative risk dementia 051 95 confidence interval 033 079 compared engaging 0 1 activity associations marked apolipoprotein e genotype apoe 4 allele noncarriers absent carriers similar pattern observed alzheimers disease vascular dementia mechanisms explain observed relations deserve study
0.29024228.15781953.html.plaintext.txt	5	abstract top abstract introduction materials methods results discussion references physical activity may help preserve cognitive function decrease dementia risk epidemiologic findings inconsistent authors conducted prospective study determine association physical activity risk dementia alzheimers disease vascular dementia us study population comprised 3375 men women aged 65 years older free dementia baseline participated cardiovascular health cognition study 1992 2000 leisure time energy expenditure activity index reflecting number different physical activities calculated analyses based cox proportional hazards models 480 incident cases dementia average 54 years follow multivariate adjustment participants highest quartile physical energy expenditure relative risk dementia 085 95 confidence interval 061 119 compared lowest quartile participants engaging 4 activities relative risk dementia 051 95 confidence interval 033 079 compared engaging 0 1 activity associations marked apolipoprotein e genotype apoe 4 allele noncarriers absent carriers similar pattern observed alzheimers disease vascular dementia mechanisms explain observed relations deserve study
0.29024228.15781953.html.plaintext.txt	6	aged alzheimer disease dementia exercise motor activity physical fitness risk factors
0.29024228.15781953.html.plaintext.txt	7	abbreviations apoe apolipoprotein e genotype chcs cardiovascular health cognition study chs cardiovascular health study mri magnetic resonance imaging 3ms modified mini mental state
0.29024228.15781953.html.plaintext.txt	8	introduction top abstract introduction materials methods results discussion references dementia condition characterized global decline cognitive functioning major public health problem worldwide estimated 19 4 million persons currently living alzheimers disease common type dementia united states alone 1 unless effective preventive strategy realized number dementia cases expected expand number persons living later decades continues increase 2 advancing age family history dementia educational level presence apolipoprotein e genotype apoe 4 allele remain established risk factors alzheimers disease 3
0.29024228.15781953.html.plaintext.txt	9	mounting body evidence supports role physical activity means maintain cognitive performance physical activity may preserve neuronal plasticity increase synapses dendritic receptors following injury release hormonal factors may assist neuronal creation function brain derived neurotrophic factor epinephrine 4 addition physical activity lowers cardiovascular risk decreases blood pressure increases high density lipoprotein cholesterol levels glucose tolerance 5 may related neuronal integrity cognitive function 6 7 finally engaging physical activity may indicate enriched social environment may decrease dementia risk 8
0.29024228.15781953.html.plaintext.txt	10	mounting body evidence supports role physical activity means maintain cognitive performance physical activity may preserve neuronal plasticity increase synapses dendritic receptors following injury release hormonal factors may assist neuronal creation function brain derived neurotrophic factor epinephrine 4 addition physical activity lowers cardiovascular risk decreases blood pressure increases high density lipoprotein cholesterol levels glucose tolerance 5 may related neuronal integrity cognitive function 6 7 finally engaging physical activity may indicate enriched social environment may decrease dementia risk 8
0.29024228.15781953.html.plaintext.txt	11	several randomized trials reported enhanced neurocognitive function following exercise training 9 addition observational studies 10 13 shown inverse association physical activity cognitive decline among older adults however inverse association physical activity alzheimers disease found 10 14 19 20 23 studies diminished physical activity may also different roles various forms dementia
0.29024228.15781953.html.plaintext.txt	12	several randomized trials reported enhanced neurocognitive function following exercise training 9 addition observational studies 10 13 shown inverse association physical activity cognitive decline among older adults however inverse association physical activity alzheimers disease found 10 14 19 20 23 studies diminished physical activity may also different roles various forms dementia
0.29024228.15781953.html.plaintext.txt	13	study examined relation physical activity incident dementia subtypes alzheimers disease vascular dementia using data large community based cohort older adults also assessed possibility association physical activity dementia may different apoe 4 carriers versus noncarriers
0.29024228.15781953.html.plaintext.txt	14	study examined relation physical activity incident dementia subtypes alzheimers disease vascular dementia using data large community based cohort older adults also assessed possibility association physical activity dementia may different apoe 4 carriers versus noncarriers
0.29024228.15781953.html.plaintext.txt	15	materials methods top abstract introduction materials methods results discussion references subject selection cardiovascular health study chs population based prospective cohort study initiated 1989 identify factors related cardiovascular disease older adults 24 target population consisted adults aged 65 years older residing one four us communities sacramento county california washington county maryland forsyth county north carolina pittsburgh pennsylvania eligible persons drawn health care financing administration medicare enrollment lists random sampling three age strata 65 74 75 84 85 years total 5201 men women agreed participate initial recruiting phase 1989 1991 additional 687 african americans joined study 1992 1993 total n 5888
0.29024228.15781953.html.plaintext.txt	16	materials methods top abstract introduction materials methods results discussion references subject selection cardiovascular health study chs population based prospective cohort study initiated 1989 identify factors related cardiovascular disease older adults 24 target population consisted adults aged 65 years older residing one four us communities sacramento county california washington county maryland forsyth county north carolina pittsburgh pennsylvania eligible persons drawn health care financing administration medicare enrollment lists random sampling three age strata 65 74 75 84 85 years total 5201 men women agreed participate initial recruiting phase 1989 1991 additional 687 african americans joined study 1992 1993 total n 5888
0.29024228.15781953.html.plaintext.txt	17	cardiovascular health cognition study chcs 25 27 ancillary study chs started 1992 chs participants invited undergo cerebral magnetic resonance imaging mri participate cognitive testing chcs cohort consisted 3660 668 percent participation rate 28 persons brain mris available 3608 persons mri measures cognition assessed time compared nonparticipants chcs participants younger educated less likely cardiovascular disease 29 institutional review boards participating institution approved research protocols chs chcs participants provided written informed consent
0.29024228.15781953.html.plaintext.txt	18	cardiovascular health cognition study chcs 25 27 ancillary study chs started 1992 chs participants invited undergo cerebral magnetic resonance imaging mri participate cognitive testing chcs cohort consisted 3660 668 percent participation rate 28 persons brain mris available 3608 persons mri measures cognition assessed time compared nonparticipants chcs participants younger educated less likely cardiovascular disease 29 institutional review boards participating institution approved research protocols chs chcs participants provided written informed consent
0.29024228.15781953.html.plaintext.txt	19	data collection physical activity information physical activity collected trained interviewers chs baseline 1989 1990 chcs baseline 1992 1994 modified minnesota leisure time activity questionnaire 30 31 asked participants frequency duration 15 different types activities previous 2 weeks activities selected previously shown common among older adults 32 included walking household chores mowing raking gardening hiking jogging biking exercise cycling dancing aerobics bowling golfing general exercise swimming
0.29024228.15781953.html.plaintext.txt	20	data collection physical activity information physical activity collected trained interviewers chs baseline 1989 1990 chcs baseline 1992 1994 modified minnesota leisure time activity questionnaire 30 31 asked participants frequency duration 15 different types activities previous 2 weeks activities selected previously shown common among older adults 32 included walking household chores mowing raking gardening hiking jogging biking exercise cycling dancing aerobics bowling golfing general exercise swimming
0.29024228.15781953.html.plaintext.txt	21	activities assigned metabolic equivalents ml o2minute mets according intensity 30 leisure time energy expenditure kilocaloriesweek estimated person kilocalorie expenditure chs baseline chcs baseline averaged obtain estimate habitual physical activity levels older adulthood used current analysis single measure physical activity used participants values missing one testing periods n 416
0.29024228.15781953.html.plaintext.txt	22	activities assigned metabolic equivalents ml o2minute mets according intensity 30 leisure time energy expenditure kilocaloriesweek estimated person kilocalorie expenditure chs baseline chcs baseline averaged obtain estimate habitual physical activity levels older adulthood used current analysis single measure physical activity used participants values missing one testing periods n 416
0.29024228.15781953.html.plaintext.txt	23	express diversity physical activity activity index calculated number different activities subject participated previous 2 weeks raking mowing collapsed single category represent yard work resulting potential range index 0 14 activities activity indices chs baseline chcs baseline averaged represent activity index used present study similar aggregate scores physical activity used previous studies dementia risk 16 19
0.29024228.15781953.html.plaintext.txt	24	express diversity physical activity activity index calculated number different activities subject participated previous 2 weeks raking mowing collapsed single category represent yard work resulting potential range index 0 14 activities activity indices chs baseline chcs baseline averaged represent activity index used present study similar aggregate scores physical activity used previous studies dementia risk 16 19
0.29024228.15781953.html.plaintext.txt	25	apoe genotyping methods apoe genotyping chs described elsewhere 29 briefly genomic dna extracted whole blood samples amplified using polymerase chain reaction cleaving electrophoresis agarose gels restriction patterns determined according methods hixson vernier 33 apoe genotypes grouped apoe 4 carriers 24 34 44 genotypes noncarriers 22 23 33 genotypes
0.29024228.15781953.html.plaintext.txt	26	covariates measurements obtained chcs baseline examination also considered sociodemographic variables included age gender educational level ethnicity information smoking alcohol intake postmenopausal hormone replacement therapy use self reported prevalent cases myocardial infarction angina stroke transient ischemic attack congestive heart failure baseline ascertained participant self report physicians diagnosis functional impairment measured using modified version instrument assessing basic activities daily living instrumental activities daily living national health interview survey 34 social network assessed using lubben social network scale 35 series questions asking participants life satisfaction personal relationships summed represent measure social support center epidemiologic studies depression scale 36 administered chcs baseline sensitive version mini mental state examination modified mini mental state 3ms examination 37 administered annually 3ms assesses several domains cognition greater detail mini mental state examination scores ranging 0 100 higher scores reflect better performance person receive clinical evaluation attempts made evaluate cognition using telephone interview cognitive status 38 participants died examinations information obtained using informant questionnaire cognitive decline elderly 39 data concerning circumstances death
0.29024228.15781953.html.plaintext.txt	27	self reported weight height also recorded chcs baseline body mass index calculated weight kilograms per height meters squared blood pressure measured standardized manner trained personnel participant seated 5 minutes average two readings calculated analysis hypertension defined previous diagnosis hypertension taking hypertensive medication current systolic blood pressure 140 mmhg diastolic blood pressure 90 mmhg total cholesterol high density lipoprotein cholesterol triglycerides determined fasting samples using standard methods low density lipoprotein cholesterol estimated friedewald formula 40 persons considered diabetic validated medical diagnosis diabetes fasting glucose level 126 mgdl higher
0.29024228.15781953.html.plaintext.txt	28	self reported weight height also recorded chcs baseline body mass index calculated weight kilograms per height meters squared blood pressure measured standardized manner trained personnel participant seated 5 minutes average two readings calculated analysis hypertension defined previous diagnosis hypertension taking hypertensive medication current systolic blood pressure 140 mmhg diastolic blood pressure 90 mmhg total cholesterol high density lipoprotein cholesterol triglycerides determined fasting samples using standard methods low density lipoprotein cholesterol estimated friedewald formula 40 persons considered diabetic validated medical diagnosis diabetes fasting glucose level 126 mgdl higher
0.29024228.15781953.html.plaintext.txt	29	cerebral mris conducted chcs baseline scored overall severity white matter lesions according scale developed chs researchers 41 white matter lesion severity score 3 considered within normal limits group older adults whereas score 3 considered indicative neurodegenerative changes
0.29024228.15781953.html.plaintext.txt	30	cerebral mris conducted chcs baseline scored overall severity white matter lesions according scale developed chs researchers 41 white matter lesion severity score 3 considered within normal limits group older adults whereas score 3 considered indicative neurodegenerative changes
0.29024228.15781953.html.plaintext.txt	31	diagnosis dementia dementia status type chcs classified 1999 2000 using multistage process 25 27 initially participants classified local study site dementia risk stratum high low persons deemed high risk 1 3ms score 80 within last two study visits 2 decline 5 points 3ms within follow period 3 telephone interview cognitive status score 28 informant questionnaire cognitive decline elderly score 36 4 incident stroke 5 diagnosis dementia documented medical records 6 resided nursing home study period
0.29024228.15781953.html.plaintext.txt	32	diagnosis dementia dementia status type chcs classified 1999 2000 using multistage process 25 27 initially participants classified local study site dementia risk stratum high low persons deemed high risk 1 3ms score 80 within last two study visits 2 decline 5 points 3ms within follow period 3 telephone interview cognitive status score 28 informant questionnaire cognitive decline elderly score 36 4 incident stroke 5 diagnosis dementia documented medical records 6 resided nursing home study period
0.29024228.15781953.html.plaintext.txt	33	pittsburgh site participants alive could traced invited center 1999 2000 full neuropsychiatric examination regardless dementia risk three remaining sites high risk participants described minority participants participants cognitive data incomplete invited comprehensive evaluation attend clinic visit medical records proxy previous telephone interviews used diagnosis diagnosis based deficit performance two cognitive domains sufficiently severe affect subjects activities daily living history normal intellectual function dementia criteria designed identify subjects syndromes could include relatively preserved memory functions eg frontotemporal dementia thus memory deficit required diagnosis dementia 26
0.29024228.15781953.html.plaintext.txt	34	pittsburgh site participants alive could traced invited center 1999 2000 full neuropsychiatric examination regardless dementia risk three remaining sites high risk participants described minority participants participants cognitive data incomplete invited comprehensive evaluation attend clinic visit medical records proxy previous telephone interviews used diagnosis diagnosis based deficit performance two cognitive domains sufficiently severe affect subjects activities daily living history normal intellectual function dementia criteria designed identify subjects syndromes could include relatively preserved memory functions eg frontotemporal dementia thus memory deficit required diagnosis dementia 26
0.29024228.15781953.html.plaintext.txt	35	participants identified dementia reviewed adjudication committee made neurology psychiatry experts diagnosis alzheimers disease based national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda 42 criteria diagnosis vascular dementia based alzheimers disease diagnostic treatment centers criteria 43 time dementia onset established first diagnosis recorded medical records otherwise midpoint two annual chs follow interviews marked change cognition leading final dementia diagnosis
0.29024228.15781953.html.plaintext.txt	36	participants identified dementia reviewed adjudication committee made neurology psychiatry experts diagnosis alzheimers disease based national institute neurological communicative disorders stroke alzheimers disease related disorders association nincds adrda 42 criteria diagnosis vascular dementia based alzheimers disease diagnostic treatment centers criteria 43 time dementia onset established first diagnosis recorded medical records otherwise midpoint two annual chs follow interviews marked change cognition leading final dementia diagnosis
0.29024228.15781953.html.plaintext.txt	37	statistical analyses survival analysis used assess association activity level time onset dementia using cox proportional hazards regression multivariate models adjusted age gender race apoe genotype educational level difficulty activities daily living instrumental activities daily living lubben social network scale social support baseline 3ms score white matter grade hazard ratios 95 percent confidence intervals computed tests linear trend across quartiles physical activity computed introducing cox models variable median quartile continuous variable effect modification assessed stratification introducing product terms multivariate cox models statistical analyses performed using stata software version 70 44
0.29024228.15781953.html.plaintext.txt	38	statistical analyses survival analysis used assess association activity level time onset dementia using cox proportional hazards regression multivariate models adjusted age gender race apoe genotype educational level difficulty activities daily living instrumental activities daily living lubben social network scale social support baseline 3ms score white matter grade hazard ratios 95 percent confidence intervals computed tests linear trend across quartiles physical activity computed introducing cox models variable median quartile continuous variable effect modification assessed stratification introducing product terms multivariate cox models statistical analyses performed using stata software version 70 44
0.29024228.15781953.html.plaintext.txt	39	results top abstract introduction materials methods results discussion references 3608 chcs participants excluded 227 dementia baseline six whose dementia status could determined remaining 3375 subjects 480 developed incident dementia 54 years follow median 60 range 003 84 years figure 1
0.29024228.15781953.html.plaintext.txt	40	results top abstract introduction materials methods results discussion references 3608 chcs participants excluded 227 dementia baseline six whose dementia status could determined remaining 3375 subjects 480 developed incident dementia 54 years follow median 60 range 003 84 years figure 1
0.29024228.15781953.html.plaintext.txt	41	view larger version 18k figure 1 cardiovascular health cognition study sample selection 1992 1993 follow 1999 2000 united states vad vascular dementia ad alzheimers disease
0.29024228.15781953.html.plaintext.txt	42	view larger version 18k figure 1 cardiovascular health cognition study sample selection 1992 1993 follow 1999 2000 united states vad vascular dementia ad alzheimers disease
0.29024228.15781953.html.plaintext.txt	43	table 1 describes participant characteristics chcs baseline developed dementia compared older lower educational level likely carry apoe 4 allele poorer cognitive performance 3ms baseline physical difficulties likely show white matter disease cerebral mri incident dementia cases also likely history stroke cardiovascular disease hypertension
0.29024228.15781953.html.plaintext.txt	44	table 1 describes participant characteristics chcs baseline developed dementia compared older lower educational level likely carry apoe 4 allele poorer cognitive performance 3ms baseline physical difficulties likely show white matter disease cerebral mri incident dementia cases also likely history stroke cardiovascular disease hypertension
0.29024228.15781953.html.plaintext.txt	45	view table table 1 baseline characteristics participants cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	46	average leisure time physical activity expenditure 1213 kcal per week standard deviation 1388 304 participants completely sedentary leisure time kilocalorie expenditure 0 persons reported engaging 2 3 different activities mean 27 standard deviation 14 walking household chores common 775 percent 830 percent active persons engaging activities respectively approximately one third sample engaged activities gardening yard work organized exercise program
0.29024228.15781953.html.plaintext.txt	47	average leisure time physical activity expenditure 1213 kcal per week standard deviation 1388 304 participants completely sedentary leisure time kilocalorie expenditure 0 persons reported engaging 2 3 different activities mean 27 standard deviation 14 walking household chores common 775 percent 830 percent active persons engaging activities respectively approximately one third sample engaged activities gardening yard work organized exercise program
0.29024228.15781953.html.plaintext.txt	48	relation physical activity participant characteristics displayed table 2 males caucasians participants higher educational levels persons fewer functional difficulties activities daily livinginstrumental activities daily living levels physical activity higher relatively sedentary participants quartile 1 likely hypertensive diabetic smoke higher levels high density lipoprotein cholesterol triglycerides compared active participants similar associations found baseline characteristics activity index number activities table 3 spearman correlation energy expenditure activity index 069 p 0001
0.29024228.15781953.html.plaintext.txt	49	relation physical activity participant characteristics displayed table 2 males caucasians participants higher educational levels persons fewer functional difficulties activities daily livinginstrumental activities daily living levels physical activity higher relatively sedentary participants quartile 1 likely hypertensive diabetic smoke higher levels high density lipoprotein cholesterol triglycerides compared active participants similar associations found baseline characteristics activity index number activities table 3 spearman correlation energy expenditure activity index 069 p 0001
0.29024228.15781953.html.plaintext.txt	50	view table table 2 participant characteristics quartile leisure time energy expenditure cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	51	view table table 3 participant characteristics activity index activities previous 2 weeks cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	52	leisure time energy expenditure inversely associated risk dementia although adjustment age covariates trend longer significant table 4 point estimates suggested inverse relation alzheimers disease vascular dementia none analyses vascular dementia reached significance
0.29024228.15781953.html.plaintext.txt	53	leisure time energy expenditure inversely associated risk dementia although adjustment age covariates trend longer significant table 4 point estimates suggested inverse relation alzheimers disease vascular dementia none analyses vascular dementia reached significance
0.29024228.15781953.html.plaintext.txt	54	view table table 4 hazard ratios incident dementia level leisure time energy expenditure cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	55	number physical activities inversely associated dementia risk table 5 inverse association persisted multivariate adjustment adjusted hazard ratios cause dementia incidence 10 reference 090 090 058 0 1 2 3 4 activities respectively p trend 0004 trend remained significant models adjusted total energy expenditure data shown
0.29024228.15781953.html.plaintext.txt	56	number physical activities inversely associated dementia risk table 5 inverse association persisted multivariate adjustment adjusted hazard ratios cause dementia incidence 10 reference 090 090 058 0 1 2 3 4 activities respectively p trend 0004 trend remained significant models adjusted total energy expenditure data shown
0.29024228.15781953.html.plaintext.txt	57	view table table 5 hazard ratios incident dementia activity index activities previous 2 weeks cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	58	analyses stratified apoe 4 carrier state inverse association energy expenditure activity index dementia risk limited apoe 4 noncarriers table 6 figure 2 multivariate adjusted hazard ratios type dementia comparing highest lowest quartile energy expenditure apoe 4 noncarriers 068 p trend 001 hazard ratio comparing highest lowest quartile activity index 044 p trend 0001 corresponding hazard ratios energy expenditure activity index apoe 4 carriers 129 p trend 053 120 p trend 068 p values interaction energy expenditure activity index apoe 4 carrier status 006 0003 respectively pattern observed alzheimers disease vascular dementia figure 2
0.29024228.15781953.html.plaintext.txt	59	analyses stratified apoe 4 carrier state inverse association energy expenditure activity index dementia risk limited apoe 4 noncarriers table 6 figure 2 multivariate adjusted hazard ratios type dementia comparing highest lowest quartile energy expenditure apoe 4 noncarriers 068 p trend 001 hazard ratio comparing highest lowest quartile activity index 044 p trend 0001 corresponding hazard ratios energy expenditure activity index apoe 4 carriers 129 p trend 053 120 p trend 068 p values interaction energy expenditure activity index apoe 4 carrier status 006 0003 respectively pattern observed alzheimers disease vascular dementia figure 2
0.29024228.15781953.html.plaintext.txt	60	view table table 6 hazard ratios incident dementia level physical activity stratified apoe cardiovascular health cognition study united states 1992 2000
0.29024228.15781953.html.plaintext.txt	61	view larger version 28k figure 2 five year cumulative incidence dementia function leisure time energy expenditure activity index among apolipoprotein e genotype apoe 4 carriers noncarriers united states cardiovascular health cognition study 1992 2000 bold curves cause dementia thin solid curves alzheimers disease dashed curves vascular dementia bars frequency distribution physical activity within apoe genotype stratum
0.29024228.15781953.html.plaintext.txt	62	view larger version 28k figure 2 five year cumulative incidence dementia function leisure time energy expenditure activity index among apolipoprotein e genotype apoe 4 carriers noncarriers united states cardiovascular health cognition study 1992 2000 bold curves cause dementia thin solid curves alzheimers disease dashed curves vascular dementia bars frequency distribution physical activity within apoe genotype stratum
0.29024228.15781953.html.plaintext.txt	63	persons may less active less physically able active therefore repeated analysis excluding subjects one instrumental activities daily living impairments one activities daily living impairments associations energy expenditure activity index dementia risk effect modification apoe carrier status similar
0.29024228.15781953.html.plaintext.txt	64	persons may less active less physically able active therefore repeated analysis excluding subjects one instrumental activities daily living impairments one activities daily living impairments associations energy expenditure activity index dementia risk effect modification apoe carrier status similar
0.29024228.15781953.html.plaintext.txt	65	discussion top abstract introduction materials methods results discussion references large prospective cohort study community dwelling older adults identified inverse association physical activity dementia risk apoe 4 noncarriers found association apoe 4 carriers associations similar alzheimers disease vascular dementia results also suggest participating number different activities may important frequency intensity duration physical activity respect dementia risk
0.29024228.15781953.html.plaintext.txt	66	discussion top abstract introduction materials methods results discussion references large prospective cohort study community dwelling older adults identified inverse association physical activity dementia risk apoe 4 noncarriers found association apoe 4 carriers associations similar alzheimers disease vascular dementia results also suggest participating number different activities may important frequency intensity duration physical activity respect dementia risk
0.29024228.15781953.html.plaintext.txt	67	findings prospective studies physical activity dementia inconsistent 10 15 17 19 22 23 45 among japanese elders regular physical activity associated lower risk alzheimers disease vascular dementia incidence 15 similarly older french participants engaged three social leisure activities versus none 80 percent lower overall dementia risk 16 17 canadian study health aging physical activity inversely associated cause dementia alzheimers disease 10 inverse association vascular dementia observed women 45 wang et al 22 however observe association physical activity dementia incidence social mental productive activities accounted although investigators examined three types physical activities subjects participated activities religious orders study 23 bronx aging study 21 also failed identify relation activities physical per se risk dementia report association cognitive activity reduced dementia incidence neither studies accounted apoe genotype analysis however although measure cognitive activities directly physical activities often occur conjunction social cognitive stimulation
0.29024228.15781953.html.plaintext.txt	68	findings prospective studies physical activity dementia inconsistent 10 15 17 19 22 23 45 among japanese elders regular physical activity associated lower risk alzheimers disease vascular dementia incidence 15 similarly older french participants engaged three social leisure activities versus none 80 percent lower overall dementia risk 16 17 canadian study health aging physical activity inversely associated cause dementia alzheimers disease 10 inverse association vascular dementia observed women 45 wang et al 22 however observe association physical activity dementia incidence social mental productive activities accounted although investigators examined three types physical activities subjects participated activities religious orders study 23 bronx aging study 21 also failed identify relation activities physical per se risk dementia report association cognitive activity reduced dementia incidence neither studies accounted apoe genotype analysis however although measure cognitive activities directly physical activities often occur conjunction social cognitive stimulation
0.29024228.15781953.html.plaintext.txt	69	physical activity may protect dementia risk several mechanisms experimental studies demonstrated physical exercise activity facilitates learning increasing expression genes promoting neurogenesis neural plasticity 4 46 although several neural substrates may mediate exercise induced effects neuronal structure integrity research suggests central role brain derived neurotrophic factor 4 46 levels factor hippocampi diminished patients alzheimers disease 47 nonneural vascular adaptations also enhanced exercise including increased cerebral blood flow substrate exchange 48 increased cerebral capillary density 49 decreased accumulation radical oxidative proteins 50
0.29024228.15781953.html.plaintext.txt	70	physical activity may protect dementia risk several mechanisms experimental studies demonstrated physical exercise activity facilitates learning increasing expression genes promoting neurogenesis neural plasticity 4 46 although several neural substrates may mediate exercise induced effects neuronal structure integrity research suggests central role brain derived neurotrophic factor 4 46 levels factor hippocampi diminished patients alzheimers disease 47 nonneural vascular adaptations also enhanced exercise including increased cerebral blood flow substrate exchange 48 increased cerebral capillary density 49 decreased accumulation radical oxidative proteins 50
0.29024228.15781953.html.plaintext.txt	71	addition physical activity may surrogate overall life engagement greater social activity persons developed social networks lower risk cause mortality persons socially isolated social supports attenuate rate cognitive decline older adults 51 social networks may also promote overall health particularly cardiovascular risk factors thereby may impact dementia risk similarly involvement physical activities associated mastery self efficacy 52 turn attributes may motivate persons attentive health needs health behaviors adjusted social network social support multivariate models however activity index continued associated dementia risk physical activity operating social mechanisms appears level captured two measures social functioning
0.29024228.15781953.html.plaintext.txt	72	addition physical activity may surrogate overall life engagement greater social activity persons developed social networks lower risk cause mortality persons socially isolated social supports attenuate rate cognitive decline older adults 51 social networks may also promote overall health particularly cardiovascular risk factors thereby may impact dementia risk similarly involvement physical activities associated mastery self efficacy 52 turn attributes may motivate persons attentive health needs health behaviors adjusted social network social support multivariate models however activity index continued associated dementia risk physical activity operating social mechanisms appears level captured two measures social functioning
0.29024228.15781953.html.plaintext.txt	73	involvement number different activities likely requires organization memory skills necessary flexibly schedule attend shift among activities organizational executive memory processes regulated neuroanatomical regions adversely affected aging dementing illnesses exercising may help buffer preserve cognitive reserves face cognitive decline via continued use corresponding cortical synaptic stimulation intact neurons 53 cross sectional studies variety lifestyle activities positively associated indices cognition among nondemented older women particularly domain memory m carlson johns hopkins medical institutions unpublished manuscript
0.29024228.15781953.html.plaintext.txt	74	involvement number different activities likely requires organization memory skills necessary flexibly schedule attend shift among activities organizational executive memory processes regulated neuroanatomical regions adversely affected aging dementing illnesses exercising may help buffer preserve cognitive reserves face cognitive decline via continued use corresponding cortical synaptic stimulation intact neurons 53 cross sectional studies variety lifestyle activities positively associated indices cognition among nondemented older women particularly domain memory m carlson johns hopkins medical institutions unpublished manuscript
0.29024228.15781953.html.plaintext.txt	75	alternatively physical activity may index healthier lifestyle resulting less exposure factors affect cognitive function precipitate dementia current study engaging larger number different activities generally associated favorable health profile health behaviors
0.29024228.15781953.html.plaintext.txt	76	alternatively physical activity may index healthier lifestyle resulting less exposure factors affect cognitive function precipitate dementia current study engaging larger number different activities generally associated favorable health profile health behaviors
0.29024228.15781953.html.plaintext.txt	77	previous studies 54 56 apoe 4 carriers attain benefit noncarriers physical activity terms blood pressure lipid patterns similarly findings suggest differing risk patterns dementia physical activity apoe genotype imply potential protective effect associated physical activity enough overcome effect apoe 4 alleles physical activity dementia simply unrelated persons apoe 4 genotypes however findings contrast previous study inverse association physical activity cognitive decline observed predominantly apoe 4 carriers 13 difficult know whether findings extend dementia elderly persons experience cognitive decline progress clinical dementia note however interaction physical activity apoe 4 study based 28 cases cognitive decline thus subject considerable variability replication findings larger studies required resolve apparent discrepancy
0.29024228.15781953.html.plaintext.txt	78	previous studies 54 56 apoe 4 carriers attain benefit noncarriers physical activity terms blood pressure lipid patterns similarly findings suggest differing risk patterns dementia physical activity apoe genotype imply potential protective effect associated physical activity enough overcome effect apoe 4 alleles physical activity dementia simply unrelated persons apoe 4 genotypes however findings contrast previous study inverse association physical activity cognitive decline observed predominantly apoe 4 carriers 13 difficult know whether findings extend dementia elderly persons experience cognitive decline progress clinical dementia note however interaction physical activity apoe 4 study based 28 cases cognitive decline thus subject considerable variability replication findings larger studies required resolve apparent discrepancy
0.29024228.15781953.html.plaintext.txt	79	chcs one largest prospective studies older adults comprehensive information subclinical clinical cognitive functioning dementia status cardiovascular factors addition physical activity collected using standardized methods 29 prospective design chcs enabled us collect information physical activity advance dementia diagnosis therefore minimizing selection recall biases
0.29024228.15781953.html.plaintext.txt	80	chcs one largest prospective studies older adults comprehensive information subclinical clinical cognitive functioning dementia status cardiovascular factors addition physical activity collected using standardized methods 29 prospective design chcs enabled us collect information physical activity advance dementia diagnosis therefore minimizing selection recall biases
0.29024228.15781953.html.plaintext.txt	81	update information physical activity follow preclinical symptoms may reduce activity levels compromising ability establish temporality although misclassification exposure possible participants present analysis cognitively stable 3ms score 80 time physical activity information collected furthermore able adjust baseline 3ms cognitive scores analyses basis considerations reasonable suggest misclassification exposure would nondifferential would biased results toward null
0.29024228.15781953.html.plaintext.txt	82	update information physical activity follow preclinical symptoms may reduce activity levels compromising ability establish temporality although misclassification exposure possible participants present analysis cognitively stable 3ms score 80 time physical activity information collected furthermore able adjust baseline 3ms cognitive scores analyses basis considerations reasonable suggest misclassification exposure would nondifferential would biased results toward null
0.29024228.15781953.html.plaintext.txt	83	findings without limitations able assess physical activity levels older adult life unclear period life physical activity relevant preserving cognition impacting dementia risk finding number activities stronger association dementia risk kilocalorie expenditure may artifact measurement reliability minnesota leisure time activity questionnaire may lower low moderate levels activity 57 levels older adults participate therefore possible number activities may sensitive indicator levels furthermore persons established physical activity habits may precise recall persons exercise sporadically similarly recall number activities may reliable specifics exercise frequency duration factors heavily weighted calculating total energy expenditure sample number activities significantly positively correlated total physical activity energy expenditure understanding components physical activity reduce dementia risk deserves attention
0.29024228.15781953.html.plaintext.txt	84	findings without limitations able assess physical activity levels older adult life unclear period life physical activity relevant preserving cognition impacting dementia risk finding number activities stronger association dementia risk kilocalorie expenditure may artifact measurement reliability minnesota leisure time activity questionnaire may lower low moderate levels activity 57 levels older adults participate therefore possible number activities may sensitive indicator levels furthermore persons established physical activity habits may precise recall persons exercise sporadically similarly recall number activities may reliable specifics exercise frequency duration factors heavily weighted calculating total energy expenditure sample number activities significantly positively correlated total physical activity energy expenditure understanding components physical activity reduce dementia risk deserves attention
0.29024228.15781953.html.plaintext.txt	85	must also consider possibility reduction number different physical activities early symptom dementia addressed possibility using several different approaches first excluded persons 3ms score less 80 prevalent dementia baseline however possible 3ms sensitive enough detect persons subclinical dementing illness persons included study second adjusted analyses baseline cognitive function inverse association number physical activities dementia risk persisted third reran analysis excluding persons developed incident dementia within first year follow results essentially unchanged furthermore used information physical activity two time points approximately 5 years apart obtain stable estimate regular physical activity older adulthood prior dementia onset finally also evaluated association physical activity dementia risk excluding persons one difficulties activities daily living instrumental activities daily living results similar
0.29024228.15781953.html.plaintext.txt	86	must also consider possibility reduction number different physical activities early symptom dementia addressed possibility using several different approaches first excluded persons 3ms score less 80 prevalent dementia baseline however possible 3ms sensitive enough detect persons subclinical dementing illness persons included study second adjusted analyses baseline cognitive function inverse association number physical activities dementia risk persisted third reran analysis excluding persons developed incident dementia within first year follow results essentially unchanged furthermore used information physical activity two time points approximately 5 years apart obtain stable estimate regular physical activity older adulthood prior dementia onset finally also evaluated association physical activity dementia risk excluding persons one difficulties activities daily living instrumental activities daily living results similar
0.29024228.15781953.html.plaintext.txt	87	summary study provides support hypothesis engaging number different physical activities protects subsequent risk cause dementia alzheimers disease vascular dementia average 54 year follow although potential benefits exercise may limited apoe 4 noncarriers physical activity already recommended enhance cardiovascular health help maintain independence quality life older adults 52 confirmation findings substantiation biologic mechanism activity reduces dementia risk may provide additional impetus persons remain become active number activities later life
0.29024228.15781953.html.plaintext.txt	88	summary study provides support hypothesis engaging number different physical activities protects subsequent risk cause dementia alzheimers disease vascular dementia average 54 year follow although potential benefits exercise may limited apoe 4 noncarriers physical activity already recommended enhance cardiovascular health help maintain independence quality life older adults 52 confirmation findings substantiation biologic mechanism activity reduces dementia risk may provide additional impetus persons remain become active number activities later life
0.29024228.15781953.html.plaintext.txt	89	acknowledgments research reported article supported contracts n01 hc 85079 n01 hc 85086 n01 hc 35129 n01 hc 15103 national heart lung blood institute nhlbi grant ag15928 national institute aging
0.29024228.15781953.html.plaintext.txt	90	authors thank corrine dulberg annette fitzpatrick assistance data used analysis roberto pastor barriuso help preparing figures
0.29024228.15781953.html.plaintext.txt	91	chs conducted supported nhlbi collaboration chs investigators manuscript reviewed chs nhlbi scientific content consistency data interpretation previous chs publications significant comments incorporated prior submission publication
0.29024228.15781953.html.plaintext.txt	92	chs conducted supported nhlbi collaboration chs investigators manuscript reviewed chs nhlbi scientific content consistency data interpretation previous chs publications significant comments incorporated prior submission publication
0.29024228.15781953.html.plaintext.txt	93	participating chs investigators institutions investigators listed provided signed permission acknowledged steering committee chairman dr curt d furberg wake forest university school medicine winston salem north carolina nhlbi project office dr jean olson wake forest university school medicine dr gregory l burke wake forest university ecg reading center dr pentti m rautaharju university california davis dr john robbins johns hopkins university baltimore maryland dr linda p fried johns hopkins university mri reading center dr nick bryan dr norman j beauchamp university pittsburgh pittsburgh pennsylvania dr lewis h kuller university california irvine echocardiography reading center baseline dr julius m gardin georgetown medical center echocardiography reading center washington dc follow dr john gottdiener new england medical center boston ultrasound reading center massachusetts dr daniel h oleary university vermont central blood analysis laboratory burlington vermont dr russell p tracy university arizona tucson pulmonary reading center dr paul enright retinal reading center university wisconsin madison dr ronald klein university washington coordinating center seattle dr richard kronmal full list participating chs investigators institutions found following website httpwwwchs nhlbiorg
0.29024228.15781953.html.plaintext.txt	94	participating chs investigators institutions investigators listed provided signed permission acknowledged steering committee chairman dr curt d furberg wake forest university school medicine winston salem north carolina nhlbi project office dr jean olson wake forest university school medicine dr gregory l burke wake forest university ecg reading center dr pentti m rautaharju university california davis dr john robbins johns hopkins university baltimore maryland dr linda p fried johns hopkins university mri reading center dr nick bryan dr norman j beauchamp university pittsburgh pittsburgh pennsylvania dr lewis h kuller university california irvine echocardiography reading center baseline dr julius m gardin georgetown medical center echocardiography reading center washington dc follow dr john gottdiener new england medical center boston ultrasound reading center massachusetts dr daniel h oleary university vermont central blood analysis laboratory burlington vermont dr russell p tracy university arizona tucson pulmonary reading center dr paul enright retinal reading center university wisconsin madison dr ronald klein university washington coordinating center seattle dr richard kronmal full list participating chs investigators institutions found following website httpwwwchs nhlbiorg
0.29024228.15781953.html.plaintext.txt	95	references top abstract introduction materials methods results discussion references us general accounting office alzheimers disease estimates prevalence united states report secretary health human services washington dc health education human services division 1998 report gaohehs 98 16 post sg future scenarios prevention delay alzheimer disease onset high risk groups ethical perspective j prev med 199916105 10crossrefisimedline cummings jl cole g alzheimer disease jama 20022872335 8free full text cotman cw engesser cesar c exercise enhances protects brain function exerc sport sci rev 20023075 9crossrefisimedline pate rr pratt m blair sn et al physical activity public health recommendation centers disease control prevention american college sports medicine jama 1995273402 7abstract crawford jg alzheimers disease risk factors related cerebral blood flow med hypotheses 199646367 77crossrefisimedline crawford jg alzheimers disease risk factors related cerebral blood flow additional evidence med hypotheses 19985025 36isimedline fratiglioni l wang hx ericsson k et al influence social network occurrence dementia community based longitudinal study lancet 20003551315 19crossrefisimedline anstey k christensen h education activity health blood pressure apolipoprotein e predictors cognitive change old age review gerontology 200046163 77crossrefisimedline laurin d verreault r lindsay j et al physical activity risk cognitive impairment dementia elderly persons arch neurol 200158498 504abstractfree full text yaffe k barnes d nevitt m et al prospective study physical activity cognitive decline elderly women women walk arch intern med 20011611703 8abstractfree full text rogers rl meyer js mortel kf reaching retirement age physical activity sustains cerebral perfusion cognition j geriatr soc 199038123 8isimedline schuit aj feskens ej launer lj et al physical activity cognitive decline role apolipoprotein e4 allele med sci sports exerc 200133772 7isimedline broe ga henderson creasey h et al case control study alzheimers disease australia neurology 1990401698 707abstract yoshitake kiyohara y kato et al incidence risk factors vascular dementia alzheimers disease defined elderly japanese population hisayama study neurology 1995451161 8abstract fabrigoule c letenneur l dartigues jf et al social leisure activities risk dementia prospective longitudinal study j geriatr soc 199543485 90isimedline helmer c damon d letenneur l et al marital status risk alzheimers disease french population based cohort study neurology 1999531953 8abstractfree full text friedland rp fritsch smyth ka et al patients alzheimers disease reduced activities midlife compared healthy control group members proc natl acad sci u 2001983440 5abstractfree full text scarmeas n levy g tang mx et al influence leisure activity incidence alzheimers disease neurology 2001572236 42abstractfree full text broe ga creasey h jorm af et al health habits risk cognitive impairment dementia old age prospective study effects exercise smoking alcohol consumption aust n z j public health 199822621 3isimedline verghese j lipton rb katz mj et al leisure activities risk dementia elderly n engl j med 20033482508 16abstractfree full text wang hx karp winblad b et al late life engagement social leisure activities associated decreased risk dementia longitudinal study kungsholmen project j epidemiol 20021551081 7abstractfree full text wilson rs mendes de leon cf barnes ll et al participation cognitively stimulating activities risk incident alzheimer disease jama 2002287742 8abstractfree full text fried lp borhani enright p et al cardiovascular health study design rationale ann epidemiol 19911263 76medline lyketsos cg lopez o jones b et al prevalence neuropsychiatric symptoms dementia mild cognitive impairment results cardiovascular health study jama 20022881475 83abstractfree full text lopez ol kuller lh fitzpatrick et al evaluation dementia cardiovascular health cognition study neuroepidemiology 2003221 12crossrefisimedline kuller lh lopez ol newman et al risk factors dementia cardiovascular health cognition study neuroepidemiology 20032213 22crossrefisimedline price tr manolio ta kronmal ra et al silent brain infarction magnetic resonance imaging neurological abnormalities community dwelling older adults cardiovascular health study chs collaborative research group stroke 1997281158 64abstractfree full text kuller lh shemanski l manolio et al relationship apoe mri findings cognitive function cardiovascular health study stroke 199829388 98abstractfree full text taylor hl jacobs dr schucker b et al questionnaire assessment leisure time physical activities j chronic dis 197831741 55crossrefisimedline siscovick ds fried l mittelmark m et al exercise intensity subclinical cardiovascular disease elderly cardiovascular health study j epidemiol 1997145977 86abstract mcphillips jb pellettera km barrett connor e et al exercise patterns population older adults j prev med 1989565 72isimedline hixson j vernier d restriction isotyping human apolipoprotein e gene amplification cleavage hhai j lipid res 199031545 8abstract fitti je kovar mg supplement aging 1984 national health interview survey vital health stat 1 1987jun1 115 lubben je assessing social networks among elderly populations fam community health 19881142 52 radloff ls ces d scale self report depression scale research general population appl psychol meas 19771385 401 teng el chui hc modified mini mental state 3ms examination j clin psychiatry 198748314 18isimedline brandt j spencer m folstein m telephone interview cognitive status neuropsychiatry neuropsychol behav neurol 19881111 17 jorm af korten ae assessment cognitive decline elderly informant interview br j psychiatry 1988152209 13abstract friedewald wt levy ri fredrickson ds estimation concentration low density lipoprotein cholesterol plasma without use preparative ultracentrifuge clin chem 197218499 502abstractfree full text bryan rn manolio ta scherz ld et al method using mr evaluate effects cardiovascular disease brain cardiovascular health study j radiol 1994151625 33 mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract chui hc victoroff ji margolin d et al criteria diagnosis ischemic vascular dementia proposed state california alzheimers disease diagnostic treatment centers neurology 199242473 80abstract stata corporation stata statistical software version 70 college station tx stata corporation 2000 hebert r lindsay j verreault r et al vascular dementia incidence risk factors canadian study health aging stroke 2000311487 93abstractfree full text molteni r ying z gomez pinilla f differential effects acute chronic exercise plasticity related genes rat hippocampus revealed microarray eur j neurosci 2002161107 16crossrefisimedline phillips hs hains jm armanini m et al bdnf mrna decreased hippocampus individuals alzheimers disease neuron 19917695 702isimedline ide k secher nh cerebral blood flow metabolism exercise prog neurobiol 200061397 414crossrefisimedline black je isaacs kr anderson bj et al learning causes synaptogenesis whereas motor activity causes angiogenesis cerebellar cortex adult rats proc natl acad sci u 1990875568 72abstractfree full text radak z taylor aw ohno h et al adaptation exercise induced oxidative stress muscle brain exerc immunol rev 2001790 107isimedline seemen te crimmins e social environment effects health aging integrating epidemiologic demographic approaches perspectives ann n y acad sci 200195488 117abstractfree full text american college sports medicine position stand exercise physical activity older adults med sci sports exerc 199830992 1008isimedline swaab df lucassen pj salehi et al reduced neuronal activity reactivation alzheimers disease prog brain res 1998117343 77isimedline hagberg jm ferrell re dengel dr et al exercise training induced blood pressure plasma lipid improvements hypertensives may genotype dependent hypertension 19993418 23abstractfree full text hagberg jm ferrell re katzel li et al apolipoprotein e genotype exercise training induced increases plasma high density lipoprotein hdl hdl 2 cholesterol levels overweight men metabolism 199948943 5isimedline st amand j prudhomme d moorjani et al apolipoprotein e polymorphism relationships physical fitness plasma lipoprotein lipid levels men women med sci sports exerc 199931692 7isimedline richardson mt leon jacobs dr jr et al comprehensive evaluation minnesota leisure time physical activity questionnaire j clin epidemiol 199447271 81isimedline
0.29024228.15781953.html.plaintext.txt	96	references top abstract introduction materials methods results discussion references us general accounting office alzheimers disease estimates prevalence united states report secretary health human services washington dc health education human services division 1998 report gaohehs 98 16 post sg future scenarios prevention delay alzheimer disease onset high risk groups ethical perspective j prev med 199916105 10crossrefisimedline cummings jl cole g alzheimer disease jama 20022872335 8free full text cotman cw engesser cesar c exercise enhances protects brain function exerc sport sci rev 20023075 9crossrefisimedline pate rr pratt m blair sn et al physical activity public health recommendation centers disease control prevention american college sports medicine jama 1995273402 7abstract crawford jg alzheimers disease risk factors related cerebral blood flow med hypotheses 199646367 77crossrefisimedline crawford jg alzheimers disease risk factors related cerebral blood flow additional evidence med hypotheses 19985025 36isimedline fratiglioni l wang hx ericsson k et al influence social network occurrence dementia community based longitudinal study lancet 20003551315 19crossrefisimedline anstey k christensen h education activity health blood pressure apolipoprotein e predictors cognitive change old age review gerontology 200046163 77crossrefisimedline laurin d verreault r lindsay j et al physical activity risk cognitive impairment dementia elderly persons arch neurol 200158498 504abstractfree full text yaffe k barnes d nevitt m et al prospective study physical activity cognitive decline elderly women women walk arch intern med 20011611703 8abstractfree full text rogers rl meyer js mortel kf reaching retirement age physical activity sustains cerebral perfusion cognition j geriatr soc 199038123 8isimedline schuit aj feskens ej launer lj et al physical activity cognitive decline role apolipoprotein e4 allele med sci sports exerc 200133772 7isimedline broe ga henderson creasey h et al case control study alzheimers disease australia neurology 1990401698 707abstract yoshitake kiyohara y kato et al incidence risk factors vascular dementia alzheimers disease defined elderly japanese population hisayama study neurology 1995451161 8abstract fabrigoule c letenneur l dartigues jf et al social leisure activities risk dementia prospective longitudinal study j geriatr soc 199543485 90isimedline helmer c damon d letenneur l et al marital status risk alzheimers disease french population based cohort study neurology 1999531953 8abstractfree full text friedland rp fritsch smyth ka et al patients alzheimers disease reduced activities midlife compared healthy control group members proc natl acad sci u 2001983440 5abstractfree full text scarmeas n levy g tang mx et al influence leisure activity incidence alzheimers disease neurology 2001572236 42abstractfree full text broe ga creasey h jorm af et al health habits risk cognitive impairment dementia old age prospective study effects exercise smoking alcohol consumption aust n z j public health 199822621 3isimedline verghese j lipton rb katz mj et al leisure activities risk dementia elderly n engl j med 20033482508 16abstractfree full text wang hx karp winblad b et al late life engagement social leisure activities associated decreased risk dementia longitudinal study kungsholmen project j epidemiol 20021551081 7abstractfree full text wilson rs mendes de leon cf barnes ll et al participation cognitively stimulating activities risk incident alzheimer disease jama 2002287742 8abstractfree full text fried lp borhani enright p et al cardiovascular health study design rationale ann epidemiol 19911263 76medline lyketsos cg lopez o jones b et al prevalence neuropsychiatric symptoms dementia mild cognitive impairment results cardiovascular health study jama 20022881475 83abstractfree full text lopez ol kuller lh fitzpatrick et al evaluation dementia cardiovascular health cognition study neuroepidemiology 2003221 12crossrefisimedline kuller lh lopez ol newman et al risk factors dementia cardiovascular health cognition study neuroepidemiology 20032213 22crossrefisimedline price tr manolio ta kronmal ra et al silent brain infarction magnetic resonance imaging neurological abnormalities community dwelling older adults cardiovascular health study chs collaborative research group stroke 1997281158 64abstractfree full text kuller lh shemanski l manolio et al relationship apoe mri findings cognitive function cardiovascular health study stroke 199829388 98abstractfree full text taylor hl jacobs dr schucker b et al questionnaire assessment leisure time physical activities j chronic dis 197831741 55crossrefisimedline siscovick ds fried l mittelmark m et al exercise intensity subclinical cardiovascular disease elderly cardiovascular health study j epidemiol 1997145977 86abstract mcphillips jb pellettera km barrett connor e et al exercise patterns population older adults j prev med 1989565 72isimedline hixson j vernier d restriction isotyping human apolipoprotein e gene amplification cleavage hhai j lipid res 199031545 8abstract fitti je kovar mg supplement aging 1984 national health interview survey vital health stat 1 1987jun1 115 lubben je assessing social networks among elderly populations fam community health 19881142 52 radloff ls ces d scale self report depression scale research general population appl psychol meas 19771385 401 teng el chui hc modified mini mental state 3ms examination j clin psychiatry 198748314 18isimedline brandt j spencer m folstein m telephone interview cognitive status neuropsychiatry neuropsychol behav neurol 19881111 17 jorm af korten ae assessment cognitive decline elderly informant interview br j psychiatry 1988152209 13abstract friedewald wt levy ri fredrickson ds estimation concentration low density lipoprotein cholesterol plasma without use preparative ultracentrifuge clin chem 197218499 502abstractfree full text bryan rn manolio ta scherz ld et al method using mr evaluate effects cardiovascular disease brain cardiovascular health study j radiol 1994151625 33 mckhann g drachman d folstein m et al clinical diagnosis alzheimers disease report nincds adrda work group auspices department health human services task force alzheimers disease neurology 198434939 44abstract chui hc victoroff ji margolin d et al criteria diagnosis ischemic vascular dementia proposed state california alzheimers disease diagnostic treatment centers neurology 199242473 80abstract stata corporation stata statistical software version 70 college station tx stata corporation 2000 hebert r lindsay j verreault r et al vascular dementia incidence risk factors canadian study health aging stroke 2000311487 93abstractfree full text molteni r ying z gomez pinilla f differential effects acute chronic exercise plasticity related genes rat hippocampus revealed microarray eur j neurosci 2002161107 16crossrefisimedline phillips hs hains jm armanini m et al bdnf mrna decreased hippocampus individuals alzheimers disease neuron 19917695 702isimedline ide k secher nh cerebral blood flow metabolism exercise prog neurobiol 200061397 414crossrefisimedline black je isaacs kr anderson bj et al learning causes synaptogenesis whereas motor activity causes angiogenesis cerebellar cortex adult rats proc natl acad sci u 1990875568 72abstractfree full text radak z taylor aw ohno h et al adaptation exercise induced oxidative stress muscle brain exerc immunol rev 2001790 107isimedline seemen te crimmins e social environment effects health aging integrating epidemiologic demographic approaches perspectives ann n y acad sci 200195488 117abstractfree full text american college sports medicine position stand exercise physical activity older adults med sci sports exerc 199830992 1008isimedline swaab df lucassen pj salehi et al reduced neuronal activity reactivation alzheimers disease prog brain res 1998117343 77isimedline hagberg jm ferrell re dengel dr et al exercise training induced blood pressure plasma lipid improvements hypertensives may genotype dependent hypertension 19993418 23abstractfree full text hagberg jm ferrell re katzel li et al apolipoprotein e genotype exercise training induced increases plasma high density lipoprotein hdl hdl 2 cholesterol levels overweight men metabolism 199948943 5isimedline st amand j prudhomme d moorjani et al apolipoprotein e polymorphism relationships physical fitness plasma lipoprotein lipid levels men women med sci sports exerc 199931692 7isimedline richardson mt leon jacobs dr jr et al comprehensive evaluation minnesota leisure time physical activity questionnaire j clin epidemiol 199447271 81isimedline
0.29792902.15632261.html.plaintext.txt	0	meta analysis nonsteroidal antiinflammatory drug use risk dementia anton j m de craen jacobijn gussekloo bram vrijsen rudi g j westendorp
0.29792902.15632261.html.plaintext.txt	1	section gerontology geriatrics department general internal medicine leiden university medical center leiden netherlands
0.29792902.15632261.html.plaintext.txt	2	received publication march 23 2004 accepted publication august 11 2004
0.29792902.15632261.html.plaintext.txt	3	abstract top abstract introduction materials methods results discussion references authors performed systematic review summarize epidemiologic evidence association use nonsteroidal antiinflammatory drugs nsaids risk dementia total 25 case control cohort studies reported odds ratiorelative risk included study specific log relative risks weighted inverse variances obtain pooled relative risks 95 confidence intervals authors divided reports studies prevalent dementia cases studies incident dementia cases studies cognitive decline used clinical endpoint pooled relative risks three groups studies 051 95 confidence interval ci 037 070 079 95 ci 068 092 123 95 ci 070 231 respectively within subgroups heterogeneity present studies prevalent cases p 0001 benefit nsaids preventing dementia cognitive impairment 50 studies prevalent dementia cases declined 20 studies incident dementia cases absent studies cognitive decline used endpoint authors conclude reported beneficial effects nsaids may result various forms bias recall bias prescription bias publication bias
0.29792902.15632261.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references authors performed systematic review summarize epidemiologic evidence association use nonsteroidal antiinflammatory drugs nsaids risk dementia total 25 case control cohort studies reported odds ratiorelative risk included study specific log relative risks weighted inverse variances obtain pooled relative risks 95 confidence intervals authors divided reports studies prevalent dementia cases studies incident dementia cases studies cognitive decline used clinical endpoint pooled relative risks three groups studies 051 95 confidence interval ci 037 070 079 95 ci 068 092 123 95 ci 070 231 respectively within subgroups heterogeneity present studies prevalent cases p 0001 benefit nsaids preventing dementia cognitive impairment 50 studies prevalent dementia cases declined 20 studies incident dementia cases absent studies cognitive decline used endpoint authors conclude reported beneficial effects nsaids may result various forms bias recall bias prescription bias publication bias
0.29792902.15632261.html.plaintext.txt	5	alzheimer disease anti inflammatory agents non steroidal dementia meta analysis
0.29792902.15632261.html.plaintext.txt	6	abbreviations ci confidence interval nsaids nonsteroidal antiinflammatory drugs
0.29792902.15632261.html.plaintext.txt	7	introduction top abstract introduction materials methods results discussion references many observational studies investigated association use nonsteroidal antiinflammatory drugs nsaids risk alzheimer disease dementia cognitive decline 1 30 studies differed greatly design population exposure many found inverse association others found association recently results number secondary prevention studies reported showed beneficial effect use nsaids cognitive function 31 33 results primary prevention trials available hence whether nsaids truly favorable effect preventing dementia remains controversial 34 performed systematic review literature summarize epidemiologic evidence association use nsaids risk dementia identify possible sources heterogeneity studies
0.29792902.15632261.html.plaintext.txt	8	introduction top abstract introduction materials methods results discussion references many observational studies investigated association use nonsteroidal antiinflammatory drugs nsaids risk alzheimer disease dementia cognitive decline 1 30 studies differed greatly design population exposure many found inverse association others found association recently results number secondary prevention studies reported showed beneficial effect use nsaids cognitive function 31 33 results primary prevention trials available hence whether nsaids truly favorable effect preventing dementia remains controversial 34 performed systematic review literature summarize epidemiologic evidence association use nsaids risk dementia identify possible sources heterogeneity studies
0.29792902.15632261.html.plaintext.txt	9	materials methods top abstract introduction materials methods results discussion references systematic search started using widely quoted 1996 review nsaids risk alzheimer disease 35 two ways 1 evaluated articles included review 2 used science citation index identify studies cited review next searched medline database using search term nsaid combined alzheimer disease dementia cognitive decline limited studies humans apply language restriction titles abstracts search strategies independently examined eligibility two us j m c j g case doubt full article retrieved eligibility discussed original articles reviews retrieved whole process repeated references identified studies reviews
0.29792902.15632261.html.plaintext.txt	10	materials methods top abstract introduction materials methods results discussion references systematic search started using widely quoted 1996 review nsaids risk alzheimer disease 35 two ways 1 evaluated articles included review 2 used science citation index identify studies cited review next searched medline database using search term nsaid combined alzheimer disease dementia cognitive decline limited studies humans apply language restriction titles abstracts search strategies independently examined eligibility two us j m c j g case doubt full article retrieved eligibility discussed original articles reviews retrieved whole process repeated references identified studies reviews
0.29792902.15632261.html.plaintext.txt	11	eligibility criteria data collection studies eligible inclusion satisfied following three criteria 1 case control cohort study humans 2 exposure defined use nsaid 3 cases defined alzheimer disease dementia cognitive impairment
0.29792902.15632261.html.plaintext.txt	12	data independently extracted study two reviewers j m c j g using preprinted forms recorded study design characteristics exposure definitions cases controls prevalent incident case ascertainment total number cases exposed group total number cases unexposed group measure association odds ratio relative risk hazard ratio magnitude association corresponding 95 percent confidence interval variables adjusted analysis separate results reported within one study alzheimer disease dementia results dementia recorded varying levels nsaid use reported took results largest group nsaid users
0.29792902.15632261.html.plaintext.txt	13	statistical analysis results cohort studies typically expressed relative risk hazard ratio results case control studies usually expressed odds ratio hazard ratio ratio instantaneous probability outcome event alzheimer disease dementia cognitive decline exposed group compared nonexposed group considered relative risk dementia rare event 5 percent odds ratios case control studies also good estimates relative risk simplicity refer relative risk three types measures association logarithm relative risk corresponding standard error taken directly studies calculated reported 95 percent confidence interval provided data points meta analysis used dersimonian laird 36 random effects model compute pooled relative risks assess statistical heterogeneity exclude outliers simply basis statistical test heterogeneity expected meta analysis epidemiologic studies searched sources ie methodological biologic subgroup sensitivity analyses carried appropriate evaluated publication bias means visual inspection funnel plots formal statistical testing 37 funnel plot relative risk study displayed weight study inverse square standard error funnel plots generally show peak point studies smaller standard errors found usually represents point approximate true effect formal statistical assessment funnel plot asymmetry done linear regression analysis log odds ratio divided standard error regressed inverse standard error 37 reported p values intercept regression analysis provides measure asymmetry case control studies incident dementia cases cohort studies classified studies incident cases studies cognition main outcome interest among users nonusers nsaids classified studies cognitive decline cases
0.29792902.15632261.html.plaintext.txt	14	statistical analysis results cohort studies typically expressed relative risk hazard ratio results case control studies usually expressed odds ratio hazard ratio ratio instantaneous probability outcome event alzheimer disease dementia cognitive decline exposed group compared nonexposed group considered relative risk dementia rare event 5 percent odds ratios case control studies also good estimates relative risk simplicity refer relative risk three types measures association logarithm relative risk corresponding standard error taken directly studies calculated reported 95 percent confidence interval provided data points meta analysis used dersimonian laird 36 random effects model compute pooled relative risks assess statistical heterogeneity exclude outliers simply basis statistical test heterogeneity expected meta analysis epidemiologic studies searched sources ie methodological biologic subgroup sensitivity analyses carried appropriate evaluated publication bias means visual inspection funnel plots formal statistical testing 37 funnel plot relative risk study displayed weight study inverse square standard error funnel plots generally show peak point studies smaller standard errors found usually represents point approximate true effect formal statistical assessment funnel plot asymmetry done linear regression analysis log odds ratio divided standard error regressed inverse standard error 37 reported p values intercept regression analysis provides measure asymmetry case control studies incident dementia cases cohort studies classified studies incident cases studies cognition main outcome interest among users nonusers nsaids classified studies cognitive decline cases
0.29792902.15632261.html.plaintext.txt	15	results top abstract introduction materials methods results discussion references searching science citation index yielded 402 publications referring review mcgeer et al 35 medline search yielded 337 publications retrieval potential articles subsequent discussion found 30 studies meeting eligibility criteria 1 30 four studies 1 4 excluded relative risk could extracted report one study report association 1 two studies found association 2 3 one study compared cognitive function patients alzheimer disease taking nsaids patients alzheimer disease taking nsaids 4 one study 5 excluded based data another publication descriptive details remaining 25 studies included meta analysis presented table 1 eleven studies used prevalent cases 6 16 10 studies used incident cases 17 26 four studies used cognitive decline clinical outcome 27 30 definition length exposure use nsaids varied among studies
0.29792902.15632261.html.plaintext.txt	16	results top abstract introduction materials methods results discussion references searching science citation index yielded 402 publications referring review mcgeer et al 35 medline search yielded 337 publications retrieval potential articles subsequent discussion found 30 studies meeting eligibility criteria 1 30 four studies 1 4 excluded relative risk could extracted report one study report association 1 two studies found association 2 3 one study compared cognitive function patients alzheimer disease taking nsaids patients alzheimer disease taking nsaids 4 one study 5 excluded based data another publication descriptive details remaining 25 studies included meta analysis presented table 1 eleven studies used prevalent cases 6 16 10 studies used incident cases 17 26 four studies used cognitive decline clinical outcome 27 30 definition length exposure use nsaids varied among studies
0.29792902.15632261.html.plaintext.txt	17	view table table 1 description studies use nonsteroidal antiinflammatory drugs risk dementia table 2 presents individual relative risks 25 retrieved studies divided reports studies prevalent cases studies incident cases studies cognitive decline endpoint funnel plot figure 1 shows relative risks 25 studies plotted weights relative risk smaller one indicates use nsaids beneficial pooled relative risks three groups studies 051 95 percent confidence interval ci 037 070 studies prevalent dementia cases 079 95 percent ci 068 092 studies incident dementia cases 123 95 percent ci 070 231 studies cognitive decline endpoint within subgroups heterogeneity present studies prevalent cases p 0001 studies incident cases p 060 statistical testing heterogeneity studies cognitive decline used endpoint gave p value 008 within three subgroups indication presence publication bias studies prevalent cases p 004 whereas indication studies incident cases p 096 studies cognitive decline used endpoint p 038
0.29792902.15632261.html.plaintext.txt	18	view table figure 1 funnel plot relative risks 25 studies use nonsteroidal antiinflammatory drugs risk dementia weight study weight calculated inverse square standard error log relative risk
0.29792902.15632261.html.plaintext.txt	19	furthermore analyzed case control studies incident dementia cases cohort studies separately case control studies incident dementia cases gave pooled relative risk 077 95 percent ci 061 096 cohort studies gave pooled relative risk estimate 079 95 percent ci 061 101
0.29792902.15632261.html.plaintext.txt	20	furthermore analyzed case control studies incident dementia cases cohort studies separately case control studies incident dementia cases gave pooled relative risk 077 95 percent ci 061 096 cohort studies gave pooled relative risk estimate 079 95 percent ci 061 101
0.29792902.15632261.html.plaintext.txt	21	finally results randomized clinical trials evaluated efficacy nsaid placebo presented table 3 trials included patients alzheimer disease patients probable alzheimer disease none trials showed statistically significant reduction cognitive decline
0.29792902.15632261.html.plaintext.txt	22	finally results randomized clinical trials evaluated efficacy nsaid placebo presented table 3 trials included patients alzheimer disease patients probable alzheimer disease none trials showed statistically significant reduction cognitive decline
0.29792902.15632261.html.plaintext.txt	23	view table table 3 summary results placebo controlled trials use nonsteroidal antiinflammatory drugs alzheimer disease discussion top abstract introduction materials methods results discussion references results study indicate benefit nsaids preventing dementia cognitive impairment 50 percent studies prevalent dementia cases declined 20 percent studies incident dementia cases absent studies cognitive decline used endpoint
0.29792902.15632261.html.plaintext.txt	24	least three forms bias could explain benefit nsaids larger studies prevalent cases studies incident cases recall bias prescription bias publication bias first subjects studies prevalent cases impaired memory time study makes data collection cases controls likely different resulting recall bias second prescription bias occurs frequently studies prevalent cases demented patients reduced perception pain 38 39 possibly leading reduced use nsaids moreover adverse effects nsaids physicians might less inclined prescribe nsaids demented subjects hence studies prevalent cases reduced intake nsaids might consequence dementia cause third apparent funnel plot studies prevalent cases heterogeneous skewed left follow studies resulting larger pooled estimates benefit nsaid use studies
0.29792902.15632261.html.plaintext.txt	25	least three forms bias could explain benefit nsaids larger studies prevalent cases studies incident cases recall bias prescription bias publication bias first subjects studies prevalent cases impaired memory time study makes data collection cases controls likely different resulting recall bias second prescription bias occurs frequently studies prevalent cases demented patients reduced perception pain 38 39 possibly leading reduced use nsaids moreover adverse effects nsaids physicians might less inclined prescribe nsaids demented subjects hence studies prevalent cases reduced intake nsaids might consequence dementia cause third apparent funnel plot studies prevalent cases heterogeneous skewed left follow studies resulting larger pooled estimates benefit nsaid use studies
0.29792902.15632261.html.plaintext.txt	26	found difference relative risk case control studies incident dementia cases cohort studies although potential recall bias case control studies theoretically higher however total number 10 studies investigate presence recall bias rather small therefore interpretation absence significant difference two types design incident dementia cases interpreted caution
0.29792902.15632261.html.plaintext.txt	27	found difference relative risk case control studies incident dementia cases cohort studies although potential recall bias case control studies theoretically higher however total number 10 studies investigate presence recall bias rather small therefore interpretation absence significant difference two types design incident dementia cases interpreted caution
0.29792902.15632261.html.plaintext.txt	28	10 studies incident cases dementia within 10 studies four case control studies incident dementia cases six cohort studies types study gave similar pooled estimate relative risk recall bias major form bias relative risk case control studies smaller however wide confidence intervals around estimates small number studies difficult ascertain whether studies truly equal estimates
0.29792902.15632261.html.plaintext.txt	29	10 studies incident cases dementia within 10 studies four case control studies incident dementia cases six cohort studies types study gave similar pooled estimate relative risk recall bias major form bias relative risk case control studies smaller however wide confidence intervals around estimates small number studies difficult ascertain whether studies truly equal estimates
0.29792902.15632261.html.plaintext.txt	30	significant association nsaid use studies incident cases dementia significant association studies cognitive decline used outcome prescription bias might also cause difference incident subjects cognitive decline relatively free cognitive dysfunction baseline incident cases dementia relatively later stage disease earlier stages disease prescription bias might present explore whether prescription bias cause observed association nsaid use alzheimer disease whether true beneficial effect decided upon randomized clinical trials whose patients without early signs alzheimer disease 40
0.29792902.15632261.html.plaintext.txt	31	significant association nsaid use studies incident cases dementia significant association studies cognitive decline used outcome prescription bias might also cause difference incident subjects cognitive decline relatively free cognitive dysfunction baseline incident cases dementia relatively later stage disease earlier stages disease prescription bias might present explore whether prescription bias cause observed association nsaid use alzheimer disease whether true beneficial effect decided upon randomized clinical trials whose patients without early signs alzheimer disease 40
0.29792902.15632261.html.plaintext.txt	32	period nsaid use disease onset relatively short difficult differentiate cause effect short period exposure outcome reduced intake nsaids among subjects dementia could also consequence disease four studies 14 16 20 26 tried avoid bias evaluating use acetaminophen control differing patterns drug use demented nondemented subjects many authors argued demented nondemented subjects differ acetaminophen use vary nsaid use nsaids must associated better cognitive function think however demented patients might report less pain nondemented subjects nsaids first drugs prescribed less frequently means studies prevalent cases likely suffer prescription bias studies incident cases
0.29792902.15632261.html.plaintext.txt	33	period nsaid use disease onset relatively short difficult differentiate cause effect short period exposure outcome reduced intake nsaids among subjects dementia could also consequence disease four studies 14 16 20 26 tried avoid bias evaluating use acetaminophen control differing patterns drug use demented nondemented subjects many authors argued demented nondemented subjects differ acetaminophen use vary nsaid use nsaids must associated better cognitive function think however demented patients might report less pain nondemented subjects nsaids first drugs prescribed less frequently means studies prevalent cases likely suffer prescription bias studies incident cases
0.29792902.15632261.html.plaintext.txt	34	alzheimer disease common dementia insidious onset also important know different studies used index date studies prevalent cases took date diagnosis dementia three studies incident dementia cases took date first symptoms disease 17 21 24 seven studies incident dementia cases used date diagnosis dementia three studies date onset symptoms used similar relative risk estimates seven studies date diagnosis used
0.29792902.15632261.html.plaintext.txt	35	alzheimer disease common dementia insidious onset also important know different studies used index date studies prevalent cases took date diagnosis dementia three studies incident dementia cases took date first symptoms disease 17 21 24 seven studies incident dementia cases used date diagnosis dementia three studies date onset symptoms used similar relative risk estimates seven studies date diagnosis used
0.29792902.15632261.html.plaintext.txt	36	publications used meta analysis originate one cohort example canadian study health aging rotterdam study contributed two publications however cases one publication addressed association prevalent dementia cases publication addressed association incident dementia cases hence decided include articles analyses moreover study named established populations epidemiologic studies elderly consists four cohorts analyses used estimates reported separate cohorts study reported saag et al 27 uses data iowa cohort hanlon et al 28 use data duke cohort study reported rozzini et al 5 uses data east boston massachusetts new haven connecticut iowa cohorts discussing results rozzini et al indicate study saag et al substantially different measure cognitive functioning analytical approach making comparability study study problematic 5 p 1029 including study rozzini et al analyses would overweighted data iowa cohort established populations epidemiologic studies elderly could chosen include study reported rozzini et al analyses instead study saag et al would resulted lower pooled relative risk however including study reported rozzini et al instead study saag et al affect interpretation data
0.29792902.15632261.html.plaintext.txt	37	publications used meta analysis originate one cohort example canadian study health aging rotterdam study contributed two publications however cases one publication addressed association prevalent dementia cases publication addressed association incident dementia cases hence decided include articles analyses moreover study named established populations epidemiologic studies elderly consists four cohorts analyses used estimates reported separate cohorts study reported saag et al 27 uses data iowa cohort hanlon et al 28 use data duke cohort study reported rozzini et al 5 uses data east boston massachusetts new haven connecticut iowa cohorts discussing results rozzini et al indicate study saag et al substantially different measure cognitive functioning analytical approach making comparability study study problematic 5 p 1029 including study rozzini et al analyses would overweighted data iowa cohort established populations epidemiologic studies elderly could chosen include study reported rozzini et al analyses instead study saag et al would resulted lower pooled relative risk however including study reported rozzini et al instead study saag et al affect interpretation data
0.29792902.15632261.html.plaintext.txt	38	five studies used cognitive decline endpoint used different cognitive measures hence cannot exclude nsaids might beneficial effect specific cognitive domain however average effect use nsaids cognitive decline null consistent finding randomized trials far shown beneficial effect course dementia measured cognitive subscale alzheimer disease assessment scale moreover two studies excluded meta analysis 2 3 relative risk could extracted showed association use nsaid cognitive decline
0.29792902.15632261.html.plaintext.txt	39	five studies used cognitive decline endpoint used different cognitive measures hence cannot exclude nsaids might beneficial effect specific cognitive domain however average effect use nsaids cognitive decline null consistent finding randomized trials far shown beneficial effect course dementia measured cognitive subscale alzheimer disease assessment scale moreover two studies excluded meta analysis 2 3 relative risk could extracted showed association use nsaid cognitive decline
0.29792902.15632261.html.plaintext.txt	40	recent meta analysis nsaids risk dementia concluded nsaids offer protection development alzheimer disease 41 p 128 conclusion based mainly observation short term users 1 month far less risk reduction long term users 24 months relative risk 095 vs 027 respectively authors address possible confounding factors 42 explain discrepancy studies prevalent cases studies incident cases discrepancy risk reduction short term long term users well explained recall bias prescription bias including studies cognitive decline endpoint thereby creating distance exposure effect demonstrate bias confounding likely explanations observed association
0.29792902.15632261.html.plaintext.txt	41	traditional teaching holds alzheimer disease vascular dementia two separate clinical entities differentiated careful clinical necropsy evaluation several recent observations however suggest situation might different vascular risk factors also contribute alzheimer disease 43 conversely ss amyloid depositions also frequently found subjects vascular dementia 44 hence likely alzheimer disease vascular dementia two extreme expressions one disease entity dementia 45 prominent feature disease entities progressive cognitive decline hence combining comparing various endpoints one analysis gives good indication possible benefits nsaids various stages disease
0.29792902.15632261.html.plaintext.txt	42	traditional teaching holds alzheimer disease vascular dementia two separate clinical entities differentiated careful clinical necropsy evaluation several recent observations however suggest situation might different vascular risk factors also contribute alzheimer disease 43 conversely ss amyloid depositions also frequently found subjects vascular dementia 44 hence likely alzheimer disease vascular dementia two extreme expressions one disease entity dementia 45 prominent feature disease entities progressive cognitive decline hence combining comparing various endpoints one analysis gives good indication possible benefits nsaids various stages disease
0.29792902.15632261.html.plaintext.txt	43	randomized clinical trials found beneficial effect nsaids preventing cognitive decline 31 33 might three explanations negative studies first protective effect nsaids second studies carried subjects early signs cognitive impairment administration antiinflammatory drugs point disease process might simply late third recently demonstrated various nsaids differential propensities inflammatory response deposition ss amyloid 46 finding calls identification critical pathways inflammatory response corresponding drugs capable interfering pathway
0.29792902.15632261.html.plaintext.txt	44	randomized clinical trials found beneficial effect nsaids preventing cognitive decline 31 33 might three explanations negative studies first protective effect nsaids second studies carried subjects early signs cognitive impairment administration antiinflammatory drugs point disease process might simply late third recently demonstrated various nsaids differential propensities inflammatory response deposition ss amyloid 46 finding calls identification critical pathways inflammatory response corresponding drugs capable interfering pathway
0.29792902.15632261.html.plaintext.txt	45	conclusion benefit nsaids preventing dementia cognitive impairment 50 percent studies prevalent dementia cases declined 20 percent studies incident dementia cases absent studies cognitive decline used endpoint indicates beneficial effects nsaids observational studies likely result recall bias prescription bias publication bias large costly trials designed assess potential protective effects nsaids specific critical pathways inflammatory process dementia amendable drug intervention identified
0.29792902.15632261.html.plaintext.txt	46	conclusion benefit nsaids preventing dementia cognitive impairment 50 percent studies prevalent dementia cases declined 20 percent studies incident dementia cases absent studies cognitive decline used endpoint indicates beneficial effects nsaids observational studies likely result recall bias prescription bias publication bias large costly trials designed assess potential protective effects nsaids specific critical pathways inflammatory process dementia amendable drug intervention identified
0.29792902.15632261.html.plaintext.txt	47	notes correspondence dr j m de craen section gerontology geriatrics c2 r leiden university medical center po box 9600 leiden 2300 rc netherlands e mail craenatlumcnl u d
0.29792902.15632261.html.plaintext.txt	48	references top abstract introduction materials methods results discussion references mackenzie ira munoz dg nonsteroidal anti inflammatory drug use alzheimer type pathology aging neurology 199850986 90abstract may fe moore mt stewart rb et al lack association nonsteroidal anti inflammatory drug use cognitive decline elderly gerontology 199238275 9isimedline prince m rabe hesketh brennan p antiarthritic drugs decrease risk cognitive decline neurology 199850374 9abstract rich jb rasmusson dx folstein mf et al nonsteroidal anti inflammatory drugs alzheimer disease neurology 19954551 5abstract rozzini r ferrucci l losonczy k et al protective effect chronic nsaid use cognitive decline older persons j geriatr soc 1996441025 9isimedline mcgeer pl harada n kimura h et al prevalence dementia amongst elderly japanese leprosy apparent effect chronic drug therapy dementia 19923146 9isi breitner jcs gau ba welsh ka et al inverse association anti inflammatory treatments alzheimer disease initial results co twin control study neurology 199444227 32abstract canadian study health aging risk factors alzheimer disease canada neurology 1994442073 80abstract lucca u tettamanti m forloni g et al nonsteroidal antiinflammatory drug use alzheimer disease biol psychiatry 199436854 6crossrefisimedline andersen k launer lj ott et al nonsteroidal anti inflammatory drugs decrease risk alzheimer disease rotterdam study neurology 1995451441 5abstract breitner jcs welsh ka helms mj et al delayed onset alzheimer disease nonsteroidal anti inflammatory histamine h2 blocking drugs neurobiol aging 199516523 30crossrefisimedline endoh m kunishita tabira effect anti leprosy drugs prevention alzheimer disease ss amyloid neurotoxicity j neurol sci 199916528 30crossrefisimedline anthony jc breitner jcs zandi pp et al reduced prevalence ad users nsaids h2 receptor antagonists neurology 2000542066 71abstractfree full text broe ga grayson da creasey hm et al anti inflammatory drugs protect alzheimer disease low doses arch neurol 2000571586 91abstractfree full text landi f cesari m onder g et al non steroidal anti inflammatory drug nsaid use alzheimer disease community dwelling elderly patients j geriatr psychiatry 200311179 85abstractfree full text nilsson se johansson b takkinen et al aspirin protect alzheimer dementia study swedish population based sample aged 80 years eur j clin pharmacol 200359313 19crossref kukull wa larson eb stergachis et al non steroidal anti inflammatory drug use risk alzheimer disease abstract neurology 199444suppl 2a237 fourrier letenneur l begaud b et al nonsteroidal antiinflammatory drug use cognitive function elderly inconclusive results population based cohort study j clin epidemiol 1996491201crossrefisimedline henderson jorm af christensen h et al aspirin anti inflammatory drugs risk dementia int j geriat psychiatry 199712926 3030co2 y disease duration nsaid use neurology 199748626 32abstract beard cm waring sc o brien pc et al nonsteroidal anti inflammatory drug use alzheimer disease case control study rochester minnesota 1980 1984 mayo clin proc 199873951 5isimedline cornelius c fratiglioni l fastbom j et al support protective effect nsaids alzheimer disease follow population based study abstract neurobiol aging 199819suppl 4s28 veld ba ruitenberg hofman et al nonsteroidal antiinflammatory drugs risk alzheimer disease n engl j med 20013451515 21abstractfree full text wolfson c perrault moride et al case control analysis nonsteroidal anti inflammatory drugs alzheimer disease protective neuroepidemiology 20022181 6crossrefisimedline lindsay j laurin d verreault r et al risk factors alzheimer disease prospective analysis canadian study health aging j epidemiol 2002156445 53abstractfree full text zandi pp anthony jc hayden km et al reduced incidence ad nsaid h2 receptor antgonists cache county study neurology 200259880 6abstractfree full text saag kg rubenstein lm chrischilles ea et al nonsteroidal antiinflammatory drugs cognitive decline elderly j rheumatol 1995222142 7isimedline hanlon jt schmader ke landerman lr et al relation prescription nonsteroidal antiinflammatory drug use cognitive function among community dwelling elderly ann epidemiol 1997787 94crossrefisimedline jonker c comijs hc smit jh aspirin nsaids reduce risk cognitive decline elderly persons results form population based study neurobiol aging 200324583 8crossrefisimedline hee kang j grodstein f regular use nonsteroidal anti inflammatory drugs cognitive function aging women neurology 2003601591 7abstractfree full text scharf mander ugoni et al double blind placebo controlled trial diclofenacmisoprostol alzheimer disease neurology 199953197 201abstractfree full text aisen p schmeidler j pasinetti gm randomized pilot study nimesulide treatment alzheimer disease neurology 2002581050 4abstractfree full text aisen ps schafer ka grundman m et al effects rofecoxib naproxen vs placebo alzheimer disease progression randomized controlled trial jama 20032892819 26abstractfree full text helmuth l nsaids prevention protecting brain killing pain science 20022971262 3abstractfree full text mcgeer pl schulzer m mcgeer eg arthritis anti inflammatory agents possible protective factors alzheimer disease review 17 epidemiologic studies neurology 199647425 32abstract dersimonian r laird n meta analysis clinical trials control clin trials 19867177 88crossrefisimedline egger m davey smith g schneider m et al bias meta analysis detected simple graphical test bmj 1997315629 34abstractfree full text benedetti f vighetti ricco c et al pain threshold tolerance alzheimer disease pain 199980377 82crossrefisimedline scherder e bouma slaets j et al repeated pain assessment alzheimer disease dement geriatr cogn disord 200112400 7crossrefisimedline martin bk meinert cl breitner jc et al double placebo design prevention trial alzheimer disease control clin trials 20022393 9crossrefisimedline etminan m gill samii effect non steroidal anti inflammatory drugs risk alzheimer disease systematic review meta analysis observational studies bmj 2003327128 31abstractfree full text robertson m effect nsaids risk alzheimer disease confounding factors discussed letter bmj 2003327751free full text haan m shemanski l jagust wj et al predictors cognitive change cardiovascular health study role cardiovascular genetic risk factors jama 199928240 6abstractfree full text ince pg pathological correlates late onset dementia multicentre community based population england wales neuropathology group medical research council cognitive function ageing study mrc cfas lancet 2001357169 75crossrefisimedline kalaria rn role cerebral ischemia alzheimer disease neurobiol aging 200021321 30crossrefisimedline weggen eriksen jl das p et al subset nsaids lower amyloidogenic ass42 independently cyclooxygenase activity nature 2001414212 16crossrefisimedline article abstract free full text pdf alert article cited alert correction posted services email article friend similar articles journal similar articles isi web science similar articles pubmed alert new issues journal add personal archive download citation manager search citing articles isi web science 3 disclaimer request permissions google scholar articles de craen j m articles westendorp r g j pubmed pubmed citation articles de craen j m articles westendorp r g j online issn 1476 6256 print issn 0002 9262 copyright 2006 johns hopkins bloomberg school public health oxford journals oxford university press site map terms conditions privacy policy frequently asked questions oxford university press sites oxford university press american national biography booksellers information service childrens fiction poetry childrens reference corporate special sales dictionaries dictionary national biography digital reference english language teaching higher education textbooks humanities international education unit law medicine music online products oxford english dictionary reference rights permissions science school books social sciences short introductions worlds classics
0.29792902.15632261.html.plaintext.txt	49	references top abstract introduction materials methods results discussion references mackenzie ira munoz dg nonsteroidal anti inflammatory drug use alzheimer type pathology aging neurology 199850986 90abstract may fe moore mt stewart rb et al lack association nonsteroidal anti inflammatory drug use cognitive decline elderly gerontology 199238275 9isimedline prince m rabe hesketh brennan p antiarthritic drugs decrease risk cognitive decline neurology 199850374 9abstract rich jb rasmusson dx folstein mf et al nonsteroidal anti inflammatory drugs alzheimer disease neurology 19954551 5abstract rozzini r ferrucci l losonczy k et al protective effect chronic nsaid use cognitive decline older persons j geriatr soc 1996441025 9isimedline mcgeer pl harada n kimura h et al prevalence dementia amongst elderly japanese leprosy apparent effect chronic drug therapy dementia 19923146 9isi breitner jcs gau ba welsh ka et al inverse association anti inflammatory treatments alzheimer disease initial results co twin control study neurology 199444227 32abstract canadian study health aging risk factors alzheimer disease canada neurology 1994442073 80abstract lucca u tettamanti m forloni g et al nonsteroidal antiinflammatory drug use alzheimer disease biol psychiatry 199436854 6crossrefisimedline andersen k launer lj ott et al nonsteroidal anti inflammatory drugs decrease risk alzheimer disease rotterdam study neurology 1995451441 5abstract breitner jcs welsh ka helms mj et al delayed onset alzheimer disease nonsteroidal anti inflammatory histamine h2 blocking drugs neurobiol aging 199516523 30crossrefisimedline endoh m kunishita tabira effect anti leprosy drugs prevention alzheimer disease ss amyloid neurotoxicity j neurol sci 199916528 30crossrefisimedline anthony jc breitner jcs zandi pp et al reduced prevalence ad users nsaids h2 receptor antagonists neurology 2000542066 71abstractfree full text broe ga grayson da creasey hm et al anti inflammatory drugs protect alzheimer disease low doses arch neurol 2000571586 91abstractfree full text landi f cesari m onder g et al non steroidal anti inflammatory drug nsaid use alzheimer disease community dwelling elderly patients j geriatr psychiatry 200311179 85abstractfree full text nilsson se johansson b takkinen et al aspirin protect alzheimer dementia study swedish population based sample aged 80 years eur j clin pharmacol 200359313 19crossref kukull wa larson eb stergachis et al non steroidal anti inflammatory drug use risk alzheimer disease abstract neurology 199444suppl 2a237 fourrier letenneur l begaud b et al nonsteroidal antiinflammatory drug use cognitive function elderly inconclusive results population based cohort study j clin epidemiol 1996491201crossrefisimedline henderson jorm af christensen h et al aspirin anti inflammatory drugs risk dementia int j geriat psychiatry 199712926 3030co2 y disease duration nsaid use neurology 199748626 32abstract beard cm waring sc o brien pc et al nonsteroidal anti inflammatory drug use alzheimer disease case control study rochester minnesota 1980 1984 mayo clin proc 199873951 5isimedline cornelius c fratiglioni l fastbom j et al support protective effect nsaids alzheimer disease follow population based study abstract neurobiol aging 199819suppl 4s28 veld ba ruitenberg hofman et al nonsteroidal antiinflammatory drugs risk alzheimer disease n engl j med 20013451515 21abstractfree full text wolfson c perrault moride et al case control analysis nonsteroidal anti inflammatory drugs alzheimer disease protective neuroepidemiology 20022181 6crossrefisimedline lindsay j laurin d verreault r et al risk factors alzheimer disease prospective analysis canadian study health aging j epidemiol 2002156445 53abstractfree full text zandi pp anthony jc hayden km et al reduced incidence ad nsaid h2 receptor antgonists cache county study neurology 200259880 6abstractfree full text saag kg rubenstein lm chrischilles ea et al nonsteroidal antiinflammatory drugs cognitive decline elderly j rheumatol 1995222142 7isimedline hanlon jt schmader ke landerman lr et al relation prescription nonsteroidal antiinflammatory drug use cognitive function among community dwelling elderly ann epidemiol 1997787 94crossrefisimedline jonker c comijs hc smit jh aspirin nsaids reduce risk cognitive decline elderly persons results form population based study neurobiol aging 200324583 8crossrefisimedline hee kang j grodstein f regular use nonsteroidal anti inflammatory drugs cognitive function aging women neurology 2003601591 7abstractfree full text scharf mander ugoni et al double blind placebo controlled trial diclofenacmisoprostol alzheimer disease neurology 199953197 201abstractfree full text aisen p schmeidler j pasinetti gm randomized pilot study nimesulide treatment alzheimer disease neurology 2002581050 4abstractfree full text aisen ps schafer ka grundman m et al effects rofecoxib naproxen vs placebo alzheimer disease progression randomized controlled trial jama 20032892819 26abstractfree full text helmuth l nsaids prevention protecting brain killing pain science 20022971262 3abstractfree full text mcgeer pl schulzer m mcgeer eg arthritis anti inflammatory agents possible protective factors alzheimer disease review 17 epidemiologic studies neurology 199647425 32abstract dersimonian r laird n meta analysis clinical trials control clin trials 19867177 88crossrefisimedline egger m davey smith g schneider m et al bias meta analysis detected simple graphical test bmj 1997315629 34abstractfree full text benedetti f vighetti ricco c et al pain threshold tolerance alzheimer disease pain 199980377 82crossrefisimedline scherder e bouma slaets j et al repeated pain assessment alzheimer disease dement geriatr cogn disord 200112400 7crossrefisimedline martin bk meinert cl breitner jc et al double placebo design prevention trial alzheimer disease control clin trials 20022393 9crossrefisimedline etminan m gill samii effect non steroidal anti inflammatory drugs risk alzheimer disease systematic review meta analysis observational studies bmj 2003327128 31abstractfree full text robertson m effect nsaids risk alzheimer disease confounding factors discussed letter bmj 2003327751free full text haan m shemanski l jagust wj et al predictors cognitive change cardiovascular health study role cardiovascular genetic risk factors jama 199928240 6abstractfree full text ince pg pathological correlates late onset dementia multicentre community based population england wales neuropathology group medical research council cognitive function ageing study mrc cfas lancet 2001357169 75crossrefisimedline kalaria rn role cerebral ischemia alzheimer disease neurobiol aging 200021321 30crossrefisimedline weggen eriksen jl das p et al subset nsaids lower amyloidogenic ass42 independently cyclooxygenase activity nature 2001414212 16crossrefisimedline article abstract free full text pdf alert article cited alert correction posted services email article friend similar articles journal similar articles isi web science similar articles pubmed alert new issues journal add personal archive download citation manager search citing articles isi web science 3 disclaimer request permissions google scholar articles de craen j m articles westendorp r g j pubmed pubmed citation articles de craen j m articles westendorp r g j online issn 1476 6256 print issn 0002 9262 copyright 2006 johns hopkins bloomberg school public health oxford journals oxford university press site map terms conditions privacy policy frequently asked questions oxford university press sites oxford university press american national biography booksellers information service childrens fiction poetry childrens reference corporate special sales dictionaries dictionary national biography digital reference english language teaching higher education textbooks humanities international education unit law medicine music online products oxford english dictionary reference rights permissions science school books social sciences short introductions worlds classics
0.3005403.12566388.html.plaintext.txt	0	identification multiple loci alzheimer disease consanguineous israeli arab community lindsay farrer12345 abdalla bowirrat1 robert p friedland7 kristin waraska6 amos d korczyn8 clinton baldwin16
0.3005403.12566388.html.plaintext.txt	1	identification multiple loci alzheimer disease consanguineous israeli arab community lindsay farrer12345 abdalla bowirrat1 robert p friedland7 kristin waraska6 amos d korczyn8 clinton baldwin16
0.3005403.12566388.html.plaintext.txt	2	1department medicine genetics program 2department neurology 3department genetics genomics 4department epidemiology 5department biostatistics 6center human genetics boston university schools medicine public health boston ma 02118 usa 7department neurology case western reserve university cleveland oh 44106 usa 8department neurology tel aviv university tel aviv israel
0.3005403.12566388.html.plaintext.txt	3	received october 30 2002 accepted december 16 2002
0.3005403.12566388.html.plaintext.txt	4	abstract top abstract introduction results discussion materials methods references observed unusually high prevalence dementia alzheimer type dat wadi ara inbred arab community northern israel comprising 850 persons age 60 years family studies revealed one third dat cases members one hamula tribal group within wadi ara map chromosomal loci contributing dat susceptibility conducted 10 cm scan series five cases five controls selected hamula markers 18 chromosomal regions showed significant allelic association dat p 005 locations chromosomes 2 9 10 remained significant testing additional affected non demented individuals significant associations also observed markers chromosome 12 overlap locus implicated previous genome scans analysis allele frequency distributions 12 markers spanning 20 cm chromosome 9 narrowed possible location dat susceptibility gene 13 cm interval d9s157 d9s259 significant result p23x10 7 analysis 14 markers spanning 24 cm chromosome 12 narrowed possible location 14 cm interval distal lrp1 locus significant result p13x10 6 evidence linkage chromosome 9 stemmed primarily excess homozygosity marker alleles cases compared controls suggesting gene location behaves either recessive additive fashion unique characteristics community together emergent human genome data allow rapid identification dat genes candidate regions
0.3005403.12566388.html.plaintext.txt	5	abstract top abstract introduction results discussion materials methods references observed unusually high prevalence dementia alzheimer type dat wadi ara inbred arab community northern israel comprising 850 persons age 60 years family studies revealed one third dat cases members one hamula tribal group within wadi ara map chromosomal loci contributing dat susceptibility conducted 10 cm scan series five cases five controls selected hamula markers 18 chromosomal regions showed significant allelic association dat p 005 locations chromosomes 2 9 10 remained significant testing additional affected non demented individuals significant associations also observed markers chromosome 12 overlap locus implicated previous genome scans analysis allele frequency distributions 12 markers spanning 20 cm chromosome 9 narrowed possible location dat susceptibility gene 13 cm interval d9s157 d9s259 significant result p23x10 7 analysis 14 markers spanning 24 cm chromosome 12 narrowed possible location 14 cm interval distal lrp1 locus significant result p13x10 6 evidence linkage chromosome 9 stemmed primarily excess homozygosity marker alleles cases compared controls suggesting gene location behaves either recessive additive fashion unique characteristics community together emergent human genome data allow rapid identification dat genes candidate regions
0.3005403.12566388.html.plaintext.txt	6	introduction top abstract introduction results discussion materials methods references alzheimers disease ad progressive neurodegenerative disease characterized memory loss language deterioration impaired visuo spatial skills poor judgment neuropathologically extracellular amyloid plaque deposition intra neuronal neurofibrillary tangles neuronal loss ad usually begins age 65 however onset may occur early age 30 early onset forms disease appear strong genetic component mutations several genes identified including amyloid precursor gene app 104760 presenilin 1 psen1 104311 presenilin 2 psen2 600759
0.3005403.12566388.html.plaintext.txt	7	introduction top abstract introduction results discussion materials methods references alzheimers disease ad progressive neurodegenerative disease characterized memory loss language deterioration impaired visuo spatial skills poor judgment neuropathologically extracellular amyloid plaque deposition intra neuronal neurofibrillary tangles neuronal loss ad usually begins age 65 however onset may occur early age 30 early onset forms disease appear strong genetic component mutations several genes identified including amyloid precursor gene app 104760 presenilin 1 psen1 104311 presenilin 2 psen2 600759
0.3005403.12566388.html.plaintext.txt	8	basis common late onset form ad less well understood genetic risk factor highest attributable risk ad 4 allele apoe gene chromosome 19q 1 among caucasians odds ad 4 homozygotes 34 heterozygotes 149 32 respectively greater associated 3 homozygotes 2 many genes studied possible role gene products disease proximity known ad loci evidence implicating susceptibility genes much less compelling associations reported fewer 40 genes 34 yet none clearly established ad risk factor linkage studies implicated regions chromosomes 9 5 10 6 8 12 9 11 candidate genes regions include insulin degrading enzyme ide chromosome 10 2 macroglobulin a2m low density lipoprotein receptor related gene lrp1 chromosome 12 81213 although none proven ad gene 14 17
0.3005403.12566388.html.plaintext.txt	9	basis common late onset form ad less well understood genetic risk factor highest attributable risk ad 4 allele apoe gene chromosome 19q 1 among caucasians odds ad 4 homozygotes 34 heterozygotes 149 32 respectively greater associated 3 homozygotes 2 many genes studied possible role gene products disease proximity known ad loci evidence implicating susceptibility genes much less compelling associations reported fewer 40 genes 34 yet none clearly established ad risk factor linkage studies implicated regions chromosomes 9 5 10 6 8 12 9 11 candidate genes regions include insulin degrading enzyme ide chromosome 10 2 macroglobulin a2m low density lipoprotein receptor related gene lrp1 chromosome 12 81213 although none proven ad gene 14 17
0.3005403.12566388.html.plaintext.txt	10	report examined genetic basis dementia alzheimer type dat unique community population based study screened residents ages 60 years older n821 wadi ara arab community near tel aviv northern israel observed prevalence higher found israel china europe usa even adjustment age education gender 1819 unusually high prevalence apparently due increased frequency apoe 4 allele actually reduced community 002 non demented elders compared caucasians 20 hypothesized increased prevalence dat wadi ara associated limited number unique susceptibility alleles whose frequency enriched inbreeding current residents wadi ara members 14 hamulas family groups recently minimal immigration emigration community designed carried efficient 10 cm genome scan exploiting unique population structure results study confirm existence dat loci chromosomes 9 10 12 provide evidence new dat locus chromosome 2
0.3005403.12566388.html.plaintext.txt	11	report examined genetic basis dementia alzheimer type dat unique community population based study screened residents ages 60 years older n821 wadi ara arab community near tel aviv northern israel observed prevalence higher found israel china europe usa even adjustment age education gender 1819 unusually high prevalence apparently due increased frequency apoe 4 allele actually reduced community 002 non demented elders compared caucasians 20 hypothesized increased prevalence dat wadi ara associated limited number unique susceptibility alleles whose frequency enriched inbreeding current residents wadi ara members 14 hamulas family groups recently minimal immigration emigration community designed carried efficient 10 cm genome scan exploiting unique population structure results study confirm existence dat loci chromosomes 9 10 12 provide evidence new dat locus chromosome 2
0.3005403.12566388.html.plaintext.txt	12	results top abstract introduction results discussion materials methods references genome scan high prevalence dat wadi ara may course explained environmental genetic factors genetic hypothesis bolstered examination 187 pedigrees showing smaller number surnames families containing dat cases without dat cases fact one third 168 prevalent dat cases one 14 hamulas despite large concentration dat cases hamula individual pedigrees contained one living affected member therefore traditional family based linkage study approaches feasible however given high degree inbreeding wadi ara evidenced frequent first cousin second cousin marriages limited number founders reasoned prevalent dat susceptibility alleles may identical descent therefore frequency distributions alleles genotypes markers linked dat locus would differ dat cases controls 10 cm genome scan conducted genotyping 375 markers abi genome scan panel dnas five dat cases ages 68 85 years five non demented controls ages 63 85 years different families hamula highest disease prevalence markers 18 linkage regions 13 different chromosomes showed significant difference allele frequency distribution dat cases controls table 1 many instances difference attributable specific allele evidence either excess marker homozygosity cases compared controls association genotype level
0.3005403.12566388.html.plaintext.txt	13	results top abstract introduction results discussion materials methods references genome scan high prevalence dat wadi ara may course explained environmental genetic factors genetic hypothesis bolstered examination 187 pedigrees showing smaller number surnames families containing dat cases without dat cases fact one third 168 prevalent dat cases one 14 hamulas despite large concentration dat cases hamula individual pedigrees contained one living affected member therefore traditional family based linkage study approaches feasible however given high degree inbreeding wadi ara evidenced frequent first cousin second cousin marriages limited number founders reasoned prevalent dat susceptibility alleles may identical descent therefore frequency distributions alleles genotypes markers linked dat locus would differ dat cases controls 10 cm genome scan conducted genotyping 375 markers abi genome scan panel dnas five dat cases ages 68 85 years five non demented controls ages 63 85 years different families hamula highest disease prevalence markers 18 linkage regions 13 different chromosomes showed significant difference allele frequency distribution dat cases controls table 1 many instances difference attributable specific allele evidence either excess marker homozygosity cases compared controls association genotype level
0.3005403.12566388.html.plaintext.txt	14	view table table 1 markers showing association ad genome wide scan follow studies markers whose allele frequency distribution differed significantly p 005 cases controls genotyped enlarged sample 100 dat cases 110 controls selected entire cohort results remained significant enlarged sample pursued analysis additional markers flanking positive signals significant allelic association remained locations chromosomes 2 9 10 fig 1 also genotyped several markers region chromosome 12 implicated linkage studies 591011 genome scan evidence allelic association also found location fig 1
0.3005403.12566388.html.plaintext.txt	15	view larger version 69k figure 1 association ad markers chromosomes 2 9 10 12 allelic association test results plotted significance levels expressed log scale
0.3005403.12566388.html.plaintext.txt	16	view larger version 69k figure 1 association ad markers chromosomes 2 9 10 12 allelic association test results plotted significance levels expressed log scale
0.3005403.12566388.html.plaintext.txt	17	region showing association chromosome 2 13 cm interval d2s305 d2s2201 significant allelic distribution difference observed d2s305 global p001 position 407 see fig 1 genotype level remarkable difference found d2s310 located 1 cm away marker 10 dat cases 0 controls carriers 135 bp allele p0005
0.3005403.12566388.html.plaintext.txt	18	region showing association chromosome 2 13 cm interval d2s305 d2s2201 significant allelic distribution difference observed d2s305 global p001 position 407 see fig 1 genotype level remarkable difference found d2s310 located 1 cm away marker 10 dat cases 0 controls carriers 135 bp allele p0005
0.3005403.12566388.html.plaintext.txt	19	chromosome 9 significant allelic association observed four markers located interval 32 45 cm fig 1 associations three markers d9s925 d9s9162 d9s259 due representation specific allele examination revealed significant excess homozygosity marker alleles marker allele d9s171 dat cases compared non demented subjects table 2 observation alleles sizes 244 bp greater 165 dat cases none controls contributed highly significant association afm220xf2 p23x10 7
0.3005403.12566388.html.plaintext.txt	20	view table table 2 evidence additive recessive ad locus chromosome 9 taking account results genome scan previous linkage studies evaluated intensively 90 cm interval chromosome 10 fig 1 although significant allelic associations observed markers located separate linkage groups eg d10s1426 59 cm p0007 d10s1225 808 cm p 002 d10s1765 1088 cm p0004 conservative conclusion dat susceptibility gene located interval 105 cm 1153 cm contains four contiguous markers d10s1686 d10s1765 d10s1753 d10s583 showing evidence allelic association fig 1 genotypic association involving carriers associated allele data shown concomitant allelic genotypic association observed two chromosome 10 markers d10s1426 d10s208
0.3005403.12566388.html.plaintext.txt	21	genotyping efforts chromosome 12 focused region near distal lrp1 implicated linkage association studies outbred populations 101322 whereas association evident among markers within 5 cm lrp1 six markers 5 20 cm distal lrp1 associated dat population fig 1 allele 216 d12s1686 present 44 dat cases 27 controls p0006 three alleles 256258260 d12s1722 accounted 14 dat chromosomes absent controls p13x10 6 allele 216 d12s326 significantly represented p00008 chromosomes dat cases 40 compared controls 26
0.3005403.12566388.html.plaintext.txt	22	genotyping efforts chromosome 12 focused region near distal lrp1 implicated linkage association studies outbred populations 101322 whereas association evident among markers within 5 cm lrp1 six markers 5 20 cm distal lrp1 associated dat population fig 1 allele 216 d12s1686 present 44 dat cases 27 controls p0006 three alleles 256258260 d12s1722 accounted 14 dat chromosomes absent controls p13x10 6 allele 216 d12s326 significantly represented p00008 chromosomes dat cases 40 compared controls 26
0.3005403.12566388.html.plaintext.txt	23	discussion top abstract introduction results discussion materials methods references designed unconventional 10 cm genome scan identify loci dat highly inbred israeli arab community highest known prevalence dat world 18 history region suggests residents community descendants small number founder individuals since remained relatively closed society high degree consanguinity 10 distantly related individuals five dat cases five non demented controls one extended kindred genotyped approach efficient economical relying course assumption genes contributing dat wadi ara identical descent prevalent among affected members genome scan 375 microsatellite markers revealed evidence association p 005 18 locations however testing additional markers larger number people association chromosomes 2 9 10 remained
0.3005403.12566388.html.plaintext.txt	24	discussion top abstract introduction results discussion materials methods references designed unconventional 10 cm genome scan identify loci dat highly inbred israeli arab community highest known prevalence dat world 18 history region suggests residents community descendants small number founder individuals since remained relatively closed society high degree consanguinity 10 distantly related individuals five dat cases five non demented controls one extended kindred genotyped approach efficient economical relying course assumption genes contributing dat wadi ara identical descent prevalent among affected members genome scan 375 microsatellite markers revealed evidence association p 005 18 locations however testing additional markers larger number people association chromosomes 2 9 10 remained
0.3005403.12566388.html.plaintext.txt	25	arguably strategy genome scan high false negative rate failed detect dat locus chromosome 12 motivated linkage findings previous studies outbred populations genotyped many closely spaced markers region adjacent distal lrp1 observed significant association dat careful inspection results genome scan revealed two markers flanking linked region d12s83 765 cm d12s351 967 cm failed show association genome scan follow fig 1 unfortunately genotyping assay one marker interval d12s326 816 cm yielded significant result follow analysis failed genome scan thus accounting false negative result locus large number alleles per locus table 3 may increased false negative rate observations illustrate potentially serious limitation 10 cm genome scan using subjects nonetheless strategy successfully detected loci chromosomes 2 9 10
0.3005403.12566388.html.plaintext.txt	26	arguably strategy genome scan high false negative rate failed detect dat locus chromosome 12 motivated linkage findings previous studies outbred populations genotyped many closely spaced markers region adjacent distal lrp1 observed significant association dat careful inspection results genome scan revealed two markers flanking linked region d12s83 765 cm d12s351 967 cm failed show association genome scan follow fig 1 unfortunately genotyping assay one marker interval d12s326 816 cm yielded significant result follow analysis failed genome scan thus accounting false negative result locus large number alleles per locus table 3 may increased false negative rate observations illustrate potentially serious limitation 10 cm genome scan using subjects nonetheless strategy successfully detected loci chromosomes 2 9 10
0.3005403.12566388.html.plaintext.txt	27	view table table 3 polymorphism characteristics among markers regions showing linkage results study attest utility genetic isolates including region middle east 23 25 mapping genes responsible disease susceptibility outbred caucasian populations strategy evaluating linkage disequilibrium microsatellite marker alleles dat differs traditional linkage approaches genetic isolates several respects first focused efforts regions identified genome scan including 10 individuals second dat patients current cohort purportedly descendants 14 founder matings members distinct pedigrees gene mapping designs rely linkage family based association approaches 23 25 thus suitable situation relationships individuals sample distant unclear third although efficacy linkage disequilibrium mapping isolated founder populations recessive traits demonstrated hastbacka colleagues 26 efficacy approach proven complex traits notably allele frequency dependent homozygosity mapping method enabled localization gene recessive deafness bali using 13 affected individuals 27 require evaluation dna parents thus perhaps well suited wadi ara population however effectively limited recessive traits
0.3005403.12566388.html.plaintext.txt	28	four chromosomal regions implicated study reported previously suggesting may authentic loci rather chance findings marker chromosome 2 showing significant association dat d2s305 located 6 10 cm two markers showing linkage disequilibrium case control sample finland 28 chromosome 9 location overlaps peaks observed two studies overlapping data sets 529 chromosome 10 location several studies 782930 detected evidence association chromosome 12 population precise region 20 35 cm distal linkage peaks observed others 9 112231 thus unclear region identified chromosome 12 reported studies
0.3005403.12566388.html.plaintext.txt	29	four chromosomal regions implicated study reported previously suggesting may authentic loci rather chance findings marker chromosome 2 showing significant association dat d2s305 located 6 10 cm two markers showing linkage disequilibrium case control sample finland 28 chromosome 9 location overlaps peaks observed two studies overlapping data sets 529 chromosome 10 location several studies 782930 detected evidence association chromosome 12 population precise region 20 35 cm distal linkage peaks observed others 9 112231 thus unclear region identified chromosome 12 reported studies
0.3005403.12566388.html.plaintext.txt	30	multiple markers tested chromosomes 2 9 10 12 findings reconsidered transforming p values significant result location lod scores z according guidelines interpreting linkage results 32 locations chromosomes 9 12 highly significant z55 48 respectively chromosome 10 locus certainly suggestive linkage z21 significant result chromosome 2 z15 falls cutoff 17 proposed suggestive linkage however finding would still considered significant replicates prior linkage finding 28
0.3005403.12566388.html.plaintext.txt	31	multiple markers tested chromosomes 2 9 10 12 findings reconsidered transforming p values significant result location lod scores z according guidelines interpreting linkage results 32 locations chromosomes 9 12 highly significant z55 48 respectively chromosome 10 locus certainly suggestive linkage z21 significant result chromosome 2 z15 falls cutoff 17 proposed suggestive linkage however finding would still considered significant replicates prior linkage finding 28
0.3005403.12566388.html.plaintext.txt	32	identification multiple loci genetic isolate unexpected one loci might represent false positive result although discussed four loci correspond approximate locations identified studies populations likely explanation unfortunate aggregation multiple susceptibility loci single community heterogeneity consistent remarkably high prevalence dat wadi ara 18 alternatively high prevalence dat explained oligogenic mode transmission requiring coincident inheritance susceptibility alleles multiple loci discrimination among hypotheses require simultaneous examination marker haplotypes preferably actual susceptibility alleles locus groups affected non demented individuals
0.3005403.12566388.html.plaintext.txt	33	identification multiple loci genetic isolate unexpected one loci might represent false positive result although discussed four loci correspond approximate locations identified studies populations likely explanation unfortunate aggregation multiple susceptibility loci single community heterogeneity consistent remarkably high prevalence dat wadi ara 18 alternatively high prevalence dat explained oligogenic mode transmission requiring coincident inheritance susceptibility alleles multiple loci discrimination among hypotheses require simultaneous examination marker haplotypes preferably actual susceptibility alleles locus groups affected non demented individuals
0.3005403.12566388.html.plaintext.txt	34	wadi ara one highest prevalence rates dat world 18 low frequency apoe 4 allele non demented individuals 24 dat cases 36 indicates genetic basis disorder population due entirely loci 20 low impact apoe ad risk reported yoruba living nigeria baseline frequency 4 20 incidence ad low 3334 contrast pericak vance colleagues observed apoe 33 genotype among ad cases amish inbred religious sect 35 however amish lower prevalence dementia wadi ara even outbred caucasian populations european origin non genetic factors including diet low levels education physical activity may also partly responsible high prevalence disease wadi ara 36
0.3005403.12566388.html.plaintext.txt	35	surprised high degree marker polymorphism suggesting might greater degree admixture populations predicted see table 3 alternatively large number alleles may due relative instability microsatellilte markers generation generation interestingly substantial marker polymorphism also observed study ad 98 members genetic isolate finland 28 finnish study global tests allelic association significant 005 level 21 366 markers tested genome wide two thirds regions confirmed follow analysis additional linked markers high proportion marker heterozygosity perhaps enabling detection individual marker association hindered meaningful haplotype analysis without parental data establish linkage phase power estimating haplotypes sample poor even assistance maximum likelihood approaches 37 efficacious strategy assessing linkage disequilibrium small intervals defined haplotypes ultimately identifying candidate genes evaluation single nucleotide polymorphisms snps
0.3005403.12566388.html.plaintext.txt	36	surprised high degree marker polymorphism suggesting might greater degree admixture populations predicted see table 3 alternatively large number alleles may due relative instability microsatellilte markers generation generation interestingly substantial marker polymorphism also observed study ad 98 members genetic isolate finland 28 finnish study global tests allelic association significant 005 level 21 366 markers tested genome wide two thirds regions confirmed follow analysis additional linked markers high proportion marker heterozygosity perhaps enabling detection individual marker association hindered meaningful haplotype analysis without parental data establish linkage phase power estimating haplotypes sample poor even assistance maximum likelihood approaches 37 efficacious strategy assessing linkage disequilibrium small intervals defined haplotypes ultimately identifying candidate genes evaluation single nucleotide polymorphisms snps
0.3005403.12566388.html.plaintext.txt	37	results study implicate several potential ad genes apob adam17 located candidate region chromosome 2 apob main apolipoprotein chylomicrons low density lipoproteins ldl important lipid cholesterol metabolism adam17 disintegrin metalloprotease responsible s2 cleavage notch1 cleavage makes notch1 susceptible cleavage gamma secretase like protease leading activation notch pathway 38 analogous action presenilins also act notch pathway peak chromosome 10 d10s1686 d10s583 includes several genes previously associated ad including cholesterol 25 hydroxylase ch25h encodes membrane protein synthesizes oxysterol regulators lipid metabolism 39 insulin degrading enzyme ide neutral metalloproteinase shown degrade beta amyloid 40 important protein found plaques seen ad urinary plasminogen activator plau protease converts plasminogen plasmin elevated ad patients 41
0.3005403.12566388.html.plaintext.txt	38	results study implicate several potential ad genes apob adam17 located candidate region chromosome 2 apob main apolipoprotein chylomicrons low density lipoproteins ldl important lipid cholesterol metabolism adam17 disintegrin metalloprotease responsible s2 cleavage notch1 cleavage makes notch1 susceptible cleavage gamma secretase like protease leading activation notch pathway 38 analogous action presenilins also act notch pathway peak chromosome 10 d10s1686 d10s583 includes several genes previously associated ad including cholesterol 25 hydroxylase ch25h encodes membrane protein synthesizes oxysterol regulators lipid metabolism 39 insulin degrading enzyme ide neutral metalloproteinase shown degrade beta amyloid 40 important protein found plaques seen ad urinary plasminogen activator plau protease converts plasminogen plasmin elevated ad patients 41
0.3005403.12566388.html.plaintext.txt	39	observation excess chromosome 9 marker homozygosity among dat patients consistent recessive inheritance known genes familial early onset ad ie app ps1 ps2 expressed autosomal dominant fashion effect apoe 4 one bona fide gene late onset ad ad risk additive 242 although genetic modeling studies based data outbred families found evidence recessive inheritance 43 45 recessive model rejected analysis families lacking apoe 4 allele 46 consanguineous populations provide unique opportunity discern recessively behaving genes diseases manifesting late life
0.3005403.12566388.html.plaintext.txt	40	observation excess chromosome 9 marker homozygosity among dat patients consistent recessive inheritance known genes familial early onset ad ie app ps1 ps2 expressed autosomal dominant fashion effect apoe 4 one bona fide gene late onset ad ad risk additive 242 although genetic modeling studies based data outbred families found evidence recessive inheritance 43 45 recessive model rejected analysis families lacking apoe 4 allele 46 consanguineous populations provide unique opportunity discern recessively behaving genes diseases manifesting late life
0.3005403.12566388.html.plaintext.txt	41	potential caveat study lack neuropathological evidence ad patient community unfortunately brain autopsy could performed violates religious customs therefore possible subjects dementing illnesses especially vascular dementia may misclassified dat however concern lessened corroborating evidence brain mri scans performed portion dat patients see methods diagnostic validity also supported finding linkage three regions previously implicated harboring ad loci
0.3005403.12566388.html.plaintext.txt	42	potential caveat study lack neuropathological evidence ad patient community unfortunately brain autopsy could performed violates religious customs therefore possible subjects dementing illnesses especially vascular dementia may misclassified dat however concern lessened corroborating evidence brain mri scans performed portion dat patients see methods diagnostic validity also supported finding linkage three regions previously implicated harboring ad loci
0.3005403.12566388.html.plaintext.txt	43	identification chromosomal segments showing association linkage first step toward discovery genetic defects increase susceptibility ad together large amount gene information available feasible systematically identify snps potential candidate genes evaluate association ad given snp map considerably dense microsatellite marker map likely candidate regions reduced significantly haplotype analysis using small blocks snps
0.3005403.12566388.html.plaintext.txt	44	identification chromosomal segments showing association linkage first step toward discovery genetic defects increase susceptibility ad together large amount gene information available feasible systematically identify snps potential candidate genes evaluate association ad given snp map considerably dense microsatellite marker map likely candidate regions reduced significantly haplotype analysis using small blocks snps
0.3005403.12566388.html.plaintext.txt	45	materials methods top abstract introduction results discussion materials methods references subjects subjects ascertained prevalence study dementia conducted wadi ara geographically defined area northern israel comprising three arab villages 18 among 853 residents ages 60 years older prevalence day october 1 1995 821 available consented participate study subjects interviewed examined arabic speaking physician ab previously trained memory clinic subject underwent battery standard cognitive tests modified fit cultural linguistic characteristics community 18 diagnosis dat determined using dsm iv criteria 47 diagnosis ad conventionally reserved patients diagnosed using nincdsadrda criteria 48 persons mild cognitive impairment demented subjects whose medical history laboratory cognitive test results suggested presence illnesses vascular dementia parkinson disease normal pressure hydrocephalus pseudodementia depression excluded evidence ischemic stroke white matter disease present 215 dat patients ages ranging 71 91 years brain mri scan suggesting relatively subjects misclassified peripheral blood samples obtained 1997 2000 650 survivors dna biochemical analysis
0.3005403.12566388.html.plaintext.txt	46	materials methods top abstract introduction results discussion materials methods references subjects subjects ascertained prevalence study dementia conducted wadi ara geographically defined area northern israel comprising three arab villages 18 among 853 residents ages 60 years older prevalence day october 1 1995 821 available consented participate study subjects interviewed examined arabic speaking physician ab previously trained memory clinic subject underwent battery standard cognitive tests modified fit cultural linguistic characteristics community 18 diagnosis dat determined using dsm iv criteria 47 diagnosis ad conventionally reserved patients diagnosed using nincdsadrda criteria 48 persons mild cognitive impairment demented subjects whose medical history laboratory cognitive test results suggested presence illnesses vascular dementia parkinson disease normal pressure hydrocephalus pseudodementia depression excluded evidence ischemic stroke white matter disease present 215 dat patients ages ranging 71 91 years brain mri scan suggesting relatively subjects misclassified peripheral blood samples obtained 1997 2000 650 survivors dna biochemical analysis
0.3005403.12566388.html.plaintext.txt	47	dna analysis dna extracted whole blood according procedures described previously 18 fluorescently labeled primers microsatellite markers used study purchased applied biosytem abi used 10 microl pcr reaction 5 ng genomic dna products different size fluorescent label combined applied either abi 377 gel based dna sequencer abi 3700 capillary dna sequencer genotyper program abi used determine allele sizes laboratory technicians blinded subject identifying information associated sample id number plate contained multiple control samples ensure quality genotyping allele determination
0.3005403.12566388.html.plaintext.txt	48	dna analysis dna extracted whole blood according procedures described previously 18 fluorescently labeled primers microsatellite markers used study purchased applied biosytem abi used 10 microl pcr reaction 5 ng genomic dna products different size fluorescent label combined applied either abi 377 gel based dna sequencer abi 3700 capillary dna sequencer genotyper program abi used determine allele sizes laboratory technicians blinded subject identifying information associated sample id number plate contained multiple control samples ensure quality genotyping allele determination
0.3005403.12566388.html.plaintext.txt	49	statistical analysis allele genotype associations assessed using sas version 802 software exact tests used evaluate associations genome scan global 2 tests used follow studies enlarged sample number alleles genotypes microsatellite markers far exceeded expected genetic isolate many 19 alleles 60 genotypes frequency distributions global tests inspected visually suggest one two single allele collapsed genotype group tests reported significant p values p005 based latter tests unless indicated otherwise adjusted multiple testing correct testing multiple markers chromosome follow studies p values transformed lod scores using equivalence
0.3005403.12566388.html.plaintext.txt	50	adapted allele sharing models developed kong cox 49 lod scores interpreted according criteria recommended lander kruglyak 32 marker positions obtained online genethon linkage map available wwwncbinlmnihgovmapviewmapsearchcgi
0.3005403.12566388.html.plaintext.txt	51	adapted allele sharing models developed kong cox 49 lod scores interpreted according criteria recommended lander kruglyak 32 marker positions obtained online genethon linkage map available wwwncbinlmnihgovmapviewmapsearchcgi
0.3005403.12566388.html.plaintext.txt	52	acknowledgements thank dr yoav chapman dr miriam birnbaum performing dna extraction apoe genotyping many samples corey adams initiating genotyping effort study work supported part grants national institutes health u01 ag17173 institute study aging
0.3005403.12566388.html.plaintext.txt	53	acknowledgements thank dr yoav chapman dr miriam birnbaum performing dna extraction apoe genotyping many samples corey adams initiating genotyping effort study work supported part grants national institutes health u01 ag17173 institute study aging
0.3005403.12566388.html.plaintext.txt	54	footnotes correspondence addressed genetics program l 320 boston university school medicine 715 albany street boston ma 02118 usa tel 1 617 6385393 fax 617 6384275 email farreratbuedu
0.3005403.12566388.html.plaintext.txt	55	footnotes correspondence addressed genetics program l 320 boston university school medicine 715 albany street boston ma 02118 usa tel 1 617 6385393 fax 617 6384275 email farreratbuedu
0.3005403.12566388.html.plaintext.txt	56	references top abstract introduction results discussion materials methods references corder eh saunders strittmatter wj schmechel de gaskell pc small gw roses ad haines jl pericak vance ma 1993 gene dose apolipoprotein e type 4 allele risk alzheimers disease late onset families science 261 921 923isimedline
0.3005403.12566388.html.plaintext.txt	57	apa 1994 diagnostic statistical manual mental disorders 4th edn american psychiatric association washington dc
0.3005403.12566388.html.plaintext.txt	58	apa 1994 diagnostic statistical manual mental disorders 4th edn american psychiatric association washington dc
0.30746758.9300660.html.plaintext.txt	0	genetics parkinsons disease genetics parkinsons disease robert l nussbaum mihael h polymeropoulos
0.30746758.9300660.html.plaintext.txt	1	laboratory genetic diseases research national human genome research institute bethesda md 20892 4472 usa
0.30746758.9300660.html.plaintext.txt	2	past 40 years research parkinsons disease pd predominantly province epidemiologists interested pursuing connection disease environmental factors viral infection neurotoxins hereditary influences actually discounted high monozygotic twin discordance rate found studies later shown inadequate inconclusive recently resurgence interest investigating hereditary factors pd became apparent positive family history major risk factor disease meanwhile also became increasingly apparent neuropathological studies common idiopathic form parkinsons disease fact pathological correlate ie existence lewy bodies eosinophilic cytoplasmic inclusion body distributed diffusely throughout substnatia nigra hypothalamus hippocampus autonomic ganglia olfactory tracts although candidate gene approaches linkage pd families rewarding genome wide scan mapped pd 4q21 23 one large family pd diffuse lewy bodies candidate gene alpha synuclein resides gene encodes presynaptic protein peptide fragment known constituent alzheimers disease plaques identification missense mutation alpha synuclein gene four independent pd families suggests least fraction familial pd diffuse lewy bodies result abnormal protein interferes normal protein degradation leading development inclusions ultimately neuronal cell death may common pathogenetic mechanisms involved alpha synuclein mutations pd beta amyloid presenilin gene mutations alzheimers disease introduction
0.30746758.9300660.html.plaintext.txt	3	past 40 years research parkinsons disease pd predominantly province epidemiologists interested pursuing connection disease environmental factors viral infection neurotoxins hereditary influences actually discounted high monozygotic twin discordance rate found studies later shown inadequate inconclusive recently resurgence interest investigating hereditary factors pd became apparent positive family history major risk factor disease meanwhile also became increasingly apparent neuropathological studies common idiopathic form parkinsons disease fact pathological correlate ie existence lewy bodies eosinophilic cytoplasmic inclusion body distributed diffusely throughout substnatia nigra hypothalamus hippocampus autonomic ganglia olfactory tracts although candidate gene approaches linkage pd families rewarding genome wide scan mapped pd 4q21 23 one large family pd diffuse lewy bodies candidate gene alpha synuclein resides gene encodes presynaptic protein peptide fragment known constituent alzheimers disease plaques identification missense mutation alpha synuclein gene four independent pd families suggests least fraction familial pd diffuse lewy bodies result abnormal protein interferes normal protein degradation leading development inclusions ultimately neuronal cell death may common pathogenetic mechanisms involved alpha synuclein mutations pd beta amyloid presenilin gene mutations alzheimers disease introduction
0.30746758.9300660.html.plaintext.txt	4	parkinsons disease pd first described james parkinson 1817 1 180 years diagnosis remained primarily clinical one disease common prevalence 500 000 1 000 000 united states 2 life time risk 1 40 making pd second common neurodegenerative disease alzheimers disease ad 2 well 100 years neurologists aware significant role heredity development pd number factors quite recently hampered genetic research pd
0.30746758.9300660.html.plaintext.txt	5	parkinsons disease pd first described james parkinson 1817 1 180 years diagnosis remained primarily clinical one disease common prevalence 500 000 1 000 000 united states 2 life time risk 1 40 making pd second common neurodegenerative disease alzheimers disease ad 2 well 100 years neurologists aware significant role heredity development pd number factors quite recently hampered genetic research pd
0.30746758.9300660.html.plaintext.txt	6	first factor lack agreement precisely constitutes typical pd whether familial forms disease real pd attitude typified one medical school professor hospital rounds colleague asserted lack family history diagnostic criterion pd result research pd emphasized familial forms disease seen mark directed real pd idea little genetic contribution etiology pd strengthened series twin studies 3 6 1980s failed demonstrate increased concordance rates pd monozygotic versus dizygotic twins
0.30746758.9300660.html.plaintext.txt	7	first factor lack agreement precisely constitutes typical pd whether familial forms disease real pd attitude typified one medical school professor hospital rounds colleague asserted lack family history diagnostic criterion pd result research pd emphasized familial forms disease seen mark directed real pd idea little genetic contribution etiology pd strengthened series twin studies 3 6 1980s failed demonstrate increased concordance rates pd monozygotic versus dizygotic twins
0.30746758.9300660.html.plaintext.txt	8	second reason research efforts may emphasized role heredity pd striking results epidemiological studies linking pd environmental agents viruses neurotoxins much research communitys energies efforts became focused identifying nature effects environmental agents thought responsible causing disease 1918 influenza pandemic associated encephalitis lethargica late sequela post encephalitic pd pointed viral infection major cause pd 7 significance association seemed strong one point one investigator suggested pd would disappear 1980 clinical entity survivors pandemic grew old died 7 strong support environmental cause pd occurrence irreversible symptoms signs pd occurring injection illicit drug preparations contaminated n methyl 4 phenyl 1236 tetrahydropyridine mptp 8 9 mptp metabolites interfere complex electron transport chain thus depleting cells products oxidative phosphorylation exposing dopaminergic neurons substantia nigra irreversible damage energy depletion oxidative stress free radicals 2 10
0.30746758.9300660.html.plaintext.txt	9	second reason research efforts may emphasized role heredity pd striking results epidemiological studies linking pd environmental agents viruses neurotoxins much research communitys energies efforts became focused identifying nature effects environmental agents thought responsible causing disease 1918 influenza pandemic associated encephalitis lethargica late sequela post encephalitic pd pointed viral infection major cause pd 7 significance association seemed strong one point one investigator suggested pd would disappear 1980 clinical entity survivors pandemic grew old died 7 strong support environmental cause pd occurrence irreversible symptoms signs pd occurring injection illicit drug preparations contaminated n methyl 4 phenyl 1236 tetrahydropyridine mptp 8 9 mptp metabolites interfere complex electron transport chain thus depleting cells products oxidative phosphorylation exposing dopaminergic neurons substantia nigra irreversible damage energy depletion oxidative stress free radicals 2 10
0.30746758.9300660.html.plaintext.txt	10	although viral encephalitis environmental toxin mptp clearly capable damaging substantia nigra 1990s seen re emergence interest genetic causes idiopathic pd primarily efforts neurologists r duvoisin z wszolek result currently much research investigating role heredity gene environment interactions causing pd rather choosing false dichotomy exclusive environmental genetic etiology geneticists attempting synthesis epidemiological genetic data focusing three areas inquiry inherited somatic mitochondrial genome abnormalities causing defects energy metabolism ii candidate gene linkage association studies genes encoding drug metabolizing enzymes iii whole genome scans locate identify genes involved families highly penetrant autosomal dominant pd two excellent relatively recent reviews genetic aspects parkinsons disease published 11 12 clinical phenotype
0.30746758.9300660.html.plaintext.txt	11	many areas genetics definition phenotype one difficult contentious obstacles facing geneticist accurate clinical diagnosis crucial trying categorize patients families genetic studies certainly heterogeneous disorder multiple etiologies generally accepted motor symptoms pd parkinsonism result deficiency dysfunction dopamine neurons producing dopamine pars compacta substantia nigra regardless etiology however idiopathic pd common form disease difficult approach genetic study name mean different things different researchers
0.30746758.9300660.html.plaintext.txt	12	many areas genetics definition phenotype one difficult contentious obstacles facing geneticist accurate clinical diagnosis crucial trying categorize patients families genetic studies certainly heterogeneous disorder multiple etiologies generally accepted motor symptoms pd parkinsonism result deficiency dysfunction dopamine neurons producing dopamine pars compacta substantia nigra regardless etiology however idiopathic pd common form disease difficult approach genetic study name mean different things different researchers
0.30746758.9300660.html.plaintext.txt	13	clinician diagnosis parkinsons disease based finding least two four primary motor signs disease tremor bradykinesia muscular rigidity postural instability also frequently seen considered primary diagnostic criteria dementia defects gastrointestinal motility dysautonomia responsiveness l dopa therapy disease progressive usually insidious onset mid late adulthood one study 13 100 patients three quarters patients carrying diagnosis pd determined qualified neurologists actually disease confirmed autopsy study clinical diagnostic criteria made stringent retrospectively specificity rose 93 expense drop sensitivity 68
0.30746758.9300660.html.plaintext.txt	14	clinician diagnosis parkinsons disease based finding least two four primary motor signs disease tremor bradykinesia muscular rigidity postural instability also frequently seen considered primary diagnostic criteria dementia defects gastrointestinal motility dysautonomia responsiveness l dopa therapy disease progressive usually insidious onset mid late adulthood one study 13 100 patients three quarters patients carrying diagnosis pd determined qualified neurologists actually disease confirmed autopsy study clinical diagnostic criteria made stringent retrospectively specificity rose 93 expense drop sensitivity 68
0.30746758.9300660.html.plaintext.txt	15	neuropathologist autopsy demonstration diffuse lewy body disease come hallmark pd 14 diffuse lewy body disease lewy body characteristic intracellular cytoplasmic inclusion named beginning 20th century discoverer found many regions brain particularly neurons substantia nigra nuclei brain stem hypothalamus hippocampus autonomic neurons esophagus gastrointestinal tract occasionally cortex 12 lewy bodies frequently found brains patients dying pd even though extreme variation age onset severity clinical manifestations pd 100 patients carrying diagnosis pd came autopsy 24 patients lewy bodies found pd instead causes clinical signs 15 however presence lewy bodies per se uniquely pathognomic pd form alzheimers disease known lewy body variant ad described lewy bodies found brain cortex along pathognomic amyloid plaques neurofibrillary tangles ad 16 conversely possible motor dysfunction characteristic pd even familial basis without pathological process whose characteristic marker lewy body reviewed 12 examples hereditary parkinsonism syndromes without diffuse lewy body disease include juvenile autosomal recessive parkinsonism mapping chromosome 6q25 27 17 rapidly progressive autosomal dominant parkinsonism associated dementia dystonia disinhibition located chromosome 17q21 x linked dystonia parkinsonism 18 20 well defined rare familial disorders motor signs parkinsonism common diffuse lewy body pd certainly different diseases case acquired parkinsonism due mptp toxicity typical lewy body pathology pd seen acute mptp exposure humans monkeys undergoing chronic mptp administration although atypical inclusions reported brains animals 21 23 thus past 10 years neurologists come accept highly prevalent disorder idiopathic pd distinctive disorder usually occurring middle late adulthood characteristic pathology diffuse lewy body disease classical motor central nervous system manifestations parkinsonism 14 24 25 purposes review concentrate genetics common form disease genetic epidemiology pd
0.30746758.9300660.html.plaintext.txt	16	neuropathologist autopsy demonstration diffuse lewy body disease come hallmark pd 14 diffuse lewy body disease lewy body characteristic intracellular cytoplasmic inclusion named beginning 20th century discoverer found many regions brain particularly neurons substantia nigra nuclei brain stem hypothalamus hippocampus autonomic neurons esophagus gastrointestinal tract occasionally cortex 12 lewy bodies frequently found brains patients dying pd even though extreme variation age onset severity clinical manifestations pd 100 patients carrying diagnosis pd came autopsy 24 patients lewy bodies found pd instead causes clinical signs 15 however presence lewy bodies per se uniquely pathognomic pd form alzheimers disease known lewy body variant ad described lewy bodies found brain cortex along pathognomic amyloid plaques neurofibrillary tangles ad 16 conversely possible motor dysfunction characteristic pd even familial basis without pathological process whose characteristic marker lewy body reviewed 12 examples hereditary parkinsonism syndromes without diffuse lewy body disease include juvenile autosomal recessive parkinsonism mapping chromosome 6q25 27 17 rapidly progressive autosomal dominant parkinsonism associated dementia dystonia disinhibition located chromosome 17q21 x linked dystonia parkinsonism 18 20 well defined rare familial disorders motor signs parkinsonism common diffuse lewy body pd certainly different diseases case acquired parkinsonism due mptp toxicity typical lewy body pathology pd seen acute mptp exposure humans monkeys undergoing chronic mptp administration although atypical inclusions reported brains animals 21 23 thus past 10 years neurologists come accept highly prevalent disorder idiopathic pd distinctive disorder usually occurring middle late adulthood characteristic pathology diffuse lewy body disease classical motor central nervous system manifestations parkinsonism 14 24 25 purposes review concentrate genetics common form disease genetic epidemiology pd
0.30746758.9300660.html.plaintext.txt	17	familial clustering pd observed century ago 11 25 10 15 pd patients reported positive family history accurate measurement frequency pd among relatives affected patients made difficult inaccuracy making diagnosis pd history relative insensitivity lack specificity clinical exam variability age onset rarity autopsy data required making diagnosis diffuse lewy body disease relatives reported pd 1980s genetic contribution pd thought highly unlikely series twin studies failed demonstrate increased concordance pd monozygotic versus dizygotic twins 3 6 pointed however 26 studies interpretable number twins studied duration observation either support reject genetic contribution pd inadequate nearly 80 function dopaminergic neurons substantia nigra must lost symptoms occur 27 reliance clinical diagnosis alone lack follow makes determination concordance extremely insensitive evidence clinical evaluation determine concordance twin studies far insensitive comes use positron emission tomography measure 18fluorodopa uptake basal ganglia 28 concordance rate among monozygotic twins increased 18fluorodopa uptake basal ganglia used diagnosis preclinical dysfunction substantia nigra 29 result lack increased concordance twin studies essentially discounted result inconclusive insensitive methodology
0.30746758.9300660.html.plaintext.txt	18	familial clustering pd observed century ago 11 25 10 15 pd patients reported positive family history accurate measurement frequency pd among relatives affected patients made difficult inaccuracy making diagnosis pd history relative insensitivity lack specificity clinical exam variability age onset rarity autopsy data required making diagnosis diffuse lewy body disease relatives reported pd 1980s genetic contribution pd thought highly unlikely series twin studies failed demonstrate increased concordance pd monozygotic versus dizygotic twins 3 6 pointed however 26 studies interpretable number twins studied duration observation either support reject genetic contribution pd inadequate nearly 80 function dopaminergic neurons substantia nigra must lost symptoms occur 27 reliance clinical diagnosis alone lack follow makes determination concordance extremely insensitive evidence clinical evaluation determine concordance twin studies far insensitive comes use positron emission tomography measure 18fluorodopa uptake basal ganglia 28 concordance rate among monozygotic twins increased 18fluorodopa uptake basal ganglia used diagnosis preclinical dysfunction substantia nigra 29 result lack increased concordance twin studies essentially discounted result inconclusive insensitive methodology
0.30746758.9300660.html.plaintext.txt	19	recently number epidemiological studies 30 36 differing methodological approaches study populations published found support familial contribution pd case control studies positive family history found single greatest risk factor pd 25 30 36 family studies family history positive pd found 10 24 patients relative risk pd first degree relatives pd patients ranged 4 10 largest studies frequency pd 2 1458 first degree relatives 233 pd patients significantly higher frequency 1 seen 7834 first degree relatives 1172 age matched controls 30
0.30746758.9300660.html.plaintext.txt	20	recently number epidemiological studies 30 36 differing methodological approaches study populations published found support familial contribution pd case control studies positive family history found single greatest risk factor pd 25 30 36 family studies family history positive pd found 10 24 patients relative risk pd first degree relatives pd patients ranged 4 10 largest studies frequency pd 2 1458 first degree relatives 233 pd patients significantly higher frequency 1 seen 7834 first degree relatives 1172 age matched controls 30
0.30746758.9300660.html.plaintext.txt	21	attempt integrate current knowledge familial nature pd possible role defects energy metabolism causing disease toxicity mptp research proceeded two parallel tracks looking mitochondrial genome abnormalities pd applying linkage association methods affected individuals using polymorphisms drug metabolizing enzymes modest deficiencies complex electron transport chain reviewed 2 reported substantia nigra 21 muscle 37 39 peripheral blood cells 39 40 pd patients whether abnormalities primary secondary disease process unknown mitochondrial genome aging brain demonstrate striking departures normal 41 42 analysis mitochondrial genome blood brain pd patients failed reveal consistent hereditary somatic deletion pd patients compared age matched control blood brain samples reviewed 2 small studies suggested significant association certain mitochondrial dna polymorphisms pd sample sizes small replication ongoing 42 43 thus appears consistent abnormalities oxidative phosphorylation particularly complex pd direct causative role inherited acquired mutation mitochondrial genome remains unproved
0.30746758.9300660.html.plaintext.txt	22	attempt integrate current knowledge familial nature pd possible role defects energy metabolism causing disease toxicity mptp research proceeded two parallel tracks looking mitochondrial genome abnormalities pd applying linkage association methods affected individuals using polymorphisms drug metabolizing enzymes modest deficiencies complex electron transport chain reviewed 2 reported substantia nigra 21 muscle 37 39 peripheral blood cells 39 40 pd patients whether abnormalities primary secondary disease process unknown mitochondrial genome aging brain demonstrate striking departures normal 41 42 analysis mitochondrial genome blood brain pd patients failed reveal consistent hereditary somatic deletion pd patients compared age matched control blood brain samples reviewed 2 small studies suggested significant association certain mitochondrial dna polymorphisms pd sample sizes small replication ongoing 42 43 thus appears consistent abnormalities oxidative phosphorylation particularly complex pd direct causative role inherited acquired mutation mitochondrial genome remains unproved
0.30746758.9300660.html.plaintext.txt	23	view possible involvement neurotoxins pd research also directed towards identifying variation certain drug metabolizing enzymes might predispose certain individuals greater toxicity environmental agents association studies pd focused polymorphisms drug metabolizing enzymes cytochrome p450ia1 encoded cypia1 gene debrisoquine 4 hydroxylase cytochrome p450 encoded cyp2d6 gene well monoamine oxidase b enzymes encoded maoa maob association studies always fraught difficulties arising unrecognized ascertainment bias stratification unfortunately nature late onset disease means parental genotypes required permit use dependable transmission disequilibrium test association usually available 44 nonetheless number studies suggested significant association pd loci encoding cytochrome p450 enzymes monoamine oxidase japan mspi restriction fragment length polymorphism cypi1a found associated 2 fold higher risk pd heterozygotes 65 fold higher homozygotes 45 association studies cyp2d6 gene revealed highly significant 4 fold increased risk among patients disease onset age 50 spanish population although association seen united states british samples 46 47 particular haplotype maoa locus found 3 fold common among pd patients compared controls another haplotype 3 fold less common among affected patients 48 associations found maob locus 48 49 thus preliminary data support modest association certain alleles loci pd history many association studies replication findings difficult requires larger carefully controlled studies accepted definite
0.30746758.9300660.html.plaintext.txt	24	view possible involvement neurotoxins pd research also directed towards identifying variation certain drug metabolizing enzymes might predispose certain individuals greater toxicity environmental agents association studies pd focused polymorphisms drug metabolizing enzymes cytochrome p450ia1 encoded cypia1 gene debrisoquine 4 hydroxylase cytochrome p450 encoded cyp2d6 gene well monoamine oxidase b enzymes encoded maoa maob association studies always fraught difficulties arising unrecognized ascertainment bias stratification unfortunately nature late onset disease means parental genotypes required permit use dependable transmission disequilibrium test association usually available 44 nonetheless number studies suggested significant association pd loci encoding cytochrome p450 enzymes monoamine oxidase japan mspi restriction fragment length polymorphism cypi1a found associated 2 fold higher risk pd heterozygotes 65 fold higher homozygotes 45 association studies cyp2d6 gene revealed highly significant 4 fold increased risk among patients disease onset age 50 spanish population although association seen united states british samples 46 47 particular haplotype maoa locus found 3 fold common among pd patients compared controls another haplotype 3 fold less common among affected patients 48 associations found maob locus 48 49 thus preliminary data support modest association certain alleles loci pd history many association studies replication findings difficult requires larger carefully controlled studies accepted definite
0.30746758.9300660.html.plaintext.txt	25	view association apolipoprotein e allele 4 late onset ad 50 clearly interest investigate whether similar association exists pd either without dementia apolipoprotein e4 allele least two studies failed show association 51 52 note one study find significant association apoe4 lewy body variant ad pd supporting idea lewy body variant ad pd distinct disorders 16
0.30746758.9300660.html.plaintext.txt	26	view association apolipoprotein e allele 4 late onset ad 50 clearly interest investigate whether similar association exists pd either without dementia apolipoprotein e4 allele least two studies failed show association 51 52 note one study find significant association apoe4 lewy body variant ad pd supporting idea lewy body variant ad pd distinct disorders 16
0.30746758.9300660.html.plaintext.txt	27	genetic contribution pd received substantial support identification number families pd diffuse lewy body disease inherited autosomal dominant trait 32 34 53 58 penetrance appeared age dependent rising 43 early adulthood 85 age 70 one family town contursi near salerno italy 56 linkage analysis allowed gene pd autopsy proven diffuse lewy body disease mapped long arm chromosome 4 4q21 q23 59 positive mapping studies published date although essentially negative linkage studies reported variety candidate genes pedigrees apparent autosomal dominant inheritance lewy body positive pd 60 note anticipation seen families multiple generations affected pd 57 58 ascribed primarily ascertainment bias families 55 repeat expansion detection method failed show evidence expanded cag trinucleotide repeat contursi pd kindred 61
0.30746758.9300660.html.plaintext.txt	28	genetic contribution pd received substantial support identification number families pd diffuse lewy body disease inherited autosomal dominant trait 32 34 53 58 penetrance appeared age dependent rising 43 early adulthood 85 age 70 one family town contursi near salerno italy 56 linkage analysis allowed gene pd autopsy proven diffuse lewy body disease mapped long arm chromosome 4 4q21 q23 59 positive mapping studies published date although essentially negative linkage studies reported variety candidate genes pedigrees apparent autosomal dominant inheritance lewy body positive pd 60 note anticipation seen families multiple generations affected pd 57 58 ascribed primarily ascertainment bias families 55 repeat expansion detection method failed show evidence expanded cag trinucleotide repeat contursi pd kindred 61
0.30746758.9300660.html.plaintext.txt	29	figure 1 sequence exon 4 alpha synuclein gene control individual b sequence exon 4 mutant allele individual affected parkinsons disease contursi kindred arrows indicate transition mutation g resulting missense mutation ala thr position 53 protein
0.30746758.9300660.html.plaintext.txt	30	particularly prescient paper published 1996 sommer rocca suggested autosomal dominant pd might caused missense mutation cellular protein changes physical chemical properties leading accumulation abnormal protein neuronal death 62 hypothesis received substantial support linkage mapping pd 4q21 q23 contursi pedigree suggested number candidate genes pd mapped region one alpha synuclein particularly good candidate protein neuron specific presynaptic membrane protein 63 originally identified encodes peptide named nacp non abeta component ad amyloid isolated plaques ad 64 65 sequencing alpha synuclein gene affected individuals contursi kindred fig 1 revealed affected members kindred heterozygous missense mutation alanine threonine position 53 protein segregated pd family 66 missense mutation found three additional unrelated pd families greek origin absent 314 chromosomes control european populations including nearly 200 chromosomes obtained random controls area near contursi evidence mutation causes pd based entirely finding mutation four unrelated families finding absent large set controls definitive proof requires elucidation mechanism mutation causes disease
0.30746758.9300660.html.plaintext.txt	31	particularly prescient paper published 1996 sommer rocca suggested autosomal dominant pd might caused missense mutation cellular protein changes physical chemical properties leading accumulation abnormal protein neuronal death 62 hypothesis received substantial support linkage mapping pd 4q21 q23 contursi pedigree suggested number candidate genes pd mapped region one alpha synuclein particularly good candidate protein neuron specific presynaptic membrane protein 63 originally identified encodes peptide named nacp non abeta component ad amyloid isolated plaques ad 64 65 sequencing alpha synuclein gene affected individuals contursi kindred fig 1 revealed affected members kindred heterozygous missense mutation alanine threonine position 53 protein segregated pd family 66 missense mutation found three additional unrelated pd families greek origin absent 314 chromosomes control european populations including nearly 200 chromosomes obtained random controls area near contursi evidence mutation causes pd based entirely finding mutation four unrelated families finding absent large set controls definitive proof requires elucidation mechanism mutation causes disease
0.30746758.9300660.html.plaintext.txt	32	note nearly 30 different proteins identified immunologically lewy bodies pd lewy body variant ad 67 including ubiquitin beta amyloid precursor protein implicated ad date however published data indicating whether lewy bodies contain peptides derived alpha synuclein interesting note nacp peptide fragment alpha synuclein unusual protein adopts extended non globular conformation known natively unfolded random coil vitro random coil domains promote protein protein interactions make protein amyloidogenic vitro 68 discovery alpha synuclein mutated predisposes high probability development pd families autosomal dominant disease suggests structural abnormality protein either changing conformation altering normal proteolytic processing may inciting event protein aggregation leading pd similar pathogenic mechanism hypothesized mutant cellular proteins presenilins beta amyloid causing ad 69 future
0.30746758.9300660.html.plaintext.txt	33	note nearly 30 different proteins identified immunologically lewy bodies pd lewy body variant ad 67 including ubiquitin beta amyloid precursor protein implicated ad date however published data indicating whether lewy bodies contain peptides derived alpha synuclein interesting note nacp peptide fragment alpha synuclein unusual protein adopts extended non globular conformation known natively unfolded random coil vitro random coil domains promote protein protein interactions make protein amyloidogenic vitro 68 discovery alpha synuclein mutated predisposes high probability development pd families autosomal dominant disease suggests structural abnormality protein either changing conformation altering normal proteolytic processing may inciting event protein aggregation leading pd similar pathogenic mechanism hypothesized mutant cellular proteins presenilins beta amyloid causing ad 69 future
0.30746758.9300660.html.plaintext.txt	34	last years major shift thinking focus pd research resulted rebirth interest investigating genetic contribution disease change focus already begun bear fruit form developing consensus relationship diffuse lewy body disease pd leading much improved genetic epidemiological investigations disorder identification families clear autosomal dominant inheritance patterns identification least one gene particular missense mutation predisposes high probability development disease pd research poised begin ask fundamental questions pathogenesis human patients classical parkinsons disease references 1 parkinson j 1817 essay shaking palsy sherwood neely jones london
0.30746758.9300660.html.plaintext.txt	35	last years major shift thinking focus pd research resulted rebirth interest investigating genetic contribution disease change focus already begun bear fruit form developing consensus relationship diffuse lewy body disease pd leading much improved genetic epidemiological investigations disorder identification families clear autosomal dominant inheritance patterns identification least one gene particular missense mutation predisposes high probability development disease pd research poised begin ask fundamental questions pathogenesis human patients classical parkinsons disease references 1 parkinson j 1817 essay shaking palsy sherwood neely jones london
0.30746758.9300660.html.plaintext.txt	36	11 vieregge p 1994 genetic factors etiology idiopathic parkinsons disease j neural transm park dis dement sect 8 1 37 medline abstract
0.30746758.9300660.html.plaintext.txt	37	69 haass c 1996 presenile presenilin presenilin genes early onset alzheimers disease curr opin neurol 9 254 259 medline abstract
0.30746758.9300660.html.plaintext.txt	38	correspondence addressed tel 1 301 402 2039 fax 1 301 402 2170 email rlnussnhgrinihgov
0.30746758.9300660.html.plaintext.txt	39	correspondence addressed tel 1 301 402 2039 fax 1 301 402 2170 email rlnussnhgrinihgov
0.30746758.9300660.html.plaintext.txt	40	page maintained oup admin last updated fri sep 12 180923 bst 1997 part oup journals world wide web service copyright oxford university press 1997
0.30746758.9300660.html.plaintext.txt	41	page maintained oup admin last updated fri sep 12 180923 bst 1997 part oup journals world wide web service copyright oxford university press 1997
0.31976065.12765971.html.plaintext.txt	0	polymorphisms insulin degrading enzyme gene associated type 2 diabetes men nhlbi framingham heart study samer karamohamed1 serkalem demissie2 jeannine volcjak1 chunyu liu1 nancy heard costa1 jun liu1 christina m shoemaker1 carolien panhuysen3 james b meigs4 peter wilson3 larry d atwood12 l adrienne cupples2 alan herbert1
0.31976065.12765971.html.plaintext.txt	1	1 framingham heart study genetics laboratory department neurology boston university school medicine boston massachusetts 2 department biostatistics boston university school public health boston massachusetts 3 department medicine boston university school medicine boston massachusetts 4 general internal medicine clinical epidemiology units general medicine division department medicine massachusetts general hospital harvard medical school boston massachusetts
0.31976065.12765971.html.plaintext.txt	2	abstract top abstract introduction research design methods references linkage studies mapped susceptibility gene type 2 diabetes long arm chromosome 10 previously identified quantitative trait locus affects fasting blood glucose within framingham heart study cohort one candidate gene region insulin degrading enzyme ide gk rat model associated nonobese type 2 diabetes single nucleotide polymorphisms snps used map haplotype block 3 end ide revealed association hba1c fasting plasma glucose fpg mean fasting plasma glucose mfpg measured 20 years strongest associations found sample unrelated men lowest trait values associated haplotype tt f032 containing minor allele rs2209772 major allele rs1887922 snp fpg p 0001 mfpg p 0003 hba1c p 0025 another haplotype cc f016 associated elevated hba1c p 0002 type 2 diabetes p 0001 odds ratio 196 95 ci 128 300 evidence presented supports possibility ide susceptibility gene diabetes populations european descent
0.31976065.12765971.html.plaintext.txt	3	abstract top abstract introduction research design methods references linkage studies mapped susceptibility gene type 2 diabetes long arm chromosome 10 previously identified quantitative trait locus affects fasting blood glucose within framingham heart study cohort one candidate gene region insulin degrading enzyme ide gk rat model associated nonobese type 2 diabetes single nucleotide polymorphisms snps used map haplotype block 3 end ide revealed association hba1c fasting plasma glucose fpg mean fasting plasma glucose mfpg measured 20 years strongest associations found sample unrelated men lowest trait values associated haplotype tt f032 containing minor allele rs2209772 major allele rs1887922 snp fpg p 0001 mfpg p 0003 hba1c p 0025 another haplotype cc f016 associated elevated hba1c p 0002 type 2 diabetes p 0001 odds ratio 196 95 ci 128 300 evidence presented supports possibility ide susceptibility gene diabetes populations european descent
0.31976065.12765971.html.plaintext.txt	4	introduction top abstract introduction research design methods references previous studies identified linkage chromosome 10q23 q25 fasting plasma glucose fpg 1 mean fasting plasma glucose mfpg levels measured 20 years 1 hba1c 1 type 2 diabetes 2 ratio fasting insulin fasting glucose 3 apparent replication linkage different studies using populations mixed european descent made region attractive investigation
0.31976065.12765971.html.plaintext.txt	5	introduction top abstract introduction research design methods references previous studies identified linkage chromosome 10q23 q25 fasting plasma glucose fpg 1 mean fasting plasma glucose mfpg levels measured 20 years 1 hba1c 1 type 2 diabetes 2 ratio fasting insulin fasting glucose 3 apparent replication linkage different studies using populations mixed european descent made region attractive investigation
0.31976065.12765971.html.plaintext.txt	6	one candidate gene 10q23 q25 falls edge linkage peak 1 beneath reported groups 23 insulin degrading enzyme ide insulysin ec 342456 polymorphisms ide associated type 2 diabetes goto kakizaki gk rat model 4 ide degrade number peptides including insulin igf ii transforming growth factor atrial natriuretic peptide oxidatively damaged proteins 5
0.31976065.12765971.html.plaintext.txt	7	examine association ide variants fpg mfpg hba1c analyzed single nucleotide polymorphisms snps within near ide gene sample unrelated subjects set families framingham heart study fhs tables 1 2 6 snp positions minor allele frequencies fa november 2002 draft university california santa cruz genome browser given table 3 shown fig 1 assess completeness map linkage disequilibrium ld region evaluated using ldmap program based malecot model one ld unit ldu defined distance kilobases association two markers falls e 1 fig 1 7 flat line indicates complete ld markers defines haplotype block one haplotype block observed 5 end ide agreement previously published report 8 another 3 end fig 1 map thus gives reasonably complete view recombination history region sample
0.31976065.12765971.html.plaintext.txt	8	examine association ide variants fpg mfpg hba1c analyzed single nucleotide polymorphisms snps within near ide gene sample unrelated subjects set families framingham heart study fhs tables 1 2 6 snp positions minor allele frequencies fa november 2002 draft university california santa cruz genome browser given table 3 shown fig 1 assess completeness map linkage disequilibrium ld region evaluated using ldmap program based malecot model one ld unit ldu defined distance kilobases association two markers falls e 1 fig 1 7 flat line indicates complete ld markers defines haplotype block one haplotype block observed 5 end ide agreement previously published report 8 another 3 end fig 1 map thus gives reasonably complete view recombination history region sample
0.31976065.12765971.html.plaintext.txt	9	view table table 1 descriptive statistics 1780 unrelated individuals sex
0.31976065.12765971.html.plaintext.txt	10	view table table 2 descriptive statistics 182 families 1078 participants sex
0.31976065.12765971.html.plaintext.txt	11	view table table 3 marker positions chromosone 10 relative ide
0.31976065.12765971.html.plaintext.txt	12	view larger version 31k fig 1 physical map ld snp association ide locus region ld estimates made using program ldmap httpcedargeneticssotonacukpublichtml 7 one ldu corresponds distance association two markers reduced e 1 position ide shown direction transcription indicated arrow b snp map unrelated male subjects base location snp names given table 3 plotted negative logarithm p values given table 4 position ide shown direction transcription indicated arrow
0.31976065.12765971.html.plaintext.txt	13	examined association snps fpg n 1640 hba1c n 1311 unrelated subjects highly significant association observed rs1887922 genotypes fa 019 subjects hba1c levels p 00001 table 4 snp also associated fpg p 003 mfpg p 002 snp 3 ide gene rs2209972 fa 037 showed similar less significant pattern association levels fpg p 003 hba1c p 0005 markers placed 5 ide gene revealed significant association
0.31976065.12765971.html.plaintext.txt	14	examined association snps fpg n 1640 hba1c n 1311 unrelated subjects highly significant association observed rs1887922 genotypes fa 019 subjects hba1c levels p 00001 table 4 snp also associated fpg p 003 mfpg p 002 snp 3 ide gene rs2209972 fa 037 showed similar less significant pattern association levels fpg p 003 hba1c p 0005 markers placed 5 ide gene revealed significant association
0.31976065.12765971.html.plaintext.txt	15	view table table 4 global p values test association three genotypes snp traits unrelated subjects men women
0.31976065.12765971.html.plaintext.txt	16	stronger associations found rs1887922 sex specific analyses unrelated men pooled sample table 5 results shown fig 1 negative logarithms p values logp table 5 plotted snp positions table 3 significance association diminished slightly adjustment bmi results shown
0.31976065.12765971.html.plaintext.txt	17	view table table 5 global p values unrelated male subjects test association genotypes snp trait values
0.31976065.12765971.html.plaintext.txt	18	attempted replicate rs1887922 results different sample methodology testing family set using fbat 9 additive model borderline associations found rs1887922 levels fpg p 0085 hba1c p 0055 found significant associations rs2209972 family set might expected due weaker associations observed unrelated sample
0.31976065.12765971.html.plaintext.txt	19	attempted replicate rs1887922 results different sample methodology testing family set using fbat 9 additive model borderline associations found rs1887922 levels fpg p 0085 hba1c p 0055 found significant associations rs2209972 family set might expected due weaker associations observed unrelated sample
0.31976065.12765971.html.plaintext.txt	20	evaluate whether particular polymorphisms ide accounted linkage previously reported 1 3 adjusted linkage model rs1887922 polymorphism change either peak height peak position found results shown suggesting another gene present region accounts linkage signal
0.31976065.12765971.html.plaintext.txt	21	evaluate whether particular polymorphisms ide accounted linkage previously reported 1 3 adjusted linkage model rs1887922 polymorphism change either peak height peak position found results shown suggesting another gene present region accounts linkage signal
0.31976065.12765971.html.plaintext.txt	22	tested whether common polymorphisms associated type 2 diabetes unrelated subjects considered rs1887922 snp revealed borderline association type 2 diabetes p 0079 table 2 sex specific analyses men conducted table 5 significant association type 2 diabetes seen p 0022
0.31976065.12765971.html.plaintext.txt	23	tested whether common polymorphisms associated type 2 diabetes unrelated subjects considered rs1887922 snp revealed borderline association type 2 diabetes p 0079 table 2 sex specific analyses men conducted table 5 significant association type 2 diabetes seen p 0022
0.31976065.12765971.html.plaintext.txt	24	also analyzed traits using haplotypes based snps rs2209972 minor allele rs1887922 minor allele c within sample unrelated men statistical significance directionality association traits haplotypes indicated z scores presented fig 2a 10 tt haplotype associated lower trait levels cc haplotype associated higher levels estimated regression coefficients trait presented fig 2b reveal consistent trend lower trait values traits associated tt haplotype higher values cc haplotype
0.31976065.12765971.html.plaintext.txt	25	also analyzed traits using haplotypes based snps rs2209972 minor allele rs1887922 minor allele c within sample unrelated men statistical significance directionality association traits haplotypes indicated z scores presented fig 2a 10 tt haplotype associated lower trait levels cc haplotype associated higher levels estimated regression coefficients trait presented fig 2b reveal consistent trend lower trait values traits associated tt haplotype higher values cc haplotype
0.31976065.12765971.html.plaintext.txt	26	view larger version 37k fig 2 two four locus haplotype analysis sample unrelated men haplotypes constructed using rs2207992 rs1887922 association traits fpg n 822 mfpg n 876 hba1c n 626 determined empirically permutation using haploscore 10 global haplotype specific p values given test values significant p 005 bold b regression coefficient estimates ss quantitative traits odds ratio estimates qualitative traits measure association particular haplotype trait 10 values derived using inferred haplotype probabilities individual predictors values significant p 005 bold c haplotypes based four locus model hba1c values global p 0002 output score haploscore 10 shown lower associations observed snps rs967878 rs884526 analyzed individually explained presence major allele haplotypes high low trait values thus diminishing contrast minor allele trait values
0.31976065.12765971.html.plaintext.txt	27	adding snps rs967878 minor allele rs884526 minor allele improve model revealed haplotype tatt f30 associated lowest trait values haplotype ccgc f16 associated highest trait values fig 2c consistent two locus analysis lower associations observed snps rs967878 rs884526 analyzed individually may explained presence major allele haplotypes high low trait values thus diminishing contrasts minor allele trait values fig 2c haplotype analysis performed families due problems obtaining estimated haplotypes presence ld 11
0.31976065.12765971.html.plaintext.txt	28	adding snps rs967878 minor allele rs884526 minor allele improve model revealed haplotype tatt f30 associated lowest trait values haplotype ccgc f16 associated highest trait values fig 2c consistent two locus analysis lower associations observed snps rs967878 rs884526 analyzed individually may explained presence major allele haplotypes high low trait values thus diminishing contrasts minor allele trait values fig 2c haplotype analysis performed families due problems obtaining estimated haplotypes presence ld 11
0.31976065.12765971.html.plaintext.txt	29	also tested association two locus haplotypes type 2 diabetes global model significant whole sample tested contrast global models sex specific analyses men significant indicated cc haplotype associated increased risk type 2 diabetes p 0001 global simulated p value model 0014 odds ratio type 2 diabetes cc haplotype relative tt haplotype 196 95 ci 13 30
0.31976065.12765971.html.plaintext.txt	30	also tested association two locus haplotypes type 2 diabetes global model significant whole sample tested contrast global models sex specific analyses men significant indicated cc haplotype associated increased risk type 2 diabetes p 0001 global simulated p value model 0014 odds ratio type 2 diabetes cc haplotype relative tt haplotype 196 95 ci 13 30
0.31976065.12765971.html.plaintext.txt	31	evaluate whether subjects type 2 diabetes prediabetes accounted sex specific associations observed men met criterion impaired plasma glucose ipg excluded analysis significant global associations rs1887922 snp glycemic trait levels still seen subsidiary male dataset fpg p 0006 hba1c p 0004 mfpg similarly haplotype tt associated low trait values hba1c p 0009 global p model 0023 cc haplotype high trait values hba1c p 0003 results indicate role ide locus normal glucose homeostasis
0.31976065.12765971.html.plaintext.txt	32	evaluate whether subjects type 2 diabetes prediabetes accounted sex specific associations observed men met criterion impaired plasma glucose ipg excluded analysis significant global associations rs1887922 snp glycemic trait levels still seen subsidiary male dataset fpg p 0006 hba1c p 0004 mfpg similarly haplotype tt associated low trait values hba1c p 0009 global p model 0023 cc haplotype high trait values hba1c p 0003 results indicate role ide locus normal glucose homeostasis
0.31976065.12765971.html.plaintext.txt	33	thus present evidence association polymorphic markers ide gene 10q23 q25 levels fpg mfpg hba1c type 2 diabetes effect rs1887922 rs2209972 trait levels individual snps pronounced men may partly due increased number men ipg unrelated set compared women however associations still statistically significant following exclusion men ipg analysis men suggesting explanation male specific susceptibility reported two murine models type 2 diabetes associated obesity 1213 one model based crosses nonlt obese nzohi mice number susceptibility genes determine threshold type 2 diabetes mapped none lie y chromosome 12 android obesity previously described major risk factor type 2 diabetes 14 although associations reported persist adjustment bmi
0.31976065.12765971.html.plaintext.txt	34	thus present evidence association polymorphic markers ide gene 10q23 q25 levels fpg mfpg hba1c type 2 diabetes effect rs1887922 rs2209972 trait levels individual snps pronounced men may partly due increased number men ipg unrelated set compared women however associations still statistically significant following exclusion men ipg analysis men suggesting explanation male specific susceptibility reported two murine models type 2 diabetes associated obesity 1213 one model based crosses nonlt obese nzohi mice number susceptibility genes determine threshold type 2 diabetes mapped none lie y chromosome 12 android obesity previously described major risk factor type 2 diabetes 14 although associations reported persist adjustment bmi
0.31976065.12765971.html.plaintext.txt	35	tt haplotype representing minor allele rs2209972 major allele rs1887992 associated lowered trait values suggesting encodes ide variant reduced activity increases efficiency insulin signaling less insulin would therefore needed reduce blood glucose levels contrast cc haplotype ide variant may diminish insulin action leading higher trait values type 2 diabetes
0.31976065.12765971.html.plaintext.txt	36	tt haplotype representing minor allele rs2209972 major allele rs1887992 associated lowered trait values suggesting encodes ide variant reduced activity increases efficiency insulin signaling less insulin would therefore needed reduce blood glucose levels contrast cc haplotype ide variant may diminish insulin action leading higher trait values type 2 diabetes
0.31976065.12765971.html.plaintext.txt	37	associations hba1c fpg map 3 region ide unlikely involve protease domain enzyme lies 5 end gene 5 similarly mutations ide gk rat model type 2 diabetes affect protease activity 4 number alternative molecular mechanisms provide plausible explanations delayed diminished action ide example change 3 untranslated region ide may affect stability translation message altering levels ide protein produced alternatively coding polymorphisms carboxyl terminal region protein may modify cellular localization homodimerization 15 interaction protein partners
0.31976065.12765971.html.plaintext.txt	38	associations hba1c fpg map 3 region ide unlikely involve protease domain enzyme lies 5 end gene 5 similarly mutations ide gk rat model type 2 diabetes affect protease activity 4 number alternative molecular mechanisms provide plausible explanations delayed diminished action ide example change 3 untranslated region ide may affect stability translation message altering levels ide protein produced alternatively coding polymorphisms carboxyl terminal region protein may modify cellular localization homodimerization 15 interaction protein partners
0.31976065.12765971.html.plaintext.txt	39	genes 10q23 q25 appear contribute linkage region reported previously others us glycemic traits 1 3 signal fpg diminished adjustment rs1887922 snp association studies may efficient linkage studies identifying genetic determinants complex traits allele frequency relatively high effect small 16 finding consistent associations see ide cc haplotype f16 twice likely associated type 2 diabetes tt haplotype typing additional snps necessary identify gene variants 10q23 25 affect glucose homeostasis
0.31976065.12765971.html.plaintext.txt	40	genes 10q23 q25 appear contribute linkage region reported previously others us glycemic traits 1 3 signal fpg diminished adjustment rs1887922 snp association studies may efficient linkage studies identifying genetic determinants complex traits allele frequency relatively high effect small 16 finding consistent associations see ide cc haplotype f16 twice likely associated type 2 diabetes tt haplotype typing additional snps necessary identify gene variants 10q23 25 affect glucose homeostasis
0.31976065.12765971.html.plaintext.txt	41	proposed typing one snp per haplotype block sufficient genome wide association studies 1718 show two snps rs1887922 rs884526 haplotype block vary association trait values due different haplotypes minor allele found typing one snp per haplotype block may sufficient cases reliably detect exclude associations candidate loci complex diseases
0.31976065.12765971.html.plaintext.txt	42	proposed typing one snp per haplotype block sufficient genome wide association studies 1718 show two snps rs1887922 rs884526 haplotype block vary association trait values due different haplotypes minor allele found typing one snp per haplotype block may sufficient cases reliably detect exclude associations candidate loci complex diseases
0.31976065.12765971.html.plaintext.txt	43	research design methods top abstract introduction research design methods references subjects used subjects two samples 1 group unrelated subjects framingham offspring cohort recruited early 1970s 2 subgroup 182 families coming largest 330 pedigrees fhs latter group contains majority included genome scan results reported meigs et al 1 descriptive statistics presented tables 1 2 study approved boston university irb written informed consent obtained subject
0.31976065.12765971.html.plaintext.txt	44	research design methods top abstract introduction research design methods references subjects used subjects two samples 1 group unrelated subjects framingham offspring cohort recruited early 1970s 2 subgroup 182 families coming largest 330 pedigrees fhs latter group contains majority included genome scan results reported meigs et al 1 descriptive statistics presented tables 1 2 study approved boston university irb written informed consent obtained subject
0.31976065.12765971.html.plaintext.txt	45	traits trait measurements previously described 1 sample unrelated subjects fpg measured exam cycle 5 available 1640 offspring participants mfpg average fpg value 1739 offspring three measures fpg five exams spanned 20 years hba1c determined 1311 individuals exam 5 family set fpg available 837 individuals mfpg 951 individuals hba1c 528 individuals diabetes status type 2 diabetes defined either hypoglycemic medication two fpg levels 7 mmoll 125 mgdl time exams 1 6 using criterion 148 men unrelated sample 11 women classified diabetic subjects tables 1 2 less stringent criterion ipg defined fpg 61 mmoll 110 mgdl 2 h postchallenge plasma glucose 78 mmoll 140 mgdl anyone treated type 2 diabetes questionnaire used collect information alcohol cigarette consumption hormone therapy physical activity index calculated weighted average hours spent various activity levels 19
0.31976065.12765971.html.plaintext.txt	46	genotyping snps scored sequenom maldi tof mass spectrometer 20
0.31976065.12765971.html.plaintext.txt	47	statistical analysis standardized residuals calculated using linear regression models incorporated age age squared age cubed sex smoking physical activity bmi alcohol consumption covariates separate regression models used men women residuals models ranked normalized 1 transformation diminished slightly significance results reported sample unrelated subjects associations traits genotypes snp evaluated using regression models additionally association haplotypes tested using haploscore 10 haplotype effects estimated using regression logistic procedures sas haplotype effects estimated two stage procedure first individual haplotypes inferred em algorithm using snphap d clayton httpwww genecimrcamacukclaytonsoftware inferred haplotype probabilities used predictors regression models effect measures analyses compare haplotype haplotypes global significance haplotype phenotype associations determined using empirical p values 1000 permutations obtained haploscore 10 related individuals family based empirical test association implemented program fbat used additive model 9
0.31976065.12765971.html.plaintext.txt	48	acknowledgments fhs supported subcontract national heart lung blood institute nhlbi national institutes health nih dr p wolf principal investigator nihnhlbi contracts no1 hc 38083 nihnhlbi n01 hc 25195 study also supported part grant american diabetes association ada dr herbert principal investigator jbm supported ada career development award
0.31976065.12765971.html.plaintext.txt	49	thank staff fhs genetics laboratory work performed support study dr christopher o donnell careful reading manuscript earlier version manuscript reviewed dr mark mccarthy thank providing preprint manuscript diabetes 2003 press ide polymorphisms uk study
0.31976065.12765971.html.plaintext.txt	50	thank staff fhs genetics laboratory work performed support study dr christopher o donnell careful reading manuscript earlier version manuscript reviewed dr mark mccarthy thank providing preprint manuscript diabetes 2003 press ide polymorphisms uk study
0.31976065.12765971.html.plaintext.txt	51	footnotes address correspondence reprint requests alan herbert framingham heart study genetics laboratory department neurology boston university school medicine 715 albany st boston ma 02118 e mail aherbertatbuedu u d
0.31976065.12765971.html.plaintext.txt	52	received publication 1 october 2002 accepted revised form 18 february 2003
0.31976065.12765971.html.plaintext.txt	53	fhs framingham heart study fpg fasting plasma glucose ide insulin degrading enzyme ipg impaired plasma glucose ld linkage disequilibrium ldu ld unit mfpg mean fpg snp single nucleotide polymorphism
0.31976065.12765971.html.plaintext.txt	54	references top abstract introduction research design methods references meigs jb panhuysen ci myers rh wilson pw cupples la genome wide scan loci linked plasma levels glucose hba1c community based sample caucasian pedigrees framingham offspring study diabetes51 833 402002abstractfree full text wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n rao pv wishart m bottazzo gf foxon r howell smedley d cardon lr menzel mccarthy mi genomewide scan loci predisposing type 2 diabetes uk population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1q j hum genet69 553 5692001medline ghosh watanabe rm valle tt hauser er magnuson vl langefeld cd ally ds mohlke kl silander k kohtamaki k chines p balow jr j birznieks g chang j eldridge w erdos mr karanjawala ze knapp ji kudelko k martin c morales mena musick musick pfahl c porter r rayman jb finland united states investigation non insulin dependent diabetes mellitus genetics fusion study autosomal genome scan genes predispose type 2 diabetes j hum genet67 1174 11852000medline fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk rats hum mol genet9 2149 21582000abstractfree full text duckworth wc bennett rg hamel fg insulin degradation progress potential endocr rev19 608 6241998abstractfree full text kannel wb feinleib m mcnamara pm garrison rj castelli wp investigation coronary heart disease families framingham offspring study j epidemiol110 281 2901979abstract maniatis n collins xu cf mccarthy lc hewett dr tapper w ennis ke x morton ne first linkage disequilibrium ld maps delineation hot cold blocks diplotype analysis proc natl acad sci u a99 2228 22332002abstractfree full text abraham r myers wavrant devrieze f hamshere ml thomas hv marshall h compton d spurlock g turic d hoogendoorn b kwon jm petersen rc tangalos e norton j morris jc bullock r liolitsa d lovestone hardy j goate o donovan m williams j owen mj jones l substantial linkage disequilibrium across insulin degrading enzyme locus association late onset alzheimer disease hum genet109 646 6522001medline horvath xu x laird nm family based association test method strategies studying general genotype phenotype associations eur j hum genet9 301 3062001medline schaid dj rowland cm tines de jacobson rm poland ga score tests association traits haplotypes linkage phase ambiguous j hum genet70 425 4342002medline schaid dj mcdonnell sk wang l cunningham jm thibodeau sn caution pedigree haplotype inference software assumes linkage equilibrium j hum genet71 992 9952002medline leiter eh reifsnyder pc flurkey k partke hj junger e herberg l niddm genes mice deleterious synergism parental genomes contributes diabetogenic thresholds diabetes47 1287 12951998abstract leiter eh kintner j flurkey k beamer wg naggert jk physiologic endocrinologic characterization male sex biased diabetes c57blksj mice congenic fat mutation carboxypeptidease e locus endocrine10 57 661999medline wajchenberg bl subcutaneous visceral adipose tissue relation metabolic syndrome endocr rev21 697 7382000abstractfree full text chesneau v rosner mr functional human insulin degrading enzyme expressed bacteria protein expr purif19 91 982000medline ardlie kg kruglyak l seielstad m patterns linkage disequilibrium human genome nat rev genet3 299 3092002medline gabriel sb schaffner sf nguyen h moore jm roy j blumenstiel b higgins j defelice m lochner faggart m liu cordero sn rotimi c adeyemo cooper r ward r lander es daly mj altshuler d structure haplotype blocks human genome science296 2225 22292002abstractfree full text risch n merikangas k future genetic studies complex human diseases letter science273 1516 15171996medline kannel wb sorlie p health benefits physical activity framingham study arch intern med139 857 8611979medline buetow kh edmonson m macdonald r clifford r yip p kelley j little dp strausberg r koester h cantor cr braun high throughput development characterization genomewide collection gene based single nucleotide polymorphism markers chip based matrix assisted laser desorptionionization time flight mass spectrometry proc natl acad sci u a98 581 5842001abstractfree full text
0.32454574.11823323.html.plaintext.txt	0	new drugs alzheimers disease dementias roger bullock mrcpsych
0.32454574.11823323.html.plaintext.txt	1	department old age psychiatry kingshill research centre avon wiltshire mental health trust victoria hospital swindon sni 4hz uk tel 44 01 793 437501 fax 44 01 793 437521
0.32454574.11823323.html.plaintext.txt	2	department old age psychiatry kingshill research centre avon wiltshire mental health trust victoria hospital swindon sni 4hz uk tel 44 01 793 437501 fax 44 01 793 437521
0.32454574.11823323.html.plaintext.txt	3	background alzheimers disease management involves symptomatic drug treatments passed national institute clinical excellence disease modification goal
0.32454574.11823323.html.plaintext.txt	4	background alzheimers disease management involves symptomatic drug treatments passed national institute clinical excellence disease modification goal
0.32454574.11823323.html.plaintext.txt	5	aims review current developmental drugs alzheimers disease usage clinical context known facts proposed specific models
0.32454574.11823323.html.plaintext.txt	6	method brief evidence based review made using literature available evidence consensus groups absent
0.32454574.11823323.html.plaintext.txt	7	results good evidence support use cholinesterase inhibitors perhaps vitamin e oestrogen anti inflammatory agents show possibility enough evidence support routine use
0.32454574.11823323.html.plaintext.txt	8	results good evidence support use cholinesterase inhibitors perhaps vitamin e oestrogen anti inflammatory agents show possibility enough evidence support routine use
0.32454574.11823323.html.plaintext.txt	9	conclusions symptomatic treatments exist alzheimers disease observational studies increasing knowledge brain biology leading towards treatment options old age psychiatrists valuable treatments learn use
0.32454574.11823323.html.plaintext.txt	10	conclusions symptomatic treatments exist alzheimers disease observational studies increasing knowledge brain biology leading towards treatment options old age psychiatrists valuable treatments learn use
0.32454574.11823323.html.plaintext.txt	11	cholinergic hypothesis alzheimers disease davies maloney 1976 led development number strategies enhance failing cholinergic neurons thus neurotransmitter acetylcholine consistent therapeutic effect seen using inhibitors enzyme acetylcholinesterase cleaves transmitter cholinergic synapse three compounds licensed treatment alzheimers disease donepezil rivastigmine galantamine increased awareness alzheimers disease unfortunately cost pressures hindered development uk even though experienced users donepezil rivastigmine found consistent results cameron et al 2000 evans et al 2000 matthews et al 2000 acetylcholinesterase inhibitors acheis considered stepping stone better disease modifying compounds bullock 1998 although undoubtedly class drug yet reached clinic acheis remain main treatment option time variety protocols treatment harvey 1999 superseded uk national institute clinical excellence 2001 guidelines use three drugs
0.32454574.11823323.html.plaintext.txt	12	cholinergic hypothesis alzheimers disease davies maloney 1976 led development number strategies enhance failing cholinergic neurons thus neurotransmitter acetylcholine consistent therapeutic effect seen using inhibitors enzyme acetylcholinesterase cleaves transmitter cholinergic synapse three compounds licensed treatment alzheimers disease donepezil rivastigmine galantamine increased awareness alzheimers disease unfortunately cost pressures hindered development uk even though experienced users donepezil rivastigmine found consistent results cameron et al 2000 evans et al 2000 matthews et al 2000 acetylcholinesterase inhibitors acheis considered stepping stone better disease modifying compounds bullock 1998 although undoubtedly class drug yet reached clinic acheis remain main treatment option time variety protocols treatment harvey 1999 superseded uk national institute clinical excellence 2001 guidelines use three drugs
0.32454574.11823323.html.plaintext.txt	13	practical dilemmas use acetylcholinesterase inhibitors
0.32454574.11823323.html.plaintext.txt	14	achei class drugs affect measured domains dementia much way consistency effect evident fig 1 shows cognition scores averaged pivotal trials three licensed compounds symptomatic response lasting approximately 8 months followed decline remains significantly placebo group longer periods supports preclinical cholinergic hypotheses davies maloney 1976 exciting symptomatic treatment end complex disease process analogous use levodopa parkinsons disease achei class continues present practical scientific challenges clinicians need resolved meanwhile different treatments continue development
0.32454574.11823323.html.plaintext.txt	15	achei class drugs affect measured domains dementia much way consistency effect evident fig 1 shows cognition scores averaged pivotal trials three licensed compounds symptomatic response lasting approximately 8 months followed decline remains significantly placebo group longer periods supports preclinical cholinergic hypotheses davies maloney 1976 exciting symptomatic treatment end complex disease process analogous use levodopa parkinsons disease achei class continues present practical scientific challenges clinicians need resolved meanwhile different treatments continue development
0.32454574.11823323.html.plaintext.txt	16	view larger version 18k fig 1 combined clinical trial data three licensed acetylcholinesterase inhibitors rivastigmine donepezil galantamine versus placebo graph shows change cognition scores patients assessed 6 week intervals positive change improvement adas cog alzheimers disease assessment scale cognitive section
0.32454574.11823323.html.plaintext.txt	17	view larger version 18k fig 1 combined clinical trial data three licensed acetylcholinesterase inhibitors rivastigmine donepezil galantamine versus placebo graph shows change cognition scores patients assessed 6 week intervals positive change improvement adas cog alzheimers disease assessment scale cognitive section
0.32454574.11823323.html.plaintext.txt	18	trials acheis response measured scales used found average 40 patients studied corey bloom et al 1998 rogers et al 1998 raskind et al 2000 compares favourably drugs chronic illness acheis low numbers needed treat nnts livingston katona 2000 using scores published data donepezil nnt 4 rivastigmine 7 galantamine 3 high placebo response often questioned common mental health studies masks large non drug treatment effect responders non responders identified criteria may harsh nature response needs research definition currently hard predictor response non response identified schneider farlow 1995 apoe4 allele suggested marker poor response subsequent studies suggested correlation
0.32454574.11823323.html.plaintext.txt	19	trials acheis response measured scales used found average 40 patients studied corey bloom et al 1998 rogers et al 1998 raskind et al 2000 compares favourably drugs chronic illness acheis low numbers needed treat nnts livingston katona 2000 using scores published data donepezil nnt 4 rivastigmine 7 galantamine 3 high placebo response often questioned common mental health studies masks large non drug treatment effect responders non responders identified criteria may harsh nature response needs research definition currently hard predictor response non response identified schneider farlow 1995 apoe4 allele suggested marker poor response subsequent studies suggested correlation
0.32454574.11823323.html.plaintext.txt	20	absence valid biological markers alzheimers disease measuring effect intervention may disease requires patients treated reasonable length time perhaps 6 months reality depends economics uk prescribers tend work subsets mild moderate dementia excluding institutional patients advanced disease prescribing community based patients medication supervised ratified nice guidelines
0.32454574.11823323.html.plaintext.txt	21	absence valid biological markers alzheimers disease measuring effect intervention may disease requires patients treated reasonable length time perhaps 6 months reality depends economics uk prescribers tend work subsets mild moderate dementia excluding institutional patients advanced disease prescribing community based patients medication supervised ratified nice guidelines
0.32454574.11823323.html.plaintext.txt	22	various models prescribing exist involving titration dose minimise side effects particularly gastrointestinal ones donepezil advantage two dose steps rivastigmine galantamine offer wider range making tailoring individual patients perhaps precise whichever drug chosen dose taken maximum tolerated within licence least 3 months treatment given considering whether inadequate response rigidity may mean late responders miss potential benefit within limited budget allow patients exposure treatment
0.32454574.11823323.html.plaintext.txt	23	various models prescribing exist involving titration dose minimise side effects particularly gastrointestinal ones donepezil advantage two dose steps rivastigmine galantamine offer wider range making tailoring individual patients perhaps precise whichever drug chosen dose taken maximum tolerated within licence least 3 months treatment given considering whether inadequate response rigidity may mean late responders miss potential benefit within limited budget allow patients exposure treatment
0.32454574.11823323.html.plaintext.txt	24	one drug work intolerable side effects another tried although three drugs belong class different published information switching drugs convention switching drugs leave interval five times half life first drug commencing second 60 hours rivastigmine 15 days donepezil consensus suggests 3 days left treatment rivastigmine galantamine week left following donepezil treatment based clinical practice controlled trial published
0.32454574.11823323.html.plaintext.txt	25	one drug work intolerable side effects another tried although three drugs belong class different published information switching drugs convention switching drugs leave interval five times half life first drug commencing second 60 hours rivastigmine 15 days donepezil consensus suggests 3 days left treatment rivastigmine galantamine week left following donepezil treatment based clinical practice controlled trial published
0.32454574.11823323.html.plaintext.txt	26	three drugs similar yet different individual characteristics table 1 clinically relevant differences unproven interesting hypotheses arising
0.32454574.11823323.html.plaintext.txt	27	three drugs similar yet different individual characteristics table 1 clinically relevant differences unproven interesting hypotheses arising
0.32454574.11823323.html.plaintext.txt	28	view table table 1 attributes three licensed acetylcholinesterase inhibitors
0.32454574.11823323.html.plaintext.txt	29	donepezil donepezil selective acetylcholinesterase ache selectivity claimed reduce side effect profile published clinical data shown increased tolerability paradoxically alzheimers disease level ache falls disease progresses arendt 1992 matched rise butyrylcholinesterase buche function unknown forms part plaques appears come activated glial cells buche inhibition means unclear rivastigmine galantamine inhibit donepezil may work differently later disease although published evidence supported
0.32454574.11823323.html.plaintext.txt	30	donepezil donepezil selective acetylcholinesterase ache selectivity claimed reduce side effect profile published clinical data shown increased tolerability paradoxically alzheimers disease level ache falls disease progresses arendt 1992 matched rise butyrylcholinesterase buche function unknown forms part plaques appears come activated glial cells buche inhibition means unclear rivastigmine galantamine inhibit donepezil may work differently later disease although published evidence supported
0.32454574.11823323.html.plaintext.txt	31	rivastigmine rivastigmine preferentially inhibits one four ache subtypes g1 found particularly hypothalamus cortex subtype implicated plaque maturation whether added clinical benefit specificity unproven
0.32454574.11823323.html.plaintext.txt	32	rivastigmine rivastigmine preferentially inhibits one four ache subtypes g1 found particularly hypothalamus cortex subtype implicated plaque maturation whether added clinical benefit specificity unproven
0.32454574.11823323.html.plaintext.txt	33	galantamine galantamine produces effect presynaptic nicotinic receptors called allosteric modulation physostigmine codeine produces increased amounts acetylcholine synapse direct effect presynaptic release clinical impact unknown published evidence significance desirability required may modulation rather agonism protects downregulation post synaptic receptors may allow drug work longer studies needed confirm modulation also improves attention demonstrated galantamine donepezil rivastigmine alzheimers disease
0.32454574.11823323.html.plaintext.txt	34	galantamine galantamine produces effect presynaptic nicotinic receptors called allosteric modulation physostigmine codeine produces increased amounts acetylcholine synapse direct effect presynaptic release clinical impact unknown published evidence significance desirability required may modulation rather agonism protects downregulation post synaptic receptors may allow drug work longer studies needed confirm modulation also improves attention demonstrated galantamine donepezil rivastigmine alzheimers disease
0.32454574.11823323.html.plaintext.txt	35	drugs licensed mild moderate alzheimers disease patients mild disease already significant illness receive treatment even minimal symptoms treating mildly affected patients mean smaller responses protocols reflect long term follow needed show continuing effect beyond expected clinical trials moderate disease covers wide range morbidity trials mini mental state examination mmse folstein et al 1975 score 10 nice guidelines 12 patients scoring lower end range host symptoms acheis may valuable symptomatic effects behaviour effect underlying disease trial data metrifonate another achei withdrawn side effects showed improvement neuropsychiatric symptoms alzheimers disease especially apathy hallucinations agitation cummings et al 1998 effect noticeable dementia lewy bodies improvements mmse scores neuropsychiatric symptoms demonstrated rivastigmine mckeith et al 2000 suggests dementia treated time symptomatic delay retention qualify life aim early disease moving towards symptomatic relief progression occurs published results available severe dementia though open label follow trials suggests drugs continue working cholinergic deficit increases
0.32454574.11823323.html.plaintext.txt	36	drugs licensed mild moderate alzheimers disease patients mild disease already significant illness receive treatment even minimal symptoms treating mildly affected patients mean smaller responses protocols reflect long term follow needed show continuing effect beyond expected clinical trials moderate disease covers wide range morbidity trials mini mental state examination mmse folstein et al 1975 score 10 nice guidelines 12 patients scoring lower end range host symptoms acheis may valuable symptomatic effects behaviour effect underlying disease trial data metrifonate another achei withdrawn side effects showed improvement neuropsychiatric symptoms alzheimers disease especially apathy hallucinations agitation cummings et al 1998 effect noticeable dementia lewy bodies improvements mmse scores neuropsychiatric symptoms demonstrated rivastigmine mckeith et al 2000 suggests dementia treated time symptomatic delay retention qualify life aim early disease moving towards symptomatic relief progression occurs published results available severe dementia though open label follow trials suggests drugs continue working cholinergic deficit increases
0.32454574.11823323.html.plaintext.txt	37	acheis dementias plus cholinergic therapies clinical trials ongoing acheis vascular dementia mixed dementia result available yet cholinergic system implicated disorders hoped findings positive study rivastigmine dementia lewy bodies produced positive results mckeith et al 2000 acetylcholinesterases studied potential treatment mild cognitive impairment rational assumption 55 patients problem go develop alzheimers disease intervention may profound effect burden disease overall study anticholinergic therapy frontotemporal dementia way present
0.32454574.11823323.html.plaintext.txt	38	acheis dementias plus cholinergic therapies clinical trials ongoing acheis vascular dementia mixed dementia result available yet cholinergic system implicated disorders hoped findings positive study rivastigmine dementia lewy bodies produced positive results mckeith et al 2000 acetylcholinesterases studied potential treatment mild cognitive impairment rational assumption 55 patients problem go develop alzheimers disease intervention may profound effect burden disease overall study anticholinergic therapy frontotemporal dementia way present
0.32454574.11823323.html.plaintext.txt	39	muscarinic agonists tried alzheimers disease drugs narrow therapeutic window side effects become intolerable date clinical trial shown significant effects cognition nicotinic drugs also still early trial stages similar tolerability problems overcome promising efficacy data
0.32454574.11823323.html.plaintext.txt	40	muscarinic agonists tried alzheimers disease drugs narrow therapeutic window side effects become intolerable date clinical trial shown significant effects cognition nicotinic drugs also still early trial stages similar tolerability problems overcome promising efficacy data
0.32454574.11823323.html.plaintext.txt	41	research alzheimers disease led understanding pathological mechanisms involved inflammation occurs evidenced inflammatory markers found example complement attack complex levels similar found ischaemic heart disease mcgeer mcgeer 1998 basic science coupled observation sufferers rheumatoid arthritis lower rate alzheimers disease stewart et al 1997 led trials anti inflammatory drugs treatment alzheimers disease trials prednisolone successful ongoing work cyclo oxygenase inhibitors especially cox 2 animal human clinical trials may show benefit drugs without long term side effects current practice recommend use routinely
0.32454574.11823323.html.plaintext.txt	42	research alzheimers disease led understanding pathological mechanisms involved inflammation occurs evidenced inflammatory markers found example complement attack complex levels similar found ischaemic heart disease mcgeer mcgeer 1998 basic science coupled observation sufferers rheumatoid arthritis lower rate alzheimers disease stewart et al 1997 led trials anti inflammatory drugs treatment alzheimers disease trials prednisolone successful ongoing work cyclo oxygenase inhibitors especially cox 2 animal human clinical trials may show benefit drugs without long term side effects current practice recommend use routinely
0.32454574.11823323.html.plaintext.txt	43	another observational study shown women hormone replacement therapy hrt reduced rate alzheimers disease robinson et al 1994 protective effect oestrogen nervous system vasculature well documented birge 1997 clinical trials progress test efficacy oestrogen therapy 17 oestradiol particularly early treatment study results encouraging mulnard et al 2000 absence published positive studies hrt cannot recommended use treatment alzheimers disease although seem use increasing alzheimers disease prophylaxis particularly usa
0.32454574.11823323.html.plaintext.txt	44	another observational study shown women hormone replacement therapy hrt reduced rate alzheimers disease robinson et al 1994 protective effect oestrogen nervous system vasculature well documented birge 1997 clinical trials progress test efficacy oestrogen therapy 17 oestradiol particularly early treatment study results encouraging mulnard et al 2000 absence published positive studies hrt cannot recommended use treatment alzheimers disease although seem use increasing alzheimers disease prophylaxis particularly usa
0.32454574.11823323.html.plaintext.txt	45	antioxidants shown benefit several areas chronic ill health including alzheimers disease study selegiline vitamin e effect disease progression sano et al 1997 showed positive effect rate increasing dependency delayed institutionalisation however yet replicated vitamin e inexpensive relatively safe trial high dosage 2000 iu institutionalisation expensive return treatment potentially high rigorously proven many clinics routinely suggesting use vitamin e patients alzheimers disease usually 1000 iu possible may benefit dementias neurodegenerative disease well
0.32454574.11823323.html.plaintext.txt	46	antioxidants shown benefit several areas chronic ill health including alzheimers disease study selegiline vitamin e effect disease progression sano et al 1997 showed positive effect rate increasing dependency delayed institutionalisation however yet replicated vitamin e inexpensive relatively safe trial high dosage 2000 iu institutionalisation expensive return treatment potentially high rigorously proven many clinics routinely suggesting use vitamin e patients alzheimers disease usually 1000 iu possible may benefit dementias neurodegenerative disease well
0.32454574.11823323.html.plaintext.txt	47	nootropic drugs available prescription germany best known gingko biloba extract nicergoline piracetam precise modes action unclear yet seem produce effect well controlled studies
0.32454574.11823323.html.plaintext.txt	48	nootropic drugs available prescription germany best known gingko biloba extract nicergoline piracetam precise modes action unclear yet seem produce effect well controlled studies
0.32454574.11823323.html.plaintext.txt	49	glutamate increasingly implicated dementia pathogenesis n methyl d aspartate nmda blockade putative therapy memantine nmda blocker positive results reported severe alzheimers disease eg winblad poritis 1999 leading application regulatory approval use dementia
0.32454574.11823323.html.plaintext.txt	50	glutamate increasingly implicated dementia pathogenesis n methyl d aspartate nmda blockade putative therapy memantine nmda blocker positive results reported severe alzheimers disease eg winblad poritis 1999 leading application regulatory approval use dementia
0.32454574.11823323.html.plaintext.txt	51	nerve cell destruction seems secondary activation glial cells stabilisation glial cells may reduce rate alzheimers disease dementias several compounds propentofylline purportedly effect especially vitro date shown therapeutic effect clinically remains potential area research
0.32454574.11823323.html.plaintext.txt	52	nerve cell destruction seems secondary activation glial cells stabilisation glial cells may reduce rate alzheimers disease dementias several compounds propentofylline purportedly effect especially vitro date shown therapeutic effect clinically remains potential area research
0.32454574.11823323.html.plaintext.txt	53	cortical cholinergic system diffusely spread long way cell bodies therefore dependent nerve growth factor ngf sustain reduction ngf may associated alzheimers disease studies injecting ngf cannulae cerebrospinal fluid showed effect practical solution attempts formulate active portion ngf oral preparation crosses blood brain barrier ongoing meanwhile xanthine derivative leteprinim potassium seems stimulating effect ngf start clinical trial
0.32454574.11823323.html.plaintext.txt	54	cortical cholinergic system diffusely spread long way cell bodies therefore dependent nerve growth factor ngf sustain reduction ngf may associated alzheimers disease studies injecting ngf cannulae cerebrospinal fluid showed effect practical solution attempts formulate active portion ngf oral preparation crosses blood brain barrier ongoing meanwhile xanthine derivative leteprinim potassium seems stimulating effect ngf start clinical trial
0.32454574.11823323.html.plaintext.txt	55	pathological basis alzheimers disease presence amyloid plaques neurofibrillary tangles work focused amyloid cascade produces plaques various drugs development modify amyloid metabolism imminent clinical trial injection beta amyloid protein vaccinate individual produce antibody response might remove amyloid nervous tissue mice procedure relieved symptoms genetic alzheimers disease animal models schenk et al 1999 prevented plaque formation younger mice method tried humans uk usa represents first true attempt disease modification
0.32454574.11823323.html.plaintext.txt	56	pathological basis alzheimers disease presence amyloid plaques neurofibrillary tangles work focused amyloid cascade produces plaques various drugs development modify amyloid metabolism imminent clinical trial injection beta amyloid protein vaccinate individual produce antibody response might remove amyloid nervous tissue mice procedure relieved symptoms genetic alzheimers disease animal models schenk et al 1999 prevented plaque formation younger mice method tried humans uk usa represents first true attempt disease modification
0.32454574.11823323.html.plaintext.txt	57	classical pathological change development tangles made abnormal tau protein tau pathology known exist neurodegenerative conditions important area research treating dementing diseases frontotemporal dementia progressive supranuclear palsy hyperphosphorylation occurs alzheimers disease may amenable therapeutic intervention experimental models support drugs clinical trials yet
0.32454574.11823323.html.plaintext.txt	58	classical pathological change development tangles made abnormal tau protein tau pathology known exist neurodegenerative conditions important area research treating dementing diseases frontotemporal dementia progressive supranuclear palsy hyperphosphorylation occurs alzheimers disease may amenable therapeutic intervention experimental models support drugs clinical trials yet
0.32454574.11823323.html.plaintext.txt	59	basic science research gradually unlocking pathological sequences dementia especially alzheimers disease provide theoretical treatment opportunities began acheis stage amyloid modification first time therapeutic options exist alzheimers disease soon available dementias may simple using vitamin e combinations therapy maximise benefit table 2 although treatments still predominantly symptomatic offer relief patients increased clinicians awareness condition taken old age psychiatry roots social psychiatry point psychopharmacology important role challenge learn use treatments effectively means everyone speciality uses treatments opportunity contribute debate prospects development next 10 years make one exciting dynamic areas medicine work
0.32454574.11823323.html.plaintext.txt	60	basic science research gradually unlocking pathological sequences dementia especially alzheimers disease provide theoretical treatment opportunities began acheis stage amyloid modification first time therapeutic options exist alzheimers disease soon available dementias may simple using vitamin e combinations therapy maximise benefit table 2 although treatments still predominantly symptomatic offer relief patients increased clinicians awareness condition taken old age psychiatry roots social psychiatry point psychopharmacology important role challenge learn use treatments effectively means everyone speciality uses treatments opportunity contribute debate prospects development next 10 years make one exciting dynamic areas medicine work
0.32454574.11823323.html.plaintext.txt	61	view table table 2 current potential treatments dementia
0.32454574.11823323.html.plaintext.txt	62	clinical implications limitations
0.32454574.11823323.html.plaintext.txt	63	clinical implications anticholinesterase therapy major contribution therapeutic treatment regimen alzheimers disease endorsed national institute clinical excellence psychopharmacology alzheimers disease important addition old age psychiatrists skills professional development requirements services need move towards diagnosis early mild dementia rather intervene moderate severe stages
0.32454574.11823323.html.plaintext.txt	64	clinical implications anticholinesterase therapy major contribution therapeutic treatment regimen alzheimers disease endorsed national institute clinical excellence psychopharmacology alzheimers disease important addition old age psychiatrists skills professional development requirements services need move towards diagnosis early mild dementia rather intervene moderate severe stages
0.32454574.11823323.html.plaintext.txt	65	limitations funding new drugs may hard obtain especially areas basic service needs unmet require attention first symptomatic treatments need drugs change course illness single therapy likely solution alzheimers disease need learn best use cholinesterase inhibitors combine new drugs arrive initiated level primary care
0.32454574.11823323.html.plaintext.txt	66	limitations funding new drugs may hard obtain especially areas basic service needs unmet require attention first symptomatic treatments need drugs change course illness single therapy likely solution alzheimers disease need learn best use cholinesterase inhibitors combine new drugs arrive initiated level primary care
0.32454574.11823323.html.plaintext.txt	67	author thanks colleagues used drugs date participation various consensus groups order fill gaps review evidence remains weak
0.32454574.11823323.html.plaintext.txt	68	arendt 1992 changes acetylcholinesterase butyrylcholinesterase alzheimers disease resemble embryonic development study molecular forms neurochemistry international 21 381 396medline
0.32454574.11823323.html.plaintext.txt	69	bullock r 1998 drug treatment early alzheimers disease advances psychiatric treatment 4 126 134
0.32454574.11823323.html.plaintext.txt	70	national institute clinical excellence 2001 guidance use donepezil rivastigmine galantamine treatment alzheimers disease london nice
0.32454574.11823323.html.plaintext.txt	71	received publication april 20 2000 revision received may 29 2000 accepted publication june 8 2001
0.32454574.11823323.html.plaintext.txt	72	received publication april 20 2000 revision received may 29 2000 accepted publication june 8 2001
0.32454574.11823323.html.plaintext.txt	73	highlights issue elizabeth walsh bjp 2002 180 0 full text
0.32454574.11823323.html.plaintext.txt	74	old age psychiatry alistair burns ian g mckeith bjp 2002 180 97 98 full text
0.34450078.11823322.html.plaintext.txt	0	genotype phenotype alzheimers disease clive holmes mrcpsych
0.34450078.11823322.html.plaintext.txt	1	thornhill research unit university southampton moorgreen hospital botley road west end southampton so30 3jb uk
0.34450078.11823322.html.plaintext.txt	2	background patients alzheimers disease show wide variation clinical phenotype genetic research largely concerned role mutations common variants risk factors disease genetic factors also influence clinical phenotype
0.34450078.11823322.html.plaintext.txt	3	background patients alzheimers disease show wide variation clinical phenotype genetic research largely concerned role mutations common variants risk factors disease genetic factors also influence clinical phenotype
0.34450078.11823322.html.plaintext.txt	4	aims examine evidence genetic factors influence clinical expression disease addition influencing risk
0.34450078.11823322.html.plaintext.txt	5	method selective review made key literature
0.34450078.11823322.html.plaintext.txt	6	results mutations three genes coding amyloid precursor protein presenilin 1 presenilin 2 common variation 4 another gene apoe shown lead earlier development disease recently genetic association twin studies suggested role genetic factors development aspects clinical phenotype notably appearance non cognitive symptoms
0.34450078.11823322.html.plaintext.txt	7	results mutations three genes coding amyloid precursor protein presenilin 1 presenilin 2 common variation 4 another gene apoe shown lead earlier development disease recently genetic association twin studies suggested role genetic factors development aspects clinical phenotype notably appearance non cognitive symptoms
0.34450078.11823322.html.plaintext.txt	8	conclusions alzheimers disease genetic variation influences number aspects clinical phenotype
0.34450078.11823322.html.plaintext.txt	9	early family twin studies indicated number genes important part play development alzheimers disease variation genes including rare mutations common polymorphisms appears confer increased risk development disease however apparent increased risk may largely explained effects genetic variation clinical phenotype alzheimers disease particularly age disease presents recently proposed genetic variation may also explain features clinical phenotype including development non cognitive symptoms
0.34450078.11823322.html.plaintext.txt	10	early family twin studies indicated number genes important part play development alzheimers disease variation genes including rare mutations common polymorphisms appears confer increased risk development disease however apparent increased risk may largely explained effects genetic variation clinical phenotype alzheimers disease particularly age disease presents recently proposed genetic variation may also explain features clinical phenotype including development non cognitive symptoms
0.34450078.11823322.html.plaintext.txt	11	clearest evidence genetic contribution aetiology alzheimers disease existence families disease transmitted clear autosomal dominant pattern study one large pedigrees revealed transmission generation generation single point mutation gene amyloid precursor protein app found chromosome 21 family members developing early onset alzheimers disease studies families led discovery point mutations gene later presence mutations two genes encoding presenilin 1 ps 1 presenilin 2 ps 2 found chromosomes 14 1 respectively date 12 alzheimers disease related mutations discovered app gene 69 mutations ps 1 gene 5 mutations ps 2 gene significantly research suggests different mutations three genes lead common result increase ss a4 peptide fragment app forms core neuritic plaques found brains people alzheimers disease
0.34450078.11823322.html.plaintext.txt	12	clearest evidence genetic contribution aetiology alzheimers disease existence families disease transmitted clear autosomal dominant pattern study one large pedigrees revealed transmission generation generation single point mutation gene amyloid precursor protein app found chromosome 21 family members developing early onset alzheimers disease studies families led discovery point mutations gene later presence mutations two genes encoding presenilin 1 ps 1 presenilin 2 ps 2 found chromosomes 14 1 respectively date 12 alzheimers disease related mutations discovered app gene 69 mutations ps 1 gene 5 mutations ps 2 gene significantly research suggests different mutations three genes lead common result increase ss a4 peptide fragment app forms core neuritic plaques found brains people alzheimers disease
0.34450078.11823322.html.plaintext.txt	13	findings immense importance terms elucidating biological pathogenesis alzheimers diease important recognise three causal genes may account 30 50 autosomal dominant early onset cases around 10 familial early onset cases cruts et al 1998 thus given majority cases 95 alzheimers disease occurs age 60 years clear genetic mutations make small contribution risk developing disease general
0.34450078.11823322.html.plaintext.txt	14	findings immense importance terms elucidating biological pathogenesis alzheimers diease important recognise three causal genes may account 30 50 autosomal dominant early onset cases around 10 familial early onset cases cruts et al 1998 thus given majority cases 95 alzheimers disease occurs age 60 years clear genetic mutations make small contribution risk developing disease general
0.34450078.11823322.html.plaintext.txt	15	inheritance late onset alzheimers disease complex early onset form cross sectional studies presence positive family history late onset alzheimers disease consistent risk factor subjects late onset form clear autosomal dominant pattern inheritance rare twin family studies suggest polygenic multifactorial mode inheritance consequence elucidation genetic risk factors late onset alzheimers disease requires different methods used early onset disease simple mendelian patterns inheritance association studies far dominated genetics late onset alzheimers disease studies look variation frequency allele samples unrelated patients late onset alzheimers disease compared unrelated control subjects studies resulted number candidate genes proposed importance risk factors late onset alzheimers disease include associations variation genes encoding low density lipoprotein vldl receptor ps 1 intronic mutation associated early onset alzheimers disease butyrylcholinesterase angiotensin 1 converting enzyme 1 antichymotrypsin human leucocyte antigen hla complex 2 macroglobulin low density lipoprotein like receptor serotonin transporter interleukin 1 typically interest candidates diminished independent replication forthcoming little evidence remains important role genetic variation vldl receptor ps 1 1 antichymotrypsin genes development late onset alzheimers disease candidate genes still advocates remain hotly disputed
0.34450078.11823322.html.plaintext.txt	16	inheritance late onset alzheimers disease complex early onset form cross sectional studies presence positive family history late onset alzheimers disease consistent risk factor subjects late onset form clear autosomal dominant pattern inheritance rare twin family studies suggest polygenic multifactorial mode inheritance consequence elucidation genetic risk factors late onset alzheimers disease requires different methods used early onset disease simple mendelian patterns inheritance association studies far dominated genetics late onset alzheimers disease studies look variation frequency allele samples unrelated patients late onset alzheimers disease compared unrelated control subjects studies resulted number candidate genes proposed importance risk factors late onset alzheimers disease include associations variation genes encoding low density lipoprotein vldl receptor ps 1 intronic mutation associated early onset alzheimers disease butyrylcholinesterase angiotensin 1 converting enzyme 1 antichymotrypsin human leucocyte antigen hla complex 2 macroglobulin low density lipoprotein like receptor serotonin transporter interleukin 1 typically interest candidates diminished independent replication forthcoming little evidence remains important role genetic variation vldl receptor ps 1 1 antichymotrypsin genes development late onset alzheimers disease candidate genes still advocates remain hotly disputed
0.34450078.11823322.html.plaintext.txt	17	recently results number linkage studies become available methods used linkage studies complex non mendelian diseases late onset alzheimers disease less powerful used early onset form however studies reveal areas interest genome might later explored association studies complete genomic screen series multiplex families affected late onset alzheimers disease revealed five regions interest chromosomes 4 6 12 19 20 excluding effects apoe4 locus maximum log likelihood ratio lod score study occurred region located short arm chromosome 12 pericak vance et al 1997 however two subsequent studies following similar methods blacker et al 1998 wu et al 1998 unable confirm linkage area large sibpair study kehoe et al 1999 revealed many possible loci showing linkage late onset alzheimers disease include loci chromosomes 1 5 9 10 12 14 19 close apoe 21 close app gene currently main focus attention chromosome 10 two independent studies showing evidence susceptibility locus region ertekin taner et al 2000 myers et al 2000 however clear large number loci implicated disagreement studies predicted areas interest findings demonstrate limitations approach also serve emphasise polygenic nature late onset alzheimers disease exploration areas association studies positional candidate approach likely dominate genetics alzheimers disease future
0.34450078.11823322.html.plaintext.txt	18	recently results number linkage studies become available methods used linkage studies complex non mendelian diseases late onset alzheimers disease less powerful used early onset form however studies reveal areas interest genome might later explored association studies complete genomic screen series multiplex families affected late onset alzheimers disease revealed five regions interest chromosomes 4 6 12 19 20 excluding effects apoe4 locus maximum log likelihood ratio lod score study occurred region located short arm chromosome 12 pericak vance et al 1997 however two subsequent studies following similar methods blacker et al 1998 wu et al 1998 unable confirm linkage area large sibpair study kehoe et al 1999 revealed many possible loci showing linkage late onset alzheimers disease include loci chromosomes 1 5 9 10 12 14 19 close apoe 21 close app gene currently main focus attention chromosome 10 two independent studies showing evidence susceptibility locus region ertekin taner et al 2000 myers et al 2000 however clear large number loci implicated disagreement studies predicted areas interest findings demonstrate limitations approach also serve emphasise polygenic nature late onset alzheimers disease exploration areas association studies positional candidate approach likely dominate genetics alzheimers disease future
0.34450078.11823322.html.plaintext.txt	19	genetic risk factors advocated role development late onset alzheimers disease least controversial remains increased risk associated possession one copies apoe4 allele coding apolipoprotein e apoe variant 4 significantly importance apoe4 determined using positional candidate gene approach since finding studies artiga et al 1998 bullido et al 1998 lambert et al 1998 also suggested association number polymorphisms within transcriptional regulatory region apoe gene late onset alzheimers disease independent apoe 4 status based data suggested two independent mechanisms risk late onset alzheimers disease modified apoe gene first variations coding regions alter functional properties apoe second presence promoter variants result quantitative differences apoe expression artiga et al 1998 however hypothesis controversial recent studies helisalmi et al 1999 zurutuza et al 2000 failed support independence apoe promoter variants development alzheimers disease
0.34450078.11823322.html.plaintext.txt	20	genetic risk factors advocated role development late onset alzheimers disease least controversial remains increased risk associated possession one copies apoe4 allele coding apolipoprotein e apoe variant 4 significantly importance apoe4 determined using positional candidate gene approach since finding studies artiga et al 1998 bullido et al 1998 lambert et al 1998 also suggested association number polymorphisms within transcriptional regulatory region apoe gene late onset alzheimers disease independent apoe 4 status based data suggested two independent mechanisms risk late onset alzheimers disease modified apoe gene first variations coding regions alter functional properties apoe second presence promoter variants result quantitative differences apoe expression artiga et al 1998 however hypothesis controversial recent studies helisalmi et al 1999 zurutuza et al 2000 failed support independence apoe promoter variants development alzheimers disease
0.34450078.11823322.html.plaintext.txt	21	genetic influences clinical phenotype
0.34450078.11823322.html.plaintext.txt	22	age onset families carrying mutations app gene ages onset largely within range 40 65 years date app mutation carrier reported unaffected beyond age 67 years families carrying mutations ps 1 gene earliest ages onset fall largely within range 35 55 years although one family member recently recorded onset 24 years wisniewski et al 1998 mutations largely associated early onset familial alzheimers disease least two mutations ala79val his163tyr observed late onset alzheimers disease may non penetrant cruts et al 1998 families carrying mutations ps 2 gene ages onset largely within range 40 70 years thus show overlap late onset alzheimers disease penetrance high may 100 least two reported cases non penetrance age 80 years bird et al 1996
0.34450078.11823322.html.plaintext.txt	23	age onset families carrying mutations app gene ages onset largely within range 40 65 years date app mutation carrier reported unaffected beyond age 67 years families carrying mutations ps 1 gene earliest ages onset fall largely within range 35 55 years although one family member recently recorded onset 24 years wisniewski et al 1998 mutations largely associated early onset familial alzheimers disease least two mutations ala79val his163tyr observed late onset alzheimers disease may non penetrant cruts et al 1998 families carrying mutations ps 2 gene ages onset largely within range 40 70 years thus show overlap late onset alzheimers disease penetrance high may 100 least two reported cases non penetrance age 80 years bird et al 1996
0.34450078.11823322.html.plaintext.txt	24	familial influence age onset late onset alzheimers disease may substantial thus one study affected sib pairs suggests shared familial effects may account 40 variance tunstall et al 2000 indeed studies shown late onset disease age onset approximately 6 years earlier individuals carry two copies apoe4 allele compared non carriers led suggestion apoe4 allele risk factor alzheimers disease mainly old age alzheimers disease death competing risks factor leading earlier age onset alzheimers disease elderly hence development disease prior death associated alzheimers disease evidence confirming hypothesis come large study approximately 5000 individuals meyer et al 1998 study showed clear decline relative risk developing late onset alzheimers disease subjects increasing age clear plateau beyond new cases disease reported age plateau reached earlier carriers apoe4 allele thus appears clear apoe4 allele predominant effect determining individual develops late onset alzheimers disease meyer et al 1998
0.34450078.11823322.html.plaintext.txt	25	familial influence age onset late onset alzheimers disease may substantial thus one study affected sib pairs suggests shared familial effects may account 40 variance tunstall et al 2000 indeed studies shown late onset disease age onset approximately 6 years earlier individuals carry two copies apoe4 allele compared non carriers led suggestion apoe4 allele risk factor alzheimers disease mainly old age alzheimers disease death competing risks factor leading earlier age onset alzheimers disease elderly hence development disease prior death associated alzheimers disease evidence confirming hypothesis come large study approximately 5000 individuals meyer et al 1998 study showed clear decline relative risk developing late onset alzheimers disease subjects increasing age clear plateau beyond new cases disease reported age plateau reached earlier carriers apoe4 allele thus appears clear apoe4 allele predominant effect determining individual develops late onset alzheimers disease meyer et al 1998
0.34450078.11823322.html.plaintext.txt	26	non cognitive features genetic risk factors alzheimers disease associated non cognitive symptoms one might anticipate subjects family history disease increased frequency symptoms likewise one would expect association known genetic risk factors alzheimers disease including genes app ps 1 ps 2 apoe 4 allele symptoms alzheimers disease
0.34450078.11823322.html.plaintext.txt	27	non cognitive features genetic risk factors alzheimers disease associated non cognitive symptoms one might anticipate subjects family history disease increased frequency symptoms likewise one would expect association known genetic risk factors alzheimers disease including genes app ps 1 ps 2 apoe 4 allele symptoms alzheimers disease
0.34450078.11823322.html.plaintext.txt	28	fact appears little consistent evidence association either positive family history alzheimers disease variation known candidate genes increase frequency non cognitive symptoms occurring first time within disease thus seems unlikely major genetic risk factors development late onset alzheimers disease substantial role play development non cognitive symptoms within late onset disease however mean symptoms genetic basis since genes may influence phenotypic expression disease without involved directly aetiology indeed early studies shown evidence association positive family history depressive illness increase frequency depressive symptoms occurring first time within alzheimers disease pearlson et al 1990 early findings supported sib pair study tunstall et al 2000 showing familial factors role development depressive illness late onset alzheimers disease addition small study also suggests role familial factors wide variety non cognitive symptoms including agitation aggression psychosis
0.34450078.11823322.html.plaintext.txt	29	fact appears little consistent evidence association either positive family history alzheimers disease variation known candidate genes increase frequency non cognitive symptoms occurring first time within disease thus seems unlikely major genetic risk factors development late onset alzheimers disease substantial role play development non cognitive symptoms within late onset disease however mean symptoms genetic basis since genes may influence phenotypic expression disease without involved directly aetiology indeed early studies shown evidence association positive family history depressive illness increase frequency depressive symptoms occurring first time within alzheimers disease pearlson et al 1990 early findings supported sib pair study tunstall et al 2000 showing familial factors role development depressive illness late onset alzheimers disease addition small study also suggests role familial factors wide variety non cognitive symptoms including agitation aggression psychosis
0.34450078.11823322.html.plaintext.txt	30	direct approach also adopted whereby common genetic polymorphisms previously showing associations neuropsychiatric conditions found associated non cognitive symptoms late onset alzheimers disease example one study holmes et al 1998 people late onset alzheimers disease found association common polymorphic variations 5 ht2a 5 ht2c serotonin receptor genes 102 tc cys23ser polymorphisms respectively previously implicated schizophrenia bipolar affective disorder psychotic symptoms alzheimers disease associations found presence c102 allele presence visual auditory hallucinations presence ser23 allele visual hallucinations another study sweet et al 1998 found evidence suggest association psychosis aggression patients alzheimers disease carry common polymorphisms dopamine receptor genes drd1 drd3 studies need replicated suggest common receptor polymorphisms may role genesis psychotic non cognitive symptoms implicated genetic risk factors late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	31	direct approach also adopted whereby common genetic polymorphisms previously showing associations neuropsychiatric conditions found associated non cognitive symptoms late onset alzheimers disease example one study holmes et al 1998 people late onset alzheimers disease found association common polymorphic variations 5 ht2a 5 ht2c serotonin receptor genes 102 tc cys23ser polymorphisms respectively previously implicated schizophrenia bipolar affective disorder psychotic symptoms alzheimers disease associations found presence c102 allele presence visual auditory hallucinations presence ser23 allele visual hallucinations another study sweet et al 1998 found evidence suggest association psychosis aggression patients alzheimers disease carry common polymorphisms dopamine receptor genes drd1 drd3 studies need replicated suggest common receptor polymorphisms may role genesis psychotic non cognitive symptoms implicated genetic risk factors late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	32	cognitive decline study date looked rates decline carriers app ps 1 ps 2 mutations patients late onset alzheimers disease positive family history alzheimers disease show evidence increased rates decline majority studies also failed show relationships possession apoe4 allele increased rates decline lack association interesting since implies genetic factors may determine disease starts rate degeneration clearly caution required interpreting negative finding may associations always difficult establish large number confounding factors may influence cognitive deterioration well difficulties use psychometric scales short periods indeed study craft et al 1998 suggested increased rate cognitive decline apoe4 carriers may detectable using long follow period
0.34450078.11823322.html.plaintext.txt	33	cognitive decline study date looked rates decline carriers app ps 1 ps 2 mutations patients late onset alzheimers disease positive family history alzheimers disease show evidence increased rates decline majority studies also failed show relationships possession apoe4 allele increased rates decline lack association interesting since implies genetic factors may determine disease starts rate degeneration clearly caution required interpreting negative finding may associations always difficult establish large number confounding factors may influence cognitive deterioration well difficulties use psychometric scales short periods indeed study craft et al 1998 suggested increased rate cognitive decline apoe4 carriers may detectable using long follow period
0.34450078.11823322.html.plaintext.txt	34	duration mean duration illness families ps 1 mutations significantly shorter range 58 68 years families ps 2 range 44 108 years app mutations range 90 16 years reflecting severity ps 1 associated alzheimers disease studies late onset alzheimers disease suggest duration illness tends longer people positive family history carriers apoe4 allele however since shown relationship longer holds true confounding effects age onset taken account thus late onset alzheimers disease increased survival directly related earlier age onset influenced number factors exclusively genetic
0.34450078.11823322.html.plaintext.txt	35	clinical implications limitations
0.34450078.11823322.html.plaintext.txt	36	clinical implications number genes implicated risk factors development alzheimers disease variation genes appears major effect determining disease develop aspects clinical phenotype notably non cognitive symptoms also influenced genetic variation
0.34450078.11823322.html.plaintext.txt	37	clinical implications number genes implicated risk factors development alzheimers disease variation genes appears major effect determining disease develop aspects clinical phenotype notably non cognitive symptoms also influenced genetic variation
0.34450078.11823322.html.plaintext.txt	38	limitations number risk genes yet identified influence unknown genes clinical phenotype yet undetermined influence genetic variation non cognitive symptoms relatively unexplored
0.34450078.11823322.html.plaintext.txt	39	limitations number risk genes yet identified influence unknown genes clinical phenotype yet undetermined influence genetic variation non cognitive symptoms relatively unexplored
0.34450078.11823322.html.plaintext.txt	40	received publication may 16 2000 revision received may 14 2001 accepted publication may 23 2001
0.34450078.11823322.html.plaintext.txt	41	received publication may 16 2000 revision received may 14 2001 accepted publication may 23 2001
0.34450078.11823322.html.plaintext.txt	42	highlights issue elizabeth walsh bjp 2002 180 0 full text
0.34450078.11823322.html.plaintext.txt	43	old age psychiatry alistair burns ian g mckeith bjp 2002 180 97 98 full text
0.3856874.12716770.html.plaintext.txt	0	association haplotype analysis insulin degrading enzyme ide gene strong positional biological candidate type 2 diabetes susceptibility christopher j groves12 steven wiltshire23 damian smedley3 katherine r owen4 timothy m frayling4 mark walker5 graham hitman6 jonathan c levy1 stephen o rahilly7 stephan menzel2 andrew hattersley4 mark mccarthy123
0.3856874.12716770.html.plaintext.txt	1	association haplotype analysis insulin degrading enzyme ide gene strong positional biological candidate type 2 diabetes susceptibility christopher j groves12 steven wiltshire23 damian smedley3 katherine r owen4 timothy m frayling4 mark walker5 graham hitman6 jonathan c levy1 stephen o rahilly7 stephan menzel2 andrew hattersley4 mark mccarthy123
0.3856874.12716770.html.plaintext.txt	2	1 oxford centre diabetes endocrinology metabolism oxford uk 2 wellcome trust centre human genetics oxford uk 3 genetics genomics research institute imperial college faculty medicine hammersmith hospital london uk 4 centre molecular genetics peninsular medical school exeter uk 5 school clinical medical sciences university newcastle newcastle uk 6 department diabetes metabolic medicine bart london queen mary school medicine dentistry london uk 7 departments medicine clinical biochemistry addenbrooke hospital cambridge uk
0.3856874.12716770.html.plaintext.txt	3	abstract top abstract research design methods references gene insulin degrading enzyme ide represents strong positional biological candidate type 2 diabetes susceptibility ide maps chromosome 10q233 region linked diabetes several populations rat homolog directly implicated diabetes susceptibility known functions ide support important role glucose homeostasis sought evidence association ide variation diabetes mutation screening defining local haplotype structure genotyping variants delineating common haplotypic diversity initial case control analysis 628 diabetic probands multiplex sibships 604 control subjects found haplotypic associations although one variant ide2 179tc showed modest association diabetes odds ratio or125 p 003 linkage partitioning analyses failed support association provided borderline evidence different variant ide10 ivs20 405ag p 006 neither variant associated diabetes replication sought 377 early onset diabetic subjects 825 control subjects though combined analysis typed cohorts indicated nominally significant effect ide2 121 104 140 p 0013 absence convincing support association linkage partitioning analyses continuous measures glycemia conclude analysis 2400 samples provides compelling evidence variation ide contributes diabetes susceptibility humans
0.3856874.12716770.html.plaintext.txt	4	linkage disequilibrium analysis within candidate genes represents final common pathway identification diabetes susceptibility genes candidate selection typically based positional information linkage studies humans rodent models andor perceived match gene function pathophysiology condition
0.3856874.12716770.html.plaintext.txt	5	linkage disequilibrium analysis within candidate genes represents final common pathway identification diabetes susceptibility genes candidate selection typically based positional information linkage studies humans rodent models andor perceived match gene function pathophysiology condition
0.3856874.12716770.html.plaintext.txt	6	several independent lines evidence suggest role gene encoding insulin degrading enzyme ide locuslink reference 3416 ec reference 342456 type 2 diabetes pathogenesis making promising candidate analysis first ide maps region chromosome 10q showing evidence linkage type 2 diabetes several populations genomewide scan 573 uk type 2 diabetic pedigrees evidence linkage multipoint logarithm odds lod 199 peaked near d10s1765 4 mb ide conditional analyses suggested epistatic interaction well replicated susceptibility locus chromosome 1q 1 linkage 10q also reported finns 2 north american europeans 3 mexican americans 4 french 5 though latter two map 40 50 cm telomeric may reflect distinct locus
0.3856874.12716770.html.plaintext.txt	7	second rat homolog ide directly implicated type 2 diabetes susceptibility gk rat model 67 locus poststimulation glycemia mapped region rat chromosome 1 syntenic human 10q23 26 89 subsequently localized 1 cm region around ide 10 two amino acid substitutions ide found susceptible congenic strains together conferred postprandial hyperglycemia reduced insulin degradation isolated muscle cells diabetes related phenotypes 10
0.3856874.12716770.html.plaintext.txt	8	second rat homolog ide directly implicated type 2 diabetes susceptibility gk rat model 67 locus poststimulation glycemia mapped region rat chromosome 1 syntenic human 10q23 26 89 subsequently localized 1 cm region around ide 10 two amino acid substitutions ide found susceptible congenic strains together conferred postprandial hyperglycemia reduced insulin degradation isolated muscle cells diabetes related phenotypes 10
0.3856874.12716770.html.plaintext.txt	9	third known presumed functions ide consistent role type 2 diabetes pathogenesis ide 110 kda zn2 regulated metalloproteinase displays wide expression profile including insulin responsive tissues strong species conservation attests important biological functions diverse cellular metabolic roles proposed 1112 although remain controversial 13 ide seems play major role breakdown insulin insulin responsive tissues 14 thereby influencing extent cellular response insulin 11 association ide activity insulin clearance resistance supported vitro clinical studies 14 16 furthermore substrate specificity ide coincides peptides capable amyloid formation including amylin insulin indicating ide may prevent accumulation amyloidogenic peptides 12 disruption scavenging function might thereby promote aggregation islet amyloid characteristic type 2 diabetes contribute deficient ss cell capacity
0.3856874.12716770.html.plaintext.txt	10	third known presumed functions ide consistent role type 2 diabetes pathogenesis ide 110 kda zn2 regulated metalloproteinase displays wide expression profile including insulin responsive tissues strong species conservation attests important biological functions diverse cellular metabolic roles proposed 1112 although remain controversial 13 ide seems play major role breakdown insulin insulin responsive tissues 14 thereby influencing extent cellular response insulin 11 association ide activity insulin clearance resistance supported vitro clinical studies 14 16 furthermore substrate specificity ide coincides peptides capable amyloid formation including amylin insulin indicating ide may prevent accumulation amyloidogenic peptides 12 disruption scavenging function might thereby promote aggregation islet amyloid characteristic type 2 diabetes contribute deficient ss cell capacity
0.3856874.12716770.html.plaintext.txt	11	congruence positional biological candicacy led us evaluate role ide variation diabetes susceptibility humans mutation screening exons adjacent intronic sequence 600 bp 5 sequence probands 10q linked pedigrees identified six confirmed variants table 1 fig 1 convenience termed ide single nucleotide polymorphisms snps 2 3 4 5 8 9 accordance previous nomenclature 17 detect uncommon ide6 ide7 variants previously reported 17 ide1 ide10 mapped outside sequence surveyed none variants appeared strong functional credentials based sequence context putative nonsynonymous exon 15 coding polymorphism reported dbsnp rs2229708 validated sequencing direct genotyping analysis 348 european collection cell cultures ecacc control samples confirmed extensive linkage disequilibrium across gene pairwise d values 060 fig 1 six common haplotypes hap1 hap6 identified accounting 97 chromosomes fig 1 basis allele frequencies ide5 ide6 ide7 5 intermarker linkage disequilibrium patterns ide3 concordant ide1 snps 1 2 4 8 9 10 selected genotyping
0.3856874.12716770.html.plaintext.txt	12	congruence positional biological candicacy led us evaluate role ide variation diabetes susceptibility humans mutation screening exons adjacent intronic sequence 600 bp 5 sequence probands 10q linked pedigrees identified six confirmed variants table 1 fig 1 convenience termed ide single nucleotide polymorphisms snps 2 3 4 5 8 9 accordance previous nomenclature 17 detect uncommon ide6 ide7 variants previously reported 17 ide1 ide10 mapped outside sequence surveyed none variants appeared strong functional credentials based sequence context putative nonsynonymous exon 15 coding polymorphism reported dbsnp rs2229708 validated sequencing direct genotyping analysis 348 european collection cell cultures ecacc control samples confirmed extensive linkage disequilibrium across gene pairwise d values 060 fig 1 six common haplotypes hap1 hap6 identified accounting 97 chromosomes fig 1 basis allele frequencies ide5 ide6 ide7 5 intermarker linkage disequilibrium patterns ide3 concordant ide1 snps 1 2 4 8 9 10 selected genotyping
0.3856874.12716770.html.plaintext.txt	13	view table table 1 ide variants relevant study
0.3856874.12716770.html.plaintext.txt	14	view larger version 52k fig 1 genomic position linkage disequilibrium relationships haplotype frequencies variants within ide gene depiction ide gene displays exon distribution scale see distances provided genomic location snps examined study middle panel details linkage disequilibrium parameters d diagonal p value calculated 348 random uk samples ecacc sample six snps genotyped lower panel lists ten frequent haplotypes estimated typed data sets frequencies con1 control subjects made ecacc dif samples w2p case set
0.3856874.12716770.html.plaintext.txt	15	snps hardy weinberg equilibrium data sets except ide4 p 001 ide9 p 004 diabetes families study dif control sample samples retyped 100 concordance haplotype patterns provided indication mistyping novel haplotypes generated modest departures equilibrium likely therefore reflect stochastic variation exceptional given number tests performed
0.3856874.12716770.html.plaintext.txt	16	allele genotype frequencies warren 2 proband w2p cases n 628 control group con1 subjects n 604 shown table 2 see research design methods group characteristics nominally significant association detected w2p con1 samples ide2 genotypes p 0045 alleles p 0030 odds ratio c allele 125 95 ci 102 152 global difference haplotype frequency distribution fig 1 groups p 033 however since hap2 defined c allele ide2 haplotype also frequent probands con1 control subjects p 003 uncorrected males females differ snp haplotype frequencies additional associations uncovered sex stratified analyses
0.3856874.12716770.html.plaintext.txt	17	allele genotype frequencies warren 2 proband w2p cases n 628 control group con1 subjects n 604 shown table 2 see research design methods group characteristics nominally significant association detected w2p con1 samples ide2 genotypes p 0045 alleles p 0030 odds ratio c allele 125 95 ci 102 152 global difference haplotype frequency distribution fig 1 groups p 033 however since hap2 defined c allele ide2 haplotype also frequent probands con1 control subjects p 003 uncorrected males females differ snp haplotype frequencies additional associations uncovered sex stratified analyses
0.3856874.12716770.html.plaintext.txt	18	view table table 2 genotype allele frequencies ide haplotype tag ht snps
0.3856874.12716770.html.plaintext.txt	19	determine whether associations might evident families apparent 10q linkage subdivided w2p sample according family nonparametric linkage npl score 10q locus linkage partitioning methods applied several recent type 2 diabetes studies 18 21 used linkage partitioning purely exploratory capacity given uncertainties statistical properties methods evidence linkage confirmed well possible consequences partitioning bias stratifying proband genotype alone difference evident linked unlinked probands ide haplotype frequencies p 086 ide2 genotypes p 061 ide10 genotypes p 018 association previously seen ide2 w2p con1 attenuated linked probands considered genotypes p 010 alleles p 008 difference ide10 genotype frequencies 10q linked probands con1 control subjects p 034 however complementary analysis testing whether ide genotype partitioned evidence 10q linkage encouraging families proband carried weakly associated ide2 genotypes ct cc lod score d10s1765 increased 172 196 p 009 increment analysis based ide10 genotype grouping ga gg yielded lod 212 p 006
0.3856874.12716770.html.plaintext.txt	20	determine whether associations might evident families apparent 10q linkage subdivided w2p sample according family nonparametric linkage npl score 10q locus linkage partitioning methods applied several recent type 2 diabetes studies 18 21 used linkage partitioning purely exploratory capacity given uncertainties statistical properties methods evidence linkage confirmed well possible consequences partitioning bias stratifying proband genotype alone difference evident linked unlinked probands ide haplotype frequencies p 086 ide2 genotypes p 061 ide10 genotypes p 018 association previously seen ide2 w2p con1 attenuated linked probands considered genotypes p 010 alleles p 008 difference ide10 genotype frequencies 10q linked probands con1 control subjects p 034 however complementary analysis testing whether ide genotype partitioned evidence 10q linkage encouraging families proband carried weakly associated ide2 genotypes ct cc lod score d10s1765 increased 172 196 p 009 increment analysis based ide10 genotype grouping ga gg yielded lod 212 p 006
0.3856874.12716770.html.plaintext.txt	21	clarification role ide2 ide10 variants sought genotyping early onset type 2 diabetic cases yt2d warren 2 trios w2t large control resource con2 young onset case groups similar clinical characteristics table 3 genotypes combined appropriate tests homogeneity replication cohorts average age diagnosis 15 years earlier sibpair probands however rigorous exclusion non type 2 diabetes high parental prevalence typical late onset type 2 diabetes cohorts 2223 argue appreciable qualitative differences genetic basis type 2 diabetes susceptibility initial replication cohorts typing ide2 ide10 effectively reduces ide haplotypic diversity three common haplotypes fig 1 genotype allele counts shown table 2 data hardy weinberg equilibrium replication cohorts found significant association either snp ide2 genotypes p 014 alleles p 017 c allele 117094 145 ide10 p 080 2 10 haplotype p 041 regardless whether data stratified sex full exeter family study efs cohort n 841 association either snp fasting plasma glucose combined sex stratified analyses
0.3856874.12716770.html.plaintext.txt	22	clarification role ide2 ide10 variants sought genotyping early onset type 2 diabetic cases yt2d warren 2 trios w2t large control resource con2 young onset case groups similar clinical characteristics table 3 genotypes combined appropriate tests homogeneity replication cohorts average age diagnosis 15 years earlier sibpair probands however rigorous exclusion non type 2 diabetes high parental prevalence typical late onset type 2 diabetes cohorts 2223 argue appreciable qualitative differences genetic basis type 2 diabetes susceptibility initial replication cohorts typing ide2 ide10 effectively reduces ide haplotypic diversity three common haplotypes fig 1 genotype allele counts shown table 2 data hardy weinberg equilibrium replication cohorts found significant association either snp ide2 genotypes p 014 alleles p 017 c allele 117094 145 ide10 p 080 2 10 haplotype p 041 regardless whether data stratified sex full exeter family study efs cohort n 841 association either snp fasting plasma glucose combined sex stratified analyses
0.3856874.12716770.html.plaintext.txt	23	view table table 3 clinical characteristics populations studied
0.3856874.12716770.html.plaintext.txt	24	selected ide basis positional biological candidacy type 2 diabetes susceptibility gene undertaken detailed survey variation within gene unable compile clear evidence association ide variation type 2 diabetes despite fact analyses utilized several large well characterized populations selection diabetic individuals early onset positive family history designed enhance detection type 2 diabetes susceptibility alleles snp showing association initial case control analysis ide2 associated replication set however worth noting combined ide2 across initial replication sets achieve nominal significance combined allele c 121 104 140 p 0013 result demands cautious interpretation given allowance low though unquantifiable prior odds even strong biological candidates ide harbor substantial susceptibility effects lack support analyses performed variant emerging initial analyses ide10 showed ability partition evidence linkage showed evidence association type 2 diabetes combined allele 101 087 117 p 091
0.3856874.12716770.html.plaintext.txt	25	selected ide basis positional biological candidacy type 2 diabetes susceptibility gene undertaken detailed survey variation within gene unable compile clear evidence association ide variation type 2 diabetes despite fact analyses utilized several large well characterized populations selection diabetic individuals early onset positive family history designed enhance detection type 2 diabetes susceptibility alleles snp showing association initial case control analysis ide2 associated replication set however worth noting combined ide2 across initial replication sets achieve nominal significance combined allele c 121 104 140 p 0013 result demands cautious interpretation given allowance low though unquantifiable prior odds even strong biological candidates ide harbor substantial susceptibility effects lack support analyses performed variant emerging initial analyses ide10 showed ability partition evidence linkage showed evidence association type 2 diabetes combined allele 101 087 117 p 091
0.3856874.12716770.html.plaintext.txt	26	survey ide variation covered exons adjacent intronic sequence promoter none variants identified earlier screen uk subjects 17 strong credentials impact ide structure andor function clearly findings support hypothesis variation within ide exclusively responsible linkage signal detected chromosome 10q however association study cannot exclude possibility variants typed especially ide2 lesser susceptibility role present study estimate 95 power detect association ide2 type 2 diabetes multiplicative model genotypic relative risk 12 threshold p value 005 falls 60 stringent significance threshold p 0001 designed reflect modest prior odds candidate selected plays biologically significant susceptibility role furthermore cannot entirely exclude possibility ide variants studied marked contribution type 2 diabetes susceptibility variants must lie outside regions surveyed display limited linkage disequilibrium typed variants current understanding linkage disequilibrium patterns within human populations indicates analyses seek associations using snps capturing haplotypic diversity within gene interest good power detect associations yet unidentified common variants within gene 24
0.3856874.12716770.html.plaintext.txt	27	survey ide variation covered exons adjacent intronic sequence promoter none variants identified earlier screen uk subjects 17 strong credentials impact ide structure andor function clearly findings support hypothesis variation within ide exclusively responsible linkage signal detected chromosome 10q however association study cannot exclude possibility variants typed especially ide2 lesser susceptibility role present study estimate 95 power detect association ide2 type 2 diabetes multiplicative model genotypic relative risk 12 threshold p value 005 falls 60 stringent significance threshold p 0001 designed reflect modest prior odds candidate selected plays biologically significant susceptibility role furthermore cannot entirely exclude possibility ide variants studied marked contribution type 2 diabetes susceptibility variants must lie outside regions surveyed display limited linkage disequilibrium typed variants current understanding linkage disequilibrium patterns within human populations indicates analyses seek associations using snps capturing haplotypic diversity within gene interest good power detect associations yet unidentified common variants within gene 24
0.3856874.12716770.html.plaintext.txt	28	research design methods top abstract research design methods references subjects clinical characteristics cohorts studied provided table 3 initial case control analyses compared unrelated index probands n 628 diabetes uk warren 2 sibpair repository w2p 1 control samples two sources 1 348 random uk population samples camr salisbury uk ecacc 2 256 uk subjects ascertained diabetes families study dif subjects latter normoglycemic fasting glucose 60mmoll without family history diabetes combined control samples designated con1 replication analyses combined two collections young onset type 2 diabetes subjects similar clinical characteristics 1 offspring parent offspring trios n 142 ascertained type 2 diabetes w2t 22 2 young onset 45 years type 2 diabetic subjects n 235 yt2d 23 cases compared 841 unrelated parents consecutive birth cohort efs 825 normoglycemic con2 23 case samples therefore selected inherited type 2 diabetes via early onset andor positive family history non type 2 diabetes excluded using combination clinical immunological genetic criteria 122 confirmation glycemic status control populations limited fasting plasma glucose measures dif efs samples subjects exclusively britishirish caucasian origin except small proportion non british european ancestry w2t set
0.3856874.12716770.html.plaintext.txt	29	research design methods top abstract research design methods references subjects clinical characteristics cohorts studied provided table 3 initial case control analyses compared unrelated index probands n 628 diabetes uk warren 2 sibpair repository w2p 1 control samples two sources 1 348 random uk population samples camr salisbury uk ecacc 2 256 uk subjects ascertained diabetes families study dif subjects latter normoglycemic fasting glucose 60mmoll without family history diabetes combined control samples designated con1 replication analyses combined two collections young onset type 2 diabetes subjects similar clinical characteristics 1 offspring parent offspring trios n 142 ascertained type 2 diabetes w2t 22 2 young onset 45 years type 2 diabetic subjects n 235 yt2d 23 cases compared 841 unrelated parents consecutive birth cohort efs 825 normoglycemic con2 23 case samples therefore selected inherited type 2 diabetes via early onset andor positive family history non type 2 diabetes excluded using combination clinical immunological genetic criteria 122 confirmation glycemic status control populations limited fasting plasma glucose measures dif efs samples subjects exclusively britishirish caucasian origin except small proportion non british european ancestry w2t set
0.3856874.12716770.html.plaintext.txt	30	gene structure mutation detection genomic structure ide determined blast alignment human mrna sequence m21188 finished genomic sequence bac clone al356128 confirmed ide 25 exons distributed positions 9309 9322 mb ncbi30 assembly chromosome 10 variant detection performed direct sequencing directions big dye terminator chemistry perkin elmer applied biosystems warrington uk abi3700 capillary sequencer included exons 50 bp flanking introns 600 bp 5 untranslated region utr 27 amplicons primer sequences provided online table 1 httpdiabetesdiabetesjournalsorg total 11 individuals sequenced eight type 2 diabetic probands sibships affected identical descent chromosomes flanking microsatellites d10s1765 d10s185 probands assuming 10q linkage enriched 10q susceptibility variants estimate 90 power detect disease associated variants assuming multiplicative models genotype relative risk 15 allele frequencies 87 three unaffected siblings families doubly discordant 10q haplotypes covering ide compared affected sibs
0.3856874.12716770.html.plaintext.txt	31	gene structure mutation detection genomic structure ide determined blast alignment human mrna sequence m21188 finished genomic sequence bac clone al356128 confirmed ide 25 exons distributed positions 9309 9322 mb ncbi30 assembly chromosome 10 variant detection performed direct sequencing directions big dye terminator chemistry perkin elmer applied biosystems warrington uk abi3700 capillary sequencer included exons 50 bp flanking introns 600 bp 5 untranslated region utr 27 amplicons primer sequences provided online table 1 httpdiabetesdiabetesjournalsorg total 11 individuals sequenced eight type 2 diabetic probands sibships affected identical descent chromosomes flanking microsatellites d10s1765 d10s185 probands assuming 10q linkage enriched 10q susceptibility variants estimate 90 power detect disease associated variants assuming multiplicative models genotype relative risk 15 allele frequencies 87 three unaffected siblings families doubly discordant 10q haplotypes covering ide compared affected sibs
0.3856874.12716770.html.plaintext.txt	32	snp genotyping selected ide snps genotyped using combination approaches including restriction fragment length polymorphism detection artificial induced restriction sites tetra primer amplification refractory mutation methods assays first two types included obligate restriction sites internal digest controls assay details see online table 2 httpdiabetesdiabetesjournalsorg
0.3856874.12716770.html.plaintext.txt	33	statistical methods genotype allele frequency distributions compared standard contingency table methods exact probability estimation using statxact cytel cambridge ma genotype comparisons used kruskal wallis statistic given ordinal categorization separate data sets eg w2t yt2d sets combined contingency table analyses appropriate homogeneity testing haplotype patterns estimated maximum likelihood methods snphap www genecimrcamacukclaytonsoftware haplotype frequency distributions compared likelihood ratio testing significance determined permutation 10000 replicates measures linkage disequilibrium snps derived using pm permutation model free analysis program 25 assess evidence linkage partitioning 18 21 two complementary approaches adopted first w2p probands subdivided linked positive family npl score ide unlinked variant frequency comparisons repeated second evidence linkage 10q recomputed using genehunter plus 1 conditioning proband ide genotype significance changes linkage statistic determined permutation 10000 replicates power calculations described assume simplicity cases ascertained affected sibpairs incorporate ascertainment selection control samples population based
0.3856874.12716770.html.plaintext.txt	34	acknowledgments work supported diabetes uk also supported ascertainment many samples collected european union gift consortium qlg2 ct 1999 00546 south west national health service research directorate
0.3856874.12716770.html.plaintext.txt	35	thank participated collections many health professionals contributed thank dr sian ellard laboratory organization diane jarvis dna extraction dr lesley jones cardiff sharing ide variant data prof paul burton colleagues leicester valuable statistical insights
0.3856874.12716770.html.plaintext.txt	36	footnotes address correspondence reprint requests prof mark mccarthy robert turner professor diabetes oxford centre diabetes endocrinology metabolism churchill site old road headington oxford ox3 7lj uk e mail markmccarthyatdrloxacuk u d
0.3856874.12716770.html.plaintext.txt	37	footnotes address correspondence reprint requests prof mark mccarthy robert turner professor diabetes oxford centre diabetes endocrinology metabolism churchill site old road headington oxford ox3 7lj uk e mail markmccarthyatdrloxacuk u d
0.3856874.12716770.html.plaintext.txt	38	received publication 5 november 2002 accepted revised form 10 february 2003
0.3856874.12716770.html.plaintext.txt	39	additional information article found online appendix httpdiabetesdiabetesjournalsorg
0.3856874.12716770.html.plaintext.txt	40	con control dif diabetes families study ecacc european collection cell cultures hap haplotype ide insulin degrading enzyme lod logarithm odds ncbi national center biotechnology information npl nonparametric linkage odds ratio snp single nucleotide polymorphism utr untranslated region w2p warren 2 probands w2t warren 2 trios yt2d young type 2 diabetes
0.3856874.12716770.html.plaintext.txt	41	references top abstract research design methods references wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n subba rao pv wishart m foxon r howell smedley d cardon lr menzel mccarthy mi genome wide scan loci predisposing type 2 diabetes uk population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1q j hum genet69 553 5692001medline ghosh watanabe rm valle tt hauser er magnuson vl langefeld cd ally dsmohlke kl silander k kohtamaki k chines p balow jr j birznieks g chang j eldridge w erdos mr karanjawala ze knapp ji kudelko k martin c morales mena musick musick pfahl c porter r rayman jb rha d segal l shapiro sharaf r shurtleff b tannenbaum j te c tovar j unni welch c whiten r witt blaschak harvan j douglas ja duren wl epstein mp fingerlin te kaleta hs langer em li c mceachin rc stringham hm trager e white pp eriksson j toivanen l vidgren g nylund sj tuomilehto wolf e ross eh demirchyan e hagopian wa buchanan ta tuomilehto j bergman rn collins fs boehnke m finland united states investigation non insulin dependent diabetes mellitus genetics fusion study autosomal genome scan genes predispose type 2 diabetes j hum genet67 1174 11852000medline meigs jb panhuysen ci myers rh wilson pw cupples la genome wide scan loci linked plasma levels glucose hba1c community based sample caucasian pedigrees framingham offspring study diabetes51 833 8402002abstractfree full text duggirala r blangero j almasy l dyer td williams kl leach rj o connell p stern mp linkage type 2 diabetes mellitus age onset genetic location chromosome 10q mexican americans j hum genet64 1127 11401999medline vionnet n hani eh dupont gallina francke dotte de matos f durand e lepetre f lecouer c gallina p zekiri l dina c froguel p genomewide search type 2 diabetes susceptibility genes french whites evidence novel susceptibility locus early onset diabetes chromosome 3q27 qter independent replication type 2 diabetes locus chromosome 1q21 q24 j hum genet67 1470 14802000medline galli j li ls glaser ostenson cg jiao h fakhrai rad h jacob hj lander es luthman h genetic analysis non insulin dependent diabetes mellitus gk rat nat genet12 31 371996medline gauguier d froguel p parent v bernard c bihoreau mt portha b james mr penicaud l lathrop m ktorza chromosomal mapping genetic loci associated non insulin dependent diabetes gk rat nat genet12 38 431996medline galli j fakhrai rad h kamel marcus c norgren luthman h pathophysiological genetic characterization major diabetes locus gk rats diabetes48 2463 24701999abstract kaisaki pj rouard m danoy pa wallis rh collins sc rice m levy er lathrop m bihoreau mt gauguier d detailed comparative gene map rat chromosome 1 mouse human genomes physical mapping evolutionary chromosomal breakpoint genomics64 32 432000medline fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk rats hum mol genet9 2149 21582000abstractfree full text duckworth wc bennett rg hamel fg insulin degradation progress potential endocr rev19 608 6241998abstractfree full text kurochkin iv insulin degrading enzyme embarking amyloid destruction trends biochem sci26 421 4252001medline authier f posner bi bergeron jjm insulin degrading enzyme clin invest med19 149 1601996medline seta ka roth ra overexpression insulin degrading enzyme cellular localization effects insulin signalling biochem biophys res commun231 167 1711997medline jones cn pei d staris p polonsky ks chen yd reaven gm alterations glucose stimulated insulin secretory dose response curve insulin clearance nondiabetic insulin resistant individuals j clin endocrinol metab82 1834 18381997abstractfree full text misbin ri almira ec cleman mw insulin degradation serum patient apparent insulin resistance j clin endocrinol metab52 177 1801981abstract abraham r myers devrieze fw hamshere mv thomas hm marshall h compton d spurlock g turic d hoogendoorn b kwon jm petersen rc tangalos e norton j morris jc bullock r liolitsa d lovestone hardy j goate o donovan m williams j owen mj jones l substantial linkage disequilibrium across insulin degrading enzyme locus association late onset alzheimer disease hum genet109 646 6522001medline horikawa y oda n cox nj li x orho melander m hara m hinokio y lindner tm mashima h schwarz peh del bosque plata l horikawa y oda y yoshiuchi colilla polonsky ks wei concannon p iwasaki n schulze j baier lj bogardus c groop l boerwinkle e hanis cl bell gi genetic variation gene encoding calpain 10 associated type 2 diabetes mellitus nat genet26 163 1752000medline sun l cox nj mcpeek ms statistical method identification polymorphisms explain linkage results j hum genet70 399 4112002medline li c scott lj boehnke m allele sharing linkage analysis subsets families stratified based associated allele abstract j hum genet71 suppl 574 2002 farook vs hanson rl wolford jk bogardus c prochazka m molecular analysis kcnj10 1q candidate gene type 2 diabetes pima indians diabetes51 3342 33462002abstractfree full text frayling tm walker m mccarthy mi evans jc ayres allen li ellard lynn turner rc o rahilly hitman ga hattersley parent offspring trios resource facilitate identification type 2 diabetes genes diabetes48 2475 24791999abstract minton j hattersley owen kr mccarthy mi walker m barrett frayling tm association studies genetic variation wfs1 gene type 2 diabetes uk populations diabetes51 1287 12902002abstractfree full text gabriel sb schaffner sf nguyen h moore jm roy j blumenstiel b higgins j defelice m lochner faggart m liu cordero sn rotimi c adeyemo cooper r ward r lander es daly mj altshuler d structure haplotype blocks human genome science296 2225 22292002abstractfree full text zhao jh curtis d sham pc model free analysis permutation test allelic association hum hered50 133 1392000medline
0.39201447.15277398.html.plaintext.txt	0	quantitative trait loci near insulin degrading enzyme ide gene contribute variation plasma insulin levels harvest f gu1 suad efendic1 sofia nordman1 claes goran ostenson1 kerstin brismar1 anthony j brookes2 jonathan prince2
0.39201447.15277398.html.plaintext.txt	1	quantitative trait loci near insulin degrading enzyme ide gene contribute variation plasma insulin levels harvest f gu1 suad efendic1 sofia nordman1 claes goran ostenson1 kerstin brismar1 anthony j brookes2 jonathan prince2
0.39201447.15277398.html.plaintext.txt	2	1 department molecular medicine rolf luft center diabetes research karolinska hospital stockholm sweden 2 center genomics bioinformatics karolinska institute stockholm sweden
0.39201447.15277398.html.plaintext.txt	3	abstract top abstract research design methods references insulin degrading enzyme ide plays principal role proteolysis several peptides addition insulin encoded ide resides region chromosome 10q linked type 2 diabetes two recent studies presented genetic association data ide type 2 diabetes one positive negative neither explored fundamental question whether polymorphism ide measurable influence insulin levels human populations address possibility 14 single nucleotide polymorphisms snps linkage disequilibrium block encompassing ide genotyped sample 321 impaired glucose tolerant 403 nondiabetic control subjects analyses based haplotypic genotypes diplotypes constructed snps differentiate common extant haplotypes extending across ide provided compelling evidence association fasting insulin levels p 00009 2 h insulin levels p 00027 homeostasis model assessment insulin resistance p 00001 bmi p 00067 effects exclusively evident men strongest evidence effect single marker obtained rs2251101 located near 3 untranslated region ide 2 h insulin levels p 0000023 diplotype analyses however suggest presence multiple interacting trait modifying sequences region results indicate polymorphism innear ide contributes large proportion variance plasma insulin levels correlated traits questions sex specificity allelic heterogeneity need taken consideration molecular basis observed phenotypic effects unfolds
0.39201447.15277398.html.plaintext.txt	4	abstract top abstract research design methods references insulin degrading enzyme ide plays principal role proteolysis several peptides addition insulin encoded ide resides region chromosome 10q linked type 2 diabetes two recent studies presented genetic association data ide type 2 diabetes one positive negative neither explored fundamental question whether polymorphism ide measurable influence insulin levels human populations address possibility 14 single nucleotide polymorphisms snps linkage disequilibrium block encompassing ide genotyped sample 321 impaired glucose tolerant 403 nondiabetic control subjects analyses based haplotypic genotypes diplotypes constructed snps differentiate common extant haplotypes extending across ide provided compelling evidence association fasting insulin levels p 00009 2 h insulin levels p 00027 homeostasis model assessment insulin resistance p 00001 bmi p 00067 effects exclusively evident men strongest evidence effect single marker obtained rs2251101 located near 3 untranslated region ide 2 h insulin levels p 0000023 diplotype analyses however suggest presence multiple interacting trait modifying sequences region results indicate polymorphism innear ide contributes large proportion variance plasma insulin levels correlated traits questions sex specificity allelic heterogeneity need taken consideration molecular basis observed phenotypic effects unfolds
0.39201447.15277398.html.plaintext.txt	5	gene encoding insulin degrading enzyme ide located chromosome 10q23 q24 within region linked type 2 diabetes related quantitative traits 1 4 ide major enzyme responsible insulin proteolysis vitro 5 shares structural functional homology bacterial protease iii may function termination insulin response 67 mice ide hypofunction induced ide gene disruption leads hyperinsulinemia 8 furthermore ide activity diabetic goto kakizaki gk rat reduced 30 polymorphism ide likely main contributing factor 9 congruence positional functional data indicates sequence variation ide may play role modifying insulin metabolism human populations two recent genetic association studies investigated ide region relation type 2 diabetes one produced significant evidence effects type 2 diabetes plasma glucose levels 10 whereas explored case control models obtained evidence association 11 neither studies however attempted directly relate ide variants measures insulin metabolism
0.39201447.15277398.html.plaintext.txt	6	gene encoding insulin degrading enzyme ide located chromosome 10q23 q24 within region linked type 2 diabetes related quantitative traits 1 4 ide major enzyme responsible insulin proteolysis vitro 5 shares structural functional homology bacterial protease iii may function termination insulin response 67 mice ide hypofunction induced ide gene disruption leads hyperinsulinemia 8 furthermore ide activity diabetic goto kakizaki gk rat reduced 30 polymorphism ide likely main contributing factor 9 congruence positional functional data indicates sequence variation ide may play role modifying insulin metabolism human populations two recent genetic association studies investigated ide region relation type 2 diabetes one produced significant evidence effects type 2 diabetes plasma glucose levels 10 whereas explored case control models obtained evidence association 11 neither studies however attempted directly relate ide variants measures insulin metabolism
0.39201447.15277398.html.plaintext.txt	7	evaluate potential influence genetic variation ide insulin levels correlated quantitative traits haplotype tagging strategy used 12 swedish sample consisting 321 impaired glucose tolerance igt 403 nondiabetic control subjects table 1 study follows recent report 13 examined 26 polymorphic markers extending across ide relation alzheimer disease large swedish population used define regional linkage disequilibrium ld structure highlighted ld block spanning 276 kb around ide three single nucleotide polymorphism snp markers identified capable delineating common haplotypes 5 swedes subsequently used tests association
0.39201447.15277398.html.plaintext.txt	8	evaluate potential influence genetic variation ide insulin levels correlated quantitative traits haplotype tagging strategy used 12 swedish sample consisting 321 impaired glucose tolerance igt 403 nondiabetic control subjects table 1 study follows recent report 13 examined 26 polymorphic markers extending across ide relation alzheimer disease large swedish population used define regional linkage disequilibrium ld structure highlighted ld block spanning 276 kb around ide three single nucleotide polymorphism snp markers identified capable delineating common haplotypes 5 swedes subsequently used tests association
0.39201447.15277398.html.plaintext.txt	9	view table table 1 clinical characteristics igt nondiabetic control subjects
0.39201447.15277398.html.plaintext.txt	10	present study 14 snp markers extending locally across ide examined fig 1 including previously identified tag markers began genotyping entire male sample define ld structure identify common haplotypes 14 markers found hardy weinberg equilibrium pairwise marker correlations suggested strong ld region agreement earlier data 13 common haplotypes 5 frequency inferred haplotyper using 14 markers similar obtained based slightly modified marker set 13 ld estimates inferred haplotypes entire sample shown figs 2 3 respectively definition patil et al 14 08 used confirm studied region represent ld block also confirmed selection three tag markers equivalent previously used 13 would able delineate common haplotypes opted explore use alternative equally valid marker sets note variety different approaches exist defining optimal snp sets 15 explored use issues may relevance attempts replicating refuting present data ld structures differ markedly divergent populations kk kidd ajb personal communication
0.39201447.15277398.html.plaintext.txt	11	present study 14 snp markers extending locally across ide examined fig 1 including previously identified tag markers began genotyping entire male sample define ld structure identify common haplotypes 14 markers found hardy weinberg equilibrium pairwise marker correlations suggested strong ld region agreement earlier data 13 common haplotypes 5 frequency inferred haplotyper using 14 markers similar obtained based slightly modified marker set 13 ld estimates inferred haplotypes entire sample shown figs 2 3 respectively definition patil et al 14 08 used confirm studied region represent ld block also confirmed selection three tag markers equivalent previously used 13 would able delineate common haplotypes opted explore use alternative equally valid marker sets note variety different approaches exist defining optimal snp sets 15 explored use issues may relevance attempts replicating refuting present data ld structures differ markedly divergent populations kk kidd ajb personal communication
0.39201447.15277398.html.plaintext.txt	12	view larger version 48k fig 1 details examined snps ide
0.39201447.15277398.html.plaintext.txt	13	view larger version 68k fig 2 pairwise ld 14 snp markers extending across ide
0.39201447.15277398.html.plaintext.txt	14	view larger version 24k fig 3 common haplotypes extending across ide
0.39201447.15277398.html.plaintext.txt	15	initial analyses intention reduce number exploratory tests examining critical set phenotypes limited number haplotypic genotypes also referable diplotypes brevity opted use latter term throughout report principal criterion diplotype construction inferred high probability thus reflect fidelity combinations common haplotypes individual presence limited allelic heterogeneity advantageous single marker tests fail detect effects due insufficient complex patterns ld pathogenic variants addition testing many single markers requires substantial degree multiple testing selection quantitative phenotypes analyses included six traits typically examined relation diabetes 16 18 listed table 1 note studies 1920 investigated ide relation diabetes report efforts relate genotypes either insulin levels obesity trait distributions highly skewed partially skewed six studied phenotypes thus log transformed data modeled correlations traits extremely high expected data shown
0.39201447.15277398.html.plaintext.txt	16	initial analyses intention reduce number exploratory tests examining critical set phenotypes limited number haplotypic genotypes also referable diplotypes brevity opted use latter term throughout report principal criterion diplotype construction inferred high probability thus reflect fidelity combinations common haplotypes individual presence limited allelic heterogeneity advantageous single marker tests fail detect effects due insufficient complex patterns ld pathogenic variants addition testing many single markers requires substantial degree multiple testing selection quantitative phenotypes analyses included six traits typically examined relation diabetes 16 18 listed table 1 note studies 1920 investigated ide relation diabetes report efforts relate genotypes either insulin levels obesity trait distributions highly skewed partially skewed six studied phenotypes thus log transformed data modeled correlations traits extremely high expected data shown
0.39201447.15277398.html.plaintext.txt	17	diplotypes inferred using three selected haplotype tagging markers fig 3 tested six traits highlighted table 1 men women separately six eight possible haplotypes predicted using markers sequences h1 tcg h2 tca h3 cca h4 tta h5 ttg h6 ccg posterior probability estimates excess 080 phase calls represent various combinations haplotypes threshold set retaining individuals analyses significant consistent effects upon traits evident notable exception fasting glucose 2 h glucose levels importantly effects evident exclusively men agreement results obtained karamohamed et al 10 results analyses shown fig 4 data male sample presented analyses combined igt individuals nondiabetic control subjects adjusted uniform phenotypic differences including group identity factor anova models diplotype group interaction terms second order factorial anova models significant analyses based probabilistically inferred data considered important also explore models entail use phase known data accomplished excluding individuals heterozygous two sites individuals one heterozygote site definition phase known demonstrate additional analysis performed men four associated traits shown fig 4 insulin 2 h insulin homeostasis model assessment insulin resistance homa ir bmi results revealed association four significance highest bmi f7220 35 p 00014 data comparisons shown reference fig 4 groups excluded analysis h1h3 h2h5 h3h4 h3h5
0.39201447.15277398.html.plaintext.txt	18	diplotypes inferred using three selected haplotype tagging markers fig 3 tested six traits highlighted table 1 men women separately six eight possible haplotypes predicted using markers sequences h1 tcg h2 tca h3 cca h4 tta h5 ttg h6 ccg posterior probability estimates excess 080 phase calls represent various combinations haplotypes threshold set retaining individuals analyses significant consistent effects upon traits evident notable exception fasting glucose 2 h glucose levels importantly effects evident exclusively men agreement results obtained karamohamed et al 10 results analyses shown fig 4 data male sample presented analyses combined igt individuals nondiabetic control subjects adjusted uniform phenotypic differences including group identity factor anova models diplotype group interaction terms second order factorial anova models significant analyses based probabilistically inferred data considered important also explore models entail use phase known data accomplished excluding individuals heterozygous two sites individuals one heterozygote site definition phase known demonstrate additional analysis performed men four associated traits shown fig 4 insulin 2 h insulin homeostasis model assessment insulin resistance homa ir bmi results revealed association four significance highest bmi f7220 35 p 00014 data comparisons shown reference fig 4 groups excluded analysis h1h3 h2h5 h3h4 h3h5
0.39201447.15277398.html.plaintext.txt	19	view larger version 114k fig 4 diplotype association quantitative traits men mean values plus minus se fasting glucose 2 h glucose b fasting insulin c 2 h insulin d homa e bmi f men according diplotype groups estimated using haplotyper untransformed data shown categories less six observations excluded f ratios anova omnibus tests performed log transformed data traits associated p values shown upper right corner diagram number individuals category shown base column
0.39201447.15277398.html.plaintext.txt	20	attempt refine possible position pathogenic variants region single marker tests conducted phenotypes provided evidence association diplotype models considering multiple testing issues noted strongest individual finding homa ir p 00001 affords 500 individual tests strict multiple testing correction renders finding insignificant given 005 tests using 14 markers performed male sample diplotype analyses gave us priori reason suspect latent associations single markers would present female set results shown fig 5 consistent effects rs2251101 rs2249960 seen upon traits common allele rs2251101 rare allele rs2249960 associated lower trait levels marker rs2251101 rs1887922 tested fasting glucose levels latter specifically reported karamohamed et al 10 two markers extremely high ld r2 05 fig 2 neither marker showed evidence association acknowledge present study less power aforementioned one result rs2251101 upon multiple phenotypes nonetheless supports likely presence primary trait modifying sequence 3 region ide speculated 10 effect rs1887922 2 h insulin levels significant however albeit considerably attenuated comparison rs2251101 explore effects rs2251101 final model fitted rare allele homozygotes heterozygotes combined compared common allele homozygotes results follows f1366 91 p 00028 f1363 184 p 0000023 f1365 70 p 00085 f1365 114 p 00008 fasting insulin 2 h insulin homa ir bmi respectively although throughout study tests conducted combined igt normal samples correction applied possible differences considered important confirm effect exists populations least one analysis using model focusing rs2251101 marker 2 h insulin trait significant effects observed igt f1155 130 p 00004 normal f1206 65 p 0011 groups cases common allele homozygote group lowest trait levels
0.39201447.15277398.html.plaintext.txt	21	attempt refine possible position pathogenic variants region single marker tests conducted phenotypes provided evidence association diplotype models considering multiple testing issues noted strongest individual finding homa ir p 00001 affords 500 individual tests strict multiple testing correction renders finding insignificant given 005 tests using 14 markers performed male sample diplotype analyses gave us priori reason suspect latent associations single markers would present female set results shown fig 5 consistent effects rs2251101 rs2249960 seen upon traits common allele rs2251101 rare allele rs2249960 associated lower trait levels marker rs2251101 rs1887922 tested fasting glucose levels latter specifically reported karamohamed et al 10 two markers extremely high ld r2 05 fig 2 neither marker showed evidence association acknowledge present study less power aforementioned one result rs2251101 upon multiple phenotypes nonetheless supports likely presence primary trait modifying sequence 3 region ide speculated 10 effect rs1887922 2 h insulin levels significant however albeit considerably attenuated comparison rs2251101 explore effects rs2251101 final model fitted rare allele homozygotes heterozygotes combined compared common allele homozygotes results follows f1366 91 p 00028 f1363 184 p 0000023 f1365 70 p 00085 f1365 114 p 00008 fasting insulin 2 h insulin homa ir bmi respectively although throughout study tests conducted combined igt normal samples correction applied possible differences considered important confirm effect exists populations least one analysis using model focusing rs2251101 marker 2 h insulin trait significant effects observed igt f1155 130 p 00004 normal f1206 65 p 0011 groups cases common allele homozygote group lowest trait levels
0.39201447.15277398.html.plaintext.txt	22	view larger version 49k fig 5 single marker quantitative trait tests men
0.39201447.15277398.html.plaintext.txt	23	summary provide strong evidence sequence variation within near ide contributes variability measures insulin metabolism several compelling features results first study study karamohamed et al 10 suggest primary functional variant occurs 3 region ide addition marker previously exhibited maximum evidence association rs1887922 10 strong ld marker rs2251101 greatest effect present study true pathogenic variant likely high ld indeed could one markers second studies suggest effects either exclusively predominantly male subjects numerous studies detected genetic effects exclusively men 2021 sex specificity may major confounding factor genetic analyses 22 third marker strongest association quantitative traits related alzheimer disease recent study 13 rs2251101 among 26 markers importantly however present analyses suggest may one functionally relevant polymorphic site near ide evident diplotype models single haplotype appears responsible either elevating reducing trait levels number possible interactions also apparent evidence allelic heterogeneity interaction general make fine mapping responsible variants daunting task 23 need considered future studies investigating ide region
0.39201447.15277398.html.plaintext.txt	24	summary provide strong evidence sequence variation within near ide contributes variability measures insulin metabolism several compelling features results first study study karamohamed et al 10 suggest primary functional variant occurs 3 region ide addition marker previously exhibited maximum evidence association rs1887922 10 strong ld marker rs2251101 greatest effect present study true pathogenic variant likely high ld indeed could one markers second studies suggest effects either exclusively predominantly male subjects numerous studies detected genetic effects exclusively men 2021 sex specificity may major confounding factor genetic analyses 22 third marker strongest association quantitative traits related alzheimer disease recent study 13 rs2251101 among 26 markers importantly however present analyses suggest may one functionally relevant polymorphic site near ide evident diplotype models single haplotype appears responsible either elevating reducing trait levels number possible interactions also apparent evidence allelic heterogeneity interaction general make fine mapping responsible variants daunting task 23 need considered future studies investigating ide region
0.39201447.15277398.html.plaintext.txt	25	directly addressed question whether variation ide influences risk type 2 diabetes two studies tested relationship produced either modest evidence association despite examining large clinical samples study provides evidence association fasting glucose levels primary phenotype used distinguish diabetic patients rather present data likely capture fundamental influence ide upon circulating insulin levels whereby genetically determined deficit enzyme activity may lead hyperinsulinemia could manifest modulator role type 2 diabetes might relevant phenotypes coronary heart disease 24 primary hypertension 25 believe continued replication efforts normal morbid populations well functional studies highly merited needed elucidate molecular basis clinical relevance observed phenotypic effects
0.39201447.15277398.html.plaintext.txt	26	directly addressed question whether variation ide influences risk type 2 diabetes two studies tested relationship produced either modest evidence association despite examining large clinical samples study provides evidence association fasting glucose levels primary phenotype used distinguish diabetic patients rather present data likely capture fundamental influence ide upon circulating insulin levels whereby genetically determined deficit enzyme activity may lead hyperinsulinemia could manifest modulator role type 2 diabetes might relevant phenotypes coronary heart disease 24 primary hypertension 25 believe continued replication efforts normal morbid populations well functional studies highly merited needed elucidate molecular basis clinical relevance observed phenotypic effects
0.39201447.15277398.html.plaintext.txt	27	research design methods top abstract research design methods references clinical characteristics subjects igt nondiabetic healthy individuals provided table 1 total 321 igt subjects 403 nondiabetic control subjects selected stockholm diabetes prevention program 16 18 subjects igt previously diagnosed according world health organization 1985 criteria medical treatment nondiabetic healthy subjects normal birth body weight bmi 25 kgm2 relatives first second degree diabetes participants study swedish ancestry selected districts stockholm informed consent received subjects study approved local ethics committee karolinska institute genomic dna extracted peripheral blood using puregene dna purification kit gentra minneapolis mn
0.39201447.15277398.html.plaintext.txt	28	research design methods top abstract research design methods references clinical characteristics subjects igt nondiabetic healthy individuals provided table 1 total 321 igt subjects 403 nondiabetic control subjects selected stockholm diabetes prevention program 16 18 subjects igt previously diagnosed according world health organization 1985 criteria medical treatment nondiabetic healthy subjects normal birth body weight bmi 25 kgm2 relatives first second degree diabetes participants study swedish ancestry selected districts stockholm informed consent received subjects study approved local ethics committee karolinska institute genomic dna extracted peripheral blood using puregene dna purification kit gentra minneapolis mn
0.39201447.15277398.html.plaintext.txt	29	quantitative trait measurements insulin resistance assessed homa 26 homa ir calculated present study using formula fasting plasma glucose millimoles per liter x fasting plasma insulin milliunits per milliliter225
0.39201447.15277398.html.plaintext.txt	30	quantitative trait measurements insulin resistance assessed homa 26 homa ir calculated present study using formula fasting plasma glucose millimoles per liter x fasting plasma insulin milliunits per milliliter225
0.39201447.15277398.html.plaintext.txt	31	snp selection verification 14 snps examined study listed table 2 details may found dbsnp database httpwwwncbinlmnihgovsnp respective ids surrounding 50 bp sequences direction examined repeats duplicated sequences using repeatmasker httpwwwrepeatmaskerorg blast httpwwwncbinlmnihgovblast verify snps polymorphic study populations snp tested set 32 swedish control samples assays 32 samples monomorphic excluded analysis convenience nomenclature used throughout report refer snps used recent report 13
0.39201447.15277398.html.plaintext.txt	32	genotyping genotyping snps performed using induced fluorescence resonance energy transfer modification dynamic allele specific hybridization 2728 pcrs run 10 20 microl volumes 15 mmoll mgcl2 using 5 20 ng genomic dna oligonucleotide sequences dynamic allele specific hybridization pcr assays snps presented previously 13
0.39201447.15277398.html.plaintext.txt	33	statistical analysis deviation hardy weinberg equilibrium genotypes individual loci assessed using 2 statistic deviation normality trait distributions assessed using kolgomorov smirnov test correlations traits established using spearman statistic tests association genotypes quantitative traits performed using anova log transformed data included age group igt normal covariates analyses statistical analyses performed using statview version 50 abacus concepts piscataway nj haplotype frequencies estimated using haplotyper program 29 ld marker pairs estimated using r2 metric 30
0.39201447.15277398.html.plaintext.txt	34	acknowledgments study supported novo nordisk consortium swedish research council loo hans osterman foundation vetenskapligt arbete inom diabetologi foundation swedish diabetes association
0.39201447.15277398.html.plaintext.txt	35	thank subjects participating present study dr bo ding ylva behr valuable discussion camilla lagerberg yvonne stromberg excellent assistance
0.39201447.15277398.html.plaintext.txt	36	thank subjects participating present study dr bo ding ylva behr valuable discussion camilla lagerberg yvonne stromberg excellent assistance
0.39201447.15277398.html.plaintext.txt	37	footnotes homa ir homeostasis model assessment insulin resistance ide insulin degrading enzyme igt impaired glucose tolerance ld linkage disequilibrium snp single nucleotide polymorphism
0.39201447.15277398.html.plaintext.txt	38	address correspondence reprint requests suad efendic rolf luft center diabetes research department molecular medicine l6b2 karolinska hospital se 171 76 stockholm sweden e mail suadefendicatmolmedkise
0.39201447.15277398.html.plaintext.txt	39	received publication february 23 2003 accepted revised form april 22 2004
0.39201447.15277398.html.plaintext.txt	40	references top abstract research design methods references meigs jb panhuysen ci myers rh wilson pw cupples la genome wide scan loci linked plasma levels glucose hba1c community based sample caucasian pedigrees framingham offspring study diabetes51 833 8402002abstractfree full text wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n rao pv wishart m bottazzo gf foxon r howell smedley d cardon lr menzel mccarthy mi genomewide scan loci predisposing type 2 diabetes u k population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1q j hum genet69 553 5692001medline ghosh watanabe rm valle tt hauser er magnuson vl langefeld cd ally ds mohlke kl silander k kohtamaki k chines p balow j jr birznieks g chang j eldridge w erdos mr karanjawala ze knapp ji kudelko k martin c morales mena musick musick pfahl c porter r rayman jb finland united states investigation non insulin dependent diabetes mellitus genetics fusion study autosomal genome scan genes predispose type 2 diabetes j hum genet67 1174 11852000medline duggirala r blangero j almasy l dyer td williams kl leach rj o connell p stern mp linkage type 2 diabetes mellitus age onset genetic location chromosome 10q mexican americans j hum genet64 1127 11401999medline duckworth wc bennett rg hamel fg insulin degradation progress potential endocr rev19 608 6241998abstractfree full text affholter ja cascieri ma bayne ml brange j casaretto m roth ra identification residues insulin molecule important binding insulin degrading enzyme biochemistry29 7727 77331990medline affholter ja hsieh cl francke u roth ra insulin degrading enzyme stable expression human complementary dna characterization protein product chromosomal mapping human mouse genes mol endocrinol4 1125 11351990abstract farris w mansourian chang y lindsley l eckman ea frosch mp eckman cb tanzi re selkoe dj guenette insulin degrading enzyme regulates levels insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivo proc natl acad sci u a100 4162 41672003abstractfree full text fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk rats hum mol genet9 2149 21582000abstractfree full text karamohamed demissie volcjak j liu c heard costa n liu j shoemaker cm panhuysen ci meigs jb wilson p atwood ld cupples la herbert polymorphisms insulin degrading enzyme gene associated type 2 diabetes men nhlbi framingham heart study diabetes52 1562 15672003abstractfree full text groves cj wiltshire smedley d owen kr frayling tm walker m hitman ga levy jc o rahilly menzel hattersley mccarthy mi association haplotype analysis insulin degrading enzyme ide gene strong positional biological candidate type 2 diabetes susceptibility diabetes52 1300 13052003abstractfree full text johnson gc esposito l barratt bj smith heward j di genova g ueda h cordell hj eaves ia dudbridge f twells rc payne f hughes w nutland stevens h carr p tuomilehto wolf e tuomilehto j gough sc clayton dg todd ja haplotype tagging identification common disease genes nat genet29 233 2372001medline prince ja feuk l gu hf gatz m blennow k brookes aj genetic variation haplotype block spanning ide knsl1 hhex influences alzheimer disease hum mutat22 363 3712003medline patil n berno aj hinds da barrett wa doshi jm hacker cr kautzer cr lee dh marjoribanks c mcdonough dp nguyen bt norris mc sheehan jb shen n stern d stokowski rp thomas dj trulson mo vyas kr frazer ka blocks limited haplotype diversity revealed high resolution scanning human chromosome 21 science294 1719 17232001abstractfree full text horne bd camp nj principal component analysis selection optimal snp sets capture intragenic variation genet epidemiol26 11 212004medline carlsson persson p g grill v alvarsson m efendic norman svanstrom l ostenson c g weight history glucose tolerance insulin levels middle aged swedish men j epidemiology148 539 5451998abstract grill v persson g carlsson norman alvarsson m ostensson c g svanstrom l efendic family history diabetes middle aged swedish men gender unrelated factor associated insulinopenia newly diagnosed diabetic subjects diabetologia42 15 231999 agardh ee ahlbom andersson efendic grill v hallqvist j norman ostenson cg work stress low sense coherence associated type 2 diabetes middle aged swedish women diabetes care26 719 7242003abstractfree full text zondervan kt cardon lr complex interplay among factors influence allelic association nat rev genet5 89 1002004medline o donnell cj lindpaintner k larson mg rao vs ordovas jm schaefer ej myers rh levy d evidence association genetic linkage angiotensin converting enzyme locus hypertension blood pressure men women framingham heart study circulation97 1766 17721998abstractfree full text wittrup hh tybjaerg hansen steffensen r deeb ss brunzell jd jensen g nordestgaard bg mutations lipoprotein lipase gene associated ischemic heart disease men copenhagen city heart study arterioscler thromb vasc biol19 1535 15401999abstractfree full text mccarthy jj meyer j moliterno dj newby lk rogers wj topol ej evidence substantial effect modification gender large scale genetic association study metabolic syndrome among coronary heart disease patients hum genet114 87 982003medline cox r bouzekri n martin southam l hugill golamaully m cooper r adeyemo soubrier f ward r angiotensin 1 converting enzyme ace plasma concentration influenced multiple ace linked quantitative trait nucleotides hum mol genet11 2969 29772002abstractfree full text despres jp lamarche b mauriege p cantin b lupien pj dagenais gr risk factors ischaemic heart disease time measure insulin editorial eur heart j17 1453 14541996medline andersen ub olsen mh dige petersen h ibsen h exercise blood pressure related insulin resistance subjects two hypertensive parents blood press12 314 3182003medline matthews dr rudenski naylor ba treacher df turner rc homeostasis model assessment insulin resistance beta cell function fasting plasma glucose insulin concentrations man diabetologia28 412 4191985medline jobs m howell wm stromqvist l mayr brookes aj dash 2 flexible low cost high throughput snp genotyping dynamic allele specific hybridization membrane arrays genome res13 916 9242003abstractfree full text prince ja feuk l howell wm jobs m emahazion blennow k brookes aj robust accurate single nucleotide polymorphism genotyping dynamic allele specific hybridization dash design criteria assay validation genome res11 152 1622001abstractfree full text niu qin zs xu x liu js bayesian haplotype inference multiple linked single nucleotide polymorphisms j hum genet70 157 1692002medline hill wg estimation linkage disequilibrium randomly mating populations heredity33 229 2391974medline
0.39201447.15277398.html.plaintext.txt	41	references top abstract research design methods references meigs jb panhuysen ci myers rh wilson pw cupples la genome wide scan loci linked plasma levels glucose hba1c community based sample caucasian pedigrees framingham offspring study diabetes51 833 8402002abstractfree full text wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n rao pv wishart m bottazzo gf foxon r howell smedley d cardon lr menzel mccarthy mi genomewide scan loci predisposing type 2 diabetes u k population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1q j hum genet69 553 5692001medline ghosh watanabe rm valle tt hauser er magnuson vl langefeld cd ally ds mohlke kl silander k kohtamaki k chines p balow j jr birznieks g chang j eldridge w erdos mr karanjawala ze knapp ji kudelko k martin c morales mena musick musick pfahl c porter r rayman jb finland united states investigation non insulin dependent diabetes mellitus genetics fusion study autosomal genome scan genes predispose type 2 diabetes j hum genet67 1174 11852000medline duggirala r blangero j almasy l dyer td williams kl leach rj o connell p stern mp linkage type 2 diabetes mellitus age onset genetic location chromosome 10q mexican americans j hum genet64 1127 11401999medline duckworth wc bennett rg hamel fg insulin degradation progress potential endocr rev19 608 6241998abstractfree full text affholter ja cascieri ma bayne ml brange j casaretto m roth ra identification residues insulin molecule important binding insulin degrading enzyme biochemistry29 7727 77331990medline affholter ja hsieh cl francke u roth ra insulin degrading enzyme stable expression human complementary dna characterization protein product chromosomal mapping human mouse genes mol endocrinol4 1125 11351990abstract farris w mansourian chang y lindsley l eckman ea frosch mp eckman cb tanzi re selkoe dj guenette insulin degrading enzyme regulates levels insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivo proc natl acad sci u a100 4162 41672003abstractfree full text fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk rats hum mol genet9 2149 21582000abstractfree full text karamohamed demissie volcjak j liu c heard costa n liu j shoemaker cm panhuysen ci meigs jb wilson p atwood ld cupples la herbert polymorphisms insulin degrading enzyme gene associated type 2 diabetes men nhlbi framingham heart study diabetes52 1562 15672003abstractfree full text groves cj wiltshire smedley d owen kr frayling tm walker m hitman ga levy jc o rahilly menzel hattersley mccarthy mi association haplotype analysis insulin degrading enzyme ide gene strong positional biological candidate type 2 diabetes susceptibility diabetes52 1300 13052003abstractfree full text johnson gc esposito l barratt bj smith heward j di genova g ueda h cordell hj eaves ia dudbridge f twells rc payne f hughes w nutland stevens h carr p tuomilehto wolf e tuomilehto j gough sc clayton dg todd ja haplotype tagging identification common disease genes nat genet29 233 2372001medline prince ja feuk l gu hf gatz m blennow k brookes aj genetic variation haplotype block spanning ide knsl1 hhex influences alzheimer disease hum mutat22 363 3712003medline patil n berno aj hinds da barrett wa doshi jm hacker cr kautzer cr lee dh marjoribanks c mcdonough dp nguyen bt norris mc sheehan jb shen n stern d stokowski rp thomas dj trulson mo vyas kr frazer ka blocks limited haplotype diversity revealed high resolution scanning human chromosome 21 science294 1719 17232001abstractfree full text horne bd camp nj principal component analysis selection optimal snp sets capture intragenic variation genet epidemiol26 11 212004medline carlsson persson p g grill v alvarsson m efendic norman svanstrom l ostenson c g weight history glucose tolerance insulin levels middle aged swedish men j epidemiology148 539 5451998abstract grill v persson g carlsson norman alvarsson m ostensson c g svanstrom l efendic family history diabetes middle aged swedish men gender unrelated factor associated insulinopenia newly diagnosed diabetic subjects diabetologia42 15 231999 agardh ee ahlbom andersson efendic grill v hallqvist j norman ostenson cg work stress low sense coherence associated type 2 diabetes middle aged swedish women diabetes care26 719 7242003abstractfree full text zondervan kt cardon lr complex interplay among factors influence allelic association nat rev genet5 89 1002004medline o donnell cj lindpaintner k larson mg rao vs ordovas jm schaefer ej myers rh levy d evidence association genetic linkage angiotensin converting enzyme locus hypertension blood pressure men women framingham heart study circulation97 1766 17721998abstractfree full text wittrup hh tybjaerg hansen steffensen r deeb ss brunzell jd jensen g nordestgaard bg mutations lipoprotein lipase gene associated ischemic heart disease men copenhagen city heart study arterioscler thromb vasc biol19 1535 15401999abstractfree full text mccarthy jj meyer j moliterno dj newby lk rogers wj topol ej evidence substantial effect modification gender large scale genetic association study metabolic syndrome among coronary heart disease patients hum genet114 87 982003medline cox r bouzekri n martin southam l hugill golamaully m cooper r adeyemo soubrier f ward r angiotensin 1 converting enzyme ace plasma concentration influenced multiple ace linked quantitative trait nucleotides hum mol genet11 2969 29772002abstractfree full text despres jp lamarche b mauriege p cantin b lupien pj dagenais gr risk factors ischaemic heart disease time measure insulin editorial eur heart j17 1453 14541996medline andersen ub olsen mh dige petersen h ibsen h exercise blood pressure related insulin resistance subjects two hypertensive parents blood press12 314 3182003medline matthews dr rudenski naylor ba treacher df turner rc homeostasis model assessment insulin resistance beta cell function fasting plasma glucose insulin concentrations man diabetologia28 412 4191985medline jobs m howell wm stromqvist l mayr brookes aj dash 2 flexible low cost high throughput snp genotyping dynamic allele specific hybridization membrane arrays genome res13 916 9242003abstractfree full text prince ja feuk l howell wm jobs m emahazion blennow k brookes aj robust accurate single nucleotide polymorphism genotyping dynamic allele specific hybridization dash design criteria assay validation genome res11 152 1622001abstractfree full text niu qin zs xu x liu js bayesian haplotype inference multiple linked single nucleotide polymorphisms j hum genet70 157 1692002medline hill wg estimation linkage disequilibrium randomly mating populations heredity33 229 2391974medline
0.40214586.14747300.html.plaintext.txt	0	increased risk type 2 diabetes alzheimer disease juliette janson12 thomas laedtke1 joseph e parisi2 peter o brien3 ronald c petersen4 peter c butler5
0.40214586.14747300.html.plaintext.txt	1	increased risk type 2 diabetes alzheimer disease juliette janson12 thomas laedtke1 joseph e parisi2 peter o brien3 ronald c petersen4 peter c butler5
0.40214586.14747300.html.plaintext.txt	2	1 endocrine research unit mayo clinic rochester minnesota 2 department pathology mayo clinic rochester minnesota 3 department biostatistics mayo clinic rochester minnesota 4 department neurology health sciences research mayo clinic rochester minnesota 5 division endocrinology diabetes keck school medicine university southern california los angeles california
0.40214586.14747300.html.plaintext.txt	3	abstract top abstract research design methods results discussion references alzheimer disease type 2 diabetes characterized increased prevalence aging genetic predisposition comparable pathological features islet brain amyloid derived amyloid ss protein brain alzheimer disease islet amyloid derived islet amyloid polypeptide pancreas type 2 diabetes evidence growing link precursors amyloid deposition brain pancreas pathogenesis alzheimer disease type 2 diabetes respectively given similarities questioned whether may common underlying mechanism predisposing islet cerebral amyloid address first examined prevalence type 2 diabetes community based controlled study mayo clinic alzheimer disease patient registry adpr follows patients alzheimer disease versus control subjects without alzheimer disease addition clinical study performed pathological study autopsy cases community determine whether increased prevalence islet amyloid patients alzheimer disease increased prevalence cerebral amyloid patients type 2 diabetes patients enrolled adpr alzheimer disease n 100 non alzheimer disease control subjects n 138 classified according fasting glucose concentration fpg nondiabetic fpg 110 mgdl impaired fasting glucose ifg fpg 110 125 mgdl type 2 diabetes fpg 126 mgdl mean slope fpg 10 years case also compared alzheimer disease non alzheimer disease control subjects pancreas brain examined autopsy specimens obtained 105 humans first 28 cases alzheimer disease disease vs 21 non alzheimer disease control subjects second 35 subjects type 2 diabetes vs 21 non type 2 diabetes control subjects presence islet brain amyloid type 2 diabetes 35 vs 18 p 005 ifg 46 vs 24 p 001 prevalent alzheimer disease versus non alzheimer disease control subjects 81 cases alzheimer disease either type 2 diabetes ifg slope increase fpg age 10 years also greater alzheimer disease non alzheimer disease control subjects p 001 islet amyloid frequent p 005 extensive p 005 patients alzheimer disease non alzheimer disease control subjects however diffuse neuritic plaques common type 2 diabetes control subjects cases type 2 diabetes present duration type 2 diabetes correlated density diffuse p 0001 neuritic plaques p 001 community cohort southeast minnesota type 2 diabetes ifg common patients alzheimer disease control subjects pathological hallmark type 2 diabetes islet amyloid however increase brain plaque formation cases type 2 diabetes although present correlated extent duration diabetes data support hypothesis patients alzheimer disease vulnerable type 2 diabetes possibility linkage processes responsible loss brain cells ss cells diseases
0.40214586.14747300.html.plaintext.txt	4	abstract top abstract research design methods results discussion references alzheimer disease type 2 diabetes characterized increased prevalence aging genetic predisposition comparable pathological features islet brain amyloid derived amyloid ss protein brain alzheimer disease islet amyloid derived islet amyloid polypeptide pancreas type 2 diabetes evidence growing link precursors amyloid deposition brain pancreas pathogenesis alzheimer disease type 2 diabetes respectively given similarities questioned whether may common underlying mechanism predisposing islet cerebral amyloid address first examined prevalence type 2 diabetes community based controlled study mayo clinic alzheimer disease patient registry adpr follows patients alzheimer disease versus control subjects without alzheimer disease addition clinical study performed pathological study autopsy cases community determine whether increased prevalence islet amyloid patients alzheimer disease increased prevalence cerebral amyloid patients type 2 diabetes patients enrolled adpr alzheimer disease n 100 non alzheimer disease control subjects n 138 classified according fasting glucose concentration fpg nondiabetic fpg 110 mgdl impaired fasting glucose ifg fpg 110 125 mgdl type 2 diabetes fpg 126 mgdl mean slope fpg 10 years case also compared alzheimer disease non alzheimer disease control subjects pancreas brain examined autopsy specimens obtained 105 humans first 28 cases alzheimer disease disease vs 21 non alzheimer disease control subjects second 35 subjects type 2 diabetes vs 21 non type 2 diabetes control subjects presence islet brain amyloid type 2 diabetes 35 vs 18 p 005 ifg 46 vs 24 p 001 prevalent alzheimer disease versus non alzheimer disease control subjects 81 cases alzheimer disease either type 2 diabetes ifg slope increase fpg age 10 years also greater alzheimer disease non alzheimer disease control subjects p 001 islet amyloid frequent p 005 extensive p 005 patients alzheimer disease non alzheimer disease control subjects however diffuse neuritic plaques common type 2 diabetes control subjects cases type 2 diabetes present duration type 2 diabetes correlated density diffuse p 0001 neuritic plaques p 001 community cohort southeast minnesota type 2 diabetes ifg common patients alzheimer disease control subjects pathological hallmark type 2 diabetes islet amyloid however increase brain plaque formation cases type 2 diabetes although present correlated extent duration diabetes data support hypothesis patients alzheimer disease vulnerable type 2 diabetes possibility linkage processes responsible loss brain cells ss cells diseases
0.40214586.14747300.html.plaintext.txt	5	islet langerhans type 2 diabetes characterized ss cell loss 12 islet amyloid derived islet amyloid polypeptide iapp 3 5 protein coexpressed secreted insulin ss cells brain dysfunction alzheimer disease characterized loss neocortical neurons 6 focal amyloid deposits consist locally expressed amyloid ss protein assp 7 13 prevalence alzheimer disease type 2 diabetes increases age genetic components 14 19
0.40214586.14747300.html.plaintext.txt	6	islet langerhans type 2 diabetes characterized ss cell loss 12 islet amyloid derived islet amyloid polypeptide iapp 3 5 protein coexpressed secreted insulin ss cells brain dysfunction alzheimer disease characterized loss neocortical neurons 6 focal amyloid deposits consist locally expressed amyloid ss protein assp 7 13 prevalence alzheimer disease type 2 diabetes increases age genetic components 14 19
0.40214586.14747300.html.plaintext.txt	7	assp iapp spontaneously form amyloid aggregates aqueous environment 782021 role aggregates iapp assp ss cell cortical neuronal death type 2 diabetes alzheimer disease controversial small amyloid aggregates either proteins cytotoxic 22 25 mechanism cytotoxicity mediated small protein aggregates hypothesized induction membrane damage 25 27 case iapp evidence exists suggest abnormal aggregation occurs initially intracellularly cell death iapp derived fibrils accumulate extracellularly 242829 similar mechanisms also possible alzheimer disease vivo even though iapp assp present aqueous environment health neither protein forms fibrils suggesting mechanisms exist prevent otherwise spontaneous process mechanisms likely include chaperone protein pathway system protein trafficking via intracellular binding proteins chaperone proteins bind nascent proteins facilitate transport within cell 30
0.40214586.14747300.html.plaintext.txt	8	assp iapp spontaneously form amyloid aggregates aqueous environment 782021 role aggregates iapp assp ss cell cortical neuronal death type 2 diabetes alzheimer disease controversial small amyloid aggregates either proteins cytotoxic 22 25 mechanism cytotoxicity mediated small protein aggregates hypothesized induction membrane damage 25 27 case iapp evidence exists suggest abnormal aggregation occurs initially intracellularly cell death iapp derived fibrils accumulate extracellularly 242829 similar mechanisms also possible alzheimer disease vivo even though iapp assp present aqueous environment health neither protein forms fibrils suggesting mechanisms exist prevent otherwise spontaneous process mechanisms likely include chaperone protein pathway system protein trafficking via intracellular binding proteins chaperone proteins bind nascent proteins facilitate transport within cell 30
0.40214586.14747300.html.plaintext.txt	9	previously hypothesized iapp amyloid formation type 2 diabetes may occur circumstances genetic variance results relative decreased affinity chaperone protein pathway trafficking iapp 31 plausible low affinity binding one chaperone proteins iapp may shared similar low affinity binding assp support hypothesis schwartz 32 suggested might relationship amyloid deposits brain pancreatic islets
0.40214586.14747300.html.plaintext.txt	10	previously hypothesized iapp amyloid formation type 2 diabetes may occur circumstances genetic variance results relative decreased affinity chaperone protein pathway trafficking iapp 31 plausible low affinity binding one chaperone proteins iapp may shared similar low affinity binding assp support hypothesis schwartz 32 suggested might relationship amyloid deposits brain pancreatic islets
0.40214586.14747300.html.plaintext.txt	11	used clinical studies living patients community based control subjects pathological studies examine existence shared risk alzheimer disease type 2 diabetes clinical studies took advantage unique community based olmsted county mn cohort well characterized patients alzheimer disease control subjects without alzheimer disease 33 address question type 2 diabetes common alzheimer disease pathology studies studied brain pancreas autopsy cases community address hypotheses 1 islet amyloid frequent patients alzheimer disease control subjects without alzheimer disease 2 amyloid deposits common brain patients type 2 diabetes nondiabetic humans
0.40214586.14747300.html.plaintext.txt	12	used clinical studies living patients community based control subjects pathological studies examine existence shared risk alzheimer disease type 2 diabetes clinical studies took advantage unique community based olmsted county mn cohort well characterized patients alzheimer disease control subjects without alzheimer disease 33 address question type 2 diabetes common alzheimer disease pathology studies studied brain pancreas autopsy cases community address hypotheses 1 islet amyloid frequent patients alzheimer disease control subjects without alzheimer disease 2 amyloid deposits common brain patients type 2 diabetes nondiabetic humans
0.40214586.14747300.html.plaintext.txt	13	research design methods top abstract research design methods results discussion references clinical studies primary objective mayo clinic alzheimer disease patient registry adpr acquire cohort patients alzheimer disease matched non alzheimer disease control subjects assessment progression alzheimer disease clinically respect imaging neurological studies patients southeastern minnesota dementia identified time routine general medical examination department community internal medicine mayo clinic studies approved mayo clinic institutional review board suspicion alzheimer disease routine periodic medical examination neurological evaluation included mini mental state exam geriatric depression scale hachinski ischemic scale short test mental status record independent living extensive neuropsychological testing performed 33 age sex matched control subjects randomly identified community clinics enrolled cases detailed evaluation confirm rule control subjects alzheimer disease patient enrolled adpr case alzheimer disease control followed annually clinical studies included fasting blood glucose measurement recruitment adpr haphazard ie deliberately biased respect presence absence diabetes blood glucose concentration exclusion criteria 1 chronic treatment glucocorticoids 2 history pancreatitis 3 type 1 diabetes distinction type 1 type 2 diabetes made conventional clinical criteria features favoring type 1 diabetes included lean bmi weight loss young age onset insulin requirement onset documented ketoacidosis presence autoimmune diseases family history autoimmune disease features favoring type 2 diabetes included strong family history prolonged insulin independent treatment obesity absence autoimmune diseases later age onset acknowledged distinction type 1 type 2 diabetes without error view large number cases present studies high prevalence type 2 versus type 1 diabetes unlikely conclusions present studies influenced erroneous inclusion cases type 1 diabetes table 1
0.40214586.14747300.html.plaintext.txt	14	research design methods top abstract research design methods results discussion references clinical studies primary objective mayo clinic alzheimer disease patient registry adpr acquire cohort patients alzheimer disease matched non alzheimer disease control subjects assessment progression alzheimer disease clinically respect imaging neurological studies patients southeastern minnesota dementia identified time routine general medical examination department community internal medicine mayo clinic studies approved mayo clinic institutional review board suspicion alzheimer disease routine periodic medical examination neurological evaluation included mini mental state exam geriatric depression scale hachinski ischemic scale short test mental status record independent living extensive neuropsychological testing performed 33 age sex matched control subjects randomly identified community clinics enrolled cases detailed evaluation confirm rule control subjects alzheimer disease patient enrolled adpr case alzheimer disease control followed annually clinical studies included fasting blood glucose measurement recruitment adpr haphazard ie deliberately biased respect presence absence diabetes blood glucose concentration exclusion criteria 1 chronic treatment glucocorticoids 2 history pancreatitis 3 type 1 diabetes distinction type 1 type 2 diabetes made conventional clinical criteria features favoring type 1 diabetes included lean bmi weight loss young age onset insulin requirement onset documented ketoacidosis presence autoimmune diseases family history autoimmune disease features favoring type 2 diabetes included strong family history prolonged insulin independent treatment obesity absence autoimmune diseases later age onset acknowledged distinction type 1 type 2 diabetes without error view large number cases present studies high prevalence type 2 versus type 1 diabetes unlikely conclusions present studies influenced erroneous inclusion cases type 1 diabetes table 1
0.40214586.14747300.html.plaintext.txt	15	view table table 1 study cases clinical studies
0.40214586.14747300.html.plaintext.txt	16	protocol 1 type 2 diabetes common alzheimer disease recruitment criteria provided total 100 patients alzheimer disease 138 non alzheimer disease control subjects protocol 1 cases control subjects classified according criteria american diabetes association one three groups nondiabetic 110 mgdl impaired fasting glucose ifg 110 125 mgdl type 2 diabetes 126 mgdl based recent glucose concentration measurements individuals taking blood glucose lowering treatment diabetes classified type 2 diabetes regardless recent fasting glucose concentration
0.40214586.14747300.html.plaintext.txt	17	protocol 1 type 2 diabetes common alzheimer disease recruitment criteria provided total 100 patients alzheimer disease 138 non alzheimer disease control subjects protocol 1 cases control subjects classified according criteria american diabetes association one three groups nondiabetic 110 mgdl impaired fasting glucose ifg 110 125 mgdl type 2 diabetes 126 mgdl based recent glucose concentration measurements individuals taking blood glucose lowering treatment diabetes classified type 2 diabetes regardless recent fasting glucose concentration
0.40214586.14747300.html.plaintext.txt	18	protocol 2 increase fasting plasma glucose age greater alzheimer disease also examined changes fasting plasma glucose fpg aging cohort patients subject regressed annual median fpg value age used obtain predicted fpg value subject decade also compare slopes regression lines groups alzheimer disease versus control subjects using two sided rank sum test included analysis patients required fpg values recorded spanned least 10 consecutive years age 50 greater least one value available calendar year ages border050 years considered criteria resulted study population 52 patients alzheimer disease 105 non alzheimer disease control subjects
0.40214586.14747300.html.plaintext.txt	19	protocol 2 increase fasting plasma glucose age greater alzheimer disease also examined changes fasting plasma glucose fpg aging cohort patients subject regressed annual median fpg value age used obtain predicted fpg value subject decade also compare slopes regression lines groups alzheimer disease versus control subjects using two sided rank sum test included analysis patients required fpg values recorded spanned least 10 consecutive years age 50 greater least one value available calendar year ages border050 years considered criteria resulted study population 52 patients alzheimer disease 105 non alzheimer disease control subjects
0.40214586.14747300.html.plaintext.txt	20	pathology studies case recruitment alzheimer disease patients group 1 control subjects non alzheimer disease group 2 enrolled mayo clinic adpr study life 33 death non alzheimer disease alzheimer disease cases autopsy examination brain diagnosis alzheimer disease absence confirmed using cerad consortium establish registry alzheimer disease criteria 34 pathology study include 1 cases clinically pathologically confirmed alzheimer disease non alzheimer disease 2 cases autopsy including brain pancreas 3 cases fpg documented mayo clinic within 2 years alzheimer disease 100 non alzheimer disease 100 cases 1 year non alzheimer disease 100 alzheimer disease 89 complete autopsies death mean fpg value subject mean least two independent measurements alzheimer disease patients sex age matched control subjects life per mayo clinic adpr study still matched age death 84 plus minus 8 vs 85 plus minus 4 years alzheimer disease vs non alzheimer disease p 07 alzheimer disease diagnosed 55 plus minus 24 range 13 99 years death
0.40214586.14747300.html.plaintext.txt	21	pathology studies case recruitment alzheimer disease patients group 1 control subjects non alzheimer disease group 2 enrolled mayo clinic adpr study life 33 death non alzheimer disease alzheimer disease cases autopsy examination brain diagnosis alzheimer disease absence confirmed using cerad consortium establish registry alzheimer disease criteria 34 pathology study include 1 cases clinically pathologically confirmed alzheimer disease non alzheimer disease 2 cases autopsy including brain pancreas 3 cases fpg documented mayo clinic within 2 years alzheimer disease 100 non alzheimer disease 100 cases 1 year non alzheimer disease 100 alzheimer disease 89 complete autopsies death mean fpg value subject mean least two independent measurements alzheimer disease patients sex age matched control subjects life per mayo clinic adpr study still matched age death 84 plus minus 8 vs 85 plus minus 4 years alzheimer disease vs non alzheimer disease p 07 alzheimer disease diagnosed 55 plus minus 24 range 13 99 years death
0.40214586.14747300.html.plaintext.txt	22	type 2 diabetes cases group 3 fpg 126 mgdl identified via mayo clinic autopsy records inclusion 1 died 6 years preceding study 2 also olmsted county 3 autopsy including brain pancreas 4 general medical examination performed including fpg mayo clinic year death exclusion criteria included inadequate preservation pancreatic tissue anatomic study type 1 diabetes secondary causes diabetes diagnosis diabetes cohort 12 plus minus 9 years death selection criteria yielded 35 cases mean age death younger type 2 diabetes alzheimer disease cases 73 plus minus 8 vs 84 plus minus 8 years p 0001 therefore identified mayo clinic autopsy records additional control group consisting 21 cases group 4 age bmi sex matched type 2 diabetic patients normal fpg documented within 1 year death also meeting criteria 1 4 group 3 groups 3 4 included haphazardly ie consciously biased respect presence absence alzheimer disease characteristics four study groups summarized table 2
0.40214586.14747300.html.plaintext.txt	23	type 2 diabetes cases group 3 fpg 126 mgdl identified via mayo clinic autopsy records inclusion 1 died 6 years preceding study 2 also olmsted county 3 autopsy including brain pancreas 4 general medical examination performed including fpg mayo clinic year death exclusion criteria included inadequate preservation pancreatic tissue anatomic study type 1 diabetes secondary causes diabetes diagnosis diabetes cohort 12 plus minus 9 years death selection criteria yielded 35 cases mean age death younger type 2 diabetes alzheimer disease cases 73 plus minus 8 vs 84 plus minus 8 years p 0001 therefore identified mayo clinic autopsy records additional control group consisting 21 cases group 4 age bmi sex matched type 2 diabetic patients normal fpg documented within 1 year death also meeting criteria 1 4 group 3 groups 3 4 included haphazardly ie consciously biased respect presence absence alzheimer disease characteristics four study groups summarized table 2
0.40214586.14747300.html.plaintext.txt	24	view table table 2 study cases pathology
0.40214586.14747300.html.plaintext.txt	25	protocol 3 islet amyloid increased patients alzheimer disease address question studied pancreas samples obtained autopsy 28 cases alzheimer disease 21 without alzheimer disease groups 1 2 table 2 addition 35 cases type 2 diabetes 21 without type 2 diabetes studied point reference protocol 3 included total 105 cases
0.40214586.14747300.html.plaintext.txt	26	protocol 3 islet amyloid increased patients alzheimer disease address question studied pancreas samples obtained autopsy 28 cases alzheimer disease 21 without alzheimer disease groups 1 2 table 2 addition 35 cases type 2 diabetes 21 without type 2 diabetes studied point reference protocol 3 included total 105 cases
0.40214586.14747300.html.plaintext.txt	27	protocol 4 brain amyloid common patients type 2 diabetes address question studied brain samples 28 cases 19 without type 2 diabetes groups 3 4 table 2 reference 26 cases alzheimer disease 19 without alzheimer disease studied paraffin blocks superiormidfrontal gyrus available resulting 92 cases entering protocol 4
0.40214586.14747300.html.plaintext.txt	28	protocol 4 brain amyloid common patients type 2 diabetes address question studied brain samples 28 cases 19 without type 2 diabetes groups 3 4 table 2 reference 26 cases alzheimer disease 19 without alzheimer disease studied paraffin blocks superiormidfrontal gyrus available resulting 92 cases entering protocol 4
0.40214586.14747300.html.plaintext.txt	29	light microscopy pancreas brain samples obtained autopsy four groups described slides examined blinded identity case light microscopy
0.40214586.14747300.html.plaintext.txt	30	pancreas sequential sections obtained paraffin embedded pancreas tail samples stained hematoxylineosin congo red immunostaining insulin 29 nature pink amyloid deposits congo red stained slides confirmed greenorange birefringence polarized light least 25 islets per specimen scored presence extent islet amyloid extent amyloid deposition classified per islet scale 0 4 0 deposits 1 one deposit 2 small deposits 3 major deposition 4 endocrine cells left confluent deposits
0.40214586.14747300.html.plaintext.txt	31	brain samples superiormidfrontal gyrus collected density neuritic diffuse plaques neurofibrillary tangle nft determined visualizing neurofilaments paraffin sections superiormidfrontal gyrus stained modified bielschowsky technique per sample number neuritic plaques diffuse plagues nft determined five microscope fields 2 mm2
0.40214586.14747300.html.plaintext.txt	32	statistical analysis protocols 1 2 rank sum test used compare age 2 tests used compare number groups according classification sex diabetic nondiabetic ifg status two sided rank sum test used compare slope fasting glucose versus age
0.40214586.14747300.html.plaintext.txt	33	statistical analysis protocols 1 2 rank sum test used compare age 2 tests used compare number groups according classification sex diabetic nondiabetic ifg status two sided rank sum test used compare slope fasting glucose versus age
0.40214586.14747300.html.plaintext.txt	34	protocols 3 4 unpaired two tailed student test used compare age bmi groups nonparametric mann whitney test used compare frequency extent islet amyloid fpg density neuritic plaques diffuse plagues nft among groups 2 test used compare number alzheimer disease non alzheimer disease subjects type 2 diabetes spearman rank correlations used examine relationships among diffuse plagues neuritic plaques nft density versus duration diabetes death age death type 2 diabetes
0.40214586.14747300.html.plaintext.txt	35	results top abstract research design methods results discussion references clinical studies prevalence type 2 diabetes ifg living cohort alzheimer disease versus non alzheimer disease control subjects trend fpg aging protocol 1 difference age sex distribution alzheimer disease non alzheimer disease control group table 1 bmi slightly significantly higher control subjects versus alzheimer disease prevalence type 2 diabetes 346 vs 181 p 005 ifg 462 vs 238 p 001 greater alzheimer disease versus non alzheimer disease control group fig 1 81 alzheimer disease cases therefore either type 2 diabetes ifg
0.40214586.14747300.html.plaintext.txt	36	results top abstract research design methods results discussion references clinical studies prevalence type 2 diabetes ifg living cohort alzheimer disease versus non alzheimer disease control subjects trend fpg aging protocol 1 difference age sex distribution alzheimer disease non alzheimer disease control group table 1 bmi slightly significantly higher control subjects versus alzheimer disease prevalence type 2 diabetes 346 vs 181 p 005 ifg 462 vs 238 p 001 greater alzheimer disease versus non alzheimer disease control group fig 1 81 alzheimer disease cases therefore either type 2 diabetes ifg
0.40214586.14747300.html.plaintext.txt	37	view larger version 16k fig 1 protocol 1 prevalence diabetes ifg olmsted county community based cohort cases alzheimer disease ad control subjects non alzheimer disease non ad top protocol 2 slope fpg concentration versus age cohort bottom ttdm type 2 diabetes
0.40214586.14747300.html.plaintext.txt	38	protocol 2 trend fpg aging examined gradual increase aging groups p 001 vs change however alzheimer disease group greater increase per year compared non alzheimer disease control subjects 083 vs 057 mg dl 1 y 1 p 001 fig 1 greater rate increase blood glucose preserved alzheimer disease cases diabetes excluded analysis
0.40214586.14747300.html.plaintext.txt	39	pathology studies islet amyloid alzheimer disease protocol 3 brain amyloid type 2 diabetes protocol 4 protocol 3 islet amyloid alzheimer disease frequency extent islet amyloid higher alzheimer disease group versus non alzheimer disease group p 005 fig 2 despite trend toward lower bmi alzheimer disease 243 plus minus 34 vs 271 plus minus 67 kgm2 alzheimer disease vs non alzheimer disease p 006 expected frequency extent islet amyloid greater type 2 diabetes group 3 versus non type 2 diabetes group 4 p 0001 fig 2
0.40214586.14747300.html.plaintext.txt	40	pathology studies islet amyloid alzheimer disease protocol 3 brain amyloid type 2 diabetes protocol 4 protocol 3 islet amyloid alzheimer disease frequency extent islet amyloid higher alzheimer disease group versus non alzheimer disease group p 005 fig 2 despite trend toward lower bmi alzheimer disease 243 plus minus 34 vs 271 plus minus 67 kgm2 alzheimer disease vs non alzheimer disease p 006 expected frequency extent islet amyloid greater type 2 diabetes group 3 versus non type 2 diabetes group 4 p 0001 fig 2
0.40214586.14747300.html.plaintext.txt	41	view larger version 14k fig 2 protocol 3 frequency islet amyloid top extent islet amyloid bottom patients alzheimer disease ad control subjects non alzheimer disease non ad patients type 2 diabetes ttdm control group non ttdm individual values medians line
0.40214586.14747300.html.plaintext.txt	42	inclusion cases autopsy protocol blinded respect presence absence diabetes requirement fpg documented subsequent analysis fpg concentrations revealed prevalence type 2 diabetes fpg 126 mgdl alzheimer disease group 32 non alzheimer disease cases 14 p 015 mean fpg alzheimer disease higher control subjects 126 plus minus 8 vs 110 plus minus 6 mgdl p 009
0.40214586.14747300.html.plaintext.txt	43	inclusion cases autopsy protocol blinded respect presence absence diabetes requirement fpg documented subsequent analysis fpg concentrations revealed prevalence type 2 diabetes fpg 126 mgdl alzheimer disease group 32 non alzheimer disease cases 14 p 015 mean fpg alzheimer disease higher control subjects 126 plus minus 8 vs 110 plus minus 6 mgdl p 009
0.40214586.14747300.html.plaintext.txt	44	protocol 4 brain amyloid type 2 diabetes density diffuse neuritic plaques nft different patients type 2 diabetes versus nondiabetic control subjects p 007 p 03 p 04 respectively table 3 expected density neuritic plaques diffuse plaques nft greater p 005 alzheimer disease cases group 1 versus non alzheimer disease group 2
0.40214586.14747300.html.plaintext.txt	45	protocol 4 brain amyloid type 2 diabetes density diffuse neuritic plaques nft different patients type 2 diabetes versus nondiabetic control subjects p 007 p 03 p 04 respectively table 3 expected density neuritic plaques diffuse plaques nft greater p 005 alzheimer disease cases group 1 versus non alzheimer disease group 2
0.40214586.14747300.html.plaintext.txt	46	view table table 3 brain pathology
0.40214586.14747300.html.plaintext.txt	47	22 28 type 2 diabetes cases year diagnosis diabetes documented diffuse plaques detected 12 neuritic plaques 7 22 cases type 2 diabetes documented age onset diabetes positive relationship duration known diabetes extent diffuse plaques rs 08 p 0001 neuritic plaques rs 09 p 001 cases fig 3 contrast neither type 2 diabetes non type 2 diabetes correlation density either plaques age death
0.40214586.14747300.html.plaintext.txt	48	22 28 type 2 diabetes cases year diagnosis diabetes documented diffuse plaques detected 12 neuritic plaques 7 22 cases type 2 diabetes documented age onset diabetes positive relationship duration known diabetes extent diffuse plaques rs 08 p 0001 neuritic plaques rs 09 p 001 cases fig 3 contrast neither type 2 diabetes non type 2 diabetes correlation density either plaques age death
0.40214586.14747300.html.plaintext.txt	49	view larger version 12k fig 3 protocol 4 relationship density diffuse plaques rs 08 p 0001 top neuritic plaques rs 09 p 001 bottom versus duration diabetes patients type 2 diabetes cases included duration diabetes documented respective plaque type detected y equal zero
0.40214586.14747300.html.plaintext.txt	50	discussion top abstract research design methods results discussion references report prevalence type 2 diabetes ifg increased well characterized community cohort patients alzheimer disease southeast minnesota related pathology studies also report increased frequency islet amyloid patients alzheimer disease however brain amyloid increased patients type 2 diabetes versus non type 2 diabetes density diffuse neuritic plaques present associated duration diabetes
0.40214586.14747300.html.plaintext.txt	51	discussion top abstract research design methods results discussion references report prevalence type 2 diabetes ifg increased well characterized community cohort patients alzheimer disease southeast minnesota related pathology studies also report increased frequency islet amyloid patients alzheimer disease however brain amyloid increased patients type 2 diabetes versus non type 2 diabetes density diffuse neuritic plaques present associated duration diabetes
0.40214586.14747300.html.plaintext.txt	52	studies initially undertaken test hypothesis may shared predisposition development islet amyloid brain amyloid patients alzheimer disease type 2 diabetes respectively postulate arose close resemblance pathology brain alzheimer disease islets type 2 diabetes diseases locally expressed protein assp alzheimer disease iapp type 2 diabetes deposited amyloid deposits gradual decline number cells respective proteins amyloid deposits assp iapp likely oligomeric precursors cytotoxic 222335 40 mechanism may relate membrane disruption 25 27 however yet still clear explanation amyloidogenic proteins form amyloid fibrils develop type 2 diabetes alzheimer disease proteins spontaneously form amyloid fibrils vitro aqueous environment present cell mechanisms must exist health prevent aggregation presumably include chaperone protein pathway 30 newly synthesized proteins bound chaperone protein function preventing insoluble proteins eg iapp assp aggregating cells trafficking protein appropriate subcellular location chaperon proteins described promiscuous chaperone protein binds traffics numerous different proteins structurally similar properties 30 individual chaperone proteins traffic structurally similar peptides possible iapp assp share one chaperone proteins fig 4 amino acid sequence structural properties amino acid iapp1 37 assp1 42 shown aligned reveal major overlap 90 structural properties iapp20 28 assp25 33 areas hydrophobic therefore likely target binding chaperone proteins furthermore region iapp well established amyloidogenic sequence 36 assp25 35 neurotoxic 41 recently suggested toxic intermediate form iapp assp oligomers recognized antibody suggesting strong structural relationship 42
0.40214586.14747300.html.plaintext.txt	53	studies initially undertaken test hypothesis may shared predisposition development islet amyloid brain amyloid patients alzheimer disease type 2 diabetes respectively postulate arose close resemblance pathology brain alzheimer disease islets type 2 diabetes diseases locally expressed protein assp alzheimer disease iapp type 2 diabetes deposited amyloid deposits gradual decline number cells respective proteins amyloid deposits assp iapp likely oligomeric precursors cytotoxic 222335 40 mechanism may relate membrane disruption 25 27 however yet still clear explanation amyloidogenic proteins form amyloid fibrils develop type 2 diabetes alzheimer disease proteins spontaneously form amyloid fibrils vitro aqueous environment present cell mechanisms must exist health prevent aggregation presumably include chaperone protein pathway 30 newly synthesized proteins bound chaperone protein function preventing insoluble proteins eg iapp assp aggregating cells trafficking protein appropriate subcellular location chaperon proteins described promiscuous chaperone protein binds traffics numerous different proteins structurally similar properties 30 individual chaperone proteins traffic structurally similar peptides possible iapp assp share one chaperone proteins fig 4 amino acid sequence structural properties amino acid iapp1 37 assp1 42 shown aligned reveal major overlap 90 structural properties iapp20 28 assp25 33 areas hydrophobic therefore likely target binding chaperone proteins furthermore region iapp well established amyloidogenic sequence 36 assp25 35 neurotoxic 41 recently suggested toxic intermediate form iapp assp oligomers recognized antibody suggesting strong structural relationship 42
0.40214586.14747300.html.plaintext.txt	54	view larger version 13k fig 4 structural overlap iapp assp major overlap 90 structural properties iapp20 28 assp25 33 amino acids classified acidic basic b nonpolar np polar uncharged pu gray boxed hatched areas identical amino acids gray boxed areas amino acids similar structural properties
0.40214586.14747300.html.plaintext.txt	55	chaperone protein pathway trafficking assp iapp shared decreased capacity trafficking either might also shared circumstances aggregation either proteins might occur resulting development relevant phenotype alzheimer disease andor type 2 diabetes addition type 2 diabetes alzheimer disease increase prevalence aging cell chaperone protein capacity declines aging 43 would expected reveal partial deficiency chaperone capacity aging therefore one potential explanation reported shared risk alzheimer disease type 2 diabetes similar pathology iapp assp share one chaperone proteins functional defect shared pathway decreased chaperone protein binding decreased chaperone protein availability results shared vulnerability assp aggregate ss pleated sheets cortical cells iapp aggregate ss cells
0.40214586.14747300.html.plaintext.txt	56	chaperone protein pathway trafficking assp iapp shared decreased capacity trafficking either might also shared circumstances aggregation either proteins might occur resulting development relevant phenotype alzheimer disease andor type 2 diabetes addition type 2 diabetes alzheimer disease increase prevalence aging cell chaperone protein capacity declines aging 43 would expected reveal partial deficiency chaperone capacity aging therefore one potential explanation reported shared risk alzheimer disease type 2 diabetes similar pathology iapp assp share one chaperone proteins functional defect shared pathway decreased chaperone protein binding decreased chaperone protein availability results shared vulnerability assp aggregate ss pleated sheets cortical cells iapp aggregate ss cells
0.40214586.14747300.html.plaintext.txt	57	alternative hypothesis account reported overlap islet amyloid brain amyloid subtle hyperglycemia causes alzheimer disease possibility reviewed finch cohen 44 finch cohen proposed progressive increase plasma glucose concentration occurs aging general population may important pathogenesis alzheimer disease proposed may mediated induction oxidative stress glycosylation key regulatory proteins 4546 current study least partly supportive interesting hypothesis present density diffuse neuritic plaques brain increased duration diabetes age prolonged exposure hyperglycemia thus might trigger brain plaque formation risk however hypothesis overall increase pathological features alzheimer disease cases type 2 diabetes compared control subjects consistent previous pathological report 47
0.40214586.14747300.html.plaintext.txt	58	alternative hypothesis account reported overlap islet amyloid brain amyloid subtle hyperglycemia causes alzheimer disease possibility reviewed finch cohen 44 finch cohen proposed progressive increase plasma glucose concentration occurs aging general population may important pathogenesis alzheimer disease proposed may mediated induction oxidative stress glycosylation key regulatory proteins 4546 current study least partly supportive interesting hypothesis present density diffuse neuritic plaques brain increased duration diabetes age prolonged exposure hyperglycemia thus might trigger brain plaque formation risk however hypothesis overall increase pathological features alzheimer disease cases type 2 diabetes compared control subjects consistent previous pathological report 47
0.40214586.14747300.html.plaintext.txt	59	high risk underlying vascular disease diabetes reported increase rates vascular dementia diabetes 4849 furthermore hypertension hyperlipidemia strongly associated diabetes 50 risk factors vascular dementia 51 54 another potential mechanism decreased cognitive function long standing diabetes recurrent hypoglycemia 55 57 however present studies included cases type 2 diabetes recurrent hypoglycemia rare comparison type 1 diabetes
0.40214586.14747300.html.plaintext.txt	60	high risk underlying vascular disease diabetes reported increase rates vascular dementia diabetes 4849 furthermore hypertension hyperlipidemia strongly associated diabetes 50 risk factors vascular dementia 51 54 another potential mechanism decreased cognitive function long standing diabetes recurrent hypoglycemia 55 57 however present studies included cases type 2 diabetes recurrent hypoglycemia rare comparison type 1 diabetes
0.40214586.14747300.html.plaintext.txt	61	multiple factors might influence relationship dementia type 2 diabetes well differences populations inclusion criteria likely contribute conflicting epidemiological data field studies suggest prevalence alzheimer disease increased type 2 diabetes 58 60 whereas others reported decreased 61 66 comparable 484967 71 confounding factor studies including current one alzheimer disease often accompanied decreased bmi presumed result decreased food intake potent risk factor development type 2 diabetes increased bmi possible association conditions obscured relative protective effect decreased bmi alzheimer disease alternatively possible people alzheimer disease exercise less therefore decreased insulin sensitivity increased risk type 2 diabetes type 2 diabetes tends develop younger age alzheimer disease associated decreased life expectancy early death complications diabetes might obscure subsequent development alzheimer disease current pathology studies unique inasmuch alzheimer disease non alzheimer disease groups fully characterized life autopsy although numbers small provocative distinct increase risk islet amyloid patients alzheimer disease despite lower bmi clinical data protocols 1 2 also community based cases defined extensively respect presence absence dementia followed relatively long term 33 interest population based study region showed association type 2 diabetes alzheimer disease 59 whereas former study examined records known cases type 2 diabetes rochester area time study diagnosis dementia alzheimer disease 1455 cases present study focused much smaller cohort patients alzheimer disease 100 cases control subjects 138 cases enrolled adpr 33 wherein diagnosis alzheimer disease rigorously established patients followed annually study thereafter deceased included autopsy studies one factor might caused discrepancies reported studies changing definition diabetes present study uses criteria adopted fpg concentrations 1997 expert committee convened american diabetes association 72 consequence report plasma glucose concentration required establish diagnosis diabetes decreased 140 mgdl 126 mgdl furthermore high risk group established subsequent development diabetes fpg concentration 110 125 mgdl studies used higher values diagnosis diabetes would report lower prevalence rates alzheimer disease control subjects possibly observe differences groups might evident criteria used
0.40214586.14747300.html.plaintext.txt	62	multiple factors might influence relationship dementia type 2 diabetes well differences populations inclusion criteria likely contribute conflicting epidemiological data field studies suggest prevalence alzheimer disease increased type 2 diabetes 58 60 whereas others reported decreased 61 66 comparable 484967 71 confounding factor studies including current one alzheimer disease often accompanied decreased bmi presumed result decreased food intake potent risk factor development type 2 diabetes increased bmi possible association conditions obscured relative protective effect decreased bmi alzheimer disease alternatively possible people alzheimer disease exercise less therefore decreased insulin sensitivity increased risk type 2 diabetes type 2 diabetes tends develop younger age alzheimer disease associated decreased life expectancy early death complications diabetes might obscure subsequent development alzheimer disease current pathology studies unique inasmuch alzheimer disease non alzheimer disease groups fully characterized life autopsy although numbers small provocative distinct increase risk islet amyloid patients alzheimer disease despite lower bmi clinical data protocols 1 2 also community based cases defined extensively respect presence absence dementia followed relatively long term 33 interest population based study region showed association type 2 diabetes alzheimer disease 59 whereas former study examined records known cases type 2 diabetes rochester area time study diagnosis dementia alzheimer disease 1455 cases present study focused much smaller cohort patients alzheimer disease 100 cases control subjects 138 cases enrolled adpr 33 wherein diagnosis alzheimer disease rigorously established patients followed annually study thereafter deceased included autopsy studies one factor might caused discrepancies reported studies changing definition diabetes present study uses criteria adopted fpg concentrations 1997 expert committee convened american diabetes association 72 consequence report plasma glucose concentration required establish diagnosis diabetes decreased 140 mgdl 126 mgdl furthermore high risk group established subsequent development diabetes fpg concentration 110 125 mgdl studies used higher values diagnosis diabetes would report lower prevalence rates alzheimer disease control subjects possibly observe differences groups might evident criteria used
0.40214586.14747300.html.plaintext.txt	63	another potential confounding factor previous well present studies recruitment bias studies performed major tertiary referral centers mayo clinic subject bias efforts made minimize present clinical studies recruitment patients local community community clinics mayo medical center patients therefore attending mayo clinic community clinics primary care recruited either alzheimer disease control groups clinical studies nonetheless recruitment bias may introduced study failure affected patients seek medical care therefore unavailable consideration present study greater proportion women men clinical studies might part reflection recruitment bias also potentially due shorter life span men women alzheimer disease diagnosed autopsy studies alzheimer disease cases control subjects islet amyloid would subject ascertainment bias adpr since cases adpr death autopsy studies type 2 diabetes cases versus control subjects brain amyloid sought minimize deliberate bias including recent autopsies reverse sequence cases appropriate inclusion criteria people autopsy course subgroup general population bias considered notwithstanding limitations opportunity presenting autopsy data cases well characterized life compared autopsy studies
0.40214586.14747300.html.plaintext.txt	64	another potential confounding factor previous well present studies recruitment bias studies performed major tertiary referral centers mayo clinic subject bias efforts made minimize present clinical studies recruitment patients local community community clinics mayo medical center patients therefore attending mayo clinic community clinics primary care recruited either alzheimer disease control groups clinical studies nonetheless recruitment bias may introduced study failure affected patients seek medical care therefore unavailable consideration present study greater proportion women men clinical studies might part reflection recruitment bias also potentially due shorter life span men women alzheimer disease diagnosed autopsy studies alzheimer disease cases control subjects islet amyloid would subject ascertainment bias adpr since cases adpr death autopsy studies type 2 diabetes cases versus control subjects brain amyloid sought minimize deliberate bias including recent autopsies reverse sequence cases appropriate inclusion criteria people autopsy course subgroup general population bias considered notwithstanding limitations opportunity presenting autopsy data cases well characterized life compared autopsy studies
0.40214586.14747300.html.plaintext.txt	65	conclusion report increased prevalence type 2 diabetes ifg community cohort patients alzheimer disease followed olmsted county rochester minnesota also report increased islet amyloid patients alzheimer disease compared control subjects however observe increased frequency brain amyloid cases type 2 diabetes although cases type 2 diabetes brain amyloid extent amyloid increased longer duration diabetes correlate extend age patients type 2 diabetes taken together clinical pathological studies support possible link neurodegenerative processes lead loss cortical brain cells alzheimer disease loss ss cells type 2 diabetes
0.40214586.14747300.html.plaintext.txt	66	conclusion report increased prevalence type 2 diabetes ifg community cohort patients alzheimer disease followed olmsted county rochester minnesota also report increased islet amyloid patients alzheimer disease compared control subjects however observe increased frequency brain amyloid cases type 2 diabetes although cases type 2 diabetes brain amyloid extent amyloid increased longer duration diabetes correlate extend age patients type 2 diabetes taken together clinical pathological studies support possible link neurodegenerative processes lead loss cortical brain cells alzheimer disease loss ss cells type 2 diabetes
0.40214586.14747300.html.plaintext.txt	67	acknowledgments study funded grants national institute aging mayo adpr ag 06786 mayo alzheimer disease research center ag 16574 jep rcp dk59579 pcb larry hillblom foundation pcb
0.40214586.14747300.html.plaintext.txt	68	acknowledge excellent technical assistance jane kahl karen laakso staff mayo alzheimer disease research center excellent editorial assistance kim denkers thank robert rizza suggestions support
0.40214586.14747300.html.plaintext.txt	69	acknowledge excellent technical assistance jane kahl karen laakso staff mayo alzheimer disease research center excellent editorial assistance kim denkers thank robert rizza suggestions support
0.40214586.14747300.html.plaintext.txt	70	address correspondence reprint requests dr peter c butler division endocrinology diabetes keck school medicine university southern california 1333 san pablo street bmt b11 los angeles ca 90033 e mail pbutleratuscedu
0.40214586.14747300.html.plaintext.txt	71	received publication august 13 2003 accepted revised form october 27 2003
0.40214586.14747300.html.plaintext.txt	72	assp amyloid ss protein adpr alzheimer disease patient registry fpg fasting plasma glucose iapp islet amyloid polypeptide ifg impaired fasting glucose nft neurofibrillary tangle
0.40214586.14747300.html.plaintext.txt	73	references top abstract research design methods results discussion references westermark p wilander e influence amyloid deposits islet volume maturity onset diabetes mellitus diabetologia15 417 4211978medline clark wells ca buley id cruickshank jk vanhegan ri matthews dr cooper gj holman rr turner rc islet amyloid increased cells reduced b cells exocrine fibrosis quantitative changes pancreas type 2 diabetes diabetes res9 151 1591988medline cooper gj willis ac clark turner rc sim rb reid kb purification characterization peptide amyloid rich pancreases type 2 diabetic patients proc natl acad sci u a84 8628 86321987abstract westermark p wernstedt c wilander e hayden dw o brien td johnson kh amyloid fibrils human insulinoma islets langerhans diabetic cat derived neuropeptide like protein also present normal islet cells proc natl acad sci u a84 3881 38851987abstract johnson kh o brien td hayden dw jordan k ghobrial hk mahoney wc westermark p immunolocalization islet amyloid polypeptide iapp pancreatic beta cells means peroxidase antiperoxidase pap protein gold techniques j pathol130 1 81988abstract braak h braak e human entorhinal cortex normal morphology lamina specific pathology various diseases neurosci res15 6 311992medline glenner gg wong cw alzheimer disease initial report purification characterization novel cerebrovascular amyloid protein biochem biophys res commun120 885 8901984medline masters cl simms g weinman na multhaup g mcdonald bl beyreuther k amyloid plaque core protein alzheimer disease syndrome proc natl acad sci u a82 4245 42491985abstract masters cl multhaup g simms g pottgiesser j martins rn beyreuther k neuronal origin cerebral amyloid neurofibrillary tangles alzheimer disease contain protein amyloid plaque cores blood vessels embo j4 2757 27631985abstract bahmanyar higgins ga goldgaber d lewis da morrison jh wilson mc shankar sk gajdusek dc localization amyloid beta protein messenger rna brains patients alzheimer disease science237 77 801987medline goedert m neuronal localization amyloid beta protein precursor mrna normal human brain alzheimer disease embo j6 3627 36321987abstract card jp meade rp davis lg immunocytochemical localization precursor protein beta amyloid rat central nervous system neuron1 835 8461988medline shivers bd hilbich c multhaup g salbaum m beyreuther k seeburg ph alzheimer disease amyloidogenic glycoprotein expression pattern rat brain suggests role cell contact embo j7 1365 13701988abstract van broeckhoven c genthe vandenberghe horsthemke b backhovens h raeymaekers p van hul w wehnert gheuens j cras p et al failure familial alzheimer disease segregate a4 amyloid gene several european families nature329 153 1551987medline tanzi re st george hyslop ph haines jl polinsky rj nee l foncin jf neve rl mcclatchey ai conneally pm gusella jf genetic defect familial alzheimer disease tightly linked amyloid beta protein gene nature329 156 1571987medline st george hyslop ph haines jl farrer la polinsky r van broeckhoven c goate mclachlan dr orr h bruni ac sorbi et al genetic linkage studies suggest alzheimer disease single homogeneous disorder fad collaborative study group nature347 194 1971990medline wilson pw anderson km kannel wb epidemiology diabetes mellitus elderly framingham study j med805a 3 91986 barnett ah eff c leslie rd pyke da diabetes identical twins study 200 pairs diabetologia20 87 931981medline newman b selby jv king mc slemenda c fabsitz r friedman gd concordance type 2 non insulin dependent diabetes mellitus male twins diabetologia30 763 7681987medline hilbich c kisters woike b reed j masters cl beyreuther k aggregation secondary structure synthetic amyloid beta a4 peptides alzheimer disease j mol biol218 149 1631991medline glenner gg eanes ed wiley ca amyloid fibrils formed segment pancreatic islet amyloid protein biochem biophys res commun155 608 6141988medline lorenzo razzaboni b weir gc yankner ba pancreatic islet cell toxicity amylin associated type 2 diabetes mellitus nature368 756 7601994medline schubert d behl c lesley r brack dargusch r sagara y kimura h amyloid peptides toxic via common oxidative mechanism proc natl acad sci u a92 1989 19931995abstract o brien td butler pc kreutter dk kane la eberhardt nl human islet amyloid polypeptide expression cos 1 cells model intracellular amyloidogenesis j pathol147 609 6161995abstract janson j ashley rh harrison d mcintyre butler pc mechanism islet amyloid polypeptide toxicity membrane disruption intermediate sized toxic amyloid particles diabetes48 491 4981999abstract mirzabekov ta lin mc kagan bl pore formation cytotoxic islet amyloid peptide amylin j biol chem271 1988 19921996abstractfree full text lashuel ha hartley d petre bm waltz lansbury pt neurodegenerative disease amyloid pores pathogenic mutations nature418 291 2002 couce m kane la o brien td charlesworth j soeller w mcneish j kreutter d roche p butler pc treatment growth hormone dexamethasone mice transgenic human islet amyloid polypeptide causes islet amyloidosis ss cell dysfunction diabetes45 1094 11011996abstract o brien td butler ae roche pc johnson kh butler pc islet amyloid polypeptide human insulinomas evidence intracellular amyloidogenesis diabetes43 329 3361994abstract craig ea weissman js horwich al heat shock proteins molecular chaperones mediators protein conformation turnover cell cell78 365 3721994medline butler pc eberhardt nl o brien td islet amyloid polypeptide iapp insulin secretion molecular biology diabetes draznin b leroith d eds totowa nj humana press1994 p381 398 schwartz p senile cerebral pancreatic insular cardiac amyloidosis trans n y acad sci27 393 4131965medline petersen rc kokmen e tangalos e ivnik rj kurland lt mayo clinic alzheimer disease patient registry aging2 408 4151990medline gearing m mirra ss hedreen jc sumi sm hansen la heyman consortium establish registry alzheimer disease cerad part x neuropathology confirmation clinical diagnosis alzheimer disease neurology45 461 4661995abstract betsholtz c christmansson l engstrom u rorsman f svensson v johnson kh westermark p sequence divergence specific region islet amyloid polypeptide iapp explains differences islet amyloid formation species febs lett251 261 2641989medline westermark p engstrom u johnson kh westermark gt betsholtz c islet amyloid polypeptide pinpointing amino acid residues linked amyloid fibril formation proc natl acad sci u a87 5036 50401990abstract zhang liu j saafi el cooper gj induction apoptosis human amylin rinm5f islet beta cells associated enhanced expression p53 p21waf1cip1 febs lett455 315 3201999medline zhang liu j macgibbon g dragunow m cooper gj increased expression activation c jun contributes human amylin induced apoptosis pancreatic islet beta cells j mol biol324 271 2852002medline bai jz saafi el shang cooper gj role ca2 apoptosis evoked human amylin pancreatic islet beta cells biochem j343 53 611999medline tucker hm rydel re wright estus human amylin induces apoptotic pattern gene expression concomitant cortical neuronal apoptosis j neurochem71 506 5161998medline laczko holly konya z soos k varga j hollosi m penke b conformational mapping amyloid peptides putative neurotoxic 25 35 region biochem biophys res commun205 120 1261994medline kayed r head e thompson jl mcintire tm milton sc glabe cg common structure soluble amyloid oligomers implies common mechanism pathogenesis science300 486 4892003abstractfree full text blake mj edelsman r feulner gj nortone dd holbrook nj stress induced heat shock protein 70 expression adrenal cortex adrenocorticotropic hormone sensitive age dependent response proc natl acad sci u a88 9873 98771991abstract finch ce cohen dm aging metabolism alzheimer disease review hypothesis exp neurol143 82 1021997medline yan sd stern d schmidt rage receptor advanced glycation end products rage dark side glucose eur j clin invest27 179 1811997medline sasaki n toki chowei h saito nakao n hayashi y takeuchi m makita z immunohistochemical distribution receptor advanced glycation end products neurons astrocytes alzheimer disease brain res888 256 2622001medline heitner j dickson d diabetics increased alzheimer type pathology age matched control subjects retrospective postmortem immunocytochemical histofluorescent study neurology49 1306 13111997abstract curb jd rodriguez bl abbott rd petrovitch h ross gw masaki kh foley d blanchette pl harris chen r white lr longitudinal association vascular alzheimer dementias diabetes glucose tolerance neurology52 971 9751999abstractfree full text mackight c rockwood k awalt e mcdowell diabetes mellitus risk dementia alzheimer disease vascular cognitive impairment canadian study health aging dement geriatr cogn disord14 77 832002medline isomaa b almgren p tuomi forsen b lahti k nissen m taskinen m r groop l cardiovascular morbidity mortality associated metabolic syndrome diabetes care24 683 6892001abstractfree full text sasaki n fukatsu r tsuzuki k hayashi y yoshida fujii n koike wakayama yanagihara r garruto r amano n makita z advanced glycation end products alzheimer disease neurodegenerative diseases j pathol153 1149 11551998abstractfree full text mast h thompson jl lee sh mohr jp sacco rl hypertension diabetes mellitus determinants multiple lacunar infarcts stroke26 30 331995abstractfree full text tatemichi tk desmond dw paik m figueroa m gropen ti stern y sano m remien r williams jb mohr jp et al clinical determinants dementia related stroke ann neurol33 568 5751993medline desmond dw tatemichi tk paik m stern y risk factors cerebrovascular disease correlates cognitive function stroke free cohort arch neurol50 162 1661993abstract mccall al impact diabetes ncs diabetes41 557 5701992abstract biessels gj kappelle ac bravenboer b erkelens dw gibsen wh cerebral function diabetes mellitus diabetologia37 643 6501994medline langen sj deary ij hepburn da frier bm cumulative cognitive impairment following recurrent severe hypoglycaemia adult patients insulin treated diabetes mellitus diabetologia34 337 3441991medline ott stolk rp van harskamp f pols h hofman breteler m diabetes mellitus risk dementia rotterdam study neurology53 1937 19421999abstractfree full text leibson cl rocca wa hanson va cha r kokmen e o brien pc palumbo pj risk dementia among persons diabetes mellitus population based cohort study j epidemiol145 301 3081997abstract luchsinger ja tang m x yaakov shea mayeux r diabetes mellitus risk alzheimer disease dementia stroke multiethnic cohort j epidemiol154 635 6412001abstractfree full text bucht g adolfsson r lithner f winblad b changes blood glucose insulin secretion patients senile dementia alzheimer type acta med scand213 387 3921983medline wolf klein gp silversone fa brod ms levy foley cj termotto v breuer j alzheimer patients healthier j geriatr soc36 219 2241988medline ferini strambi l smirne garanchini p pinto p franceschi m clinical epidemiological aspects alzheimer disease presenile onset case control study neuroepidemiology9 39 491990medline landin k blennow k wallin gottfries c g low blood pressure blood glucose levels alzheimer disease evidence hypometabolic disorder j intern med233 357 3631993medline mortel kf wood pavol ma meyer js rexer jl analysis familial individual risk factors among patients ischemic vascular dementia alzheimer disease angiology44 599 6051993medline neilson ka nolan jh berchtold nc sandman ca mulnard ra cotman cw apolipoprotein e genotyping diabetic dementia patients diabetes rare alzheimer disease j geriatr soc44 1 81996medline heyman wilkinson stafford ja helms mj sigmon ah weinberg alzheimer disease study epidemiological aspects ann neurol15 335 3411984medline broe ga henderson creasey h mccusker e korten ae jorm af longley w anthony jc case controlled study alzheimer disease australia neurology40 1698 17071990abstract kokmen e beard cm chandra v offord kp schoenberg bs ballard dj clinical risk factors alzheimer disease population based case control study neurology41 1393 13971991abstract thorpe j widman lp wallin beiswanger j blumenthal ht comorbidity chronic age dependent diseases dementia aging clin exp res6 159 1661994 curb jd roderiquez bl petrovich h masaki kh burchfiel cm ross w chen r harris white lr relationship diabetes glucose tolerance alzheimer disease vascular dementia abstract 488 neurobiol aging17 suppl s122 1996 expert committee diagnosis classification diabetes mellitus diabetes care20 1183 11971997medline
0.40214586.14747300.html.plaintext.txt	74	references top abstract research design methods results discussion references westermark p wilander e influence amyloid deposits islet volume maturity onset diabetes mellitus diabetologia15 417 4211978medline clark wells ca buley id cruickshank jk vanhegan ri matthews dr cooper gj holman rr turner rc islet amyloid increased cells reduced b cells exocrine fibrosis quantitative changes pancreas type 2 diabetes diabetes res9 151 1591988medline cooper gj willis ac clark turner rc sim rb reid kb purification characterization peptide amyloid rich pancreases type 2 diabetic patients proc natl acad sci u a84 8628 86321987abstract westermark p wernstedt c wilander e hayden dw o brien td johnson kh amyloid fibrils human insulinoma islets langerhans diabetic cat derived neuropeptide like protein also present normal islet cells proc natl acad sci u a84 3881 38851987abstract johnson kh o brien td hayden dw jordan k ghobrial hk mahoney wc westermark p immunolocalization islet amyloid polypeptide iapp pancreatic beta cells means peroxidase antiperoxidase pap protein gold techniques j pathol130 1 81988abstract braak h braak e human entorhinal cortex normal morphology lamina specific pathology various diseases neurosci res15 6 311992medline glenner gg wong cw alzheimer disease initial report purification characterization novel cerebrovascular amyloid protein biochem biophys res commun120 885 8901984medline masters cl simms g weinman na multhaup g mcdonald bl beyreuther k amyloid plaque core protein alzheimer disease syndrome proc natl acad sci u a82 4245 42491985abstract masters cl multhaup g simms g pottgiesser j martins rn beyreuther k neuronal origin cerebral amyloid neurofibrillary tangles alzheimer disease contain protein amyloid plaque cores blood vessels embo j4 2757 27631985abstract bahmanyar higgins ga goldgaber d lewis da morrison jh wilson mc shankar sk gajdusek dc localization amyloid beta protein messenger rna brains patients alzheimer disease science237 77 801987medline goedert m neuronal localization amyloid beta protein precursor mrna normal human brain alzheimer disease embo j6 3627 36321987abstract card jp meade rp davis lg immunocytochemical localization precursor protein beta amyloid rat central nervous system neuron1 835 8461988medline shivers bd hilbich c multhaup g salbaum m beyreuther k seeburg ph alzheimer disease amyloidogenic glycoprotein expression pattern rat brain suggests role cell contact embo j7 1365 13701988abstract van broeckhoven c genthe vandenberghe horsthemke b backhovens h raeymaekers p van hul w wehnert gheuens j cras p et al failure familial alzheimer disease segregate a4 amyloid gene several european families nature329 153 1551987medline tanzi re st george hyslop ph haines jl polinsky rj nee l foncin jf neve rl mcclatchey ai conneally pm gusella jf genetic defect familial alzheimer disease tightly linked amyloid beta protein gene nature329 156 1571987medline st george hyslop ph haines jl farrer la polinsky r van broeckhoven c goate mclachlan dr orr h bruni ac sorbi et al genetic linkage studies suggest alzheimer disease single homogeneous disorder fad collaborative study group nature347 194 1971990medline wilson pw anderson km kannel wb epidemiology diabetes mellitus elderly framingham study j med805a 3 91986 barnett ah eff c leslie rd pyke da diabetes identical twins study 200 pairs diabetologia20 87 931981medline newman b selby jv king mc slemenda c fabsitz r friedman gd concordance type 2 non insulin dependent diabetes mellitus male twins diabetologia30 763 7681987medline hilbich c kisters woike b reed j masters cl beyreuther k aggregation secondary structure synthetic amyloid beta a4 peptides alzheimer disease j mol biol218 149 1631991medline glenner gg eanes ed wiley ca amyloid fibrils formed segment pancreatic islet amyloid protein biochem biophys res commun155 608 6141988medline lorenzo razzaboni b weir gc yankner ba pancreatic islet cell toxicity amylin associated type 2 diabetes mellitus nature368 756 7601994medline schubert d behl c lesley r brack dargusch r sagara y kimura h amyloid peptides toxic via common oxidative mechanism proc natl acad sci u a92 1989 19931995abstract o brien td butler pc kreutter dk kane la eberhardt nl human islet amyloid polypeptide expression cos 1 cells model intracellular amyloidogenesis j pathol147 609 6161995abstract janson j ashley rh harrison d mcintyre butler pc mechanism islet amyloid polypeptide toxicity membrane disruption intermediate sized toxic amyloid particles diabetes48 491 4981999abstract mirzabekov ta lin mc kagan bl pore formation cytotoxic islet amyloid peptide amylin j biol chem271 1988 19921996abstractfree full text lashuel ha hartley d petre bm waltz lansbury pt neurodegenerative disease amyloid pores pathogenic mutations nature418 291 2002 couce m kane la o brien td charlesworth j soeller w mcneish j kreutter d roche p butler pc treatment growth hormone dexamethasone mice transgenic human islet amyloid polypeptide causes islet amyloidosis ss cell dysfunction diabetes45 1094 11011996abstract o brien td butler ae roche pc johnson kh butler pc islet amyloid polypeptide human insulinomas evidence intracellular amyloidogenesis diabetes43 329 3361994abstract craig ea weissman js horwich al heat shock proteins molecular chaperones mediators protein conformation turnover cell cell78 365 3721994medline butler pc eberhardt nl o brien td islet amyloid polypeptide iapp insulin secretion molecular biology diabetes draznin b leroith d eds totowa nj humana press1994 p381 398 schwartz p senile cerebral pancreatic insular cardiac amyloidosis trans n y acad sci27 393 4131965medline petersen rc kokmen e tangalos e ivnik rj kurland lt mayo clinic alzheimer disease patient registry aging2 408 4151990medline gearing m mirra ss hedreen jc sumi sm hansen la heyman consortium establish registry alzheimer disease cerad part x neuropathology confirmation clinical diagnosis alzheimer disease neurology45 461 4661995abstract betsholtz c christmansson l engstrom u rorsman f svensson v johnson kh westermark p sequence divergence specific region islet amyloid polypeptide iapp explains differences islet amyloid formation species febs lett251 261 2641989medline westermark p engstrom u johnson kh westermark gt betsholtz c islet amyloid polypeptide pinpointing amino acid residues linked amyloid fibril formation proc natl acad sci u a87 5036 50401990abstract zhang liu j saafi el cooper gj induction apoptosis human amylin rinm5f islet beta cells associated enhanced expression p53 p21waf1cip1 febs lett455 315 3201999medline zhang liu j macgibbon g dragunow m cooper gj increased expression activation c jun contributes human amylin induced apoptosis pancreatic islet beta cells j mol biol324 271 2852002medline bai jz saafi el shang cooper gj role ca2 apoptosis evoked human amylin pancreatic islet beta cells biochem j343 53 611999medline tucker hm rydel re wright estus human amylin induces apoptotic pattern gene expression concomitant cortical neuronal apoptosis j neurochem71 506 5161998medline laczko holly konya z soos k varga j hollosi m penke b conformational mapping amyloid peptides putative neurotoxic 25 35 region biochem biophys res commun205 120 1261994medline kayed r head e thompson jl mcintire tm milton sc glabe cg common structure soluble amyloid oligomers implies common mechanism pathogenesis science300 486 4892003abstractfree full text blake mj edelsman r feulner gj nortone dd holbrook nj stress induced heat shock protein 70 expression adrenal cortex adrenocorticotropic hormone sensitive age dependent response proc natl acad sci u a88 9873 98771991abstract finch ce cohen dm aging metabolism alzheimer disease review hypothesis exp neurol143 82 1021997medline yan sd stern d schmidt rage receptor advanced glycation end products rage dark side glucose eur j clin invest27 179 1811997medline sasaki n toki chowei h saito nakao n hayashi y takeuchi m makita z immunohistochemical distribution receptor advanced glycation end products neurons astrocytes alzheimer disease brain res888 256 2622001medline heitner j dickson d diabetics increased alzheimer type pathology age matched control subjects retrospective postmortem immunocytochemical histofluorescent study neurology49 1306 13111997abstract curb jd rodriguez bl abbott rd petrovitch h ross gw masaki kh foley d blanchette pl harris chen r white lr longitudinal association vascular alzheimer dementias diabetes glucose tolerance neurology52 971 9751999abstractfree full text mackight c rockwood k awalt e mcdowell diabetes mellitus risk dementia alzheimer disease vascular cognitive impairment canadian study health aging dement geriatr cogn disord14 77 832002medline isomaa b almgren p tuomi forsen b lahti k nissen m taskinen m r groop l cardiovascular morbidity mortality associated metabolic syndrome diabetes care24 683 6892001abstractfree full text sasaki n fukatsu r tsuzuki k hayashi y yoshida fujii n koike wakayama yanagihara r garruto r amano n makita z advanced glycation end products alzheimer disease neurodegenerative diseases j pathol153 1149 11551998abstractfree full text mast h thompson jl lee sh mohr jp sacco rl hypertension diabetes mellitus determinants multiple lacunar infarcts stroke26 30 331995abstractfree full text tatemichi tk desmond dw paik m figueroa m gropen ti stern y sano m remien r williams jb mohr jp et al clinical determinants dementia related stroke ann neurol33 568 5751993medline desmond dw tatemichi tk paik m stern y risk factors cerebrovascular disease correlates cognitive function stroke free cohort arch neurol50 162 1661993abstract mccall al impact diabetes ncs diabetes41 557 5701992abstract biessels gj kappelle ac bravenboer b erkelens dw gibsen wh cerebral function diabetes mellitus diabetologia37 643 6501994medline langen sj deary ij hepburn da frier bm cumulative cognitive impairment following recurrent severe hypoglycaemia adult patients insulin treated diabetes mellitus diabetologia34 337 3441991medline ott stolk rp van harskamp f pols h hofman breteler m diabetes mellitus risk dementia rotterdam study neurology53 1937 19421999abstractfree full text leibson cl rocca wa hanson va cha r kokmen e o brien pc palumbo pj risk dementia among persons diabetes mellitus population based cohort study j epidemiol145 301 3081997abstract luchsinger ja tang m x yaakov shea mayeux r diabetes mellitus risk alzheimer disease dementia stroke multiethnic cohort j epidemiol154 635 6412001abstractfree full text bucht g adolfsson r lithner f winblad b changes blood glucose insulin secretion patients senile dementia alzheimer type acta med scand213 387 3921983medline wolf klein gp silversone fa brod ms levy foley cj termotto v breuer j alzheimer patients healthier j geriatr soc36 219 2241988medline ferini strambi l smirne garanchini p pinto p franceschi m clinical epidemiological aspects alzheimer disease presenile onset case control study neuroepidemiology9 39 491990medline landin k blennow k wallin gottfries c g low blood pressure blood glucose levels alzheimer disease evidence hypometabolic disorder j intern med233 357 3631993medline mortel kf wood pavol ma meyer js rexer jl analysis familial individual risk factors among patients ischemic vascular dementia alzheimer disease angiology44 599 6051993medline neilson ka nolan jh berchtold nc sandman ca mulnard ra cotman cw apolipoprotein e genotyping diabetic dementia patients diabetes rare alzheimer disease j geriatr soc44 1 81996medline heyman wilkinson stafford ja helms mj sigmon ah weinberg alzheimer disease study epidemiological aspects ann neurol15 335 3411984medline broe ga henderson creasey h mccusker e korten ae jorm af longley w anthony jc case controlled study alzheimer disease australia neurology40 1698 17071990abstract kokmen e beard cm chandra v offord kp schoenberg bs ballard dj clinical risk factors alzheimer disease population based case control study neurology41 1393 13971991abstract thorpe j widman lp wallin beiswanger j blumenthal ht comorbidity chronic age dependent diseases dementia aging clin exp res6 159 1661994 curb jd roderiquez bl petrovich h masaki kh burchfiel cm ross w chen r harris white lr relationship diabetes glucose tolerance alzheimer disease vascular dementia abstract 488 neurobiol aging17 suppl s122 1996 expert committee diagnosis classification diabetes mellitus diabetes care20 1183 11971997medline
0.40480462.14976159.html.plaintext.txt	0	law mass action applied neurodegenerative disease hypothesis concerning etiology pathogenesis complex diseases andrew singleton amanda myers john hardy
0.40480462.14976159.html.plaintext.txt	1	laboratory neurogenetics national institute aging national institutes health building 10 room 6c103 msc1589 bethesda md 20892 usa
0.40480462.14976159.html.plaintext.txt	2	received january 2 2004 revised february 3 2004 accepted february 9 2004
0.40480462.14976159.html.plaintext.txt	3	abstract top abstract introduction diseases methodological considerations conclusions predictions references loci underlying autosomal dominant forms neurodegenerative disease identified prion mutations cause gerstmann straussler syndrome hereditary creuzfeldt jakob disease tau mutations cause autosomal dominant frontal temporal dementia synuclein mutations cause autosomal dominant parkinsons disease cases pathogenic mutation protein deposited diseased tissue cases whole protein deposited alzheimers disease mutations app presenilin 1 2 cause autosomal dominant disease substrate proteases respectively responsible production deposited peptide ass thus cases mutations lead disease mechanism involves deposition process briefly review remarkably predictable biology also point seems sporadic forms diseases predisposed genetic variability loci strongly suggesting quantity normal protein produced influences risk sporadic forms disease evidence assertion strongest parkinsons disease pd genetic variability synuclein expression affects risk developing disease although oldest evidence notion increased expression normal sequence protein lead disease comes observation alzheimers disease trisomy 21 cases observations make predictions concerning etiology pathogenesis neurodegenerative diseases general
0.40480462.14976159.html.plaintext.txt	4	abstract top abstract introduction diseases methodological considerations conclusions predictions references loci underlying autosomal dominant forms neurodegenerative disease identified prion mutations cause gerstmann straussler syndrome hereditary creuzfeldt jakob disease tau mutations cause autosomal dominant frontal temporal dementia synuclein mutations cause autosomal dominant parkinsons disease cases pathogenic mutation protein deposited diseased tissue cases whole protein deposited alzheimers disease mutations app presenilin 1 2 cause autosomal dominant disease substrate proteases respectively responsible production deposited peptide ass thus cases mutations lead disease mechanism involves deposition process briefly review remarkably predictable biology also point seems sporadic forms diseases predisposed genetic variability loci strongly suggesting quantity normal protein produced influences risk sporadic forms disease evidence assertion strongest parkinsons disease pd genetic variability synuclein expression affects risk developing disease although oldest evidence notion increased expression normal sequence protein lead disease comes observation alzheimers disease trisomy 21 cases observations make predictions concerning etiology pathogenesis neurodegenerative diseases general
0.40480462.14976159.html.plaintext.txt	5	introduction top abstract introduction diseases methodological considerations conclusions predictions references last 15 years remarkable progress understanding etiology autosomal dominant neurodegenerative diseases loci underlying autosomal dominant forms creuzfeldt jakob disease 1 frontal temporal dementia 2 parkinsons disease identified 3 case underlying locus encoded protein often deposited disease creuzfeldt jakob disease prion protein frontal temporal dementia tau parkinsons disease synuclein alzheimers disease situation little complex deposited peptide ass derived fragment app protein metabolized secretase complex key component complex presenilins mutations either app presenilin 1 2 lead disease 4 6
0.40480462.14976159.html.plaintext.txt	6	introduction top abstract introduction diseases methodological considerations conclusions predictions references last 15 years remarkable progress understanding etiology autosomal dominant neurodegenerative diseases loci underlying autosomal dominant forms creuzfeldt jakob disease 1 frontal temporal dementia 2 parkinsons disease identified 3 case underlying locus encoded protein often deposited disease creuzfeldt jakob disease prion protein frontal temporal dementia tau parkinsons disease synuclein alzheimers disease situation little complex deposited peptide ass derived fragment app protein metabolized secretase complex key component complex presenilins mutations either app presenilin 1 2 lead disease 4 6
0.40480462.14976159.html.plaintext.txt	7	findings well established driven therapeutics research especially allowed development animal models diseases well defined therapeutic targets 7 examples precise pathologic species protein obscure one debated whether deposits intermediate species oligomer responsible extensively investigated balance recent data favoring smaller intermediate species toxic entities 8 however generality fact mutated protein example deposited suggests process pathogenicity related although perhaps separable process deposition
0.40480462.14976159.html.plaintext.txt	8	findings well established driven therapeutics research especially allowed development animal models diseases well defined therapeutic targets 7 examples precise pathologic species protein obscure one debated whether deposits intermediate species oligomer responsible extensively investigated balance recent data favoring smaller intermediate species toxic entities 8 however generality fact mutated protein example deposited suggests process pathogenicity related although perhaps separable process deposition
0.40480462.14976159.html.plaintext.txt	9	studying autosomal dominant forms diseases researchers hope gain insight common sporadic forms mechanistic perspective certainly case however perhaps surprisingly last 4 years become clear case many diseases least haplotype mendelian pathogenic locus influences disease risk sporadic disease
0.40480462.14976159.html.plaintext.txt	10	studying autosomal dominant forms diseases researchers hope gain insight common sporadic forms mechanistic perspective certainly case however perhaps surprisingly last 4 years become clear case many diseases least haplotype mendelian pathogenic locus influences disease risk sporadic disease
0.40480462.14976159.html.plaintext.txt	11	review briefly summarise data make predictions concerning etiology pathogenesis neurodegenerative diseases first though worth noting haplotypic association means mechanistic perspective absence coding changes haplotypic association implies genetic variability either amount expression protein alternate splicing protein contributes disease risk
0.40480462.14976159.html.plaintext.txt	12	review briefly summarise data make predictions concerning etiology pathogenesis neurodegenerative diseases first though worth noting haplotypic association means mechanistic perspective absence coding changes haplotypic association implies genetic variability either amount expression protein alternate splicing protein contributes disease risk
0.40480462.14976159.html.plaintext.txt	13	diseases top abstract introduction diseases methodological considerations conclusions predictions references prion diseases prion gene two common coding variants caucasian populations one prion m129 prion v129 910 long recognized homozygosity codon 129 predisposes sporadic disease presumably necessity prion prion interactions symmetry considerations 910 however addition well established risk recent genetic data shown prion haplotype confers additional risk idiopathic disease 11 clearly suggesting genetic variability prion expression contributes disease risk genetic data establish whether high expressors low expressors susceptible since prion knockout mice completely resistant disease 12 parsimonious expect express high levels prion protein homozygotes codon 129 susceptible disease
0.40480462.14976159.html.plaintext.txt	14	diseases top abstract introduction diseases methodological considerations conclusions predictions references prion diseases prion gene two common coding variants caucasian populations one prion m129 prion v129 910 long recognized homozygosity codon 129 predisposes sporadic disease presumably necessity prion prion interactions symmetry considerations 910 however addition well established risk recent genetic data shown prion haplotype confers additional risk idiopathic disease 11 clearly suggesting genetic variability prion expression contributes disease risk genetic data establish whether high expressors low expressors susceptible since prion knockout mice completely resistant disease 12 parsimonious expect express high levels prion protein homozygotes codon 129 susceptible disease
0.40480462.14976159.html.plaintext.txt	15	alzheimers disease extensive sequencing app gene late onset alzheimers disease failed identify mutations 13 however analysis data sibpairs affected late onset alzheimers disease consistently suggested app locus form disease 1415 suggests genetic variability app locus contributes disease risk although precise variability identified finding consistent longstanding observation individuals trisomy 21 inevitably develop alzheimer pathology fifth decade 16 however cases syndrome caused triplication chromosome 21 distal app gene develop alzheimers disease 17 thus three copies app gene leads alzheimer pathology fifth decade yet unidentified genetic variability app locus appears contribute disease risk
0.40480462.14976159.html.plaintext.txt	16	alzheimers disease extensive sequencing app gene late onset alzheimers disease failed identify mutations 13 however analysis data sibpairs affected late onset alzheimers disease consistently suggested app locus form disease 1415 suggests genetic variability app locus contributes disease risk although precise variability identified finding consistent longstanding observation individuals trisomy 21 inevitably develop alzheimer pathology fifth decade 16 however cases syndrome caused triplication chromosome 21 distal app gene develop alzheimers disease 17 thus three copies app gene leads alzheimer pathology fifth decade yet unidentified genetic variability app locus appears contribute disease risk
0.40480462.14976159.html.plaintext.txt	17	frontal temporal dementia tangle diseases mutations tau gene cause many cases autosomal dominant frontal temporal dementia tau pathology many sporadic diseases tau pathology occurs usually tangles also pick bodies argyrophilic grains 18 two genetic haplotype clades caucasian populations designated h1 h2 differ intron sizes promoter sequence wobble bases 19 h1 haplotype frequency 75 caucasians thus h1 homozygotes constitute 60 populations however individuals one three sporadic tau diseases progressive supranuclear palsy 19 corticobasal degeneration 20 argyrophilic grain disease 21 although picks disease 22 guam disease 23 show robust association h1 homozygosity frequency h1 homozygotes 95 data show clearly variability either tau expression tau splicing variability contribute disease risk case difficult determine whether control splicing control expression key variable indeed clear many mutations lead mendelian disease altering alternate splicing 224
0.40480462.14976159.html.plaintext.txt	18	frontal temporal dementia tangle diseases mutations tau gene cause many cases autosomal dominant frontal temporal dementia tau pathology many sporadic diseases tau pathology occurs usually tangles also pick bodies argyrophilic grains 18 two genetic haplotype clades caucasian populations designated h1 h2 differ intron sizes promoter sequence wobble bases 19 h1 haplotype frequency 75 caucasians thus h1 homozygotes constitute 60 populations however individuals one three sporadic tau diseases progressive supranuclear palsy 19 corticobasal degeneration 20 argyrophilic grain disease 21 although picks disease 22 guam disease 23 show robust association h1 homozygosity frequency h1 homozygotes 95 data show clearly variability either tau expression tau splicing variability contribute disease risk case difficult determine whether control splicing control expression key variable indeed clear many mutations lead mendelian disease altering alternate splicing 224
0.40480462.14976159.html.plaintext.txt	19	parkinsons diseaselewy body dementia mutations synuclein gene cause autosomal dominant parkinsons disease synuclein primary component lewy bodies pathognomic feature parkinsons disease 25 genetic variability synuclein promoter contributes risk sporadic parkinsons disease 2627 associated promoter allele stronger promoter 28 perhaps convincingly triplication whole synuclein locus causes autosomal dominant parkinsons diseaselewy body dementia onset age fourth decade 29 duplication locus leads disease fifth decade 30 thus parkinsons disease clear dose relationship synuclein expression disease occurrence normal genetic variability promoter contributing risk typical idiopathic disease multiplications locus causing mendelian disease onset age determined precise dose protein studies cell lines affected individuals kindreds reveal amount synuclein produced correlates disease singleton et al unpublished data 31
0.40480462.14976159.html.plaintext.txt	20	parkinsons diseaselewy body dementia mutations synuclein gene cause autosomal dominant parkinsons disease synuclein primary component lewy bodies pathognomic feature parkinsons disease 25 genetic variability synuclein promoter contributes risk sporadic parkinsons disease 2627 associated promoter allele stronger promoter 28 perhaps convincingly triplication whole synuclein locus causes autosomal dominant parkinsons diseaselewy body dementia onset age fourth decade 29 duplication locus leads disease fifth decade 30 thus parkinsons disease clear dose relationship synuclein expression disease occurrence normal genetic variability promoter contributing risk typical idiopathic disease multiplications locus causing mendelian disease onset age determined precise dose protein studies cell lines affected individuals kindreds reveal amount synuclein produced correlates disease singleton et al unpublished data 31
0.40480462.14976159.html.plaintext.txt	21	methodological considerations top abstract introduction diseases methodological considerations conclusions predictions references problems assessment haplotypic expression rigorous assessment impact haplotypic variation quantitative gene expression splicing surprisingly difficult problem 32 usual method test variability control expression tie artificial arbitrary reporter construct bacterially derived reporter gene measure transient effect expression tumor derived cell line clearly experiments unlikely yield data direct relevance subtle effects variation gene expression development allele specific gene expression methods 3334 offers hope subtle effects studied although methods arduous require access large numbers well maintained human brain specimens 33
0.40480462.14976159.html.plaintext.txt	22	methodological considerations top abstract introduction diseases methodological considerations conclusions predictions references problems assessment haplotypic expression rigorous assessment impact haplotypic variation quantitative gene expression splicing surprisingly difficult problem 32 usual method test variability control expression tie artificial arbitrary reporter construct bacterially derived reporter gene measure transient effect expression tumor derived cell line clearly experiments unlikely yield data direct relevance subtle effects variation gene expression development allele specific gene expression methods 3334 offers hope subtle effects studied although methods arduous require access large numbers well maintained human brain specimens 33
0.40480462.14976159.html.plaintext.txt	23	conclusions predictions top abstract introduction diseases methodological considerations conclusions predictions references diseases referred thus strong evidence frank mutations pathologic locus cause autosomal dominant disease protein deposition genetic variability expression normal protein contributes risk idiopathic disease alzheimers disease deposited protein peptide fragment primary locus mutations cleaving enzyme also lead disease simple observations lead predictions mutant wild type proteins quantitatively different qualitatively different properties cases diseases protein deposition part process polyglutamine diseases als genetic variability promoter gene considered factor influencing applicable risk sporadic disease age onset familial disease see 35 suggestions might also case huntingtons disease polyglutamine diseases deposited fragment cleaved precursor molecule genetic variability cleaving proteases interactors influence stability assessed risk factor loci loci impact risk diseases general may merely cause effect altering levels primary proteins either transcription factors responsible protein breakdown
0.40480462.14976159.html.plaintext.txt	24	conclusions predictions top abstract introduction diseases methodological considerations conclusions predictions references diseases referred thus strong evidence frank mutations pathologic locus cause autosomal dominant disease protein deposition genetic variability expression normal protein contributes risk idiopathic disease alzheimers disease deposited protein peptide fragment primary locus mutations cleaving enzyme also lead disease simple observations lead predictions mutant wild type proteins quantitatively different qualitatively different properties cases diseases protein deposition part process polyglutamine diseases als genetic variability promoter gene considered factor influencing applicable risk sporadic disease age onset familial disease see 35 suggestions might also case huntingtons disease polyglutamine diseases deposited fragment cleaved precursor molecule genetic variability cleaving proteases interactors influence stability assessed risk factor loci loci impact risk diseases general may merely cause effect altering levels primary proteins either transcription factors responsible protein breakdown
0.40480462.14976159.html.plaintext.txt	25	findings unexpected perhaps chemists know power law mass action perhaps surprised us may profound implications determining risks neurodegenerative disease 36 course one therapeutic approach cases therefore would aim reduce concentrations toxic proteins relevant tissue compartment either decreased production increased breakdown
0.40480462.14976159.html.plaintext.txt	26	findings unexpected perhaps chemists know power law mass action perhaps surprised us may profound implications determining risks neurodegenerative disease 36 course one therapeutic approach cases therefore would aim reduce concentrations toxic proteins relevant tissue compartment either decreased production increased breakdown
0.40480462.14976159.html.plaintext.txt	27	acknowledgements work supported nianih intramural programme
0.40480462.14976159.html.plaintext.txt	28	footnotes correspondence addressed tel 1 3014513829 fax 1 3014800335 email hardyjatmailnihgov
0.40480462.14976159.html.plaintext.txt	29	footnotes correspondence addressed tel 1 3014513829 fax 1 3014800335 email hardyjatmailnihgov
0.40480462.14976159.html.plaintext.txt	30	references top abstract introduction diseases methodological considerations conclusions predictions references owen f poulter m lofthouse r collinge j crow tj risby d baker hf ridley rm hsiao k prusiner sb 1989 insertion prion protein gene familial creutzfeldt jakob disease lancet 1 51 52crossref
0.40480462.14976159.html.plaintext.txt	31	rogaeva e 2002 solved unsolved mysteries genetics early onset alzheimers disease neuromol med 2 1 10crossref
0.40480462.14976159.html.plaintext.txt	32	hutton m 2000 missing tau mutation identified ann neurol 47 417 41833co2 2linktypedoi crossrefmedline
0.43645546.14764623.html.plaintext.txt	0	alzheimers disease one disorder many genes lars bertram rudolph e tanzi
0.43645546.14764623.html.plaintext.txt	1	genetics aging research unit department neurology massgeneral institute neurodegenerative diseases massachusetts general hospital harvard medical school charlestown ma usa
0.43645546.14764623.html.plaintext.txt	2	received january 13 2004 accepted january 26 2004
0.43645546.14764623.html.plaintext.txt	3	abstract top abstract introduction 2003 good vintage conclusion references research alzheimers disease ad genetics extremely prolific past decade currently 10 genes reported show either positive negative evidence disease association per month review 90 studies 2003 reporting total 127 association findings candidate genes ad positive results largely contradictory identified three loci chromosomes 6p21 10q24 11q23 yielded positive results three independent studies addition well established ad association gene encoding apolipoprotein e apoe based data suggest may prudent investigators pay closer attention issues power replicability haplotype structure prior initial publication serve greatly decrease likelihood false positive false negative findings reported future years
0.43645546.14764623.html.plaintext.txt	4	introduction top abstract introduction 2003 good vintage conclusion references several characteristics make search novel alzheimers disease ad genes particularly promising first importantly heritability ad high demonstrated various studies examining familial segregation disease past decades 1 3 accordingly probability actually finding relevant disease causing predisposing genes relatively high well possibly even genetically complex neuropsychiatric disorders like parkinsons disease schizophrenia affective disorders 4 thus far ad achieved four genes app psen1 psen2 apoe variation latter also plays significant role common late onset form disorder see fully penetrant mutations app psen1 psen2 hand lead rare early onset familial forms ad via increased generation ass42 ss amyloid deposition major neuropathological hallmark disease secondly direct evidence based simulation well empirical data presence additional ad risk genes besides apoe instance recent simulation study predicted existence four seven additional ad genes searching age onset modifiers simulating variety different disease inheritance models 3 number corresponds well empirical data obtained full genome searches overlap 11 chromosomes six show significant results least one study table 1 finally progressive neurodegeneration gradually leading cognitive decline dementia ad patients exhibits distinct well established histopathological features upon post mortem examination allowing verification clinical ad 5 currently accuracy clinical ad diagnosis near beyond 90 academic centers 6 8 allows significant reduction number phenocopies study populations using published research criteria thereby increases power subsequent genetic epidemiological analyses
0.43645546.14764623.html.plaintext.txt	5	view table table 1 overview concordant linkageassociation regions observed full genome screens published 2003 disease specific characteristics together advent relatively inexpensive powerful high throughput genotyping technologies near completion human genome sequence led steep increase number laboratories studying genetics ad worldwide date less 12 full genome screens using linkage association based methodologies published ad using overlapping identical samples employing different sets genetic markers andor analytic strategies 8 19 table 1 hand number locus specific candidate gene based ad association studies become nearly intractable course 2003 10 genes reported show either positive negative evidence association different ad phenotypes per month peer reviewed journals listed ncbis pubmed despite vast efforts single gene yet emerged attain nearly degree replication consistency observed literally hundreds laboratories studying association apoe 4 ad review present discuss findings genetic ad association studies published 2003 excluding explicitly searching causes early onset familial ad cases ie private mutations using data example attempt pinpoint methodological difficulties likely underlie remarkable failure replicate genetic findings using current approaches
0.43645546.14764623.html.plaintext.txt	6	2003 good vintage ad genetics top abstract introduction 2003 good vintage conclusion references genome screens outlined year 2003 almost unprecedented terms number studies attempting unravel causes ad genetics three full genome screens 81819 using association genetic linkage methods added nine studies already reported literature late onset ad study study comparison using p value 001 cut reveals total 16 regions 11 chromosomes yield positive signals across least two studies markers 25 mb apart table 1 interestingly chromosomes strongest consistent signals ie 6 9 10 12 19 21 already implicated least 3 years earlier received support 2003 based criteria new ad region emerge 2003 chromosome 2p23 24 position 19 29 mb interestingly region implicated studies using association methods fairly isolated homogeneous populations ie finns wadi ara 1418 note inclusion exclusion criteria applied arbitrary may overestimate total number positive signals however allow comparison across multitude methodologically divergent approaches facilitate interpretation analyses based actual candidate genes
0.43645546.14764623.html.plaintext.txt	7	candidate gene studies searching pubmed wwwncbinlmnihgovpubmed keywords alzheimer association associated papers published january 1 december 31 2003 retrieved total 1037 studies december 28 2003 90 directly deal genetic association candidate polymorphisms ad seen table 2 studies examined total 55 genetic loci locus set markers within 5 mb genomic interval 20 different chromosomes total 55 analyzed genes within loci found positive judged authors 68 tested negative interestingly even 10 years discovery largest number n18 reports focusing single gene dealt association apoe ad using new polymorphisms new samplesethnic groups new phenotypes studies considered total 38 positive 67 negative papers remained
0.43645546.14764623.html.plaintext.txt	8	view table table 2 overview chromosomal loci tested genetic association ad 2003 2003 represents one prolific vintages late onset ad genetic studies next pressing question large quantity studies also dilute quality product perhaps even making unpalatable quaff answer opinion yes least majority cases growing consensus success rate reliability genetic association studies complex diseases depend fulfillment several criteria 2021 three discussed detail addition classic requirements least plausible biological andor positional candidacy investigated locus well direct proof pathophysiological consequences positive disease association former criterion fulfilled vast majority ad candidate genes investigated thus far latter condition elusive due several factors generally bedevil study genetic association complex diseases linkage disequilibrium actual functionally relevant disease modifying variant small effect sizes impede detection significant effects using basic molecular biochemical assays possibly involvement yet unknown pathophysiological mechanisms situation apoe 4 ad serves good example genetic association per se extremely well established past decade still consensus association translates pathophysiologically 2223
0.43645546.14764623.html.plaintext.txt	9	thus attempting uncover functional consequences putative new disease association propose emphasis must placed criteria allow better distinction false positive well false negative findings prior initial publication
0.43645546.14764623.html.plaintext.txt	10	power sample size structure enable investigators detect effect sizes moderate small extent obvious concern reports negative outcome power study also governs rate false positive findings ie probability observed significant association indeed genuine observed chance 24 26 factors influencing ability detect meaningful effects include attributable risk polymorphism overall genetic variance degree linkage disequilibrium ld associated allele actual disease predisposing variant mode inheritance lesser extent disease prevalence variables course difficult estimate true disease gene unknown power given sample size fairly easily calculated variety possible plausible scenarios practice however still remains exception recent study estimated minimal number cases controls sufficient achieve 80 power 005 usually far greater 200 actual disease allele tested directly even favorable circumstances 26 interesting regardless estimates 20 studies published 2003 still used smaller sample sizes thus probably suitable use reaching reliable conclusion
0.43645546.14764623.html.plaintext.txt	11	replicability result validatedreplicated independent sample sufficient size reports significant associations putative candidate genes ad every chromosome human genome past 10 years 27 none findings exception apoe 4 yet replicated consistently many seemingly positive result could validated independent dataset prior first publication several authors long suggesting guidelines proper quality control genetic association findings 2021252829 current inflation probable false positive reports may avoided independent replication sought earlier independent sample cannot found house establishment least temporary consortia collaborative laboratories test others positive signals prior publication would represent easy effective means restore credibility upon review 2003 ad genetics literature less 20 studies either referred findings two independent samples published tandem independent reports investigating candidate genes andor genetic variants
0.43645546.14764623.html.plaintext.txt	12	replicability result validatedreplicated independent sample sufficient size reports significant associations putative candidate genes ad every chromosome human genome past 10 years 27 none findings exception apoe 4 yet replicated consistently many seemingly positive result could validated independent dataset prior first publication several authors long suggesting guidelines proper quality control genetic association findings 2021252829 current inflation probable false positive reports may avoided independent replication sought earlier independent sample cannot found house establishment least temporary consortia collaborative laboratories test others positive signals prior publication would represent easy effective means restore credibility upon review 2003 ad genetics literature less 20 studies either referred findings two independent samples published tandem independent reports investigating candidate genes andor genetic variants
0.43645546.14764623.html.plaintext.txt	13	haplotype structure authors made attempts elucidate structure underlying haplotype architecture current systematic assessment haplotype structures various regions throughout genome past 3 4 years emphasized importance performing haplotype systematic ld analyses searching novel complex disease genes 3031 especially effect sizes expected lower conferred apoe 4 addition increasing power analyses approach also reduces number statistical tests need performed lead decrease false positive findings several recently published complex disease associations would impossible observe without thorough assessment underlying haplotype architecture 32 34 along lines recent studies apoe shown locus would easily identified means haplotype analysis alone even without prior knowledge 4 polymorphism 3536 yet 2003 one third studies investigated one polymorphism per locus half carried less thorough assessment haplotype structure ie four polymorphisms per gene
0.43645546.14764623.html.plaintext.txt	14	haplotype structure authors made attempts elucidate structure underlying haplotype architecture current systematic assessment haplotype structures various regions throughout genome past 3 4 years emphasized importance performing haplotype systematic ld analyses searching novel complex disease genes 3031 especially effect sizes expected lower conferred apoe 4 addition increasing power analyses approach also reduces number statistical tests need performed lead decrease false positive findings several recently published complex disease associations would impossible observe without thorough assessment underlying haplotype architecture 32 34 along lines recent studies apoe shown locus would easily identified means haplotype analysis alone even without prior knowledge 4 polymorphism 3536 yet 2003 one third studies investigated one polymorphism per locus half carried less thorough assessment haplotype structure ie four polymorphisms per gene
0.43645546.14764623.html.plaintext.txt	15	90 papers published 2003 topic genetic association candidate genes different ad phenotypes 21 23 fulfilled least two criteria likely many observed discrepancies across studies could explained lack methodological thoroughness nonetheless three loci addition apoe tested positive across least three studies chromosomes 6p21 10q24 11q23 table 2 loci covered remainder review
0.43645546.14764623.html.plaintext.txt	16	90 papers published 2003 topic genetic association candidate genes different ad phenotypes 21 23 fulfilled least two criteria likely many observed discrepancies across studies could explained lack methodological thoroughness nonetheless three loci addition apoe tested positive across least three studies chromosomes 6p21 10q24 11q23 table 2 loci covered remainder review
0.43645546.14764623.html.plaintext.txt	17	chromosome 6p21 chromosomal region implicated harboring putative ad gene early 1980 based association finding variants highly polymorphic major histocompatibility complex region hla 30 mb ad small case control study 37 two potential ad candidates map within 5 mb interval genes encoding hereditary haemochromatosis protein hfe 26 mb tumor necrosis factor alpha tnfa 31 mb 2003 two studies reported significant evidence association latter two genes 3839 two studies confirm findings 4041 another candidate gene located region hapa1b found associated certain neuropsychological variables 42 disease risk 43 finally one study investigated variation onset age function hla a2 allele small sample ad patients find significant effects 44 literature search association studies genes including years 2003 yielded least 15 positive studies 10 reports found evidence genetic involvement factors evidence direct involvement tnfa ass production toxicity 45 direct proof pathogenetic relevance genesproteins remains seen furthermore full genome screens ad genes consistently yielded signals 6p21 residing 39 42 mb whereas associated genes map 10 mb proximal thus increasing evidence supporting existence putative ad locus 6p21 general possibility actual disease gene yet identified cannot excluded despite overlapping positive results year past studies
0.43645546.14764623.html.plaintext.txt	18	chromosome 6p21 chromosomal region implicated harboring putative ad gene early 1980 based association finding variants highly polymorphic major histocompatibility complex region hla 30 mb ad small case control study 37 two potential ad candidates map within 5 mb interval genes encoding hereditary haemochromatosis protein hfe 26 mb tumor necrosis factor alpha tnfa 31 mb 2003 two studies reported significant evidence association latter two genes 3839 two studies confirm findings 4041 another candidate gene located region hapa1b found associated certain neuropsychological variables 42 disease risk 43 finally one study investigated variation onset age function hla a2 allele small sample ad patients find significant effects 44 literature search association studies genes including years 2003 yielded least 15 positive studies 10 reports found evidence genetic involvement factors evidence direct involvement tnfa ass production toxicity 45 direct proof pathogenetic relevance genesproteins remains seen furthermore full genome screens ad genes consistently yielded signals 6p21 residing 39 42 mb whereas associated genes map 10 mb proximal thus increasing evidence supporting existence putative ad locus 6p21 general possibility actual disease gene yet identified cannot excluded despite overlapping positive results year past studies
0.43645546.14764623.html.plaintext.txt	19	chromosome 10q24 six candidate loci analyzed region 10q21 10q25 2003 three reported associated ad phenotypes across multiple samples ie cdc2vr22 tnfrsf6ide gsto12 locus found associated one group investigators located 90 94 mb encompasses genes tnfrsf6 90 mb idekiff11hhex 46 48 probably best candidate biological grounds ide encoding insulin degrading enzyme protein ide metalloprotease shown degrade monomeric ass aggregate oligomeric forms ultimately ss amyloid plaques 49 several issues proposed mode action still remain controversial eg precise cellular location ass cleavage relevance ide functiondysfunction development ad number animal models available showing predicted effects vivo 50 52 2003 two papers published showing allelic association microsatellite markers region 5354 two reports find association ide variants nearby markers ad 5556 note data one negative studies 55 actually largely overlaps positive paper edland et al 46 important exception authors first paper account potential interactions ide apoe 4 status may crucial since latter study found significant effect ide ad risk individuals lacking apoe 4 allele clearly studies independent samples sufficient size necessary elucidate potential role ide variants development ad general population
0.43645546.14764623.html.plaintext.txt	20	addition ide locus total four genes long arm chromosome 10 found associated ad two cdc2 vr22 map 30 mb proximal ide two gsto12 prss11 map 10 30 mb distal none associations yet confirmed independent ad samples noteworthy two genes also found associated neurodegenerative illnesses frontotemporal dementia cdc2 57 parkinsons disease gsto12 58 potentially suggesting common pathway leading neuronal cell death across syndromes cdc2 encodes cell division cycle 2 protein involved phosphorylation tau app found neurons bearing neurofibrillary tangles gsto1 2 encode glutathione transferase omega 1 2 involved physiological response oxidative stress may particular responsible regulating expression inflammatory cytokines like il1 ss thus plausible ad candidate genes positional well biologicalbiochemical grounds studies still necessary elucidate proposed roles influencing risk andor age onset ad general population
0.43645546.14764623.html.plaintext.txt	21	addition ide locus total four genes long arm chromosome 10 found associated ad two cdc2 vr22 map 30 mb proximal ide two gsto12 prss11 map 10 30 mb distal none associations yet confirmed independent ad samples noteworthy two genes also found associated neurodegenerative illnesses frontotemporal dementia cdc2 57 parkinsons disease gsto12 58 potentially suggesting common pathway leading neuronal cell death across syndromes cdc2 encodes cell division cycle 2 protein involved phosphorylation tau app found neurons bearing neurofibrillary tangles gsto1 2 encode glutathione transferase omega 1 2 involved physiological response oxidative stress may particular responsible regulating expression inflammatory cytokines like il1 ss thus plausible ad candidate genes positional well biologicalbiochemical grounds studies still necessary elucidate proposed roles influencing risk andor age onset ad general population
0.43645546.14764623.html.plaintext.txt	22	chromosome 11q23 region near tip long arm chromosome 11 implicated one full genome screens published date 8 therefore appear table 1 yet total three studies showing significant association ad candidate gene 2003 bace encoding ss site app cleaving enzyme ss secretase 59 61 protein excellent ad candidate biochemical grounds ss secretase cleavage app ass liberated precursor via secretase cleavage interestingly contrast putative ad associations discussed appears high degree consistency respect site allelic nature underlying findings positive studies including initial report nowotny colleagues published 2001 62 observe representations g allele synonymous snp located codon 262 exon 5 ad cases compared healthy controls furthermore studies observed effect pronounced carriers apoe 4 allele yielding significantly elevated odds ratios ranging 2 7
0.43645546.14764623.html.plaintext.txt	23	chromosome 11q23 region near tip long arm chromosome 11 implicated one full genome screens published date 8 therefore appear table 1 yet total three studies showing significant association ad candidate gene 2003 bace encoding ss site app cleaving enzyme ss secretase 59 61 protein excellent ad candidate biochemical grounds ss secretase cleavage app ass liberated precursor via secretase cleavage interestingly contrast putative ad associations discussed appears high degree consistency respect site allelic nature underlying findings positive studies including initial report nowotny colleagues published 2001 62 observe representations g allele synonymous snp located codon 262 exon 5 ad cases compared healthy controls furthermore studies observed effect pronounced carriers apoe 4 allele yielding significantly elevated odds ratios ranging 2 7
0.43645546.14764623.html.plaintext.txt	24	contrast four positive associations equal number studies literature showing apparent effects bace polymorphism ad however must pointed one studied early onset familial ad cases 63 remaining studies account potential interaction apoe 4 allele 64 66 unless done similar situation encountered variants tested ide see firm conclusions reached whether exon 5 polymorphism bace genetic risk factor ad samples thus three known app cleaving enzymes associated proteins adam910 17 ss bace bace2 secretase psen1 aph1a ncstn pen2 already tested genetic association ad phenotypes bace currently shows promise genuine relevant risk factor late onset ad case putative ad genes studies using sufficiently sized samples appropriate analytic strategies need performed general conclusions reached note first study examining putative genetic role bace late onset ad 2004 also reports significant effect exon 5 polymorphism case control sample chinese origin 67
0.43645546.14764623.html.plaintext.txt	25	contrast four positive associations equal number studies literature showing apparent effects bace polymorphism ad however must pointed one studied early onset familial ad cases 63 remaining studies account potential interaction apoe 4 allele 64 66 unless done similar situation encountered variants tested ide see firm conclusions reached whether exon 5 polymorphism bace genetic risk factor ad samples thus three known app cleaving enzymes associated proteins adam910 17 ss bace bace2 secretase psen1 aph1a ncstn pen2 already tested genetic association ad phenotypes bace currently shows promise genuine relevant risk factor late onset ad case putative ad genes studies using sufficiently sized samples appropriate analytic strategies need performed general conclusions reached note first study examining putative genetic role bace late onset ad 2004 also reports significant effect exon 5 polymorphism case control sample chinese origin 67
0.43645546.14764623.html.plaintext.txt	26	conclusion top abstract introduction 2003 good vintage conclusion references year 2003 extremely productive terms studies examining potential associations candidate genes ad phenotypes vast majority results previous years remains controversial cases could due factors disease specific eg larger anticipated genetic heterogeneity andor small effect sizes individual risk alleles good proportion controversies probably caused methodological issues based recent empirical simulation data regarding genetic make complex diseases power association studies general propose attention paid providing power estimates based structure analyzed sample variety effect sizes allele frequencies ii replicating positive signal least one independent population sufficient size power prior initial publication iii thoroughly assessing haplotype structure investigated locus especially reaching negative conclusions together statistical techniques take account potential interactions genetic non genetic factors allow adequate correction multiple comparisons adherence criteria ensure successful distinction clinically relevant irrelevantfalse positive findings eventually good vintage wine strategy elevate quality ad genetics research par quantity
0.43645546.14764623.html.plaintext.txt	27	acknowledgements work sponsored grants nimh nia adrc alzheimer association lb fellow harvard center neurodegeneration repair hcnr fellow deutsche forschungsgemeinschaft dfg
0.43645546.14764623.html.plaintext.txt	28	footnotes correspondence addressed genetics aging research unit department neurology massachusetts general hospital 114 16th street charlestown ma 02129 usa tel 1 6177266845 fax 1 6177241823 email tanziathelixmghharvardedu
0.43645546.14764623.html.plaintext.txt	29	footnotes correspondence addressed genetics aging research unit department neurology massachusetts general hospital 114 16th street charlestown ma 02129 usa tel 1 6177266845 fax 1 6177241823 email tanziathelixmghharvardedu
0.43645546.14764623.html.plaintext.txt	30	references top abstract introduction 2003 good vintage conclusion references rao vs cupples van duijn cm kurz green rc chui h duara r auerbach sa volicer l wells j et al 1996 evidence major gene inheritance alzheimer disease families patients without apolipoprotein e epsilon 4 j hum genet 59 664 675isimedline
0.43645546.14764623.html.plaintext.txt	31	poirier j 2000 apolipoprotein e alzheimers disease role amyloid catabolism ann ny acad sci 924 81 90abstractfree full text
0.43713617.11809755.html.plaintext.txt	0	insulin degrading enzyme rapidly removes amyloid precursor protein intracellular domain aicd dieter edbauer michael willem sven lammich harald steiner christian haass
0.43713617.11809755.html.plaintext.txt	1	department biochemistry laboratory alzheimers parkinsons disease research adolf butenandt institute ludwig maximilians university schillerstrasse 44 80336 munich germany
0.43713617.11809755.html.plaintext.txt	2	received publication december 5 2001 revised form january 22 2002
0.43713617.11809755.html.plaintext.txt	3	abstract top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	4	intramembranous secretase cleavage amyloid precursor protein app dependent biologically active presenilins ps notch also undergoes similar ps dependent secretase like cleavage resulting liberation notch intracellular domain nicd critically required developmental signal transduction secretase processing app results production similar fragment called aicd app intracellular domain may function nuclear signaling well aicd like nicd rapidly removed using battery protease inhibitors demonstrate aicd contrast nicd degraded cytoplasmic metalloprotease vitro degradation aicd reconstituted cytoplasmic fractions obtained neuronal non neuronal cells taking account inhibition profile cytoplasmic localization identified three candidate enzymes neurolysin thimet oligopeptidase insulin degrading enzyme ide also known insulysin involved degradation bioactive peptides brain insulin well characterized substrate ide added vitro degradation assay removal aicd efficiently blocked moreover overexpression ide resulted enhanced degradation aicd whereas overexpression inactive ide e111q mutant affect aicd degradation finally immunodepletion ide significantly reduced aicd degrading activity therefore data demonstrate ide one proteases implicated removal extracellular also removes cytoplasmic product secretase cleaved app introduction top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	5	intramembranous secretase cleavage amyloid precursor protein app dependent biologically active presenilins ps notch also undergoes similar ps dependent secretase like cleavage resulting liberation notch intracellular domain nicd critically required developmental signal transduction secretase processing app results production similar fragment called aicd app intracellular domain may function nuclear signaling well aicd like nicd rapidly removed using battery protease inhibitors demonstrate aicd contrast nicd degraded cytoplasmic metalloprotease vitro degradation aicd reconstituted cytoplasmic fractions obtained neuronal non neuronal cells taking account inhibition profile cytoplasmic localization identified three candidate enzymes neurolysin thimet oligopeptidase insulin degrading enzyme ide also known insulysin involved degradation bioactive peptides brain insulin well characterized substrate ide added vitro degradation assay removal aicd efficiently blocked moreover overexpression ide resulted enhanced degradation aicd whereas overexpression inactive ide e111q mutant affect aicd degradation finally immunodepletion ide significantly reduced aicd degrading activity therefore data demonstrate ide one proteases implicated removal extracellular also removes cytoplasmic product secretase cleaved app introduction top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	6	current evidence strongly implicates aggregation deposition amyloid peptide a1 brains alzheimers disease patients invariant pathological feature 1 generated amyloid precursor protein app endoproteolytic processing two sequential cleavages first secretase followed secretase required liberate review see refs 2 3 intramembranous secretase cleavage dependent biologically active presenilins ps may unusual aspartyl proteases 4 5 probably constitute active site secretase review see refs 2 3 pss involved proteolytic processing app also similar intramembraneous cut notch 6 notch like app type transmembrane protein undergoes similar endoproteolytic processing pathways review see refs 2 3 ectodomain shedding notch cleaved within close transmembrane domain secretase like s3 protease activity s3 cut finally liberates notch intracellular domain nicd key molecule developmental signal transduction 7 cleavage notch s3 ps dependent blocked secretase inhibitors 6 consistent role pss notch signaling ps1ps2 double knockout mice phenotype similar notch1 mice 8 notch cleavage completely inhibited ps deficient cells 9 10 requirement pss nicd formation secretase cleavage app provided basis hypothesis secretase generated cytoplasmic domain app may also carry important function nuclear signaling recently several reports 11 15 described secretase generated cytoplasmic fragment app termed aicd app intracellular domain 13 analogy nicd aicd generated ps dependent mechanism since ps1 gene knockout well dominant negative ps1 mutation d385n inhibited aicd generation 13 moreover secretase inhibitors including ones known bind pss also blocked aicd generation vivo vitro 12 13 15 interestingly n terminus aicd predominantly generated cut amino acids 49 50 amyloid domain expected secretase cut amino acids 40 42 13 15 cleavage releases vivo 50 amino acid long aicd fragment cytoplasm predicted 57 59 amino acid fragment sequence comparison revealed cleavage occurs similar position s3 cleavage notch 13 15 taken together analogies app notch processing may favor idea aicd like nicd physiological function nuclear signal transduction indeed recent findings highly sensitive reporter gene assays supported hypothesis aicd may involved gene transcription 16 however aicd alone sufficient allow detection significant transcriptional activity reporter gene assays upon co transfection fe65 nuclear adaptor protein shown bind app cytoplasmic tail 17 19 significant transcriptional activity observed 16 may related observation recombinant 59 amino acid aicd like molecules stabilized co expression fe65 20 although latter confirmed others 21
0.43713617.11809755.html.plaintext.txt	7	current evidence strongly implicates aggregation deposition amyloid peptide a1 brains alzheimers disease patients invariant pathological feature 1 generated amyloid precursor protein app endoproteolytic processing two sequential cleavages first secretase followed secretase required liberate review see refs 2 3 intramembranous secretase cleavage dependent biologically active presenilins ps may unusual aspartyl proteases 4 5 probably constitute active site secretase review see refs 2 3 pss involved proteolytic processing app also similar intramembraneous cut notch 6 notch like app type transmembrane protein undergoes similar endoproteolytic processing pathways review see refs 2 3 ectodomain shedding notch cleaved within close transmembrane domain secretase like s3 protease activity s3 cut finally liberates notch intracellular domain nicd key molecule developmental signal transduction 7 cleavage notch s3 ps dependent blocked secretase inhibitors 6 consistent role pss notch signaling ps1ps2 double knockout mice phenotype similar notch1 mice 8 notch cleavage completely inhibited ps deficient cells 9 10 requirement pss nicd formation secretase cleavage app provided basis hypothesis secretase generated cytoplasmic domain app may also carry important function nuclear signaling recently several reports 11 15 described secretase generated cytoplasmic fragment app termed aicd app intracellular domain 13 analogy nicd aicd generated ps dependent mechanism since ps1 gene knockout well dominant negative ps1 mutation d385n inhibited aicd generation 13 moreover secretase inhibitors including ones known bind pss also blocked aicd generation vivo vitro 12 13 15 interestingly n terminus aicd predominantly generated cut amino acids 49 50 amyloid domain expected secretase cut amino acids 40 42 13 15 cleavage releases vivo 50 amino acid long aicd fragment cytoplasm predicted 57 59 amino acid fragment sequence comparison revealed cleavage occurs similar position s3 cleavage notch 13 15 taken together analogies app notch processing may favor idea aicd like nicd physiological function nuclear signal transduction indeed recent findings highly sensitive reporter gene assays supported hypothesis aicd may involved gene transcription 16 however aicd alone sufficient allow detection significant transcriptional activity reporter gene assays upon co transfection fe65 nuclear adaptor protein shown bind app cytoplasmic tail 17 19 significant transcriptional activity observed 16 may related observation recombinant 59 amino acid aicd like molecules stabilized co expression fe65 20 although latter confirmed others 21
0.43713617.11809755.html.plaintext.txt	8	aicd plays role signal transduction activity may regulated case nicd ubiquitin dependent proteasomal degradation pathway prevents nicd accumulation constitutive signaling 6 22 23 aicd also rapidly degraded apparently protease activity different proteasome 12 21 therefore searched protease activity involved aicd degradation surprisingly found aicd efficiently degraded insulin degrading enzyme ide thiol dependent metalloprotease known degrade insulin glucagon peptide hormones 24 interestingly ide also implicated clearance extracellular review see ref 25 data therefore suggest therapeutic stimulation ide activity remove also affect aicd metabolism potential function nuclear signal transduction experimental procedures top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	9	aicd plays role signal transduction activity may regulated case nicd ubiquitin dependent proteasomal degradation pathway prevents nicd accumulation constitutive signaling 6 22 23 aicd also rapidly degraded apparently protease activity different proteasome 12 21 therefore searched protease activity involved aicd degradation surprisingly found aicd efficiently degraded insulin degrading enzyme ide thiol dependent metalloprotease known degrade insulin glucagon peptide hormones 24 interestingly ide also implicated clearance extracellular review see ref 25 data therefore suggest therapeutic stimulation ide activity remove also affect aicd metabolism potential function nuclear signal transduction experimental procedures top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	10	cell lines cell culture human embryonic kidney 293 cells hek293 cultured dulbeccos modified eagles medium supplemented 10 fetal bovine serum 1 penicillinstreptomycin 200 microgml g418 select app expression 200 microgml zeocin select ide expression hek293 cells stably expressing rat ide variants generated transfection hek293 cells stably expressing app695 containing swedish mutation swapp 26 mouse neuroblastoma n2a cells stably expressing swapp cultured described previously 27
0.43713617.11809755.html.plaintext.txt	11	cell lines cell culture human embryonic kidney 293 cells hek293 cultured dulbeccos modified eagles medium supplemented 10 fetal bovine serum 1 penicillinstreptomycin 200 microgml g418 select app expression 200 microgml zeocin select ide expression hek293 cells stably expressing rat ide variants generated transfection hek293 cells stably expressing app695 containing swedish mutation swapp 26 mouse neuroblastoma n2a cells stably expressing swapp cultured described previously 27
0.43713617.11809755.html.plaintext.txt	12	protease inhibitors protease inhibitors used following final concentrations vitro assays aicd degradation protease inhibitor mix without edta 1 x complete roche molecular biochemicals dapt 1 microm gift boehringer ingelheim kg edta 5 mm sigma 110 o phenanthroline pnt 5 mm sigma phosphoramidon 100 microm calbiochem bestatin 200 microm calbiochem clasto lactacystin lactone 10 microm sigma mg132 50 microm calbiochem n ethylmaleimide nem 01 10 mm sigma dynorphin 1 13 05 mm bachem pro ile 5 mm bachem cfp aay pab cfp 100 microm gift ian smith insulin 2 250 microgml sigma zincov 100 microm calbiochem e64 50 microm roche molecular biochemicals phenylmethylsulfonyl fluoride 1 mm sigma leupeptin 1 microgml roche molecular biochemicals aprotinin 2 microgml roche molecular biochemicals antipain 50 microgml roche molecular biochemicals pepstatin 2 microgml calbiochem
0.43713617.11809755.html.plaintext.txt	13	protease inhibitors protease inhibitors used following final concentrations vitro assays aicd degradation protease inhibitor mix without edta 1 x complete roche molecular biochemicals dapt 1 microm gift boehringer ingelheim kg edta 5 mm sigma 110 o phenanthroline pnt 5 mm sigma phosphoramidon 100 microm calbiochem bestatin 200 microm calbiochem clasto lactacystin lactone 10 microm sigma mg132 50 microm calbiochem n ethylmaleimide nem 01 10 mm sigma dynorphin 1 13 05 mm bachem pro ile 5 mm bachem cfp aay pab cfp 100 microm gift ian smith insulin 2 250 microgml sigma zincov 100 microm calbiochem e64 50 microm roche molecular biochemicals phenylmethylsulfonyl fluoride 1 mm sigma leupeptin 1 microgml roche molecular biochemicals aprotinin 2 microgml roche molecular biochemicals antipain 50 microgml roche molecular biochemicals pepstatin 2 microgml calbiochem
0.43713617.11809755.html.plaintext.txt	14	cdna constructs rat ide cdna gift r roth cloned pcdna31zeo invitrogen nonfunctional ide e111q mutant generated pcr mediated mutagenesis using appropriate primers
0.43713617.11809755.html.plaintext.txt	15	antibodies polyclonal antibody 6687 20 c terminal amino acids app 5 monoclonal antibody 9b12 human ide 28 described antibody 9b12 also recognizes rat ide
0.43713617.11809755.html.plaintext.txt	16	antibodies polyclonal antibody 6687 20 c terminal amino acids app 5 monoclonal antibody 9b12 human ide 28 described antibody 9b12 also recognizes rat ide
0.43713617.11809755.html.plaintext.txt	17	aicd generationdegradation vitro characterize protease activity involved aicd degradation used previously established vitro assay 13 hek293 cells resuspended 05 ml10 cm dish ice cold hypotonic homogenization buffer 10 mm mops ph 70 10 mm kcl without protease inhibitors incubated ice 10 min following homogenization ice tight fitting homogenizer 30 strokes post nuclear supernatant prepared centrifugation 1000 x g 15 min 4 degrees c crude membranes isolated post nuclear supernatant centrifugation 16000 x g 40 min 4 degrees c membranes resuspended 50 microl10 cm dish assay buffer 150 mm sodium citrate ph 64 supplemented indicated protease inhibitors aicd generated incubation samples 37 degrees c 2 h volume 25 microlassay termination assay reactions ice samples separated pellet p100 supernatant s100 fractions ultracentrifugation 1 h 100000 x g 4 degrees c s100 fraction separated sds page 10 20 tris tricine gels invitrogen 165 tris tricine gels 29 analyzed immunoblotting antibody 6687 detection using enhanced chemiluminescence ecl amersham biosciences
0.43713617.11809755.html.plaintext.txt	18	aicd generationdegradation vitro characterize protease activity involved aicd degradation used previously established vitro assay 13 hek293 cells resuspended 05 ml10 cm dish ice cold hypotonic homogenization buffer 10 mm mops ph 70 10 mm kcl without protease inhibitors incubated ice 10 min following homogenization ice tight fitting homogenizer 30 strokes post nuclear supernatant prepared centrifugation 1000 x g 15 min 4 degrees c crude membranes isolated post nuclear supernatant centrifugation 16000 x g 40 min 4 degrees c membranes resuspended 50 microl10 cm dish assay buffer 150 mm sodium citrate ph 64 supplemented indicated protease inhibitors aicd generated incubation samples 37 degrees c 2 h volume 25 microlassay termination assay reactions ice samples separated pellet p100 supernatant s100 fractions ultracentrifugation 1 h 100000 x g 4 degrees c s100 fraction separated sds page 10 20 tris tricine gels invitrogen 165 tris tricine gels 29 analyzed immunoblotting antibody 6687 detection using enhanced chemiluminescence ecl amersham biosciences
0.43713617.11809755.html.plaintext.txt	19	alkaline extraction membranes crude membranes prepared resuspended 05 ml10 cm dish 100 mm na2co3 ph 110 30 incubated ice 15 min ultracentrifugation 1 h 100000 x g 4 degrees c two consecutive washes assay buffer carbonate extracted membranes resuspended 50 microl10 cm dish assay buffer analyzed aicd degradation
0.43713617.11809755.html.plaintext.txt	20	alkaline extraction membranes crude membranes prepared resuspended 05 ml10 cm dish 100 mm na2co3 ph 110 30 incubated ice 15 min ultracentrifugation 1 h 100000 x g 4 degrees c two consecutive washes assay buffer carbonate extracted membranes resuspended 50 microl10 cm dish assay buffer analyzed aicd degradation
0.43713617.11809755.html.plaintext.txt	21	preparation cytosol cytosol prepared indicated cell lines ultracentrifugation post nuclear supernatant fraction 100000 x g 1 h 4 degrees c soluble s100 fraction used cytosol
0.43713617.11809755.html.plaintext.txt	22	preparation cytosol cytosol prepared indicated cell lines ultracentrifugation post nuclear supernatant fraction 100000 x g 1 h 4 degrees c soluble s100 fraction used cytosol
0.43713617.11809755.html.plaintext.txt	23	reconstitution aicd degradation vitro cytosol free membranes generated three consecutive washes membranes assay buffer centrifugation 100000 x g 30 min 4 degrees c cytosol free membranes resuspended assay buffer 20 microlassay mixed aliquots 5 microl cytosol fractions containing indicated protein amounts aicd generated described assays insulin aicd first generated cytosol free membranes described ultracentrifugation membrane free s100 fractions containing preformed aicd mixed cytosol preparations supplemented indicated amounts insulin assayed aicd degradation described
0.43713617.11809755.html.plaintext.txt	24	reconstitution aicd degradation vitro cytosol free membranes generated three consecutive washes membranes assay buffer centrifugation 100000 x g 30 min 4 degrees c cytosol free membranes resuspended assay buffer 20 microlassay mixed aliquots 5 microl cytosol fractions containing indicated protein amounts aicd generated described assays insulin aicd first generated cytosol free membranes described ultracentrifugation membrane free s100 fractions containing preformed aicd mixed cytosol preparations supplemented indicated amounts insulin assayed aicd degradation described
0.43713617.11809755.html.plaintext.txt	25	immunodepletion ide ide depleted cytosol preparations generated immunoprecipitation 2 h 4 degrees c using excess amounts antibody 9b12 prebound rabbit anti mouse antibody sigma protein sepharose control mock immunoprecipitation lacking antibody 9b12 carried rabbit anti mouse antibody prebound protein sepharose results top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	26	immunodepletion ide ide depleted cytosol preparations generated immunoprecipitation 2 h 4 degrees c using excess amounts antibody 9b12 prebound rabbit anti mouse antibody sigma protein sepharose control mock immunoprecipitation lacking antibody 9b12 carried rabbit anti mouse antibody prebound protein sepharose results top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	27	aicd rapidly degraded metalloprotease activity others previously demonstrated aicd efficiently generated vitro secretase ps dependent manner crude membrane fractions prepared centrifugation 10000 16000 x g 11 14 however vitro generated aicd extremely rapidly degraded addition protease inhibitor mix containing edta necessary stabilize aicd 11 12 identify protease involved extremely rapid degradation pathway vitro assay carried presence variety protease inhibitors fig 1 absence inhibitor aicd could detected demonstrating 37 degrees c aicd degradation even faster de novo synthesis consistent previous results general protease inhibitor mix including edta inhibited aicd degradation additional presence secretase inhibitor dapt inhibited aicd generation expected 13 interestingly protease inhibitor mix without edta block aicd degradation suggesting involvement divalent metal ion dependent proteolytic activity aicd generation indeed metal chelators edta pnt allowed robust accumulation aicd used either alone combination however specific metalloprotease inhibitors phosphoramidon bestatin inhibitor aminopeptidases inhibit degradation aicd aicd degradation affected inhibitors cysteine proteases e64 leupeptin serine proteases phenylmethylsulfonyl fluoride aspartyl proteases pepstatin data shown interestingly potent proteasome inhibitors clasto lactacystin lactone mg132 also block aicd degradation fig 1 contrast nicd shown rapidly degraded ubiquitin dependent proteasomal degradation pathway 6 22 23 thus although aicd nicd generated ps dependent protease degraded different proteolytic activities taken together conclude likely metalloprotease involved aicd degradation
0.43713617.11809755.html.plaintext.txt	28	aicd rapidly degraded metalloprotease activity others previously demonstrated aicd efficiently generated vitro secretase ps dependent manner crude membrane fractions prepared centrifugation 10000 16000 x g 11 14 however vitro generated aicd extremely rapidly degraded addition protease inhibitor mix containing edta necessary stabilize aicd 11 12 identify protease involved extremely rapid degradation pathway vitro assay carried presence variety protease inhibitors fig 1 absence inhibitor aicd could detected demonstrating 37 degrees c aicd degradation even faster de novo synthesis consistent previous results general protease inhibitor mix including edta inhibited aicd degradation additional presence secretase inhibitor dapt inhibited aicd generation expected 13 interestingly protease inhibitor mix without edta block aicd degradation suggesting involvement divalent metal ion dependent proteolytic activity aicd generation indeed metal chelators edta pnt allowed robust accumulation aicd used either alone combination however specific metalloprotease inhibitors phosphoramidon bestatin inhibitor aminopeptidases inhibit degradation aicd aicd degradation affected inhibitors cysteine proteases e64 leupeptin serine proteases phenylmethylsulfonyl fluoride aspartyl proteases pepstatin data shown interestingly potent proteasome inhibitors clasto lactacystin lactone mg132 also block aicd degradation fig 1 contrast nicd shown rapidly degraded ubiquitin dependent proteasomal degradation pathway 6 22 23 thus although aicd nicd generated ps dependent protease degraded different proteolytic activities taken together conclude likely metalloprotease involved aicd degradation
0.43713617.11809755.html.plaintext.txt	29	view larger version 23k fig 1 chelators divalent metal ions block aicd degradation membrane preparations incubated 37 degrees c 2 h presence absence indicated protease inhibitors membranes pelleted ultracentrifugation aicd analyzed soluble fraction immunoblotting antibody 6687 note aicd degradation blocked protease inhibitor mix pi mix well metal chelators edta pnt inhibitors proteasome clasto lactacystin lactone mg132
0.43713617.11809755.html.plaintext.txt	30	aicd degraded cytoplasmic protease next investigated whether metalloprotease activity involved aicd degradation cytosolic membrane bound first assayed crude membranes aicd degradation alkaline extraction na2co3 separates peripheral integral membrane proteins 30 shown fig 2a aicd could recovered absence pntedta na2co3 extracted membranes suggesting aicd degrading activity either peripherally attached membrane soluble addition data confirm previous findings secretase integrally membrane bound 11 next separated crude membranes residual cytosol additional centrifugation shown crude membranes used vitro assay aicd could recovered absence pntedta fig 2b due rapid degradation contrast crude membranes used additional re centrifugation 100000 x g robust accumulation aicd observed absence pntedta fig 2b thus data suggest aicd degrading activity soluble protease primarily located within cytoplasm prove cytoplasmic localization aicd degrading activity vitro degradation assay performed washed cytosol free membranes allowed robust accumulation aicd absence pntedta degrading activity could reconstituted addition increasing amounts cytosol hek293 mouse neuroblastoma n2a cells fig 2c results conclude cytoplasmic metalloprotease present peripheral well neuronal cells involved aicd degradation
0.43713617.11809755.html.plaintext.txt	31	aicd degraded cytoplasmic protease next investigated whether metalloprotease activity involved aicd degradation cytosolic membrane bound first assayed crude membranes aicd degradation alkaline extraction na2co3 separates peripheral integral membrane proteins 30 shown fig 2a aicd could recovered absence pntedta na2co3 extracted membranes suggesting aicd degrading activity either peripherally attached membrane soluble addition data confirm previous findings secretase integrally membrane bound 11 next separated crude membranes residual cytosol additional centrifugation shown crude membranes used vitro assay aicd could recovered absence pntedta fig 2b due rapid degradation contrast crude membranes used additional re centrifugation 100000 x g robust accumulation aicd observed absence pntedta fig 2b thus data suggest aicd degrading activity soluble protease primarily located within cytoplasm prove cytoplasmic localization aicd degrading activity vitro degradation assay performed washed cytosol free membranes allowed robust accumulation aicd absence pntedta degrading activity could reconstituted addition increasing amounts cytosol hek293 mouse neuroblastoma n2a cells fig 2c results conclude cytoplasmic metalloprotease present peripheral well neuronal cells involved aicd degradation
0.43713617.11809755.html.plaintext.txt	32	view larger version 30k fig 2 aicd degraded cytosolic metalloprotease alkaline extraction separates aicd degrading activity aicd generating activity crude membrane preparations subjected alkaline extraction na2co3 following centrifugation 100000 x g two subsequent washes membranes incubated 37 degrees c 2 h presence absence pntedta aicd analyzed fig 1 note aicd recovered absence pntedta upon removal degrading activity alkaline extraction na2co3 without affecting aicd generating secretase activity b aicd degrading activity removed ultracentrifugation crude membrane preparations incubated directly preparation p16 fractions additional centrifugation 100000 x g p100 fractions 37 degrees c 2 h presence absence pntedta aicd analyzed described legend fig 1 note aicd recovered even absence pntedta additional ultracentrifugation p16 fractions c aicd degrading activity present cytosol cytosol free membrane preparations incubated 37 degrees c 2 h presence absence pntedta together indicated amounts cytosol fractions hek293 mouse n2a cells aicd analyzed described legend fig 1 note dose dependent degradation aicd presence cytosol derived kidney neuronal cells
0.43713617.11809755.html.plaintext.txt	33	identification candidate enzymes responsible aicd degradation based inhibition profile cytoplasmic localization aicd degrading activity searched merops protease data base wwwmeropscouk candidate aicd degrading enzymes search revealed three cytoplasmic candidate proteases two metalloprotease families m3a m16a families could responsible degradation aicd thimet oligopeptidase top m3a family neurolysin m3a family ide insulysin m16a family consistent candidate proteases thiol group dependent 31 32 sh alkylating agents nem strongly inhibited aicd degradation fig 3a next discriminate proteases could involved aicd degradation vitro assay carried presence absence dynorphin 1 13 known inhibitor top neurolysin 31 potentially also ide dipeptide pro ile highly specific neurolysin inhibitor 31 cfp aay pab cfp potent top less potent neurolysin inhibitor 33 insulin well characterized substrate ide functions competitive inhibitor investigated well 24 shown fig 3b weak inhibition aicd degradation dynorphin 1 13 suggests either top neurolysin candidate protease without excluding ide however pro ile block aicd degradation ruling neurolysin candidate protease fig 3b since cfp also block aicd degradation fig 3b ide remained candidate aicd degradation indeed insulin competed aicd degrading activity present cytosol derived n2a cells dose dependent manner fig 3c bovine serum albumin used control unspecific inhibition degradation effect fig 3c similar results obtained cytosol hek293 cells data shown thus data indicate ide may one aicd degrading enzymes n2a hek293 cells
0.43713617.11809755.html.plaintext.txt	34	view larger version 37k fig 3 identification candidate metalloproteases involved aicd degradation sh alkylating agent nem inhibits aicd degradation crude membrane preparations incubated 37 degrees c 2 h presence absence indicated concentrations nem aicd analyzed described legend fig 1 b aicd degradation reduced dynorphin 1 13 specific neurolysin inhibitor pro ile specific top inhibitor cfp crude membrane preparations assayed aicd degradation fig 1 c dose dependent inhibition aicd degradation insulin aicd generated incubation cytosol free membranes 2 h 37 degrees c subsequently separated membranes ultracentrifugation s100 fractions containing preformed aicd mixed cytosol 8 microg derived n2a cells indicated amounts insulin bovine serum albumin assayed aicd degradation incubation 2 h 37 degrees c described legend fig 1 note dose dependent inhibition aicd degradation insulin bovine serum albumin
0.43713617.11809755.html.plaintext.txt	35	ide degrades aicd prove whether ide aicd degrading enzyme generated hek293 cell lines stably overexpressing rat ide inactive ide mutant ide e111q glutamate hxxeh active site motif changed glutamine 34 35 shown fig 4a immunoblotting cytosol fractions confirmed overexpression wt mutant ide proteins cytosol fractions derived cells overexpressing wt ide contained significantly higher aicd degrading activity cytosol fractions ide e111q overexpressing cells fig 4b finally cytosol hek293 cells immunodepleted endogenous ide immunoprecipitation excess amounts anti ide antibody fig 4c aicd generation assayed cytosol free membranes presence fractions shown fig 4d dose dependent aicd degradation observed non depleted control fractions contrast markedly reduced aicd degrading activity ide depleted cytosol fractions thus data strongly suggest ide major aicd degrading enzyme
0.43713617.11809755.html.plaintext.txt	36	view larger version 26k fig 4 ide aicd degrading enzyme cytosol fractions hek293 cells stably co expressing swedish mutant app rat wt ide inactive rat ide e111q mutant analyzed ide expression immunoblotting antibody 9b12 note increased levels ide variants cytosol fraction upon overexpression b overexpressed rat ide inactive ide e111q efficiently degrades aicd cytosol free membrane preparations incubated 37 degrees c 2 h described legend fig 2c presence absence pntedta indicated amounts cytosol fractions hek293 cells stably overexpressing ide inactive ide e111q mutant note overexpressed wt ide strongly enhances aicd degradation compared inactive ide c immunodepletion ide cytosol fractions hek293 cells immunodepleted endogenous ide immunoprecipitation antibody 9b12 control mock immunoprecipitation lacking antibody 9b12 carried note significant depletion ide antibody 9b12 d cytosol fractions immunodepleted ide assayed aicd degradation described legend fig 2c note immunodepletion ide blocks degradation aicd discussion top abstract introduction experimental procedures results discussion references
0.43713617.11809755.html.plaintext.txt	37	pss may function facilitating nuclear signaling function well proven role ps nicd generation recently corresponding cytoplasmic fragment app aicd identified 13 15 aicd generated remarkably similar molecular mechanism like nicd fig 5 aicd functions nuclear signaling proposed cao sudhof 16 one may expect rapid clearance fragment since constitutive uncontrolled signaling must avoided indeed case nicd rapidly removed ubiquitin dependent proteasomal degradation pathway 6 22 23 show aicd degraded proteasome completely different protease namely ide fig 5 biochemical properties ide make ideal candidate aicd degradation highly expressed cellular compartment aicd common enzyme brain tissue abundant app expression observed preferentially degrades small cytoplasmic peptides 20 50 amino acids length review see ref 24
0.43713617.11809755.html.plaintext.txt	38	pss may function facilitating nuclear signaling function well proven role ps nicd generation recently corresponding cytoplasmic fragment app aicd identified 13 15 aicd generated remarkably similar molecular mechanism like nicd fig 5 aicd functions nuclear signaling proposed cao sudhof 16 one may expect rapid clearance fragment since constitutive uncontrolled signaling must avoided indeed case nicd rapidly removed ubiquitin dependent proteasomal degradation pathway 6 22 23 show aicd degraded proteasome completely different protease namely ide fig 5 biochemical properties ide make ideal candidate aicd degradation highly expressed cellular compartment aicd common enzyme brain tissue abundant app expression observed preferentially degrades small cytoplasmic peptides 20 50 amino acids length review see ref 24
0.43713617.11809755.html.plaintext.txt	39	view larger version 22k fig 5 distinct pathways involved degradation aicd nicd aicd nicd generated ps dependent secretase s3 protease cleavages similar sites within membrane following liberation membrane nicd probably also aicd translocate nucleus nucleus nicd activates transcription notch target genes proteasomal degradation nicd prevents accumulation constitutive signaling contrast nicd aicd degraded ide like neprilysin also involved extracellular degradation secreted
0.43713617.11809755.html.plaintext.txt	40	found extremely rapid turnover aicd even exceeds kinetics de novo production vitro consistent high levels ide cytoplasm many cells tissues although identified ide major aicd degrading enzyme non neuronal neuronal cell lysates cannot exclude possibility enzymes may degrade aicd cells ide activity expression low 24
0.43713617.11809755.html.plaintext.txt	41	found extremely rapid turnover aicd even exceeds kinetics de novo production vitro consistent high levels ide cytoplasm many cells tissues although identified ide major aicd degrading enzyme non neuronal neuronal cell lysates cannot exclude possibility enzymes may degrade aicd cells ide activity expression low 24
0.43713617.11809755.html.plaintext.txt	42	interestingly overexpressed artificial 59 amino acid aicd variants localized nucleus extent 20 21 however contrast endogenous aicd correct n terminus far detected within nucleus due rather rapid turnover endogenous aicd apparent lack nuclear localization one may question function small peptide nuclear signaling however one needs point nicd could detected nucleus long time sensitive techniques lacking indeed using hypersensitive reporter gene assays cao sudhof 16 could provide indirect evidence cytoplasmic fragment app identical vivo existing aicd complexed fe65 histone acetyltransferase tip60 could mediate gene transcription however nuclear transport authentic aicd formation nuclear tip60 fe65 aicd complex remains shown identification ide aicd degrading enzyme may facilitate research putative role aicd nuclear signaling since function could strongly enhanced inhibition aicd degradation
0.43713617.11809755.html.plaintext.txt	43	interestingly overexpressed artificial 59 amino acid aicd variants localized nucleus extent 20 21 however contrast endogenous aicd correct n terminus far detected within nucleus due rather rapid turnover endogenous aicd apparent lack nuclear localization one may question function small peptide nuclear signaling however one needs point nicd could detected nucleus long time sensitive techniques lacking indeed using hypersensitive reporter gene assays cao sudhof 16 could provide indirect evidence cytoplasmic fragment app identical vivo existing aicd complexed fe65 histone acetyltransferase tip60 could mediate gene transcription however nuclear transport authentic aicd formation nuclear tip60 fe65 aicd complex remains shown identification ide aicd degrading enzyme may facilitate research putative role aicd nuclear signaling since function could strongly enhanced inhibition aicd degradation
0.43713617.11809755.html.plaintext.txt	44	interestingly ide degrades aicd also involved clearance secreted brain 36 40 although major degrading activity appears neprilysin 41 43 surprisingly degrading ide appears released living cells 36 37 small amounts far unknown cellular mechanisms contrast secreted aicd released cytoplasm rapidly degraded ide since ide one clearing enzymes tempting increase activity lower amyloid burden alzheimers disease patients indeed major goal behind identification degrading enzymes finding ide involved degradation also removal aicd may important implications therapeutic strategies involving manipulation ide activity one assumes aicd required nuclear signaling enhanced removal interfere aicd mediated functions moreover therapeutic strategies inhibition secretase activity also interfere aicd production case major reduction acid mediated signaling may occur could also detrimental implications careful analysis aicd function metabolism therefore required understand biological function app nuclear signaling also safety ongoing therapeutic trials acknowledgements
0.43713617.11809755.html.plaintext.txt	45	interestingly ide degrades aicd also involved clearance secreted brain 36 40 although major degrading activity appears neprilysin 41 43 surprisingly degrading ide appears released living cells 36 37 small amounts far unknown cellular mechanisms contrast secreted aicd released cytoplasm rapidly degraded ide since ide one clearing enzymes tempting increase activity lower amyloid burden alzheimers disease patients indeed major goal behind identification degrading enzymes finding ide involved degradation also removal aicd may important implications therapeutic strategies involving manipulation ide activity one assumes aicd required nuclear signaling enhanced removal interfere aicd mediated functions moreover therapeutic strategies inhibition secretase activity also interfere aicd production case major reduction acid mediated signaling may occur could also detrimental implications careful analysis aicd function metabolism therefore required understand biological function app nuclear signaling also safety ongoing therapeutic trials acknowledgements
0.43713617.11809755.html.plaintext.txt	46	thank ian smith top inhibitors richard roth rat ide cdna antibody 9b12 human ide klaus fuchs dapt gopal thinakaran mouse n2a cells stably expressing swapp magdalena sastre discussion
0.43713617.11809755.html.plaintext.txt	47	work supported boehringer ingelheim pharma kg stipend l deutsche forschungsgemeinschaft dfgthe costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.43713617.11809755.html.plaintext.txt	48	senior authors correspondence may addressed tel 49 89 5996 471472 fax 49 89 5996 415 e mail chaasspbmmeduni muenchende c h tel 49 89 5996 480 fax 49 89 5996 415 e mail hsteinerpbmmeduni muenchende h
0.43713617.11809755.html.plaintext.txt	49	published jbc papers press january 23 2002 doi 101074jbcm111571200
0.43713617.11809755.html.plaintext.txt	50	abbreviations used amyloid peptide app amyloid precursor protein aicd app intracellular domain ide insulin degrading enzyme nicd notch intracellular domain ps presenilin hek human embryonic kidney dapt n n 35 difluorophenacetyl l alanyl phenylglycine butyl ester pnt 110 o phenanthroline nem n ethylmaleimide mops 4 morpholinepropanesulfonic acid tricine n 2 hydroxy 11 bishydroxymethylethylglycine top thimet oligopeptidase wt wild type
0.43713617.11809755.html.plaintext.txt	51	references top abstract introduction experimental procedures results discussion references 1 selkoe d j 1999 nature 399 a23 a31crossrefmedline order article via infotrieve 2 esler w p wolfe m 2001 science 293 1449 1454abstractfree full text 3 walter j kaether c steiner h haass c 2001 curr opin neurobiol 11 585 590crossrefmedline order article via infotrieve 4 wolfe m xia w ostaszewski b l diehl kimberly w selkoe d j 1999 nature 398 513 517crossrefmedline order article via infotrieve 5 steiner h kostka m romig h basset g pesold b hardy j capell meyn l grim m g baumeister r fechteler k haass c 2000 nat cell biol 2 848 851crossrefmedline order article via infotrieve 6 de strooper b annaert w cupers p saftig p craessaerts k mumm j schroeter e h schrijvers v wolfe m ray w j goate kopan r 1999 nature 398 518 522crossrefmedline order article via infotrieve 7 mumm j kopan r 2000 dev biol 228 151 165crossrefmedline order article via infotrieve 8 donoviel d b hadjantonakis k ikeda m zheng h hyslop p bernstein 1999 genes dev 13 2801 2810abstractfree full text 9 herreman serneels l annaert w collen d schoonjans l de strooper b 2000 nat cell biol 2 461 462crossrefmedline order article via infotrieve 10 zhang z nadeau p song w donoviel d yuan m bernstein yankner b 2000 nat cell biol 2 463 465crossrefmedline order article via infotrieve 11 mclendon c xin ziani cherif c murphy m p findlay k lewis p pinnix sambamurti k wang r fauq golde e 2000 faseb j 14 2383 2386abstractfree full text 12 pinnix musunuru u tun h sridharan golde eckman c ziani cherif c onstead l sambamurti k 2001 j biol chem 276 481 487abstractfree full text 13 sastre m steiner h fuchs k capell multhaup g condron m m teplow d b haass c 2001 embo rep 2 835 841abstractfree full text 14 gu y misonou h sato dohmae n takio k ihara y 2001 j biol chem 276 35235 35238abstractfree full text 15 yu c kim h ikeuchi xu h gasparini l wang r sisodia 2001 j biol chem 276 43756 43760abstractfree full text 16 cao x sudhof c 2001 science 293 115 120abstractfree full text 17 borg j p ooi j levy e margolis b 1996 mol cell biol 16 6229 6241abstract 18 fiore f zambrano n minopoli g donini v duilio russo 1995 j biol chem 270 30853 30856abstractfree full text 19 mcloughlin d m miller c c 1996 febs lett 397 197 200crossrefmedline order article via infotrieve 20 kimberly w zheng j b guenette selkoe d j 2001 j biol chem 276 40288 40292abstractfree full text 21 cupers p orlans craessaerts k annaert w de strooper b 2001 j neurochem 78 1168 1178crossrefmedline order article via infotrieve 22 oberg c li j pauley wolf e gurney m lendahl u 2001 j biol chem 276 35847 35853abstractfree full text 23 gupta rossi n le bail o gonen h brou c logeat f six e ciechanover israel 2001 j biol chem 276 34371 34378abstractfree full text 24 authier f posner b bergeron j j 1996 clin invest med 19 149 160medline order article via infotrieve 25 selkoe d j 2001 neuron 32 177 180medline order article via infotrieve 26 citron m oltersdorf haass c mcconlogue l hung y seubert p vigo pelfrey c lieberburg selkoe d j 1992 nature 360 672 674crossrefmedline order article via infotrieve 27 thinakaran g teplow d b siman r greenberg b sisodia 1996 j biol chem 271 9390 9397abstractfree full text 28 shii k roth r 1986 proc natl acad sci u 83 4147 4151abstract 29 schagger h von jagow g 1987 anal biochem 166 368 379medline order article via infotrieve 30 fujiki y hubbard l fowler lazarow p b 1982 j cell biol 93 97 102abstract 31 barrett j brown m dando p m knight c g mckie n rawlings n d serizawa 1995 methods enzymol 248 529 556medline order article via infotrieve 32 becker b roth r 1995 methods enzymol 248 693 703medline order article via infotrieve 33 shrimpton c n abbenante g lew r smith 2000 biochem j 345 351 356crossrefmedline order article via infotrieve 34 becker b roth r 1992 proc natl acad sci u 89 3835 3839abstract 35 perlman r k gehm b d kuo w l rosner m r 1993 j biol chem 268 21538 21544abstractfree full text 36 vekrellis k ye z qiu w q walsh d hartley d chesneau v rosner m r selkoe d j 2000 j neurosci 20 1657 1665abstractfree full text 37 qiu w q walsh d m ye z vekrellis k zhang j podlisny m b rosner m r safavi hersh l b selkoe d j 1998 j biol chem 273 32730 32738abstractfree full text 38 mukherjee song e kihiko ehmann m goodman j p jr pyrek j estus hersh l b 2000 j neurosci 20 8745 8749abstractfree full text 39 mcdermott j r gibson m 1997 neurochem res 22 49 56medline order article via infotrieve 40 kurochkin v goto 1994 febs lett 345 33 37crossrefmedline order article via infotrieve 41 iwata n tsubuki takaki y watanabe k sekiguchi m hosoki e kawashima morishima m lee h j hama e sekine aizawa y saido c 2000 nat med 6 143 150crossrefmedline order article via infotrieve 42 iwata n tsubuki takaki y shirotani k lu b gerard n p gerard c hama e lee h j saido c 2001 science 292 1550 1552abstractfree full text 43 shirotani k tsubuki iwata n takaki y harigaya w maruyama k kiryu seo kiyama h iwata h tomita iwatsubo saido c 2001 j biol chem 276 21895 21901abstractfree full text
0.43713617.11809755.html.plaintext.txt	52	copyright 2002 american society biochemistry molecular biology inc
0.5010976.15944156.html.plaintext.txt	0	yeast tractable genetic system functional studies insulin degrading enzyme seonil kim andrea n lapham christopher g k freedman tiffany l reed walter k schmidt
0.5010976.15944156.html.plaintext.txt	1	departments cellular biology biochemistry molecular biology university georgia athens georgia 30602
0.5010976.15944156.html.plaintext.txt	2	received publication december 17 2004 revised form june 7 2005
0.5010976.15944156.html.plaintext.txt	3	abstract top abstract introduction experimental procedures results discussion references developed yeast expression genetic system functional studies insulin degrading enzyme ide cleaves inactivates certain small peptide molecules including insulin neurotoxic peptide show heterologously expressed rat ide enzymatically active judged ability ide containing yeast extracts cleave insulin vitro also show ide promote vivo production yeast factor mating pheromone function normally attributed yeast enzymes axl1p ste23p however ide cannot substitute function axl1p promoting haploid axial budding repressing haploid invasive growth activities require uncharacterized activity axl1p particulate fractions enriched axl1p ste23p incapable cleaving insulin suggesting functional conservation enzymes may bidirectionally conserved made practical use genetic system confirm residues composing extended zinc metalloprotease motif m16a family enzymes required enzymatic activity ide ste23p axl1p determined ide axl1p require intact c terminus optimal activity expect tractable genetic system developed useful investigating enzymatic structurefunction properties ide possibly identification novel ide alleles altered substrate specificity
0.5010976.15944156.html.plaintext.txt	4	abstract top abstract introduction experimental procedures results discussion references developed yeast expression genetic system functional studies insulin degrading enzyme ide cleaves inactivates certain small peptide molecules including insulin neurotoxic peptide show heterologously expressed rat ide enzymatically active judged ability ide containing yeast extracts cleave insulin vitro also show ide promote vivo production yeast factor mating pheromone function normally attributed yeast enzymes axl1p ste23p however ide cannot substitute function axl1p promoting haploid axial budding repressing haploid invasive growth activities require uncharacterized activity axl1p particulate fractions enriched axl1p ste23p incapable cleaving insulin suggesting functional conservation enzymes may bidirectionally conserved made practical use genetic system confirm residues composing extended zinc metalloprotease motif m16a family enzymes required enzymatic activity ide ste23p axl1p determined ide axl1p require intact c terminus optimal activity expect tractable genetic system developed useful investigating enzymatic structurefunction properties ide possibly identification novel ide alleles altered substrate specificity
0.5010976.15944156.html.plaintext.txt	5	introduction top abstract introduction experimental procedures results discussion references insulin degrading enzyme ide1 ec 342456 ec broad substrate specificity able cleave inactivate number small molecules including peptides insulin 1 3 animal models ide deficiency correlates increased levels insulin increased risks type 2 diabetes alzheimer disease 4 6 despite findings biological role ide importance clearance insulin remains fully clarified 7
0.5010976.15944156.html.plaintext.txt	6	ste23p axl1p proteins saccharomyces cerevisiae significant sequence homology ide 36 19 identity respectively 8 genetic mutational studies indicate ste23p axl1p required proteolytic maturation yeast factor mating pheromone lipid modified peptide produced multistep process 9 10 pheromone produced mata haploid cells required yeast mating fusion mata mat haploid cells form diploid cell although ste23p axl1p independently promote factor maturation enzymes fully redundant ste23p significantly less efficient axl1p producing biologically active pheromone 9
0.5010976.15944156.html.plaintext.txt	7	ste23p axl1p proteins saccharomyces cerevisiae significant sequence homology ide 36 19 identity respectively 8 genetic mutational studies indicate ste23p axl1p required proteolytic maturation yeast factor mating pheromone lipid modified peptide produced multistep process 9 10 pheromone produced mata haploid cells required yeast mating fusion mata mat haploid cells form diploid cell although ste23p axl1p independently promote factor maturation enzymes fully redundant ste23p significantly less efficient axl1p producing biologically active pheromone 9
0.5010976.15944156.html.plaintext.txt	8	axl1p several cellular roles addition role pheromone production axl1p required efficient post conjugation fusion haploid mating partners 11 role may indirectly related ability axl1p produce factor limiting levels pheromone similarly lead fusion defects 12 axl1p also required maintenance axial budding pattern characteristic haploid yeast 8 9 absence axl1p haploid yeasts exhibit bipolar budding pattern typical diploid cells function axl1p process require proteolytic activity suggesting axl1p bi functional enzyme 9 axl1p also represses invasive growth haploid yeast 13 14 whether proteolytic bud site selection another activity axl1p required process reported contrast axl1p reported cellular role ste23p factor production additional functions enzyme likely ste23p expressed mat diploid cell types produce factor2
0.5010976.15944156.html.plaintext.txt	9	axl1p several cellular roles addition role pheromone production axl1p required efficient post conjugation fusion haploid mating partners 11 role may indirectly related ability axl1p produce factor limiting levels pheromone similarly lead fusion defects 12 axl1p also required maintenance axial budding pattern characteristic haploid yeast 8 9 absence axl1p haploid yeasts exhibit bipolar budding pattern typical diploid cells function axl1p process require proteolytic activity suggesting axl1p bi functional enzyme 9 axl1p also represses invasive growth haploid yeast 13 14 whether proteolytic bud site selection another activity axl1p required process reported contrast axl1p reported cellular role ste23p factor production additional functions enzyme likely ste23p expressed mat diploid cell types produce factor2
0.5010976.15944156.html.plaintext.txt	10	ide ste23p axl1p members m16a protease subfamily m16a proteases characterized core inverted zinc metalloprotease motif typically located within first 200 residues enzymes pair glutamic acid residues 70 77 amino acids distal core motif ie hxxehx69ex6e spacing core motif distal glutamates invariant 46 m16a enzymes identified far except case axl1p spacing 76 residues histidine residues distal glutamate residue putative zinc ligands mutational alteration residues inactivates ide axl1p 9 15 16 members m16a subfamily including ide sensitive thiol modifiers suggesting cysteine residues critical proper structure active site overall tertiary quaternary structure proteins 1 15 sequence alignment ide yeast orthologs reveals two conserved cysteine residues one within core metalloprotease motif residue reportedly altered without affecting enzymatic activity 15 conserved cysteine exactly 67 amino acids distal extended motif hxxehx69ex6ex67c distal cysteine conserved escherichia coli protease iii bacterial m16a enzyme insensitive thiol modifiers 17
0.5010976.15944156.html.plaintext.txt	11	ide ste23p axl1p members m16a protease subfamily m16a proteases characterized core inverted zinc metalloprotease motif typically located within first 200 residues enzymes pair glutamic acid residues 70 77 amino acids distal core motif ie hxxehx69ex6e spacing core motif distal glutamates invariant 46 m16a enzymes identified far except case axl1p spacing 76 residues histidine residues distal glutamate residue putative zinc ligands mutational alteration residues inactivates ide axl1p 9 15 16 members m16a subfamily including ide sensitive thiol modifiers suggesting cysteine residues critical proper structure active site overall tertiary quaternary structure proteins 1 15 sequence alignment ide yeast orthologs reveals two conserved cysteine residues one within core metalloprotease motif residue reportedly altered without affecting enzymatic activity 15 conserved cysteine exactly 67 amino acids distal extended motif hxxehx69ex6ex67c distal cysteine conserved escherichia coli protease iii bacterial m16a enzyme insensitive thiol modifiers 17
0.5010976.15944156.html.plaintext.txt	12	sequence similarity ide ste23p axl1p prompted us investigate hypothesis proteins conserved enzymatic properties substrate specificity end present evidence indicating rat ide substitute axl1p ste23p factor production known functions axl1p importantly findings establish yeast genetically tractable system future studies ide function made practical use system create characterize novel mutations alter enzymatic properties ide
0.5010976.15944156.html.plaintext.txt	13	sequence similarity ide ste23p axl1p prompted us investigate hypothesis proteins conserved enzymatic properties substrate specificity end present evidence indicating rat ide substitute axl1p ste23p factor production known functions axl1p importantly findings establish yeast genetically tractable system future studies ide function made practical use system create characterize novel mutations alter enzymatic properties ide
0.5010976.15944156.html.plaintext.txt	14	experimental procedures top abstract introduction experimental procedures results discussion references strains media yeast strains used study listed table plasmid bearing versions strains generated transformation indicated plasmids according published methods 18 strains routinely grown 30 degrees c synthetic complete dropout sc media described previously 19
0.5010976.15944156.html.plaintext.txt	15	experimental procedures top abstract introduction experimental procedures results discussion references strains media yeast strains used study listed table plasmid bearing versions strains generated transformation indicated plasmids according published methods 18 strains routinely grown 30 degrees c synthetic complete dropout sc media described previously 19
0.5010976.15944156.html.plaintext.txt	16	view table table strains used study
0.5010976.15944156.html.plaintext.txt	17	plasmids plasmids used study indicated table ii plasmids p80 cen ura3 axl1 p137 cen ura3 ste23 described previously kindly provided dr c boone university toronto 9 plasmids used study created pcr directed recombination mediated plasmid construction andor standard molecular methods 20
0.5010976.15944156.html.plaintext.txt	18	plasmids plasmids used study indicated table ii plasmids p80 cen ura3 axl1 p137 cen ura3 ste23 described previously kindly provided dr c boone university toronto 9 plasmids used study created pcr directed recombination mediated plasmid construction andor standard molecular methods 20
0.5010976.15944156.html.plaintext.txt	19	view table table ii plasmids used study
0.5010976.15944156.html.plaintext.txt	20	general strategy epitope tagging axl1 ste23 ide encoding plasmids involved creation novel restriction site end respective open reading frame subcloning triply iterated ha tag pws371 cen ura3 axl1 2ha created modifying p80 follows ncoi site inserted immediately prior stop codon axl1 dna fragment encoding triply iterated ha tag inserted actuality two tandem copies tag inserted plasmid modified delete portion 5 untranslated region corresponding xhoi fragment order reduce overall size plasmid 121 106 kb deletion effect protein expression pws482 cen ura3 ste23 2ha created modifying p137 similar manner described p80 instance bamhi site introduced immediately prior stop codon ste23 triply iterated ha tag inserted pws371 two tandem copies tag actually inserted pws511 2 micro ura3 ppgk ide ha created pcr amplification ide psr rat ide pcr product ends homologous parent yeast vector psm703 bglii restriction site immediately stop codon ide 21 bglii site used insertion triply iterated ha epitope tag pws496 identical pws511 except contains two copies triply iterated ha tag restriction digest analysis dna sequencing used confirm presence tag plasmids described
0.5010976.15944156.html.plaintext.txt	21	general strategy epitope tagging axl1 ste23 ide encoding plasmids involved creation novel restriction site end respective open reading frame subcloning triply iterated ha tag pws371 cen ura3 axl1 2ha created modifying p80 follows ncoi site inserted immediately prior stop codon axl1 dna fragment encoding triply iterated ha tag inserted actuality two tandem copies tag inserted plasmid modified delete portion 5 untranslated region corresponding xhoi fragment order reduce overall size plasmid 121 106 kb deletion effect protein expression pws482 cen ura3 ste23 2ha created modifying p137 similar manner described p80 instance bamhi site introduced immediately prior stop codon ste23 triply iterated ha tag inserted pws371 two tandem copies tag actually inserted pws511 2 micro ura3 ppgk ide ha created pcr amplification ide psr rat ide pcr product ends homologous parent yeast vector psm703 bglii restriction site immediately stop codon ide 21 bglii site used insertion triply iterated ha epitope tag pws496 identical pws511 except contains two copies triply iterated ha tag restriction digest analysis dna sequencing used confirm presence tag plasmids described
0.5010976.15944156.html.plaintext.txt	22	general strategy creation site directed mutations plasmids also involved pcr directed recombination mediated plasmid construction brief dna fragment encoding appropriate segment target open reading frame amplified pcr one oligonucleotides contained mutation interest typically silent restriction site dna fragments co transformed target plasmid linearized gapped restriction enzymes near intended site mutation recombinant plasmids recovered yeast amplified e coli screened restriction analysis andor sequencing verify presence mutation mutant alleles confirmed immunoblot encode full length protein
0.5010976.15944156.html.plaintext.txt	23	general strategy creation site directed mutations plasmids also involved pcr directed recombination mediated plasmid construction brief dna fragment encoding appropriate segment target open reading frame amplified pcr one oligonucleotides contained mutation interest typically silent restriction site dna fragments co transformed target plasmid linearized gapped restriction enzymes near intended site mutation recombinant plasmids recovered yeast amplified e coli screened restriction analysis andor sequencing verify presence mutation mutant alleles confirmed immunoblot encode full length protein
0.5010976.15944156.html.plaintext.txt	24	epitope tagging ste23p straightforward dna sequencing intermediate plasmid construction pws482 revealed extra nucleotide near 3 end open reading frame present public sequence ste23 presence extra nucleotide confirmed ste23 sequence derived three different sources p137 pcr products derived chromosomal amplification ste23 gene two distinct strain backgrounds ih1783 yph499 independent group 22 proposed recently identical sequence annotation part effort identify mistakes published genome sequences extra nucleotide alters extends translation ste23 open reading frame amino acids 971 988 code 18 distinct amino acids additional 39 amino acids gained extension original proposed translation
0.5010976.15944156.html.plaintext.txt	25	epitope tagging ste23p straightforward dna sequencing intermediate plasmid construction pws482 revealed extra nucleotide near 3 end open reading frame present public sequence ste23 presence extra nucleotide confirmed ste23 sequence derived three different sources p137 pcr products derived chromosomal amplification ste23 gene two distinct strain backgrounds ih1783 yph499 independent group 22 proposed recently identical sequence annotation part effort identify mistakes published genome sequences extra nucleotide alters extends translation ste23 open reading frame amino acids 971 988 code 18 distinct amino acids additional 39 amino acids gained extension original proposed translation
0.5010976.15944156.html.plaintext.txt	26	protein extract preparations whole cell protein extracts western analysis prepared naohtrichloroacetic acid method 23 brief mid log cells amount equivalent 2 ml 10 a600 culture harvested centrifugation washed cold water resuspended 1 ml cold water treated solution 2 n naoh 1 m mercaptoethanol proteins released precipitated trichloroacetic acid 115 final recovered centrifugation resuspended urea sample buffer usb 250 mm tris ph 80 6 m urea 4 sds 001 bromphenol blue heated cleared insoluble material analysis sds page immunoblotting ha tagged proteins detected chemiluminescence ecl kit roche applied science immunodecorating proteins mouse anti ha horseradish peroxidase conjugated rabbit anti mouse antibodies
0.5010976.15944156.html.plaintext.txt	27	protein extract preparations whole cell protein extracts western analysis prepared naohtrichloroacetic acid method 23 brief mid log cells amount equivalent 2 ml 10 a600 culture harvested centrifugation washed cold water resuspended 1 ml cold water treated solution 2 n naoh 1 m mercaptoethanol proteins released precipitated trichloroacetic acid 115 final recovered centrifugation resuspended urea sample buffer usb 250 mm tris ph 80 6 m urea 4 sds 001 bromphenol blue heated cleared insoluble material analysis sds page immunoblotting ha tagged proteins detected chemiluminescence ecl kit roche applied science immunodecorating proteins mouse anti ha horseradish peroxidase conjugated rabbit anti mouse antibodies
0.5010976.15944156.html.plaintext.txt	28	particulate fractions used vitro assays prepared mechanical breakage yeast cells expressing either ide ste23p axl1p 24 25 brief mid log cells harvested washed cold 10 mm nan3 treated trisdithiothreitol 100 mm tris ph 94 10 mm dithiothreitol 10 min ice cells resuspended oxalyticase buffer 50 mm kpi ph 75 14 m sorbitol 10 mm nan3 containing oxalyticase 1 microga600 enzogenetics corvallis incubated 30 min 30 degrees c gentle mixing spheroplasts harvested centrifugation resuspended cold lysis buffer 50 mm tris ph 75 02 m sorbitol 1 mm edta containing protease inhibitors 1 microgml leupeptin chymostatin pepstatin aprotinin 1 mm phenylmethylsulfonyl fluoride lysed using glass dounce homogenizer primary lysate cleared twice cell debris centrifugation 500 x g 10 min fractionated supernatant particulate fractions centrifugation 16000 x g 10 min fractions adjusted 1 mgml lysis buffer stored 80 degrees c aliquots
0.5010976.15944156.html.plaintext.txt	29	particulate fractions used vitro assays prepared mechanical breakage yeast cells expressing either ide ste23p axl1p 24 25 brief mid log cells harvested washed cold 10 mm nan3 treated trisdithiothreitol 100 mm tris ph 94 10 mm dithiothreitol 10 min ice cells resuspended oxalyticase buffer 50 mm kpi ph 75 14 m sorbitol 10 mm nan3 containing oxalyticase 1 microga600 enzogenetics corvallis incubated 30 min 30 degrees c gentle mixing spheroplasts harvested centrifugation resuspended cold lysis buffer 50 mm tris ph 75 02 m sorbitol 1 mm edta containing protease inhibitors 1 microgml leupeptin chymostatin pepstatin aprotinin 1 mm phenylmethylsulfonyl fluoride lysed using glass dounce homogenizer primary lysate cleared twice cell debris centrifugation 500 x g 10 min fractionated supernatant particulate fractions centrifugation 16000 x g 10 min fractions adjusted 1 mgml lysis buffer stored 80 degrees c aliquots
0.5010976.15944156.html.plaintext.txt	30	assess effect chaotropic agents association ide ste23p axl1p yeast particulate fraction freshly prepared samples particulate fraction exposed either 1 m nacl 01 m na2co3 ph 115 1 sds buffer alone 10 min ice samples subjected centrifugation 16000 x g 10 min equivalent portions supernatant particulate fraction analyzed sds page immunoblot described
0.5010976.15944156.html.plaintext.txt	31	insulin degradation assay insulin degradation assays carried essentially described previously using yeast derived lysates source enzyme activity 4 brief reactions assembled contain 05 mgml yeast lysate 60 pm 10000 cpm 125i insulin linco research st charles mo 50 microl reaction buffer 50 mm tris 02 m sorbitol ph 75 1 mm edta samples incubated 37 degrees c times indicated appropriate figure legend final sample preparation involved addition bovine serum albumin 1 final trichloroacetic acid precipitation 10 final 10 min ice centrifugation 16000 x g 10 min 4 degrees c supernatant containing insulin fragments transferred new tube radioactivity associated supernatant particulate fractions determined using wallac counter perkinelmer life sciences
0.5010976.15944156.html.plaintext.txt	32	insulin degradation assay insulin degradation assays carried essentially described previously using yeast derived lysates source enzyme activity 4 brief reactions assembled contain 05 mgml yeast lysate 60 pm 10000 cpm 125i insulin linco research st charles mo 50 microl reaction buffer 50 mm tris 02 m sorbitol ph 75 1 mm edta samples incubated 37 degrees c times indicated appropriate figure legend final sample preparation involved addition bovine serum albumin 1 final trichloroacetic acid precipitation 10 final 10 min ice centrifugation 16000 x g 10 min 4 degrees c supernatant containing insulin fragments transferred new tube radioactivity associated supernatant particulate fractions determined using wallac counter perkinelmer life sciences
0.5010976.15944156.html.plaintext.txt	33	yeast mating assay evaluate ability plasmid transformed mata axl1 ste23 strains promote factor production patch mating tests performed using ih1793 mat lys1 established methods 26 test provides indirect assessment m16a enzyme function factor production mata cells entirely dependent plasmid encoded copy m16a enzyme brief master plates prepared patching mata yeast strains expressing axl1p ste23p ide onto yepd agar plates 2 3 days growth patches replica printed onto lawns mat cells ih1793 spread minimal media agar plates replica printed plates incubated 2 days 30 degrees c mat cell suspensions prepared approximately cell density solutions 1 10 100 yepd prepared mixtures yepd appropriate amount sterile h2o trace amount yepd added minimal media allows limited survival auxotrophic haploid cells necessary mating process decreasing yepd amount shortens survival window haploid cells thus results decreased mating efficiency diploid cells result mating events prototrophic thus growth diploids test indicative mating functional m16a enzyme
0.5010976.15944156.html.plaintext.txt	34	yeast mating assay evaluate ability plasmid transformed mata axl1 ste23 strains promote factor production patch mating tests performed using ih1793 mat lys1 established methods 26 test provides indirect assessment m16a enzyme function factor production mata cells entirely dependent plasmid encoded copy m16a enzyme brief master plates prepared patching mata yeast strains expressing axl1p ste23p ide onto yepd agar plates 2 3 days growth patches replica printed onto lawns mat cells ih1793 spread minimal media agar plates replica printed plates incubated 2 days 30 degrees c mat cell suspensions prepared approximately cell density solutions 1 10 100 yepd prepared mixtures yepd appropriate amount sterile h2o trace amount yepd added minimal media allows limited survival auxotrophic haploid cells necessary mating process decreasing yepd amount shortens survival window haploid cells thus results decreased mating efficiency diploid cells result mating events prototrophic thus growth diploids test indicative mating functional m16a enzyme
0.5010976.15944156.html.plaintext.txt	35	mass spectroscopy factor mating pheromone produced yeast expressing ide ste23p axl1p purified according published methods analyzed mass spectroscopy 26 brief yeast cultured polypropylene culture tubes factor secreted yeast cultures recovered washing polypropylene culture tubes methanol secreted factor adsorbs polypropylene removed organic solvents enriched factor samples concentrated speed vac desalted using zip tip c18 beads millipore washed three times 01 trifluoroacetic acid eluted 70 acetonitrile subjected maldi toftof mass spectroscopy using cyano 4 hydroxycinnamic acid matrix 4700 proteomics analyzer spectrometer applied biosystems foster city ca factor halo assay total secreted factor produced saturated cultures indicated strains recovered described enriched samples dried speed vac resuspended 50 microl meoh 2 fold serial dilutions samples prepared yepd spotted onto lawn rc757 mat sst2 1 his6 met1 can1 cyh2 rc631 mata sst2 1 his6 met1 can1 cyh2 rme ade2 1 ura1 cells latter served control unlikely possibility toxic product produced ide expressing strain 27 formation spot lawn indicative presence pheromone sample relative potency pheromone determined serial dilutions sample highest dilution biological activity referred end point equivalent concentration 12 pg microl factor 28
0.5010976.15944156.html.plaintext.txt	36	mass spectroscopy factor mating pheromone produced yeast expressing ide ste23p axl1p purified according published methods analyzed mass spectroscopy 26 brief yeast cultured polypropylene culture tubes factor secreted yeast cultures recovered washing polypropylene culture tubes methanol secreted factor adsorbs polypropylene removed organic solvents enriched factor samples concentrated speed vac desalted using zip tip c18 beads millipore washed three times 01 trifluoroacetic acid eluted 70 acetonitrile subjected maldi toftof mass spectroscopy using cyano 4 hydroxycinnamic acid matrix 4700 proteomics analyzer spectrometer applied biosystems foster city ca factor halo assay total secreted factor produced saturated cultures indicated strains recovered described enriched samples dried speed vac resuspended 50 microl meoh 2 fold serial dilutions samples prepared yepd spotted onto lawn rc757 mat sst2 1 his6 met1 can1 cyh2 rc631 mata sst2 1 his6 met1 can1 cyh2 rme ade2 1 ura1 cells latter served control unlikely possibility toxic product produced ide expressing strain 27 formation spot lawn indicative presence pheromone sample relative potency pheromone determined serial dilutions sample highest dilution biological activity referred end point equivalent concentration 12 pg microl factor 28
0.5010976.15944156.html.plaintext.txt	37	invasive growth assay ability haploid yeast cells invade yeast agar determined using plate washing assay 14 brief cell suspensions spotted onto sc ura plates cells grown 4 days 30 degrees c plates washed running h2o gently rubbing surface agar plate gloved finger agar plates scanned prior immediately washing
0.5010976.15944156.html.plaintext.txt	38	invasive growth assay ability haploid yeast cells invade yeast agar determined using plate washing assay 14 brief cell suspensions spotted onto sc ura plates cells grown 4 days 30 degrees c plates washed running h2o gently rubbing surface agar plate gloved finger agar plates scanned prior immediately washing
0.5010976.15944156.html.plaintext.txt	39	view larger version 63k fig 1 yeast expressed ide expected size associated particulate fraction protein extracts prepared yeast containing empty vector vectors encoding ha tagged axl1p ste23p ide equivalent amounts sample lanes 1 3 9 2 fold serial dilutions ste23p lanes 4 8 ide lanes 10 14 samples analyzed sds page immunoblot using anti ha antibody b total yeast lysate containing ha tagged ide subjected differential centrifugation 16000 x g corresponding particulate p supernatant fractions recovered equivalent amounts protein 10 microg analyzed sds page immunoblotting ha monoclonal antibody c samples yeast particulate fractions containing epitope tagged axl1p ste23p ide treated either lysis buffer 1 m nacl 01 m na2co3 ph 115 1 sds separated supernatant particulate p fractions centrifugation equivalent percentage sample evaluated sds page immunoblot using anti ha antibody strains used y272 transformed prs316 vector pws482 ste23 2ha pws496 ide 2ha either pws371 cen axl1 2ha pws372 2 micro axl1 2ha b c
0.5010976.15944156.html.plaintext.txt	40	budding assay mid log cells grown selective liquid media harvested concentrate cell suspension 2 times cells treated 10 microgml calcofluor sigma 5 min cells washed twice h2o absorbed onto polylysine coated glass slides viewed x100 zeiss axioplan microscope equipped fluorescence optics fluorescent images captured using digital camera optronics dei 750 bud scars 100 cells evaluated categorized three patterns axial bipolar random axial pattern defined bud scars located solely one pole cell bipolar pattern scars poles random pattern displayed least one bud scar region poles 8 9
0.5010976.15944156.html.plaintext.txt	41	budding assay mid log cells grown selective liquid media harvested concentrate cell suspension 2 times cells treated 10 microgml calcofluor sigma 5 min cells washed twice h2o absorbed onto polylysine coated glass slides viewed x100 zeiss axioplan microscope equipped fluorescence optics fluorescent images captured using digital camera optronics dei 750 bud scars 100 cells evaluated categorized three patterns axial bipolar random axial pattern defined bud scars located solely one pole cell bipolar pattern scars poles random pattern displayed least one bud scar region poles 8 9
0.5010976.15944156.html.plaintext.txt	42	results top abstract introduction experimental procedures results discussion references ide heterologously expressed yeast many yeast enzymes required factor production functionally replaced orthologs eukaryotic species 29 34 thus hypothesized ide could rescue mating defect strain lacking axl1p ste23p prior evaluating ability ide substitute functions yeast m16a enzymes first determined whether yeast could used heterologous expression ide created plasmids encoding epitope tagged versions genes encoding ide yeast orthologs proteases dna fragment encoding ha epitope tag placed 3 end gene addition tag alter activities enzymes see fig 3b
0.5010976.15944156.html.plaintext.txt	43	results top abstract introduction experimental procedures results discussion references ide heterologously expressed yeast many yeast enzymes required factor production functionally replaced orthologs eukaryotic species 29 34 thus hypothesized ide could rescue mating defect strain lacking axl1p ste23p prior evaluating ability ide substitute functions yeast m16a enzymes first determined whether yeast could used heterologous expression ide created plasmids encoding epitope tagged versions genes encoding ide yeast orthologs proteases dna fragment encoding ha epitope tag placed 3 end gene addition tag alter activities enzymes see fig 3b
0.5010976.15944156.html.plaintext.txt	44	evaluation protein extracts strains expressing tagged proteases revealed tagged protein could detected protein expected size immunoblot fig 1a also observed ide ste23p expressed 10 times higher levels axl1p determined comparison immunoblot signals constitutive phosphoglycerate kinase pgk promoter used drive ide expression abundant expression ide unexpected native promoters used drive ste23p axl1p expression relative abundance ste23p axl1p somewhat unexpected especially ste23p promote factor production efficiently axl1p thus reason decreased ability ste23p promote mating cannot simply attributed reduced protein expression comparison axl1p
0.5010976.15944156.html.plaintext.txt	45	ide associated particulate yeast fraction subcellular distribution ide mammalian systems reported primarily cytosolic extracellular peroxisomal localizations also described 35 36 ascertain effect heterologous expression subcellular distribution ide subjected total yeast lysate differential fractionation comparison equal amounts loaded protein immunoblot observed ide yeast m16a enzymes highly enriched particulate fraction associated 16000 x g centrifugation lysate p16 although significant amount ste23p found supernatant fraction fig 1b particular experiment axl1p encoded multicopy plasmid facilitate detection hence stronger signal relative observed total extracts see fig 1a
0.5010976.15944156.html.plaintext.txt	46	ide associated particulate yeast fraction subcellular distribution ide mammalian systems reported primarily cytosolic extracellular peroxisomal localizations also described 35 36 ascertain effect heterologous expression subcellular distribution ide subjected total yeast lysate differential fractionation comparison equal amounts loaded protein immunoblot observed ide yeast m16a enzymes highly enriched particulate fraction associated 16000 x g centrifugation lysate p16 although significant amount ste23p found supernatant fraction fig 1b particular experiment axl1p encoded multicopy plasmid facilitate detection hence stronger signal relative observed total extracts see fig 1a
0.5010976.15944156.html.plaintext.txt	47	although localization ste23p reported previously axl1p known transiently associate components form sub plasma membrane complex required establishing bud sites whether ide ste23p assemble complex unknown better understand nature association ide axl1p ste23p p16 yeast fraction performed extractions particulate fraction various chaotropic agents fig 1c analysis revealed high ph detergent treatments significantly disrupted association proteins p16 fraction whereas salt buffer alone minor impact profile consistent ide ste23p ax1p peripheral membrane proteins andor components large macromolecular complex sediments experimental conditions
0.5010976.15944156.html.plaintext.txt	48	although localization ste23p reported previously axl1p known transiently associate components form sub plasma membrane complex required establishing bud sites whether ide ste23p assemble complex unknown better understand nature association ide axl1p ste23p p16 yeast fraction performed extractions particulate fraction various chaotropic agents fig 1c analysis revealed high ph detergent treatments significantly disrupted association proteins p16 fraction whereas salt buffer alone minor impact profile consistent ide ste23p ax1p peripheral membrane proteins andor components large macromolecular complex sediments experimental conditions
0.5010976.15944156.html.plaintext.txt	49	yeast expressed ide retains proteolytic activity next determined whether yeast expressed ide could cleave insulin well characterized substrate ide using previously described insulin degradation assay yeast derived particulate fractions 4 25 high degree enrichment m16a enzymes yeast particulate fractions samples used exclusively source activity vitro assays analysis enzymatic activity indicated ide containing samples insulin cleaving activity whereas samples containing axl1p ste23p activity sample prepared yeast lacking enzymes fig 2a source residual activity preparations unknown likely due nonspecific enzymatic activity rather additional ide homolog 110 phenanthroline well documented ide inhibitor inhibit residual activity fig 2b whether axl1p ste23p proteases preparations incapable cleaving insulin altered substrate specificity sub optimal reaction conditions reasons yet determined
0.5010976.15944156.html.plaintext.txt	50	yeast expressed ide retains proteolytic activity next determined whether yeast expressed ide could cleave insulin well characterized substrate ide using previously described insulin degradation assay yeast derived particulate fractions 4 25 high degree enrichment m16a enzymes yeast particulate fractions samples used exclusively source activity vitro assays analysis enzymatic activity indicated ide containing samples insulin cleaving activity whereas samples containing axl1p ste23p activity sample prepared yeast lacking enzymes fig 2a source residual activity preparations unknown likely due nonspecific enzymatic activity rather additional ide homolog 110 phenanthroline well documented ide inhibitor inhibit residual activity fig 2b whether axl1p ste23p proteases preparations incapable cleaving insulin altered substrate specificity sub optimal reaction conditions reasons yet determined
0.5010976.15944156.html.plaintext.txt	51	ide described thiol zinc dependent metalloprotease 35 determined ide heterologously expressed functional form next wanted confirm observed insulin degrading activity detected hallmarks ide mediated insulin degradation examined effect alkylating ie iodoacetamide n ethylmaleimide metal ion chelating agents ie 110 phenanthroline edta ide activity fig 2b alkylating agents inhibited ide dependent insulin degrading activity inhibitory effect also observed 110 phenanthroline nonchelating agent 47 phenanthroline structurally similar edta measurably inhibit enzymatic activity extensive pretreatment edta reportedly required inhibition ide 15 inhibitor profile observed insulin degrading activity yeast identical reported ide establishes yeast synthesize ide possessing enzymatic properties described ide found metazoans 35
0.5010976.15944156.html.plaintext.txt	52	ide described thiol zinc dependent metalloprotease 35 determined ide heterologously expressed functional form next wanted confirm observed insulin degrading activity detected hallmarks ide mediated insulin degradation examined effect alkylating ie iodoacetamide n ethylmaleimide metal ion chelating agents ie 110 phenanthroline edta ide activity fig 2b alkylating agents inhibited ide dependent insulin degrading activity inhibitory effect also observed 110 phenanthroline nonchelating agent 47 phenanthroline structurally similar edta measurably inhibit enzymatic activity extensive pretreatment edta reportedly required inhibition ide 15 inhibitor profile observed insulin degrading activity yeast identical reported ide establishes yeast synthesize ide possessing enzymatic properties described ide found metazoans 35
0.5010976.15944156.html.plaintext.txt	53	view larger version 19k fig 2 ide functionally expressed yeast particulate fractions isolated yeast expressing ide axl1p ste23p equivalent amount fraction 5 microg assayed insulin degradation activity time course according established methods see experimental procedures degradation insulin indicated presence recovered insulin fragments cannot precipitated trichloroacetic acid b effect various agents activity yeast expressed ide evaluated activities determined 0 min 120 min time points abbreviations used follows nem 1 mm n ethylmaleimide iaa 1 mm iodoacetamide 110 1 mm 110 phenanthroline 47 1 mm 47 phenanthroline edta 10 mm edta
0.5010976.15944156.html.plaintext.txt	54	ide promote yeast mating many yeast enzymes required factor production functionally replaced orthologous enzymes species 29 34 similar fashion determined ide expression rescue mating defect yeast strain lacking axl1 ste23 mata axl1 ste23 fig 3a top row mating defect strain due inability produce yeast factor whether axl1p ste23p extension ide participate directly indirectly pheromone production rigorously established 9 nevertheless result establishes ide yeast enzymes axl1p ste23p similarly promote yeast factor production thus evolutionarily conserved activity simplest explanation findings enzymes directly participate pheromone production enzymes shared substrate specificity respect cleavage factor precursor
0.5010976.15944156.html.plaintext.txt	55	ide promote yeast mating many yeast enzymes required factor production functionally replaced orthologous enzymes species 29 34 similar fashion determined ide expression rescue mating defect yeast strain lacking axl1 ste23 mata axl1 ste23 fig 3a top row mating defect strain due inability produce yeast factor whether axl1p ste23p extension ide participate directly indirectly pheromone production rigorously established 9 nevertheless result establishes ide yeast enzymes axl1p ste23p similarly promote yeast factor production thus evolutionarily conserved activity simplest explanation findings enzymes directly participate pheromone production enzymes shared substrate specificity respect cleavage factor precursor
0.5010976.15944156.html.plaintext.txt	56	yeast mating sensitive number variables including available nutrients depleted nutrient conditions mating less efficient taken advantage property yeast mating evaluate effectiveness ide rescuing mating defect yeast lacking ste23p axl1p expected observed decreasing nutrient conditions correlated decreased mating strains ste23p ide expressing strains showed significant reductions mating relative axl1p expressing strain fig 3a epitope tagged versions enzymes similar activity profile assay fig 3b relatively poor ability ste23p promote mating respect axl1p consistent previous reports properties enzyme may attributable number factors including altered substrate specificity andor altered subcellular localization pattern prevents interaction substrates 9 likewise reduced mating observed ide may attributable similar factors reduced mating observed ide ste23p expressing cells simply due low expression enzymes expressed significantly higher levels axl1p see fig 1
0.5010976.15944156.html.plaintext.txt	57	yeast mating sensitive number variables including available nutrients depleted nutrient conditions mating less efficient taken advantage property yeast mating evaluate effectiveness ide rescuing mating defect yeast lacking ste23p axl1p expected observed decreasing nutrient conditions correlated decreased mating strains ste23p ide expressing strains showed significant reductions mating relative axl1p expressing strain fig 3a epitope tagged versions enzymes similar activity profile assay fig 3b relatively poor ability ste23p promote mating respect axl1p consistent previous reports properties enzyme may attributable number factors including altered substrate specificity andor altered subcellular localization pattern prevents interaction substrates 9 likewise reduced mating observed ide may attributable similar factors reduced mating observed ide ste23p expressing cells simply due low expression enzymes expressed significantly higher levels axl1p see fig 1
0.5010976.15944156.html.plaintext.txt	58	view larger version 70k fig 3 yeast expressed ide promotes yeast mating factor pheromone production mating competence mata ste23 axl1 cells transformed indicated m16a enzyme encoded plasmid evaluated using patch mating test selective growth diploid cells minimal media indicative mating patch mating tests conducted using mat lys1 lawns containing various amounts nutrients 100 10 1 yepd top bottom lowering amount yepd lawn increases stringency mating test allows discrimination differences mating efficiency otherwise observable permissive mating conditions 100 yepd b patch mating tests conducted using mata strains expressing ha epitope tagged m16a proteases mildly stringent mating conditions 10 yepd c factor produced strains described b recovered walls culture tubes using organic solvent concentrated samples analyzed spot halo test strain grown saturation volume media formation spot lawn mat rc757 cells indicative presence pheromone sample relative pheromone potency determined serial dilution sample highest dilution activity referred end point equivalent concentration 12 pg microl factor 28 d 2 fold serial dilutions ide sample prepared yepd spotted onto lawn rc631 mata sst2 1 his6 met1 can1 cyh2 rme ade2 1 ura1 serving control possibility toxic product produced ide expressing strain 27 strains used ih1783 transformed prs316 wild type wt y272 transformed prs316 vector p80 axl1 p137 ste23 pws491 ide pws371 axl1 2ha pws482 ste23 2ha pws496 ide 2ha
0.5010976.15944156.html.plaintext.txt	59	straightforward explanation reduced mating observed ste23p ide expressing strains strains reduced factor production comparison axl1p expressing strains thus compared relative amounts factor produced strains lifetime culture used bioassay relies natural growth arrest response mat cells factor pheromone detect quantifiably measure factor activity samples analysis revealed ide ste23p expressing strains produce significantly less factor axl1p expressing strain despite fact ide ste23p significantly overexpressed relative axl1p fig 3c ide derived sample also bioassayed using mata cells cells fail undergo growth arrest response factor pheromone thus served control unlikely scenario ide expressing strains producing toxic secreted product growth inhibition mata cells observed ide derived sample fig 3d
0.5010976.15944156.html.plaintext.txt	60	straightforward explanation reduced mating observed ste23p ide expressing strains strains reduced factor production comparison axl1p expressing strains thus compared relative amounts factor produced strains lifetime culture used bioassay relies natural growth arrest response mat cells factor pheromone detect quantifiably measure factor activity samples analysis revealed ide ste23p expressing strains produce significantly less factor axl1p expressing strain despite fact ide ste23p significantly overexpressed relative axl1p fig 3c ide derived sample also bioassayed using mata cells cells fail undergo growth arrest response factor pheromone thus served control unlikely scenario ide expressing strains producing toxic secreted product growth inhibition mata cells observed ide derived sample fig 3d
0.5010976.15944156.html.plaintext.txt	61	factor mating pheromone isoprenylated carboxymethylated dodecapeptide yiikgvfwdpacfarnesylmethyl alterations chemical form factor eg lipid removal primary sequence alterations impact function pheromone 37 example factor lacking tyrosine residue 25 biological activity full length pheromone judged yeast mating tests 37 thus reduced production factor pheromone ide ste23p expressing yeast could attributable cleavage factor precursor site asn tyr cleavage site recognized axl1p determine whether pheromone products produced ide ste23p axl1p identical determined mass factor species generated enzymes using maldi toftof mass spectroscopy several major species detected samples including 1629 da peak corresponds exactly mass bona fide factor fig 4 c ide ste23p axl1p samples respectively species negative control fig 4d 1629 da species still observed samples data de isotoped fig 4 e g remained absent negative control fig 4h based observations reasoned 1629 da species indeed factor implies ide ste23p axl1p similar cleavage specificities
0.5010976.15944156.html.plaintext.txt	62	factor mating pheromone isoprenylated carboxymethylated dodecapeptide yiikgvfwdpacfarnesylmethyl alterations chemical form factor eg lipid removal primary sequence alterations impact function pheromone 37 example factor lacking tyrosine residue 25 biological activity full length pheromone judged yeast mating tests 37 thus reduced production factor pheromone ide ste23p expressing yeast could attributable cleavage factor precursor site asn tyr cleavage site recognized axl1p determine whether pheromone products produced ide ste23p axl1p identical determined mass factor species generated enzymes using maldi toftof mass spectroscopy several major species detected samples including 1629 da peak corresponds exactly mass bona fide factor fig 4 c ide ste23p axl1p samples respectively species negative control fig 4d 1629 da species still observed samples data de isotoped fig 4 e g remained absent negative control fig 4h based observations reasoned 1629 da species indeed factor implies ide ste23p axl1p similar cleavage specificities
0.5010976.15944156.html.plaintext.txt	63	although species apparent de isotoped data ide ste23p derived samples indicated mass range additional species evident samples axl1p derived sample three additional species observed 1480 1526 1718 da fig 4g one distinct species observed negative control 1587 da additional species reproducibly detected experiments2 mass range shown panels inclusive masses theoretical mfa1 derived factor species either lacking n terminal tyrosine 1467 da extended n terminal asparagine 1744 da none four unidentified species matched alternative factor cleavage products nature species therefore unknown
0.5010976.15944156.html.plaintext.txt	64	although species apparent de isotoped data ide ste23p derived samples indicated mass range additional species evident samples axl1p derived sample three additional species observed 1480 1526 1718 da fig 4g one distinct species observed negative control 1587 da additional species reproducibly detected experiments2 mass range shown panels inclusive masses theoretical mfa1 derived factor species either lacking n terminal tyrosine 1467 da extended n terminal asparagine 1744 da none four unidentified species matched alternative factor cleavage products nature species therefore unknown
0.5010976.15944156.html.plaintext.txt	65	genetic evaluation ide mutants ability yeast expressed ide promote factor production suggests yeast mating used phenotype evaluate function ide mutant alleles test hypothesis created site directed deletion mutations ide tested ability mutants promote mating using genetic system confirmed residues comprising core metalloprotease motif hxxeh ide essential promoting mating fig 5a residues required activity ste23p axl1p well fig 5 b c respectively distal glutamate extended motif hxxehx69ex6e also determined essential activity three enzymes whereas penultimate glutamate dispensable axl1p activity penultimate glutamate required activity mitochondrial processing peptidase m16b protease proposed aid metal coordination enzyme 38
0.5010976.15944156.html.plaintext.txt	66	genetic evaluation ide mutants ability yeast expressed ide promote factor production suggests yeast mating used phenotype evaluate function ide mutant alleles test hypothesis created site directed deletion mutations ide tested ability mutants promote mating using genetic system confirmed residues comprising core metalloprotease motif hxxeh ide essential promoting mating fig 5a residues required activity ste23p axl1p well fig 5 b c respectively distal glutamate extended motif hxxehx69ex6e also determined essential activity three enzymes whereas penultimate glutamate dispensable axl1p activity penultimate glutamate required activity mitochondrial processing peptidase m16b protease proposed aid metal coordination enzyme 38
0.5010976.15944156.html.plaintext.txt	67	addition addressing importance established active site residues investigated functional importance cysteine residues function ide initially investigated role two cysteine residues invariably conserved ide ste23p axl1p hxcehx69ex6ex67c suspecting one residues likely target sulfhydryl modifying agents inactivate certain m16a enzymes independent mutations residues alter abilities ide ste23p axl1p promote mating fig 5 mutation proximal cysteine ide c110a reportedly alter thiol sensitivity profile ide 15 similarly found mutation distal cysteine ide c257a effect thiol sensitivity ide2 also determined combining mutations one molecule c110ac257a alter mating function fig 5a moreover sensitivity ide thiol modifiers unaffected2 similar results observed cysteine residues conserved ide ste23p axl1p c819a c414a respectively mutated fig 5a
0.5010976.15944156.html.plaintext.txt	68	addition addressing importance established active site residues investigated functional importance cysteine residues function ide initially investigated role two cysteine residues invariably conserved ide ste23p axl1p hxcehx69ex6ex67c suspecting one residues likely target sulfhydryl modifying agents inactivate certain m16a enzymes independent mutations residues alter abilities ide ste23p axl1p promote mating fig 5 mutation proximal cysteine ide c110a reportedly alter thiol sensitivity profile ide 15 similarly found mutation distal cysteine ide c257a effect thiol sensitivity ide2 also determined combining mutations one molecule c110ac257a alter mating function fig 5a moreover sensitivity ide thiol modifiers unaffected2 similar results observed cysteine residues conserved ide ste23p axl1p c819a c414a respectively mutated fig 5a
0.5010976.15944156.html.plaintext.txt	69	m16a enzymes large proteins typically molecular mass excess 100000 da metalloprotease motif m16a enzymes localized near n terminal end enzymes absence structural data enzymes sought determine whether catalytic domain ide self contained within n terminal portion enzyme c terminally truncated forms ide created evaluated ability promote pheromone production truncations created fusions gfp alter ability ide function fig 6a ide 1 1019 systematic deletions c terminus ide revealed relatively short truncations inactivated ide judged yeast mating tests deletion analysis axl1p revealed similar requirement intact c terminus although deletion required axl1p inactivation considerably larger fig 6a axl1p 1 1076 site directed mutation residue conserved ide axl1p functionalnonfunctional truncation boundary axl1p ie ser 965 ide ser 1081 axl1p reveal essential requirement residue either enzyme fig 5
0.5010976.15944156.html.plaintext.txt	70	m16a enzymes large proteins typically molecular mass excess 100000 da metalloprotease motif m16a enzymes localized near n terminal end enzymes absence structural data enzymes sought determine whether catalytic domain ide self contained within n terminal portion enzyme c terminally truncated forms ide created evaluated ability promote pheromone production truncations created fusions gfp alter ability ide function fig 6a ide 1 1019 systematic deletions c terminus ide revealed relatively short truncations inactivated ide judged yeast mating tests deletion analysis axl1p revealed similar requirement intact c terminus although deletion required axl1p inactivation considerably larger fig 6a axl1p 1 1076 site directed mutation residue conserved ide axl1p functionalnonfunctional truncation boundary axl1p ie ser 965 ide ser 1081 axl1p reveal essential requirement residue either enzyme fig 5
0.5010976.15944156.html.plaintext.txt	71	site directed truncation mutants created study evaluated protein expression using immunoblots site directed mutants judged expressed well relevant wild type control except ste23p e192a expressed level approximately one quarter wild type2 exception mutant results rule trivial possibility inactive ide axl1p ste23p mutants nonfunctional poor expression cannot exclude possibility mutants nonfunctional malfolding unknown reasons evaluation axl1p truncation mutants revealed expressed levels similar full length axl1p gfp fusion protein contrast ide truncation mutants similarly expressed fig 6b observed decreased expression certain truncations suggesting c terminus ide reasons unknown required normal steady state expression decreased expression alone cannot account loss activity ide one nonfunctional truncation ide 1 973 expressed comparably full length ide gfp fusion importantly expression levels observed nonfunctional truncations axl1p ide encoded multicopy plasmids significantly respective full length fusion encoded low copy plasmid judged immunoblot analysis suggesting lowered expression alone cannot account absence function mutants
0.5010976.15944156.html.plaintext.txt	72	site directed truncation mutants created study evaluated protein expression using immunoblots site directed mutants judged expressed well relevant wild type control except ste23p e192a expressed level approximately one quarter wild type2 exception mutant results rule trivial possibility inactive ide axl1p ste23p mutants nonfunctional poor expression cannot exclude possibility mutants nonfunctional malfolding unknown reasons evaluation axl1p truncation mutants revealed expressed levels similar full length axl1p gfp fusion protein contrast ide truncation mutants similarly expressed fig 6b observed decreased expression certain truncations suggesting c terminus ide reasons unknown required normal steady state expression decreased expression alone cannot account loss activity ide one nonfunctional truncation ide 1 973 expressed comparably full length ide gfp fusion importantly expression levels observed nonfunctional truncations axl1p ide encoded multicopy plasmids significantly respective full length fusion encoded low copy plasmid judged immunoblot analysis suggesting lowered expression alone cannot account absence function mutants
0.5010976.15944156.html.plaintext.txt	73	view larger version 25k fig 4 mass spectroscopic analysis factor produced ide ste23p axl1p expressing yeast strains factor species secreted indicated mata strains enriched conditioned media described fig 3c samples subjected maldi toftof mass spectroscopy using cyano 4 hydroxycinnamic acid matrix strains used y272 transformed pws496 ide 2ha pws482 ste23 2ha pws372 axl1 2ha prs316 vector d respectively de isotoping data shown d resulted data presented e h respectively strains also contained psm463 2 micro trp1 mfa1
0.5010976.15944156.html.plaintext.txt	74	yeast expressed ide cannot substitute known functions axl1p axl1p involved regulating several cellular processes besides pheromone production example axl1p required repressing haploid invasive growth 14 haploid invasion occurs readily upon deletion axl1 phenotype fully reversed introduction plasmid borne copy axl1 order address ability ide substitute function axl1p invasive phenotype axl1p deficient strain axl1 expressed ide examined also investigated ability protease active site mutant axl1p suppress invasive growth found ide expression could repress invasive growth whereas axl1p active site mutant suppressed invasive growth fig 7
0.5010976.15944156.html.plaintext.txt	75	yeast expressed ide cannot substitute known functions axl1p axl1p involved regulating several cellular processes besides pheromone production example axl1p required repressing haploid invasive growth 14 haploid invasion occurs readily upon deletion axl1 phenotype fully reversed introduction plasmid borne copy axl1 order address ability ide substitute function axl1p invasive phenotype axl1p deficient strain axl1 expressed ide examined also investigated ability protease active site mutant axl1p suppress invasive growth found ide expression could repress invasive growth whereas axl1p active site mutant suppressed invasive growth fig 7
0.5010976.15944156.html.plaintext.txt	76	axl1p also well described role maintenance axial budding pattern haploid yeast 9 ste23p reportedly role process determine whether ide could substitute function axl1p axial bud site selection expressed ide haploid strain defective axial budding evaluated budding pattern calcofluor staining bud scars consistent previous findings observed bipolar budding phenotype absence axl1p expression table iii vector axial budding phenotype observed upon introduction plasmid encoding axl1p axl1 strain axl1 whereas bipolar budding predominant pattern either ste23 ide introduced
0.5010976.15944156.html.plaintext.txt	77	axl1p also well described role maintenance axial budding pattern haploid yeast 9 ste23p reportedly role process determine whether ide could substitute function axl1p axial bud site selection expressed ide haploid strain defective axial budding evaluated budding pattern calcofluor staining bud scars consistent previous findings observed bipolar budding phenotype absence axl1p expression table iii vector axial budding phenotype observed upon introduction plasmid encoding axl1p axl1 strain axl1 whereas bipolar budding predominant pattern either ste23 ide introduced
0.5010976.15944156.html.plaintext.txt	78	view table table iii budding patterns observed axl1p ste23p ide expressing strains
0.5010976.15944156.html.plaintext.txt	79	view larger version 44k fig 5 evaluation ide ste23p axl1p mutants c alanine substitution point mutations created ide ste23p b axl1p c functions mutant enzymes evaluated patch mating tests described fig 3a permissive conditions 100 yepd mutations created sites invariably conserved ide ste23p axl1p include residues compose extended metalloprotease motif enzymes hxxehx69ex6e mutants exhibiting robust mating active unmodified parent enzyme judged mating tests stringent conditions strain used y272 transformed ide encoding plasmids pws511 ide ha pws531 ide ha h108a pws532 ide ha c110a pws533 ide ha e111a pws590 ide ha h112a pws591 ide ha e182a pws592 ide ha e189a pws572 ide ha c257a pws598 ide ha c414a pws599 ide ha c819a pws 573 ide has965a pws600 ide ha c110a c257a ste23p encoding plasmids pws482 ste23 2ha pws514 ste23 2ha h118a pws527 ste23 2ha120ca pws512 ste23 2ha e121a pws515 ste23 2ha h122a pws567 ste23 2ha e192a pws513 ste23 2ha e199a pws571 ste23 2hac267a axl1p encoding plasmids pws371 axl1 2ha pws388 axl1 2ha h68a pws534 axl1 2ha c70a pws389 axl1 2ha e71a pws390 axl1 2ha h72a pws391 axl1 2ha e149a pws392 axl1 2ha e156a pws569 axl1 2ha ca pws568 axl1 2ha s1081a
0.5010976.15944156.html.plaintext.txt	80	view larger version 85k fig 6 evaluation gfp labeled ide axl1p truncation mutants full length c terminally truncated versions ide axl1p created fusions gfp activities fusions evaluated patch mating tests permissive conditions 100 yepd truncations exhibiting robust mating active full length fusion judged mating tests stringent conditions except axl1 1 1081 reduced mating phenotype amino acids gfp fused indicated arrows shaded gray residues within c terminal regions ide axl1p conserved shown protein alignment mating tests arrowheads residue region targeted site directed mutational analysis see fig 5 indicated filled arrowhead b protein extracts prepared yeast containing vectors encoding gfp tagged ide equivalent amounts sample analyzed sds page immunoblot using anti gfp antibody strain used y272 transformed ide encoding plasmids pws539 ide 1 960 gfp pws548 ide 1 965 gfp pws549 ide 1 968 gfp pws550 ide 1 973 gfp pws538 ide 1 1019 gfp axl1p encoding plasmids pws551 axl1 1 1076 gfp pws541 axl1 1 1081 gfp pws552 axl1 1 1084 gfp pws553 axl1 1 1089 gfp pws380 axl1 1 1208 gfp
0.5010976.15944156.html.plaintext.txt	81	discussion top abstract introduction experimental procedures results discussion references majority studies ide relied vitro biochemical assays 1 recently knock overexpression mouse models described ide 4 6 vitro vivo model systems led better understanding biochemical physiological properties ide proposed roles type 2 diabetes alzheimer disease 4 39 41
0.5010976.15944156.html.plaintext.txt	82	discussion top abstract introduction experimental procedures results discussion references majority studies ide relied vitro biochemical assays 1 recently knock overexpression mouse models described ide 4 6 vitro vivo model systems led better understanding biochemical physiological properties ide proposed roles type 2 diabetes alzheimer disease 4 39 41
0.5010976.15944156.html.plaintext.txt	83	view larger version 48k fig 7 ide cannot repress haploid invasive growth plasmids encoding ha tagged axl1p axl1p h68a ide transformed axl1 haploid strain equal cell density suspensions strains spotted onto sc ura allowed grow 4 days plates washed running water remove surface lying cells b presence cells washing step indicative invasive growth strains used sy3687 transformed prs316 wild type wt sy3721 axl1his3 transformed prs316 vector pws371 axl1 2ha pws388 axl1 2ha h68a pws496 ide 2ha
0.5010976.15944156.html.plaintext.txt	84	study developed yeast tractable genetic model system studying functional properties ide determined yeast used express functional form ide importantly ide promote factor production activity normally associated yeast enzymes axl1p ste23p homology ide results imply members m16a metalloprotease family enzymes belong may shared substrate specificity fact three enzymes promote factor production supports hypothesis however inability demonstrate insulin cleavage yeast enzymes implies substrate specificity ste23p axl1p may restricted whether yeast enzymes cleave established ide substrates currently investigation also investigating ability m16a enzymes cleave factor studies enzymes may benefit development tractable genetic system
0.5010976.15944156.html.plaintext.txt	85	study developed yeast tractable genetic model system studying functional properties ide determined yeast used express functional form ide importantly ide promote factor production activity normally associated yeast enzymes axl1p ste23p homology ide results imply members m16a metalloprotease family enzymes belong may shared substrate specificity fact three enzymes promote factor production supports hypothesis however inability demonstrate insulin cleavage yeast enzymes implies substrate specificity ste23p axl1p may restricted whether yeast enzymes cleave established ide substrates currently investigation also investigating ability m16a enzymes cleave factor studies enzymes may benefit development tractable genetic system
0.5010976.15944156.html.plaintext.txt	86	additional finding study ide enriched exclusively partition yeast particulate fraction suspect heterologously expressed ide either incorporated membranes loosely associated peripheral membrane protein assembling macromolecular complex partially sediments conditions used isolation particulate fraction although ide reportedly associates peroxisomes localization unlikely experimental conditions impose induction required formation yeast peroxisomes 42 moreover putative c terminal peroxisomal targeting signal found ide although potentially functional yeast blocked epitope tag yeast expressed enzyme alternatively ide may associating undefined membrane sites axl1p reported associate transiently components form sub plasma membrane complex required budding 43 thus also conceivable ide assembling complex nonfunctional component ultimately defining subcellular localization ste23p may provide insight subcellular targeting ide two enzymes appear conserved sequence enzymatic properties ide axl1p
0.5010976.15944156.html.plaintext.txt	87	additional finding study ide enriched exclusively partition yeast particulate fraction suspect heterologously expressed ide either incorporated membranes loosely associated peripheral membrane protein assembling macromolecular complex partially sediments conditions used isolation particulate fraction although ide reportedly associates peroxisomes localization unlikely experimental conditions impose induction required formation yeast peroxisomes 42 moreover putative c terminal peroxisomal targeting signal found ide although potentially functional yeast blocked epitope tag yeast expressed enzyme alternatively ide may associating undefined membrane sites axl1p reported associate transiently components form sub plasma membrane complex required budding 43 thus also conceivable ide assembling complex nonfunctional component ultimately defining subcellular localization ste23p may provide insight subcellular targeting ide two enzymes appear conserved sequence enzymatic properties ide axl1p
0.5010976.15944156.html.plaintext.txt	88	view larger version 31k fig 8 schematic m16a enzyme sequences sequences ide ste23p e coli protease iii axl1p represented schematic format top bottom respectively schematic drawn scale representation divided several domains borders domains vi operationally defined sites insertions 10 residues found axl1p sequence determined multiple sequence alignment clustalw four proteins domains ends molecules dark gray represent sequences variable length conserved enzymes n terminal sequences range 19 69 residues c terminal sequences range 35 127 residues relative position shortest c terminal truncation yielding nonfunctional mutant shown filled arrowhead values schematic represent percent identity indicated ide domain corresponding domains either ste23p e coli protease iii axl1p determined using dna strider 13 default settings b d several conserved motifs identified within domains b ii c v d purposes figure conserved motif defined block amino acids 10 50 identical highly conserved residues ie st kr aiv second motif listed domain found within x69 sequence extended metalloprotease motif whereas third found within x57 sequence residues boldface mutated study neither cys 257 found near end domain cys 414 found beginning domain iv within conserved motifs
0.5010976.15944156.html.plaintext.txt	89	genetic model system developed far reaching utility characterization mutant ide alleles provided practical example utility detailing functional importance residues compose extended metalloprotease motif hxxehx69ex6e addition mutational study allows us make certain conclusions cysteine residues imparts sensitivity ide thiol modifiers provided single cysteine residue target thiol modification ide study excludes targets two cysteine residues invariably conserved three enzymes cys 110 cys 257 ide two cysteines semi conserved ide yeast m16a enzymes cys 414 cys 819 ide double c110ac257a mutant also remains sensitive thiol modifiers currently developing vitro assay monitoring activities ste23p axl1p expect determination whether enzymes sensitive thiol modifiers aid final identification cysteine residues targeted thiol modifiers enzyme family second practical example utility genetic system demonstrate first time c terminal region required activity ide absence structural information ide suspect c terminal region may required stabilizing overall tertiary possibly quaternary structure ide active site
0.5010976.15944156.html.plaintext.txt	90	genetic model system developed far reaching utility characterization mutant ide alleles provided practical example utility detailing functional importance residues compose extended metalloprotease motif hxxehx69ex6e addition mutational study allows us make certain conclusions cysteine residues imparts sensitivity ide thiol modifiers provided single cysteine residue target thiol modification ide study excludes targets two cysteine residues invariably conserved three enzymes cys 110 cys 257 ide two cysteines semi conserved ide yeast m16a enzymes cys 414 cys 819 ide double c110ac257a mutant also remains sensitive thiol modifiers currently developing vitro assay monitoring activities ste23p axl1p expect determination whether enzymes sensitive thiol modifiers aid final identification cysteine residues targeted thiol modifiers enzyme family second practical example utility genetic system demonstrate first time c terminal region required activity ide absence structural information ide suspect c terminal region may required stabilizing overall tertiary possibly quaternary structure ide active site
0.5010976.15944156.html.plaintext.txt	91	genetic system also useful investigating role residues function ide example several conserved sequence motifs identified multiple sequence alignment m16a enzymes fig 8 future studies aimed determining whether motifs important function m16a enzymes addition investigate whether e coli protease iii support factor production yeast system could conceivably used investigate structurefunction relationships enigmatic protease also lacks defined cellular role 44
0.5010976.15944156.html.plaintext.txt	92	genetic system also useful investigating role residues function ide example several conserved sequence motifs identified multiple sequence alignment m16a enzymes fig 8 future studies aimed determining whether motifs important function m16a enzymes addition investigate whether e coli protease iii support factor production yeast system could conceivably used investigate structurefunction relationships enigmatic protease also lacks defined cellular role 44
0.5010976.15944156.html.plaintext.txt	93	another potential utility genetic model system theoretical ability rapidly identify ide mutants altered substrate specificity already demonstrated system amenable screening specific mutant ide alleles ability promote mating approach could used identify ide mutants altered specificity toward factor envision positive genetic selection takes advantage observations ide dependent mating essentially nonexistent reduced nutrient levels fig 3a highly stringent mating conditions yeast harboring ide mutants could screened expectation enhanced factor production would mating competent ide mutants would represent candidates improved factor recognition ie altered substrate specificity conceivably mutants might also altered specificity insulin andor ide mutants enhanced activity toward substrates could potentially used therapeutic agents diabetes alzheimer disease
0.5010976.15944156.html.plaintext.txt	94	another potential utility genetic model system theoretical ability rapidly identify ide mutants altered substrate specificity already demonstrated system amenable screening specific mutant ide alleles ability promote mating approach could used identify ide mutants altered specificity toward factor envision positive genetic selection takes advantage observations ide dependent mating essentially nonexistent reduced nutrient levels fig 3a highly stringent mating conditions yeast harboring ide mutants could screened expectation enhanced factor production would mating competent ide mutants would represent candidates improved factor recognition ie altered substrate specificity conceivably mutants might also altered specificity insulin andor ide mutants enhanced activity toward substrates could potentially used therapeutic agents diabetes alzheimer disease
0.5010976.15944156.html.plaintext.txt	95	data clearly demonstrate axl1pste23p dependent step factor production supported ide result surprising given high degree similarity enzymes greater curiosity observation yeast enzymes required factor production functionally replaced mammalian counterparts first three steps associated factor production ie isoprenylation caax proteolysis carboxymethylation part biosynthetic pathway isoprenylated proteins ras rhob subsequent two proteolytic steps associated factor production analogous counterparts mammals thus ability mammalian enzymes promote latter steps entirely serendipitous reflects existence orphan biosynthetic pathway integrates steps associated factor biosynthesis latter analogy suspect molecule produced pathway would serve secreted signaling molecule possibly functioning regulate cell cell fusion events occur development certain tissues curiously morphological biochemical differentiation l6 myoblasts myotubes reported involve ide 45 46 thus analogy factor production hypothesize role ide cells might produce signaling molecule derived precursor aliphatic amino acid motif n terminal extension readily cleaved ide whether molecule exists mammalian systems remains determined
0.5010976.15944156.html.plaintext.txt	96	data clearly demonstrate axl1pste23p dependent step factor production supported ide result surprising given high degree similarity enzymes greater curiosity observation yeast enzymes required factor production functionally replaced mammalian counterparts first three steps associated factor production ie isoprenylation caax proteolysis carboxymethylation part biosynthetic pathway isoprenylated proteins ras rhob subsequent two proteolytic steps associated factor production analogous counterparts mammals thus ability mammalian enzymes promote latter steps entirely serendipitous reflects existence orphan biosynthetic pathway integrates steps associated factor biosynthesis latter analogy suspect molecule produced pathway would serve secreted signaling molecule possibly functioning regulate cell cell fusion events occur development certain tissues curiously morphological biochemical differentiation l6 myoblasts myotubes reported involve ide 45 46 thus analogy factor production hypothesize role ide cells might produce signaling molecule derived precursor aliphatic amino acid motif n terminal extension readily cleaved ide whether molecule exists mammalian systems remains determined
0.5010976.15944156.html.plaintext.txt	97	footnotes work supported part funds university georgia costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.5010976.15944156.html.plaintext.txt	98	footnotes work supported part funds university georgia costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.5010976.15944156.html.plaintext.txt	99	supported university georgia graduate school assistantship
0.5010976.15944156.html.plaintext.txt	100	correspondence addressed dept biochemistry molecular biology 120 green st athens ga 30602 tel 706 583 8241 fax 706 542 1738 e mail wschmidtatbmbugaedu u d
0.5010976.15944156.html.plaintext.txt	101	correspondence addressed dept biochemistry molecular biology 120 green st athens ga 30602 tel 706 583 8241 fax 706 542 1738 e mail wschmidtatbmbugaedu u d
0.5010976.15944156.html.plaintext.txt	102	1 abbreviations used ide insulin degrading enzyme ha hemagglutinin maldi tof matrix assisted laser desorption ionization time flight gfp green fluorescent protein
0.5010976.15944156.html.plaintext.txt	103	acknowledgments grateful drs claiborne glover michelle momany ron orlando lance wells members respective laboratories technical advice access equipment critical discussions also thank pamela freshley chandra moore help plasmid constructions
0.5010976.15944156.html.plaintext.txt	104	acknowledgments grateful drs claiborne glover michelle momany ron orlando lance wells members respective laboratories technical advice access equipment critical discussions also thank pamela freshley chandra moore help plasmid constructions
0.5010976.15944156.html.plaintext.txt	105	references top abstract introduction experimental procedures results discussion references becker b roth r 1995 methods enzymol 248 693 703medline order article via infotrieve qiu w q walsh d m ye z vekrellis k zhang j podlisny m b rosner m r safavi hersh l b selkoe d j 1998 j biol chem 273 32730 32738abstractfree full text edbauer d willem m lammich steiner h haass c 2002 j biol chem 277 13389 13393abstractfree full text farris w mansourian chang y lindsley l eckman e frosch m p eckman c b tanzi r e selkoe d j guenette 2003 proc natl acad sci u 100 4162 4167abstractfree full text leissring m farris w chang y walsh d m wu x sun x frosch m p selkoe d j 2003 neuron 40 1087 1093crossrefmedline order article via infotrieve miller b c eckman e sambamurti k dobbs n chow k m eckman c b hersh l b thiele d l 2003 proc natl acad sci u 100 6221 6226abstractfree full text tanzi r e moir r d wagner l 2004 neuron 43 605 608crossrefmedline order article via infotrieve fujita oka c arikawa y katagai tonouchi kuhara misumi y 1994 nature 372 567 570medline order article via infotrieve adames n blundell k ashby m n boone c 1995 science 270 464 467abstract chen p sapperstein choi j d michaelis 1997 j cell biol 136 251 269abstractfree full text elia l marsh l 1998 j cell biol 142 1473 1485abstractfree full text brizzio v gammie e nijbroek g l michaelis rose m 1996 j cell biol 135 1727 1739abstract palecek p parikh kron j 2000 genetics 156 1005 1023abstractfree full text cullen p j sprague g f jr 2002 mol biol cell 13 2990 3004abstractfree full text perlman r k gehm b d kuo w l rosner m r 1993 j biol chem 268 21538 21544abstractfree full text perlman r k rosner m r 1994 j biol chem 269 33140 33145abstractfree full text ding l becker b suzuki roth r 1992 j biol chem 267 2414 2420abstractfree full text elble r 1992 biotechniques 13 18 20medline order article via infotrieve michaelis herskowitz 1988 mol cell biol 8 1309 1318medline order article via infotrieve oldenburg k r vo k michaelis paddon c 1997 nucleic acids res 25 451 452abstractfree full text seta k roth r 1997 biochem biophys res commun 231 167 171crossrefmedline order article via infotrieve brachat dietrich f voegeli zhang z stuart l lerch gates k gaffney philippsen p 2003 genome biol 4 r45crossrefmedline order article via infotrieve fujimura kamada k nouvet f j michaelis 1997 j cell biol 136 271 285abstractfree full text schmidt w k tam fujimura kamada k michaelis 1998 proc natl acad sci u 95 11175 11180abstractfree full text schmidt w k tam michaelis 2000 j biol chem 275 6227 6233abstractfree full text nijbroek g l michaelis 1998 methods enzymol 292 193 212medline order article via infotrieve chan r k otte c 1982 mol cell biol 2 11 20medline order article via infotrieve marcus caldwell g miller d xue c b naider f becker j m 1991 mol cell biol 11 3603 3612medline order article via infotrieve yalovsky trueblood c e callan k l narita j o jenkins m rine j gruissem w 1997 mol cell biol 17 1986 1994abstract dai q choy e chiu v romano j slivka r steitz michaelis philips m r 1998 j biol chem 273 15030 15034abstractfree full text tam nouvet f fujimura kamada k slunt h sisodia michaelis 1998 j cell biol 142 635 649abstractfree full text bracha k lavy m yalovsky 2002 j biol chem 277 29856 29864abstractfree full text cadinanos j schmidt w k fueyo varela lopez otin c freije j m 2003 biochem j 370 1047 1054crossrefmedline order article via infotrieve cadinanos j varela mandel d schmidt w k diaz perales lopezotin c freije j m p 2003 j biol chem 278 42091 42097abstractfree full text duckworth w c bennett r g hamel f g 1998 endocr rev 19 608 624abstractfree full text morita m kurochkin v motojima k goto takano okamura sato r yokota imanaka 2000 cell struct funct 25 309 315crossrefmedline order article via infotrieve caldwell g wang h xue c b jiang y lu h f naider f becker j m 1994 j biol chem 269 19817 19826abstractfree full text striebel h m rysavy p adamec j spizek j kalousek f 1996 arch biochem biophys 335 211 218crossrefmedline order article via infotrieve fakhrai rad h nikoshkov kamel fernstrom m zierath j r norgren luthman h galli j 2000 hum mol genet 9 2149 2158abstractfree full text karamohamed demissie volcjak j liu c heard costa n liu j shoemaker c m panhuysen c meigs j b wilson p atwood l d cupples l herbert 2003 diabetes 52 1562 1567abstractfree full text farris w mansourian leissring m eckman e bertram l eckman c b tanzi r e selkoe d j 2004 j pathol 164 1425 1434abstractfree full text lazarow p b 2003 curr opin cell biol 15 489 497crossrefmedline order article via infotrieve lord m inose f hiroko hata fujita chant j 2002 curr biol 12 1347 1352crossrefmedline order article via infotrieve roth r 2004 handbook proteolytic enzymes barrett j rawlings n d woessner j f eds 2nd ed pp 868 871 elsevier academic press london kayalar c wong w 1989 j biol chem 264 8928 8934abstractfree full text kayalar c wong w hendrickson l 1990 j cell biochem 44 137 151crossrefmedline order article via infotrieve sikorski r hieter p 1989 genetics 122 19 27abstractfree full text article abstract full text pdf versions article 2803027481 recent m414192200v1 purchase article view shopping cart alert article cited alert correction posted citation map services email article friend similar articles journal similar articles pubmed alert new issues journal download citation manager copyright permissions google scholar articles kim articles schmidt w k articles citing article pubmed pubmed citation articles kim articles schmidt w k
0.5010976.15944156.html.plaintext.txt	106	home help feedback subscriptions archive search table contents asbmb journals molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright 2005 american society biochemistry molecular biology
0.5654884.15749695.html.plaintext.txt	0	mutation active site residues insulin degrading enzyme alters allosteric interactions eun suk song abigail daily michael g fried maria aparecida juliano luiz juliano louis b hersh
0.5654884.15749695.html.plaintext.txt	1	mutation active site residues insulin degrading enzyme alters allosteric interactions eun suk song abigail daily michael g fried maria aparecida juliano luiz juliano louis b hersh
0.5654884.15749695.html.plaintext.txt	2	department molecular cellular biochemistry university kentucky lexington kentucky 40536 department biophysics escola paulista de medicina sao paulo 04023 900 brazil
0.5654884.15749695.html.plaintext.txt	3	received publication february 18 2005
0.5654884.15749695.html.plaintext.txt	4	abstract top abstract introduction materials methods results discussion references active site glutamate glu111 active site histidine his112 insulin degrading enzyme ide mutated mutant enzymes exhibit addition large decrease catalytic activity change substrate velocity response sigmoidal one seen native enzyme hill coefficient 2 hyperbolic response 2 aminobenzoyl ggflrkhgq n 24 dinitrophenylethylenediamine substrate atp triphosphate increase reaction rate wild type enzyme 50 80 fold effect dampened glutamate mutants effect less 3 fold increase activity changed inhibition histidine mutants sedimentation equilibrium shows ide mutants exhibit similar oligomeric distribution wild type enzyme predominantly monomeric triphosphate little effect oligomeric state triphosphate induce aggregation many ide mutants thus oligomeric state ide correlate kinetic properties his112 mutants shown bind zinc lower affinity wild type enzyme glutamate mutants displayed altered cleavage profile peptide endorphin wild type ide cleaved endorphin leu17 phe18 phe18 lys19 whereas glutamate mutants cleaved sites addition lys19 asn20 met5 thr6 thus active site mutations ide suggested reduce catalytic activity also cause local conformational changes affect allosteric properties enzyme
0.5654884.15749695.html.plaintext.txt	5	abstract top abstract introduction materials methods results discussion references active site glutamate glu111 active site histidine his112 insulin degrading enzyme ide mutated mutant enzymes exhibit addition large decrease catalytic activity change substrate velocity response sigmoidal one seen native enzyme hill coefficient 2 hyperbolic response 2 aminobenzoyl ggflrkhgq n 24 dinitrophenylethylenediamine substrate atp triphosphate increase reaction rate wild type enzyme 50 80 fold effect dampened glutamate mutants effect less 3 fold increase activity changed inhibition histidine mutants sedimentation equilibrium shows ide mutants exhibit similar oligomeric distribution wild type enzyme predominantly monomeric triphosphate little effect oligomeric state triphosphate induce aggregation many ide mutants thus oligomeric state ide correlate kinetic properties his112 mutants shown bind zinc lower affinity wild type enzyme glutamate mutants displayed altered cleavage profile peptide endorphin wild type ide cleaved endorphin leu17 phe18 phe18 lys19 whereas glutamate mutants cleaved sites addition lys19 asn20 met5 thr6 thus active site mutations ide suggested reduce catalytic activity also cause local conformational changes affect allosteric properties enzyme
0.5654884.15749695.html.plaintext.txt	6	introduction top abstract introduction materials methods results discussion references generally accepted accumulation amyloid peptides a1 particularly amyloid peptide 1 42 plays central role pathogenesis alzheimer disease ad mechanisms leading accumulation late onset ad currently unknown could result either overproduction peptide decreased clearance case autosomal dominant ad clear early onset disease linked increased production results mutations one several genes app ps1 presenilin 1 ps2 presenilin 2 1 4 however scattering evidence late onset ad attributable overproduction 5 recent reports 6 8 secretase involved amyloid peptide synthesis increased sporadic ad patients whether increase cause consequence ad whether increase activity seen larger patient populations remains established
0.5654884.15749695.html.plaintext.txt	7	introduction top abstract introduction materials methods results discussion references generally accepted accumulation amyloid peptides a1 particularly amyloid peptide 1 42 plays central role pathogenesis alzheimer disease ad mechanisms leading accumulation late onset ad currently unknown could result either overproduction peptide decreased clearance case autosomal dominant ad clear early onset disease linked increased production results mutations one several genes app ps1 presenilin 1 ps2 presenilin 2 1 4 however scattering evidence late onset ad attributable overproduction 5 recent reports 6 8 secretase involved amyloid peptide synthesis increased sporadic ad patients whether increase cause consequence ad whether increase activity seen larger patient populations remains established
0.5654884.15749695.html.plaintext.txt	8	clearance currently receiving considerable attention key regulatory mechanism brain levels appear two paths clearance brain one pathway involves equilibration central nervous system plasma mediated cerebral spinal fluid 9 11 pathway involves clearance proteolysis 12 15 number peptidases implicated clearance received attention supported vivo studies peptidase deficient mice include neprilysin 16 17 insulysin ide 18 19 endothelin converting enzyme 20 21 genetic studies suggested linkage late onset ad ide linkage region chromosome 10q late onset alzheimer disease reported several groups 22 25 region chromosome within 195 kilobases ide gene however date analysis refined point linkage ide unequivocally established
0.5654884.15749695.html.plaintext.txt	9	clearance currently receiving considerable attention key regulatory mechanism brain levels appear two paths clearance brain one pathway involves equilibration central nervous system plasma mediated cerebral spinal fluid 9 11 pathway involves clearance proteolysis 12 15 number peptidases implicated clearance received attention supported vivo studies peptidase deficient mice include neprilysin 16 17 insulysin ide 18 19 endothelin converting enzyme 20 21 genetic studies suggested linkage late onset ad ide linkage region chromosome 10q late onset alzheimer disease reported several groups 22 25 region chromosome within 195 kilobases ide gene however date analysis refined point linkage ide unequivocally established
0.5654884.15749695.html.plaintext.txt	10	specificity ide complex enzyme cleaves variety peptides primarily exclusively basic bulky hydrophobic residues 31 32 kurochkin 33 suggested ide cleaves peptides propensity form pleated sheet structures cleavage ide results loss neurotoxic effects peptide prevents deposition onto synthetic amyloid deposit 34 recently shown ide exhibits allosteric properties activated peptide substrates interestingly peptides activated ide toward peptide cleavage toward insulin cleavage 35 established ide exists mixture monomers dimers tetramers course studies allosteric properties ide generated number active site mutants control enzymes noted although activity mutants significantly reduced residual catalytic properties altered report results studies
0.5654884.15749695.html.plaintext.txt	11	specificity ide complex enzyme cleaves variety peptides primarily exclusively basic bulky hydrophobic residues 31 32 kurochkin 33 suggested ide cleaves peptides propensity form pleated sheet structures cleavage ide results loss neurotoxic effects peptide prevents deposition onto synthetic amyloid deposit 34 recently shown ide exhibits allosteric properties activated peptide substrates interestingly peptides activated ide toward peptide cleavage toward insulin cleavage 35 established ide exists mixture monomers dimers tetramers course studies allosteric properties ide generated number active site mutants control enzymes noted although activity mutants significantly reduced residual catalytic properties altered report results studies
0.5654884.15749695.html.plaintext.txt	12	materials methods top abstract introduction materials methods results discussion references synthesis fluorogenic peptide substrate abz ggflrkhgqeddnp previously described 36 dynorphin 9 dynorphin 10 dynorphin 17 dynorphin b 9 insulin obtained bachem amyloid peptide 1 40 product california research peptide inc endorphin obtained multiple peptide systems national institute drug abuse research tools program reagents obtained best grade available commercially
0.5654884.15749695.html.plaintext.txt	13	materials methods top abstract introduction materials methods results discussion references synthesis fluorogenic peptide substrate abz ggflrkhgqeddnp previously described 36 dynorphin 9 dynorphin 10 dynorphin 17 dynorphin b 9 insulin obtained bachem amyloid peptide 1 40 product california research peptide inc endorphin obtained multiple peptide systems national institute drug abuse research tools program reagents obtained best grade available commercially
0.5654884.15749695.html.plaintext.txt	14	activity assays ide activity routinely measured fluorogenic peptide abz ggflrkhgq eddnp increase fluorescence occurred upon cleavage peptide residues r k 36 followed spectramax gemini xs fluorescence plate reader using excitation wavelength 318 nm emission wavelength 419 nm
0.5654884.15749695.html.plaintext.txt	15	activity assays ide activity routinely measured fluorogenic peptide abz ggflrkhgq eddnp increase fluorescence occurred upon cleavage peptide residues r k 36 followed spectramax gemini xs fluorescence plate reader using excitation wavelength 318 nm emission wavelength 419 nm
0.5654884.15749695.html.plaintext.txt	16	ide dependent hydrolysis insulin endorphin amyloid peptide 1 40 dynorphin peptides followed reverse phase hplc using c4 column linear gradient 01 trifluoroacetic acid 95 water 5 acetonitrile 01 trifluoroacetic acid 50 water 50 acetonitrile peptides followed absorbance 214 nm quantified peak area
0.5654884.15749695.html.plaintext.txt	17	ide dependent hydrolysis insulin endorphin amyloid peptide 1 40 dynorphin peptides followed reverse phase hplc using c4 column linear gradient 01 trifluoroacetic acid 95 water 5 acetonitrile 01 trifluoroacetic acid 50 water 50 acetonitrile peptides followed absorbance 214 nm quantified peak area
0.5654884.15749695.html.plaintext.txt	18	preparation purification ide mutants various his112 glu111 rat ide mutants prepared pfast bac htb using site directed mutagenesis kit stratagene noted methionine located 42 residues downstream methionine 1 ide cdna appears represent major translational start site 37 thus his112 would actually his70 glu111 would glu69 however retained original numbering system avoid confusion earlier publications oligonucleotides used mutagenesis base changes wild type sequence underlined listed table
0.5654884.15749695.html.plaintext.txt	19	preparation purification ide mutants various his112 glu111 rat ide mutants prepared pfast bac htb using site directed mutagenesis kit stratagene noted methionine located 42 residues downstream methionine 1 ide cdna appears represent major translational start site 37 thus his112 would actually his70 glu111 would glu69 however retained original numbering system avoid confusion earlier publications oligonucleotides used mutagenesis base changes wild type sequence underlined listed table
0.5654884.15749695.html.plaintext.txt	20	view table table oligonucleotides used
0.5654884.15749695.html.plaintext.txt	21	based secondary structure predicting programs phd 38 phdsec 39 ide predicted helical region residues 107 116 encompasses mutated residues none mutations predicted affect ability region form helix
0.5654884.15749695.html.plaintext.txt	22	based secondary structure predicting programs phd 38 phdsec 39 ide predicted helical region residues 107 116 encompasses mutated residues none mutations predicted affect ability region form helix
0.5654884.15749695.html.plaintext.txt	23	recombinant ide various mutants expressed sf 9 cells fusion protein containing n terminal hexahistidine affinity tag followed linker containing tobacco etch virus protease cleavage site 35 wild type ide mutants purified select hc nickel affinity gel column sigma experiments enzyme used his6 ide however verify lack effect n terminal hexahistidine linker tobacco etch virus protease used remove region previously described 35
0.5654884.15749695.html.plaintext.txt	24	recombinant ide various mutants expressed sf 9 cells fusion protein containing n terminal hexahistidine affinity tag followed linker containing tobacco etch virus protease cleavage site 35 wild type ide mutants purified select hc nickel affinity gel column sigma experiments enzyme used his6 ide however verify lack effect n terminal hexahistidine linker tobacco etch virus protease used remove region previously described 35
0.5654884.15749695.html.plaintext.txt	25	sedimentation equilibrium analysis analytical ultracentrifugation performed 40 plus minus 01 degrees c beckman xl centrifuge using 60 ti rotor scans obtained 280 nm step size 0001 cm approach equilibrium considered complete scans made 6 h apart indistinguishable typically equilibration times equal greater 20 h met criterion five scans averaged sample rotor speed previous results 3 indicated ide self associates monomer dimer tetramer pattern sedimentation equilibrium data therefore analyzed according equation 1
0.5654884.15749695.html.plaintext.txt	26	eq 1 ar absorbance radial position r m0 d0 t0 absorbances monomer dimer tetramer respectively reference radius ro parameter m reduced molecular weight monomer m mm1 22rt mm monomer molecular weight partial specific volume solvent density rotor angular velocity r gas constant absolute temperature base line offset solvent density measured using mettler density meter partial specific volume ide calculated amino acid composition using method cohn edsall 40 data sets obtained samples run three different rotor speeds fit simultaneously equation 1 using global fitting method first described johnson co workers 41
0.5654884.15749695.html.plaintext.txt	27	results top abstract introduction materials methods results discussion references ide zinc metallopeptidase inverzincin family containing signature active site sequence h108xxeh two histidines conjunction downstream glutamate glu189 believed act ligands active site zinc 37 42 zincins glutamate 111 believed directly involved catalysis probably acting general base facilitate removal proton water molecule attacks scissile bond effect mutating active site glutamate histidine reported produce inactive enzyme 37 42 since noted varying extents inactivation mutating similar residues related zinc metallopeptidase puromycin sensitive aminopeptidase 43 quantitated effect mutating his112 glu111 ide
0.5654884.15749695.html.plaintext.txt	28	results top abstract introduction materials methods results discussion references ide zinc metallopeptidase inverzincin family containing signature active site sequence h108xxeh two histidines conjunction downstream glutamate glu189 believed act ligands active site zinc 37 42 zincins glutamate 111 believed directly involved catalysis probably acting general base facilitate removal proton water molecule attacks scissile bond effect mutating active site glutamate histidine reported produce inactive enzyme 37 42 since noted varying extents inactivation mutating similar residues related zinc metallopeptidase puromycin sensitive aminopeptidase 43 quantitated effect mutating his112 glu111 ide
0.5654884.15749695.html.plaintext.txt	29	two mutants his112 h112q h112d generated well four mutants glu111 e111v e111l e111a e111f initially compared kinetics various his112 glu111 mutants using fluorogenic substrate abz ggflrkhgq eddnp although native ide clearly displayed sigmoidal substrate binding curve fig 1 his112 mutants four glu111 mutants displayed classical hyperbolic substrate binding curves illustrated e111f mutant fig 1 table ii summarizes kinetic parameters mutants his112 mutants exhibited 3 5 fold increase km kcat decreased close 7000 fold h112d mutant less 100 fold h112q mutant mutation active site glutamate valine leucine alanine phenylalanine produced enzyme forms effects km variable essentially change e111l e111f mutants greater 7 fold increase e111a mutant range kcat values glu111 mutants varied decrease 9000 fold e111a decrease 68000 fold e111l
0.5654884.15749695.html.plaintext.txt	30	two mutants his112 h112q h112d generated well four mutants glu111 e111v e111l e111a e111f initially compared kinetics various his112 glu111 mutants using fluorogenic substrate abz ggflrkhgq eddnp although native ide clearly displayed sigmoidal substrate binding curve fig 1 his112 mutants four glu111 mutants displayed classical hyperbolic substrate binding curves illustrated e111f mutant fig 1 table ii summarizes kinetic parameters mutants his112 mutants exhibited 3 5 fold increase km kcat decreased close 7000 fold h112d mutant less 100 fold h112q mutant mutation active site glutamate valine leucine alanine phenylalanine produced enzyme forms effects km variable essentially change e111l e111f mutants greater 7 fold increase e111a mutant range kcat values glu111 mutants varied decrease 9000 fold e111a decrease 68000 fold e111l
0.5654884.15749695.html.plaintext.txt	31	view larger version 18k fig 1 comparison kinetics wild type ide kinetics e111f mutant reactions conducted 50 mm tris hcl ph 74 wild type ide 50 ng enzyme top e111f mutant 30 microg enzyme bottom using abz ggflrkhgqeddnp variable substrate
0.5654884.15749695.html.plaintext.txt	32	view table table ii kinetic properties ide mutants abz ggflrkhgq eddnp substrate
0.5654884.15749695.html.plaintext.txt	33	activity determined 20 mm potassium phosphate buffer ph 73
0.5654884.15749695.html.plaintext.txt	34	also examined effect glu111 his112 mutations hydrolysis three physiological peptide substrates ide insulin endorphin amyloid peptide 1 40 shown table iii saturating substrate conditions endorphin amyloid peptide 1 40 hydrolysis decreased 107 fold glu111 mutants 106 fold his112 mutants insulin substrate hydrolysis could detected glu111 mutants conditions decrease 107 fold could detected whereas his112 mutants insulin hydrolysis decreased 3 x 106 fold h112q 107 fold h112d
0.5654884.15749695.html.plaintext.txt	35	also examined effect glu111 his112 mutations hydrolysis three physiological peptide substrates ide insulin endorphin amyloid peptide 1 40 shown table iii saturating substrate conditions endorphin amyloid peptide 1 40 hydrolysis decreased 107 fold glu111 mutants 106 fold his112 mutants insulin substrate hydrolysis could detected glu111 mutants conditions decrease 107 fold could detected whereas his112 mutants insulin hydrolysis decreased 3 x 106 fold h112q 107 fold h112d
0.5654884.15749695.html.plaintext.txt	36	view table table iii rates hydrolysis physiological peptides ide mutants
0.5654884.15749695.html.plaintext.txt	37	activity determined 50 mm tris hcl buffer ph 74 10 microm peptide rates hydrolysis determined following substrate disappearance hplc
0.5654884.15749695.html.plaintext.txt	38	ide found contain cationic regulatory site distinct active site binds nucleotide triphosphates primarily triphosphate moiety 44 binding polyanion site increases rate small peptides substrates larger physiological substrates insulin amyloid peptide since active site histidine glutamate mutations caused loss allosteric interactions tested whether mutant enzymes could still activated atp triphosphate shown table iv using abz ggflrkhgq eddnp dynorphin b 9 substrate glu111 mutants activated atp much lesser extent compared wild type enzyme similar effect observed triphosphate activator
0.5654884.15749695.html.plaintext.txt	39	ide found contain cationic regulatory site distinct active site binds nucleotide triphosphates primarily triphosphate moiety 44 binding polyanion site increases rate small peptides substrates larger physiological substrates insulin amyloid peptide since active site histidine glutamate mutations caused loss allosteric interactions tested whether mutant enzymes could still activated atp triphosphate shown table iv using abz ggflrkhgq eddnp dynorphin b 9 substrate glu111 mutants activated atp much lesser extent compared wild type enzyme similar effect observed triphosphate activator
0.5654884.15749695.html.plaintext.txt	40	view table table iv effect atp pppi mutant ide activity
0.5654884.15749695.html.plaintext.txt	41	activity determined 10 microm abz ggflrkhgq eddnp 10 microm dynorphin b 9 50 mm tris hcl buffer ph 74 presence 5 mm atp 5 mm pppi compared absence addition specific activities absence added atp pppi abz ggflrkhgq eddnp substrate follows wild type ide 8131 nmolminmg e111a 75 nmolminmg e111v 27 nmolminmg e111f 52 nmolminmg e111l 0092 nmolminmg h112d 281 nmolminmg h112q 847 nmolminmg
0.5654884.15749695.html.plaintext.txt	42	activity determined 10 microm abz ggflrkhgq eddnp 10 microm dynorphin b 9 50 mm tris hcl buffer ph 74 presence 5 mm atp 5 mm pppi compared absence addition specific activities absence added atp pppi abz ggflrkhgq eddnp substrate follows wild type ide 8131 nmolminmg e111a 75 nmolminmg e111v 27 nmolminmg e111f 52 nmolminmg e111l 0092 nmolminmg h112d 281 nmolminmg h112q 847 nmolminmg
0.5654884.15749695.html.plaintext.txt	43	his112 mutants affected differently atp triphosphate acted inhibitors rather activators h112q mutant triphosphate effective inhibitor abz ggflrkhgq eddnp hydrolysis micromolar concentrations microm microm whereas activation wild type enzyme required millimolar concentrations mm mm illustrated fig 2
0.5654884.15749695.html.plaintext.txt	44	his112 mutants affected differently atp triphosphate acted inhibitors rather activators h112q mutant triphosphate effective inhibitor abz ggflrkhgq eddnp hydrolysis micromolar concentrations microm microm whereas activation wild type enzyme required millimolar concentrations mm mm illustrated fig 2
0.5654884.15749695.html.plaintext.txt	45	view larger version 15k fig 2 comparison effect triphosphate hydrolysis abz ggflrkhgq eddnp wild type ide top ide h112q mutant bottom activity determined 50 mm tris hcl buffer ph 74 10 microm abz ggflrkhgq eddnp substrate indicated concentration pppi reactions wild type enzyme contained 50 ng protein whereas h112q mutant contained 10 microg protein wild type enzyme activity absence added pppi 035 nmolmin although shown effect pppi activity wild type enzyme concentration range used h112q mutant
0.5654884.15749695.html.plaintext.txt	46	used sedimentation equilibrium determine effect active site mutations ide oligomerization fig 3 previously reported tris buffer wild type enzyme appeared predominantly mixture monomers dimers 44 monomer predominant species addition 4 mm triphosphate maintained monomer dominant species eliminated small amount dimers 44 study found h112q mutant appeared monomeric trace higher aggregate possibly tetramer present addition pppi decreased solubility significantly change distribution oligomeric species contrast h112d mutant appeared less soluble showed predominantly tetramers addition pppi decreased solubility clearly showed presence primarily monomers higher aggregates present e111a e111f e111l appeared monomers trace tetramer present e111v exhibited poor solubility could analyzed addition pppi e111l e111a effect distribution species induced aggregation e111a complete aggregation e111f thus clear correlation oligomeric state enzyme activity
0.5654884.15749695.html.plaintext.txt	47	view larger version 26k fig 3 sedimentation equilibrium analysis wild type e111a mutant ide proteins samples dissolved 50 mm tris hcl buffer ph 74 brought sedimentation equilibrium 10000 rpm 4 degrees c open circles wild type ide filled circles e111a mutant ide smooth curves represent global fits equation 1 data sets obtained 10000 15000 20000 rpm small symmetric residuals demonstrate compatibility equation data data wild type mutant ide consistent mixtures monomeric enzyme predominates relatively small mol fractions higher oligomers
0.5654884.15749695.html.plaintext.txt	48	perlman et al 42 showed his112 zinc coordinating residue provided evidence active site zinc lost h112q mutant reexamined issue h112q h112d mutants accomplish looked ability edta o phenanthroline inhibit residual activity mutants shown table v inclusion 01 mm edta 01 mm o phenanthroline assay little effect activity wild type ide similarly 01 mm edta 01 mm o phenanthroline effect rate insulin hydrolysis glutamate mutants data shown contrast metal chelating agents completely inhibited activity histidine mutants shown table v although shown significant inhibition wild type enzyme glutamate mutants observed higher concentrations edta 1 mm o phenanthroline 1 mm thus his112 mutants appear retain active site zinc zinc bound weakly thus looked ability zinc increase reaction rate mutants shown fig 4 addition zinc concentration range 01 10 microm caused maximal 18 fold increase activity h112q mutant 12 fold increase activity h112d mutant followed inhibition higher zinc concentrations contrast zinc concentrations tested slightly inhibitory wild type activity
0.5654884.15749695.html.plaintext.txt	49	view table table v effect metal chelators mutant ide activity
0.5654884.15749695.html.plaintext.txt	50	activity determined 50 mm tris hcl ph 74 either 10 microm abz ggflrkhgq eddnp substrate 10 microm insulin values parenthesis substrate 01 mm edta 01 mm o phenanthroline added indicated
0.5654884.15749695.html.plaintext.txt	51	activity determined 50 mm tris hcl ph 74 either 10 microm abz ggflrkhgq eddnp substrate 10 microm insulin values parenthesis substrate 01 mm edta 01 mm o phenanthroline added indicated
0.5654884.15749695.html.plaintext.txt	52	view larger version 11k fig 4 effect zinc activity wild type ide his112 mutants activity determined 50 mm tris hcl buffer ph 74 10 microm abz ggflrkhgq eddnp substrate indicated concentration zncl2
0.5654884.15749695.html.plaintext.txt	53	order determine whether mutations introduced ide affected enzyme specificity looked cleavage pattern three physiological peptides endorphin insulin amyloid peptide 1 40 using mutants listed table ii insulin amyloid peptide 1 40 substrate observed initial cleavage products various mutants wild type enzyme illustrated insulin cleavage e111f mutant fig 5 previously noted 32 native ide cleaved endorphin thr17 leu18 leu18 phe19 bonds two histidine mutants produced cleavage pattern however glutamate 111 mutants produced addition cleavage leu17 phe18 phe18 lys19 cleavage lys19 asn20 met5 thr6 illustrated fig 5 e111f mutant based result also compared cleavage small dynorphin related peptides native ide e111v mutant found dynorphin 9 dynorphin 10 dynorphin 17 dynorphin b 9 change cleavage site
0.5654884.15749695.html.plaintext.txt	54	order determine whether mutations introduced ide affected enzyme specificity looked cleavage pattern three physiological peptides endorphin insulin amyloid peptide 1 40 using mutants listed table ii insulin amyloid peptide 1 40 substrate observed initial cleavage products various mutants wild type enzyme illustrated insulin cleavage e111f mutant fig 5 previously noted 32 native ide cleaved endorphin thr17 leu18 leu18 phe19 bonds two histidine mutants produced cleavage pattern however glutamate 111 mutants produced addition cleavage leu17 phe18 phe18 lys19 cleavage lys19 asn20 met5 thr6 illustrated fig 5 e111f mutant based result also compared cleavage small dynorphin related peptides native ide e111v mutant found dynorphin 9 dynorphin 10 dynorphin 17 dynorphin b 9 change cleavage site
0.5654884.15749695.html.plaintext.txt	55	view larger version 20k fig 5 hplc chromatograms showing cleavage endorphin insulin ide e111f mutant top reaction mixtures containing 10 microm insulin 50 mm tris hcl ph 74 reacted wild type ide 01 microg 30 min b e112q 50 microg 1 h c reaction products separated gradient hplc vydac c4 reverse phase column described materials methods product peaks collected identified mass spectrometry peak 1 insulin b1 9 peak 2 insulin b1 10 peak 3 insulin a1 13 peak 4 insulin a1 14 peak insulin chain peak b insulin b chain bottom reaction mixtures containing 10 microm endorphin reacted wild type ide 01 microg 15 min b e111f 50 microg 1 h c peak 1 endorphin 19 31 peak 2 endorphin 18 31 peak 3 endorphin 1 17 peak 4 endorphin 1 18 peak 5 endorphin 20 31 peak 6 endorphin 1 19 peak 7 endorphin 6 31
0.5654884.15749695.html.plaintext.txt	56	discussion top abstract introduction materials methods results discussion references mutation residues within active site motif hexxhor hxxeh zinc metallopeptidases reported lead loss catalytic activity however cases presence residual activity quantified generally lack availability large amounts mutant protein cases active site glutamate mutated 45 49 although mutant enzyme reported catalytically inactive determined inactive enzyme retains ability bind substrate 37 42 43 45
0.5654884.15749695.html.plaintext.txt	57	discussion top abstract introduction materials methods results discussion references mutation residues within active site motif hexxhor hxxeh zinc metallopeptidases reported lead loss catalytic activity however cases presence residual activity quantified generally lack availability large amounts mutant protein cases active site glutamate mutated 45 49 although mutant enzyme reported catalytically inactive determined inactive enzyme retains ability bind substrate 37 42 43 45
0.5654884.15749695.html.plaintext.txt	58	active site glutamate glu111 active site histidine his112 ide previously mutated 37 42 his112 mutant transiently expressed cos cells appeared inactive measured crude extracts insulin substrate however mutant retained ability bind insulin determined cross linking studies 37 noted insulin cross linking actually increased mutant relative wild type enzyme attributed relaxation rigid conformation stabilized zinc evidence increased flexibility active site came demonstration treatment native enzyme o phenanthroline increased extent cross linking however o phenanthroline increase cross linking h112q mutant
0.5654884.15749695.html.plaintext.txt	59	active site glutamate glu111 active site histidine his112 ide previously mutated 37 42 his112 mutant transiently expressed cos cells appeared inactive measured crude extracts insulin substrate however mutant retained ability bind insulin determined cross linking studies 37 noted insulin cross linking actually increased mutant relative wild type enzyme attributed relaxation rigid conformation stabilized zinc evidence increased flexibility active site came demonstration treatment native enzyme o phenanthroline increased extent cross linking however o phenanthroline increase cross linking h112q mutant
0.5654884.15749695.html.plaintext.txt	60	using radioactive zinc concluded h112q mutant bind zinc finding residual activity two his112 mutants glu111 mutants reduced treatment metal chelators indicates mutants contain zinc zinc bound considerably weakly native protein thus results his112 glu111 mutants support extend general conclusions perlman rosner 37 mutation active site histidine causes change conformation active site ide results presented suggest due loss zinc binding probably due local conformational changes occur within active site
0.5654884.15749695.html.plaintext.txt	61	using radioactive zinc concluded h112q mutant bind zinc finding residual activity two his112 mutants glu111 mutants reduced treatment metal chelators indicates mutants contain zinc zinc bound considerably weakly native protein thus results his112 glu111 mutants support extend general conclusions perlman rosner 37 mutation active site histidine causes change conformation active site ide results presented suggest due loss zinc binding probably due local conformational changes occur within active site
0.5654884.15749695.html.plaintext.txt	62	rather surprising finding mutation either catalytic glutamate zinc coordinating histidine converts substrate velocity curves sigmoidal hyperbolic thus homotropic allosteric activation previously reported us 35 absent mutants since established ide exist oligomeric state 32 35 50 51 one possible explanation active site ide interface two subunits mutation active site residues produces local conformational change affects subunit interaction appear case since 35 perlman et al 42 shown formation oligomers containing active inactive subunits abrogate activity however mixed oligomer eliminate allosteric activation 35 thus data probably explained proposal active site mutations produce local conformational change transmitted adjacent subunit although end result appears differences local conformational changes produced mutating catalytic glutamate mutating zinc coordinating histidine evident observation cleavage profile endorphin altered glutamate mutants histidine mutants
0.5654884.15749695.html.plaintext.txt	63	rather surprising finding mutation either catalytic glutamate zinc coordinating histidine converts substrate velocity curves sigmoidal hyperbolic thus homotropic allosteric activation previously reported us 35 absent mutants since established ide exist oligomeric state 32 35 50 51 one possible explanation active site ide interface two subunits mutation active site residues produces local conformational change affects subunit interaction appear case since 35 perlman et al 42 shown formation oligomers containing active inactive subunits abrogate activity however mixed oligomer eliminate allosteric activation 35 thus data probably explained proposal active site mutations produce local conformational change transmitted adjacent subunit although end result appears differences local conformational changes produced mutating catalytic glutamate mutating zinc coordinating histidine evident observation cleavage profile endorphin altered glutamate mutants histidine mutants
0.5654884.15749695.html.plaintext.txt	64	addition active site mutations affecting kinetics substrate binding mutations also desensitized enzyme activation triphosphates form atp triphosphate large increase activity seen native enzyme significantly reduced either effect less 3 fold increase activity glutamate mutants even amazing effect seen active site histidine mutants particularly h112q case triphosphate changed activator rather potent inhibitor clearly indicates active site mutants conformationally different wild type enzyme modulated additional conformational changes produced binding triphosphate moiety
0.5654884.15749695.html.plaintext.txt	65	addition active site mutations affecting kinetics substrate binding mutations also desensitized enzyme activation triphosphates form atp triphosphate large increase activity seen native enzyme significantly reduced either effect less 3 fold increase activity glutamate mutants even amazing effect seen active site histidine mutants particularly h112q case triphosphate changed activator rather potent inhibitor clearly indicates active site mutants conformationally different wild type enzyme modulated additional conformational changes produced binding triphosphate moiety
0.5654884.15749695.html.plaintext.txt	66	sedimentation equilibrium data show exception h112d mutant native enzyme mutants predominantly monomeric triphosphate affect qualitative oligomerization mechanism soluble enzyme increased tendency form insoluble aggregates case e111a e111f mutants aggregation may reflect conformational change due triphosphate binding thus obvious correlation oligomeric state activity finding monomeric native enzyme consistent allosteric properties hand gel filtration shows native enzyme existing dimers tetramers higher protein concentrations dynamic light scattering shows exclusively tetramers thus clear ide exist number different oligomerization states would suggest allosteric kinetics observed result substrate induced oligomerization case mutant ide perhaps altered local conformational change active site transmitted protein prevents formation oligomers
0.5654884.15749695.html.plaintext.txt	67	sedimentation equilibrium data show exception h112d mutant native enzyme mutants predominantly monomeric triphosphate affect qualitative oligomerization mechanism soluble enzyme increased tendency form insoluble aggregates case e111a e111f mutants aggregation may reflect conformational change due triphosphate binding thus obvious correlation oligomeric state activity finding monomeric native enzyme consistent allosteric properties hand gel filtration shows native enzyme existing dimers tetramers higher protein concentrations dynamic light scattering shows exclusively tetramers thus clear ide exist number different oligomerization states would suggest allosteric kinetics observed result substrate induced oligomerization case mutant ide perhaps altered local conformational change active site transmitted protein prevents formation oligomers
0.5654884.15749695.html.plaintext.txt	68	footnotes work supported part national institute health grants da02243 l b h ag19323 l b h dk54289 m g f grants alzheimers association l b h fundacao de amparo pesquisa estado de sao paulo fapesp l j conselho nacional de desenvolvimento cientifico e tecnologico cnpq l j human frontiers science progress grant rg 000432000 m l j costs publication article defrayed part payment page charges article must therefore hereby marked advertisement accordance 18 usc section 1734 solely indicate fact
0.5654884.15749695.html.plaintext.txt	69	correspondence sent dept molecular cellular biochemistry college medicine university kentucky 800 rose st lexington ky 40536 0084 tel 859 323 5549 fax 859 323 1727 e mail lhershatukyedu u d
0.5654884.15749695.html.plaintext.txt	70	correspondence sent dept molecular cellular biochemistry college medicine university kentucky 800 rose st lexington ky 40536 0084 tel 859 323 5549 fax 859 323 1727 e mail lhershatukyedu u d
0.5654884.15749695.html.plaintext.txt	71	1 abbreviations used amyloid peptides pppi tripolyphosphate ad alzheimer disease ide insulin degrading enzyme hplc high pressure liquid chromatography abz 2 aminobenzoyl eddnp n 24 dinitrophenylethylenediamine
0.5654884.15749695.html.plaintext.txt	72	acknowledgments mass spectral data obtained university kentucky mass spectrometry facility mass spectrometry facility university kentucky center structural biology thank drs dr jack p goodman haining zhu xiaoning lu assisting mass spectral analysis
0.5654884.15749695.html.plaintext.txt	73	references top abstract introduction materials methods results discussion references st george hyslop p h 1993 molecular genetics alzheimers disease raven press new york sherrington r rogaev e liang y rogaeva e levesque g ikeda m chi h lin c li g holman k tsuda mar l foncin j f bruni c montesi m p 1995 nature 375 754 760crossrefmedline order article via infotrieve levy lahad e wasco w poorkaj p romano d m oshima j pettingell w h yu c jondro p d schmidt d wang k crowley c fu y h guenette y galas d nemens e 1995 science 269 973 977medline order article via infotrieve rogaev e sherrington r rogaeva e levesque g ikeda m liang y chi h lin c holman k tsuda mar l sorbi nacmias b piacentini amaducci l 1995 nature 376 775 778crossrefmedline order article via infotrieve leissring m lu condron m m teplow d b stein r l farris w selkoe dj 2003 j biol chem 278 37314 37320abstractfree full text fukumoto h cheung bs hyman b irizarry m c 2002 arch neurol 59 1381 1389abstractfree full text yang l b lindholm k yan r citron m xia w yang x l beach sue l wong p price d li r shen y 2003 nat med 9 3 4crossrefmedline order article via infotrieve li r lindholm k yang l b yue x citron m yan r beach sue l sabbagh m cai h wong p price d shen y 2004 proc natl acad sci u 101 3632 3637abstractfree full text demattos r b bales k r cummins d j dodart j c paul m holtzman d m 2001 proc natl acad sci u 98 8850 8855abstractfree full text demattos r b bales k r cummins d j paul m holtzman d m 2002 science 295 2264 2267abstractfree full text zlokovic b v 2004 j neurochem 89 807 811crossrefmedline order article via infotrieve qiu w q ye z kholodenko d seubert p selkoe d j 1997 j biol chem 272 6641 6646abstractfree full text mukherjee hersh l b 2002 j alzheimers dis 4 341 348medline order article via infotrieve hersh l b 2003 curr pharm des 9 449 454crossrefmedline order article via infotrieve carson j turner j 2002 j neurochem 81 1 8crossrefmedline order article via infotrieve iwata n tsubuki takaki y watanabe k sekiguchi m hosoki e kawashima morishima m lee h j hama e sekine aizawa y saido c 2000 nat med 6 143 150crossrefmedline order article via infotrieve marr r guan h rockenstein e kindy m gage f h verma masliah e hersh l b 2004 j mol neurosci 22 5 12crossrefmedline order article via infotrieve miller b c eckman e sambamurti k dobbs n chow k m eckman c b hersh l b thiele d l 2003 proc natl acad sci u 100 6221 6226abstractfree full text farris w mansourian chang y lindsley l eckman ea frosch mp eckman c b tanzi r e selkoe d j guenette 2003 proc natl acad sci u 100 4162 4167abstractfree full text eckman e reed d k eckman c b 2001 j biol chem 276 24540 24548abstractfree full text eckman e watson m marlow l sambamurti k eckman c b 2003 j biol chem 278 2081 2084abstractfree full text bertram l blacker d mullin k keeney d jones j basu yhu mcinnis m g go r c vekrellis k selkoe d j saunders j tanzi r e 2000 science 290 2302 2303abstractfree full text ertekin taner n graff radford n younkin l h eckman c baker m adamson j ronald j blangero j hutton m younkin g 2000 science 290 2303 2304abstractfree full text ertekin taner n allen m fadale d scanlin l younkin l petersen r c graff radford n younkin g 2004 hum mutat 23 334 342crossrefmedline order article via infotrieve myers holmans p marshall h kwon j meyer d ramic d shears booth j devrieze f w crook r hamshere m abraham r tunstall n rice f carty lillystone kehoe p rudrasingham v jones l lovestone perez tur j williams j owen m j hardy j goate m 2000 science 290 2304 2305abstractfree full text duckworth w c bennett r g hamel f g 1998 endocr rev 19 608 624abstractfree full text seta k roth r 1997 biochem biophys res commun 231 167 171crossrefmedline order article via infotrieve vekrellis k ye z qiu w q walsh d hartley d chesneau v rosner m r selkoe d j 2000 j neurosci 20 1657 1665abstractfree full text qiu w q walsh d m ye z vekrellis k zhang j podlisny m b rosner m r safavi hersh l b selkoe d j 1998 j biol chem 273 32730 32738abstractfree full text farris w mansourian leissring m eckman e bertram l eckman c b tanzi r e selkoe d j 2004 j pathol 164 1425 1434abstractfree full text authier f posner b bergeron j j m 1996 clin invest med 19 149 160medline order article via infotrieve safavi miller b c cottam l hersh l b 1996 biochemistry 35 14318 14325crossrefmedline order article via infotrieve kurochkin v 2001 trends biochem sci 26 421 425crossrefmedline order article via infotrieve mukherjee song e kihiko m goodman j p jr pyrek j estus hersh l b 2000 j neurosci 20 8745 8749abstractfree full text song e juliano m juliano l hersh l b 2003 j biol chem 278 49789 49794abstractfree full text csuhai e juliano m pyrek j harms c juliano l hersh l b 1999 anal biochem 269 149 154crossrefmedline order article via infotrieve perlman r k rosner m r 1994 j biol chem 269 33140 33146abstractfree full text rost b 1996 methods enzymol 266 525 539crossrefmedline order article via infotrieve rost b sander c 1993 j mol biol 232 584 599crossrefmedline order article via infotrieve cohn e j edsall j 1943 proteins amino acids peptides ions dipolar ions pp 370 381 reinhold new york johnson m l correia j j yphantis d halvorson h r 1981 biophys j 36 575 588abstract perlman r k gehm b d kuo w l rosner m r 1993 j biol chem 268 21538 21544abstractfree full text thompson m w govindaswami m hersh l b 2003 arch biochem biophys 413 236 242crossrefmedline order article via infotrieve song es juliano m juliano l fried m g wagner l hersh l b 2004 j biol chem 279 54216 54220abstractfree full text devault nault c zollinger m fournie zaluski m c roques b p crine p boileau g 1988 j biol chem 263 4033 4040abstractfree full text wetterholm medina j f radmark o shapiro r haeggstrom j z vallee b l samuelsson b 1992 proc natl acad sci u 89 9141 9145abstractfree full text vazeux g wang j corvol p llorens cortes c 1996 j biol chem 271 9069 9074abstractfree full text cha j auld d 1997 biochemistry 36 16019 16024crossrefmedline order article via infotrieve kubo m mitsuda y takagi m imanaka 1992 appl environ microbiol 58 3779 3783abstract ding l becker b suzuki roth r 1992 j biol chem 267 2414 2420abstractfree full text shii k yokono k baba roth r 1986 diabetes 36 675 683 article abstract full text pdf versions article 2801817701 recent m501896200v1 purchase article view shopping cart alert article cited alert correction posted citation map services email article friend similar articles journal similar articles pubmed alert new issues journal download citation manager copyright permissions google scholar articles song e articles hersh l b articles citing article pubmed pubmed citation articles song e articles hersh l b
0.5654884.15749695.html.plaintext.txt	74	home help feedback subscriptions archive search table contents asbmb journals molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright 2005 american society biochemistry molecular biology
0.5852807.12941771.html.plaintext.txt	0	insulin degrading enzyme inhibitor decreases amylin degradation increases amylin induced cytotoxicity increases amyloid formation insulinoma cell cultures robert g bennett12 frederick g hamel12 william c duckworth345
0.5852807.12941771.html.plaintext.txt	1	1 department internal medicine university nebraska medical center omaha nebraska 2 department medical research veterans affairs medical center omaha nebraska 3 endocrinology section carl hayden va medical center phoenix arizona 4 molecular cellular biology program arizona state university tempe arizona 5 department medicine university arizona tucson arizona
0.5852807.12941771.html.plaintext.txt	2	1 department internal medicine university nebraska medical center omaha nebraska 2 department medical research veterans affairs medical center omaha nebraska 3 endocrinology section carl hayden va medical center phoenix arizona 4 molecular cellular biology program arizona state university tempe arizona 5 department medicine university arizona tucson arizona
0.5852807.12941771.html.plaintext.txt	3	abstract top abstract research design methods results discussion references amylin islet amyloid polypeptide chief component islet amyloid found type 2 diabetes amylin fibril precursors may cytotoxic pancreatic ss cells little known prevention amylin aggregation investigated role insulin degrading enzyme ide amylin degradation amyloid deposition cytotoxicity rin m5f insulinoma cells human 125i labeled amylin degradation inhibited 46 65 addition 100 nmoll human amylin insulin respectively 125i labeled insulin degradation inhibited 100 nmoll human amylin rat amylin insulin 50 50 73 respectively ide inhibitor bacitracin inhibited amylin degradation 78 insulin degradation 100 amyloid staining congo red fluorescence detectable 100 nmoll amylin pronounced 1000 nmoll amylin treatment 48 h bacitracin treatment markedly increased staining amylin concentrations bacitracin amylin caused dramatic decrease cell viability compared amylin alone 68 25 respectively 10 nmoll amylin summary rin m5f cells degraded amylin insulin common proteolytic pathway ide inhibition bacitracin impaired amylin degradation increased amyloid formation increased amylin induced cytotoxicity suggesting role ide amylin clearance prevention amylin aggregation
0.5852807.12941771.html.plaintext.txt	4	abstract top abstract research design methods results discussion references amylin islet amyloid polypeptide chief component islet amyloid found type 2 diabetes amylin fibril precursors may cytotoxic pancreatic ss cells little known prevention amylin aggregation investigated role insulin degrading enzyme ide amylin degradation amyloid deposition cytotoxicity rin m5f insulinoma cells human 125i labeled amylin degradation inhibited 46 65 addition 100 nmoll human amylin insulin respectively 125i labeled insulin degradation inhibited 100 nmoll human amylin rat amylin insulin 50 50 73 respectively ide inhibitor bacitracin inhibited amylin degradation 78 insulin degradation 100 amyloid staining congo red fluorescence detectable 100 nmoll amylin pronounced 1000 nmoll amylin treatment 48 h bacitracin treatment markedly increased staining amylin concentrations bacitracin amylin caused dramatic decrease cell viability compared amylin alone 68 25 respectively 10 nmoll amylin summary rin m5f cells degraded amylin insulin common proteolytic pathway ide inhibition bacitracin impaired amylin degradation increased amyloid formation increased amylin induced cytotoxicity suggesting role ide amylin clearance prevention amylin aggregation
0.5852807.12941771.html.plaintext.txt	5	type 2 diabetes characterized loss pancreatic ss cell mass accompanied presence islet amyloid deposits pancreas 1 major component islet amyloid amylin also known islet amyloid polypeptide polypeptide copackaged cosecreted insulin pancreatic ss cells 2 presently unclear whether islet amyloid merely consequence diabetes actually contributes progression disease however evidence intermediate precursors amylin fibrils cytotoxic ss cells whereas mature amyloid fibrils toxic suggesting ss cell toxicity may precede deposition islet amyloid 34 amylin continually produced individuals without type 2 diabetes mere presence amylin insufficient induce amylin induced ss cell toxicity islet amyloid transgenic animals producing human amyloidogenic amylin fail develop islet amyloid 5 7 additional diabetic traits introduced islet amyloid detected 8 10 therefore protective mechanism prevents amyloid deposition normal conditions impaired diabetic conditions proteolysis major pathway regulation protein levels degradation amylin may contribute prevention islet amyloid aggregation ss cell toxicity islet amyloid may therefore result imbalance amylin levels impaired degradation amylin present understanding proteolytic pathways contribute degradation amylin incomplete
0.5852807.12941771.html.plaintext.txt	6	type 2 diabetes characterized loss pancreatic ss cell mass accompanied presence islet amyloid deposits pancreas 1 major component islet amyloid amylin also known islet amyloid polypeptide polypeptide copackaged cosecreted insulin pancreatic ss cells 2 presently unclear whether islet amyloid merely consequence diabetes actually contributes progression disease however evidence intermediate precursors amylin fibrils cytotoxic ss cells whereas mature amyloid fibrils toxic suggesting ss cell toxicity may precede deposition islet amyloid 34 amylin continually produced individuals without type 2 diabetes mere presence amylin insufficient induce amylin induced ss cell toxicity islet amyloid transgenic animals producing human amyloidogenic amylin fail develop islet amyloid 5 7 additional diabetic traits introduced islet amyloid detected 8 10 therefore protective mechanism prevents amyloid deposition normal conditions impaired diabetic conditions proteolysis major pathway regulation protein levels degradation amylin may contribute prevention islet amyloid aggregation ss cell toxicity islet amyloid may therefore result imbalance amylin levels impaired degradation amylin present understanding proteolytic pathways contribute degradation amylin incomplete
0.5852807.12941771.html.plaintext.txt	7	enzyme responsible cellular proteolysis insulin insulin degrading enzyme ide 11 substrate specificity ide amyloidogenic polypeptides including atrial natriuretic peptide anp glucagon ss amyloid peptide found alzheimer disease therefore may act scavenger clears amyloidogenic peptides prevent amyloid deposition 1112 recently showed amylin also ide substrate 13 therefore ide may involved controlling levels amylin degradation similar role regulating levels alzheimer related ss amyloid peptide 14 gk rat model type 2 diabetes ide identified diabetes susceptibility gene recently described ide null mice show impaired glucose metabolism models cellular insulin degrading activity found impaired therefore possible diabetes ide dysfunction also results impaired amylin degradation increased amylin aggregation eventually islet amyloid deposition present study performed address following questions 1 amylin insulin degraded ss cells common pathway 2 inhibition ide alter amylin degradation islet amyloid formation 3 ide inhibition affect cytotoxic properties amylin toward ss cells answer questions pancreatic ss cell derived cell line used characterize amylin degradation
0.5852807.12941771.html.plaintext.txt	8	enzyme responsible cellular proteolysis insulin insulin degrading enzyme ide 11 substrate specificity ide amyloidogenic polypeptides including atrial natriuretic peptide anp glucagon ss amyloid peptide found alzheimer disease therefore may act scavenger clears amyloidogenic peptides prevent amyloid deposition 1112 recently showed amylin also ide substrate 13 therefore ide may involved controlling levels amylin degradation similar role regulating levels alzheimer related ss amyloid peptide 14 gk rat model type 2 diabetes ide identified diabetes susceptibility gene recently described ide null mice show impaired glucose metabolism models cellular insulin degrading activity found impaired therefore possible diabetes ide dysfunction also results impaired amylin degradation increased amylin aggregation eventually islet amyloid deposition present study performed address following questions 1 amylin insulin degraded ss cells common pathway 2 inhibition ide alter amylin degradation islet amyloid formation 3 ide inhibition affect cytotoxic properties amylin toward ss cells answer questions pancreatic ss cell derived cell line used characterize amylin degradation
0.5852807.12941771.html.plaintext.txt	9	research design methods top abstract research design methods results discussion references materials human rat amylin purchased bachem torrance ca human amylin radiolabeled 125i cooh terminal purchased peninsula labs san carlos ca 125i insulin mono iodinated 14 position chain biosynthetic human insulin provided lilly research laboratories bacitracin congo red obtained sigma ide specific monoclonal antibody 9b12 15 kindly provided dr richard roth stanford university stanford ca
0.5852807.12941771.html.plaintext.txt	10	research design methods top abstract research design methods results discussion references materials human rat amylin purchased bachem torrance ca human amylin radiolabeled 125i cooh terminal purchased peninsula labs san carlos ca 125i insulin mono iodinated 14 position chain biosynthetic human insulin provided lilly research laboratories bacitracin congo red obtained sigma ide specific monoclonal antibody 9b12 15 kindly provided dr richard roth stanford university stanford ca
0.5852807.12941771.html.plaintext.txt	11	preparation amylin solutions amylin solutions prepared immediately use 1 mgml stock solutions bsa coated test tubes prevent adhesion plastic minimize spontaneous amyloid fibril formation variable amounts contaminating low molecular weight fragments 125i labeled albumin 125i amylin purified adsorption c18 sep pak waters milford ma eluted 01 trifluoroacetic acid acetonitrile eluent lyophilized resuspended original buffer 01 moll sodium phosphate ph 74 containing 005 moll nacl 01 nan3 01 bsa frozen aliquots used
0.5852807.12941771.html.plaintext.txt	12	preparation amylin solutions amylin solutions prepared immediately use 1 mgml stock solutions bsa coated test tubes prevent adhesion plastic minimize spontaneous amyloid fibril formation variable amounts contaminating low molecular weight fragments 125i labeled albumin 125i amylin purified adsorption c18 sep pak waters milford ma eluted 01 trifluoroacetic acid acetonitrile eluent lyophilized resuspended original buffer 01 moll sodium phosphate ph 74 containing 005 moll nacl 01 nan3 01 bsa frozen aliquots used
0.5852807.12941771.html.plaintext.txt	13	cell culture rat insulinoma rin m5f cells 16 purchased american type culture collection maintained rpmi 1640 medium supplemented 10 fetal bovine serum 15 gl sodium bicarbonate 20 gl glucose 1 mmoll l glutamine 10 microgml gentamicin experiments cells subcultured 24 well plates 25 x 105 cellswell medium changed every 2 days used
0.5852807.12941771.html.plaintext.txt	14	cellular degradation amylin insulin degradation amylin insulin rin m5f cells determined trichloroacetic acid tca solubility assay using variation method previously described 17 briefly rin m5f cells 24 well plates changed serum free medium containing 01 bsa 1 h medium removed 125i amylin 125i labeled insulin serum free medium containing 01 bsa added 20000 cpmml cells incubated 37 degrees c times indicated experiments bacitracin included 1 mgml medium removed brought 02 bsa 16 tca chilled 10 min ice centrifuged 3000g 15 min radioactivity supernatants pellets counted degrading activity expressed percent tca soluble counts addition conditioned medium cells removed aliquots tested degrading activity tca solubility described
0.5852807.12941771.html.plaintext.txt	15	cellular degradation amylin insulin degradation amylin insulin rin m5f cells determined trichloroacetic acid tca solubility assay using variation method previously described 17 briefly rin m5f cells 24 well plates changed serum free medium containing 01 bsa 1 h medium removed 125i amylin 125i labeled insulin serum free medium containing 01 bsa added 20000 cpmml cells incubated 37 degrees c times indicated experiments bacitracin included 1 mgml medium removed brought 02 bsa 16 tca chilled 10 min ice centrifuged 3000g 15 min radioactivity supernatants pellets counted degrading activity expressed percent tca soluble counts addition conditioned medium cells removed aliquots tested degrading activity tca solubility described
0.5852807.12941771.html.plaintext.txt	16	immunodetection ide lysates prepared rin m5f cells lysis buffer 50 mmoll tris ph 74 containing 015 moll nacl 1 triton x 100 01 mmoll phenylmethylsulfonyl fluoride aliquots 10 microg total protein resolved 75 sds page transferred polyvinylidine fluoride membranes immunodetection membranes probed 9b12 monoclonal antibody directed ide 11000 dilution 1 h room temperature probed peroxidase conjugated goat anti mouse igg jackson immunochemicals temecula ca 15000 dilution 1 h immunoreactive proteins detected chemiluminescence
0.5852807.12941771.html.plaintext.txt	17	amyloid formation rin m5f cultures rin m5f cells seeded onto poly l lysine coated eight well glass chamber slides 105 cellscm2 medium changed serum free rpmi 1640 containing 01 bsa treatment cells treated human amylin 001 10 micromoll 48 h experiments bacitracin included 1 mgml determine involvement ide like proteolytic activity islet amyloid formation cells also treated ide inhibitor bacitracin 1 mgml time amylin addition treatment cells washed pbs fixed 5 min 4 buffered formalin stained amyloid using modified congo red staining procedure 18 briefly samples counterstained weigert iron hematoxylin 15 rinsed placed 05 hcl 70 ethanol 5 washed samples stained congo red 20 min samples immediately dehydrated xylene mounted degree amyloid formation determined fluorescence microscopy using tetramethyl rhodamine isothiocyanate filter set
0.5852807.12941771.html.plaintext.txt	18	amyloid formation rin m5f cultures rin m5f cells seeded onto poly l lysine coated eight well glass chamber slides 105 cellscm2 medium changed serum free rpmi 1640 containing 01 bsa treatment cells treated human amylin 001 10 micromoll 48 h experiments bacitracin included 1 mgml determine involvement ide like proteolytic activity islet amyloid formation cells also treated ide inhibitor bacitracin 1 mgml time amylin addition treatment cells washed pbs fixed 5 min 4 buffered formalin stained amyloid using modified congo red staining procedure 18 briefly samples counterstained weigert iron hematoxylin 15 rinsed placed 05 hcl 70 ethanol 5 washed samples stained congo red 20 min samples immediately dehydrated xylene mounted degree amyloid formation determined fluorescence microscopy using tetramethyl rhodamine isothiocyanate filter set
0.5852807.12941771.html.plaintext.txt	19	cell toxicity assessment cell toxicity studies rin m5f cells cultured 96 well plates treated human rat amylin without bacitracin described 48 h cell viability measured reduction methylthiazolyldiphenyl tetrazolium bromide mtt previously described 19
0.5852807.12941771.html.plaintext.txt	20	statistics data expressed means plus minus se degradation assays comparisons differences groups made one way anova dunnett posttest degradation assays two way anova bonferroni posttest viability assay p 005 interpreted significant analyses made using graphpad prism3 software package
0.5852807.12941771.html.plaintext.txt	21	results top abstract research design methods results discussion references amylin insulin degradation rin m5f cells examined time amount degradation limited 20 remain within linear range assay degradation 125i amylin reached 20 30 min fig 1 contrast 125i insulin degraded much slowly required 120 min incubation reach 20 degradation fig 2 addition either unlabeled amylin insulin reaction decreased degradation substrates indicating common degradative pathway addition ide inhibitor bacitracin essentially eliminated degradation amylin insulin cells detectable amylin insulin degrading activity conditioned medium data shown suggesting degradation caused uptake intracellular degradation presence ide readily detected cells immunoreactive band 110 kda fig 2 therefore rin m5f cells possess mechanisms internalize degrade insulin amylin express ide
0.5852807.12941771.html.plaintext.txt	22	results top abstract research design methods results discussion references amylin insulin degradation rin m5f cells examined time amount degradation limited 20 remain within linear range assay degradation 125i amylin reached 20 30 min fig 1 contrast 125i insulin degraded much slowly required 120 min incubation reach 20 degradation fig 2 addition either unlabeled amylin insulin reaction decreased degradation substrates indicating common degradative pathway addition ide inhibitor bacitracin essentially eliminated degradation amylin insulin cells detectable amylin insulin degrading activity conditioned medium data shown suggesting degradation caused uptake intracellular degradation presence ide readily detected cells immunoreactive band 110 kda fig 2 therefore rin m5f cells possess mechanisms internalize degrade insulin amylin express ide
0.5852807.12941771.html.plaintext.txt	23	view larger version 22k fig 1 amylin degradation rin m5f cells time degradation amylin rin m5f cells time measured production acid soluble products 125i amylin cell culture media cells also treated 01 micromoll unlabeled amylin insulin ide inhibitor bacitracin 1 mgml data expressed percent acid soluble products produced n 3 treatment amylin insulin bacitracin
0.5852807.12941771.html.plaintext.txt	24	view larger version 20k fig 2 insulin degradation rin m5f cells time degradation insulin rin m5f cells time measured production acid soluble products 125i insulin cell culture media cells also treated 01 micromoll unlabeled amylin insulin ide inhibitor bacitracin 1 mgml data expressed percent acid soluble products produced n 3 treatment amylin insulin bacitracin b lysates rin m5f probed ide specific monoclonal antibody 9b12 immunoreactive proteins detected chemiluminescence single band 110 kda detected consistent presence ide
0.5852807.12941771.html.plaintext.txt	25	characterize amylin insulin degradation rin m5f cells degradation measured increasing dosages unlabeled competitor degradation 125i amylin decreased dosage dependent manner either unlabeled insulin amylin fig 3 concentrations unlabeled insulin effective inhibitor amylin similarly degradation 125i insulin inhibited amylin insulin fig 4 insulin generally effective inhibitor observations consistent previously determined enzymatic properties ide insulin three sixfold higher affinity purified ide amylin 13 two possible complications cell culture system potential direct interaction human amylin insulin 20 membrane perturbations may impede receptor mediated uptake substrates 3 rat amylin also ide substrate 13 interact insulin cause membrane disruption rat amylin 100 nmoll inhibited insulin degradation 497 plus minus 12 baseline insulin degradation result similar found human amylin indicating reciprocal inhibition amylin insulin degradation attributable common pathway proteolysis
0.5852807.12941771.html.plaintext.txt	26	characterize amylin insulin degradation rin m5f cells degradation measured increasing dosages unlabeled competitor degradation 125i amylin decreased dosage dependent manner either unlabeled insulin amylin fig 3 concentrations unlabeled insulin effective inhibitor amylin similarly degradation 125i insulin inhibited amylin insulin fig 4 insulin generally effective inhibitor observations consistent previously determined enzymatic properties ide insulin three sixfold higher affinity purified ide amylin 13 two possible complications cell culture system potential direct interaction human amylin insulin 20 membrane perturbations may impede receptor mediated uptake substrates 3 rat amylin also ide substrate 13 interact insulin cause membrane disruption rat amylin 100 nmoll inhibited insulin degradation 497 plus minus 12 baseline insulin degradation result similar found human amylin indicating reciprocal inhibition amylin insulin degradation attributable common pathway proteolysis
0.5852807.12941771.html.plaintext.txt	27	view larger version 38k fig 3 amylin degradation rin m5f cells degradation amylin rin m5f cells measured production acid soluble products 125i amylin cell culture media cells also treated indicated concentrations nmoll unlabeled amylin unlabeled insulin data expressed percent acid soluble products produced n 6 p 005 p 0001
0.5852807.12941771.html.plaintext.txt	28	view larger version 37k fig 4 insulin degradation rin m5f cells degradation insulin rin m5f cells measured production acid soluble products 125i amylin cell culture media cells also treated indicated concentrations nmoll unlabeled amylin unlabeled insulin data expressed percent acid soluble products produced n 6 p 0001
0.5852807.12941771.html.plaintext.txt	29	amylin produced healthy individuals without formation islet amyloid mechanism must place prevent amylin aggregation normal conditions examine whether cellular degradation ide may contribute protective process cell culture system study islet amyloid formation developed rin m5f cells cultured poly l lysine coated glass chamber slides 3 days culture treated human amylin 10 1000 nmoll 48 h amyloid detected modified congo red fluorescence staining method 18 includes acidic iron hematoxylin counterstain minimizes intense autofluorescence seen using original method 21 human amylin induced dosage dependent increase staining detectable 100 nmoll pronounced 1 micromoll fig 5 finding demonstrated exogenous human amylin form amyloid deposits rin m5f cell cultures cells treated ide inhibitor bacitracin amyloid staining markedly increased intensity amylin concentrations compared cells without bacitracin including lowest amylin concentration 10 nmoll findings suggest impairment cells ability clear amylin protease characteristics consistent ide
0.5852807.12941771.html.plaintext.txt	30	amylin produced healthy individuals without formation islet amyloid mechanism must place prevent amylin aggregation normal conditions examine whether cellular degradation ide may contribute protective process cell culture system study islet amyloid formation developed rin m5f cells cultured poly l lysine coated glass chamber slides 3 days culture treated human amylin 10 1000 nmoll 48 h amyloid detected modified congo red fluorescence staining method 18 includes acidic iron hematoxylin counterstain minimizes intense autofluorescence seen using original method 21 human amylin induced dosage dependent increase staining detectable 100 nmoll pronounced 1 micromoll fig 5 finding demonstrated exogenous human amylin form amyloid deposits rin m5f cell cultures cells treated ide inhibitor bacitracin amyloid staining markedly increased intensity amylin concentrations compared cells without bacitracin including lowest amylin concentration 10 nmoll findings suggest impairment cells ability clear amylin protease characteristics consistent ide
0.5852807.12941771.html.plaintext.txt	31	view larger version 75k fig 5 bacitracin increases amyloid deposition rin m5f cells rin m5f cells treated 0 10 100 1000 nmoll human amylin indicated cells cultured absence left presence right ide inhibitor bacitracin bac deposition islet amyloid detected congo red fluorescence brightfield exposures cells shown insets magnification x100
0.5852807.12941771.html.plaintext.txt	32	amylin implicated ss cell toxicity effect ide inhibition rin m5f cell viability determined mtt reduction fig 6 treatment human amylin 48 h decreased cell viability dosage dependent manner peaking 44 1000 nmoll amylin presence bacitracin cell viability markedly lower amylin concentrations reaching maximum reduction 68 10 nmoll amylin conversely rat amylin effect viability whether without bacitracin therefore ide inhibitor increased ability amylin reduce rin m5f cell viability
0.5852807.12941771.html.plaintext.txt	33	view larger version 24k fig 6 bacitracin increases amylin induced cytotoxicity rin m5f cells treated 0 10 100 1000 nmoll human amylin 1000 nmoll rat amylin indicated cells cultured absence presence ide inhibitor bacitracin cell toxicity assessed degree mtt reduction cells n 6 p 001
0.5852807.12941771.html.plaintext.txt	34	discussion top abstract research design methods results discussion references pathologic feature type 2 diabetes presence islet amyloid deposits composed predominantly amylin 1 whether islet amyloid merely marker type 2 diabetes actually contributes disease matter discussion several lines evidence suggest association presence islet amyloid diabetes reduced ss cell mass monkeys formation islet amyloid correlates early reduced insulin secretion glucose intolerance time correlates greater deficiency insulin secretion glucose tolerance ultimately hyperglycemia 22 humans degree amyloid formation correlates severity diabetes evidenced requirement insulin replacement therapy 2324 evidence suggests ss cell death caused intermediate sized fibrils precursors islet amyloid 34 case islet amyloid deposits reflect end stage effect amylin aggregation secondary ss cell death
0.5852807.12941771.html.plaintext.txt	35	discussion top abstract research design methods results discussion references pathologic feature type 2 diabetes presence islet amyloid deposits composed predominantly amylin 1 whether islet amyloid merely marker type 2 diabetes actually contributes disease matter discussion several lines evidence suggest association presence islet amyloid diabetes reduced ss cell mass monkeys formation islet amyloid correlates early reduced insulin secretion glucose intolerance time correlates greater deficiency insulin secretion glucose tolerance ultimately hyperglycemia 22 humans degree amyloid formation correlates severity diabetes evidenced requirement insulin replacement therapy 2324 evidence suggests ss cell death caused intermediate sized fibrils precursors islet amyloid 34 case islet amyloid deposits reflect end stage effect amylin aggregation secondary ss cell death
0.5852807.12941771.html.plaintext.txt	36	factors prevent amylin fibril formation ss cell death islet amyloid deposition nondisease state understood amylin continually produced nondiabetic humans amyloid formation mere presence amylin insufficient cause fibril formation indeed transgenic animals overexpressing human amylin form amyloid deposits 5 725 confirming elevated amylin levels alone insufficient amyloid formation however diabetic conditions introduced ob mutation growth hormonesteroid treatment high fat diet animals develop islet amyloid islet dysfunction reduced insulin secretion hyperglycemia 8 10 therefore type 2 diabetes balance shifts amylin clearance deposition either increased amounts factor promotes amylin aggregation decreased amounts factor clears amylin although numerous studies regarding amylin synthesis secretion present studies amylin degradation
0.5852807.12941771.html.plaintext.txt	37	factors prevent amylin fibril formation ss cell death islet amyloid deposition nondisease state understood amylin continually produced nondiabetic humans amyloid formation mere presence amylin insufficient cause fibril formation indeed transgenic animals overexpressing human amylin form amyloid deposits 5 725 confirming elevated amylin levels alone insufficient amyloid formation however diabetic conditions introduced ob mutation growth hormonesteroid treatment high fat diet animals develop islet amyloid islet dysfunction reduced insulin secretion hyperglycemia 8 10 therefore type 2 diabetes balance shifts amylin clearance deposition either increased amounts factor promotes amylin aggregation decreased amounts factor clears amylin although numerous studies regarding amylin synthesis secretion present studies amylin degradation
0.5852807.12941771.html.plaintext.txt	38	enzyme responsible intracellular degradation insulin ide cytosolic metallothioprotease also known insulysin 1126 primary function ide mammalian tissues traditionally thought degradation insulin number proteins identified ide substrates including proteins structurally related insulin proinsulin igf ii relaxin seemingly unrelated peptides anp glucagon 11 however insulin anp glucagon contain regions form ss pleated sheets potentially amyloid forming 27 proposed rather targeting primary sequence motif ide specific toward amyloidogenic peptides 28 concept supported findings ide also degrades amylin ss amyloid peptide 132930 recent studies supported role ide type 2 diabetes alzheimer disease two conditions characterized amyloid possible genetic linkages type 2 diabetes alzheimer disease mapped chromosomal region ide gene 31 34 gk rat model type 2 diabetes ide identified diabetes susceptibility gene mutations associated model result lower cellular insulin degradation hyperglycemia reduced lipogenesis fat cells reduced glucose uptake vivo 35 recently described ide null mouse model displays impaired insulin ss amyloid degradation well hyperinsulinemia glucose intolerance cerebral accumulation ss amyloid hallmarks type 2 diabetes alzheimer disease 36 thus evidence mounting ide plays major role diseases characterized amyloid formation
0.5852807.12941771.html.plaintext.txt	39	enzyme responsible intracellular degradation insulin ide cytosolic metallothioprotease also known insulysin 1126 primary function ide mammalian tissues traditionally thought degradation insulin number proteins identified ide substrates including proteins structurally related insulin proinsulin igf ii relaxin seemingly unrelated peptides anp glucagon 11 however insulin anp glucagon contain regions form ss pleated sheets potentially amyloid forming 27 proposed rather targeting primary sequence motif ide specific toward amyloidogenic peptides 28 concept supported findings ide also degrades amylin ss amyloid peptide 132930 recent studies supported role ide type 2 diabetes alzheimer disease two conditions characterized amyloid possible genetic linkages type 2 diabetes alzheimer disease mapped chromosomal region ide gene 31 34 gk rat model type 2 diabetes ide identified diabetes susceptibility gene mutations associated model result lower cellular insulin degradation hyperglycemia reduced lipogenesis fat cells reduced glucose uptake vivo 35 recently described ide null mouse model displays impaired insulin ss amyloid degradation well hyperinsulinemia glucose intolerance cerebral accumulation ss amyloid hallmarks type 2 diabetes alzheimer disease 36 thus evidence mounting ide plays major role diseases characterized amyloid formation
0.5852807.12941771.html.plaintext.txt	40	previous study using cell free extracts 13 ide readily degraded amylin lower affinity insulin radiolabeled amylin covalently cross linked ide monoclonal antibody directed ide immunoprecipitated insulin amylin degrading activities confirming ide amylin degrading protease extended findings rat ss cell derived line amylin insulin degraded rin m5f cells insulin degraded much slowly possible reasons observation include differences binding internalization different receptors differences receptor availability eg desensitization cell toxicity differences may also attributed nature assay unlike amylin multiple cleavages required produce tca soluble fragments insulin therefore assay tends underestimate level insulin degradation amylin degradation began quickly leveled time probable explanation observation based insulin secretion cells cells changed fresh media containing labeled substrates initially endogenously produced insulin media rin cells rapidly secreted insulin reaching 5 10 nmoll 1 h would act competitive inhibitor amylin degradation amylin present tracer amounts sufficient insulin competitively inhibit amylin degradation may well produced within 30 min insulin amylin capable competitive inhibition either substrate insulin general better competitive inhibitor amylin discussed likely attributable greater affinity insulin ide possibly also different internalization properties insulin amylin efficiency unlabeled insulin inhibition insulin degradation consistent previous reports showing 50 inhibition 50 100 nmoll insulin using rin m5f cells 37 taken together data suggest insulin amylin share common pathway degradation
0.5852807.12941771.html.plaintext.txt	41	previous study using cell free extracts 13 ide readily degraded amylin lower affinity insulin radiolabeled amylin covalently cross linked ide monoclonal antibody directed ide immunoprecipitated insulin amylin degrading activities confirming ide amylin degrading protease extended findings rat ss cell derived line amylin insulin degraded rin m5f cells insulin degraded much slowly possible reasons observation include differences binding internalization different receptors differences receptor availability eg desensitization cell toxicity differences may also attributed nature assay unlike amylin multiple cleavages required produce tca soluble fragments insulin therefore assay tends underestimate level insulin degradation amylin degradation began quickly leveled time probable explanation observation based insulin secretion cells cells changed fresh media containing labeled substrates initially endogenously produced insulin media rin cells rapidly secreted insulin reaching 5 10 nmoll 1 h would act competitive inhibitor amylin degradation amylin present tracer amounts sufficient insulin competitively inhibit amylin degradation may well produced within 30 min insulin amylin capable competitive inhibition either substrate insulin general better competitive inhibitor amylin discussed likely attributable greater affinity insulin ide possibly also different internalization properties insulin amylin efficiency unlabeled insulin inhibition insulin degradation consistent previous reports showing 50 inhibition 50 100 nmoll insulin using rin m5f cells 37 taken together data suggest insulin amylin share common pathway degradation
0.5852807.12941771.html.plaintext.txt	42	specificity amylin insulin degrading activity investigated using ide inhibitor bacitracin although bacitracin specific inhibitor ide ide inhibitors eg n ethylmaleimide 110 phenanthroline highly toxic rin m5f cells rgb unpublished observations whereas bacitracin well tolerated cells amylin insulin degradation rin m5f cells markedly inhibited bacitracin bacitracin also accelerated islet amyloid formation amylin concentrations suggesting inhibition amylin degradation accelerates amylin aggregation amyloid deposition amylin implicated ss cell death cell viability examined conditions cytotoxicity induced human amylin markedly increased bacitracin treatment whereas rat amylin effect suggesting amylin degradation responsible reducing cell toxicity caused amylin amylin induced cytotoxicity ss cells shown caused intermediate amylin precursors rather mature amyloid 3 ide degrades amylin monomers formation intermediate precursors amyloid fibrils would prevented experiments performed 48 h treatment freshly prepared amylin cannot determine amylin species caused toxicity rin cells however degree cell death seen bacitracin treatment increased maximum attained even lowest amylin concentration could mean toxicity preceded amyloid deposition although amylin concentration required detection amyloid cell toxicity 10 100 nmoll high relative circulating levels local amylin concentration around ss cells unknown may well higher especially conditions stimulate insulin amylin secretion
0.5852807.12941771.html.plaintext.txt	43	specificity amylin insulin degrading activity investigated using ide inhibitor bacitracin although bacitracin specific inhibitor ide ide inhibitors eg n ethylmaleimide 110 phenanthroline highly toxic rin m5f cells rgb unpublished observations whereas bacitracin well tolerated cells amylin insulin degradation rin m5f cells markedly inhibited bacitracin bacitracin also accelerated islet amyloid formation amylin concentrations suggesting inhibition amylin degradation accelerates amylin aggregation amyloid deposition amylin implicated ss cell death cell viability examined conditions cytotoxicity induced human amylin markedly increased bacitracin treatment whereas rat amylin effect suggesting amylin degradation responsible reducing cell toxicity caused amylin amylin induced cytotoxicity ss cells shown caused intermediate amylin precursors rather mature amyloid 3 ide degrades amylin monomers formation intermediate precursors amyloid fibrils would prevented experiments performed 48 h treatment freshly prepared amylin cannot determine amylin species caused toxicity rin cells however degree cell death seen bacitracin treatment increased maximum attained even lowest amylin concentration could mean toxicity preceded amyloid deposition although amylin concentration required detection amyloid cell toxicity 10 100 nmoll high relative circulating levels local amylin concentration around ss cells unknown may well higher especially conditions stimulate insulin amylin secretion
0.5852807.12941771.html.plaintext.txt	44	summary rin m5f cells clear amylin bacitracin sensitive mechanism properties consistent ide inhibition mechanism increased amyloid formation cell toxicity data consistent emerging concept role ide diseases characterized amyloid regard interesting note transgenic animals expressing human amylin general develop islet amyloid unless diabetic conditions introduced one conditions high fat diet 9 interestingly shown increased lipid levels result impaired insulin degradation 38 free fatty acids directly inhibit ide activity 39 combination increased expression amyloidogenic amylin impaired insulin degrading activity may result formation islet amyloid models therefore possible conditions leading impaired ide activity eg elevated free fatty acids contribute amylin accumulation aggregation ss cell toxicity islet amyloid formation progression type 2 diabetes
0.5852807.12941771.html.plaintext.txt	45	summary rin m5f cells clear amylin bacitracin sensitive mechanism properties consistent ide inhibition mechanism increased amyloid formation cell toxicity data consistent emerging concept role ide diseases characterized amyloid regard interesting note transgenic animals expressing human amylin general develop islet amyloid unless diabetic conditions introduced one conditions high fat diet 9 interestingly shown increased lipid levels result impaired insulin degradation 38 free fatty acids directly inhibit ide activity 39 combination increased expression amyloidogenic amylin impaired insulin degrading activity may result formation islet amyloid models therefore possible conditions leading impaired ide activity eg elevated free fatty acids contribute amylin accumulation aggregation ss cell toxicity islet amyloid formation progression type 2 diabetes
0.5852807.12941771.html.plaintext.txt	46	acknowledgments work supported us department veterans affairs research service bly memorial research fund university nebraska medical center
0.5852807.12941771.html.plaintext.txt	47	address correspondence reprint requests robert g bennett phd research service 151 veterans affairs medical center 4101 woolworth ave omaha ne 68105 e mail rgbennetatunmcedu
0.5852807.12941771.html.plaintext.txt	48	address correspondence reprint requests robert g bennett phd research service 151 veterans affairs medical center 4101 woolworth ave omaha ne 68105 e mail rgbennetatunmcedu
0.5852807.12941771.html.plaintext.txt	49	received publication january 15 2003 accepted revised form june 3 2003
0.5852807.12941771.html.plaintext.txt	50	anp atrial natriuretic peptide ide insulin degrading enzyme mtt methylthiazolyldiphenyl tetrazolium bromide tca trichloroacetic acid
0.5852807.12941771.html.plaintext.txt	51	references top abstract research design methods results discussion references kahn se andrikopoulos verchere cb islet amyloid long recognized underappreciated pathological feature type 2 diabetesdiabetes48241 2531999abstractfree full text kahn se d alessio da schwartz mw fujimoto wy ensinck jw taborsky gj jr porte d jr evidence cosecretion islet amyloid polypeptide insulin beta cellsdiabetes39634 6381990abstract janson j ashley rh harrison d mcintyre butler pc mechanism islet amyloid polypeptide toxicity membrane disruption intermediate sized toxic amyloid particlesdiabetes48491 4981999abstract janson j soeller wc roche pc nelson rt torchia aj kreutter dk butler pc spontaneous diabetes mellitus transgenic mice expressing human islet amyloid polypeptideproc natl acad sci u a937283 72881996abstractfree full text verchere cb d alessio da wang andrikopoulos kahn se transgenic overproduction islet amyloid polypeptide amylin sufficient islet amyloid formationhorm metab res29311 3161997medline hoppener jw verbeek js de koning ej oosterwijk c van hulst kl visser vernooy hj hofhuis fm van gaalen berends mj hackeng wh et al chronic overproduction islet amyloid polypeptideamylin transgenic mice lysosomal localization human islet amyloid polypeptide lack marked hyperglycaemia hyperinsulinaemiadiabetologia361258 12651993medline fox n schrementi j nishi m ohagi chan sj heisserman ja westermark gt leckstrom westermark p steiner df human islet amyloid polypeptide transgenic mice model non insulin dependent diabetes mellitus niddmfebs lett32340 441993medline couce m kane la o brien td charlesworth j soeller w mcneish j kreutter d roche p butler pc treatment growth hormone dexamethasone mice transgenic human islet amyloid polypeptide causes islet amyloidosis beta cell dysfunctiondiabetes451094 11011996abstract verchere cb d alessio da palmiter rd weir gc bonner weir baskin dg kahn se islet amyloid formation associated hyperglycemia transgenic mice pancreatic beta cell expression human islet amyloid polypeptideproc natl acad sci u a933492 34961996abstractfree full text hoppener jw oosterwijk c nieuwenhuis mg posthuma g thijssen jh vroom tm ahren b lips cj extensive islet amyloid formation induced development type ii diabetes mellitus contributes progression pathogenesis diabetes mouse modeldiabetologia42427 4341999medline duckworth wc bennett rg hamel fg insulin degradation progress potentialendocr rev19608 6241998abstractfree full text kurochkin iv insulin degrading enzyme embarking amyloid destructiontrends biochem sci26421 4252001medline bennett rg duckworth wc hamel fg degradation amylin insulin degrading enzymej biol chem27536621 366252000abstractfree full text vekrellis k ye z qiu wq walsh d hartley d chesneau v rosner mr selkoe dj neurons regulate extracellular levels amyloid beta protein via proteolysis insulin degrading enzymej neurosci201657 16652000abstractfree full text shii k roth ra inhibition insulin degradation hepatoma cells microinjection monoclonal antibodies specific cytosolic proteaseproc natl acad sci u a834147 41511986abstract bhathena sj oie hk gazdar af voyles nr wilkins sd recant l insulin glucagon somatostatin receptors cultured cells clones rat islet cell tumordiabetes31521 5311982abstract peavy de edmondson jw duckworth wc selective effects inhibitors hormone processing insulin action isolated hepatocytesendocrinology114753 7601984abstract churukian cj improved puchtler congo red method demonstrating amyloidj histotechnol23139 1412000 hansen mb nielsen se berg k re examination development precise rapid dye method measuring cell growthcell killj immunol methods119203 2101989medline westermark p li zc westermark gt leckstrom steiner df effects beta cell granule components human islet amyloid polypeptide fibril formationfebs lett379203 2061996medline puchtler h sweat f levine m binding congo red amyloidj histochem cytochem10355 3641962 howard cf longitudinal studies development diabetes individual macaca nigradiabetologia29301 3061986medline kahn se verchere cb andrikopoulos asberry pj leonetti dl wahl pw boyko ej schwartz rs newell morris l fujimoto wy reduced amylin release characteristic impaired glucose tolerance type 2 diabetes japanese americansdiabetes47640 6451998abstract westermark p amyloid polypeptide hormones relationshipamyloid147 601994 d alessio da verchere cb kahn se hoagland v baskin dg palmiter rd ensinck jw pancreatic expression secretion human islet amyloid polypeptide transgenic mousediabetes431457 14611994abstract becker ab roth ra insulysin pitrilysin insulin degrading enzymes mammals bacteriameth enzymol248693 7031995medline sipe jd amyloidosisannu rev biochem61947 9751992medline kurochkin iv amyloidogenic determinant substrate recognition motif insulin degrading enzymefebs lett427153 1561998medline goto kurochkin iv alzheimer ss amyloid peptide interacts degraded insulin degrading enzymefebs lett34533 371994medline qiu wq walsh dm ye z vekrellis k zhang j podlisny mb rosner mr safavi hersh lb selkoe dj insulin degrading enzyme regulates extracellular levels amyloid beta protein degradationj biol chem27332730 327381998abstractfree full text wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n rao pv wishart m bottazzo gf foxon r howell smedley d cardon lr menzel mccarthy mi genomewide scan loci predisposing type 2 diabetes uk population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1qam j hum genet69553 5692001medline bertram l blacker d mullin k keeney d jones j basu yhu mcinnis mg go rc vekrellis k selkoe dj saunders aj tanzi re evidence genetic linkage alzheimer disease chromosome 10qscience2902302 23032000abstractfree full text myers holmans p marshall h kwon j meyer d ramic d shears booth j devrieze fw crook r hamshere m abraham r tunstall n rice f carty lillystone kehoe p rudrasingham v jones l lovestone perez tur j williams j owen mj hardy j goate susceptibility locus alzheimer disease chromosome 10science2902304 23052000abstractfree full text ertekin taner n graff radford n younkin lh eckman c baker m adamson j ronald j blangero j hutton m younkin sg linkage plasma abeta42 quantitative locus chromosome 10 late onset alzheimer disease pedigreesscience2902303 23042000abstractfree full text fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk ratshum mol genet92149 21582000abstractfree full text farris w mansourian chang y lindsley l eckman ea frosch mp eckman cb tanzi re selkoe dj guenette insulin degrading enzyme regulates levels insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivoproc natl acad sci u a1004162 41672003abstractfree full text bhathena sj timmers ki oie hk voyles nr recant l cytosolic insulin degrading activity islet derived tumor cell lines normal rat isletsdiabetes34121 1281985abstract oehler g bleyl h matthes kj hyperinsulinemia hepatic steatosisint j obe relat metab disord6 suppl 1137 1441982 hamel fg upward jl bennett rg vitro inhibition insulin degrading enzyme long chain fatty acids coenzyme thioestersendocrinology1442404 24082003abstractfree full text
0.5852807.12941771.html.plaintext.txt	52	references top abstract research design methods results discussion references kahn se andrikopoulos verchere cb islet amyloid long recognized underappreciated pathological feature type 2 diabetesdiabetes48241 2531999abstractfree full text kahn se d alessio da schwartz mw fujimoto wy ensinck jw taborsky gj jr porte d jr evidence cosecretion islet amyloid polypeptide insulin beta cellsdiabetes39634 6381990abstract janson j ashley rh harrison d mcintyre butler pc mechanism islet amyloid polypeptide toxicity membrane disruption intermediate sized toxic amyloid particlesdiabetes48491 4981999abstract janson j soeller wc roche pc nelson rt torchia aj kreutter dk butler pc spontaneous diabetes mellitus transgenic mice expressing human islet amyloid polypeptideproc natl acad sci u a937283 72881996abstractfree full text verchere cb d alessio da wang andrikopoulos kahn se transgenic overproduction islet amyloid polypeptide amylin sufficient islet amyloid formationhorm metab res29311 3161997medline hoppener jw verbeek js de koning ej oosterwijk c van hulst kl visser vernooy hj hofhuis fm van gaalen berends mj hackeng wh et al chronic overproduction islet amyloid polypeptideamylin transgenic mice lysosomal localization human islet amyloid polypeptide lack marked hyperglycaemia hyperinsulinaemiadiabetologia361258 12651993medline fox n schrementi j nishi m ohagi chan sj heisserman ja westermark gt leckstrom westermark p steiner df human islet amyloid polypeptide transgenic mice model non insulin dependent diabetes mellitus niddmfebs lett32340 441993medline couce m kane la o brien td charlesworth j soeller w mcneish j kreutter d roche p butler pc treatment growth hormone dexamethasone mice transgenic human islet amyloid polypeptide causes islet amyloidosis beta cell dysfunctiondiabetes451094 11011996abstract verchere cb d alessio da palmiter rd weir gc bonner weir baskin dg kahn se islet amyloid formation associated hyperglycemia transgenic mice pancreatic beta cell expression human islet amyloid polypeptideproc natl acad sci u a933492 34961996abstractfree full text hoppener jw oosterwijk c nieuwenhuis mg posthuma g thijssen jh vroom tm ahren b lips cj extensive islet amyloid formation induced development type ii diabetes mellitus contributes progression pathogenesis diabetes mouse modeldiabetologia42427 4341999medline duckworth wc bennett rg hamel fg insulin degradation progress potentialendocr rev19608 6241998abstractfree full text kurochkin iv insulin degrading enzyme embarking amyloid destructiontrends biochem sci26421 4252001medline bennett rg duckworth wc hamel fg degradation amylin insulin degrading enzymej biol chem27536621 366252000abstractfree full text vekrellis k ye z qiu wq walsh d hartley d chesneau v rosner mr selkoe dj neurons regulate extracellular levels amyloid beta protein via proteolysis insulin degrading enzymej neurosci201657 16652000abstractfree full text shii k roth ra inhibition insulin degradation hepatoma cells microinjection monoclonal antibodies specific cytosolic proteaseproc natl acad sci u a834147 41511986abstract bhathena sj oie hk gazdar af voyles nr wilkins sd recant l insulin glucagon somatostatin receptors cultured cells clones rat islet cell tumordiabetes31521 5311982abstract peavy de edmondson jw duckworth wc selective effects inhibitors hormone processing insulin action isolated hepatocytesendocrinology114753 7601984abstract churukian cj improved puchtler congo red method demonstrating amyloidj histotechnol23139 1412000 hansen mb nielsen se berg k re examination development precise rapid dye method measuring cell growthcell killj immunol methods119203 2101989medline westermark p li zc westermark gt leckstrom steiner df effects beta cell granule components human islet amyloid polypeptide fibril formationfebs lett379203 2061996medline puchtler h sweat f levine m binding congo red amyloidj histochem cytochem10355 3641962 howard cf longitudinal studies development diabetes individual macaca nigradiabetologia29301 3061986medline kahn se verchere cb andrikopoulos asberry pj leonetti dl wahl pw boyko ej schwartz rs newell morris l fujimoto wy reduced amylin release characteristic impaired glucose tolerance type 2 diabetes japanese americansdiabetes47640 6451998abstract westermark p amyloid polypeptide hormones relationshipamyloid147 601994 d alessio da verchere cb kahn se hoagland v baskin dg palmiter rd ensinck jw pancreatic expression secretion human islet amyloid polypeptide transgenic mousediabetes431457 14611994abstract becker ab roth ra insulysin pitrilysin insulin degrading enzymes mammals bacteriameth enzymol248693 7031995medline sipe jd amyloidosisannu rev biochem61947 9751992medline kurochkin iv amyloidogenic determinant substrate recognition motif insulin degrading enzymefebs lett427153 1561998medline goto kurochkin iv alzheimer ss amyloid peptide interacts degraded insulin degrading enzymefebs lett34533 371994medline qiu wq walsh dm ye z vekrellis k zhang j podlisny mb rosner mr safavi hersh lb selkoe dj insulin degrading enzyme regulates extracellular levels amyloid beta protein degradationj biol chem27332730 327381998abstractfree full text wiltshire hattersley hitman ga walker m levy jc sampson m o rahilly frayling tm bell ji lathrop gm bennett dhillon r fletcher c groves cj jones e prestwich p simecek n rao pv wishart m bottazzo gf foxon r howell smedley d cardon lr menzel mccarthy mi genomewide scan loci predisposing type 2 diabetes uk population diabetes uk warren 2 repository analysis 573 pedigrees provides independent replication susceptibility locus chromosome 1qam j hum genet69553 5692001medline bertram l blacker d mullin k keeney d jones j basu yhu mcinnis mg go rc vekrellis k selkoe dj saunders aj tanzi re evidence genetic linkage alzheimer disease chromosome 10qscience2902302 23032000abstractfree full text myers holmans p marshall h kwon j meyer d ramic d shears booth j devrieze fw crook r hamshere m abraham r tunstall n rice f carty lillystone kehoe p rudrasingham v jones l lovestone perez tur j williams j owen mj hardy j goate susceptibility locus alzheimer disease chromosome 10science2902304 23052000abstractfree full text ertekin taner n graff radford n younkin lh eckman c baker m adamson j ronald j blangero j hutton m younkin sg linkage plasma abeta42 quantitative locus chromosome 10 late onset alzheimer disease pedigreesscience2902303 23042000abstractfree full text fakhrai rad h nikoshkov kamel fernstrom m zierath jr norgren luthman h galli j insulin degrading enzyme identified candidate diabetes susceptibility gene gk ratshum mol genet92149 21582000abstractfree full text farris w mansourian chang y lindsley l eckman ea frosch mp eckman cb tanzi re selkoe dj guenette insulin degrading enzyme regulates levels insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivoproc natl acad sci u a1004162 41672003abstractfree full text bhathena sj timmers ki oie hk voyles nr recant l cytosolic insulin degrading activity islet derived tumor cell lines normal rat isletsdiabetes34121 1281985abstract oehler g bleyl h matthes kj hyperinsulinemia hepatic steatosisint j obe relat metab disord6 suppl 1137 1441982 hamel fg upward jl bennett rg vitro inhibition insulin degrading enzyme long chain fatty acids coenzyme thioestersendocrinology1442404 24082003abstractfree full text
